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InTroducTIon
The endothelium, first described over 100 
years ago as an inert anatomical barrier 
between blood and the vessel wall, is now 
recognized as a dynamic organ with secretory, 
synthetic, metabolic, and immunologic 
functions. Forming a continuous lining to 
every blood vessel in the body, endothelial 
cells play an obligatory role in modulating 
vascular tone and permeability, angiogenesis, 
and in mediating haemostatic, inflammatory 
and reparative responses to local injury. To 
fulfil these roles the endothelium is highly 
dynamic, continuously responding to spatial 
and temporal changes in mechanical and 
biochemical stimuli. such responsiveness 
is affected through receptors for growth 
factors, lipoproteins, platelet products and 
circulating hormones, which regulate changes 
in protein and mrna expression, cell 
proliferation and migration or the release of 
vasoactive and inflammatory mediators.
all vascular endothelial cells have a 
common embryonic origin but show clear 
bed-specific heterogeneity in morphology, 
function, gene and protein expression, 
determined by both environmental stimuli 
and epigenetic features acquired during 
development. Thus, the endothelium should 
not be regarded as a homogenous tissue 
but rather a conglomerate of distinct 
populations of cells sharing many common 
functions but also adapted to meet regional 
demands.1
The continuous endothelial cell layer pro-
vides an uninterrupted barrier between the 
blood and tissues in the majority of blood 
vessels and ensures tight control of perme-
ability of the blood-brain barrier. In regions 
of increased trans-endothelial transport such 
as capillaries of endocrine glands and the 
kidney, the presence of fenestrae, transcellu-
lar pores approximately 70 nm in diameter 
with a thin fenestral diaphragm across their 
opening, facilitate the selective permeability 
required for efficient absorption, secretion, 
and filtering. In hepatic sinuses, the presence 
of a discontinuous endothelium with large 
fenestrations (0.1–1 mm in diameter) lack-
ing a fenestral diaphragm, provides a highly 
permeable and poorly selective sieve essen-
tial for transfer of lipoproteins from blood 
to hepatocytes.
Beyond these structural variations, endo-
thelial heterogeneity is also manifest in 
regional differences in the release of vaso active 
and inflammatory mediators, in response to 
changes in shear stress and hypoxia, and 
in expression of pro- and anti-coagulant 
molecules. For example, endothelial expres-
sion of the pro-thrombotic mediator von 
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Willebrand factor (vWF) is a function of 
endothelial cells found in vessels of discrete 
size and/or anatomic location. similarly, 
the contribution of nitric oxide (no) to 
endothelium-dependent vasodilation is far 
greater in large conduit arteries compared to 
small resistance vessels. These regional bio-
chemical and phenotypic differences between 
endothelial cells extend to their susceptibil-
ity to injury in the face of cardiovascular risk 
factors such as hyper cholesterolemia, diabe-
tes and smoking and thus impact the func-
tion of the vasculature both in health and 
disease.
This chapter provides an overview of 
how the endothelium regulates four key 
aspects of cardiovascular homeostasis-vas-
cular tone, angiogenesis, haemostasis and 
inflammation.
endoThelIum-dePendenT 
regulaTIon oF vascular 
Tone
since the first report by Furchgott and 
Zawadski2 of endothelium-dependent 
modu lation of the contractile state of smooth 
muscle cells in the artery wall, it has become 
apparent that endothelial cells release a 
plethora of vasoactive factors in response to 
a wide range of mechanical and chemical 
stimuli. That many of these factors also 
modulate processes such as inflammation, 
cell adhesion and coagulation, highlights the 
crucial physiological role of the endothelium 
and why endothelial dysfunction is pivotal in 
the development of cardiovascular diseases 
such as atherosclerosis and hypertension. 
This section will focus on the four major 
pathways underlying endothelium-
dependent modulation of vascular tone; no, 
arachidonic acid metabolites, endothelium-
dependent hyper polarisation (edh) and 
endothelin.
Nitric oxide
The first endothelium-derived relaxing 
factor described by Furchgott and Zawadski 
was subsequently identified as no, a short-
lived free radical synthesized from l-arginine 
by endothelial no synthase (enos) and 
destroyed by reactive oxygen species (ros). 
no activates the haem-dependent enzyme, 
soluble guanylyl cyclase in surrounding 
smooth muscle cells, leading to formation of 
cyclic guanosine monophosphate (cgmP). 
subsequent protein kinase g-mediated 
phosphorylation of a diverse range of target 
proteins such as large conductance calcium-
activated potassium (BK
ca
) channels, rhoa, 
rho kinase, transient receptor potential 
(TrP) channels, myosin light chain 
phosphatase and phospholamban, leads to 
smooth muscle cell relaxation and hence 
vasodilation.3
enos is a bidomain enzyme; an n- 
terminal oxygenase domain with binding 
sites for haem, tetrahydrobiopterin, oxygen 
and the substrate l-arginine supports the 
catalytic activity, and a c-terminal reduct-
ase domain binds nicotinamide adenine 
dinucleotide phosphate (nadPh), flavin 
mononucleotide (Fmn) and flavin adenine 
dinucleotide co-factors. Transfer of electrons 
from nadPh to flavins in the reductase 
domain and then to the haem in the oxygen-
ase domain is required so that the haem iron 
can bind oxygen and catalyze the synthesis of 
no from l-arginine. Binding of the ubiqui-
tous calcium regulatory protein calmodulin 
(cam) facilitates transfer of electrons from 
the reductase to the oxygenase domain and is 
critical for activation of the enzyme.
enos is constitutively expressed in 
all endothelial cells but regulation of the 
enzyme by physiological and pathophysi-
ological stimuli occurs via a complex pat-
tern of transcriptional and post-translational 
modifications. For example, both enos 
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mrna and protein levels are increased by 
fluid shear stress via activation of a pathway 
involving both c-src-tyrosine kinase and 
transcription factor nFκB. at the post-trans-
lational level, enos activity is highly regu-
lated by substrate and cofactor availability as 
well as by endogenous inhibitors, lipid mod-
ification, direct protein-protein interactions, 
phosphorylation, o-linked glycosylation, 
and s-nitrosylation. agonists at endothe-
lial g-protein coupled receptors (gPcrs) 
such as bradykinin, and acetylcholine, elicit 
calcium-cam-dependent no production 
by via phospholipase c-mediated genera-
tion of inositol 1,4,5-trisphosphate (IP
3
) and 
subsequent release of calcium from intracel-
lular stores. however, activation of tyrosine 
kinase linked receptors such as the vascular 
endothelial growth factor (vegF) receptor, 
and mechanical stimulation of the endothe-
lium by shear stress, lead to phosphorylation 
of enos at ser1177 to increase the calcium 
sensitivity of the enzyme so that it can be 
activated at resting calcium levels. distinct 
kinase pathways can mediate enos phos-
phorylation; shear stress elicits phosphoryla-
tion of ser1177 via protein kinase a whereas 
insulin and vegF cause phosphorylation 
of the same residue via the serine/threonine 
protein kinase akt. conversely, phosphory-
lation of the enzyme at Tyr657 within the 
Fmn domain or Thr495 within the cam-
binding domain, inhibit enzyme activity.4
Within endothelial cells, enos is tar-
geted to invaginations of the cell membrane 
called caveolae, membrane microdomains 
enriched in cholesterol and sphingolipids, 
and defined by the presence of the scaffolding 
protein caveolin. caveolae sequester diverse 
receptors and signaling proteins including 
gPcrs, growth factor receptors and calcium 
regulatory proteins such as cam. Thus, tar-
geting of enos to this region facilitates com-
munication with upstream and downstream 
pathways. Within caveolae, caveolin-1 toni-
cally inhibits enos activity, thereby limiting 
the production of no; binding of calcium-
cam leads to disruption of the caveolin-1/
enos interaction and increases enos 
activity. other associated proteins such as 
platelet endothelial cell adhesion molecule-1 
(Pecam-1), modulate enos activity by 
virtue of their function as scaffolds for the 
binding of signaling molecules such as tyro-
sine kinases and phosphatases.
a vast range of stimuli such as shear stress 
generated by the viscous drag of blood flowing 
over the endothelial cell surface, circulating 
hormones (e.g. catecholamines, vasopressin), 
plasma constituents (e.g. thrombin), platelet 
products (e.g. 5-hT) and locally-produced 
chemical mediaors (e.g. bradykinin) each 
evoke no-mediated vasodilation. release 
of endothelium-derived no by such stim-
uli plays a critical role in mediating acute 
changes in local blood flow and tissue per-
fusion. shear stress-stimulated no produc-
tion is central to exercise-induced increases 
in blood flow in skeletal muscle. Production 
of no in response to 5-hT released from 
aggregating platelets, dilates coronary arteries 
thus preventing the clot from occluding the 
vessel. mice lacking enos are hypertensive 
and infusion of l-arginine analogues, com-
petitive inhibitors of enos, cause alterations 
in local blood flow and in systemic blood 
pressure, demonstrating the importance of 
endothelium-derived no in long-term con-
trol of blood pressure and blood flow in vivo. 
In humans, elevated levels of an endogenous 
inhibitor of enos, asymmetric dimethyl-
arginine, are associated with hypertension 
and increased cardiovascular risk. 
In addition to its vasodilator actions, no 
is now recognized as playing myriad other 
protective roles in the vasculature as a regu-
lator of clot formation, inflammation and 
vessel repair. loss of no-mediated vasodila-
tion, due to reduced expression or activity 
of enos and/or oxidative stress-mediated 
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reductions in no bioavailability, is a hall-
mark of endothelial dysfunction associated 
with cardiovascular risk factors such as hyper-
cholesterolemia, smoking, diabetes and obes-
ity. loss of no tip the homeostatic balance 
in favour of vasoconstriction, proliferation, 
activation of platelets and blood clot forma-
tion, and inflammation. These pathological 
processes contribute to clinical manifesta-
tions such as hypertension, atherosclerosis 
and arterial thrombosis, which are associated 
with significant morbidity and mortality. 
Metabolites of arachidonic acid: arachid-
onic acid, released from cell membrane phos-
pholipids by phospholipases, is metabolized 
by cyclooxygenase (coX), lipoxygenase 
(lo), and cytochrome P450 monooxy-
genase (cyP) enzymes to yield an array of 
endothelium-derived vasoactive factors.
Cyclooxygenases: coX enzymes metabolize 
arachidonic acid to endoperoxide intermedi-
ates which are then converted to a range of 





) through the actions of various 
synthases. Two isoforms of cyclooxygenase are 
found in the endothelium. The constitutively 
expressed coX-1 has long been regarded as 
vasculoprotective, the predominant product 
being PgI
2
 which acts on prostanoid (IP) 
receptors to cause vasodilation and inhibi-
tion of platelet aggregation via activation of 
adenylyl cyclase and subsequent elevation 
of intracellular cyclic-adenosine monophos-
phate (camP). PgI
2
 also inhibits platelet and 
lymphocyte adhesion to endothelium, limits 
vascular smooth muscle cell proliferation and 
migration, and counteracts the production of 
growth factors. 
however, evidence is now emerging that 
gPcr-mediated activation of endothelial 





 which activate thrombox-
ane (TP) receptors on smooth muscle cells 
and so function as endothelium-derived con-
tracting factors (edcFs). stimulation of TP 
receptors elicit not only vasoconstriction but 
also proliferation of vascular smooth mus-
cle cells, platelet adhesion and aggregation 
and expression of adhesion molecules on 
endothelial cells. coX-1 shows basal activ-
ity and is activated by endothelial gPcrs. 
a shift from production of endothelium-
derived relaxing factors to coX-dependent 
edcFs is implicated in endothelial dysfunc-
tion associated with ageing, diabetes and 
hypertension.6 
coX-2 was first identified as an induc-
ible form of the enzyme, regulated at the 
level of gene expression and associated with 
inflammation. however, it is expressed in 
some blood vessels in the absence of overt 
signs of inflammation and may be a major 
source of vasculoprotective PgI
2
; hence 
the deleterious cardiovascular consequences 
seen in some patients treated with selective 
coX-2 inhibitors.7
Lipoxygenases: lo enzymes deoxygen-
ate polyunsaturated fatty acids to hydroper-
oxyl metabolites. The three lo isoforms 
expressed in endothelial cells are 5-lo, 
12-lo, and 15-lo, which correspond to 
the carbon position of arachidonic acid oxy-
genation. each lo oxygenates arachidonic 
acid to form a stereospecific hydroperoxyei-
cosatetraenoic acid (hPeTe). hPeTes are 
unstable and are reduced to the correspond-
ing hydroxyeicosatetraenoic acids (heTes). 
5-lo is the initial enzyme in the synthesis 
of leukotrienes but 5-lo products do not 
seem to be involved in regulation of vascular 
tone. In contrast, products from the 12-lo 
and 15-lo pathways are vasoactive but show 
species and vessel variation in the responses 
they elicit. 12-heTe elicits relaxation of 
a number of peripheral arteries including 
human coronary vessels, but causes vasocon-
striction in dog renal arteries. 15-hPeTe 
and 15-heTe cause slight vasorelaxation 
at lower concentrations but contractions at 
higher concentrations mediated by activation 
Endothelium 5
of TP receptors. although vasoactive lo 
metabolites are produced by endothelial 
cells, elucidation of their physiological role 
has been hindered by the lack of selectivity 
of pharmacological inhibitors. 
Cytochrome P450 monooxygenases: 
cyP enzymes add oxygen across the 
double bonds of arachidonic acid to pro-
duce four cisepoxides, 14,15-, 11,12-, 8,9-, 
and 5,6-epoxyeicosatrienoic acids (eeTs). 
Two cyP enzymes have been cloned from 
human endothelium cyP2c8/9 and cyP2J2 
both of which produce mainly 14,15-eeT 
with lesser amounts of 11,12-eeT. The lat-
ter are also the major eeTs released from 
endothelial cells stimulated by gPcr 
agonists (e.g. acetylcholine, bradykinin) 
and physical stimuli such as cyclic stretch 
and shear stress. eeTs are rapidly metabo-
lized by esterification into phospholipids or 
hydration to dihydroxyeicosatrienoic acids 
by soluble epoxide hydrolase. 
eeTs are vasoactive causing vasocon-
strictions in the lung but eliciting vasodila-
tation of systemic arteries via activation of 
iberiotoxin-sensitive, BK
ca
 channels on the 
vascular smooth muscle cells. eeTs are pro-
posed mediators of edh in systemic arter-
ies, acting either as transferable factors that 
hyperpolarize and relax smooth muscle cells, 
or acting in an autocrine manner to cause 
hyperpolarisation of the endothelial cell 
membrane potential which is then spread to 
the underlying smooth muscle through gap 
junctions (see below). 
an eeT receptor on smooth muscle cells 
has not been identified but development 
of 14,15-eeT analogues such as 14,15- 
epoxyeicosa-5Z-enoic acid has revealed 
strict structural and stereoisomeric require-
ments for relaxations suggesting a specific 
binding site or receptor and BK
ca
 channel 
activation by eeTs requires a g protein 
indicating that a gPcr for eeTs exists. 
some eeTs activate vascular TrP channels, 
non-selective cation channels that can medi-
ate calcium influx. endothelium-dependent 
flow-induced dilation is linked to 5,6-eeT-
mediated activation of vanilloid type 4, 
TrPv4, channels. Formation of a complex 
of TrPv4 with BK
ca 
channels in smooth 
muscle cells may couple local increases in cal-
cium due to activation of TrPv4 by eeTs 
to membrane hyperpolarisation and vasore-
laxation.8 In contrast, endothelial stimulation 
by bradykinin or hypoxia is associated with 
activation of TrPc3 and TrPc6 channels. 
In addition to stimulating channel activity, 
eeTs elicit the rapid intracellular transloca-
tion of TrP channels into caveolae, a process 
dependent on activation of protein kinase a 
by camP, and consistent with the activation 
of a gPcr.
In some models of endothelial dysfunc-
tion, reduced bioavailability of no is coun-
teracted by increased production of eeTs 
which can maintain endothelium-dependent 
vasodilator responses. Thus, strategies aimed 
at enhancing production of endothelium-
derived eeTs or inhibiting their degradation, 
may represent a new therapeutic approach to 
endothelial dysfunction. 
Endothelium-dependent hyperpolarisation 
(EDH): observations of agonist- induced 
endothelium-dependent vasorelaxation which 
persisted in the presence of inhibitors of pros-
taglandin and no synthesis and was accom-
panied by hyperpolarisation of the vascular 
smooth muscle cell membrane potential, 
led to identification of a third endothelium-
derived relaxing factor, edhF. hyperpolari-
sation of the smooth muscle cells reduces the 
open probability of voltage-dependent cal-
cium channels thus reducing calcium influx 
to cause relaxation. a range of agents have 
been proposed to account for the actions of 
edhF including K+ ions, eeTs and c-type 
natriuretic peptide. however, in many arter-
ies, endothelium-dependent hyperpolari-
sation of vascular smooth muscle (edh) 
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actually reflects direct electrical coupling 
between endothelial and smooth muscle cells 
via myoendothelial gap junctions rather than 
the actions of a diffusible factor.9 
Irrespective of the mediator, the initiat-
ing step in edh-mediated vasorelaxation 






potassium channels on endothelial cells. 
Inhibition of endothelium-dependent relax-





channel blockers is now regarded as the hall-
mark of edh and has been documented in 
response to many agonists, in a wide range 





 channels, activated by 
increases in intracellular calcium via cam 
which is constitutively associated with the 
channels, are voltage-independent and thus 
can operate at negative membrane potentials 
close to the K+ equilibrium potential.
The lack of selective inhibitors of edh, 





ers, has hampered investigations of the phys-
iological role of this pathway but it is now 
clear that edh becomes progressively more 
important as a mediator of endothelium-
dependent vasodilation with decreased vessel 
size. The importance of edh as a regulator 
of blood flow and blood pressure in vivo is 
demonstrated by enhanced resistance artery 
tone and elevated systemic blood pressure 





channels. loss of edh, due to changes in 




channels, contributes to experimental hyper-
tension and diabetes-related erectile dys-
function. In contrast, resistance of the edh 
pathway to the deleterious actions of ros 
may allow edh-mediated vasodilation to be 
maintained in the face of reduced bioavaila-
bility of no in atherosclerosis and heart fail-





 channels is a potential thera-
peutic avenue for the future.
Endothelin: endothelins are a family of 21 
amino acid peptides, of which there are three 
members (eT-1, eT-2, eT-3). endothelial 
cells produce only eT-1; endothelin eT-2 
is produced in the kidney and intestine, 
while eT-3 has been detected in the brain, 
gastrointestinal tract, lung and kidney. eT-1 
is a potent vasoconstrictor inducing long-
lasting vasoconstriction at a half maximum 
effective concentration in the nano molar 
range, at least one order of magnitude lower 
than values reported for other vasoconstric-
tor peptides such as angiotensin II. 
eT-1 is produced constitutively by the 
endothelium but production is regulated 
at the level of gene expression; inflamma-
tory factors such as transforming growth 
factor-β (TgFβ) and tumour necrosis 
factor-α (TnFα, insulin, and angiotensin 
II up-regulate eT-1 mrna whereas no, 
PgI
2
 and shear stress cause down-regulation.) 
eT-1 is synthesized as a large protein, 
the pre-proeT-1 (203 amino acids) that is 
cleaved to pro-eT-1 (39 amino acids) and 
then to eT-1 by eT-converting enzymes. 
The half life of eT-1 protein and mrna 
is 4–7 minutes and 15–20 minutes, respec-
tively, and the majority of plasma eT-1 
(90%) is cleared by the lung during first 
passage. 
The biological effects of eT-1 are medi-





which have opposing effects on vascular tone. 
eT
a
 receptors present on vascular smooth 
muscle are responsible for the majority of 
eT-1 induced vasoconstriction; activation of 
phospholipase c increases formation of IP
3
 
and diacylglycerol, and the resultant increase 
in intracellular calcium and activation of 
protein kinase c cause vasoconstriction. eT
B
 
receptors are mainly present on endothelial 
cells and play an important role in clearing 
eT-1 from the plasma in the lung. activa-
tion of endothelial eT
B
 receptors induces 




 and no. Inhibition of eT
B
 increases 
circulating eT-1 levels and blood pressure in 
healthy subjects demonstrating that although 
eT-1 is regarded as primarily a vasoconstric-
tor, eT
B
-mediated vasodilation is physiologi-
cally important.11 
eT-1 is not only a vasoactive factor. act-
ing via eT
B
 receptors, eT-1 modulates the 
expression and degradation of extracellu-
lar matrix (ecm) and thus plays a role in 
vascular remodelling. acting via eT
a
, eT-1 
promotes smooth muscle proliferation con-
tributing to neointima formation follow-
ing vascular injury and to thickening of the 
arterial wall in pathological conditions such 
as pulmonary arterial hypertension, athero-
sclerosis and vein graft occlusion. as no 
strongly inhibits the release of eT-1 from 
the endothelium and eT-1 attenuates no-
mediated dilation, eT-1 and no are func-
tionally closely interdependent and many of 
the cardiovascular complications associated 
with endothelial dysfunction are due to an 
imbalance in this relationship. 
angIogenesIs 
angiogenesis is the growth of new blood 
vessels as a result of endothelial cells 
sprouting from existing vessels. In adults, it is 
a protective mechanism initiated in response 
to tissue hypoxia and ischemia or injury. It is 
also a key process in pathological conditions 
such as the proliferative diabetic retinopathy 
and neovascularization of tumours and 
as such, inhibitors of angiogenesis have 
received considerable interest as potential 
therapeutic strategy. The angiogenic process 
depends on a complex transcriptional 
network coordinating production and release 
of numerous cytokines and growth factors. 
recruitment and proliferation of bone 
marrow–derived endothelial progenitor 
cells to form new vessels (vasculogenesis) is 
a distinct but complimentary process which 
occurs simultaneously in ischemic and 
wounded tissue to augment perfusion.12
angiogenesis requires a sequence of indi-
vidual processes: degradation of ecm by 
metalloproteinase enzymes, proliferation and 
directional migration of endothelial cells to 
form endothelial tubes, maturation of new 
vessels by recruitment of pericytes (con-
nective tissue cells) to stabilize endothelial 
sprouts and secrete ecm molecules to form 
the vascular basement membrane and apop-
tosis to prune back immature vessels into a 
vascular network.13 The endothelial cells that 
sprout from the parent vessel, tip cells, pos-
sess long and motile filopodia that extend 
towards the source of pro-angiogenic growth 
factors and respond to other guidance cues to 
enable directional vessel growth. endothelial 
cell migration requires the dynamic regula-
tion of interactions between integrins and the 
surrounding ecm. Integrins are cell surface 
receptors which provide adhesive and signal-
ing functions and link the actin cytoskeleton 
of the cell to the ecm at areas called focal 
adhesions. Phosphorylation of focal adhesion 
kinase, a cytoplasmic non-receptor tyrosine 
kinase, in response to pro-angiogenic signal 
molecules stimulates cell contraction, thus 
allowing cell movement on adhesive contacts. 
subsequent integrin inactivation destroys the 
adhesive complex and allows detachment of 
the cell in its new location. 
cell-cell contacts between endothelial 
cells, essential for development of patent 
vessels, are mediated by cell surface receptors 
such as Pecam-1, a 130 kda member of the 
immunoglobulin superfamily, which acts like 
a docking molecule to allow other proteins 
to provide further strength to vascular struc-
tures. cadherins such as vascular endothelial 
cadherin are transmembrane proteins which 
provide weak adhesive cell-cell forces, further 
stabilized by catenins, intracellular proteins 
linking the cadherin cell surface molecule to 
the actin cytoskeleton. 
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angiogenesis in response to hypoxia 
and ischemia is largely controlled by the 
transcription factor hypoxia-inducible 
factor-1 (hIF-1).14 hIF-1 has multiple sub-
units; hIF-1α which is produced continu-
ously but is rapidly degraded in the presence 
of oxygen and hIF-1β which is constitu-
tively expressed. under hypoxic conditions, 
hIF-1α degradation is inhibited and the 
stabilized protein translocates to the nucleus, 
where it dimerizes with hIF-1β and binds 
to hypoxia response elements on more than 
60 hIF–responsive genes that function to 
enhance oxygen delivery and increase metab-
olism. central angiogenic signals driven by 
increased hIF-1 activity include vegF, 
fibroblast growth factor (FgF), platelet-
derived growth factor (PdgF) and angiopoi-
etin. after injury, local platelets release TgFβ 
and PdgF, which stimulate vessel growth. 
FgF and vegF stimulate endothelial 
cell proliferation and migration. Their high 
affinity for heparan sulfate glycosaminogly-
cans on the endothelial cell surface facilitates 
binding to receptors and provides a reservoir 
of both factors in the ecm, which can be 
released during wounding or inflammation. 
vegF stimulates endothelial replication and 
migration and increases vessel permeability 
facilitating extravasation of plasma proteins 
to form a provisional matrix for cell migra-
tion. PdgF is required for the recruitment 
and survival of pericytes for vessel stabiliza-
tion and maturation. angiopoietins have 
multiple effects the angiogenic process, par-
ticularly the interactions between endothelial 
cells, pericytes and the basement membrane. 
For example, angiopoietin-1 stimulates secre-
tion of growth factors from endothelial cells, 
which in turn stimulate differentiation of sur-
rounding pericytes into smooth muscle cells. 
conversely, angiopoietin-2 is an antagonist of 
the actions of angiopoietin-1 and so acts as a 
naturally occurring inhibitor of angiogenesis. 
overall regulation of angiogenesis is a bal-
ance between angiogenic versus angiostatic 
factors.
There is a fuller description of the ang-
iogenic process in chapter 6, which also deals 
with therapeutic angiogenesis.
haemosTasIs
The endothelium plays a pivotal role in 
regulating blood flow by exerting effects 
on the coagulation system, platelets and 
fibrinolysis.15 under normal physiological 
conditions, the endothelium provides one of 
the few surfaces which can maintain blood 
in a liquid state during prolonged contact.
a key factor in blood clot formation is 
activation of the serine protease thrombin 
which cleaves fibrinogen, producing frag-
ments that polymerise to form strands of 
fibrin. It also activates factor XIII, a fibrinoli-
gase, which strengthens fibrin-to-fibrin links, 
thereby stabilising the clot and stimulates 
platelet aggregation. heparan sulfate proteog-
lycan molecules provide an anti-thrombotic 
endothelial cell surface by serving as co-fac-
tors for antithrombin III, causing a confor-
mational change that allows this inhibitor 
to bind to and inactivate thrombin and 
other serine proteases involved in the clot-
ting cascade. The endothelium also prevents 
thrombin formation by expressing tissue fac-
tor pathway inhibitor which binds to clotting 
factor Xa. Tissue factor pathway inhibitor and 
antithrombin III both contribute to physi-
ological haemostasis, and both show impair-
ment in acquired thrombotic states. a third 
endothelial anti-coagulation mechanism is 
expression of thrombomodulin; binding of 
thrombin to cell surface thrombomodulin 
removes its pro-coagulant activity, and the 
thrombin-thrombomodulin complex acti-
vates protein c a vitamin K-dependent 
anticoagulant. activated protein c, helped 
by its cofactor protein s, inactivates clotting 
factors va and vIIa. 
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The anti-platelet properties of the 
endothelium are largely mediated by release 
of PgI
2
 and no. as in smooth muscle, 
PgI
2
 inhibits platelet aggregation through 
the activation of IP receptors and activa-
tion of adenylyl cyclase whereas no inhibits 
platelet adhesion, activation, secretion, and 
aggregation through a cgmP-dependent 
mechanism. no inhibits agonist-dependent 
increases in intra-platelet calcium to suppress 
the calcium-sensitive conformational change 
in the heterodimeric integrin glycoprotein 
IIb– IIIa required for fibrinogen binding. 
no also promotes platelet disaggregation by 
impairing the activity of phosphoinositide 
3-kinase, which normally supports confor-
mational changes in glycoprotein IIb–IIIa, 
rendering its association with fibrinogen 
irreversible. should a blood clot form, fibri-
nolysis depends primarily on the action of 
plasmin, an active protease formed from its 
precursor, plasminogen, upon stimulation by 
tissue-type plasminogen activator.
under physiological conditions, there is a 
haemostatic balance and in addition to these 
anti-thrombotic mechanisms, the endothe-
lium also synthesises several key haemostatic 
components; vWF and plasminogen activa-
tor inhibitor-1 (PaI-1) being particularly 
important. PaI-1 is secreted in response to 
angiotensin Iv, providing a link between the 
renin-angiotensin system and thrombosis. In 
addition to anti-coagulant activity, binding 
of thrombin to thrombomodulin accelerates 
its capacity to activate thrombin-activatable 
fibrinolysis inhibitor (TaFI) which cleaves 
fibrin and other proteins, resulting in the 
loss of plasminogen/plasmin and tPa bind-
ing sites and thus retarding fibrinolysis. Per-
turbations, such as those that may occur at 
sites of injury, inflammation or high hydro-
dynamic shear stress, tip this haemostatic 
balance in favour of a pro-thrombotic and 
anti-fibrinolytic microenvironment. criti-
cal steps include loss of cell surface heparin 
proteoglycan molecules and increased expres-
sion of the transmembrane glycoprotein tis-
sue factor (TF) which initiates coagulation by 
stimulating the activation of clotting factors 
IX and X, and pro-thrombinase, with subse-
quent fibrin formation. TF accumulates in 
experimentally injured vessels and accumu-
lation in some atherosclerotic plaques likely 
accounts for their high thrombogenicity. 
InFlammaTIon
development of inflammatory reactions 
by the endothelium in response to injury 
or infection is critical for the maintenance 
and/or repair of normal structure and 
function of the vessel wall. however, 
excessive inflammatory reactions can lead to 
severe tissue damage and contribute to the 
development of atherosclerosis. 
The interaction between endothe-
lial cells and inflammatory cells such as 
leuko cytes depends on the production of 
inflammatory cytokines (e.g. interleukin 
8; Il-8) to attract leukocytes and expres-
sion of adhesion molecules (e.g. selectins) 
to facilitate their migration towards the site 
of infection. loosely tethered leukocytes 
first roll over the endothelial surface, then 
arrest, spread, and finally migrate between 
endothelial cells to attach on to underlying 
ecm components.16 
leukocyte rolling involves endothelial 
adhesion molecules of the selectin family 
which transiently bind to carbohydrate lig-
ands on leukocytes to slow passage through 
the blood vessel. e- and P-selectin are 
expressed only on the surface of activated 
endothelial cells whereas l-selectin is con-
stitutively expressed on leukocytes and binds 
to ligands induced on the endothelium at 
sites of inflammation or on other leukocytes. 
The role of individual types of selectins in 
leukocyte rolling shows stimulus- and time-
dependent variation. Immediate stimulation 
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of leukocyte rolling induced by histamine 
or thrombin depends on rapid expression 
of P-selectin, surface levels of this adhesion 
molecule declining after only 30 minutes. In 
contrast, TnFα stimulates delayed leuko-
cyte rolling and adhesion to endothelial cells 
through the induction of e-selectin, sur-
face levels of which peak after 12 hours and 
decline after 24 hours. Both e- and P-selectin 
are expressed on the surface of endothe-
lial cells overlying atherosclerotic plaques, 
affirming the importance of these molecules 
in the development of atherosclerosis.
Firm adhesion of leukocytes is promoted 
by binding of chemokines such as Il-8 to 
leukocyte gPcrs resulting in rapid activa-
tion of β1 and β2 integrins to increase their 
affinity for adhesion molecules of the immu-
noglobulin superfamily, intercellular adhe-
sion molecule (Icam-1) and vascular cell 
adhesion molecule (vcam-1). Icam-1 is 
constitutively expressed on endothelial cells 
but levels are increased by stimuli such as 
TnFα peaking at 6 hours and remaining 
elevated for 72 hours. Icam-1 mediates 
firm adhesion of blood cells by acting as a 
ligand for leucocyte beta2 integrins. vcam, 
a ligand for integrins α4β1 and α4β7, prin-
cipally mediates the adhesion of monocytes, 
lymphocyte, eosinophils, and basophils to the 
endothelial surface. expression of vcam-1 
is induced by cytokines, oxidized low-density 
lipoproteins and ros acting, as with induc-
tion of Icam-1, primarily via nF-κB.
migration of leukocytes through the 
endothelium requires the transient dis-
assembly of endothelial cell junctions. Firm 
adhesion of leukocytes to the endothelium 
induces clustering of adhesion molecules like 
Icam-1 and vcam-1 triggering activation 
of intracellular signaling pathways which 
induce endothelial cell actin cytoskeleton and 
cell junction remodelling. The remodelling 
process involves numerous pathways 
including rho gTPase signaling, protein 
phosphorylation and ros generation but 
a key event is alteration of the dimerization 
of Pecam-1. Pecam-1 localizes to inter-
cellular junctions of endothelial cells, forming 
homodimers linking two cells. leukocytes 
also express Pecam-1 and the dissociation 
of Pecam-1 dimers between endothelial 
cells to form dimers between emigrating 
leukocytes and endothelial cells is critical for 
leukocyte migration. 
conclusIons
The endothelium, once viewed as an inert 
physical barrier, is a dynamic secretory organ 
fulfilling numerous roles in the maintenance 
of cardiovascular homeostasis. endothelial 
cells from different parts of the vasculature 
show highly differentiated functions as a 
consequence of both environmental stimuli and 
epigenetic modifications. advances in defining 
many endothelial functions at the molecular 
level may lead to targeted therapies to alleviate 
chronic endothelial dysfunction associated 
with the progression of cardiovascular disease. 
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Smooth muscle has an important role in 
regulating the function of a variety of hollow 
organ systems including the: vasculature, 
airways, gastrointestinal tract, uterus and 
reproductive tract, bladder and urethra and 
several other systems. Smooth muscle has 
two fundamental roles: 1) to alter the shape 
of an organ and 2) to withstand the force of 
an internal load presented to that organ. In 
order to achieve these fundamental objectives 
smooth muscles have developed mechanisms 
of mechanical coupling, which enable the 
development of powerful and coordinated 
contractions at a relatively low energy cost. For 
example, smooth muscle in the gastrointestinal 
tract must undergo intermittent but coordin­
ated phasic contractions to propel the bolus 
of food through the alimentary canal. 
Whereas in the airways and vasculature the 
smooth muscle is more often in various states 
of tonic contraction, but can be dynamically 
regulated to relax or contract in response to 
specific neuro­hormonal and haemodynamic 
signals. In keeping with the aims of this 
text, this chapter will focus on the principle 
mechanisms through which vascular smooth 
muscle functions.
SMOOTH MUSCLE (VASCULAR) 
STRUCTURE
Vascular smooth muscle cells have classically 
been envisaged as fusiform cells, on average 
200 microns long × 5 microns in diameter, 
with a large central nucleus surrounded by 
an abundant array of endoplasmic reticulum 
and golgi apparatus, with the cytosol and 
plasma membrane tapering toward the poles. 
Although the dimensions of the vascular 
smooth muscle cell narrow toward their ends 
there is clear evidence that the end­to­end 
junctions coupling smooth muscle cells are 
complex and contain a significant number 
of membrane invaginations to provide 
increased surface area for both mechanical 
tight junctions and electrical coupling via 
gap junctions (Figure 2.1). Vascular smooth 
muscle cells do not contain the complex 
t­tubule/sarcoplasmic reticulum system 
common to striated muscles, but rather they 
contain a significant number of invaginations 
along the plasma membrane called caveolae, 
which serve a similar, albeit less developed role 
to increase the cellular surface: volume ratio. 
These specialized caveolae further provide 
a unique plasma membrane environment, 
which enables clustering of specific groups 
2  •   Vascular Smooth Muscle Structure and  
Function
DAVID P WILSON
Molecular Physiology of Vascular Function Research Group,  
Discipline of Physiology, University of Adelaide, South Australia
Mechanisms of Vascular Disease14
of ion channels and receptors important in 
cellular signal transduction.
In contractile vascular smooth muscle the 
endoplasmic reticulum has been modified 
to enable Ca2+ release and reuptake and has 
therefore been termed sarcoplasmic reticulum. 
In smooth muscle cells the sarcoplasmic 
reticulum/endoplasmic reticulum (SR/ER) 
complex comprises about 5% of the total 
cell volume, with a considerable amount 
of rough endoplasmic reticulum and golgi 
apparatus adjacent to the nucleus, which 
reflects the significant capacity that smooth 
muscle has for protein synthesis and secretion. 
The fact that vascular smooth muscle has a 
fundamental role in mediating pressure and 
flow in the vasculature is reflected in the 
abundance of cytoskeletal and contractile 
proteins expressed. 
CYTOSKELETON
As with all eukaryotic cells the cytoskeleton is 
comprised of a network of many and various 
filamentous proteins, often formed by the 
polymerization of monomeric subunits. 
For example, monomers of alpha and beta 
tubulin self assemble into microtubules 
that function to provide static support 
to the cell and to enable motor protein 
mediated transport of cytosolic cargo and 
for chromosomal segregation during mitosis. 
The actin cytoskeleton and elements of 
the actin contractile myofilament are also 
generated from the polymerization of 
globular monomeric actin to form polymeric 
actin filaments. This process is dynamically 
regulated even within the time scale of 
contractile processes, i.e., as the smooth 
muscle slowly shortens it can actually 
synthesise and extend the length of the actin 
filaments. 
CONTRACTILE MYOFILAMENT
The structure of the smooth muscle acto­
myosin array is similar to striated muscle 
with several important differences: 
1. there is no troponin complex in smooth 
muscle
2. contraction is regulated by Ca2+ 
calmodulin­dependent myosin light 
chain kinase (MLCK) mediated 
phosphorylation of the regulatory light 
chains of myosin, which enables actin 
Figure 2.1: Highlights the fusiform shape of typical smooth muscle cells and the patterned array of actin 
myosin myofilaments across the cell. Smooth muscle cells have invaginations along their length to provide 
increased surface area for mechanical coupling via tight junctions and electrical coupling through Gap 
junctions. Dense bodies are thought to be similar to Z-disks found in striated muscle.
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myosin interaction and cross bridge 
cycling
3. in the absence of Ca2+ and calmodulin 
(CaM), caldesmon interacts with 
actomyosin inhibiting the activity of 
myosin ATPase
4. the activity of myosin light chain 
phosphatase (MLCP) directly causes 




5. the actin: myosin ratio is higher in 
smooth muscle averaging 15:1 in 
vascular smooth muscle in comparison 
to 6:1 in skeletal or cardiac muscle. 
There are no intercalated disks or 
z­disks, however, dense bodies in smooth 
muscle are thought to be analogous to 
z­disks (Figure 2.2). 
There are a variety of intermediate filament 
proteins but desmin and vimentin are 
particularly abundant in smooth muscle. In 
fact, desmin has been shown to be upregulated 
in several myopathies and during smooth 
muscle hypertrophy. As indicated once 
globular actin polymerizes into filaments 
they coil to form mature filamentous actin 
that then combines with tropomyosin to 
form a large actin­tropomyosin filament 
which together is arranged in side polar 
arrays with myosin II filaments (Figure 2.1). 
The myosin II thick filaments are composed 
of two 200kDa heavy chains, two 17kDa 
light chains and two phosphorylatable 
regulatory myosin light chains (LC
20
). The 
two heavy chains coil together forming a 
155nm rod, while the globular head contains 
the motor domain consisting of light chains 
and Mg2+ ATPase activity and the actin 
binding domain. The myosin is arranged in 
an anti parallel array that enables the myosin 
motors, on the heads of myosin molecules, 
to draw actin polymers along its length and 
effect shortening of the cell, so­called cross 
bridge cycling (Figure 2.2). MLCK, which is 
responsible for the Ca2+ calmodulin mediated 
phosphorylation of LC
20
 is actin associated 
while MLCP which removes the phosphoryl 
groups from LC
20
 is associated with myosin. 
(Figure 2.3)
FUNCTIONAL REGULATION OF 
VASCULAR SMOOTH MUSCLE: 
NEURONAL, HORMONAL, 
RECEPTOR MEDIATED
Smooth muscle from all hollow organs 
including blood vessels have been somewhat 
artificially categorized into either single 
unit smooth muscle or multiunit smooth 
muscle, when in reality they should likely be 
considered as a combination of both types. 
Nevertheless, historically, multiunit smooth 
muscle has been considered to be regulated 
primarily through autonomic sympathetic 
innervations, which release neurotransmitters 
from varicosities along the axon, rather than 
specifically coupling to individual cells. 
Consequently, neurotransmitters are required 
to diffuse anywhere from 5­100 nm to the 
adjacent smooth muscle membrane in order 
to activate their receptors. The activation 
of sympathetic nerves therefore causes 
membrane depolarization and activation of 
voltage dependent ion channels, the most 
prominent of which are the clinically relevant 
voltage operated Ca2+ channels (VOCC) of 
the Cav
1.2 
family, also known as the long 
acting L­type Ca2+ channels. Due to the 
mechanism of membrane depolarization, this 
form of cellular activation has been termed 
electromechanical coupling. In contrast, 
single unit smooth muscles have very little 
innervation and are primarily activated 
by autocrine and paracrine hormones, 
including noradrenalin, adrenalin, and 
angiotensin II, all of which function through 
G­protein coupled membrane receptors. 
Receptor acti vation either triggers sarcoplasmic 
reticulum­mediated Ca2+ release or membrane 
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Figure 2.2: Illustrates the patterned array of actin and myosin in smooth muscle in both cross section 
and the longitudinal axis. Following phosphorylation of the light chains of myosin, actin and myosin interact 
followed by the synchronous sliding of actin across the myosin. The movement of actin filaments toward the 
center of the cell is driven by the Mg2+ ATPase activity in the myosin heads and results in cell shortening or 
development of tension.
Figure 2.3: Illustrates the major pathways by which Ca2+ enters the cytosol, areas highlighted in blue 
indicate mechanisms by which Ca2+ exits that cell. Ca2+ entry activates Ca2+ CaM-dependent myosin light 
chain kinase leading to phosphorylation of myosin, leading to actin myosin interaction and contraction. 
Myosin phosphatase dephosphorylates myosin uncoupling actin-myosin favouring vasorelaxation. Various 
G-protein coupled receptors are capable of activating PKC/CPI-17 or RhoA/Rho kinases pathways which are 
capable of inhibiting myosin phosphatase further favouring vasoconstriction.
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depolarization through the activation of 
ion channels which may include VOCC. 
Consequently this form of activation has 
been termed pharmacomechanical coupling. 
Experimental evidence also exists to suggest 
that like striated muscle, extracellular Ca2+ 
entry in smooth muscle can also activate SR 
Ca2+ release into the cytosol, so called Ca2+ 
induced Ca2+ release, although this appears 
to be a less common mechanism of Ca2+ 
entry. Once activated, single unit smooth 
muscle cells tends to contract in synchrony 
with neighbouring smooth cells, which are 
coupled through gap junctions. Gap junctions 
are composed of 6 connexin proteins, which 
are transmembrane spanning proteins which 
assemble to form a barrel­shaped connexon 
or hemichannel in the plasma membrane. 
When two hemichannels from adjacent 
cells assemble they form a functional gap 
junction that enables the movement of ions 
(electrical coupling) and small molecules 
between adjacent cells (Figure 2.1). Evidence 
indicates that at least some of the vascular 
smooth muscle cells in most vascular beds 
are electrically coupled via gap junctions and 
may even be coupled to the endothelium in 
a similar manner. 
SMOOTH MUSCLE FUNCTION
As with other muscle types smooth muscle 
functions best when at its optimal resting 
length L
0
, which provides the ideal balance 
of actin­myosin interaction and muscle 
shortening. Vascular smooth muscle cells 
that are stretched beyond L
0
 have less than 
optimal overlap of actomyosin crossbridges 
and thus are unable to maintain or generate 
maximum force. In contrast, smooth 
muscle that is over shortened experiences 
increased internal resistance due to internal 
friction generated from having too many 
slowly cycling cross bridges. However, in 
smooth muscle the optimal length tension 
relationship is considerably more variable 
than that for skeletal or cardiac muscle, but 
appears to be directly related to the degree 
of phosphorylation of the regulatory light 
chains of myosin. The broader range of 
optimal resting length amongst smooth 
muscle may reflect the dynamic changes in 
load that exist within the vasculature and of 
the high actin:myosin ratio in smooth muscle 
relative to striated muscle. Interestingly, at 
the onset of stretch or pressurization smooth 
muscle responds via activation of stretch 
receptors (TREK and TRAK) that induce 
Ca2+ entry and consequent smooth muscle 
shortening, which directly offsets increased 
vascular wall stress. This is the important 
mechanism governing the phenomenon of 
autoregulation. It is important to note that 
although gastrointestinal smooth muscle 
appears relatively unaffected by significant 
stretch, more that 25% stretch often destroys 
the contractile properties of vascular smooth 
muscle.




Motility studies using isolated actin and 
myosin proteins have identified that the duty 
cycle of the myosin head power stroke is 
7­11 nm. Perhaps more important than the 
stroke length of the myosin is the activity of 
the myosin ATPase, which along with Ca2+/
CaM and the activation state of myosin 
light chain kinase and myosin light chain 
phosphatase, determines the extent and the 
rate of contraction of the vascular smooth 
muscle (Figure 2.3). Smooth muscle myosin 
ATPase hydrolyses ATP at a rate of ~0.16 
moles ATP/mol myosin/second, which is 
several orders of magnitude slower than 
the skeletal muscle myosin ATPase which 
hydrolyses ~10­20 moles ATP/mol myosin/
Mechanisms of Vascular Disease18
second. In part the slower ATPase rate of 
the myosin head accounts for the vastly 
slower contraction rates of vascular smooth 
muscle compared with striated muscles. 
In addition, there are a variety of different 
isoforms of smooth muscle myosin II which 
when differentially expressed will increase 
or decrease the maximum rate of smooth 
muscle contraction. For example, so called 
foetal isoforms of smooth muscle myosin II 
have a slower rate of contraction. In addition, 
these “foetal” isoforms have been shown to be 
upregulated during extended hypoxia, and 
during phenotypic remodelling of smooth 
muscle from a contractile to synthetic or 
proliferative phenotype.
Smooth muscle contraction and 
relaxation
As mentioned, unlike cardiac and skeletal 
muscle, smooth muscle does not contain 
troponin and therefore is not subject to 
troponin mediated regulation of contraction. 
Smooth muscle contraction makes use 
of another Ca2+ binding protein called 
calmodulin (CaM), which when bound 
with Ca2+ mediates the activation of the 
actin bound myofilament enzyme, myosin 
light chain kinase (MLCK), which in turn 
phosphorylates the regulatory light chains 
of myosin (LC
20
). Phosphorylation of the 
myosin LC
20
 is a critical step in smooth muscle 
contraction which causes a conformational 
change in the myosin head enabling the 
interaction of myosin with actin, cross bridge 
cycling, and contraction. Removal of cytosolic 
Ca2+ occurs through the activation of energy 
dependent plasma membrane Ca2+ ATPases 
(PMCA), Na+/Ca2+ exchangers and sarco/
endoplasmic reticulum CaATPases (SERCA) 
(Figure 2.3). However, since MLCK­
mediated phosphorylation of the serine 19 
of myosin LC
20
 generates a covalent bond, 
simply removing Ca2+ does not directly cause 
vasodilatation. However, myosin associated, 
myosin light chain phosphatase (MLCP), 
is responsible for the dephosphorylation 
of myosin LC
20
 and the consequent loss 
of smooth muscle acto­myosin interaction 
and the attenuation of cross bridge cycling 
(Figure 2.3). It is important to recognize that, 
simple removal of extracellular Ca2+ only 
stops the phosphorylation of LC
20
 and does 
not provide an explanation for subsequent 
smooth muscle relaxation since the LC
20
 
remains phosphorylated. This also partially 
explains why Ca2+ channel blockers are less 
effective in attenuating pre­existing vascular 
spasm as opposed to preventing spasm. 
ION CHANNELS IMPORTANT IN 
THE REGULATION OF SMOOTH 
MUSCLE FUNCTION 
Regulation of cellular Ca2+
There are vast arrays of ion channels, 
pumps, transporters and exchangers that are 
important in regulating ionic balance and 
smooth muscle membrane potential. Perhaps 
the best know are the electrogenic 3Na+/2K+ 
ATPase and the voltage gated L­type Ca2+ 
channels but includes: Na+/Ca2+ exchangers, 
plasma membrane Ca2+ ATPases (PMCA), 
which provide routes to extrude Ca2+ from 
the cytosol into the extracellular space, 
whereas the sarcoplasmic reticulum Ca2+ 
ATPases (SERCA) are important in removing 
Ca2+ from the cytosol back into the SR. In 
contrast, when the SR becomes depleted of 
Ca2+, Ca2+ sensor proteins in the SR termed 
stromal interacting molecule 1 (STIM1) 
translocate to the plasma membrane and 
activate an ion channel called Orai1 which 
enables refilling of SR Ca2+ stores. In addition, 
a great deal of recent research has focused 
on the non­selective cation channels of the 
transmembrane receptor potential canonical 
(TRPC) family that are thought be involved 
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in regulating Na+ and Ca2+ entry. Finally a 
series of potassium channels are involved in 
either re or hyperpolarisation of the plasma 
membrane and thereby have therapeutic 
potential in limiting extracellular Ca2+ entry 
through voltage operated Ca2+ channels and 
thereby limiting vasoconstriction.
Sources of cytosolic Ca2+ entry
Within the smooth muscle cell, Ca2+ enters 
the cytosol from the extracellular space 
or from the intracellular endoplasmic 
reticulum, which in muscle cells is termed 
the sarcoplasmic reticulum (SR). Within 
muscle the sarcoplasmic reticulum has 
become variously modified to affect Ca2+ 
release into the cytoplasm. Typically agents 
that activate the ryanodyne receptor such as 
caffeine or phospholipase C (PLC) derived 
inositol 1, 4, 5 tris phosphate (IP3) which 
activates the IP3 receptors (which are ion 
channels) in the SR cause Ca2+ to be released 
into the cytosol. Ca2+ entering the smooth 
muscle cell from the extracellular space does 
so through non­selective cation channels or 
selective Ca2+ channels, which may or may 
not be gated by voltage. To date the most 
important source of extracellular Ca2+ entry 
in vascular smooth muscle is mediated by the 
voltage dependent Ca2+ channels (VDCC). 
The primary VDCC are the long lasting Ca2+ 
channel, so called L­type or Ca
v
1.2 channels, 
which are the clinical targets of the L­type 
channel blockers the dihydropryidines, 
phenylalkamines, benzothiazapenes. More 
recent evidence indicates that a second class 
of VDCC, the transient or T­type Ca2+ 
channels also known as the Ca
v
3.X family 
may be important in mediating Ca2+ entry in 
the microvasculature. As the name suggests 
VDCC are activated by a depolarization 
of the plasma membrane, which increases 
the open probability and overall Ca2+ 
conductance into the cell. In addition, a 
variety of non­selective cation channels have 
the capacity to conduct a variety of ions 
including Ca2+ and Na+ into the smooth 
muscle cell but due to their low conductance 
are currently thought to be more important 
in regulating membrane potential and 
subsequent activation of plasma membrane 
VDCC (Figure 2.3).
Potassium channels
The insulin­dependent electrogenic 3Na+/ 
2K+ ATPase is important in establishing 
the resting membrane potential (E
M
) of the 
vascular smooth muscle cell. However, 
the activation states of several types of K+ 
channels in smooth muscle are also important 
in effecting membrane depolarization and 
hyperpolarisation and consequent smooth 
muscle contraction and relaxation, respectively. 
The inward rectifier K
IR
 channels become 
activated when the membrane becomes 
hyper polarized and beyond the equilibrium 
potential for potassium (E
K
) they transport 
more K+ ions from the extracellular space into 
the cell thereby offsetting or rectifying the 
hyperpolarizing stimulus. However, there are 
few if any physiological conditions in which 
E
M





channels conduct a small outward 
hyperpolarizing K+ current, and therefore 
along with the 3Na+/2K+ ATPase may be 
important in mediating smooth muscle tone. 
The K
V
 family of potassium channels as the 
name suggests are activated by depolarization 
and thus are thought to be an important 
control mechanism to hyperpolarize the 
smooth muscle cell following neural or 
hormonal­mediated depolarization. Agonists 
including histamine acting through the 
H1 receptor have been shown to block the 
4­aminopyridine sensitive K
V




 channels are activated 
by agents including, adenosine, calcitonin gene 
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regulated peptide (CGRP) and vasoactive 
intestinal peptide (VIP). The activation of 
K
ATP
 channels and hyperpolarization medi­
ated vasodilatation is thought to be due in 
part to activation of adenylyl cyclase and 
subsequent cAMP dependent activation of 
protein kinase A. More recent evidence has 
also indicated that K
ATP
 channels become 
activated in a protein kinase C­dependent 
manner. However, perhaps more important is 
the fact that cytosolic ATP and ADP function 
to close and open K
ATP 
channels, respectively. 
This explains part of the mechanism 
underlying the finding that vasculature in 
ischemic tissue, containing high ADP: ATP 
levels extrude K+ in an effort to hyperpolarize 
the membrane and effect vasodilatation. 
Both experimentally and clinically the 
so­called vasodilatory K+ channel openers 
including pinacidil, cromakalim, diazoxide, 
and minoxidil activate K
ATP
 channels. 
Interestingly the antidiabetic sulfonylurea 
drugs, including glibenclamide actually 
inhibit K
ATP
 channels, enabling membrane 
depolarization and activation of VOCC in 
pancreatic beta cells enabling insulin release. 
Consequently overuse of sulfonourea drugs 
may therefore interfere with the efficacy 
of vascular K+ channel openers or directly 
contribute to vasoconstriction. 
The large conductance Ca2+ activated 
potassium channels (BK
Ca
) channels are also 
voltage sensitive but the smaller conductance 
smK
Ca
 channels are less sensitive to voltage. 
This family of K+ channels are activated by 
increases in cytosolic Ca2+ which occurs after 
agonist stimulation, membrane depolarization 
or stretch/pressure­dependent activation of 
Ca2+ entry and therefore is involved in that 
arm of the myogenic mechanism involved in 
hyperpolarization.
G protein coupled receptors (GPCRs) 
trans duce signals from the autonomic nervous 
system and hormonal stimuli including brady­
kinin, noradrenalin, adrenaline, angiotensin II, 
endothelin­1, serotonin and thromboxane A
2
. 
Many GPCRs exhibit divergent subcellular 
signalling mechanisms and there is increasing 
evidence for diversity of subcellular signalling 
amongst vascular beds (Figure 2.3). For 
example, angiotensin II can be generated 
both locally within smooth muscle cells and 
systemically through the renin angiotensin 
system (RAS). In smooth muscle the 
type I AngII receptors are prototypical 
G­protein coupled receptors which couple 
through G
q11. 
Similarly endothelin­1 can 
be generated locally via endothelial cells, 
inflammatory cells or renal sources. Like 
Ang II, endothelin­1 makes use of G
q11
 in 
smooth muscle to activate PLC, releasing 
diacylglycerol (DAG) activating non selective 
cation channels which facilitates membrane 
depolarization and subsequent extracellular 
Ca2+ entry through VGCC. In addition, 
the activation of PLC generates IP3 causing 
SR­mediated Ca2+ release. DAG can also 
activate PKC leading to the phosphorylation 
of CPI­17 which specifically inhibits myosin 
phosphatase, favouring phosphorylation of 
the LC
20
 of myosin and vasoconstriction 
(Figure 2.3). However, in contrast to AngII, 
endothelin­1 also activates G
13
 coupled 
receptors activating the RhoA/ Rho associated 
kinase which leads to a direct inhibitory 
phosphorylation of myosin phosphatase, 
again favouring contraction (Figure 2.3). 
ENDOTHELIAL REGULATION 
OF SMOOTH MUSCLE 
VASODILATATION
Nitric oxide is a potent vasodilator generated 
in the endothelium which has many and 
varied effects in the vasculature including 
attenuating: platelet adhesion and aggre­
gation, cellular proliferation, and vaso­
constriction. A common theme underlying 
the influence of nitric oxide is activation 
of guanylyl cyclase, formation of cGMP, 
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activation of protein kinase G and con­
sequent activation of K+ channels effect­
ing K+ removal from the cell leading to 
membrane hyperpolarization and con­
sequent inactivation of VDCC favoring 
low intracellular Ca2+ and vasorelaxation. 
Cyclooxygenase activation in endothelial 
cells also leads to generation of prostaglandin 
PGI
2
 which leads to receptor mediated 
activation of adenylyl cyclase, generation of 
cAMP, subsequent activation of PKA and 
inhibition of K+ channels (Figure 2.4). 
SMOOTH MUSCLE 
PROLIFERATION AND VASCULAR 
REMODELLING
In the normal adult vascular wall most 
vascular smooth muscle cells subserve a 
contractile function to directly modulate 
vaso constriction and vasodilatation. However, 
during development, following injury or in 
the presence of growth factors and mitogens, 
including inflammatory cytokines and 
oxidized lipids, vascular smooth muscle can 
undergo phenotypic modulation. Vascular 
smooth muscle phenotypic modulation 
involves a partial down regulation of the 
proteins that activate the contractile apparatus 
in favour of the synthetic and proliferative 
cellular machinery i.e., the cell increases 
the abundance of; endoplasmic reticulum, 
ribosomes for protein synthesis and the 
density of the Golgi apparatus. So called 
synthetic vascular smooth muscle cells are 
therefore able to undergo very active protein 
and DNA synthesis, cell division, and in 
pathological settings are capable of taking up 
large amounts of oxidized and nonoxidized 
lipids which can contribute to lipid loading of 
vascular smooth muscle cells and the formation 
of so­called foam cells in the vascular wall. As 
the name foam cell suggests, under microscopic 
examination lipid laden smooth muscle cells 
appear much like foam. Synthetic vascular 
smooth muscle cells also secrete, external to 
the cell, a great deal of extracellular matrix 
including the proteins; collagen I, III, IV, 
and the proteoglycans, perlican, hyaluronan, 
laminin. Proliferative smooth muscle cells also 
secrete or associate with the membrane surface 
several, matrix metalloproteinases (MMPs) 
and their corres ponding tissue inhibitors of 
matrix metalloproteases (TIMPs) to enable 
correct repair and remodelling of growing or 
damaged vessels. Evidence exists that a chronic 
excess of inflammatory cytokines and growth 
factors can cause dysregulation of both 
MMPs and TIMPs which can contribute 
to inappropriate vascular remodelling. This 
remodelling plays a significant role in the 
progression of vascular stenosis, restenosis 
following mechanical interventions, the 
progression of unstable atheroma, and 
aneurysmal dissection and rupture.
Figure 2.4: outlines the major influences of prostaglandin I
2
 and nitric oxide (NO) in regulating the 
activation state of various K+ channels leading to hyperpolarization of smooth muscle cells and vasodilatation.
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At this point it is worth noting that 
proliferative smooth muscle cells have an 
attenuated response to vasoconstrictors and 
vasodilators, probably due to the down 
regulation of the contractile apparatus and 
certain elements of the subcellular signalling 
machinery that is involved in vasoconstriction. 
However, many of the ligands that normally 
lead to vasoconstriction, for example, 
noradrenalin, angiotensin II and endothelin 
also function to promote smooth muscle 
proliferation both in the context of cellular 
hypertrophy and hyperplasia. Platelet derived 
growth factor (PDGF), is a potent smooth 
muscle cell mitogen and growth stimulant 
and contributes to normal vessel repair while 
chronically elevated levels, for example, 
generated from unstable thrombus, can 
contribute to proliferative vascular disorders. 
Interestingly nitric oxide, in addition to 
functioning as a potent vasodilator also 
limits smooth muscle hyperplasia and hyper­
trophy, probably by limiting intracellular 
Ca2+ and associated Ca2+dependent vascular 
proliferation.
SUMMARY
It is clear from the preceding that there is a 
dynamic interplay between cellular Ca2+ entry 
from the extracellular space mediated by 
membrane depolarization and the activation 
of voltage dependent Ca2+ channels. 
Extracellular Ca2+ entry can be offset by the 
activation of K+ channels through either 
endothelial nitric oxide­cGMP/PKG­ or 
PGI2­cAMP/PKA­dependent mechanisms, 
both of which function to limit smooth 
muscle contraction and proliferation. 
However, the simple fact that L­type Ca2+ 
channel blockers and nitric oxide treatment 
are limited in their ability to effectively 
manage several disorders of hypercontractility 
suggests that the additional mechanisms 
including; SR Ca2+ release and regulation 
of myosin phosphatase are also important 
targets for future therapeutic development.
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Atherosclerosis, the principal cause of heart 
attack, stroke, and peripheral vascular disease, 
remains a major contributor to morbidity 
and mortality in the Western World. Disease 
progression is slow, beginning in childhood 
and usually becoming clinically manifest in 
middle age or later. Although the aetiology 
of atherosclerosis is not fully understood, 
it is generally accepted that atherosclerosis 
is a multifactorial disease induced by the 
effects of various risk factors on appropriate 
genetic backgrounds1. Many risk factors, 
such as hypercholesterolemia, modified lipo­
proteins, hypertension, diabetes, infections 
and smoking have been identified in the 
development of atherosclerosis. 
Atherosclerosis has been the focus of 
intense research for over 100 years. Since 
Anitschkow and Chalatow first reported 
that cholesterol can cause atherosclerosis, 
many investigators have intensively studied 
the role of blood cholesterol in the patho­
genesis of atherosclerosis. Although formerly 
considered a bland lipid storage disease, new 
insights into the pathogenesis of atheroscle­
rosis have emerged during the last decades, 
due to the progress of cellular and molecular 
approaches to the study of cell interactions 
in the arterial wall as well as alterations of 
lipid metabolism. These new insights were 
broadly summarized in three main theories, 
i.e. the ‘response to injury’,2 ‘oxidized low­
density lipoprotein (LDL)’, and ‘inflamma­
tion’1 hypotheses. 
The response to injury hypothesis2 relies 
on the concept that the primary cause of 
atherosclerosis is an injury to the arterial 
endothelium induced by various factors, 
i.e. smoking, mechanical stress, oxidized­
LDL, homocysteine, immunological events, 
toxins, viruses, etc. The oxidized­LDL 
hypothesis postulates that LDL oxidized by 
various factors including endothelial cells, 
macrophages and smooth muscle cells of the 
arterial wall, plays a key role in the devel­
opment of atherosclerosis. More recently, a 
widely accepted hypothesis is that athero­
sclerosis is an inflammatory disease, because 
recent advances in the basic science have 
established a fundamental role for inflam­
mation in mediating all stages of this disease 
from initiation through progression and, 
ultimately, the thrombotic complications 
of atherosclerosis.1 The aim of the present 
chapter is to summarize the data from a vari­
ety of research areas providing an overview 
of atherosclerosis focusing on mechanistic 
studies.
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ATHeROSCLeROTIC LeSIONS
The intima of large and medium sized 
arteries is composed of a monolayer of 
endothelial cells and matrix proteins and 
occasional smooth muscle cells in the sub­
endothelial space (Figure 3.1a). The media of 
the vessel contains smooth muscle cells and 
the elastic lamina built by matrix proteins, 
while the main component of adventitia is 
connective tissue. With increasing age, the 
diseased arterial wall slowly thickens and 
develops focal lesions of lipid accumulation 
in the intima. These early lesions are known 
as fatty streaks and are thought to be the sites 
of predisposition to advanced lesions called 
atherosclerotic plaques or atheroma, which 
may lead to clinical symptoms in certain 
circumstances. 
Fatty streaks 
Fatty streaks are generally the lesion types 
found in children, although they may also 
occur in adults. These lesions represent 
the early changes of atherosclerosis and are 
recognized as an increase in the number 
of intimal macrophages filled with lipid 
droplets (foam cells). A larger lesion which 
can be grossly visible is characterized by 
layers of macrophage foam cells and lipid 
droplets within intimal smooth muscle cells 
and minimal coarse­grained particles and 
heterogeneous droplets of extracellular lipid 
(Figure 3.1b). With the progression of lesion 
development, intermediate lesions as des­
cribed by pathologists, are the morphological 
and chemical bridge between fatty streaks 
and advanced lesions. These lesions appear 
in some adaptive intimal thickenings 
(progression­prone locations) in young 
adults and are characterized by pools of 
extracellular lipid in addition to other 
components of fatty streak lesions. The 
fatty streak is largely clinically benign, but 
is the precursor to later, clinically relevant 
lesions.
Plaque or atheroma 
The advanced lesion, a dense accumulation 
of extracellular lipid, known as the lipid core, 
occupies an extensive but well­defined region 
of the intima.3 No increase in fibrous tissue 
and complications such as defects of the lesion 
surface and thrombosis are present at this 
stage of disease. This atherosclerotic plaque 
is also known as atheroma (Figure 3.1c). 
The characteristic core appears to develop 
from an expansion and confluence of the 
small isolated pools of extracellular lipid that 
characterize atheroma. between the lipid 
core and the endothelial surface, the intima 
contains macrophages, smooth muscle cells, 
lymphocytes and mast cells. Capillaries 
surround the lipid core, particularly at 
the lateral margins and facing the lumen. 
Frequently macrophages, macrophage foam 
cells, and lymphocytes are more densely con­
centrated in the lesion periphery. Much of the 
tissue between the core and the surface endo­
thelium corresponds to the proteogly can­rich 
layer of the intima, although infiltrated with 
the cells just described. Advanced lesions may 
or may not narrow the arterial lumen, nor be 
visible by angiography, nor produce clinical 
manifestations. Such lesions may be clinically 
significant even though the arterial lumen is 
not narrowed, because complications may 
develop suddenly.3
In addition, two types of athero­
sclerotic plaques, i.e. ‘vulnerable’ and 
‘stable’ plaques, have been recognized.4 
Vulnerable plaques often have a well­
preserved lumen, since plaques remodel 
outward initially. The vulnerable plaque 
typically has a substantial lipid core and 
a thin fibrous cap separating the throm­
bogenic macrophages bearing tissue 
factor (TF) from the blood. At sites of lesion 
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disruption, smooth muscle cells are often 
activated, as detected by their expression of 
the transplantation antigen HLA­DR. In 
contrast, the stable plaque has a relatively 
thick fibrous cap protecting the lipid core 
from contact with the blood. Clinical data 
suggest that stable plaques more often 
show luminal narrowing detectable by 
angio graphy than do vulnerable plaques, 
but with much less chance of rupture.
HYPeRCHOLeSTeROLeMIA 
AND OXIDISeD­LDL
Accumulating evidence suggests a causal 
relationship between blood cholesterol 
and atherosclerosis. blood cholesterol 
is carried by lipoproteins, including 
LDL, very low­density lipoprotein and 
high­density lipoprotein (HDL). LDL 
is believed to be ‘bad’ lipoprotein, while 
HDL is ‘good’ and plays a protective role 
in atherogenesis.5 It is established that 
familial hypercholesterolemia related to 
increased LDL levels causes premature 
atherosclerosis and heart disease,6 whereas 
non­genetic hypercholesterolemia is 
also associated with the development of 
atherosclerosis. The consensus of many 
trials using different cholesterol­lowering 
regimens indicate that for every 10% 
reduction in cholesterol level, the deaths 
of patients with coronary heart disease 
is reduced by at least 15%. It has been 
assumed that the reduction in adverse 
clinical events when plasma cholesterol 
levels are decreased is directly related to 
the magnitude of the cholesterol lowering. 
That assumption is supported by the 
fact that the benefit relates to the change 
in cholesterol level in much the same way 
whether the cholesterol lowering is achieved 
with diet or with drugs. These findings 
suggest that blood cholesterol exerts its role 
in the pathogenesis of atherosclerosis.
LDL can be modified by oxidation in vivo 
and in vitro and is detectable in the circu­
lation as well as in atherosclerotic lesions. 
In vivo, the rate of production of oxidized­
LDL in the arterial intima is a function of 
Figure 3.1: Sections of rabbit arterial wall. Rabbits 
were fed with a standard chow-diet (a) or cholesterol-
enriched diet (0.2%) for 3 weeks (b) or 16 weeks 
(c). Their aortas were harvested and sections 
prepared and stained with hematoxilin and eosin. 
Arrows indicate the internal elastic lamina, the border 
between the intima and media of the arterial wall.
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the concentration of native LDL present. 
The mechanism whereby hypercholestero­
lemia and oxidized­LDL trigger events lead­
ing to the generation of early atherosclerotic 
lesions i.e. fatty streak (Figure 3.2) remains 
uncertain. Although rabbits and pigs were 
often used in studying this issue, the apoli­
poprotein (apo) e–deficient mouse7 and the 
LDL receptor­deficient mouse have become 
preferred animal models. Deletion and over­
expression of genes in animal models is now 
the gold standard for critically testing the 
relevance of candidate genes in atherogen­
esis. by using these models, it was observed 
that one of the earliest responses induced 
by hypercholesterolemia and oxidized­LDL 
is an increase in the expression of vascular 
cell­adhesion molecule­1 (VCAM­1), a 
key adhesion molecule for monocytes and 
T cells, on the endothelial surface lining 
the major arteries.8 Oxidized­LDL is itself 
directly chemotactic for monocytes and 
T cells, and can also be cytotoxic for endo­
thelial cells, mitogenic for macrophages and 
smooth muscle cells and stimulate the release 
of monocyte chemoattractant protein­1 
(MCP­1) and monocyte colony­stimulating 
factor (M­CSF) from endothelial cells. The 
oxidative modification hypothesis has been 
extensively reviewed.9.
Oxidized­LDL can account for the load­
ing of macrophages with cholesterol. Here, 
monocytes undergo phenotypic modification 
and take up oxidized­LDL to become foam 
cells, loaded with multiple cytoplasmic drop­
lets containing cholesterol esters.10 Recently 
there has been considerable progress in iden­
tifying the components of oxidized­LDL 
that make it a ligand for scavenger receptors. 
extensive degradation of the polyunsatu­
rated fatty acid (PUFA) in the sn­2 position 
of phospholipids by oxidation seems to 
be essential. Moreover, oxidized­LDL and 
apoptotic cells compete for binding to 
macrophage scavenger receptor, indicating 
that oxidized phospholipids in the mem­
branes of apoptotic cells are involved in their 
binding to macrophage scavenger receptors. 
Therefore, oxidized­LDL promotes foam 
cell formation that forms the earliest lesions 
in the intima, which may progress to 
advanced lesions in the presence of other 
pro­atherogenic factors (Figure 3.2).
High-density lipoproteins role in 
atheroprotection
It has been known for many years that the 
plasma concentration of HDL­C correlates 
inversely with the incidence of cardiovascular 
disease. The Framingham Heart Study showed 
that people whose HDL­C was less than 
35 mg/dL (0.91 mmol/L) at the beginning 
of the study had a future coronary risk more 
than eight times that in subjects whose 
HDL­C concentration was greater that 
65 mg/dL (1.68 mmol/L).11 In the more 
Figure 3.2: Schematic representation of the 
role of oxidized-LDL (oxLDL) in atherogenesis. 
Oxidized-LDL generated either locally or systemically 
stimulates endothelial cells (EC) expressing 
adhesion molecules, including ICAM-1, VCAM-1 
and E-selectin, which are responsible for adhesion 
of blood mononuclear cells. Oxidized-LDL is a 
chemokine for T lymphocytes (T), monocytes (M) 
and smooth muscle cells (S), and promotes foam 
cell (FC) formation, which form the early lesion fatty 
streak. 
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recent Prospective Cardiovascular Munster 
(PROCAM) Study, men with an HDL­C 
concentration of less than 35 mg/dL 
(0.91 mmol/L) at baseline were shown to 
have a four times greater risk, at six years, 
than men whose HDL­C concentration was 
greater than 35 mg/dL (0.91 mmol/L).12 In 
both studies, the risk associated with lower 
plasma HDL­C concentration was inde­
pendent of LDL­C concentration. HDLs 
have several properties that contribute to their 
ability to protect against the development of 
atherosclerosis.
The best known mechanism of athero­
protection relates to the ability of HDLs 
to promote efflux of cholesterol from foam 
cells. This process inhibits the progression 
of, and potentially promotes the regression of, 
atherosclerosis.13 High­density lipopro­
teins can also inhibit the oxidative modi­
fication of LDLs and thus reduce their 
atherogenicity. The principle mechanism 
of this anti­oxidant function resides with 
the presence of para­oxonase enzyme resid­
ing in the HDL particle,14,15 although the 
main apolipoprotein, apolipoprotein AI 
(ApoAI), has also been demonstrated to 
have anti­oxidant capacity.16 Conceivably, 
the earliest observable cellular dysfunc­
tion in the normal blood vessel, leading 
to atherogenesis, is the expression of leu­
kocyte adhesion molecules and chemok­
ines. Many studies, both in vivo and in 
vitro have shown that HDLs can inhibit 
expression of endothelial cell adhesion 
molecules and MCP­1.17­20 endothelial 
dysfunction, and subsequent platelet acti­
vation and aggregation are key elements of 
the progression of atherosclerotic plaque 
formation. The ability of HDLs to be anti­
thrombotic was demonstrated by the abil­
ity to induce prostacyclin (PGI
2
) synthesis, 
via induction of cyclo­oxygenase 2,21 and 
in addition to stimulate the generation of 
nitric oxide,22 thus reducing the endothelial 




Hypertension is a well­established risk 
factor for atherosclerosis.23 Clinical trials 
have shown that, in the highest quintile 
for diastolic pres sure, hypertension still 
contributes signifi cantly to the risk of 
atherosclerosis, even with the added 
risks of high cholesterol and smok ing. 
Induction of hypertension in the Watanabe 
heritable hyperlipidemic rabbit showed a 
synergistic effect, causing intensification of 
atherosclerosis. The fact that atherosclerotic 
lesions preferentially occur in the areas 
where hemodynamic or biomechanical stress 
is altered, e.g. bifurcation of the arteries, 
supports the idea that hypertension exerts 
its role in the pathogenesis of atherosclerosis 
via altered mechanical stress to the vessel 
wall. 
In vivo, the vessel wall is exposed to two 
main hemodynamic forces or biomechani­
cal stress: shear stress, the dragging frictional 
force created by blood flow, and mechanical 
stretch, a cyclic strain stress created by blood 
pressure.24 Shear stress stimulates endothelial 
cells to release nitric oxide and prostacyclin,25 
resulting in vessel relaxation and protection 
of vascular cells, whereas smooth muscle 
cells are stimulated by cyclic strain stress. In 
humans, atherosclerotic lesions occur prefer­
entially at bifurcations and curvatures where 
hemodynamic force is disturbed, i.e. lower 
shear stress and higher mechanical stretch. 
Although veins do not develop spontane­
ous atherosclerosis­like lesions, accelerated 
atherosclerosis occurs rapidly in venous 
bypass grafts, which bear increased bio­
mechanical forces due to alterations in blood 
pressure, i.e. vein (0­30 mm Hg) vs. artery 
(120 mm Hg). This finding supports the 
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hypothesis that mechanical stress could be a 
crucial factor in the pathogenesis of athero­
sclerosis.
The mechanism whereby mechanical 
forces are sensed by cells and transmitted 
through intracellular signal transduction 
pathways to the nucleus resulting in quan­
titative and qualitative changes in gene 
expression in the vessel wall is not fully 
understood. However, recent evidence 
indicates that mechanical stretch initiates 
intracellular  signal pathways, especially 
mitogen­activated protein kinase (MAPk) 
cascades26 which are thought to play a piv­
otal role in transmitting transmembrane 
signals required for cell proliferation, differ­
entiation and apoptosis. MAPks comprise 
a ubiquitous family of tyrosine/threonine 
kinases, and include extracellular signal­
regulated kinases (eRks), stress­activated 
protein kinases (SAPks) or c­Jun NH2­ter­
minal kinases (JNks), and p38 MAPks.27 
They are highly activated or expressed in 
atherosclerotic lesions and vessel wall stimu­
lated by acute hypertension.28
Biomechanical stress-induced cell 
death
While biomechanical force at physiological 
levels is essential to develop and maintain 
organic structure and function, at elevated 
levels mechanical stretch may result in cell 
death leading to pathological conditions. 
In recent years, however, it has become 
widely recognized that cell death, namely 
apoptosis, is not just a response to injury but 
a highly regulated and controlled process. 
Disturbances in the regulatory mechanisms 
of apoptosis often precede the development 
of atherosclerosis. exploration of the 
molecular signalling mechanisms leading 
to mechanical stress­induced apoptosis in 
cardiovascular disorders has revealed the 
crucial role of apoptosis in the pathogenesis 
of atherosclerosis.29 Recent data focussing 
on the molecular mechanisms of mechanical 
stress­induced apoptosis are summarised 
and the role of apoptosis in the development 
of atherosclerosis is highlighted. 
Recently, the first mouse model of vein 
graft atherosclerosis was established by 
grafting autologous jugular vein or vena 
cava to carotid arteries in wild­type and 
apoe­deficient mice. In many respects, the 
morphological features of this murine vas­
cular graft model resemble those of human 
graft atherosclerosis (Figure 3.3). Apoptosis 
occurred mainly in veins grafted to arteries, 
remaining unchanged in vein­to­vein 
grafts.30 The veins grafted to arteries were sub­
jected to increased biomechanical forces in the 
form of stretch stress due to blood pres­
sure. When mouse, rat and human arterial 
smooth muscle cells cultured on a flexible 
membrane were subjected to cyclic strain 
stress, apoptosis was observed in a time­ and 
strength­dependent manner. Mechanical 
stretch resulted in p38 MAPk activation. 
Smooth muscle cell lines stably transfected 
with a dominant negative rac, an upstream 
signal transducer, or overexpressing MAPk 
phosphatase­1, a negative regulator for 
MAPks, completely inhibited mechanical 
stress­stimulated p38 activation, and abol­
ished mechanical stress­induced apopto­
sis.31 Interestingly, p53­deficient vein grafts 
had lower levels of apoptosis that correlated 
with increased atherosclerotic lesions.32 
The sudden elevation in mechanical forces 
could be a strong stimulus to the grafted 
vessel wall and may result in activation 
of intra cellular signal pathways leading to 
gene expression and cell death. Thus, one 
of the earliest events in vein graft athero­
sclerosis is apop tosis, in which mechanical 
stress­induced p38­MAPk­p53 activation 
is, at least in part, responsible for transduc­
ing signals leading to apoptosis.
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Biomechanical stress and 
inflammation 
Vein graft atherosclerosis has an inflammatory 
nature characterized by mononuclear cell 
infiltration followed by smooth muscle cell 
proliferation. It has been postulated that 
biomechanical stress plays a role in adhesion 
molecule expression via MAPk signal 
transduction pathways, leading to NF­κb 
activation. Supporting this concept is the 
fact that neointimal lesions of vein grafts in 
intercellular adhesion molecule (ICAM)­1 ­/­ 
mice were reduced from 50% to 30% com­
pared to wildtype controls. ICAM­1 is critical 
in the development of venous graft athero­
sclerosis. It has been established that exposure 
of endothelial cells to shear (mechanical) stress 
results in increased expression of ICAM­1 and 
monocyte chemotactic protein­1 (MCP­1) 
via activation of transcription factor NF­κb 
and AP­1. These molecules are essential for 
leukocyte­endothelial cell interaction and 
subsequently cell infiltration, characteristic of 
the early lesions of vein grafts that undergo 
elevated blood pressure. Interestingly, mech­
anical stress also leads to smooth muscle 
cells expressing ICAM­1 via activation of 
NF­κb. In animal models, smooth muscle 
cells express ICAM­1 which is associated 
with monocyte/macrophage accumulation 
in vein grafts. Smooth muscle cells of 
ICAM­1 ­/­ mice do not express ICAM­1 
which is correlated with reduced early lesions.33 
Mechanical stress­induced adhesion molecules 
and chemokine expression in the vessel wall 
could be important for the inflammatory 
response.
Figure 3.3: Hematoxilin and eosin-stained sections of arterialized mouse vein grafts. Under anesthesia, 
vena cava veins were removed and isografted into carotid arteries (of control mice)(a) of apoE-/- mice (b). 
Animals were sacrificed 8 weeks after surgery, and the grafted tissue fragments fixed in 4% phosphate-
buffered (pH 7.2) formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin-eosin.  
Panel c is a photograph of vein graft section with higher magnification. Smaller arrow indicates a foam cell, 
and larger one indicates cholesterol crystal structure. lu indicates the lumen of the vessel.
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Biomechanical stress-induced smooth 
muscle cell proliferation 
It has been established that mechanical stress 
stimulates DNA synthesis and the prolifer­
ation of in vitro cultured smooth muscle 
cells. Hypertension increases mechanical 
force on the arterial wall up to 30%, resulting 
in marked alterations in signal transduction 
and gene expression in smooth muscle cells, 
which contribute to matrix protein synthesis, 
cell proliferation and differentiation.23 
Recently, several reports demonstrated that 
angioplasty resulted in stretching of the 
arterial wall leading to rapid activation of 
the MAPks in the regenerating carotids.34 The 
magnitude of extracellular signal­regulated 
kinase p42 (eRk42) activation positively 
correlated with the degree of balloon injury 
to the arterial wall. Ex vivo stretching of the 
vessel wall also induced significant activation 
of eRk42 kinases. These findings suggested 
that the kinase activation in the early phase 
following injury may be due to mechanical 
stimulation of the vessel wall.
In cultured smooth muscle cells, mechan­
ical forces evoked eRk activation followed 
by enhanced DNA­binding activity of tran­
scription factor AP­1. Interestingly, physi­
cal forces rapidly result in phosphorylation 
of platelet­derived growth factor (PDGF) 
receptor,35 epithelial growth factor receptor 
and vascular endothelial growth factor recep­
tor. Thus, mechanical stresses may directly 
perturb the cell surface or alter receptor 
conformation, thereby initiating signalling 
pathways normally used by growth factors. 
Suramin, a non­specific PDGF inhibitor, 
has been shown to be a growth factor recep­
tor antagonist that inhibits cell proliferation. 
When vein isografts in mice were treated 
ex vivo and in vivo with suramin, intimal 
lesions were reduced up to 70% compared 
to untreated controls. The mechanism of 
suramin­inhibited neointimal hyperplasia 
mainly involves inhibition of smooth muscle 
cell migration and proliferation via blocking 
PDGF receptor­MAPk­AP­1 signal path­
ways. Thus, research into biomechanical 
stress­regulated gene expression in athero­
sclerosis using these models could lead to a 
new therapeutic strategy in the treatment of 
this disease in humans.
INFeCTIONS AND HeAT SHOCk 
PROTeINS
Risk factors, such as high blood cholesterol, 
hypertension and smoking only explain 
a proportion of the incident cases of all 
atherosclerosis. There is a body of evidence 
that microorganisms play a role in the 
pathogenesis of atherosclerosis and may 
be a primary risk factor in people who 
do not suffer from other established risk 
factors. Accumulating evidence suggests that 
infectious organisms reside in the wall of 
atherosclerotic vessels, including cyto–
megalovirus (CMV) and Chlamydia (C) 
pneumoniae. Seroepidemiological studies 
demon strate an association between the 
pathogen­specific IgG antibodies and 
athero sclerosis.26,27 However, the data are 
inconsistent, with other studies showing no 
increased risk for atherosclerosis.38,39 One 
possible explanation for this disparity is that 
infections contributing to atherosclerosis risk 
may depend, at least in part, on the host’s 
response to the pathogen, i.e. inflammatory 
and immune reactions. 
Infections 
Several papers reviewing the infections, 
ie C.pneumoniae, H.pylori and CMV and 
atherosclerosis have been published37 and 
these will be summarised. Saikku et al40 was 
first to show a link between C.pneumoniae 
infection, coronary artery disease and athero­
sclerosis. Since then, many studies have 
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shown an association of C.pneumoniae with 
atherosclerosis. In vitro experiments have 
shown a preferential and specific attraction 
to and infection of macrophages, vascular 
endothelium and vascular smooth muscle, 
by C.Pneumoniae, thus resulting in their 
accumulation into atherosclerotic plaques.
This is supported by studies of post­mortem 
specimens of vascular tissue which found a 
high correlation between the distribution 
of atherosclerosis and C.pneumoniae41 and 
other organisms. 
H.pylori, another gram negative bacte­
ria which typically infects human gastric 
epithelial cells has been demonstrated in 
atherosclerotic plaques.38 Sero­positivity to 
H.pylori was implicated as a risk factor in 
coronary heart disease (CHD) from the first 
report in 1994. However a meta­analysis39 
of 18 studies failed to show any correlation 
between sero­positivity against H.pylori and 
the pres ence or extent of CHD. Although the 
evidence supporting involvement of H.pylori 
in atherogenesis is not conclusive, it may 
be important to differentiate between viru­
lent and avirulent strains of H.pylori to 
determine the effects on atherogenesis. 
Mayr et al42 conducted a population based 
study and investigated the effects of CagA 
(cytotoxin­associated gene A) positive and 
CagA negative strains of H.pylori. This 
study concluded that there was an increased 
risk of athero sclerosis in individuals who 
were infected with CagA positive strains of 
H.pylori. Another group has obtained similar 
results, indicating the role of this strain in 
the pathogenesis of atherosclerosis.
Heat shock proteins
The role of HSPs in disease with regard to 
their physiological functions and pathological 
involvement have been described in many 
reviews on the subject. The HSP family of 
proteins is subdivided into groups based 
on their molecular weight (e.g. HSP60 
is a 60kDa protein) and are produced by 
almost all cells and play an important role 
in the organism’s general protective response 
to environmental and metabolic stresses 
(Table 3.1). They exist in all major cellular 
compartments. For example, HSP10, 
HSP60 and HSP75 are mainly located 
in mitochondria, while others are found in 
different compartments throughout the cell. 
They have important physiological functions, 
primarily as a molecular chaperone.7 HSPs 
also appear to be important in preventing 
cellular damage during repair processes 
following injury. evidence indicates that 
HSPs may be autoantigens in some circum­
stances.43 HSP47, HSP60 and HSP70 have 
been identified as being involved in the 
pathogenesis of atherosclerosis.44
Infections and HSP expression 
In a recent study, increased HSP60 was 
demonstrated on the endothelium, smooth 
muscle cells, and mononuclear cells of all 
atherosclerotic carotid and aortic specimens, 
whereas vessels with normal intima showed 
no detectable expression of this HSP. The level 
of HSP60 expression positively correlated 
with atherosclerotic severity.45 Interestingly, 
chlamydial and human HSP60s have been 
shown to be co­expressed in atherosclerotic 
lesions. These data support the concept that 
elevated HSP expression in lesions may be 
induced by the pathogen Chlamydiae species. 
During its normal cycle generating infectious 
progeny, Chlamydiae express basal levels of 
HSP. During the lytic phases of chlamydial 
infection, host cells release their own HSP60, 
and also chlamydial HSP60 that has been 
produced by these microorganisms. Soluble 
HSP60 (sHSP) levels were significantly 
elevated in subjects with prevalent/incident 
carotid atherosclerosis and correlated to 
intima­media thickness independent of 
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age, sex and other risk factors. Interestingly, 
sHSP60 was also correlated with anti­LPS, 
anti­Chlamydia and anti­HSP60 antibodies, 
inflammation markers and chronic 
infections. 
Infections, sHSP and innate 
immunity
Infectious agents contribute to atherogenesis 
in a variety of ways. One mechanism is 
by triggering innate immune reactions 
leading to inflammatory responses. Innate 
immunity involves several different cell 
types, e.g. mononuclear phagocytes and 
endothelial cells. both endothelial cells and 
macrophages express receptors that recognize 
molecular epitopes from a broad range of 
pathogens. These receptors include various 
scavenger and Toll­like receptors (TLRs). 
So far more than 10 human TLRs have 
been identified. A variety of bacterial and 
fungal components are known TLR ligands, 
including peptidoglycan for TLR2, LPS for 
TLR4, flagellin for TLR5, and unmethylated 
CpG (cytosine and guanine separated by 
a phosphate group, which links the two 
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DNA for TLR9. It is possible that TLRs 
may be collectively responsible for detecting 
a large range of microbial pathogens. TLRs 
are evolutionarily conserved innate immune 
receptors that are shared by IL­1 receptor 
signalling to activate the NF­κb pathway 
and release inflammatory cytokines. TLR 
ligation therefore induces expression of a 
wide variety of genes such as those encoding 
proteins involved in leukocyte recruitment, 
production of reactive oxygen species, 
and phagocytosis. Activation of TLRs will 
also elicit the production of cytokines that 
augment local inflammation. Finally, TLR 
ligation may directly induce apoptosis, 
probably of key importance in the first line 
of defence.46 
expression of TLR4 in atherosclerotic 
plaques has been found, preferentially in 
lipid­rich and macrophage­infiltrated areas 
of lesions. In vitro, basal expression of mac­
rophage TLR4 was shown to be up­regulated 
by oxidized­LDL. In addition, of the nine 
TLRs, expression of TLR1, TLR2, and 
TLR4 was shown to be markedly enhanced 
in human atherosclerotic plaques. A poly­
morphism or mutation of TLR4 was shown 
to be strongly correlated with the incidence 
and development of atherosclerosis in a large 
population study (bruneck Study). Surpris­
ingly, several groups reported that recom­
binant HSP60 and HSP70 from bacteria 
and humans specifically bind to TLR4 in 
macrophages, endothelial cells and smooth 
muscle cells. Recombinant HSP60 bind­
ing to the TLR4/CD14 complex of macro­
phages and endothelial cells led to activation 
of MyD88­NF­kb pathways. HSP70 and 
mycobacterial HSP65 have a similar bind­
ing activity to TLR4/CD14 that initiates 
MyD88­NF­κb signal pathways, suggest­
ing that the TLR4/CD14 is a receptor for 
several HSPs that mediate the signal path­
ways leading to proinflammatory responses 
during infections.
In summary, infections with proathero­
genic organisms may be important in indi­
viduals lacking additional risk factors as well 
as acting synergistically with established risk 
factors. In this process, HSP may be a link 
between infections and the pathogenesis of 
atherosclerosis. Infectious agents may exert 
their role by producing their own HSPs 
and inducing host production which could 
be released into blood. The soluble form of 
HSPs contact endothelial cells and immune 
cells where innate immune responses are 
initiated. Innate immune reactions to HSPs 
result in proinflammatory responses in the 
vessel wall. Together, infections via HSPs 
contribute to the development of athero­
sclerosis (Figure 3.4). 
Figure 3.4: Schematic representation of the likely 
mechanism of action of heat shock proteins (HSPs) 
in the development of atherosclerosis in response to 
risk factors (stressor), e.g. infections. TLR, Toll-like 
receptor; APC, antigen-presenting cells.
Mechanisms of Vascular Disease36
IMMUNe ReSPONSeS
The contribution of immune responses 
to the pathogenesis of atherosclerosis has 
been recognized and much progress in this 
research field has been achieved through 
the participation of many investigators.47 
Involvement of the immune system in 
atherogenesis is supported by recent data, 
including the occurrence of granular deposits 
of immunoglobulins and co­distributed 
complement components, increased expression 
of C3b receptors (CR1) and C3b1 receptors 
(CR3) on macrophages within atherosclerotic 
lesions, but not in unaltered vessels. However, 
b cells are only found in very low numbers in 
various stages of atherosclerotic lesions, and the 
site of production for these immunoglobulins 
must, therefore, be sought elsewhere. Other 
than these humoral immune phenomena, 
it is now clear that T cells are among the 
first cells infiltrating the intima of arteries 
during the earliest stages of atherosclerosis, 
most probably before monocytes. A majority 
of these early T cells are CD4+, HLA­DR+ 
and interleukin­2 receptor+ (IL­2R+), i.e. 
activated. Others have shown that T cells in 
late atherosclerotic plaques express the low 
molecular variant of the leukocyte common 
antigen (CD45RO) and the integrin very 
late activation antigen­1 (VLA­1). Hansson 
and his group analyzing the rearrangement 
of T cell receptor (TCR) genes in these 
latter cells derived from advanced lesions, 
showed that they represent a polyclonal 
population rather than displaying restricted 
T­cell receptor TCR usage. These findings 
support the role of the immune system in 
atherogenesis.
MHC class II antigen and T cells
Regardless of which antigen these lympho­
cytes may recognize, it seems improbable that 
endothelial cells (eC) which aberrantly express 
major histocompatibility complex (MHC) 
class II antigens act as primary antigen­
presenting cells for T cell sensitization. MHC 
class II expression by eC occur concomitantly 
where T cells are found, and thus production 
of gamma­interferon (IFNγ), the major 
T­cell chemokine, is present in the intima 
directly beneath these areas. Therefore, it 
can be concluded that the expression of 
MHC class II molecules by endothelial 
cells represents a secondary rather than a 
primary phenomenon. The large majority 
of CD3+ cells in the mononuclear infiltrate 
in atherosclerotic lesions expresses TCRα/β, 
but an unexpectedly high proportion also 
express TCRγ/δ. While the latter type 
of cell only constitutes approximately 1 % of 
leukocytes in peripheral blood, enrichment 
to 10 % or more within early atherosclerotic 
lesions has been observed. The majority of 
these latter cells express the TCRγ2 chain, 
i.e. resemble the TCRγ/δ+ population found 
in the intestinal mucosa. On the other hand, 
TCR Vγ9δ2+ cells characteristic of circulat­
ing TCRγ/δ+ cells are not proportionally 
increased in the intima. Finally, endothelial 
cells and leukocytes express and synthesise 
a variety of immunological­inflammatory 
mediators, occurring in atherosclerotic lesions. 
Among others, these include interleukin­1 
(IL­1), tumour necrosis factor α (TNFα), 
lymphotoxin, IL­2, IL­6, IL­8, monocyte­
chemotactic peptide­1 and IFNγ1. Together, 
these molecules can modulate the local 
cellular immune response within emerging 
atherosclerotic lesions. 
Oxidized-LDL as a candidate antigen 
T cells isolated from human atherosclerotic 
plaques were shown to be specifically reactive 
to oxidized­LDL. One fourth of all CD4+ 
T cells cloned from human plaques recognized 
oxidized­LDL in an HLA­DR­dependent 
manner. Oxidized­LDL­specific T cells are 
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present in lymph nodes of apoe­kO mice, 
which have strong humoral as well as 
cellular immune responses to such modified 
lipoproteins. In humans, oxidized­LDL 
induces activation of a subset of peripheral 
T cells. In addition, antibodies to oxidized­
LDL can be detected in atherosclerotic 
patients and are present in atherosclerotic 
lesions, suggesting that it is a quantitatively 
important antigen. The immune response 
to oxLDL plays a pathogenetic role in 
atherosclerosis because lesion progression 
can be inhibited by immunization or 
induction of neonatal tolerance to oxLDL. It 
seems paradoxical that both tolerization and 
hyperimmunization can reduce the extent 
of disease; this may be due to the different 
effector pathways activated by these two 
kinds of treatment. 
HSP60 as a candidate antigen
As discussed above, HSPs have been 
implicated in activation of innate immune 
responses involved in the pathogenesis of 
atherosclerosis. Moreover, adaptive immune 
reactions to HSP60 have also been implicated 
in the development of atherosclerosis. In 
experimental models, rabbits immunised 
with HSP65/60 recorded induction of 
vascular inflammation, with endothelial 
activation and mononuclear cell adhesion 
demonstrated.48 The developing lesions 
also contained T cells, and cell lines derived 
from such infiltrates exhibited anti­HSP60 
reactivity. Anti­HSP60 antibodies occurred 
in peripheral blood, and immunization 
with HSP60 was found to increase fatty 
streak development in hypercholesterolemic 
rabbits and mice. In humans, antibodies 
to HSP65/60 are elevated in early and late 
atherosclerosis and may predict progression 
of atherosclerotic disease. Since heat shock 
proteins of humans and microbes are 
structurally and antigenically similar, it is 
possible that molecular mimicry between 
immune responses to microbial HSP and 
homologues expressed by vascular cells could 
account for the association between infections 
and atherosclerosis.49 based on these findings, 
Maron and co­workers provided the evidence 
that atherosclerotic lesions were reduced by 
nasal immunization with HSP65 in apoe­
deficient mice, suggesting that atherosclerosis 
might be inhibited by vaccination against 
HSP65.50 
β2-glycoprotein Ib as a candidate 
antigen
A third autoantigen, β2­glycoprotein Ib 
(β2­GPI), is present on platelets but may 
also be expressed by endothelial cells. 
Autoantibodies to β2­GPI are produced in 
several inflammatory disorders, in addition 
to atherosclerosis. The immune response to 
β2­GPI appears to be proatherogenic, because 
hyperimmunization with β2­GPI116 or trans­
fer of β2­GPI­reactive T cells aggravates fatty 
streak formation in LDLR­/­ mice. The 
pathogenic mechanism by which β2­GPI 
acts remains unclear, but it may be related to 
this protein’s capacity to bind phospholipids. 
In summary, adaptive immunity power­
fully modulates initiation and progression of 
atherosclerosis. Atherogenesis involves inter­
communication between shared pathways 
involved in adaptive and innate immunity. 
Various established and emerging risk fac­
tors for atherosclerosis modulate aspects of 
immune responses, including lipoproteins 
and their modified products, HSPs, and 
infectious agents. As the molecular details 
become understood, new potential targets 
for therapies will doubtless emerge.
INFLAMMATION
It is generally accepted that atherosclerosis 
is an inflammatory disease,1 because recent 
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findings have provided important links 
between all risk factors and the mechanisms 
of atherogenesis. Clinical studies have shown 
that this emerging biology of inflammation 
in atherosclerosis applies directly to human 
patients. elevation of markers for inflam­
mation predicts the outcome in patients with 
acute coronary syndromes.4 In addition, low­
grade chronic inflammation, as indicated by 
levels of the inflammatory marker C­reactive 
protein (CRP), prospectively defines the 
risk of atherosclerotic complications, thus 
adding to prognostic information provided 
by traditional risk factors. Certain treatments 
that reduce atherosclerosis risk also limit 
inflammation. For example, statins, used 
for lipid lowering,4 have anti­inflammatory 
effects. Amongst the known inflammatory 
triggers on the vessel wall are known risk 
factors e.g. hypercholesterolemia, oxidized­
LDL, hypertension, biomechanical stress 
and infection. These risk factors can directly 
or indirectly stimulate endothelial cells 
expressing adhesion molecules (VCAM­1, 
ICAM­1 and e­selectin) mediating sub­
sequent mononuclear cell infiltration and 
foam cell formation in the subendothelial 
space.1 In this section, some recent findings 
that have not been described above will be 
summarised.
C-reactive protein
C­reactive protein (CRP) is an acute­phase 
protein that is involved in inflammatory 
processes. It is made up of 5 identical 
subunits which are arranged in a pentagonal 
shape. CRP is predominantly synthesized 
by hepatocytes, but in response to inflam­
mation, CRP expression can be found in 
atherosclerotic plaque, aortic endothelial 
cells, monocytes and vascular smooth muscle 
cells. Inflammatory cytokines induce CRP 
gene expression and statins have been shown 
to reduce CRP levels.52 
biasucci et al53 studied a cohort of patients 
admitted with unstable angina and found 
that one half of this group had a persistently 
elevated CRP (>3mg/dL) at discharge. Those 
with elevated discharge CRP levels had a 
significantly elevated risk of recurrent 
unstable angina or MI during the subse­
quent 12 months. This group has also dem­
onstrated that CRP elevation in individuals 
presenting with severe peripheral arterial 
disease was associated with an increased risk 
of MI, independent of other vascular 
risk factors. 
CRP may be not only a marker of inflam­
mation and atherosclerosis, it may also be an 
active component participating in atherogen­
esis. CRP can bind to lipoproteins and acti­
vate the complement system via the classical 
pathway. CRP deposits have been shown in 
the arterial wall early during lesion forma­
tion, which is co­localized with the terminal 
complement complex. This suggests that 
CRP may promote atherosclerotic lesion 
formation by activating the complement sys­
tem and is involved in foam cell formation, 
which may be caused in part by the uptake 
of CRP­opsonized LDL.
CD40/CD40L
These antigens are ubiquitously expressed 
on the surface of endothelial cells, smooth 
muscle cells, macrophages, T lymphocytes, 
and platelets within human atheroma.51 The 
proatherogenic functions of CD40 ligation 
include augmented expression of matrix 
metalloproteinases, procoagulant tissue factor 
(TF), chemokines, and cyto kines. Indeed, 
interruption of CD40 signalling not only 
reduced the initiation and progression of 
atherosclerotic lesions in hypercholesterolemic 
mice in vivo, but also modulated plaque 
architecture in ways that might lower the 
risk of causing thrombosis. In addition to 
the 39­kDa cell membrane–associated form, 
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CD40L also exists as a soluble protein, 
termed sCD40L. Although lacking the 
cytoplasmic, the transmembrane region, 
and parts of the extracellular domains, this, 
the soluble form of CD40L, is considered 
to possess biological activity. Patients with 
unstable angina express higher sCD40L 
plasma levels than healthy individuals or 
patients with stable angina. Moreover, it was 
recently demonstrated that elevated plasma 
concentrations of sCD40L predict risk 
for future cardiovascular events. Although 
in vitro and in vivo studies established that 
CD40 signalling participates in athero­
sclerosis, the initial trigger for CD40/ 
CD40L expression within atheroma may be 
regulated by oxidized­LDL. Thus CD40/ 
CD40L may be a mediator in the inflam­
matory responses during the development of 
atherosclerosis.
SUMMARY AND PeRSPeCTIVeS
Atherosclerosis is an inflammatory disease 
that is initiated by multiple risk factors, 
including hypercholesterolemia, oxidized­
LDL, altered biomechanical stress, smoking 
and infections. Due to research achievements 
in recent decades, atherogenesis is no longer 
an inevitable consequence of aging—the 
statin revolution has left this in no doubt. 
better control of hypercholesterolemia can 
clearly be achieved but many questions 
remain. For example, which factor is an 
initiator for the development of athero­
sclerotic lesions, and how do other factors 
participate in the disease process. Currently, 
atherosclerosis research is highly topical. 
The mystery of the molecular mechanisms 
in this disease will yield to the current multi­
disciplinary attack by academic institutions 
and the pharmaceutical industry using the 
powerful techniques of vascular biology and 
molecular approaches. 
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IntRoDuCtIon
atherosclerosis continues to cause consider­
able morbidity and mortality, particularly in 
the western world. While risk factors have 
been clearly identified, their precise roles in 
early atherogenesis are complex. the early 
development of the plaque is dependent upon 
interactions between damaged endothelial 
cells, vessel wall smooth muscle cells and 
circulating inflammatory cells mediated by 
the release of cytokines, growth factors and 
cell adhesion molecules. Plaque formation 
may represent a cell­mediated immune 
phenomenon, with a variety of potential 
antigenic agents identified. shear stress and 
flow considerations also play a part. 
atherosclerosis begins in childhood, but 
it takes decades for atherosclerosis to evolve 
into the mature plaques responsible for 
the onset of ischaemic symptoms. Whilst 
plaque growth due to smooth muscle cell 
proliferation, matrix synthesis and lipid 
accumulation may narrow the arterial 
lumen and ultimately limit blood flow, 
uncomplicated atherosclerosis is essentially 
a benign disease. the final clinical outcome 
depends on whether a plaque becomes 
unstable, leading to acute disruption of its 
surface and exposure of its thrombogenic 
core to the luminal blood flow. the concept 
of a ‘vulnerable plaque’ was initially described 
in 19901,2 and though this initially gained 
wide acceptance, many authors now favour 
the broader concept of a ‘vulnerable patient’, 
whereby certain systemic and haematological 
conditions (e.g. relative hypercaogulability) 
must also be met before plaque rupture will 
result in symptomatic thrombosis.3
Mature atherosclerotic plaques are 
composed of a lipid core that is separated 
from the vessel lumen by a cap composed 
of fibrillar collagen. Disruption of this cap 
exposes the plaque’s underlying thrombogenic 
core to the bloodstream, resulting in 
thromboembolism. this process of ‘plaque 
rupture’ is responsible for the majority of 
acute coronary syndromes (unstable angina, 
MI)4­6,7 and ischaemic cerebral events (stroke, 
tIa, amaurosis fugax).8­10
unravelling the complex biochemical 
and haemodynamic factors leading to plaque 
rupture is one of the greatest challenges facing 
contemporary medical research. the vital 
question in plaque pathogenesis is why, after 
years of indolent growth, life­threatening 
disruption and subsequent thrombosis 
should suddenly occur. Plaque stabilisation 
may prove to be an important clinical 
strategy for preventing the development of 
complications.6 Identification of ‘vulnerable 
plaques’ (i.e., those most at risk of rupture) 
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and ‘vulnerable patients’ (i.e. those with 
predisposition to atherothrombotic occlu­
sion) would allow pharmacotherapy to be 
targeted more effectively. furthermore, a 
greater understanding of the mechanisms 
involved in plaque rupture will lead to 
improvements in preventative therapy. 
EVIDEnCE foR tHE ‘PLaQuE 
RuPtuRE’ tHEoRY’
Coronary circulation
Evidence that plaque rupture leads to acute 
coronary syndromes has been provided from 
a number of sources. Early pathological 
studies using post­mortem specimens from 
fatal cases of acute myocardial infarction 
have revealed that virtually all cases of 
coronary thrombosis are related to rupture 
or fissuring of atheromatous plaques, along 
with evidence of distal embolisation.7,11­13 
angioscopic findings in patients with stable 
angina have identified smooth atheroma 
within their coronary arteries, but disrupted 
irregular atheroma in the arteries of those 
with unstable angina.14,15 
Radiological and histological studies have 
demonstrated that patients with a plaque 
morphology consisting of large lipid cores 
and thin fibrous caps are at increased risk of 
cardiovascular events.16­18 In addition, these 
‘unstable’ plaques are not necessarily the ones 
causing severely stenotic lesions.19­21 
Cerebral circulation
a similar association between carotid plaque 
rupture and cerebrovascular events has been 
shown. In patients undergoing multiple 
tIas or stroke progression, microemboli can 
be detected in the middle cerebral artery by 
transcranial Doppler.10,22 surface ulceration 
of carotid plaques seen on ultrasound 
imaging correlates well with symptoms23 and 
echolucent (lipid­rich) plaques are at increased 
risk of causing future cerebrovascular events. 
Early work utilising carotid plaques re­
trieved at carotid endarterectomy, highlighted 
the relationship between the presence of throm­
bus and the clinical status of patients.24,25 this 
supported the theory that ischaemic attacks 
resulted from embolism rather than reduction 
in cerebral blood flow, particularly as few 
strokes occur in watershed areas.26
a number of subsequent studies demon­
strated a relationship between the presence 
of intraplaque haemorrhage and patient 
symptoms.27 Persson et al found that intra­
plaque haemorrhage appeared more frequently 
in symptomatic patients than asymptomatic 
patients,28 while Lusby suggested a relationship 
between the onset of neurological symptoms 
and development of plaque haemorrhage.29 
Intraplaque haemor rhage may potentially arise 
after cap rupture, though it now seems most 
likely that it occurs prior to plaque breakdown30 
and may play an important role in disruption 
of the fibrous cap.
the most compelling evidence for an 
association between carotid plaque rupture 
and ischaemic cerebral events, is that carotid 
endarterectomy specimens removed from 
symptomatic patients are more likely to show 
histological evidence of rupture, compared 
to those from asymptomatic patients.8,9 Van 
Damme and colleagues showed that 53% 
of complicated carotid plaques (intraplaque 
haemorrhage, haematoma, thrombus or 
ulceration) were symptomatic with a corres­
ponding neurological deficit, compared to 
21% of simple uncomplicated plaques.31
tHE RoLE of InDIVIDuaL 
CoMPonEnts of tHE 
aRtERIaL WaLL
a number of intrinsic and extrinsic factors 
have been identified that determine plaque 
vulnerability: the size and consistency of 
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the plaque core, the thickness and collagen 
content of the fibrous cap, and inflammation 
within the plaque. further factors such as 
haemodynamic stress upon the plaque may 
ultimately contribute to cap disruption. 
the evolution of a stable to unstable 
plaque with cap rupture and thrombosis can 
be outlined in the following simplistic terms 
(figure 4.1): Endothelial damage allows 
passage of inflammatory cells and LDL into 
the vessel intima; free radicals are responsible 
for oxidation of the deposited LDL, and 
oxidized­LDL promotes cytokine and pro­
tease release from macrophages; proteases 
(in addition to other factors) degrade the 
fibrous cap causing disruption, allowing 
exposure of thrombogenic material to the 
blood; local thrombotic and fibrinolytic 
activity determine the degree of thrombus 
progression or dissolution.
Each component contributing to plaque 
rupture will be discussed in further detail. the 
relevant processes occur in the endothelium, 
the lipid core, the fibrous cap and the vessel 
lumen.
The endothelium
the origin of plaque destabilization can be 
traced back to endothelial dysfunction, or 
‘activation’. the endothelium is a single layer 
of highly specialised cells lining the vessel 
wall/lumen interface. It plays a vital role in 
modulating vascular permeability, perfusion, 
contraction and haemostasis. Leukocytes do 
not bind to normal endothelium. However, 
endothelial activation leads to the early surface 
expression of cell adhesion molecules, including 
VCaM­1, ICaM­1, E­selectin and P­selectin, 
which permit leukocyte binding. Many of 
the known atherosclerosis risk factors (e.g., 
smoking, hyperlipidaemia, hyperglycaemia, 
hypertension, hyperhomocysteinaemia) exert 
their damaging effects by causing endothelial 
activation.32­37
activated endothelial cells express chemo­ 
attractant cytokines such as MCP­1, M­Csf, 
IL­1, IL­6 and tnf­α, as well as cell 
adhesion molecules. this pro­inflammatory 
environment, in conjunction with the 
altered permeability of the dysfunctional 
endothelium, mediates the migration and 
entry of leucocytes (mainly monocytes 
and lymphocytes) into the intima.38­40 
the degree of endothelial dysfunction 
depends upon the balance between endothelial 
activation and endothelial ‘passivation’ (see 
figure 4.2). nitric oxide is the predominant 
molecule responsible for passivation, and the 
endothelium acts as an autocrine organ in its 
production.41 nitric oxide is an antioxidant, 
but has other plaque­stabilizing properties 
including reducing cell adhesion molecule 
expression,42 platelet aggregation and sMC 
proliferation. Endothelial nitric oxide 
synthase, the enzyme responsible for nitric 
oxide production, is increased in people 
undergoing regular physical exertion, which 
may partly explain the benefits of exercise in 
atherosclerosis prevention.43 
Endothelial cells are exposed to 3 different 
types of mechanical force. Hydrostatic forces 
(generated by the blood) and circumferential 
stress (generated by the vessel wall) are 
responsible for endothelial injury and 
activation. the third force is haemodynamic 
shear stress (generated by the flow of blood), 
which is inversely related to atherosclerosis 
formation – areas of high shear stress 
being relatively protected.44 Despite the 
systemic nature of atherosclerosis, it is an 
anatomically focal disease with certain sites 
having a propensity for plaque formation. 
arterial bifurcations exhibit slow blood flow, 
sometimes even bi­directional flow, resulting 
in decreased shear stress. the activity of 
endothelial nitric oxide synthase is decreased 
in these areas of non­laminar blood flow.45,46 
In addition, there is increased oscillatory 
and turbulent shear stress at bifurcations, 
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Figure 4.1: The stages of plaque rupture.
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associated with an increase in oxygen 
free radical production47 and monocyte 
adhesion.48
according to Laplace’s law, the higher the 
blood pressure and the larger the luminal 
diameter, the more circumferential tension 
develops in the wall.49 this phenomenon 
combined with a radial compression of the 
vessel wall may lead to excessive stress in 
vulnerable regions of the plaque, particularly 
the cap and shoulder.50 for fibrous caps of 
the same tensile strength, those caps covering 
moderately stenotic plaques are probably more 
prone to rupture than those covering severely 
stenotic plaques, because the former have to 
bear a greater circumferential tension.51
the propagating pulse wave causes 
cyclic changes in lumen size and shape 
with deformation and bending of plaques, 
particularly those with a large soft plaque 
core. Eccentric plaques typically bend at the 
junction between the relatively stiff plaque 
and the compliant vessel wall.52 the force 
applied to this region is accentuated by 
changes in vascular tone.
High blood velocity within stenotic 
lesions may shear the endothelium away, but 
whether high wall stress alone may disrupt a 
stenotic plaque is questionable.4 the absolute 
stresses induced by wall shear are usually 
much smaller than the mechanical stresses 
imposed by blood and pulse pressure.53
It is clear that the endothelium is much 
more than an inert arterial wall lining. It is, in 
fact, a dynamic autocrine and paracrine organ 
responsible for the functional regulation of 
local haemodynamics. factors that disturb 
this delicate balance are responsible for the 
initiation of a cascade of events eventually 
leading to plaque rupture.
The lipid core
the size and consistency of the atheromatous 
core is variable and critical to the stability of 
individual lesions, with a large volume lipid 
core being one of the constituents of the 
vulnerable plaque (figure 4.3). It appears 
that the accumulation of lipids in the intima 
renders the plaque inherently unstable. 
although extremely variable, the 
‘average’ coronary plaque is predominantly 
sclerotic with the atheromatous core making 
up <30% of the plaque volume.54 the 
variability in plaque composition is poorly 
understood, with no relationship to any of 
the identified risk factors for atherosclerosis. 
Gertz and Roberts examined the histological 
composition of post­mortem plaques from 
17 infarct­related coronary arteries.55 
Figure 4.2: Factors affecting endothelial activity.
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they found much larger proportions of 
the disrupted plaques to be occupied by 
atheromatous gruel in comparison to the 
intact plaques. Davies found a similar 
relationship in aortic lesions, with 91% of 
thrombosing plaques versus 11% of intact 
plaques exhibiting a lipid core that occupied 
>40% of the total plaque volume.56 
Histological data regarding the necrotic 
core of carotid plaques is limited. there 
is, however, considerable evidence to link 
ultrasound­detected echolucent plaques 
(deemed to contain more soft or amorphous 
tissue) with symptomatology.57,58 feeley and 
colleagues demonstrated that symptomatic 
carotid plaques contained a significantly 
higher proportion of amorphous material 
than asymptomatic plaques,59 with the lipid­
rich core constituting 40% of overall plaque 
volume.60
LDL plays a more complex role in plaque 
instability than can be explained simply by 
the ‘space­occupying’ effect of accumulated 
lipid. a large core may produce a greater 
luminal narrowing, but plaque rupture 
sites are often characterized by ‘outward 
remodelling’ whereas those stenoses causing 
stable angina are more likely to be associated 
with ‘inward remodelling’.61 Indeed, it has 
been shown that in patients suffering acute 
coronary syndromes who had undergone 
angiography in the preceding months, 
the responsible lesion was recorded as 
causing a <70% stenosis in the majority of 
cases.19,20,61 this is perhaps not surprising 
since, as mentioned earlier, a larger lumen 
places increased circumferential stress on the 
plaque, predisposing it to rupture. 
as inflammatory cells cross the 
dysfunctional endothelium, cholesterol also 
enters in the form of LDL, and becomes 
trapped in the subendothelial space. this 
LDL is oxidized by free radicals creating a 
pro­inflammatory compound.62 oxidized­
LDL is taken up by intimal macrophages 
– the process being mediated via receptors 
expressed on the macrophage surface,63 
although endocytosis of native LDL has 
also been demonstrated.64 this process 
initially protects the surrounding smooth 
muscle and endothelial cells from the direct 
cytotoxic effects of oxidised­LDL, but leads 
to the formation of ‘foam cells’ (lipid­laden 
macrophages). uptake of oxidized­LDL 
stimulates the expression of cytokines and 
proteolytic enzymes, propagating the cycle 
of inflammation.
the formation of a lipid core is a balance 
between LDL deposition of cholesterol 
in the damaged intima and removal by 
HDL (figure 4.4). HDL and its carrier, 
apolipoprotein a­I, are responsible for 
so­called ‘reverse cholesterol transport’ – 
moving cholesterol from cells into the blood 
(from where it can be transferred to the 
liver for excretion in the bile).65 However, 
it may also be capable of effecting lipid 
removal directly from the plaque, one of the 
possible explanations for plaque regression 
seen with increased HDL levels.66 HDL may 
have other beneficial effects also, such as 
improving endothelial function,67 decreasing 
cell adhesion molecule expression,68 and 
inhibiting oxidation of LDL.69
In addition to the potential pro­
inflammatory role of oxidised LDL, it has 
recently been proposed that cholesterol 
accumulation may lead to plaque rupture 
via a more direct physical pathway. Changes 
Figure 4.3: Longitudinal section of carotid plaque 
demonstrating a large volume lipid core
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in local biological milieu such as decreased 
temperature or increased pH may cause in 
vitro precipitation of cholesterol into solid 
crystals. this alteration in state not only 
leads to a significant volume increase of up 
to 45%, but also leads to formation of sharp­
tipped crystals that might be capable of 
damaging surrounding tissues and initiating 
plaque rupture. using electron microscopy, 
abela et al demonstrated that such crystal 
could be seen perforating the luminal surface 
of ruptured plaques from human coronary 
arteries.70,71
The cap of the plaque
the cap of the atherosclerotic plaque 
plays a vital role in isolating the plaque’s 
thrombogenic core from the bloodstream. 
since the thickness and collagen content of 
this cap are important determinants of overall 
plaque stability,51 many authors now use 
the term ‘thin­cap fibroatheroma’ (tCfa) 
to identify those plaques most at risk of 
rupture. the accepted definition of tCfa is 
any plaque with a cap thickness of less than 
65µm. though the exact mechanisms that 
underlie progression from stable plaque to 
tCfa remain somewhat uncertain, it has 
been suggested that endothelial shear stress 
may play an important role, since tCfas 
most often arise at sites of low endothelial 
shear stress (such as bifurcations and the 
concave side of arterial bends).72
Whatever the thickness of the fibrous 
cap, it is composed largely of fibrillar 
collagens (type I and type III68), though the 
relative proportion of collagen decreases as 
the cap thins. the fibrillar collagens have a 
lower thrombogenicity than the underlying 
core, but their exposure can be responsible 
for thrombus formation following erosion 
of the overlying endothelium.73,74 this 
phenomenon accounts for one­third of acute 
coronary syndromes,75 and the subsequent 
healing process of erosions can account for 
rapid and step­wise progression in plaque 
growth, leading to sudden increases in 
stenosis or occlusion.76 
the most vulnerable area of the plaque 
is the shoulder region, where the cap is 
often at its thinnest.7 studies have shown a 
reduction in the collagen content of the cap 
around areas of plaque disruption, as well 
as steep transverse gradients of connective 
tissue constituents across ulcerated plaques.77 
this may result from a reduction in matrix 
production by smooth muscle cells, which 
exhibit diminished numbers in areas of plaque 
disruption,56 or from increased degradation 
of matrix by proteolytic enzymes. It is most 
likely, of course, that a combination of 
excessive matrix degradation and reduced 
matrix production are responsible for cap 
thinning (figure 4.5). a reduction in sMCs 
within the fibrous cap would certainly 
undermine its strength.78 Recently there has 
been interest in the role of smooth muscle cell 
Figure 4.4: Factors affecting plaque lipid content
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apoptosis in plaque cap weakening, caused 
by a combination of intrinsic and extrinsic 
factors, particularly macrophage and lipid 
derived products.79,80
More recently it has been suggested that 
plaque integrity may also be influenced 
by the development of minute, spherical 
microcalcifications within the fibrous cap. 
these microcalcifications are thought to 
represent accumulations of calcified macro­
phages or even post­apoptotic smooth muscle 
cells and result in highly focal increases in 
physical stress. the increased stress leads to 
areas of facial debonding, weakening the 




the sMC has a paradoxical role in plaque 
instability. on the one hand, sMCs are 
responsible for plaque matrix production 
and adverse arterial remodelling, while on 
the other, they produce collagens that give 
the plaque intrinsic strength. sMC inhibition 
therefore has potentially detrimental and 
beneficial effects.
In the normal arterial wall, sMCs are 
present in the media and express a different­
iated phenotype. they are contractile and do 
not divide or migrate.82 In atherosclerosis, 
when stimulated by the milieu of growth 
factors and cyokines, they ‘dedifferentiate’ 
and express a synthetic phenotype.83 In the 
media, sMCs are surrounded by a basal 
lamina consisting of type IV collagen. 
Proteolytic enzymes secreted by macrophages 
are responsible for digestion of this supporting 
framework. the released sMCs are then able 
to migrate to the intima, where they secrete 
new extracellular matrix.84 sMCs play a 
crucial role in stabilising atherosclerotic 
plaques, as they are responsible for the 
production of the cap fibrillar collagens.82 In 
this respect, sMCs are important not only 
in initial formation of the fibrotic cap, but 
also in repair of subclinical plaque rupture. 
sMCs accumulate at the rupture site and 
secrete fibrous proteins. this restores plaque 
integrity, but may also lead to rapid growth 
of the plaque causing vessel stenosis. Certain 
platelet factors, including PDGf and 
tGf­β, are felt to be particularly important 
in stimulating collagen synthesis by sMCs, 
whereas γ­interferon (from activated t­cells) 
has the opposite effect.85 
since sMCs are the only cells pro­
ducing fibrous tissue for inclusion in the 
atherosclerotic plaque, the balance between 
recruitment and degradation of these cells 
is clearly of great significance in plaque 
stability. It had previously been accepted that 
all sMCs involved in atherosclerosis were 
Figure 4.5: Factors affecting plaque collagen content
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derived from the local vessel media or intima. 
However, many groups are now examining 
the possibility that they may also be recruited 
from a circulating pool of sMC progenitor 
cells.86 the prospect of manipulating the 
activity of these progenitor cells to increase 
plaque stability is an attractive therapeutic 
target, though further work is still required 
in this area.
Whatever the true origin of plaque sMCs, 
they play a vital role in maintaining the 
structure of the plaque and sMC apoptosis 
leads to decreased collagen production, 
thinning of the fibrous cap and increased 
volume of the necrotic core.87­89 a recent, 
though small, study demonstrated that the 
proportion of sMCs undergoing apoptosis 
and the frequency of cytoplasmic remnants 
of apoptotic cells were significantly increased 
in unstable versus stable angina atherectomy 
specimens.90 apoptosis of sMCs and macro­
phages has been identified within plaques, 
but only in advanced disease with dense 
macrophage infiltration. apoptotic cells are 
deemed to have become susceptible to a form 
of cell death which is distinct from necrosis and 
is characterised by a series of morphological 
changes, starting with shrinkage of the cell 
membrane and leading on to condensation 
of nuclear chromatin, cellular fragmentation 
and eventually engulfment of apoptotic 
bodies by surrounding cells.79 
Pro­apoptotic proteins are present in 
advanced plaques, and it has been observed 
that cells derived from the plaque, but 
not the adjacent media, die when brought 
into culture.80,91 Intimal cell apoptosis may 
account for the low density of smooth muscle 
cells in unstable plaques, and may contribute 
to the events leading up to plaque disruption. 
though further study is still required, 
prevention of smooth muscle cell apoptosis 
may prove to be an important therapeutic 




It is now known that inflammation plays 
a major role in plaque progression and 
especially in the period just prior to its 
rupture.92 Macrophages control many of the 
inflammatory processes within the plaque,93 
and are responsible for the production of 
proteolytic enzymes capable of degrading the 
extracellular matrix.94,95 the predominant 
proteolytic enzymes involved in plaque 
disruption are the matrix metalloproteinases 
or MMPs.96
the MMPs are a family of proteolytic 
enzymes characterised by the presence of 
zinc ions at their active sites. all degrade 
components of the extracellular matrix, and 
are divided into 4 main classes on the basis of 
their substrate specificity (table 4.1). 
MMPs are essential in normal healthy 
individuals, playing a key role in processes 
such as wound healing.97,98 However there 
is growing interest in their role in disease 
states where ECM breakdown plays a pre­
dominant role.99 Early interest focused on a 
pathological role for MMPs in the resorption 
of periodontal structures in periodontal 
disease,100 the destruction of joints in rheuma­
toid arthritis,101 and the local invasive 
behav iour of malignancies.102 In vascular 
disease, they have been implicated in many 
of the stages of atherosclerosis but most 
particularly in acute plaque disruption.103 
the site of rupture is characterised by an 
intense inflammatory infiltrate consisting 
predominantly of macrophages,94 that under­
goes activation resulting in increased MMP 
expression. this shifts the delicate equilibrium 
towards proteolysis and away from matrix 
accumulation, making plaque disruption 
more likely (figure 4.5).
MMP activity is tightly controlled at 
several levels and expression of MMPs is 
determined at the transcriptional level by 
various cytokines and growth factors.104 
Mechanisms of Vascular Disease52
In a variety of tissue types, IL­1, PDGf 
and tnf­α stimulate expression,105,106 while 
heparin, tGf-β and corticosteroids inhibit 
expression.107,108 In recent years, there has also 
been considerable interest in the regulatory 
role of extracellular matrix metalloproteinase 
inducer (EMMPRIn). EMMPRIn was init­
ially identified as a tumour­derived protein 
that facilitated cancer cell invasion by 
stimulating MMP production in epithelial 
cells and fibroblasts.109 However, subsequent 
studies have demonstrated that EMMPRIn 
also stimulates production of MMPs by 
smooth muscle cells and monocytes, making 
it highly relevant in atherosclerosis and plaque 
instability. In addition, EMMPRIn may also 
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lead to increased production of inflammatory 
cytokines which further augment MMP 
activity as described above.110
MMPs are initially secreted as latent 
inactive proenzymes and converted to the 
active state by cleavage of a propeptide 
domain.111 the major physiological activator 
is plasmin, which in turn is regulated by 
PaI.112 thrombin has been shown to activate 
MMP­2 in vitro113 and could provide a 
mechanism for MMP activation at sites of 
vascular injury. Reactive oxygen species also 
modulate enzyme activation.114,115 
Metalloproteinase activity is further 
governed by naturally occurring MMP 
inhibitors. these ‘tissue inhibitors of metallo­
proteinases’ (tIMPs) provides a further level 
of control and overall proteolytic activity 
depends on the ratio of activated MMPs to 
tIMPs.116 
Early studies showed that MMPs were 
present at increased levels in atherosclerotic 
arteries. Raised levels of gelatinase activity 
were demonstrated in the aortas of patients 
with occlusive disease compared to healthy 
controls, and zymography revealed that this 
was predominantly MMP­9.117 subsequently, 
quantitative studies using ELIsa revealed 
a six­fold increase in MMP­9 levels in 
atherosclerotic aortas.118 the level and 
expression of MMP­2 is also increased in 
atherosclerotic aortic tissue compared with 
normal aorta.119 While expression of MMP­2 
has been detected in normal arteries, it 
appears that most MMPs are expressed only 
in atherosclerotic tissue.120 the colocalisation 
of MMP­1, ­2, ­3 and ­9 to the vulnerable 
shoulder of the plaque provided further 
evidence of their potential role in acute 
disruption.120 
More recent studies have demonstrated 
an association between MMP levels and 
markers of plaque instability. Increased 
immunostaining for MMP­9 was seen in 
12 atherectomy specimens retrieved from 
patients with unstable angina compared to 
the stable form.121 a larger study, involving 
75 carotid endarterectomy specimens, 
demon strated a close association between 
raised plaque levels of MMP­9 and a number 
of indicators of plaque instability, including 
symptomatology, cerebral embolisation and 
histological features of plaque rupture.9 
Convincing evidence therefore exists of 
increased levels of MMP­2 and ­9 in unstable 
plaques. However, intact type I and type III 
collagen molecules, which account for the 
load­bearing strength of the plaque cap, are 
not substrates for MMP­2 and ­9. While it 
has been reported that high concentrations 
of MMP­2 can degrade type I collagen in an 
in vitro environment devoid of tIMPs,122 it 
is likely that in vivo only the collagenases, 
MMP­1, ­8 and ­13, are capable of degrading 
fibrillar collagens. 
MMP­1 and ­13 levels are higher 
in ‘atheromatous’ compared to ‘fibrous’ 
plaques,123 and MMP­8 has been demon­
strated in atheroma but not normal 
arteries.124 the expression of MMP­1 is 
increased in areas of high circumferential 
stress.125 It is likely that both mechanics and 
proteolysis play a role in the degradation and 
weakening of the collagen­rich extracellular 
matrix, and understanding their interaction 
may be crucial.126
Evidence from our laboratories suggests 
that active MMP­8 is significantly raised 
in unstable plaques retrieved at carotid 
endarterectomy (figure 4.6). the ratio 
of active MMP­8 to tIMP­1 and ­2 (its 
naturally occurring inhibitors) were also 
significantly higher in the more unstable 
plaques of the 159 specimens collected in 
this study. this implies net proteolysis of 
the types of collagen found in the cap of the 
plaque by MMP­8. Immunohistochemistry 
confirmed the presence of MMP­8 protein 
within the plaque, which colocalised with 
macrophages (figure 4.7).
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Genetic variation in the genes controlling 
MMPs could theoretically be responsible 
for the susceptibility of some individuals to 
atherosclerotic plaque rupture. Early work has 
identified a number of polymorphisms that 
may be influential in this regard. Price et al 
have identified a novel genetic variation in the 
MMP­2 gene.127 Ye and colleagues detected 
a polymorphism in the promoter region of 
the MMP­3 gene that may lead to increased 
systemic levels.128 this polymorphism was 
subsequently found to be more common in 
patients suffering MI, compared to a control 
group.129 a single nucleotide polymorphism 
Figure 4.6: Plaque concentrations of active MMP-8 are significantly higher in symptomatic compared to 
asymptomatic carotid plaques: (a) from patients suffering carotid territory symptoms in the 6 months prior to 
surgery (p-value 0.0002), (b) from patients with pre-operative cerebral embolisation detected by transcranial 
Doppler (p-value 0.003) and (c) showing histological evidence of plaque rupture. Median values and 
interquartile ranges shown (p-value 0.003).
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Figure 4.7: histological sections taken from the shoulder region of a symptomatic carotid plaque.  
Some sections show disruption of the friable plaque.
(a) Low power H&E section with boxed area delineating high power view shown in (b-e). 
(b) High power H&E section demonstrating a cellular infiltrate. 
(c) strong reactivity for MMP-8 in cells.
(d) Positive staining for CD68 (macrophages). 
(e) negative immunohistochemistry control.
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(C to t transition at position –1562) has been 
shown to influence MMP­9 transcription.130 
In this study by Zhang and co­workers, 
triple­vessel coronary artery disease was 
detected by angiography in 26% of patients 
with this polymorphism compared to 15% 
of those without.130 Presenting a coherent 
picture of the interactions between various 
polymorphisms and the corresponding gene 
expression is difficult, and further complicated 
by environmental effects. However, it is clear 
that the potential exists to identify ‘at risk’ 
individuals in such a manner.
The vessel lumen
Disruption alone would not precipitate 
ischaemic syndromes without thrombus 
formation on the plaque surface, so plaque 
instability and thrombogenicity in tandem 
predispose to acute clinical events. Platelet 
adherence to the sub­endothelium after 
surface disruption leads to activation, with 
aDP and serotonin release stimulating 
further platelet recruitment and activation. 
once formed, thrombus can behave in 
three ways, dependent on the physical nature 
of the rupture and the balance between 
local fibrinolytic and coagulation processes. 
firstly, the initial thrombus may progress to 
cause occlusion of the vessel. secondly, the 
thrombus may disintegrate resulting in distal 
embolisation. thirdly, the clot can undergo 
rapid dissolution, with the healed rupture 
resulting in a variable decrease in vessel 
lumen diameter.76 
tissue factor is a major regulator of 
haemostasis.131 It is the most thrombogenic 
component of atherosclerotic plaques132 
and is expressed by numerous cell types, 
including endothelial cells. the level of tissue 
factor in coronary plaques from patients with 
unstable angina is more than twice the value 
observed in those plaques from stable angina 
patients.133 Positive immunostaining for 
tissue factor correlates with areas of intense 
macrophage infiltration and sMCs, suggesting 
a cell­mediated increased thrombogenicity 
in unstable plaques. the increase in tissue 
factor levels seems to be linked to expression 
of the CD­40 receptor on the macrophage 
cell surface. the CD­40 ligand is expressed 
on activated t­lymphocytes, and other 
atheroma­associated cells,134 which can 
therefore induce tissue factor production 
by macrophages via this signalling system. 
Expression is also regulated by cytokines and 
oxidised LDL.135,136 It has been reported that 
a blood­borne pool of tissue factor exists,137 
though in the context of plaque disruption, 
macrophage production of tissue factor 
is predominantly responsible for plaque 
thrombogenicity.133,138,139 It is interesting 
to note that many of the recognised 
cardiovascular risk factors increase the 
expression of tissue factor.140,141
tHE RoLE of anGIoGEnEsIs In 
PLaQuE RuPtuRE
angiogenesis is essential for normal growth 
and development. neovascularisation has 
been observed in plaques142 and it is postulated 
that it may play a role in atherosclerosis by 
providing growth factors and cytokines to 
regions of plaque development. 
a study of coronary atherectomy 
specimens revealed the presence of neo­
vascularisation in 50% of specimens from 
patients with unstable angina compared to 
10% of specimens from patients with stable 
angina,29 suggesting a possible role in plaque 
instability. angiogenesis may contribute to 
plaque instability by causing intraplaque 
haemorrhage or extravasation of erythrocytes 
and inflammatory mediators into the centre 
of the plaque. once red blood cells have 
leaked into the plaque, cholesterol from the 
cell membrane may become incorporated 
into the lipid core increasing its volume.143 
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this is supported by the finding that lipid­
rich plaques have a significantly higher 
microvessel density than fibrous plaques.144 
the associated delivery of inflammatory 
cells may also lead to plaque degradation 
by stimulating MMP activity as described 
earlier in this chapter.
Perhaps more importantly, most neo­
vascularisation occurs at the vulnerable 
shoulder area of the plaque. Immunostaining 
for inflammatory cells showed a close 
association between angiogenesis and 
inflammatory infiltration. In addition, a 
parallel increase in the expression of leukocyte 
adhesion molecules in the same vulnerable 
areas was demonstrated.144 
angiogenesis involves interactions between 
endothelial cells and components of the 
basement membrane matrix. MMP activity 
is required for such interactions, especially 
MMP­2 and Mt1­MMP.145 tIMPs have 
been shown to reduce angiogenesis, while 
up­regulation of MMP activity stimulates its 
increase.146 However, whilst neovascularisation 
may promote and sustain inflammatory 
infiltration, the converse may also be true, 
whereby changes in the plaque associated 
with inflammation may themselves promote 
angiogenesis. further work in this area is 
required.
tHE RoLE of InfECtIous 
aGEnts In PLaQuE RuPtuRE
the role of infectious agents in atherosclerosis 
and plaque rupture is controversial. Definitive 
proof of a causal relationship is lacking, 
although studies have reported associations 
between plaque development and Chlamydia 
pneumoniae,147­149 Helicobacter pylori,150 
cytomegalovirus,151,152 Herpes simplex virus 
types 1 and 2,153 and hepatitis a virus.154
Certain infectious agents can evoke 
cellular and molecular changes supportive of 
a role in atherogenesis.155 Work has shown 
that Chlamydial interaction with monocytes 
results in upregulation of tnf­α and 
IL­1β,156,157 both of which are associated with 
plaque development. Chlamydial production 
of the HsP­60 antigen activates human 
vascular endothelium, and increases tnf­α 
and MMP expression in macrophages.158,159 
once again, these are factors that influence 
plaque stability.
It has also been proposed that infective 
pathogens may exert their effects via direct 
infection of cells in the vessel wall. this 
establishes localised inflammation, leading 
to increased smooth muscle cell migration 
and greater uptake of oxidised low­density 
lipoprotein.160
there is some doubt about the methods 
employed for Chlamydia detection,161 and 
also the role of potential confounding factors 
in epidemiological studies.162 a large­scale 
prospective study of 15,000 healthy men in 
the united states which was controlled for 
age, smoking, socio­economic status and 
other cardiovascular risk factors, failed to 
show any association between Chlamydia 
seropositivity and the risk of MI.163 
More recently, the staMIna trial164 
demonstrated that eradication therapy 
(amoxicillin/ azithromycin, metronidazole 
and omeprazole) administered for 1­week 
after an acute coronary syndrome, sig­
nificantly reduced cardiac death and acute 
coronary syndrome readmission rates over 
the following 12 months. these effects 
were unrelated to Chlamydia pneumoniae or 
Helicobacter pylori seropositivity, however, 
suggesting that the trial therapy prevented 
lesion progression by a mechanism unrelated 
to its antibiotic action.
though the role of infection in 
atherosclerosis is still unclear, it seems that 
any causal relationship is likely to be highly 
complex and involve both direct and indirect 
pathways. Important factors may also include 
the patient’s susceptibility to infection and 
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their innate inflammatory and immune 
responses.165
RIsK PREDICtIon of PLaQuE 
InstaBILItY
Imaging
angiography can demonstrate ulceration166 
but does not appear to be able to adequately 
distinguish between stable and unstable 
plaques.167 In addition, the degree of stenosis 
detected by angiography does not correlate 
well with the future risk of events19­21 because, 
as already discussed, it is often not the most 
stenotic plaques that are at highest risk of 
rupture. 
Conventional ultrasound studies have 
shown an association between carotid plaque 
morphology and neurological symptoms168 
but have been unable to predict the risk 
of future events.23 Intravenous ultrasound 
(IVus), however, has been shown to have 
much greater resolution (100 µm) and 
provides detailed cross­sectional images of 
the arterial wall. It is also able to identify the 
increased echolucence of lipid­rich plaques 
and for a time it was thought that it might 
prove useful in detection of rupture­prone 
plaques.169 unfortunately, sensitivity and 
specificity were found to be low with this 
technique and it has largely been superseded 
by intravenous ultrasound virtual histology 
(IVus­VH). the improved spectral analysis 
offered by this technology allows more 
detailed plaque characterization and can 
provide detail on lipid content, calcification 
and volume of the necrotic core.170 Recent 
studies have shown this may be a clinically 
useful tool and demonstrated that IVus­VH 
identified more tCfas in patients with acute 
coronary syndrome than in those with stable 
angina pectoris.171
In parallel with the development of 
IVus­VH, many groups have now begun 
to use optical coherence tomography 
(oCt). also an intravenous modality, oCt 
is analogous to ultrasound imaging (using 
light rather than sound waves) and provides 
excellent spatial resolution (10­15µm). this 
allows detailed assessment of the arterial wall 
and can identify those plaques with a fibrous 
cap less than 65µm thick (i.e. tCfa) as well as 
areas of increased echolucency.172 Whilst this 
technique has yielded very encouraging results 
in the identification of culprit atherosclerotic 
lesions, it is not without its limitations. since 
blood attenuates the optical signal, the vessel 
under investigation must be proximally 
occluded for considerable periods to allow 
accurate imaging. an updated version of 
the technology has therefore been developed 
in recent years. this second generation of 
oCt is known as optical frequency domain 
imaging (ofDI) and involves much higher 
frame rates (>100 frames/sec). the higher 
frame rate allows rapid three­dimensional 
imaging of long arterial segments using high­
speed pull­back of the probe. this means 
there is no need for proximal occlusion of the 
vessel and the artery can simply be purged 
with saline just prior to imaging173 further 
investigation will be needed to assess the true 
clinical utility of this technique.
since increased inflammatory activity 
occurs prior to plaque rupture, attempts 
have been made to detect this increase, using 
local temperature measurements. thermo­
graphy studies have shown that temperature 
correlates well with macrophage cell density 
in human carotid plaques.174 the temperature 
of coro nary vessels in patients with ischaemic 
heart disease, in particular acute coronary 
syndromes, is higher than in normal controls.175 
In addition, increased local plaque temperature 
has been shown to be an independent predictor 
of adverse clinical outcome.176 
High­resolution MRI appears to character­
ize the atherosclerotic plaque better than 
other imaging techniques.177 It is more 
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accurate then angiography in measuring the 
degree of stenosis and, unlike angiography 
and IVus, is non­invasive. However, a 
multicentre trial of imaging in coronary 
artery disease found whilst that MRI could 
reliably identify significant intraluminal 
lesions and rule out proximal or three­vessel 
disease, specificity was low.178 this led to the 
suggestion that MRI may be more sensitive 
and specific if combined with intravascular 
enhancing agents such as gadolinium. using 
such a marker improved MRI specificity and 
facilitated identification of carotid tCfa.179 
MRI is still technically limited in many 
cases by small vessel size and move ment arte­
fact, and studies have not yet demonstrated the 
ability to predict risk of future cardiovascular 
events. nonetheless, advances in the technique 
suggest a potential future role for MRI in 
detection of the high­risk plaque.
Just as enhancing agents may increase 
the accuracy of MRI, they may also prove 
useful in identifying atherosclerotic lesions 
using positron emission tomography (PEt) 
and there has been increasing interest in the 
use of 18 fluorodeoxyglucose (18fDG). up­
take of this glucose analogue is increased 
in metabolically active cells and early 
animal studies suggest it enriches in plaque 
macrophages and indicates areas of neo­
vascularisation.180 However, the clinical 
appli cation of this technique has yet to be 
demonstrated.
Blood markers
It has long been established that adverse 
lipid profiles correlate with increased risk 
of MI and stroke though this is not a direct 
predictor of plaque rupture. Raised CRP 
levels have also been associated with increased 
cardiovascular risk in apparently healthy 
patients,181,182 though its use as a prognostic 
marker of clinically significant thrombosis 
remains controversial.
MMP­2 and MMP­9 are raised in the 
peripheral blood of patients suffering from 
acute coronary syndromes,183 while plasma 
MMP­9 is raised in patients with unstable 
carotid plaques.184 a recent study of 1127 
patients with coronary artery disease identified 
baseline plasma MMP­9 levels to be a novel 
predictor of cardiovascular mortality.185
similarly, raised serum levels of soluble 
intercellular adhesion molecule­1 (slCaM­1) 
have been shown to be an independent 
predictor of future coronary event in patients 
with coronary heart disease.186
Many other molecules have also been 
investigated as potential prognostic markers 
in progression of atherosclerosis, including 
cytokines, lipoproteins, myeloperoxidases 
and placental growth factor. though some 
have yielded promising results, none has yet 
been widely accepted as a reliable predictor 
of plaque rupture or clinical events.187
tHERaPY aIMED at PLaQuE 
staBILIsatIon
Pharmacotherapy to induce plaque stabil­
isation could be targeted at different aspects 
of the complex pathway leading up to plaque 
rupture, in particular: 
1. the endothelium – by increasing 
endothelial passivation
2. the lipid core – by reducing LDL 
deposition/ augmenting LDL removal
3. the fibrous cap – by increasing collagen 
deposition/ preventing collagen 
degradation
4. the vessel lumen – by altering 
the thrombogenicity of the local 
environment.
Most recent interest has focussed on the 
role of HMG Co­a reductase inhibitors, 
which appear capable of influencing plaque 
stabilisation at all these levels.
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HMG Co-A Reductase Inhibitors
HMG Co­a reductase inhibitors, or statins, 
are well known for their lipid­lowering 
action. they are the most effective group 
of therapeutic agents for lowering LDL 
and raising HDL levels. However, recent 
evidence suggests that they are also capable 
of decreasing cardiovascular events in those 
with normal cholesterol levels.188,189 the 
oxford Heart Protection study189 was a 
randomised controlled trial of simvastatin 
versus placebo in 20,536 individuals at 
high­risk of cardiovascular disease. Coronary 
death rate and other vascular events were 
significantly reduced in the simvastatin 
groups, even in patients with lipid levels 
below currently recommended targets 
(<5mmol/l total cholesterol and <3mmol/l 
LDL­cholesterol). 
In the lipid lowering arm of the anglo­
scandinavian Cardiac outcomes trial 
(asCot),188 10,305 individuals with 
total cholesterol levels <6.5mmol/l were 
randomised to either atorvastatin or placebo. 
the trial was stopped 1.7 years before 
the planned 5­year follow­up target was 
reached, as there were significantly fewer 
cardiovascular events in the atorvastatin 
group. the observed clinical benefit is 
probably a combination of lipid lowering 
below levels previously considered ‘normal’ 
and additional lipid­independent plaque 
stabilising actions. several studies have 
reported effects other than lipid­lowering 
properties, including anti­proteolytic and 
anti­inflammatory mechanisms.190,191 
statins increase nitric oxide synthase 
activity192 and encourage endothelial pas siv­
ation (figure 4.2). as discussed earlier, nitric 
oxide causes vasodilatation, inhibition of 
sMC proliferation and platelet aggregation 
and has widespread anti­inflammatory and 
anti­oxidant properties. statins also reduce 
the expression of cell adhesion molecules,193 
interfering with the adherence of monocytes 
to the endothelium.
statins may also have direct anti­
inflammatory and anti­proteolytic actions, 
which contribute to increased plaque stability. 
In cell culture and animal models, statins have 
been shown to reduce macrophage secretion 
of MMP­1, ­2, ­3 and ­9,194 and increase 
the collagen content of the plaque.195 also, 
CRP levels are decreased by statins in a lipid­
independent manner.191,196 
Work from our laboratories suggests that 
statin therapy stabilises carotid plaques by 
lowering the levels of MMP­1, MMP­9 and 
IL­6. In an observational non­randomised 
study of 137 patients, we found that 
patients on statin therapy were significantly 
less likely to have suffered carotid territory 
symptoms within the month prior to carotid 
endarterectomy. the number of patients 
undergoing spontaneous pre­operative cereb­
ral embolization was also significantly lower 
in the statin group.
HMG Co­a reductase inhibitors also 
have the potential to reduce thrombogenicity 
by decreasing tissue factor activity197 and 
lowering levels of PaI­1.198,199 
MMP Inhibition
the realisation that tissue remodelling due 
to increased MMP activity plays a key role 
in disease states has led to considerable 
interest in the potential for MMP inhibition. 
Most clinical and pre­clinical data regarding 
therapeutic manipulation of the extracellular 
matrix has been in the fields of arthritis, 
periodontal disease and cancer.103 MMP 
inhibition aimed at plaque stabilisation aims 
to redress the imbalance between enzymes 
and inhibitors, which causes excessive tissue 
degradation. Potential methods of MMP 
inhibition include the administration of: 
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Tissue Inhibitors of 
Metalloproteinases (TIMPs)
the level of tIMPs can be increased 
either by the exogenous administration of 
recombinant tIMPs or by stimulating their 
local production through gene therapy. 
Increased tIMP­1 raised the collagen, elastin 
and smooth muscle content of atherosclerotic 
lesions in animal models,200 while local gene 
transfer of tIMP­2 has been shown to 
decrease vascular remodelling in conjunction 
with lowered MMP activity (experimental 
models).201
It is difficult to extrapolate these data to 
potential applications in humans. the major 
drawback associated with tIMPs would be 
tissue delivery, since exogenous products 
would be metabolised and denatured with 
minimal tissue penetration at the intended 
site of action. systemic stimulation of 
tIMPs would almost certainly have sig­
nificant side effects precluding clinical use. 
therefore, treatment would have to take the 
form of local tissue delivery or gene therapy. 
Clearly either system will be very expensive 
to develop, so more interest has concentrated 
on the development of synthetic MMP 
inhibitors.
Synthetic MMP inhibitors
synthetic peptides work by binding to the 
zinc ion at the active site of the MMP, 
thus preventing cleavage of substrate 
collagen molecules.202 Batimastat showed 
promise in decreasing tumour development 
and metastasis (animal models)203 and 
limiting aneurysm expansion (experimental 
models),204 but is not available in an oral 
form. Marimastat, which is available orally, 
was shown to limit intimal hyperplasia205 and 
aneurysm expansion in vivo.206 It also showed 
promise in early human cancer studies, but 
caused significant musculoskeletal side effects 
in 30% of patients.207 Recent studies of 
MMI270, a more specific inhibitor (of 
MMP­2, MMP­8 and MMP­9), have shown 
a similar side effect profile.208 furthermore, 
recent animal studies of broad­spectrum 
synthetic MMP inhibitors have found them 
to be generally deleterious in terms of both 
plaque growth and plaque stability.209
Doxycycline
Doxycycline, a member of the tetracycline 
antibiotic family, is also a non­selective 
MMP inhibitor,210 with a proven safety 
profile. Clinical trials have shown that 
doxycycline is capable of decreasing cartilage 
MMP levels when given to patients prior 
to hip surgery.211 It has also been shown to 
limit intimal hyperplasia212 and aneurysm 
expansion in vivo,213 by reducing MMP­9 
activity. furthermore, when given to 
patients prior to aaa repair the expression 
of MMP­2 and MMP­9 was reduced in the 
aortic wall.214 
a randomised clinical trial of doxycycline 
versus placebo in patients prior to carotid 
endarterectomy demonstrated decreased 
plaque MMP­1 levels and a potential for 
clinical benefit.215 a phase II study of 
doxycycline administration to patients with 
small aaas recently showed that it was 
reasonably well­tolerated (92% completed 
the 6­month course) and reduced plasma 
MMP­9 levels.216 further studies are on going 
to evaluate its effects on small aneurysm 
expansion. 
ACE Inhibitors
aCE inhibitors (aCEI) and angiotensin II 
receptor antagonists decrease cardiovascular 
events, independently of their effects on blood 
pressure control. the aCEI, trandalopril, 
and the experimental angiotensin receptor 
antagonist, HR720, decrease the area 
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of atherosclerotic lesions in the thoracic 
aorta of cholesterol­fed monkeys.217 this 
was achieved without alteration of mean 
blood pressure or cholesterol levels. the 
Heart outcomes Prevention Evaluation 
(HoPE) study demonstrated a decrease in 
cardiovascular events in high­risk patients 
given ramipril as opposed to placebo.218 this 
effect could only be partly explained by the 
modest decrease in mean blood pressure seen 
between the 2 groups (3/2mmHg).
angiotensin II promotes endothelial 
activation,219 and therefore the mechanism of 
action of aCEIs could be through endothelial 
passivation (leading to a reduction in cell 
adhesion molecule expression and macrophage 
infiltration). aCEIs may also exert their 
effects through bradykinin potentiation, 
resulting in decreased smooth muscle cell 
migration, decreased inflammation and 
decreased production of oxygen free radicals 
(CoPPoLa 2008). navalkar et al provided 
biochemical evidence to support these 
hypotheses by demonstrating that irbesartan 
(an angiotensin II receptor blocker) can 
decrease plasma levels of VCaM­1, tnf­α 
and superoxide.220
With ever more detailed understanding 
of the human genome, gene therapies have 
also come under investigation in the search 
for anti­atherosclerotic therapies. Hans et 
al have demonstrated that polyaDP­ribose 
polymerase (PaRP­1), a Dna­repair protein, 
stimulates apoptosis in the presence of local 
inflammation and plays an important role 
in plaque dynamics. they went on to show 
that inhibition of PaRP­1 resulted in a 
reduction in plaque size, decreased collagen 
degradation and increased plaque smooth 
muscle content in apoE(­/­) mice.221 these 
findings suggest that PaRP­1 inhibition may 
also represent a valuable therapeutic tool, 
though its applicability in humans has yet to 
be demonstrated.
since the clinical significance of any plaque 
rupture is also governed by the intravascular 
environment, investigators continue to 
seek new therapies that may decrease the 
thrombogenicity of blood. until now, this 
has been achieved with a combination of 
aspirin and another antiplatelet agent – 
most commonly clopidogrel – but drug 
resistance and side effect profiles can limit its 
applicability. the latest class of antiplatelet 
drugs is the P2Y
12
 blockers, which inhibits 
platelet activation via blockade of the P2Y
12
 
aDP­receptor. though these drugs (such 
as prasugrel and ticagrelor) may still have 
significant side effect profiles, they seem to 
be associated with far less unwanted bleeding 
and may be effective in patients who do not 
respond to clopidogrel.222
though a number of therapeutic targets 
have shown promise in preventing plaque 
rupture, substantial work is still needed 
in this area since many of the potential 
therapeutic targets (such as smooth muscle 
cells and macrophages) have the ability to 
play both detrimental and beneficial roles in 
the complex process of atherosclerosis. 
suMMaRY
acute plaque disruption precedes the onset of 
clinical ischaemic syndromes. Exposure of the 
highly thrombogenic core to luminal blood 
results in platelet adherence and thrombosis. 
Inflammation is clearly involved in the 
process of plaque development and acute 
disruption, though the precise mechanism by 
which the inflammatory process is initiated 
remains unclear. the roles of angiogenesis, 
cellular apoptosis and infectious agents also 
require further clarification. unstable plaques 
have a large lipid core and a thin fibrous cap 
with reduced collagen content. a major 
component of plaque destabilisation appears 
to be increased matrix degradation, the 
primary regulators of which are the MMPs 
and their inhibitors. there are a number 
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of potential therapeutic options aimed at 
preventing plaque disruption. In particular, 
MMP inhibition is an attractive target for 
such pharmacotherapy.
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The global epidemic of cardiovascular disease 
(CVD) continues to rise, with atherosclerotic 
CVD remaining the lead cause of morbidity 
and mortality worldwide, comprising of 
29% of all global deaths in 2003. A majority 
of these deaths were directly caused by 
coronary artery disease (CAD) or strokes.1 
It is estimated that up to 50% of all deaths 
and disability due to CAD and strokes could 
be curtailed by a number of lifestyle and 
therapeutic approaches that directly target 
major cardiovascular risk factors.
Atherosclerosis is a systemic disease pro­
cess involving multiple vascular territories. 
The presence of established vascular disease, 
regardless of the territory involved, portends 
the greatest risk of incident cardiovascular 
events. The prevalence of asymptomatic 
coronary stenoses of greater than 50% angi­
ographic severity in non­disabling ischaemic 
stroke patients has recently been estimated 
to be 20%,2 and those patients afflicted with 
peripheral arterial disease have a probability 
of death due to CAD and stroke of 55% and 
11% respectively.3 Given the significant sys­
temic plaque burden in these patients coupled 
with corresponding high event rates, various 
anti­atherosclerotic and vascular protective 
therapies have the potential to significantly 
lower absolute clinical event rates.
PATHOLOGY
Atherosclerosis is a chronic inflammatory 
condition, characterised by the accumulation 
of inflammatory cells, lipid and apoptotic 
material within the arterial wall. The 
endothelial cell layer, a single cell layer 
lining the lumen of the vasculature, serves 
to regulate permeability of the arterial wall, 
vascular tone and tendency for thrombus 
formation. Endothelial dysfunction therefore 
results in altered permeability of the vessel 
wall, increased vascular reactivity with 
vasoconstriction and the promotion of a 
number of prothrombotic substances. Such 
abnormalities are inherently promoted by 
the reduced bioavailability of nitric oxide, 
the principal product of the endothelium. 
Following transmigration across the endo­
thelial layer, migrated monocytes transform 
into macrophages, which engulf extracellular 
lipid to become foam cells, which accumulate 
to form a fatty streak, considered the earliest 
macroscopic evidence of atherosclerosis.4 
Local smooth muscle cell migration results in 
collagen production, forming a fibrous cap, 
which separates the enlarging inflammatory 
and lipid milieu from the circulating blood 
stream. The ongoing accumulation of inflam­
matory cells, lipid and apoptotic material 
covered by a strong fibrous cap represents 
a mature atherosclerotic plaque.4 Many 
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atherosclerotic plaques remain clinically 
quiescent, however some plaques may 
progress to an advanced stage, characterised 
by progressive lumen encroachment, 
aneurysm formation and plaque rupture. 
The latter two processes are mediated 
by the degeneration of the extracellular 
collagen matrix, which in turn is driven by 
activated matrix metalloproteinase enzymes.5 
Furthermore, plaque neovascularisation 
(with the adventitial proliferation of vaso­
vasorum) leading to repeated intraplaque 
haemorrhage is now widely recognised as an 
important mediator of plaque progression 
and instability.6 
The degradation of collagen within the 
fibrous cap leads to a reduction in the tensile 
strength, which appears more pronounced at 
the shoulders regions of the plaque. Higher 
shear stress at these shoulder region, further 
predispose the thinned fibrous cap to erosion 
or rupture. This exposes plaque components 
(including the highly thrombogenic tissue 
factor) to the circulating blood stream, cul­
minating in the activation and aggregation of 
platelets and the coagulation cascade, leading 
to local thrombus formation. This thrombus 
may embolise downstream, or result in local 
occlusion of the arterial lumen to blood flow, 
with resulting acute ischaemia.7 
Anti­atherosclerotic therapies are admin­
istered for either the primary prevention 
of cardiovascular events, or to prevent the 
recurrence of events in those patients with 
established vascular disease. This chapter will 
review the role of various strategies that have 
shown clinical evidence of their atheropro­
tective effects for the prevention of cardio­
vascular disease.
RISK FACTOR MODIFICATION
Population studies have established an 
assoc iation of the presence of a number 
of modifiable cardiovascular risk factors 
with increased risk for the development 
of CVD.8,9 These risk factors include: (1) 
elevated plasma concentrations of various 
atherogenic lipoproteins, which include low­
density lipoprotein cholesterol (LDL­C), 
lipoprotein (a) and triglycerides (TGL); 
(2) reduced plasma concentrations of high­
density lipoprotein cholesterol (HDL­C); 
(3) hypertension; (4) diabetes; (5) smoking; 
and (6) obesity and the associated metabolic 
syndrome. Mechanistic studies, primary 
and secondary prevention clinical studies 
and atherosclerosis imaging studies, have 
demonstrated significant benefits following 
the reduction of pro­atherogenic lipoproteins, 
elevation of HDL­C and treating hyper­
tension, whilst the aggressive glucose 
lowering for reducing cardiovascular events 
remains controversial. 
Table 5.1: Modifiable atherogenic risk 
factors












In population studies with extensive follow­up, 
plasma concentrations of LDL­C have been 
shown to be a strong and independent 
predictor of future cardiovascular disease.8 
Established therapies to lower LDL­C 
levels include hydroxymethylglutaryl Co­A 
reductase inhibitors (statins), bile acid 
sequestrants, ezetemibe, LDL­C apheresis 
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and ileal bypass surgery. Statins however 
remain the predominant means of successful 
LDL­C lowering with an abundance of 
clinical and mechanistic evidence of the 
favourable impact these agents have upon 
atherosclerosis regression, and primary and 
secondary prevention. 
Hydroxymethylglutaryl Co­A reductase 
is the rate limiting enzyme in the pathway 
leading to the endogenous synthesis of 
cholesterol by the liver. Inhibition of this 
enzyme results in the up­regulation of 
hepatic LDL receptors, with the subsequent 
removal of LDL from the circulation. Statins 
are well tolerated, and result in substantial 
inhibition in plasma LDL­C levels, coupled 
with modest elevations in HDL­C levels. A 
minority of patients develop elevations in 
hepatic transaminases and myositis, while 
rhabdomyolysis is exceedingly rare. 
Statins have resulted in relative risk 
reductions of 20­40% of both primary10­12 
and secondary cardiovascular events.13­17 The 
West Of Scotland Coronary Prevention 
Study (WOSCOPS) was the first primary 
prevention study that highlighted a 31% 
and 33% reduction of fatal and non­fatal 
coronary events respectively in 6595 ran­
domized middle aged males (whose total 
cholesterol was greater than 6.5 mmol/L) 
who took pravastatin for 5 years.10 Follow­
ing WOSCOPS, the AFCAPS/TexCAPS 
trial randomized 6605 patients with a mean 
total cholesterol level of 5.7 mmol/L to 
lovastatin or placebo. After 5 years follow­up, 
lovastatin reduced the combined end point 
of sudden death, myocardial infarction and 
unstable angina by 33%.11 More recently, 
the JUPITER study randomized 17802 
individuals without hyperlipidaemia (mean 
LDL­C less than 3.4 mmol/L) but with an 
elevated high­sensitive C­reactive protein 
(hsCRP) of greater than 2 mg/L to daily 
rosuvastatin 20 mg or placebo. The trial was 
halted prematurely after a median follow­up 
of 1.9 years due to the rosuvastatin group 
experiencing a 23% relative risk reduction in 
the combined primary endpoint of myocar­
dial infarction, stroke, arterial revascularisa­
tion, hospitalisation for unstable angina or 
death from cardiovascular causes.12 This trial 
therefore highlighted the primary benefit of 
LDL­C lowering in patients with systemic 
inflammation.
The Scandinavian Simvastatin Survival 
Study (4S) randomized 4444 patients 
with established coronary artery disease 
and fasting total cholesterol between 5.5 to 
8 mmol/L to treatment with simvastatin or 
placebo. After 5.4 years, the primary end 
point of all­cause mortality was reduced by 
30% with simvastatin, with similar reduc­
tions in myocardial infarction and stroke.13 
Similar magnitudes of reduction in mortality 
and myocardial infarction were seen in the 
Cholesterol and Recurrent Events (CARE) 
and Long­term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) studies, which 
together evaluated the benefit of pravastatin 
versus placebo in over 13000 patients with 
prior myocardial infarction over a 5­year 
period.14,16 Additionally, the Heart Protection 
Study (HPS) randomized 20536 patients 
with established atherosclerotic CVD (or 
high­risk equivalents on the basis of diabetes 
mellitus) and total cholesterol greater than 
3.5 mmol/L to treatment with simvastatin or 
placebo.15 Significant reductions in all­cause 
mortality (13%), cardiovascular mortality 
(17%), coronary events (27%) and stroke 
(25%) were found in the simvastatin group.
Regression of atherosclerosis within the 
coronary vasculature is a validated surrogate 
end­point of the clinical event reductions 
seen with statin therapies. Studies employ­
ing intravascular ultrasound (IVUS) have 
also highlighted the benefits of LDL­C 
lowering upon the coronary vessel wall. A 
consistent finding observed in the IVUS 
trials is the strong linear relationship between 
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mean LDL­C levels achieved on statin therapy 
and the median progression­regression rate 
of atherosclerosis. In the Reversal of Athero­
sclerosis with Aggressive Lipid Lowering 
(REVERSAL) study, halting of disease pro­
gression was achieved with aggressive LDL­C 
lowering to 2.0 mmol/L with atorvastatin 
(80 mg/day), as compared with plaque pro­
gression seen in those patients randomized 
to moderate LDL­C lowering with pravas­
tatin 40 mg/d who achieved a mean LDL­C 
of 2.9 mmol/L.18 The ASTEROID (A Study 
To Evaluate the effect of Rosuvastatin On 
Intravascular ultrasound –Derived coronary 
atheroma burden) study was the first large 
scale trial to show that plaque regression could 
be achieved by intensive LDL­C lowering to 
levels lower than achieved in REVERSAL. 
Rosuvastatin 40 mg/d lowered LDL­C 
levels to 1.6 mmol/L, and reductions in all 
volumetric measures of plaque burden was 
achieved.19 More recently, a pooled analysis 
of more than 4000 patients who underwent 
serial IVUS coronary imaging in 6 trials has 
demonstrated a direct relationship between 
the baseline plaque burden, its progression 
and major adverse cardiovascular events.20 
Although the clinical benefit seen in statin 
trials is able to be predicted from the degree 
of LDL­C lowering, statins are thought to 
exert vasculoprotective effects mediated by 
a variety of mechanisms other than direct 
LDL­C lowering. These suggested pleio­
tropic mechanisms include anti­thrombotic, 
anti­inflammatory, antioxidant, vasodilatory 
and anti­proliferative effects. Although such 
effects have been studied previously, only 
the anti­inflammatory CRP­lowering effects 
have been systematically evaluated in large 
scale clinical trials.
A major benefit of statin therapy is found 
in those patients with a high inflammatory 
state. Post hoc analyses of the CARE study 
found that those subjects with circulating 
biomarkers greater than the 90th percentile 
had the greatest risk of recurrent events, and 
the greatest benefit from pravastatin occurred 
in this group.21 Further insights from 
REVERSAL revealed the superior CRP­ 
lowering effects of atorvastatin over pravasta­
tin. It is likely that this greater degree of anti­
inflammatory effects exerted by atorvastatin 
contributed to a halting of atherosclerosis 
progression,22 whereby the CRP reductions 
correlated directly with changes in atheroma 
volume seen with IVUS. The PROVE­IT 
(PRavastatin Or atorVastatin Evaluation and 
Infection Therapy) study complimented the 
imaging findings from REVERSAL using the 
identical regimen of statin therapy in a large 
cohort of patients following an acute coro­
nary syndrome (ACS), with the atorvastatin 
group experiencing significantly reduced 
clinical event rates.23 It is yet to be shown 
as to whether CRP exerts direct effects upon 
plaque biology, and appropriately designed 
clinical trials will need to be undertaken to 
study the clinical effects of new molecules 
that directly target CRP. 
The pleiotropic effects of statins have 
been postulated to result in plaque stabili­
sation, which renders the plaque less likely 
to rupture to cause clinical events. Modula­
tion of endothelial dysfunction and the anti­
inflammatory properties of statins have been 
demonstrated within a few hours following 
statin administration. As a result, the effects 
of statins have been studied early in the 
setting of ACS or prior to elective percuta­
neous coronary intervention (PCI) in stable 
patients. Patients with ACS present a rela­
tively high risk of recurrent adverse cardiovas­
cular events. Hence, the early intensive use of 
statins may improve clinical outcomes and as 
such, statins have recently been included in 
the treatment guidelines for ACS.24 The early 
benefit of statin therapy following ACS was 
demonstrated in The Myocardial Ischaemia 
Reduction with Aggressive Cholesterol Low­
ering (MIRACL) study.25 This trial enrolled 
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3086 patients with ACS and randomized this 
group to atorvastatin 80 mg/d or placebo 
commenced within 24­96 hours following 
randomization. After 16 weeks, the atorvas­
tatin group demonstrated a 14% relative risk 
reduction in the composite clinical endpoint 
of death, myocardial infarction, resuscitated 
cardiac arrest or admission for suspected 
ischaemia. Two recent meta­analyses of ran­
domized controlled trials which evaluated 
for benefits of statins compared to placebo or 
usual care following ACS have highlighted 
that the real benefit of early statin therapy 
takes at least 4­6 months to become evident, 
with the significant benefits predominantly 
limited to reductions in unstable angina.26 
A number of studies have also investigated 
the effects of high­dose statin loading upon 
the incidence of periprocedural myocardial 
infarction in the setting of PCI. A large 
series of patients undergoing elective PCI 
(n = 5052), found that patients treated with 
statins at the time of procedure had a signifi­
cant mortality reduction at 30 days (0.8% 
vs 1.5% in statin naive patients; p = 0.048); 
with this benefit being maintained at 6 month 
follow­up (2.4% vs 3.6%; p = 0.046).27 
Furthermore, in a series of 1552 patients, 
those patients that had initiated statin therapy 
prior to the procedure (39.6% of the study 
group) had a significantly lower incidence of 
periprocedural myocardial infarction (5.7% 
vs 8.1% in statin naive; p = 0.038) with a 
mortality benefit seen at 1 year (3.4% vs 
6.9%; p = 0.003).28 Statin pretreatment 
was predictive of survival chiefly in patients 
within the highest CRP quartile. The Ator­
vastatin for Reduction of Myocardial Dam­
age During Angioplasty (ARMYDA) trial 
was the first randomized prospective, pla­
cebo controlled, double­blind study that 
demonstrated a beneficial effect of statin 
pretreatment in preventing myocardial dam­
age following PCI.29 Patients with chronic 
stable angina (n = 153) were randomized to 
atorvastatin 40mg/d commencing 1 week 
pre­procedure versus placebo. Periprocedural 
myocardial infarction was detected in 5% 
of atorvastatin­treated patients compared 
to 18% in the placebo arm (p = 0.025). 
The ARMYDA ACS trial randomized 171 
patients with ACS to receive placebo or 
atorvastatin loading (80 mg 12 hours before 
coronary angiography and a 40 mg dose 
2 hours before intervention).30 The primary 
composite endpoint of 30 day death, myo­
cardial infarction and need for repeat target 
vessel revascularisation occurred in 5% of 
the treatment group compared to 17% of the 
placebo group (p = 0.04), with multivariate 
analysis indicating that atorvas tatin pretreat­
ment was associated with an 88% relative risk 
reduction of 30­day events. Furthermore, 
the ARMYDA RECAPTURE study showed 
that acute statin preloading prior to PCI in 
patients on chronic statin therapy had a pro­
tective effect with the combined endpoint of 
30 day death, myocardial infarction and tar­
get vessel revascularisation occurring in 3.7% 
of patients in the re­load group vs 9.4% in 
the placebo group (p = 0.037); a 50% rela­
tive risk reduction on multivariate analysis.31 
Both the ARMYDA ACS and ARMYDA 
RECAPTURE trial 30 day combined end­
points were largely driven by a significant 
reduction in periprocedural myocardial 
infarction. Collectively, this data highlights 
that statin pretreatment is a low risk yet 
highly effective therapy of ‘plaque’ and 
‘vessel’ stabilisation, mediated perhaps via a 
number of pleiotropic effects, in both stable 
and unstable patients undergoing coronary 
intervention, regardless of whether patients 
are statin naive or not.
The vasculoprotective effects of statins 
also extends to the perioperative period 
during noncardiac surgery. A retrospective 
case­control study of 2816 patients who 
underwent major non­cardiac vascular sur­
gery was the first study to show a 4­fold 
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significant reduction in all­cause mortality 
during the perioperative period.32 Soon after, 
the first prospective, placebo­controlled, 
blinded, randomized controlled trial evalu­
ating the effects of 2 months of statin treat­
ment upon perioperative cardiovascular 
complications after vascular surgery showed 
that the combined primary endpoint (cardiac 
death, nonfatal myocardial infarction, stroke 
or unstable angina) at 6­months was 3­fold 
higher with placebo than with atorvastatin 
20 mg/d.33 A number of retrospective stud­
ies have also evaluated the effects of statin 
therapy upon perioperative complications in 
patients undergoing noncardiac surgery. A 
large cohort (n = 780591) of patients under­
going noncardiac surgery found that in those 
70159 statin users, there was a significant 
1.4­fold reduced risk of in­hospital mor­
tality.34 The Statins for Risk Reduction in 
Surgery (STARRS) study assessed the effect 
of statins on cardiac complications in 1163 
patients undergoing vascular surgery.35 This 
study found a significantly lower periopera­
tive complication rate in the statin group 
compared to statin non­users (adjusted OR 
0.52, 95% CI 0.35­0.77). Furthermore, the 
long­term benefit of statins was observed in 
510 patients undergoing successful abdomi­
nal aortic aneurysm surgery, with a signifi­
cant reduction in all­cause mortality (18% vs 
50%; p<0.001) seen in statin users compared 
to non­statin users over a median period of 
4.7 years.36 Although a risk of statin­induced 
myopathy exists in the surgical group of 
patients taking statins, this risk is considered 
relatively modest compared to the benefits 
of statins in reducing perioperative cardiac 
events. Also noteworthy is the evidence that 
suggests that statin therapy should remain 
uninterrupted (if possible) during the peri­
operative period. Due to the lack of avail­
ability of intravenous formulations, statin 
interruption, however, is common and 
usually unintended. 
Table 5.2: LDL-C lowering summary 
points
•  Statins are the most effective means of 
LDL-C lowering
•  Statins inhibit the rate limiting enzyme in 
cholesterol synthesis
•  Statins also achieve minor elevations of 
HDL-C, modest reductions of TGL levels
•  20%-30% reduction of events in primary 
prevention studies
•  30%-40% reduction of events in secondary 
prevention studies
•  Clinical benefit proportion to degree of 
LDL-C lowering
•  Regression of coronary atherosclerosis 
achievable with substantial LDL-C 
lowering
•  Pleiotropic benefits of statins may 
contribute to benefit seen during ACS, 
peri-procedural administration during 
PCI, and peri-operatively for non-cardiac 
surgery
The complexity of HDL
Although the unequivocal benefit of 
LDL­C lowering has been demonstrated 
in a number of clinical trials, reductions in 
event rates by no more than 40% suggest 
that additional mechanisms are involved in 
mediating cardiovascular events, and that 
complementary strategies are required to 
achieve greater efficacy in cardiovascular 
risk reduction. HDL­C is emerging as an 
important therapeutic target for modulation 
of cardiovascular risk. Observational studies 
have suggested that the prevalence of low 
HDL­C levels (< 40 μg/dL, or 1.0 mmol/L) 
is greater in patients with established 
CAD, with numerous population studies 
also demonstrating an inverse relationship 
between HDL­C levels and prospective risk 
of CAD, regardless of the corresponding 
level of LDL­C.37 HDL­C was found to 
be the strongest biochemical predictor of 
cardiovascular outcome in the Framingham 
study.38 A pooled meta­analysis of four 
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population studies subsequently estimated 
that each 1 μg/dL rise in levels of HDL­C 
was associated with a 2% to 3% reduction 
in cardiovascular risk.39 
High­density lipoprotein cholesterol pos­
sesses numerous anti­atherosclerotic prop­
erties, including the promotion of reverse 
cholesterol transport, protection of both 
LDL­C particles and endothelial cells from 
oxidative changes, inhibition of cytokine 
induced expression of endothelial cell sur­
face adhesion molecules and the inhibition 
of the prothrombotic milieu associated with 
atheroma. Animal studies have provided 
support of these protective effects of HDL. 
Early studies showed that HDL infusions 
not only retard lesion formation but also 
promoted regression of established athero­
sclerotic plaque, with favourable effects also 
seen upon plaque composition.40 These stud­
ies therefore provided robust pre­clinical 
evidence that raising HDL­C levels might 
be beneficial in humans. 
There are a number of strategies that 
increase HDL­C levels. Non­pharmacological 
methods include weight loss, smoking cessa­
tion and mild alcohol consumption. Estab­
lished pharmacological strategies include 
fibrates, statins and nicotinic acid, which 
raise HDL­C levels by 10­35%, 5­15% and 
15­35% respectively. Fibrates have been 
shown to reduce clinical event rates in stud­
ies of primary and secondary prevention. 
The Helsinki Heart Study (HHS) demon­
strated that an 11% increase in HDL­C 
independently predicted the 34% reduction 
in myocardial infarction and cardiovascular 
death with gemfibrozil. Each 1% increase in 
HDL­C was associated with a 3% reduction 
in cardiovascular risk.41 A similar benefit with 
gemfibrozil was observed in patients with 
established CAD and low HDL­C levels in 
the VA­HIT (Veterans Affairs High­Density 
Lipoprotein Intervention Trial), whereby 
the 6% rise in HDL­C predicted the 22% 
reduction in myocardial infarction or cardio­
vascular death.42 
Apart from LDL­C lowering, statins 
modestly raise HDL­C levels. In a pooled 
analysis of four clinical studies, raising 
HDL­C was found to be an independent 
predictor of the benefits of statins in slow­
ing progression of coronary atherosclerosis, 
with incremental benefit regression observed 
within those patients whose HDL­C rose by 
7.5%, despite intensive LDL­C lowering.43 
Niacin is the most effective current 
method of raising HDL­C levels. Several stud­
ies have demonstrated that the use of niacin 
in combination with other lipid­modifying 
agents, had a substantial effect upon rela­
tive risk reduction and disease progression. 
The HATS (HDL in Atherosclerosis Study) 
showed that simvastatin and niacin raised 
HDL­C by 24%, lowered LDL­C by 42% 
and promoted regression of angiographically 
detectable CAD. Moreover, there was a pro­
found 60% relative risk reduction in major 
adverse cardiac events.44 The benefit of add­
ing extended release niacin to statin therapy 
was also seen in the ARBITER­2 (Arterial 
Biology for the Investigation of the Treat­
ment Effects of Reducing Cholesterol 2) 
study, whereby an increase in HDL­C levels 
of 0.21mmol/L slowed progression of carotid 
intimal­media thickness (CIMT) in patients 
with HDL­C levels below 1.2 mmol/L.45 
More recently, the addition of niacin (for 
HDL­C augmentation) was found to be 
superior to the addition of ezetemibe (for fur­
ther LDL­C lowering) in a group of patients 
already on chronic statin therapy for CAD, 
whereby the niacin/statin group experienced 
significant regression of CIMT compared 
to the ezetemibe/statin group.46 Intolerance 
due to flushing, which is mediated by activa­
tion of epidermal prostanoid receptors, 
continues to limit the widespread clinical 
use of effective doses of niacin. However, 
pharmacological strategies to inhibit these 
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epidermal prostanoid receptors in com­
bination with the delivery of niacin therapy 
may hold promise for future trials employ­
ing niacin as an effective and well­tolerated 
anti­atherosclerotic therapy. Enthusiasm also 
exists for significantly raising HDL­C levels 
via the inhibition of cholesteryl ester transfer 
protein (CETP). In humans, CETP inhibi­
tion is capable of raising HDL­C levels by 
greater than 50% and reducing LDL­C 
levels by 20%. However the ILLUMINATE 
(Investigation of Lipid Level Management 
to Understand Its Impact in Atherosclerotic 
Events) trial was prematurely halted due to a 
higher clinical event rate seen in the patients 
administered Torcetrapib (CETP inhibi­
tor).47 These unexpected effects have been 
postulated to arise from activation of the 
renin­angiotensin system as well as a direct, 
unfavourable molecule­specific vasculotoxic 
effect of Torcetrapib itself.48 The recent 
report of the safety of Anacetrapib, a next 
generation CETP inhibitor, has raised hopes 
that significant elevations in HDL­C levels 
via CETP inhibition will regress atheroscle­
rosis and eventually result in reduced clinical 
event rates.49
HDL comprise a heterogenous group of 
particles, which vary in size, shape and con­
tent of both lipid and protein. Normal or 
elevated levels of HDL are not always athero­
protective in humans. The finding that greater 
than 40% of the clinical events observed in 
the Framingham cohort occurred in sub­
jects with serum HDL­C levels greater that 
1.01 mmol/L suggests that their HDL failed 
to possess the appropriate levels of protective 
properties.50 The observation that HDL, iso­
lated from subjects with CAD despite high 
HDL­C serum levels, promotes rather than 
inhibits monocyte chemotaxis in response 
to oxidised LDL­C, provided mechanistic 
evidence that HDL may be proatherogenic 
in some individuals.51 It remains to be estab­
lished whether the size and composition of 
HDL particles bears influence upon their 
functional properties. Contrasting reports 
from population studies have demonstrated 
that HDL particle size may influence pro­
spective clinical risk. Furthermore, a poten­
tial relationship between HDL subclasses 
and cardiovascular risk has been reported to 
contribute to the relative benefit of various 
lipid­modifying therapies. In an exploratory 
analysis of VA­HIT, the generation of small 
HDL particles with gemfibrozil was dem­
onstrated to independently predict protec­
tion from cardiovascular events.52 This may 
explain why a relatively small rise in HDL­C 
levels was associated with clinical benefit. 
The observation of benefit by raising levels 
of lipid­deplete HDL particles is consistent 
with their ability to remove excess cellular 
cholesterol, prevent LDL­C oxidation, rap­
idly improve endothelial function, and pro­
mote plaque regression in humans.53 
HDL therefore remains an attractive 
target for modification by therapies aimed 
to promote cardiovascular risk reduction. 
However, the complexity of HDL presents a 
major challenge in determining the optimal 
therapeutic approach. Although a number 
of groups have proposed specific HDL­C 
targets for treatment, there is no current 
evidence that treating to a particular target 
results in clinical benefit. At the minimum, 
it would seem that attempts to raise HDL­C 
levels above levels considered to be associ­
ated with an increase in cardiovascular risk 
(1.01 mmol/L in men and 1.28 mmol/L in 
women) would be prudent. However the 
emergence of the functional quality of HDL, 
rather than absolute HDL levels, is currently 
presenting a major challenge for future drug 
development programs. It is likely that rais­
ing the right type of HDL­C may have the 
greatest impact upon cardiovascular disease 
prevention. 
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Table 5.3: HDL-C cholesterol summary 
points
• Strongest independent predictor of events
• Numerous atheroprotective properties:
Promotes cholesterol efflux
Anti-inflammatory actions
Reduces oxidation of LDL-C
Inhibits thrombogenecity
• Elevated by weight loss, smoking 
cessation and mild alcohol consumption
• Therapeutically elevated by fibrates and 
nicotinic acid
• Novel therapeutic agents that elevate 
HDL-C levels and promote HDL-C 
functionality are currently being trialled in 
humans
The controversy of triglycerides
Despite extensive research, in the setting 
of clinical trials and epidemiologic studies, 
the exact role of serum TGL levels as an 
independent risk factor for CAD remains 
uncertain. Observational studies have 
produced data in support of the independent 
predictive value of fasting TGL levels for 
incident CAD. Graziano et al. investigated the 
interrelationships between fasting TGL and 
other lipid parameters, along with non­lipid 
risk factors, against the risk of myocardial 
infarction in 340 cases and 340 age­, 
gender­ and community­matched controls. 
The relative risk of myocardial infarction 
was found to have a strong association with 
elevated fasting TGL levels that remained 
unaltered after controlling for other non­
lipid risk factors; however despite remaining 
statistically significant, the strength of this 
association was attenuated somewhat after 
controlling for HDL­C.54 Following this 
study, Jeppesen et al. examined the relationship 
between fasting TGL levels and ischaemic 
heart disease (IHD) risk in over 2,900 males 
in the Copenhagen Male Study, with 8­years 
of follow­up. Following adjustment of both 
lipid and non­lipid risk factors, men in the 
middle and highest tertile of TGL levels had 
relative risks of IHD of 1.5 (95% CI, 1.0­
2.3; p = 0.05) and 2.2 (95% CI, 1.4­3.4; 
p < 0.001) respectively, when compared with 
men in the lowest TGL tertile.55 When TGL 
levels were stratified by HDL­C levels, the 
risk of IHD increased with increasing TGL 
within each HDL­C level. Similarly, the 
larger Prospective Cardiovascular Munster 
study involving 4,849 middle­aged men who 
were followed for 8­years found TGL levels 
to be an independent risk factor for CAD 
irrespective of HDL­ or LDL­C levels.56
Therefore there is no clinical trial that 
has been designed to specifically address the 
issue of TGL lowering upon incident cardio­
vascular events. Although patients enrolled 
in the HHS experienced a 35% reduction 
in TGL levels, it was the 11% increase in 
HDL­C levels that predicted the 34% rela­
tive risk reduction in the rate of myocardial 
infarction.41 Limited data therefore exists 
from clinical trials to suggest that the spe­
cific lowering of TGL levels, independent of 
concomitant HDL­C raising/LDL­C low­
ering, will result in reduced clinical event 
rates within patients with normal or elevated 
LDL­C levels. Although current guidelines 
do not mandate screening for elevated TGL 
levels within the general population, TGL 
levels in patients afflicted with CAD (or CAD 
risk equivalent) may provide valuable prog­
nostic information for therapeutic decision­
making. At this point the presence of mild 
to moderate hypertriglyceridemia identifies a 
patient who requires more intensive manage­
ment of LDL­C, with treatment guidelines 
advocating initiation or intensification of 
statin therapy as first line treatment.
Hypertension
Epidemiologic studies have established a 
direct relationship between both systolic and 
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diastolic blood pressures and cardiovascular 
events. The strongest relationship lies 
between hypertension and cerebrovascular 
disease. Framingham data predict the life­
time risk of developing hypertension to be 
about 90% by the age of 65 years.57 The 
Multiple Risk Factors Intervention Trial 
(MRFIT) demonstrated a continuous and 
graded relationship between both systolic 
and diastolic blood pressures and death 
due to both CAD and stroke,58 with the 
strength of this relationship greatest for 
systolic blood pressure. In addition, isolated 
systolic hypertension, the commonest form 
of hypertension, portends a 2.5­fold greater 
risk of cardiovascular disease compared with 
matched, normotensive patients. 
Hypertension alters shear forces within 
the vascular lumen. Steady laminar flow stim­
ulates endothelial cellular functions which 
maintain vascular tone, thrombogenecity and 
regulated permeability. The mechanotrans­
duction of these altered shear­stress signals 
arising from the endothelial surface result in 
a number of changes contributing towards 
atherogenesis, including altered gene expres­
sion, as well as changes to vascular regulatory 
substances including nitric oxide, endothelin 
and angiotensin II. 
The use of anti­hypertensive therapy for 
primary prevention reduces cardiovascular 
events. A meta­analysis of randomised con­
trolled trials involving the reduction of 
systemic hypertension in primary preven­
tion revealed a 21% risk reduction in events 
attributed to CAD and a 37% reduction in 
the incidence of stroke.59 The Hyperten­
sion Optimization Trial (HOT) randomised 
patients with hypertension to therapy aimed 
at three groups of blood pressure targets. 
Analysis revealed the lowest incidence of 
cardiovascular events in those with a mean 
diastolic blood pressure of 82.6 mmHg, sup­
porting aggressive lowering of blood pressure 
into the ‘normal’ range.60 
The Heart Outcome Prevention Evalu­
ation (HOPE) study supports the use of 
angiotensin converting enzyme (ACE) inhi­
bition in all high risk patients. Despite the 
minimal blood pressure reduction seen in 
the ramipril arm, the use of an ACE inhibi­
tor reduced the composite vascular end point 
by 22%, supporting the critical role played 
by the renin­angiotensin system in the pro­
motion of atherogenesis.61 The second Aus­
tralian National Blood Pressure Study also 
highlighted the benefit of an ACE inhibi­
tor­based anti­hypertensive regimen signifi­
cantly lowering cardiac death in the elderly 
population as compared to a diuretic­based 
regimen.62 The Antihypertensive and Lipid­
Lowering Treatment to prevent Heart Attack 
Trial (ALLHAT) reported no overall differ­
ences in CAD outcome among patients 
treated with a diuretic­based compared to a 
calcium channel blocker­ or an ACE inhib­
itor­based treatment program.63 However, 
patients in the diuretic group experienced 
fewer episodes of heart failure than in the 
calcium channel blocker group. Although 
The Seventh Report of the Joint National 
Committee on Prevention, Detection, Evalu­
ation, and Treatment of High Blood Pressure 
(JNC 7) (National Heart, Lung, and Blood 
Institute. National Blood Pressure Education 
Table 5.4: Hypertension summary 
points
• Strong independent risk factor
• Small reductions in blood pressure result 
in marked reduction in clinical events
• Reduction of blood pressure to the normal 
range results in the least number of 
clinical events; further reductions may be 
deleterious
• Blood pressure lowering per se is of 
utmost importance, irrespective of the 
choice of anti-hypertensive agent
• ACE inhibition reduces cardiovascular 
events in all high-risk patient groups, 
regardless of baseline blood pressure
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Program, 2003) supports thiazide diuretics 
as first­step drug of choice in most hyperten­
sive patients, what is clear from the wealth 
of trial data is that blood pressure lowering 
per se is of greater importance in reducing 
cardiovascular event rates rather than the 
choice of agent(s) used.
RISK FACTOR MODIFICATION IN 
THE DIABETIC PATIENT
Glycaemic Control
The incidence of diabetes continues to 
increase worldwide, predominantly due to the 
significant rise in the prevalence of type 2 
diabetes mellitus, which now accounts for 
over 90% of all diagnosed cases. The major 
cause of morbidity and mortality in subjects 
with diabetes is attributed to atherosclerosis, 
particularly CAD. In subjects with type 2 
diabetes, it is well established that there 
is a two­ to four­fold increased risk of 
CAD, peripheral arterial disease and cerebro­
vascular disease than compared with matched 
non­diabetic controls. This persists despite 
accounting for other traditional cardio­
vascular risk factors such as hypertension, 
smoking and dyslipidaemia. Accordingly, 
treatment guidelines now consider the 
presence of diabetes to be an atherosclerosis 
equivalent, and suggest that diabetics should 
be treated in a similar fashion as those with 
established clinical cardiovascular disease in 
terms of risk factor control.64
A number of direct and indirect pathways 
contribute towards atherogenesis in diabet­
ics. Indirect pathways that are promoted 
by hyperglycaemia include worsening of 
dyslipidaemia (development of atherogenic 
dyslipidaemia; small dense LDL­C parti­
cles, reduced HDL­C levels and elevated 
TGL levels), sympathetic nervous system 
dys function and the development of renal 
dysfunction. Direct pathways (directly per­
taining to chronic hyperglycaemia) result in 
the overall reduction in the bioavailability of 
nitric oxide. The resultant endothelial dys­
function promotes vasoconstriction, pro­
inflammatory and prothrombotic tendencies 
that contribute towards the progression of 
atheroma and subsequent atherothrombosis. 
Cholesterol and blood pressure lowering 
trials have demonstrated benefit in diabetic 
patients. Given the implicit relationship 
between hyperglycaemia and virtually all 
stages of atherogenesis, one would expect 
that the strict control of blood sugar levels 
would cause corresponding reductions in 
atherosclerotic cardiovascular disease. How­
ever clinical trials evaluating the impact of 
chronic, intensive glycaemic control upon 
cardiovascular disease have produced con­
flicting results, reflecting a complex inter­
action between glycaemic control and the 
atherosclerotic disease process. 
Observational studies have tended to 
show a linear relationship between hyperg­
lycaemia and cardiovascular mortality.How­
ever for levels of glucose at or below the 
threshold for the diagnosis of diabetes, the 
relationship with cardiovascular mortality 
is less clear­cut.65,66 Recently, the results of 
large­scale intervention trials examining the 
relationship between intensive glucose con­
trol and cardiovascular outcomes have been 
published. The ACCORD (Action to Con­
trol Cardiovascular Risk in Diabetes) trial 
examined the effect of intensive glucose con­
trol (target HbA 
1c
 under 6.0%, but achiev­
ing a mean level of 6.4%) versus standard 
therapy (targeting HbA 
1c
 between 7.0­7.9%, 
achieving a mean level of 7.5%) in over 
10,000 established type 2 diabetics.67 An 
unexpected finding of a higher rate of car­
diovascular mortality (34%, p = 0.02) and 
all­cause mortality (22%, p = 0.04) within 
the intensive glycaemic arm resulted in a 
premature halting of this study after a mean 
follow­up period of 3.5 years. Despite these 
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mortality rates, there was a non­significant 
trend towards a reduction in the primary 
outcome of the composite endpoint of non­
fatal myocardial infarction, non­fatal stroke 
or cardiovascular death. Although the exact 
mechanisms of the resultant increase in mor­
tality in this trial are unknown, an association 
between higher rates of severe hypoglycaemia 
within the intensive glycaemic control arm 
was reported, with patients with the high­
est baseline HbA 
1c 
levels at greatest risk of 
hypoglycaemia compared to those with supe­
rior initial glycaemic control. In contradic­
tion to ACCORD, the ADVANCE (Action 
in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Control­
led Evaluation) trial randomised over 11,100 
type 2 diabetics to either intensive glucose 
control (achieving a mean HbA 
1c 
of 6.5%) 
or standard control (achieving a mean HbA 
1c 
of 7.3%).68 After a mean follow­up period of 
5 years, the composite primary endpoint of 
combined macrovascular and micro vascular 
events was significantly attenuated in the 
intensive glucose control group. However 
this result was primarily driven by the signifi­
cant reduction in microvascular endpoints, 
whereas there was no significant reduction in 
cardiovascular events.
In the United Kingdom Prospective 
Diabetes Study (UKPDS), 3,867 newly 
diagnosed type 2 diabetics were randomised 
to an intensive glycaemic control compared 
with conventional treatment policy.69 Over 
the ensuing 10­year period of the trial, the 
intensively treated patients achieved a mean 
HbA 
1c
 of 7.0% compared to a mean HbA
1c 
level of 7.9% in the conventionally treated 
group. The intensively treated patients expe­
rienced a 16% relative risk reduction of myo­
cardial infarction which just failed to achieve 
statistical significance (p = 0.052) compared 
to the conventionally treated group. However 
the intensively treated group did experience 
a significant 25% reduction in microvascular 
complications (p = 0.01). A sub­group of 
overweight individuals within the UKPDS 
study who were placed on metformin as 
part of their intensive glucose control regi­
men did experience a significant 39% reduc­
tion in myocardial infarction (p = 0.01) 
and a 36% reduction in all­cause mortality 
(p = 0.01). This data has been adopted to 
promote the use of metformin as a means of 
effectively reducing cardiovascular endpoints 
independently of glycaemic control. Follow­
ing the publication of the UKPDS results, all 
surviving patients of this study entered into a 
post­trial monitoring program until 2007.70 
During this follow­up period, no attempts 
were made to continue the mode and inten­
sity of glycaemic control according to their 
prior randomisation group. In the first year 
after entering the post­trial monitoring pro­
gram, any differences in the HbA 
1c
 between 
the previous 2 treatment groups was lost. 
Despite the rapid loss of glycaemic separa­
tion between the two groups in the post­trial 
follow­up program, a significant benefit of 
being previously randomised to an intensive 
glucose control regimen was still observed, 
whereby this group experienced a 15% lower 
rate of myocardial infarction (p = 0.01) as 
well as a 13% reduction in all­cause mortal­
ity (p = 0.007). Moreover, the prior reduc­
tions in microvascular endpoints as well as 
the benefits of metformin therapy were all 
maintained during this post­interventional 
follow­up study. These observations virtually 
mirror the results of the previously reported 
Diabetes Control and Complications Trial 
(DCCT); a 9­year trial highlighting the ben­
efit intensive glycaemic control significantly 
delaying the development and progression 
of diabetes­related microvascular complica­
tions in type 1 diabetics, however failing to 
show any significant benefit upon cardio­
vascular events.71 Following completion of 
the DCCT, subjects were then followed by 
the Epidemiology of Diabetes Interventions 
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and Complications (EDIC) study.72 Again, 
differences in HbA 
1c 
were quickly lost 
between the 2 treatment groups. The com­
pletion of the 11­year post trial observation 
period occurred in 2005, and despite the 
early loss in glycaemic separation between 
the prior 2 groups, the combined endpoint 
of cardiovascular events (non­fatal myo­
cardial infarction, stroke or cardiovascular 
death) were reduced by 57% (p = 0.02) in 
the group of patients previously assigned to 
intensive glucose control. 
The UKPDS follow­up study and the 
EDIC study suggest that the sustained, 
early intensive control of blood glucose 
levels eventually translates into a significant 
benefit upon the development of cardio­
vascular disease many years down the track. 
Mechanisms pertaining to this ‘legacy’ effect 
are currently unknown. At least 4 recently 
published meta­analyses (that have included 
the ACCORD and ADVANCE studies) 
have suggested that intensive versus standard 
glucose lowering reduces cardiovascular 
events without increasing cardiovascular or 
all­cause mortality. 73­75 Therefore, an HbA 
1c 
target of < 7.0% still remains an acceptable 
target for appropriate glucose control. How­
ever under certain circumstances, especially 
in the setting of newly diagnosed type 2 
diabetes and in young patients without sig­
nificant comorbidities, aiming for a lower 
HbA 
1c 
level may represent an appropriate 




The greatest benefit for diabetic patients, in 
terms of cardiovascular risk factor reduction, 
has resulted from the aggressive modification 
of plasma lipoproteins and blood pressure. 
Diabetic dyslipidaemia, characterised by 
elevated TGL levels, reduced HDL­C levels 
and the presence of small, dense LDL­C 
particles, represents a potent atherogenic 
stimulus. Weight loss and aggressive gly­
caemic control leads to an improvement 
of this lipid profile.64 Statin trials have 
demonstrated greater relative risk reductions 
in diabetic subgroups, as have trials employing 
gemfibrozil.13,42 Although the Fenofibrate 
Intervention and Event Lowering in 
Diabetes (FIELD) study did not show daily 
fenofibrate to significantly reduce the risk 
of the primary outcome of coronary events 
(death due to CAD or non­fatal myocardial 
infarction) in over 4800 type 2 diabetics, 
there was a primary reduction in the rate of 
coronary and non­coronary revascularisa­
tions as well as fewer non­fatal myocardial 
infarctions.76 Moreover, fenofibrate therapy 
resulted in the improvement in a number 
of microvascular parameters. Furthermore, 
the ACCORD study group investigated 
whether combination therapy with statin plus 
fenofibrate, as compared with statin mono­
therapy, would further reduce the risk of 
cardiovascular disease in over 5,500 type 2 
diabetics at high risk for cardiovascular 
events. The statin/fibrate combination did 
not reduce the rate of fatal cardiovascular 
events, non­fatal myocardial infarction, or 
non­fatal stroke as compared with statin 
therapy alone.77 A recent meta­analysis (of 18 
trials, over 45,000 patients) investigating the 
effects of fibrates on major clinical outcomes 
concluded that fibrates do reduce the risk of 
major cardiovascular events, largely driven 
by a 13% relative risk reduction (7­19) in 
coronary events (p<0.0001).78 Collectively, 
these trials suggest that although statin 
therapy should remain the cornerstone of 
treating dyslipidaemia in diabetics, diabetics 
with reduced HDL­C and elevated TGL 
levels may derive some additional benefit 
with the addition of fibrate therapy. 
Similarly, lowering blood pressure is of 
utmost importance in diabetics for enhanced 
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cardiovascular risk reduction, portending a 
greater risk benefit in diabetics compared with 
non­diabetics. The blood pressure lowering 
sub­study of UKPDS confirmed a signifi­
cant reduction in strokes (as well as micro­
vascular endpoints) in those with aggressive 
blood pressure control (mean on­treatment 
blood pressure of 144/82 mmHg) compared 
with the group assigned less tight control 
(who achieved a mean blood pressure of 
154/87 mmHg).79 A similar observation was 
noted within the HOPE (Heart Outcomes 
Prevention Evaluation Study) study, with the 
benefit of ramipril seen in diabetic patients 
compared to those with established vascular 
disease.61 However, more recent attempts 
to define the optimum level of blood pres­
sure control in diabetics has highlighted the 
complex relationship between blood pressure 
levels in diabetics and cardiovascular event 
rates. Until recently, it was widely felt that 
aggressive lowering of systolic blood pressure 
below 135 mmHg in diabetics would be of 
further clinical benefit. However the results 
of the ACCORD study group collaborators 
found that in type 2 diabetics at high risk 
for cardiovascular events, intensive systolic 
blood pressure lowering to levels below 
120 mmHg, as compared to less than 
140 mmHg, did not reduce the rate of 
composite outcome of fatal and nonfatal 
major cardiovascular events.80 Moreover, 
the patients assigned to intensive blood 
pressure lowering experienced significantly 
higher adverse event rates attributed to the 
antihypertensive treatment. This trial rein­
forced the notion that aggressive blood pres­
sure lowering in diabetics to values below 
130­135 mmHg may be problematic. 
The metabolic syndrome
The metabolic syndrome refers to the 
co­existence of an atherogenic lipid profile, 
elevated blood pressure, and elevated 
plasma glucose, associated with abdominal 
obesity and insulin resistance.64 Although a 
number of definitions exist, the most recent 
consensus from the International Diabetes 
Federation defines metabolic syndrome as the 
presence of central obesity (defined as waist 
circumference with ethnic specific values, 
or if body mass index exceeds 30 kg/m2, 
then central obesity can be assumed) and any 
two of the following: (1) raised TGL levels 
(> 1.7 mmol/L), (2) reduced HDL­C levels 
(< 1.03 mmol/L in males and 1.29 mmol/L 
in females), (3) raised blood pressure (systolic 
blood pressure > 130 mmHg or dia stolic 
blood pressure > 85 mmHg), (4) raised fasting 
plasma glucose level (> 5.6 mmol/L).81 
Numerous studies have investigated the 
cardiovascular risk associated with metabolic 
syndrome, with ongoing debate regarding 
the prognostic significance of the meta­
bolic syndrome for cardiovascular outcomes. 
A recent meta­analysis was conducted of 
Table 5.5: Diabetes summary points
• Diabetes and insulin resistance are both 
strong risk factors for cardiovascular 
events
• Glycaemic control correlates with clinical 
outcome
• Aggressive glycaemic control reduces 
microvascular complications
• There is a more complex relationship 
between aggressive glycaemic control and 
reduction of macrovascular events
• Early, aggressive glycaemic control may 
have a longer term ‘legacy’ effect upon 
reduction in macrovascular events
• Metformin use in obese diabetics 
significantly lowers rate of myocardial 
infarction
• Statins remain the cornerstone of lipid 
management in diabetics
• Control of blood pressure equally 
important in diabetics; however aggressive 
lowering of systolic blood pressure to 
levels < 120 mmHg may be detrimental 
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the cardiovascular risk associated with the 
metabolic syndrome (as defined by the 
National Cholesterol Education Program), 
which found the presence of metabolic syn­
drome to be associated with a 2­fold increase 
in cardiovascular outcomes and a 1.5­fold 
increase in all­cause mortality.82 It remains 
unclear, however, as to the relative contri­
bution of the individual components of the 
metabolic syndrome towards the mediation 
of cardiovascular risk. A recent study analys­
ing the risk of myocardial infarction conferred 
by the metabolic syndrome and its individual 
components in multiple ethnic populations 
was recently undertaken. It was found that 
the risk of metabolic syndrome upon myo­
cardial infarction is generally comparable to 
that conferred by some, but not all, of its 
component risk factors, whereby the associa­
tion with myocardial infarction being similar 
to that of diabetes mellitus and hyperten­
sion.83 Accordingly, a recent analysis of over 
3450 patients who participated in 7 clinical 
trials that monitored coronary atheroma 
progression with IVUS found accelerated 
disease progression in those patients with the 
metabolic syndrome. However, after adjust­
ing for its individual components, the pres­
ence of the metabolic syndrome itself was 
no longer found to be an independent pre­
dictor of disease progression.84 Infact, further 
analysis of the same patient cohort found that 
patients with diabetes mellitus had greatest 
coronary plaque burden, greater plaque pro­
gression and lumen constriction than those 
categorised as having metabolic syndrome.85 
Further studies will need to be conducted to 
ascertain the candidate mechanisms by which 
metabolic syndrome mediates cardiovascular 
risk. However given the strong relation­
ship between the presence of its component 
risk factors, the ideal anti­atherosclerotic 
approach tackling the metabolic syndrome 
would appear multi­factorial, in addition to 
weight loss and life­style measures.
FUTURE TARGETS
The current generation therapeutic approach 
for atherosclerotic cardiovascular disease 
prevention is essentially aimed directly at 
the modulation of known cardiovascular 
risk factors. Although these approaches 
have been successful in risk reduction, a 
substantial residual risk remains. Given 
our understanding of the implicit role of 
oxidative and inflammatory pathways in 
atherogenesis, therapies directly targeting 
these pathologic substrates represents a 
potential future challenge in achieving 
further risk reduction in the population. 
As a result, various novel therapeutic agents 
are undergoing clinical development. These 
include a number of anti­oxidant and anti­
inflammatory therapies. It is likely that these 
therapeutic approaches will find their way 
into clinical practice.
CONCLUSION 
Atherogenesis represents the culmination 
of a complex series of humoral events that 
promote the inflammatory cascade and 
thrombogenicity. The optimal therapeutic 
approach for both primary and secondary 
prevention of atherosclerosis still involves 
the traditional approach of global risk factor 
modification. However emerging therapies 
targeting novel markers of disease will be 
needed to tackle the residual burden of 
clinical events attributable to atherosclerosis 
despite contemporary anti­atherosclerotic 
therapies. Furthermore, emerging imaging 
and serum markers of atherosclerosis and 
its inflammatory content will enhance our 
risk prediction capabilities for cardiovascular 
events, as well as the ability to monitor 
response to anti­atherosclerotic therapies. 
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Currently, treatment options for peripheral 
vascular disease include angioplasty and 
reconstructive surgery. An attractive, less 
invasive alternative could involve the 
revascularization of ischaemic tissue by the 
induction of vascular growth. It would be 
particularly welcome for patients in whom 
current approaches are difficult or prone to 
failure, including those with conditions that 
make surgical intervention unsafe, patients 
with diffuse occlusive disease and those 
in whom there is significant downstream 
microvascular disease. Recent years have wit­
nessed major advances in the understanding 
of the molecular mechanisms underlying 
vascular formation and remodelling, as 
well as the identification of key molecules 
controlling these processes. Most research 
has focused on the induction of new vessel 
formation by stimulating angiogenesis and 
this has been the goal of the clinical trials 
directed at peripheral vascular disease. But, 
whilst the stimulation of angiogenesis may 
relieve microvascular disease, the bypass 
of occluded conduit vessels requires the 
formation of more substantial collateral 
vessels by the process of arteriogenesis. This 
chapter will review current understanding 
of the mechanisms controlling angiogenesis 
and arteriogenesis; approaches that are, and 
could be pursued to induce vessel growth 
in peripheral vascular disease, as well as 
summarizing the current status of clinical 
trials.
MECHANISMS OF VASCULAR 
GROWTH
Strategies currently being developed for the 
therapeutic induction of vessel growth have 
evolved, largely, from knowledge of the 
physiological mechanisms of developmental 
vascularisation. In development, blood vessels 
arise initially by the process of vasculogenesis 
during which precursor cells, known as 
angioblasts, differentiate into endothelial 
cells and organize into primitive vessels.1 
These vessels expand by angiogenesis, which 
includes both sprouting growth and non­
sprouting remodelling.1
Vasculogenesis
The angioblasts that give rise to endothelial 
cells in the first stages of developmental 
vascularisation originate in the mesoderm 
under the influence of fibroblast growth 
factor­2 (FGF­2).2 These differentiate into 
endothelial cells, which proliferate and 
aggregate into cords, and become lumenized 
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to form primitive vascular plexuses.1 Sig­
nalling through vascular endothelial growth 
factor receptor­2 (VEGF­R2) is crucial for 
angioblast survival and establishment of 
these first vessels.3
Endothelial cell formation from precursor 
cells, and in situ differentiation into vessels, 
was thought to be confined to develop­
mental vascularisation. However, it has now 
been shown that circulating endothelial pro­
genitor cells (EPCs) exist in the adult and 
that they can contribute to vessel formation.4 
These cells originate in the bone marrow 
and express CD34 and VEGF­R2 as well 
as the orphan receptor AC133.5 EPCs can 
incorporate into neovessels formed in heal­
ing wounds, ischaemic tissue and tumours.6 
The mechanisms controlling the incorpora­
tion of EPCs into neovessels are at present 
poorly defined although a number of growth 
factors, including VEGF, FGF2, granulocyte­ 
macrophage colony stimulating factor 
(GMCSF), angiopoietins and cytokines have 
all been shown to increase the mobilization 
of EPCs from bone marrow.7 Crude cell 
fractions that include EPCs can be expanded 
ex vivo and transplanted into ischaemic 
tissue in animal models where they have 
been reported to incorporate into neovessels.4 
Importantly, in some situations neovessels 
comprising only EPC­derived cells were 
observed. Several studies have highlighted 
that the increase in the number of circulat­
ing progenitors, induced by cell transfusion 
or enhanced mobilization, can also enhance 
restoration and integrity of the endothelial 
lining, suppress neointimal formation, and 
increase blood flow to ischaemic sites.8 Whilst 
it is possible that EPCs, or EPC­derived cells, 
can form vessels in situ, by a process similar 
to vasculogenesis, current thinking suggests 
that the principal role of vascular stem and 
progenitor cells is paracrine, that is, these 
cells promote proliferation and migration of 
existing endothelial cells, as well as produce 
additional cytokines and chemokines to 
continue stem and progenitor mobilization, 
trafficking and adhesion.9
Angiogenesis
Establishment of the vascular network in 
development, as well as new vessel formation 
in the adult, requires angiogenesis. The two 
processes of sprouting and non­sprouting 
angiogenesis are responsible for remodelling 
of the primitive vascular plexus into a 
complex functional network. In sprouting 
angiogenesis, endothelial cells are activated 
by growth factors to undergo migration, 
proliferation and morphogenesis into new 
vessels, and VEGF is the major physiological 
activator.
Ischaemia is the primary initiator of 
sprouting angiogenic growth. Low oxygen 
tension activates expression of a wide range 
of angiogenic factors including VEGF, VEGF 
receptors, angiopoietin­2 and platelet­derived 
growth factor (PDGF). Genes for these 
factors contain hypoxia responsive elements 
in their promoters and some, like VEGF, 
have been shown to be direct targets of the 
transcriptional regulator hypoxia inducible 
factor (HIF). HIF­1 is a heterodimer com­
posed of HIFα and HIFβ subunits.10 Under 
normoxic conditions HIF­1α is held at low 
intracellular concentrations by proteosomal 
degradation. With decreased oxygen tension 
HIF­1α becomes hydroxylated preventing 
its association with the von Hippel­Lindau 
ubiquitin ligase complex that is respons­
ible for directing HIF­1α for degradation.11 
Thus, HIF­1α accumulates in the cell allow­
ing it to activate transcription of hypoxia­
inducible genes via the HIFα:β dimer.
VEGF expressed in response to HIF is 
secreted by ischaemic cells and acts on endo­
thelial cells in adjacent microvessels. In these 
previously quiescent microvessels, endothelial 
activation, proliferation and migration are 
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normally suppressed by signals from ablum­
inal perivascular support cells; pericytes. 
This suppression needs to be relieved before 
angiogenesis can proceed.12 The close inter­
action between endothelial cells and pericytes 
is promoted by the ligand angiopoietin­1, 
which is produced by the pericyte and acts 
on the endothelial receptor Tie2.13 Disrup­
tion of this signalling interaction is likely 
to involve angiopoietin­2, another hypoxia­
responsive molecule.14 Angiopoietin­2 can 
act to inhibit angiopoietin­1­induced activa­
tion of Tie2.15 Once released from the pro­
stabilizing effects of pericytes, the endothelial 
cells are free to invade the perivascular space, 
aided by proteases that degrade extracellular 
matrix. Many metalloproteinases have been 
implicated in angiogenic sprouting, includ­
ing matrix metalloproteinases 2, 3, 7 and 9 
as well as other proteolytic enzymes such 
as urokinase­type plasminogen activator.16 
Migration of the activated endothelial cells 
is aided by plasma proteins that extravasate 
from the activated microvessels in response to 
the vasodilatory and pro­permeability effects 
of VEGF. This growth factor is a potent 
chemoattractant and mitogen for endothelial 
cells, and directs their migration and prolif­
eration. Interestingly, in vivo endothelial cells 
in the developing vascular sprouts respond 
differentially to VEGF, with the cells at the 
tip migrating and those behind the tip pro­
liferating.17 Migration and proliferation give 
rise to endothelial cords that become lumen­
ized, a process which is poorly understood, 
though is known to be enhanced by angio­
poietin­1.18
Neovessel maturation
Whether by vasculogenesis or angiogenesis, 
newly formed blood vessels are highly 
unstable, and are prone to haemorrhage, 
thrombosis and spontaneous regression in 
the absence of elevated growth factors.19 
Such vessels are characteristically found 
in pathological vascularisation and their 
phenotype can directly contribute to the 
disease process. Newly formed primitive 
vascular channels are maintained by local 
high concentrations of VEGF, withdrawal 
of which leads to endothelial apoptosis and 
neovessel regression.20 Transformation to 
a functional vessel requires interaction of 
endothelial cells in the nascent vessel with 
pericytes, which originate as mesenchymal 
cells that are recruited to the developing vessel 
and differentiate into pericytes on contact 
with the endothelium.21 Proliferation and 
migration of partially or fully differentiated 
pericytes along established microvessels 
also contributes to mural cell acquisition 
by sprouting neovessels, and sprouts can 
themselves recruit mesenchymal cells.22 
Migration and proliferation of pericytes is 
regulated mainly by platelet­derived growth 
factor­β (PDGFβ) secreted by endothelial 
cells. Interaction between mesenchymal 
cells and endothelial cells in a developing 
vessel produces phenotypic changes in 
both cell types. The mesenchymal cell is 
directed toward a pericyte or smooth muscle 
phenotype and the endothelial cell adopts 
the phenotype required for formation of a 
stabilized microvessel.1 Pericytes supply anti­
apoptotic ligands, including angiopoietin­1,23 
to underlying endothelial cells allowing 
neovessels to survive the decrease in VEGF 
concentrations that occur as the ischaemia is 
relieved by increased perfusion. In addition, 
pericytes suppress endothelial proliferation 
and migration, and increase deposition 
of the perivascular basement membrane, 
all of which contribute to switching the 
fragile nascent vessel into a quiescent func­
tional microvessel.24 Transforming growth 
factor­β, produced by proteolytic cleavage 
from a precursor form as a result of endo­
thelial:pericyte interaction,25 has a central 
role in these effects.
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Microvascular network maturation
Maturation of vascular channels into 
functional vessels is accompanied by 
maturation of the neovessel network. This 
involves optimization of the new vessel 
configuration, density, branching pattern 
and vessel hierarchy. Spatial distributions 
of angiogenic initiators, like VEGF, have 
a major influence on the direction of the 
initial branches. There are six members of 
the VEGF family and VEGF­A is expressed 
as a number of alternatively spliced variants; 
in humans these are mainly forms with 121, 
165, 189 and 206 amino acids.26 VEGF165, 
189 and 206 possess heparin­binding 
domains that allow these forms to interact 
with the extracellular matrix. The ability 
of VEGF isoforms to be retained by the 
matrix is important in regulating the spatial 
organization of vessel branching.27
Patterning also occurs through selective 
loss of certain vessels by regression. Another 
major determinant of network maturation 
is the branching and ‘splitting’ of vessels by 
non­sprouting angiogenesis. This occurs 
by the process of intussusception in which 
vessel lumens are internally divided by inser­
tion, and subsequent growth and stabil­
ization, of transcapillary tissue pillars.28 
The mechanism of intussusception and 
factors that regulate it are poorly understood, 
though the Tie receptors are known to have 
a role.29
Arteriogenesis
Further expansion and muscularization of 
vessels occurs by the process of arteriogenesis; 
the development of large calibre collateral 
arteries from a pre­existing network, in 
response to occlusive disease. This involves 
recruitment of additional mural cells and 
their proliferation, as well as expansion of 
the abluminal extracellular matrix. Whilst 
angiogenesis is driven by ischaemia, the 
initiator of arteriogenesis is increased fluid 
shear stress, which acts directly upon gene 
expression involved in the endothelial cell 
cycle.30 PDGFβ with its effects on smooth 
muscle cell recruitment and proliferation, 
and TGFβ, a known regulator of vascular 
extracellular matrix synthesis, are likely to be 
key regulators.
Arteriogenesis of collateral vessels has been 
demonstrated in a number of animal models 
following the occlusion of major vessels.31 
In humans, well­developed collateral vessels 
that bypass occluded arteries have been 
found frequently and those patients with the 
best developed collaterals often have mini­
mal symptoms.32 Arteriogenesis of collaterals 
in response to the occlusion of primary 
supply vessels occurs in two phases. An initial 
increase in the lumen size occurs within a few 
days and this is followed by a slower remod­
elling of smooth muscle cell and extracellular 
matrix cover.31 The early phase of this adap­
tive arteriogenesis is associated with inflam­
mation. There is monocyte attachment to 
endothelium secondary to release of mono­
cyte chemoattractant protein­1 (MCP­1), 
GMCSF and stromal­cell­derived factor­1 
(SDF­1), which recruit CD14+ monocytes 
to the activated endothelial cell surface as 
well as extravasation and accumulation in 
the adventitia and perivascular space, with 
mast cells and T lymphocytes.33 Monocytes 
have a critical role in adaptive arteriogenesis 
as experimental suppression of monocyte 
numbers decreases arteriogenesis.34 These 
cells provide growth factors to stimulate 
vessel enlargement and proteases that can act 
on the extracellular matrix to accommodate 
increased vessel size. Changes to the wall of 
the vessel involve remodelling of the media, 
with increased turnover of medial smooth 
muscle cells and a shift towards a synthetic 
phenotype, assuming a contractile pheno­
type after enlargement of arterial diameter.33 
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A new internal elastic lamina is established 
and vessel wall thickening results from 
increased extracellular matrix deposition.
THERAPEUTIC INDUCTION OF 
VASCULAR GROWTH
Most studies on the therapeutic induction of 
vessel growth at a pre­clinical level, and all 
clinical trials, have focused on angiogenesis. 
Clinical trials aimed at relieving peripheral 
vascular disease by therapeutic angiogenesis 
have had limited success. This is perhaps 
not surprising given the very limited ability 
of angiogenic growth to compensate for the 
loss of conductance vessels. It is now being 
generally recognised that revascularisation 
in peripheral vascular disease, as in coronary 
heart disease, would be best achieved by 
the therapeutic activation of collateral 
arteriogenesis. Nevertheless, the ability to 
activate angiogenesis therapeutically would 
be valuable where significant microvascular 
disease exists. In addition, the early work 
on therapeutic angiogenesis has provided 
data and approaches that may be valuable 




Induction of angiogenesis in the appropriate 
ischaemic areas and in future local 
arteriogenesis at suitable sites for collateral 
development, requires activating agents 
to be delivered in a manner that ensures 
controllable local activity and minimizes 
systemic side effects. Growth factors are 
readily degraded and if administered 
systemically would have to be used at high 
concentrations in order to ensure enough 
active growth factor reached the appropriate 
site. There are risks associated with non­local 
delivery, for example, systemically delivered 
VEGF produces severe hypotension in 
animal models.35 In addition to localization, 
activators must be present for sufficient time 
to induce optimal vascular growth.
The two principal methods used to 
deliver angiogenic activators in pre­clinical 
studies as well as clinical trials have been as 
recombinant proteins or as the genes that 
encode these proteins. Activators can be 
delivered locally via intramuscular catheters, 
direct injection into the muscle or use of 
coated stents. An important consideration in 
the use of peptide growth factors is ensur­
ing sufficient longevity of the molecules at 
the desired site. Where recombinant proteins 
are injected this would necessitate multiple 
injections during the course of treatment. 
An alternative strategy is the use of local 
reservoirs of recombinant protein, such as 
bio degradable microspheres.36 A major lim­
itation to the use of recombinant protein, 
however, is the expense and difficulty in 
obtaining large enough quantities of appro­
priate purity, especially when cocktails of 
growth factors are required.
Delivery of angiogenic factors by gene 
transfer has significant advantages over the 
administration of recombinant protein. It is 
relatively easy to produce high purity DNA 
in large quantities and the transfected genes 
remain active over a period of several days 
to several weeks. In contrast to gene therapy 
aimed at correcting genetic diseases, gene 
transfer as a means of providing short term 
local expression of therapeutic proteins has 
been successful. Surprisingly, small amounts 
of DNA plasmid vectors can be taken up by 
muscle cells in vivo and are reported to result 
in significant gene expression in humans.37 
Improvements in transfer efficiency have 
been sought by the use of liposomal carri­
ers and viral vectors. Adenovirus is the most 
common viral vector used for the delivery 
of angiogenic genes, and since genes trans­
ferred in this way do not integrate into 
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chromosomes of transduced cells, transient 
expression is provided.
There have been reports of an inflam­
matory reaction to adenoviral vectors in 
human trials, but no long term safety prob­
lems at doses appropriate for angiogenic 
therapy. Second generation adenoviral vec­
tors with deletions of E1 and E4 regions 
have better transfection efficiency and elicit 
a decreased inflammatory response38 and 
further improved adenoviral vectors can be 
expected.39 The adeno­associated viruses 
(AAV) offer an alternative viral means for 
gene delivery. AAV efficiently transduce skel­
etal muscle and vasculature.40 However, along 
with retroviruses and lentiviruses, AAV integ­
rate into the recipient genome requiring the 
development of regulatory systems if they are 
to provide controllable expression of vascular 
growth genes. As with recombinant protein, 
local delivery of genes can be accomplished 
by direct intramuscular injection, implanta­
tion of coated stents or catheters. It may also 
be possible to utilize tissue­specific endoth­
elial surface molecules for targeting vectors 
to particular vascular beds. Implantation of 
cells transfected ex vivo offers an additional 
route of local delivery. 
Angiogenic activators
Perhaps the simplest approach to activating 
angiogenesis is the administration of a soluble 
angiogenic activator. VEGF is relatively spe­
cific for endothelial cells and physiologically 
relevant. Although VEGF­A, ­B, ­C, ­D and 
–E, as well as the VEGF­R1 ligand placental 
growth factor, have all been shown to activate 
angiogenesis when administered in animal 
models, most studies have concentrated on 
VEGF­A. Administration of VEGF alone 
results in a high percentage of malformed 
capillaries in animal models.41 This growth 
factor also induces vessel permeability 
resulting in local hypotension and oedema.35 
Neovessels induced by VEGF are transient, 
with regression occurring on growth factor 
withdrawal.42 These data indicate formation 
of a sustained microvessel network may 
require relatively long term exposure to the 
angiogenic initiator.
The fibroblast growth factors have also 
been examined as potential therapeutic 
agents to induce angiogenesis in clinical 
trials. There are 23 members of the FGF fam­
ily and FGF­2 and FGF­4 have been used in 
clinical trials. FGF­1, ­2, ­4 and ­9 are highly 
mitogenic for endothelial cells, although 
these growth factors are also active on non­
endothelial cells.43 Another growth factor 
that induces angiogenesis and is in early trials 
is hepatocyte growth factor; again its effects 
are not confined to endothelial cells.44
With the recognition that physiological 
angiogenesis requires a spatially and temp­
orally co­ordinated repertoire of signals, 
attempts have been made to improve 
capillary formation by providing cocktails 
of growth factors. Indeed combination of 
VEGF with the pro­stabilizing Tie2 agon­
ist angiopoietin­1 in a mouse model does 
produce microvessels with increased lumen 
size, less thrombosis and increased perfusion 
compared with VEGF alone.18 These vessels 
are also less permeable than those formed in 
response to VEGF alone.45 Another approach 
aimed at providing a more physiological 
range of angiogenic factors is the targeting 
of HIF. Expression of a form of HIF­1α that 
is resistant to oxygen­induced degradation 
in mouse skin led to up­regulation of 
HIF­sensitive angiogenic genes and the 
stimulation of microvessel formation.46 Again 
the vessels produced were not associated 
with oedema. The cell permeable peptide, 
PR39, inhibits proteosomal degradation 
and can stabilize HIF­1α.47 PR39 stimu­
lates angio genesis in mouse heart, although 
further studies are required to determine its 
specificity.47
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Pre­clinical and early clinical studies have 
shown that angiogenesis can be induced 
in vivo by a variety of approaches. The chal­
lenge is to devise a means to stimulate the 
conversion of these neovessels into optimally 
organized, persistent and functional micro­
vascular networks.
Arteriogenic activators
Little is known about the molecular 
mechanisms of arteriogenesis. In contrast 
to the ischaemic tissue microenvironment 
in which angiogenesis occurs, collateral 
arteriogenesis in the limb takes place in 
normoxic conditions.48 In adaptive arterio­
genesis studied in animal models, the 
biochemical effects of the increased flow 
that the collaterals experience as a result of 
occlusion of conductance vessels plays a major 
role. These effects include increased wall shear 
stress as well as tangential and axial stresses. 
Increased shear can up­regulate vascular 
cell adhesion molecule­1 and intracellular 
adhesion molecule­1, as well as MCP­1 
which contributes to monocyte recruitment.49 
Growth factors are undoubtedly involved in 
adaptive arteriogenesis, but again more work 
is required to identify the key factors and their 
roles. In animal models FGF­1 and FGF­2 
were found to be unchanged during adaptive 
arteriogenesis, although there was a transient 
increase in expression of FGF­receptor­1.50
TGFβ is increased during collateral 
development and can enhance arteriogenesis 
in animal models. Several factors have 
been found to enhance arteriogenesis when 
administered to animals, including FGF­2, 
VEGF, placental growth factor, angiopoie­
tin­1 and MCP­1, although the exact mech­
anisms of action remain undefined.31 Many 
appear to have indirect actions, for example, 
VEGF and placental growth factor infusions 
are likely to enhance arteriogenesis via their 
monocyte chemoattractive activity. Given 
the great potential of therapeutic induction 
of collateral arteriogenesis for the treatment 
of peripheral vascular disease, it is important 
that a better understanding of the molecu­
lar mechanisms be gained. Identification of 
key regulators that can induce or enhance 
arterio genesis of collaterals is a priority.
Clinical trials for angiogenic therapy 
of peripheral vascular disease
There have been a number of phase 2 and 
3 clinical trials aimed at relieving peripheral 
vascular disease by angiogenic therapy. The 
Therapeutic Angiogenesis with Recombinant 
Fibroblast Growth Factor­2 for Intermittent 
Claudication (TRAFFIC) study used single 
or repeated doses of recombinant FGF­2 
delivered by arterial puncture and cross­
over catheter in patients with intermittent 
claudication. Patients receiving a single FGF­2 
dose showed a significant improvement in 
peak walking time at 90 days.51 In the 
Regional Angiogenesis with Vascular Endo­
thelial Growth Factor (RAVE) study, 
VEGF121 gene transfer by adenovirus was 
utilized but failed to produce a significant 
improvement in peak walking time at 
12 weeks.52 In contrast, in a different study 
adenoviral delivered VEGF165 given during 
angioplasty did produce an increased angio­
graphically­assessed vascularity at 3 months.53 
The Vascular Endothelial Growth Factor in 
Ischemia for Vascular Angiogenesis (VIVA) 
trial failed to show a difference between the 
treatment and placebo groups for the primary 
endpoint of walking time.54 The TALISMAN 
collaborators evaluated a plasmid­based 
angiogenic gene delivery system for the 
local expression of FGF­1 in patients with 
non­healing ulcers who were not suitable 
for invasive re­vascularisation. Whilst there 
was no difference observed in the primary 
endpoint of complete ulcer healing, there was 
a reduced risk of major amputation.55 Initial 
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reports from the ongoing Bone Marrow 
Outcome Trial in Critical Limb Ischemia 
(BONMOT­CLI), show promise for the 
intramuscular injection of autologous bone 
marrow stem cells into ischaemic limbs, 
with significant improvements in Rutherford 
categories and a trend against major limb 
amputation.56 
A meta­analysis of 5 randomised con­
trolled trials investigating the role of gene 
therapy as an option for the treatment of 
peripheral vascular disease concluded that 
the current literature does not demonstrate 
a clinical benefit for patients with periph­
eral vascular disease.57 Although these trials 
have met with limited success, together with 
phase 1 studies and earlier small trials, they 
demonstrate the feasibility and safety of 
molecular approaches to therapeutic modu­
lation of vascular growth. The trials have 
also been valuable in aiding development of 
techniques for delivering therapeutic agents, 
as well as helping clinicians refine aspects of 
trial design for future clinical work on arte­
riogenesis and angiogenesis.
The realization that therapeutic induc­
tion of collateralization by arteriogenesis 
would be most appropriate for occlusive 
disease, whilst angiogenic therapy would 
benefit patients with microvascular defects, 
should help improve selection of the most 
appropriate populations for use in future 
trials. Clear clinical end­points are required 
in such work. Where angiogenesis is the aim, 
establishment of optimal treatment modali­
ties will depend on further pre­clinical work 
focused on determining ways to establish 
mature, correctly patterned vascular net­
works. This may involve defined cocktails of 
stimulators, or activation of transcriptional 
factors triggering coordinated expression of 
stimulators. In both cases distinct spatial and 
temporal expression patterns are likely to be 
required.
CONCLUSIONS
The prospects for a molecular approach 
to stimulate vascular growth as a means 
of relieving tissue ischaemia in peripheral 
vascular disease are promising. Early clinical 
work, together with a better understanding 
of vascular growth mechanisms, has allowed 
identification of the key areas in which 
progress is required in order to bring 
therapeutic vascular growth to the clinic. yet 
Isner predicted in therapeutic angiogenesis 
‘a new frontier for vascular therapy’ in 
1996.58 That today the underlying cellular 
mechanisms and processes continue to be 
elucidated is testament to the complexity 
of this area of vascular medicine. Bypassing 
the occluded conductance vessels is now 
recognised to require collateral growth by 
arteriogenesis, rather than angiogenesis. In 
comparison to angiogenesis our under­
standing of arteriogenesis remains rudi­
mentary. Significant work is needed therefore 
to understand the mechanisms regulating 
physiological arteriogenesis as well as adaptive 
arteriogenesis, and to identify key molecular 
regulators. Activation of angiogenic growth 
will be valuable where microvascular disease 
is prevalent. Indeed, situations in which 
activation of arteriogenesis to restore con­
ductance level flow together with activation 
of angiogenesis to relieve microvascular 
defects can be envisaged. It is clear that 
optimum microvascular growth will require 
correctly patterned, functional and persistent 
mature microvessel networks. Further work 
on the basic biology of angiogenesis is needed 
to determine the best means of inducing this 
therapeutically. 
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INTRODUCTION
Restenosis is usually defined as a re-narrowing 
of the arterial lumen occurring after a 
vascular intervention intended to treat 
ischemic lesions. This loss of lumen area 
results from the injury caused by all forms 
of vascular intervention, including direct 
repair (patch angioplasty, endarterectomy) 
and intraluminal approaches (balloon 
angioplasty, atherectomy, stent angioplasty). 
While there are clear differences between 
arteries and veins (review in1), this review 
will also include discussion of stenosis after 
vein bypass grafting or creation of arterio-
venous fistula dialysis access because stenosis 
in these cases also results from injury. 
Lumen enlargement after angioplasty 
or stenting is the result of a combination 
of plaque reduction (compression and embol-
ization), plaque redistribution within or 
outside the lesion area, and vessel expansion 
(see review2). Failure occurs at early times 
because of technical problems and thrombo-
sis (e.g. small diameter vein graft, limited out-
flow, or hypercoagulability) and later times 
(1-18 months) primarily because of injury-
induced scarring. At much later times 
(> 18 months), failure primarily results 
from the ongoing atherosclerotic process. 
Although restenosis occurs within the con-
text of atherosclerosis, the clinical features 
and genetic control of atherosclerosis and 
restenosis are different.3 Atherosclerosis 
develops slowly over decades,4 while resteno-
sis occurs within months to years.5 
The costs of restenosis are considerable, 
since greater than 20% of all interventions 
fail because of restenosis. In the U.S. alone, 
it is estimated that as many as 200,000 cases 
of drug eluting stent (DES) restenosis occur 
every year (see review6). The goal of research 
in this area is to modify vascular healing 
so that injury is repaired without lumenal 
narrowing. The objectives of this chapter 
are to review mechanisms of restenosis and 
current and potential molecular targets to 
prevent restenotic lesions. 
MECHANISMS OF RESTENOSIS
Restenosis results from a combination of 
elastic recoil, thrombosis, remodelling and 
intimal hyperplasia. Three decades ago 
the prevailing view was that restenosis was 
primarily a problem of intimal hyperplasia 
caused by migration of SMCs from the media 
to the intima followed by excessive growth. 
Two decades ago a role for remodelling was 
confirmed and more recently a possible role 
for progenitor/stem cells has gained ground. 
Because recoil is not an issue after stenting 
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and is a mechanical property of elastic layers 
of the artery, we will focus on the roles 
of thrombosis, remodelling and intimal 
hyperplasia, which contribute to varying 
degrees depending on the intervention 
employed (e.g. angioplasty vs. stenting). 
Thrombosis
Thrombosis may occur after vascular 
intervention because of damage to the 
endothelium and possible intimal and medial 
dissection. Mechanisms of this process are 
presented more fully in Chapter 10 on 
the haemostatic system. Briefly, exposure 
of underlying tissue factor to blood causes 
thrombin and fibrin generation, which 
along with platelets may lead to thrombotic 
occlusion.7 Adherence of platelets is 
mediated by receptors such as the integrin, 
IIb/IIIa. Aggregation of platelets causes 
the release of numerous factors, including 
thromboxane A2, ADP, serotonin, and 
matrix metalloproteinases 2 and 9, that 
further stimulate platelet adherence and/
or aggregation.5,8 Platelets also release a 
variety of growth and chemotactic factors.8 
Thrombus can act as a scaffold through 
which SMCs migrate and both synthesize 
and degrade extracellular matrix components, 
thus reorganizing the thrombus. While 
anti-platelet therapy largely prevents acute 
thrombosis after vascular intervention, late 
thrombosis in DES remains of concern 
prompting prolonged anti-platelet therapy.6 
Even in the absence of thrombotic occlusion, 
there is considerable evidence of a relationship 
between the early thrombotic response and 
the later development of restenosis.9 Anti-
platelet therapy, particularly inhibitors of 
IIb/IIIa in both animals and humans has 
demonstrated the importance of platelets 
to the restenotic process.8,10-13 For example, 
knockout of P2y12, the ADP receptor on 
platelets, or its blockade using clopidogrel 
inhibits neointimal formation after arterial 
injury.14 Fibrin deposition on stent struts and 
decreased heparin cofactor II, a thrombin 
inhibitor, are both associated with in-stent 
restenosis15,16 (Table 7.1). Larger platelets, 
which contain more prothrombotic material 
per unit volume, are also associated with 
restenosis.17 However, the clinical relevance 
of these findings has not been fully evaluated. 
For example, low platelet responsiveness to 
clopidogrel, a predictor of thrombotic com-
plications, is not a predictor of DES 
restenosis.18
Remodelling
Remodelling refers to a change in the total area 
of the vessel (generally measured as a loss of the 
area within the external elastic lamina) that 
affects lumenal dimensions of the blood vessel 
not attributable to vaso spasm, vasodilation, 
or changes in wall area. Remodelling can be 
favorable (outward, positive, compensatory, 
or adaptive) or unfavorable (inward, negative, 
or maladaptive). Vascular remodelling 
occurs normally in response to changes in 
blood flow, wall mass, or wall tension (as 
during normal development, atherosclerotic 
lesion development, or hypertension) as an 
adaptation to maintain normal blood flow 
(see review19). Post-angioplasty, arteries show 
further gains in lumen area between 1 day 
and 1 month after angioplasty, but then lose 
some vessel area thereafter with restenotic 
arteries showing a greater loss than non-
restenotic arteries. Negative remodelling 
contributes more than intimal hyperplasia 
to restenosis after coronary and peripheral 
artery angioplasty5,96 and in vein graft 
stenosis,1,97,98 but in rigid artificial grafts and 
stented arteries intimal hyperplasia is the 
primary mechanism of restenosis.5 
The regulation of arterial remodelling 
is poorly understood, but since wall ten-
sion and shear stress are normally regulated 
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Factor (+ if 












End stage renal 
disease (+)
Fem-pop BMS 511 [20]
Coronary DES (recurrent 
restenosis)
990 [21]
Coronary BMS 34 [22]
Diabetes (+) Carotid endarterectomy 243 [23]








Coronary SES or PES 545 [28]
Coronary SES 1312 [29]
Coronary stent 3104 [30] 
SES for coronary BMS 
restenosis
244 [31]
Coronary BMS 345 [32]
Coronary BMS and 
DES 
274 [33]
Coronary angioplasty 92 [34]




Carotid endarterectomy 321 [36]
Echolucent plaque (+) Carotid endarterectomy 308 [24]
Coronary angioplasty 92 [34]
Collagen content (+) Femoral endarterectomy 217 [37]
Positively remodeled 
lesion (+)
Coronary BMS 85 [38]
Coronary BMS 113 [39]
Table 7.1:  Recent Studies of Biologically Relevant, Non-technical Factors Implicated 
in Restenosis
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Factor (+ if 













core in lesion (+)
Carotid endarterectomy 500 [40]
Atherosclerotic 
burden – Gensini 
score (+) 








Coronary BMS 47 [42]






Coronary BMS 95 [44]
Coronary angioplasty 64 [45]
Coronary angioplasty 91 [46]
Coronary BMS 58 [47]
SNPs and soluble factors
Growth Inhibitors and Stimulants
eNOS (Glu298Asp) 
(+ TT)
Coronary BMS 106 [48]
eNOS (Glu298Asp) 
(+ TT)
Coronary BMS 226 [49]






Coronary BMS 323 [50]
Coronary BMS 1807 [51]
p27 -838C>A (+ CC) Coronary BMS 715 [52]
Nurr1 haplotype (-) Coronary BMS 601 [53]
Pre-procedure 
Adiponectin (-)
Coronary BMS in end 
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Factor (+ if 











Change in adiponectin 
(-)










Angioplasty of femoral, 
popliteal arteries
172 [58]
Carotid endarterectomy 64 [59] 
Coronary DES 167 [60]




Coronary angioplasty 345 [32]
Coronary angioplasty 162 [63]
Coronary angioplasty 168 [64]
Coronary angioplasty 345 [65]







Coronary stent (type 
unclear)
165 [68]
Coronary angioplasty 171 [69]
IL-1R antagonist*2 (-) Coronary angioplasty 171 [69]
Pre-procedure IL-3 
(+)
Coronary stent (type 
unclear)
205 [70]
IL-6 SNP (-174 G/C) 
(+ CC)
Fem-pop angioplasty 281 [71]
IL-6 SNP (-174 G/C 
and -572 G/C) 
Coronary BMS 3104 [30]
Pre-procedure 
soluble CD40 ligand 
(+)
Coronary angioplasty 70 [72]
Coronary angioplasty 162 [63]
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CD11b level and 
activation on 
leukocytes (+)
Coronary BMS 62 [73]
CD18 SNP  
(1323 C/T) (+ TT)
Coronary stent 1207 [74]
CD14 SNP (-260C/T) 
(+ CC)
Coronary BMS 3104 [30]
Change in MCP-1 
blood levels (+)
Coronary DES BMS 32 [75]
TNFα –238G-1031T 
haplotype (+)
Coronary angioplasty 3104 [76]
TNFα release during 
procedure (+)





SNP (-1328G/A)  
(+ GG)
Coronary BMS 3104 [30]
Colony Stimulating 
Factor 2 SNP 
(Ile117Thr) (+ Ile)
Coronary BMS 3104 [30]
Colony Stimulating 
Factor 3 at 24 hours 
(+)
Coronary BMS 40 [78]
Oxidized LDL 
change (+)






Coronary BMS and 
SES 
41 [79]
CD34+ cells on day 
7 (+)
Coronary BMS 40 [78]
CD34+ cells (+) Coronary BMS 17 [80]
Complement/Lectin
Mannose Binding 
Lectin (MBL) 2, A/A 
alleles (+)
Carotid endarterectomy 123 [81]
Pre-procedure 
Complement C3 (+)
Carotid endarterectomy 64 [82] 
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Factor (+ if 













Coronary BMS 3104 [30]
Pre-procedure 
C1-Inhibitor (+)
Carotid endarterectomy 64 [59]
Change in VEGF 
and PDGF-AB in 
patients with MBL2 
A/A alleles (+)





Coronary BMS 3104 [30]
Asymmetric dimethyl 
arginine (+)
Angioplasty of failed 




















Heparin Cofactor II  
(-)
BMS in restenotic fem-
pop post angioplasty
63 [16]
Coronary BMS 134 [86]




Coronary BMS and 
DES 
274 [33]
Lipoprotein(a) (+) Coronary BMS 109 [88] 
Active MMP9 (+) Coronary BMS 286 [89]
MMP9 (+) Coronary stent 40 [90]
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Factor (+ if 











Active MMP3 or 
MMP9
Coronary BMS 152 [91]
MMP2 and MMP9 
(+)
Coronary DES 85 [92]
5A/6A MMP3 SNP 
(6a+) 
Coronary BMS 344 [93]
Coronary BMS 198 [94]
Coronary angioplasty 287 [94]





Coronary angioplasty 162 [63]
This table is not an inclusive list of all studies of risk factors for restenosis. Studies showing non-technical 
factors as independent risk factors for restenosis (i.e. angiography, duplex US) by multivariate analysis were 
included as were studies showing a lack of independence of these same factors. 
within a narrow range in mammals (see 
review19), it must involve the transduction 
of the forces of shear stress and wall tension 
into biochemical signals leading to the break-
ing and reforming of ECM attachments, 
both matrix to matrix and cell to matrix. 
For example, the wall thickening that occurs 
in vein grafts and hypertensive arteries nor-
malizes wall tension. A mechanoregulation 
model of remodelling proposed by grinnell 
and colleagues, in which strain-regulated 
cell migration and collagen translocation 
can produce large scale tissue movement,99 
is relevant to both vascular and cutane-
ous injury, which share several features. For 
example, skin wounds contract as do nega-
tively remodelling arteries, ECM changes are 
similar in injured skin and artery (increased 
biglycan and versican and less decorin), and 
smooth muscle actin-positive cells appear in 
the skin wound (myofibroblasts) and in the 
injured arterial adventitia. Of interest, there 
is a possible association between abnormal 
skin wound healing and restenosis.100 Sup-
port for a mechanoregulatory model comes 
from observations after vascular and cuta-
neous injury. Releasing tension by external 
wrapping of arteries and by external pressure 
or skin flapping to skin wounds causes tis-
sue regression through apoptosis and loss of 
ECM.101-103 Detaching collagen gels embed-
ded with SMCs so that they float releases 
tension and causes SMC death and inhibits 
ECM production.104 Finally, increasing 
tension by stretching arteries ex vivo and by 
external skin splinting causes cell proliferation 
and increased tissue mass.105-107 The tension 
in the cell-ECM has been shown to regulate 
which signaling pathways are utilized,99 and 
several signaling mediators are implicated in 
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the regulation of remodelling. One example 
is NO, but while NO formed by iNOS and 
nNOS inhibits negative remodelling, that 
formed by eNOS does not influence remod-
elling. Whether the particular isoform of 
NOS or the particular cell expressing NOS is 
critical is not known. The P2X4 ion channel, 
which is needed for NO production, is also 
necessary for flow-mediated remodelling, as 
is the cytoskeletal filament, vimentin, which 
is a key intracellular protein in the transmis-
sion of contractile forces.19
The roles of the adventitial, medial, and 
intimal layers of the artery in remodelling 
are not clear though each provide significant 
mechanical strength to the human artery.108 
Some data suggest that adventitial fibrosis 
and collagen accumulation contribute to 
negative remodelling.109 SMCs synthesize 
collagen fibrils in a manner dependent on 
fibronectin fiber assembly, α2β1 integrin, 
and RhoA activity, as well as an intact actin 
cytoskeleton, which is required for tension 
development.110 Of interest, blockade of 
fibronectin assembly or Rho kinase prevents 
positive arterial remodelling.111,112 Fibronec-
tin regulates signaling by the transcrip-
tion factor NFκB,113 which mediates α2β1 
integrin-directed SMC collagen gel contrac-
tion114 and remodelling of vessels caused by 
circumferential and axial stress.106,107,115,116 
Finally, inhibition of ECM protein cross 
linking by inhibition of lysyl oxidase or 
transglutaminase inhibits negative remod-
elling after angioplasty and blood flow 
reduction, respectively.117,118 Thus, arterial 
remodelling may involve the interaction of 
mechanical stress with fibronectin/collagen 
fibrillogenesis mediated by integrin/NFκB 
signaling as well as ECM cross-linking. The 
possible roles in remodelling of MMPs and 
other ECM components will be discussed 
below (sections on matrix metalloprotei-
nases and extracellular matrix/receptors). 
Finally, ongoing studies are focused on 
defining genetic determinants of murine 
flow-induced remodelling.19
Intimal hyperplasia
Intimal hyperplasia results from the net 
increase in cell number and ECM, which 
are dependent on rates of cellular migration, 
proliferation, and death and on rates of ECM 
synthesis and degradation, respectively. Our 
understanding of the underlying cellular 
mechanisms of intimal hyperplasia comes 
from animal models of vascular injury, since 
the ability to study the human response at the 
cellular and biochemical level has been limited. 
A variety of methods of arterial injury has 
been employed including a partially inflated 
Fogarty embolectomy catheter, loose-fitting 
external cuffs, endolumenal wires or nylon 
loops, adventitial electrical injury, complete 
or partial arterial ligation, and stents. Some 
of these methods share features of clinically 
used interventions (e.g. stents) while others 
do not (ligation; see review119). Despite their 
limitations, animal models of vascular injury 
have provided a general understanding of the 
sequence of events after injury.120
Sequence of Events after Injury 
The sequence of events after arterial injury 
is illustrated in Figure 7.1. Depending on 
the type of injury, endothelial cells are either 
injured or completely removed resulting 
in the loss of the quiescent endothelial cell 
layer, which inhibits SMC proliferation and 
intimal hyperplasia.121,122 Within 30 minutes 
of balloon injury up to 70% of medial SMCs 
die via apoptosis. Placement of vein grafts 
and stents into the arterial circulation, as 
well as arterial ligation, also cause apoptosis 
(review in2). Some data suggest that cell 
death increases intimal hyperplasia,123-125 but 
SMC death by itself does not appear to cause 
intimal hyperplasia.126
Prior to the start of proliferation, SMCs 
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in the media express high levels of SMC-
specific contractile proteins, such as smooth 
muscle alpha actin (SMA), and are quiescent 
with no significant ECM production. After 
injury, SMCs change to a de-differentiated 
phenotype with SMCs expressing decreased 
levels of SMC-specific contractile proteins127 
and increased levels of migration, prolifera-
tion, and ECM synthesis. The regulation of 
this transition has been studied at the trans-
criptional level for markers of SMC differ-
entiation128 and for many years it has been 
assumed that expression of these genes might 
inhibit proliferation. Recent data supports 
this for SMA in that specific mutations in 
SMA cause SMCs to proliferate faster in 
vitro and cause coronary artery disease.129
The medial SMC proliferation rate dur-
ing the first two to four days jumps from 
0.06% before injury to 10-40% in the 
injured arteries of rats, mice, rabbits, and 
non-human primates (review in2). Adventi-
tial proliferation begins earlier and is main-
tained along with medial proliferation.130 
Animal and clinical studies with stents indi-
cate that intimal hyperplasia is generally cor-
related with the degree of injury.2,15 By four 
weeks cell growth in the media and adventi-
tia returns to baseline. By eight weeks, when 
intimal growth is maximal, growth returns 
to baseline in endothelialized intima, but 
SMCs at the luminal surface in deendothe-
lialized areas continue to proliferate at a low 
rate.131
Migration of medial SMCs into the rat 
and mouse neointima occurs as early as 4 days 
after injury.132,133 The role of SMC migra-
tion in human vessels remains an unknown, 
FIGure 7.1: Sequence of events leading to intimal hyperplasia after arterial injury including histological 
cross-sections of injured rat carotid arteries: (a) normal vessel. Note the single layer of endothelium 
in the intima; (b) denuded vessel at two days. Note the loss of endothelium; (c) denuded vessel at 
two weeks. Intima is now markedly thickened due to smooth muscle migration and proliferation; and 
(d) denuded vessel at 12 weeks. Further intimal thickening has occurred. Internal elastic lamina indicated 
by an arrow.
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because the presence of intimal SMCs in nor-
mal arteries as well as in arterial lesions makes 
the measurement of migration impossible by 
currently available methods. In addition, 
the long term significance of medial SMC 
migration is uncertain, since pharmaco-
logical inhibition of migration causes only 
transient inhibition of intimal hyperplasia 
(e.g. MMP inhibitors and heparin; see 
review2). Thus, especially when there are pre-
existing intimal SMCs, the impact of medial 
SMC migration is not clear. 
There are very little data on the rate 
of growth of lesions in humans as most 
studies report baseline and final lesion size 
and serial angiography after angioplasty does 
not differentiate between negative remodel-
ling and intimal hyperplasia. Available data 
indicates that intimal growth in stents 
is greatest from 0-6 months with a small 
increase (in DES) or decrease (in BMS) 
between 6–24 months.134,135 Maximal 
intimal hyperplasia is achieved by 2 months 
after arterial injury in rats, rabbits and 
baboons131,136,137 and after stenting in rats.138 
Differences in the thrombotic response139 
as well as differences in rates of recovery of 
the endothelium140 may explain some of this 
variability. genetic differences can explain 
some but not all of these differences in 
animals as well as humans.3,141-143
A considerable number of risk factors 
for restenosis are associated with intimal 
hyperplasia (Table 7.1). Regarding renal fail-
ure and type 2 diabetes, while there are few 
studies of arterial injury in animal models 
of type 2 diabetes (in contrast to type 1)144 
or renal failure, increased intimal hyper-
plasia is observed in arterio-venous fistu-
las in a mouse model of renal failure and 
in vein grafts in a mouse model of type 2 
diabetes.145,146 In addition, SMCs obtained 
from type 2 diabetic patients display 
increased proliferative and migratory capac-
ity in vitro compared to SMCs from non-
diabetic patients.147 A SNP of p27, which 
is an inhibitor of cyclin-dependent kinases 
and proliferation,148 increases basal promoter 
activity and is associated with less restenosis.52 
Certain haplotypes of Nurr1, a transcrip-
tion factor that inhibits SMC proliferation, 
are associated with restenosis.53 eNOS SNPs 
associated with restenosis may decrease 
levels of NO, which is a SMC growth inhibi-
tor as well as vasodilator,149 Adiponectin, 
which inhibits SMC growth,150 is negatively 
associated with restenosis. In contrast, resis-
tin, which is positively associated with res-
tenosis, stimulates SMC growth.151 Finally, 
a role for cell proliferation in vein graft 
stenosis is supported by the increased prolif-
erative capacity of cells cultured from veins 
of patients that develop stenosis.152
Several predictive factors for restenosis 
may be associated with decreased blood 
flow through the lesion (Table 7.1), which 
is known to increase intimal hyperplasia 
in animal models.153 These factors include 
impaired forearm reactive hyperemia, which 
may indicate poor dilation in the lesion 
area, and high collateral function, which 
may divert blood from the lesion. Other 
factors influence eNOS, which synthesizes 
the vasodilator NO. These are an eNOS 
SNP associated with restenosis, which may 
decrease eNOS function, and asymmetric 
dimethyl arginine, which inhibits eNOS and 
which is increased in the blood of restenotic 
patients.84 Finally, a beta2 adrenergic recep-
tor SNP may decrease the vasodilatory func-
tion of this receptor30 (Table 7.1).
Origin of intimal cells
Early experiments on the arterial response 
to injury indicated that medial SMCs were 
the source of intimal cells after injury (see 2), 
but more recent studies of arterial injury 
in chimeric mice and rats suggested that a 
significant number of intimal SMCs are 
of bone marrow origin(review in;154,155 see 
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figure 7.2 for possible sources of the major 
cells of the intima). However, these data have 
been called into question by investigators 
using more robust microscopic techniques 
for detecting double labeled cells.156-159 In 
addition, while some studies have shown 
a correlation between the risk of human 
coronary BMS restenosis and the increase 
in circulating CD34+ cells and their ability 
to differentiate into SMCs in vitro,78,80 the 
significance of these data is not clear in the 
absence of data showing a contribution of 
these cells to intima formation in humans. 
Another possible source of intimal cells 
is suggested by studies in rats, pigs, and 
rabbits that indicate that adventitial cells 
migrate into the intima (review in160). 
However, other investigators did not find 
significant adventitial involvement in 
porcine coronary intima formation with161,162 
or without complete interruption of the 
media (see review154). While recent reports 
demonstrate the presence of adventitial cells 
in rat and human arteries and veins that can 
differentiate into SMCs, the contribution of 
adventitial cells to intimal hyperplasia remains 
uncertain.158,163,164 In addition, evidence from 
studies of embryonic development and with 
cultured endothelial cells demonstrate that 
endothelial cells can undergo a phenotypic 
transition to SMCs making these another 
potential source of intimal cells.165 Overall, 
the data suggest a medial and possibly 
adventitial origin of intimal SMCs. 
Inflammation
There is a strong correlation between 
inflammation and restenosis after angio-
plasty or stent placement15,166 and between 
macrophages in the primary lesion and the 
occurrence of restenosis after angioplasty167 
(reviewed in168). While many individual 
studies have not demonstrated an independent 
association between pre-procedural blood 
levels of the acute phase protein, CRP, 
and coronary restenosis, a meta-analysis of 
FIGure 7.2: Possible sources of intimal cells after arterial injury.
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coronary angioplasty studies showed CRP 
as an independent predictor (Table 7.1). In 
addition, a study of peripheral angioplasty 
showed a much stronger relationship between 
restenosis and 48 hour post-angioplasty 
CRP levels than with pre-procedural levels.58 
Whether CRP is related to vein graft stenosis 
is not clear.169
Data from models of injury that both do 
and do not denude the vessel of endothelium 
indicate that inflammation promotes inti-
mal hyperplasia. Leukocyte recruitment to 
the injured vascular wall occurs via binding 
to adherent platelets170 and to cell adhesion 
molecules that are up-regulated by injury, 
such as ICAM-1 and VCAM-1.171 Knockout 
or blockade of VCAM-1 or of the inflam-
matory cell integrin, Mac1, inhibits lesion 
formation after injury because of decreased 
leukocyte recruitment.10,172,173 Inhibition of 
monocyte recruitment using a dominant-
negative mutant of MCP-1, a major mono-
cyte chemoattractant, also inhibits intimal 
hyperplasia after angioplasty in rats, non-
human primates,174 and hypercholesterolemic 
rabbits.175 Finally, simultaneous myocardial 
infarction increases intimal hyperplasia after 
femoral artery injury possibly via increased 
levels of circulating IL-6 and TNFα.176 
A number of inflammatory factors are 
predictors of restenosis. The number of 
inflammatory cells in stented lesions,15 activa-
tion status of Mac1 on leukocytes,73 a CD18 
(a Mac1 subunit) SNP,74 and the change in 
blood levels of MCP-1 are associated with res-
tenosis75,177 (Table 7.1). Of note, rapamycin 
is anti-inflammatory.178 In addition, pred-
nisone, another anti-inflammatory drug, 
decreases late lumen loss in coronary BMS 
and the release of TNFα from the patients’ 
monocytes. This reduction in TNFα release 
correlates with late lumen loss179 (Table 7.1). 
However, there are conflicting results with 
the -174 g/C and -511 polymorphisms of 
IL-6 and IL-1, respectively, in studies of the 
coronary and peripheral circulation.66,69,180 
Despite this there is a clear association of 
inflammation with restenosis. 
Role of ECM production 
Both cell proliferation and ECM production 
contribute to intimal hyperplasia131, and 
intimal area more than doubles between 
two and eight weeks after injury because of 
ECM accumulation. The stable neointima is 
about 20% SMCs and about 80% ECM.131 
Rates of SMC replication are extremely low 
in restenotic tissue,5,181 leading glover and 
colleagues to suggest that changes in ECM 
are the major factor in restenosis several 
months to years after stent placement. Of 
interest, re-injury to the rat carotid artery one 
month after a prior balloon injury increases 
intimal lesion size entirely as a result of 
increased ECM.182 In this regard, it should 
be noted that rapamycin inhibits induction 
of major ECM proteins such as collagen 
and hyaluronan.183,184 The lack of evidence 
for substantial SMC proliferation in either 
angioplasty or stent stenosis suggests that 
therapies may be better aimed at altering the 
synthetic phenotype of SMCs, which would 
control ECM synthesis as well as proliferative 
capacity.
THE CONTRIBUTION OF 
SPECIFIC FACTORS TO 
RESTENOSIS
Growth factors/cytokines
Activated platelets, leukocytes, endothelial 
cells, macrophages, and SMCs can release a 
great number of growth factors and cytokines 
after arterial injury, including PDgF, 
FgF2, TgFβ, TgFα, vascular endothelial 
cell growth factor, macrophage colony 
stimulating factor, granulocyte macrophage 
colony stimulating factor, platelet-derived 
endothelial cell growth factor, IL-1, IL-4, 
IL-6, IL-8, IL-18, MCP, and TNF.185 Many 
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of these factors have been shown to play roles 
in intimal hyperplasia and remodelling after 
arterial injury,2 but we will focus on only 
three of these factors. 
PDgF is a family of four gene products 
(A, B, C, and D chains) that dimerize into 
five functional growth factors (AA, AB, BB, 
CC, and DD), which bind differentially to 
homo- or hetero-dimers of two receptor sub-
units, α and β (see review186). PDgF plays a 
major role in the migration of SMCs after 
injury, while playing a minor role in SMC 
proliferation.186 The β receptor subunit 
mediates intimal hyperplasia in non-human 
primates, which suggests a role for the PDgF 
isoforms B and D, and possibly C. However, 
there is also evidence for a role of PDgF-AA 
and, therefore, PDgF receptor α in intimal 
hyperplasia in the rat.186 Of interest, con-
comitant treatment of non-human primates 
with blocking antibodies to both PDgF 
receptor isoforms causes intimal regression 
in polytetrafluroethylene grafts, while treat-
ment with either alone does not.187 A single 
intravenous infusion of a humanized version 
of this PDgFRβ antibody did not alter BMS 
restenosis,188 but plasma concentrations con-
sidered effective were maintained for only 
two weeks. 
FgF2 stimulates medial SMC prolif-
eration and migration to the intima in the 
injured rat carotid, and blockade of both 
FgF2 and PDgF with antibodies results in 
an additive inhibition of intimal hyperplasia. 
However, FgF2 plays no role in the prolif-
eration of intimal SMCs, and the intimal 
hyperplastic response in FgF2 knockout 
mice is normal (see review2). However, these 
mice display decreased SMC contractility,189 
which is consistent with the observation that 
a blocking antibody to FgF2 inhibits nega-
tive remodelling in the mouse carotid tie-off 
model.190
Although infusion of TgFβ1 stimulates 
medial SMC proliferation and antibody 
blockade slightly inhibits intimal hyper plasia, 
the more striking effect of blocking the action 
of TgFβ is on remodelling and ECM produc-
tion (see review191). Blockade of TgFβ with 
a soluble receptor blocks negative remodel-
ling, the transition of adventitial fibroblasts 
to myofibroblasts, and the deposition of col-
lagen and versican. In stents, blockade of the 
TgF receptor does not alter intimal thicken-
ing but alters inflammatory cell number and 
extracellular matrix composition.192
Interactions among growth factors after 
injury are a significant though largely unex-
plored aspect of restenosis. For example, 
TgFβ can synergistically augment the mito-
genic action of PDgF and FgF2.191 In addi-
tion, IL-1β augments the proliferative effect 
of PDgF-BB on SMCs by inhibiting expres-
sion of p21 and p27, but inhibits PDgF-
BB mediated SMC migration (see review2). 
Such interactions may augment hyperplasia 
in areas of inflammation (such as near stent 
struts) by slowing SMC movement and 
increasing proliferation. 
Inhibitors
Numerous factors are inhibitors of intimal 
hyperplasia. For example, NO can inhibit 
SMC migration and proliferation after arte-
rial injury149 and prostacyclin inhibits intimal 
hyperplasia via its receptor IP.193 Heparin and 
the heparan sulfate proteoglycans, perlecan 
and syndecan-1, inhibit SMC proliferation 
and migration, thus inhibiting injury medi-
ated intimal hyperplasia.194-196 In addition, 
overexpression of heparanase, the enzyme 
responsible for degrading the heparan sulfate 
glycosaminoglycans, causes increased inti-
mal hyperplasia after stent-induced injury.197 
The normal adventitia inhibits medial SMC 
migration and proliferation.121 Similarly, nor-
mal periadventitial adipose tissue inhibits inti-
mal hyperplasia after injury at least partially 
through the action of adiponectin.198 Other 
factors known to inhibit intimal hyperplasia 
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include interferon γ, hepatocyte growth fac-
tor, interleukin 10, adrenomedulin, somato-
statin, and endothelin.2 
In recent years, it has become clear that 
the effect of a single ligand is often dictated 
by the relative expression of receptor isotypes, 
which can have opposing roles. For example, 
in the vascular system S1P binds to the 
gPCRs, S1PR1, 2, and 3. Data indicate that 
S1PR1 and S1PR3 are stimulators of intimal 
hyperplasia after injury, while S1PR2 is an 
inhibitor in this regard.199 Another gPCR 
ligand, LPA, binds to LPA1 through 5. 
LPA1 is inhibitory towards SMC migration, 
while LPA3 appears to be stimulatory.200 
Prosta glandin E
2
 also binds to gPCRs, EP1 










vasodilatation.201 Activation of EP4 increases 
ductus intimal cushion formation202 suggest-
ing the possibility that other EP receptors 
may mediate the growth inhibitory effects 
often described for PgE in vitro. 
Coagulation and fibrinolytic factors
Arterial injury in pigs and primates is 
associated with thrombosis, which is usually 
not occlusive but does release mediators of 
SMC growth and migration. Rodent models 
of arterial injury are usually not associated 
with thrombus formation,203 although it 
is possible that intimal hyperplasia is being 
driven by short-lived microthrombi or by 
thrombogenic factors such as TF7, throm-
bin,204 and factor Xa205 at levels too low to 
generate thrombus formation. While TF 
drives intimal hyperplasia after injury because 
of increased SMC migration7, after double 
injury TF mediates negative remodelling,206 
Balloon injury also increases expression 
of the plasminogen activators, urokinase and 
tissue-type plasminogen activator, in SMCs 
(review 207). The plasminogen activators, in 
turn, proteolytically activate plasmin, which 
has a major role in fibrinolysis. Several lines 
of evidence indicate that urokinase is also 
required for SMC migration and prolifera-
tion.207,208 In this regard plasma urokinase is 
a predictor of restenosis.87 Also of interest, 
the urokinase receptor interacts with PDgF 
receptor β which in turn mediates the effects 
of urokinase on migration and proliferation 
in a PDgF-independent manner.209 Finally, 
in contrast to urokinase, tissue plasminogen 
activator has been shown to inhibit SMC 
accumulation after injury and to cause posit-
ive arterial remodelling.207
Matrix metalloproteinases 
MMPs are involved in the regulation of both 
intimal hyperplasia and remodelling. Arterial 
injury in numerous species induces the 
production of a number of MMPs, including 
MMPs 2, 3, and 9,208,210 which promote 
intimal hyperplasia and are associated with 
BMS restenosis (Table 7.1).89-92 For example, 
MMP9 is increased in coronary sinus blood 
after stent placement and is associated with 
increased levels of CD34+ progenitor cells,211 
which are predictors of restenosis (Table 7.1). 
High blood flow-mediated positive remodel-
ling is mediated by MMP9.212-213 Blockade of 
MMPs with synthetic drugs has mixed results 
on intimal hyperplasia and remodelling2 
probably because of the lack of specificity 
of small molecule inhibitors. In addition, 
hydroximate-based MMP inhibitors can 
inhibit MAP kinase signaling and collagen 
synthesis, which itself can inhibit SMC 
migration.2 Finally, there are active site 
independent effects of MMPs as demonstrated 
by the inhibitory effect of MMP9 on SMC-
mediated collagen gel contraction.214
Extracellular matrix/receptors
At late times after arterial injury as SMC 
proliferation decreases, intimal hyperplasia 
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continues as the result of ECM accumulation. 
Restenotic tissue from humans demonstrates 
lower cell density and substantial amounts 
of an ECM that differs from primary 
atherosclerotic lesions from which restenotic 
lesions arise.5,215 ECM molecules induced 
by angioplasty216 and stenting217 include 
type I collagen, elastin, and hyaluronan as 
well as the proteoglycans versican, perlecan, 
biglycan, and decorin. The ECM of 
resten otic lesions has more biglycan and 
hyaluronan181,216,218,219 and no decorin, unlike 
primary plaques.5 Consistent with lesion 
formation during restenosis, both biglycan 
and hyaluronan increase SMC proliferation, 
while decorin inhibits ECM accumulation 
after injury.220-222
Cellular receptors for ECM compon-
ents by which SMCs might act to remodel 
the artery includes the integrins, discoidin 
domain receptors, TLRs, and CD44, all of 
which are induced after vascular injury.223-226 
The family of integrins provides the classic 
example of a binding partner, which is able 
to mediate subcellular signaling.227 Blockade 
of αvβ3 integrin inhibits intimal hyper plasia 
without an effect on arterial remodelling.228 
The stimulatory effect of CCN1, an ECM 
protein upregulated by injury, on intimal 
hyperplasia may be via interaction with 
integrins.229 Discoidin domain receptor 1, 
first described as a signaling receptor of col-
lagens, is required for SMC migration and 
MMP production.230 CD44 binds hyaluro-
nan, collagens, and other ECM molecules 
and mediates SMC proliferation, migra-
tion, and SMC-mediated collagen gel con-
traction.231,232 TRL2 and TLR4, which 
are important components of the innate 
immune system, recognize not only micro-
bial components but also endogenous 
molecules such as versican, biglycan, heparan 
sulfate, and hyaluronan.233-235 Both TLR2 
and TLR4 appear to be required for cuff-
mediated intimal hyperplasia226,236 and TLR4 
is also required for high blood flow-mediated 
outward remodelling.237 MyD88, which is 
a major intracellular mediator of TLR 





Current interventions that significantly 
prevent restenosis utilize DES for the 
local application of either rapamycin or 
taxol related drugs.6 The molecular targets 
of rapamycin and taxol are mTOR and 
microtubules, respectively (see review239). 
Rapamycin is known to function as an 
antiproliferative drug through the inhibitory 
effect of a rapamycin/FKBP12/mTOR 
complex. This complex inhibits pro-
proliferative molecules such as p70s6k and 
inhibits anti-proliferative molecules such as 
p27.239 mTOR has two isoforms, mTORc1 
and mTORc2. Inhibition of the latter 
isoform appears to mediate endothelial cell 
toxicity that can lead to thrombosis.240 Newer 
rapamycin analogs, such as everolimus and 
zotolorimus, show promise of decreasing 
problems with late thrombosis.6 The other 
primary type of drug currently used in DES 
is paclitaxel, which binds to the β subunit of 
tubulin thereby stabilizing microtubules and 
preventing mitotic spindle formation during 
cell division. However, this drug also has cell-
cycle independent effects on cell spreading 
and migration.239
Transcription factors 
One transcription factor that has been 
targeted is E2F, a family of transcription 
factors required for DNA synthesis and cell 
cycle progression. Two large clinical trials of 
an inhibitor of E2F were based on animal 
studies in which an E2F decoy (a short 
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double-stranded oligodeoxynucleotide that 
binds E2F) blocked intimal hyperplasia. 
Saphenous vein grafts were treated with 
the E2F decoy before implantation for 
coronary (PREVENT IV) or peripheral 
(PREVENT III) bypass. However, neither 
trial of 3400 and 1600 patients, respectively, 
showed an effect on graft failure.241,242 
Unfortunately, the use of a non-selective E2F 
decoy that inhibits all E2F family members 
may have cancelled out an effect, since a more 
recent study indicates that E2F3 stimulates 
and other E2F family members inhibit SMC 
proliferation and intimal hyperplasia.243 
Despite these negative results vein grafts 
still provide an exceptional opportunity for 
intervention ex vivo before implantation. In 
preclinical studies, other transcription factor 
targets using the decoy technology have 
included Egr-1, which has been implicated 
in many cardiovascular disorders.244 
miRNA 
It is likely that future targets will include 
miRNAs, since these small RNA molecules 
regulate multiple gene products and it is 
unlikely that a single gene will regulate 
all pathways of a complex pathology like 
restenosis. Possible miRNA targets include 
Mir-21, Mir26a, Mir143/145, and MiR-221, 
which have been shown to regulate SMC 
phenotype, growth, death, and migration as 
well as intimal hyperplasia.245-248
Inflammation targets 
One anti-inflammatory drug that has been 
tested is pimecrolimus. This drug binds to the 
cytosolic receptor FK506 binding protein, 
which inhibits the calcium-dependent 
phosphatase calcineurin and the translocation 
of the transcription factor, nuclear factor of 
activated T-cells, to the nucleus preventing 
induction of inflammatory cytokines in 
T cells and mast cells. Based on animal 
models this was expected to reduce arterial 
inflammation and, therefore, neointimal 
hyper plasia and restenosis.249 Instead, 
patients treated with pimecrolimus-eluting 
stents were reported to fare worse than 
patients treated with stents that delivered a 
combination of pimecrolimus and paclitaxel, 
or paclitaxel alone.250 However, other drugs 
are being tested. An anti-inflammatory drug 
with a long history, salicylic acid, is being 
tested as a component of the biodegradable 
backbone of a stent that also has a coat of 
sirolimus.251 Finally, liposomal alendronate, 
a bisphosphanate compound that depletes 
monocytes and inhibits restenosis in rat and 
rabbit models of injury, is in phase II trials 
testing its effects on BMS restenosis (http://
clinicaltrials.gov/ct2/show/NCT00739466). 
Overall it appears that targeting inflammation 
alone may be inadequate to inhibit restenosis, 
although it may be effective as an adjunctive 
target.249
Brachytherapy 
Brachytherapy (radiation treatment) has 
shown success as an adjunctive therapy 
for BMS restenosis after successful balloon 
angioplasty.6 While brachytherapy inhibits 
both negative remodelling and intimal 
hyperplasia, one limitation found initially 
was hyperplasia at the ends of the stents or 
the angioplasty zone when radiation was not 
complete.5,252 In addition, prior brachytherapy 
is a risk factor for stent thrombosis.6 
Brachytherapy is less common now because 
of procedural logistics, concern of long-term 
thrombosis and delayed restenosis, but more 




While angiotensin II type 1 receptors mediate 
vascular SMC migration, proliferation, and 
extracellular matrix production after arterial 
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injury and angiotensin-converting enzyme 
inhibitors or specific receptor antagonists 
reduced intimal hyperplasia in several animal 
models, large scale trials of the angiotensin-
converting enzyme inhibitor, cilazapril, 
for balloon angioplasty or BMS failed to 
show benefit.120 However, more recent 
studies show that neointimal hyperplasia 
is inhibited by the angiotensin-converting 
enzyme inhibitor, quinapril, in patients with 
the D/D and I/D genotypes of angiotensin-
converting enzyme.253,254 In addition, use of 
the angiotensin II type 1 receptor antagonist, 
valsartin, decreases the incidence of stent 
restenosis255 and a valsartin-eluting stent is 
equivalent to a rapamycin-eluting stent.256 
These data suggest that angiotensin II type 1 
receptor antagonists may be useful in 
preventing restenosis.
Cell-based therapies
Use of engineered allogeneic endothelial 
cells applied to the adventitial surface to 
prevent restenosis in peripheral interventions 
is in Phase I/II trials at this time (http://
clinicaltrials.gov/ct2/show/NCT01099215). 
This trial is based on work in a porcine stent 
model257 and utilizes the same concept as a trial 
aimed at inhibiting stenosis of arterio-venous 
fistula bypass grafts.258 A Phase IV study 
involving endothelial cells utilizes a coronary 
stent with immobilised anti-CD34 antibody 
with which to capture circulating endothelial 
progenitor cells (http://clinicaltrials.gov/
ct2/show/NCT00494247).259 Finally, the 
possibility of bioengineered bypass grafts 
developed from induced pluripotent stem 
cells or other autologous progenitors holds 
promise as these may also be engineered to 
express or repress targets of choice.260
Differential effects on endothelium 
and SMCs 
A differential effect on endothelium com-
pared to SMCs is a helpful attribute for any 
target for restenosis. The lack of selectivity 
is a problem for rapamycin for which effects 
on endothelium mediate its thrombotic 
side effects. A20 is a zinc finger protein that 
prevents intimal hyperplasia in the injured 
rat carotid artery261. Expression of A20 
in medial SMCs prevents neointima forma-
tion by shutting down inflammation and 
proliferation via inhibition of NF-κB and 
by increased expression of the cell cycle 
dependent kinase inhibitors p21waf1 and 
p27kip1. However, A20 is anti-inflammatory 
in endothelial cells by inhibiting NFκB, 
but this is antiapoptotic via inhibition of 
the activation of caspase 8. Therefore, A20 
has protective effects for endothelial cells 
and anti-proliferative effects on SMCs mak-
ing it a good candidate for inhibiting SMC 
accumulation while minimizing endothelial 
damage. Another differentially effective target 
may be Nogo. Nogo-B is expressed by both 
endothelial cells and SMCs, but it increases 
endothelial cell migration and inhibits SMC 
migration. Nogo-B is down-regulated after 
injury and intimal hyper plasia is greatly 
increased in the Nogo-B null mouse. Trans-
fection of the murine arterial adventitia or 
porcine vein graft adventitia with an adeno-
viral vector of Nogo-B greatly inhibited 
intimal hyperplasia.262
Delivery devices 
garg et al have recently reviewed the use of 
DES and future design technology for the 
coronary arteries.6,251 The issue of drug-
eluting polymers is an area of advancement 
with next generation polymers, including 
biodegradable polymers, avoiding many 
of the past problems with allergic and 
inflammatory reactions. In addition, bio-
degradable stents with and without anti-
proliferative drugs are under development. 
These would avoid long term issues of 
inflammation from a foreign body. Stents 
with multiple therapeutic targets are under 
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development. One example is a DES that 
targets SMC proliferation and platelets 
with sirolimus and cilostazol, respectively. 
Bi-directional drug delivery from stents may 
allow functional separation of effects on 
SMCs and endothelial cells. Finally, as more 
is learned about the effects of co-morbitities 
on restenosis, such as diabetes, specific DES 
or drug-eluting balloons may be developed 
to use in subsets of patients. 
A common treatment of in-stent res-
tenosis is the use of DES. However, it is 
unclear if another stent adds to the risk of 
stent thrombosis or reoccurrence of res-
tenosis. Drug-eluting balloons are being 
studied as an alternative for this situation. 
In addition, DES have not shown benefit 
in femoropopliteal arteries, which are often 
significantly occluded throughout their 
length and are subject to forces not experi-
enced by coronary arteries (e.g. compression 
and bending) that may cause strut fracture.263 
Drug-eluting balloons have shown promise 
on peripheral artery lesions.264 One advant-
age of drug-eluting balloons is illustrated by 
a study of the use of nanoparticles, since the 
nanoparticles move further into the vascular 
wall before eluting their drug cargo and thus 
avoid endothelial cell toxicity.125 There are 
many differences between DES and drug-
eluting balloons including the issue of drug 
delivery kinetics. These as well as current 
and past trials with drug-eluting balloons are 
reviewed by gray.265
Prevention vs. reversal of restenosis 
Because current strategies to treat restenosis 
are intended to prevent intimal hyperplasia, 
all patients must be treated, even though less 
than one-third of all vascular interventions 
fail. Other options are to develop the ability 
to screen for those patients at high risk or 
to develop a treatment that would reverse 
the restenotic process.261 Observations of 
various SNPs and soluble factors associated 
with restenosis (Table 7.1) suggest that 
screening may be possible in the future. The 
possibility of reversing the restenotic process 
comes from the observation that intima 
formation in stents increases for about 3 
months, but starts regressing spontaneously 
after 6 months261, as well as effects of anti-
hypertensive drugs and of A20, which induce 
vascular regression via SMC apoptosis.261,266 
In addition, when global gene expression is 
compared in two distinct models of vascular 
regression in non-human primates, only 
7 genes are regulated in the same manner 
in both models of atrophy (Kenagy et al, in 
press). Six of these atrophy-associated genes 
are also induced in vitro by the ligand for 
the death receptor Fas, suggesting that these 
genes are an important part of the cell death 
program active during atrophy. Also, a third 
of the up-regulated genes (ADAMTS4, tissue 
plasminogen activator, and hyaluronidase2) 
degrade components of the ECM, loss of 
which is a major feature of vascular atrophy. 
These commonly regulated genes may play 
a fundamental role in vascular atrophy 
and may lead to drug candidates useful for 
reversing restenosis in those situations where 
intimal hyperplasia is the primary cause. 
CONCLUSIONS
Restenosis is primarily a problem of excessive 
intimal hyperplasia and negative remodelling. 
Human risk factors for restenosis include 
diabetes, renal failure, factors associated 
with decreased blood flow, factors leading to 
decreased growth inhibition, factors leading 
to increased growth stimulation, as well as 
increased inflammation (Table 7.1). These 
data are consistent with data from animal 
models of intimal hyperplasia and support 
further research into how these factors impact 
restenosis. While animal models have been 
useful for understanding basic mechanisms 
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of restenosis, the predictive power of animal 
models for clinical efficacy is still unclear, 
particularly concerning peripheral vessels. 
Correlating animal models and clinical 
application is an active area of research.267 
In addition, most clinical studies are of the 
coronary circulation. The degree to which 
results in the coronary circulation match the 
peripheral circulation is not known, but there 
are differences. Coronary and peripheral 
vessels are embryologically distinct,268 and 
injury of the coronary artery leads to greater 
intima formation than does injury of 
peripheral arteries in pigs and dogs.269-271 In 
addition, the femoropopliteal arteries, but 
not the coronary arteries, are subject to the 
forces of compression, bending, twisting, 
and axial changes caused by joint flexion and 
external impact, which may have a significant 
effect on restenosis. 
Our greatest success at preventing resten-
osis, DES, comes as much as a result of 
engineering than of drug development. As 
endovascular techniques continue to evolve, 
the efficacy of drug targets should keep pace. 
Unfortunately, the early promise of the 
Human genome Project for new therapeutics 
aimed at human disease such as resten osis has 
not been forthcoming. genome-wide asso-
ciation studies, designed to reveal markers 
or potential causal factors, have revealed that 
cardiovascular pathologies have a complex 
genetic structure. While >20,000 genes and 
more regulatory factors of the RNA world 
have been identified, how these factors are 
related remains largely unknown. However, 
the field of systems biology is poised to have 
a significant impact on vascular biology over 
the coming decade. New types of analysis 
have revealed networks that can explain up 
to 50% of the variance of a complex clinical 
phenotype.272-273 It is hoped that a systems 
biology or similar approach will soon reveal 
key networks and regulatory hub molecules 
that control restenosis. Based on research to 
date it is likely that networks regulating cell 
differentiation, growth, inflammation, and 
ECM production, major aspects of intimal 
hyperplasia, will be featured and that hub 
molecules that link these networks will be 
identified as promising therapeutic targets.
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Vascular interventions have developed 
rapidly since the first aortic replacement with 
Dacron by Dubois in 1952. Understanding 
vascular haemodynamics and the biological 
response to implanted materials is essential 
for vascular surgeons and scientists developing 
new interventional technologies.1,2
This chapter will summarise and discuss 
the following laws, equations and phenom-
ena to give a basic understanding of the 
haemodynamic principles of the conduits 













For	 those	 who	 understand	 electrical	 
circuit theory, there is much similarity with 
haemodynamics. Understanding the physi-
ology and physics of blood flow is aided by 
the use of that recognition. When consider-
ing fluid dynamics instead of:
VIR,  (1)
where V is the voltage, I is the current and 




and R the flow resistance. 
Resistors in series and parallel govern 
degrees of ischaemia and the behaviour of 
blood flow and contribution of collaterals, 
and hence degree of ischaemia of limbs and 
organs.
The great vessels, like the aorta, are with-
out muscle and their walls are composed of 
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to behave as capacitors and store some of 
the energy in systole to be released to power 
flow in diastole, that is so important into 
vessels such as the coronary artery. The elas-
tic arteries stiffen with age and explain the 
flow changes that occur with ageing and for 
progressive arterial disease due to this most 




or venous wall with the pressure that the 
elastic tube can apply to material inside the 
tube. To assist in understanding this law 
we	 consider	 Figure	 8.1.	 in	 this	 figure,	 w, 
represents the thickness of the arterial wall, 
r is the inner radius of the artery, P the inward 
pressure force due to the elastic nature of 
the artery and T is tensional stress within the 
wall of the vessel, where the tensional stress 
points in a direction that is tangential to 
the vessel wall. Due to mass conservation the 






where it is 
usually assumed that the wall thickness, w is 
small relative to r. This law tells us that the 
inward pressure that is exerted by the vessel 
wall on the blood is directly proportional to 
the tensional stress in the wall and inversely 
proportional to the radius of the wall. Thus 
the smaller the vessel the larger the pressure 
it can apply on the blood. 
Large	thin-walled	vessels	are	low	pressure	
vessels. Increasing the pressure distends the 
vessel and increases the vessel volume which 
is	a	characteristic	property	of	veins.	For	arter-
ies to maintain pressure, the width of the wall 
must obviously be greater, so large veins are 
thin-walled and arteries are thick-walled.
One consequence of this behaviour is 
that, to a certain extent, an artery acts like 
a long cylindrical party balloon. When one 
attempts to blow up such a balloon, it is 
quite difficult to do at the first blow, however 
once the balloon reaches a particular radius, 
it usually becomes much easier to expand 
the balloon. That is you require less pressure 
to increase the size of the balloon. This phe-
nomenon is known as instability. If this hap-
pens to an artery, then we are dealing with an 
aneurysm and the relatively constant blood 
pressure will keep on increasing the size of 
the aneurysm.
The radius of the artery at which this 
instability occurs is difficult to compute 
accurately, but some fairly general arguments 
suggest that the following formula is a good 
guide: where r
c
 is the critical radius for the 
onset
rc  2r0,  (4)
of the instability and r
0
 is the initial radius 
of the artery. The median diameter of the 
aorta is 23 mm and the thus aortic rupture is 
very rare when less than 50 mm in diameter, 
which is consistent with recent clinical 
Figure 8.1: Cross section of an artery showing 
the various physical components that make up 
Laplace’s law.
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data.3,4 This guide also directs us to consider 
that the ratio of the diameters is probably 
more important than the absolute diameter 
and this should be taken into account 
when assessing aneurysms in the smaller 
diameter	vessels	of	women.	how	arterial	wall	
instability	 arises	 is	 illustrated	 in	Figure	8.2,	 
where	 in	 Figure	 8.2(a)	 we	 show	 the	 stress	
structure	 within	 a	 small	 artery.	 here	 the	
tensile stresses have a component in the 
radial direction, where the letter T labels this 
component.	in	Figure	8.2(b)	the	aneurysm/
balloon has become very large, such that 
over a small segment of the wall the artery 
has hardly any curvature. This is an extreme 
case, but it does show that there is now no 
radial component to the tensile stresses. In 
such a case, the aneurysm can expand freely 
for just about any internal arterial pressure.
NewtoNiaN	FLuiD
When we wish to describe the behaviour 
of a fluid it is necessary to know something 
about the frictional properties of the fluid. 
Consider the schematic depiction of a fluid 
shown	 in	Figure	8.3.	 in	 this	figure,	fluid	 is	
flowing from left to right along the x direc-
tion.	For	purposes	of	illustration,	we	assume	
that the speed of the fluid, u, is increasing 
with increasing height (i.e., increasing y). This 
means that elements of fluid are sliding past 
each other and so generate some frictional 
stress τ. In a Newtonian fluid, the frictional 
stress is proportional to the rate at which 
the speed changes as a function of distance, 
where µ	 is	 the	 viscosity	 (eq	 (5)).	 the	 
du/dy	 in	 equation	 (5)	 corresponds	 to	 the	
shear rate. To a reasonable approximation, 
one can assume that blood is a New tonian 
fluid, at least for flow along the major 
arteries.
τ   µ  ,dudy
   (5)
NoN-NewtoNiaN	FLuiD	
Non-Newtonian fluids have a viscosity that 
depends	on	the	strain	rate.	a	shear	thinning	
fluid is a fluid that changes from “thick” to 
“thin” when force is applied to the fluid. 
examples	 of	 such	 fluids	 are	 shampoos	 and	
paints. This behaviour usually occurs, 
because, at rest, a shear thinning fluid 
typically has a tangled molecular structure, 
which makes the fluid relatively viscous. 
When force is applied, the molecules become 
ordered, the fluid viscosity decreases and the 
fluid	begins	to	flow	more	easily.	in	Figure	8.4	 
we show the experimentally determined 
shear thinning behaviour of blood, where 
the hematocrit value for the blood is 45%. 
These data show that for high shear rates, 
which may occur in the large arteries of the 
body, the viscosity of blood is about four 
times that of water (where the viscosity of 
water	is	approximately	one	centipoise	(cP)).	
however	 for	 lower	shear	rates,	 the	viscosity	
of blood can be over one hundred times that 
of water.
This change in viscosity is mostly due to 
the	collective	behaviour	of	red	blood	cells.	at	
low shear rates, red blood cells form aggre-
gates where they stack one upon another, 
somewhat like a cylindrical pile of coins. 
These “stacks” of red blood cells are known 
Figure 8.2: Cross sections of a small artery (a) 
and a very large artery (b) showing the stress 
distribution within the artery.
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as	 “rouleaux”	 (Figure	 8.5).	when	 the	 shear	
rate increases, these aggregates of blood cells 
are broken down and the blood viscosity 
decreases.	 For	 high	 shear	 rates,	 the	 blood	
cells tend to become elongated and line up 
with the flow of the liquid. This also tends to 
decrease the viscosity of the blood.
Given that the viscosity of blood 
increases with decreasing shear, one would 
think that the viscosity of blood within the 
body should increase as blood travels from 
the arteries through the arterioles and into 
the capillaries. This is because the shear 
rate and velocity of the blood decreases as 
the blood travels from the arteries through 
to the capillaries. The viscosity of blood, 
however, may be approximately con-
stant throughout much of the body. This 
Figure 8.4: Blood viscosity as a function of shear rate for 0% and 45% hematocrit.5
Figure 8.3: Elements of fluid slide past each other and generate a frictional shear stress.
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implies that the viscosity of blood is approx-
imately constant throughout the body. 
Understanding these properties affects the 
thinking of shear stress between blood and 
effect arises due to separate physical flow 
phenomena:
First,	the	viscosity	of	blood	is	dependent	
on the hematocrit. If the hematocrit decreases 
then	the	blood	viscosity	decreases.	For	exam-
ple	 in	 Figure	 8.4	 we	 show	 the	 viscosity	 of	
blood as a function of shear rate for 45% and 
0%	hematocrit.	For	0%	hematocrit	line	the	




blood vessel decreases in diameter, the hema-
tocrit	 level	 also	decreases	 (Figure	8.6).	this	
effect occurs because the blood cells tend to 
move away from the vessel walls and travel 
where the flow velocity is a maximum. This 
behaviour	 is	 known	 as	 the	 Fahraeus	 effect	
and it has been shown to occur in tubes 
with a diameter as small as 29 μm. 6,7 Given 
that a blood cell has a diameter of around 
8	μm	it	 is	possible	 that	 the	Fahraeus	effect	
may occur in tubes with diameters less than 
29 μm.
The combination of these two effects Figure 8.5: Rouleaux blood cell network.
Figure 8.6: Hematocrit as a function of tube diameter. The initial hematocrit value for each line is 
shown in the inset box8.
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vessel walls – or more relevantly between 
blood and atheroma.
PoiSeuiLLe	FLow	
Suppose	 that	 you	 have	 a	 Newtonian	 fluid	
flowing, in a steady, non-pulsatile manner, 
down a cylindrical, non-elastic pipe of length 
L and radius a. If the pipe is long enough, the 
flow will develop a parabolic velocity profile, 
which	 is	 generally	 called	 a	 Poiseuille	 flow	
profile	(Figure	8.7).	the	flow	takes	its	name	
from	Jean	Louis	Poiseuille,	a	physician	with	
training in physics and mathematics, who 
first	described	the	flow	structure	in	1846.
The volumetric flow rate (q)	 for	 Poi-
seuille flow, i.e., the volume of fluid flowing 














 is the pressure difference 
between the two ends of the tube and µ is 
the viscosity of the fluid.
The physics of the flow is nicely described 
by this equation. That is, flow is driven by the 
pressure gradient in the tube or conversely, 
when there is flow in a tube then you must 
have a pressure gradient to drive the flow. 
Prostheses	 are	 subject	 to	 the	 intermit-
tent forces of pulsation and flow. The large 
elastic vessels are capacitors and provide on-
flow in diastole and the muscular peripheral 
vessels maintain pressure by altering resist-
ance mediated via physiological feedback. 
Current prostheses are not able to do this 
and have to withstand the forces.
Note	also	the	parameter	of	 length.	Flow	
is	 therefore	 also	 related	 to	 length.	 Patency,	
such as in femoro-popliteal synthetic con-
duits, maybe as much, if not more, related to 
length of conduit as it is to angulation across 
bend points depending on the haematologi-
cal factors depositing thrombus. This may 




in	 Basel	 and	 taught	 physics,	 anatomy	 and	
physiology and his understanding lies at the 
heart of vascular physics and relates pressure 
to	motion	and	energy.	For	a	fluid	that	has	no	
viscosity, one can write
Figure 8.7: Parabolic velocity profile for fully developed Poiseuille flow.
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where p is the pressure, ρ the mass density 
of the liquid, u the speed of the fluid, g the 
gravitational acceleration, and y the height. 
in	other	words,	the	Bernoulli	equation	states	
that the pressure plus the kinetic energy 
per unit volume, ρ2
u2 , plus the potential 
energy per unit volume, ρgy, is a constant 
at	 any	 point	 along	 the	 blood	 vessel.	 So	
for a constant height, an increase in flow 
speed implies a decrease in pressure, while 
for constant flow speed, an increase in height 
implies a decrease in pressure.
it	 should	 be	 understood	 that	 eq.	 (7)	 is	
an approximation, as it ignores the loss of 
energy due to shearing friction between the 
flowing blood and the walls of the artery. 
even	 so,	 it	 does	 provide	 us	 with	 an	 intui-
tive understanding of the physics of the arte-
rial/venous	 system.	 For	 example,	 suppose	
we wish to measure the blood pressure of a 
person. Typically one places a sleeve or an 
external cuff around the upper arm. The 
upper arm is chosen because it is at approxi-
mately the same level of the heart and so the 
pressure will not be affected by any differ-
ence in height. To measure the systolic pres-
sure, the cuff pressure is increased until all 
blood	flow	ceases	from	eq.	(7)	we	know	that	 
this “cut-off” pressure is the maximum pres-
sure in the artery. The pressure in the exter-
nal cuff is then decreased until the flow is a 
maximum. We then know that the pressure 
will be a minimum and this is the diastolic 
pressure in the artery. 
In practice, the arterial system has two 
sources of potential energy to drive the blood 
forward. The first is blood pressure and this 
is transformed into kinetic energy of flow 
during the period between systole and dias-
tole, and the second is stored energy in the 
wall of the artery – its capacitance. Con-
sider what might happen when the kinetic 
energy meets a resistive obstacle – some 
energy is dissipated as heat as with circuit 
theory and some is stored for use in dias-
tole for onward flow in the period of heart 
filling by the elasticity of the great vessels 
acting	as	a	capacitor.	however,	some	energy	
is used up as a water hammer. The repetitive 
alterations in forward pressure and resistive 
back-pressure with pulsatile flow in a physi-
ologically responding, pressurized system 
sets up the potential for the water hammer. 
The injury and healing cycle effect of these 
water hammers on atherogenesis and aneu-





fashion.	 arteries	 are	 semi-elastic	 tubes	 and	
the arteries expand and contract as the pulse 
of blood flows along the artery. The speed, c, 
at which blood flows along an artery is 
determined by the speed that a pulse of fluid 
can travel along an elastic tube. This speed is 
given,	approximately,	by	the	Moen-Korteweg	
formula:
c ≈         , Ehρ d 	(8)
where E	 is	Young’s	modulus	 for	 the	wall	of	
the artery, h is the thickness of the artery, 
d is the inner diameter of the artery and ρ is 
the	density	of	blood.	a	schematic	depiction	
of how a pulsatile wave propagates along an 
artery	is	given	in	Figure	8.8.	
as	can	be	seen	from	eq.	(8),	the	speed	at	
which blood travels along an artery is par-
tially	dependent	on	the	Young’s	Modulus	of	
the arterial wall. To illustrate the definition 
of	Young’s	Modulus	 it	 is	useful	 to	 consider	
Figure	8.9,	where	a	block	of	material	is	being	
stretched due to an applied force on one end 
of the block. 
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Figure 8.8: An exaggerated, schematic view of blood flow in an artery.
Figure 8.9: A block of material with a length, L, and side area A is subject to a force F. The applied 
force stretches the block a distance ΔL.
The block has a natural length denoted 
by L, when a force F is applied to one side 
of the block then the length of the block 
increases by Δ L. This change in length is 
known as a strain, ε, and it is defined by the 
equation
ε   .∆LL
 (9)
The stress that the force applies to the 




Young’s	Modulus	 is	defined	as	 the	 stress	





Young’s	 modulus	 is	 a	 measure	 of	 how	
easy it is to stretch and compress a material. 
thomas	Young	(1773	–	1829)	was	a	medical	
physician who made significant contributions 
to	fields	of	Physics	(through	his	experiments	
which demonstrated the wave-like nature of 
light), linguistics (via his identification of the 
Rosetta	Stone),	medicine	(with	his	studies	of	
blood flow), and structural mechanics (e.g., 
Young’s	 Modulus).	 he	 was	 well	 aware	 of	
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the elastic nature of arteries, but, somewhat 
ironically,	does	not	appear	to	have	used	Young’s	
Modulus	to	describe	their	properties.	
One consequence of aging is increasing 
stiffness in the arteries. This means that the 
Young’s	modulus	increases	and	this,	as	a	con-
sequence	 of	 eq.	 (8),	 increases	 the	 speed	 of	
pulsatile flow within the arterial system. 
MaSS	CoNVeRSioN
in	Figure	8.10	we	view	a	schematic	depiction	
of an artery that is changing in shape as one 
travels along the artery. The blood flows in at 
one end with a speed u
1
. The area at the inlet 
of the artery is given by A
1
. In its simplest 
form, the mass conservation equation 
provides us with the relationship between 
the quantities at the proximal and distal ends 














 are the outlet flow speed and 
area,	respectively.	in	plain	english,	eq.	(12)	
is another way of saying “what goes in must 
come out”.
we	can	see	from	eq.	(12)	that	if	an	artery	
becomes narrower, i.e., A
2
 becomes smaller, 
then the flow speed, u
2
, increases. This occurs 
because the mass flow is conserved and so 
if the tube becomes narrower then the flow 
rate has to increase.
Some	 diseased	 blood	 vessels	 develop	 a	
constriction	 or	 stenosis	 (Figure	 8.11).	this	
narrowing of the blood vessel wall may be 
caused by atherosclerosis or neo-intimal 
hyperplasia after an intervention. If we 
assume steady-state, Newtonian blood flow 
and ignore gravity then the pressure in a 
compromised blood vessel with a stenosis 
can	 be	 calculated	 by	 combining	 Bernoulli’s	
equation (equation 7) and the mass conser-












































 the energy last term of equa-
tion 14 becomes negative so then the blood Figure 8.10: A change in the diameter of an 
artery leads to a change in the blood flow speed.
Figure 8.11: Blood vessel with a stenosis.
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pressure is lower at the stenosed section of the 
blood vessel (the constriction) to ensure that 
the sum of the pressure and energy at each 
point along the blood vessel remains equal. 
The lower pressure at the stenosis makes the 
blood vessel with a stenosis more prone to 
collapse if an external pressure were applied 
to	 the	blood	 vessel.	 Stents	 or	drug	 -eluting	
stents may be inserted in an artery that has 
a stenosis to keep the artery open after the 
blockage has been cleared using angioplasty. 
Mass	conservation	shows	that	the	velocity	is	




number, which provides an indication of how 
blood	is	flowing	in	an	artery.	the	Reynolds’	
number is given by:
Re
 




where U is the speed of the flow, D is the 
diameter of the blood vessel, ρ the blood 
density and μ	 the	 blood	 viscosity.	 For	 an	
artery, the flow tends to change from lami-
nar	 to	 turbulent	 at	 a	 Reynolds’	 number	 of	
approximately 2000. This number should be 
treated as only a representative value, since 
the transition from laminar to turbulent flow 
may	occur	at	higher	Reynolds’	numbers.
To see a representative peak value of 
Reynolds’	number,	we	consider	an	abdomi-
nal aorta of diameter, D = 2.5 cm = 0.025 m, 
peak blood flow speed U	=	60	cm/s	=	0.6	m/s,	 
blood density ρ	=	1	gram/cc	=	1000	kg/m3 
and blood viscosity μ	=	0.0036	Pa	s.	these	
values give Re ≈	4,200.	So,	in	principle,	it	is	
possible for turbulent flow to occur in the 
aorta during the systolic phase.
Fluid	 flowing	 in	 a	 laminar	 fashion	 is	
dominated by the viscosity and at a high 
Reynolds’	 number	 by	 its	 inertia.	 a	 bruit	 is	
audible chaotic flow at high velocity with 
energy transformed to noise – inefficient 
flow that maybe disruptive as in a carotid 
stenosis – and blood needs to be able to flow 
fast in order to deliver its load at a cardiac 
output	of	up	to	30L/min	in	an	athlete.	
Turbulent flow is less efficient relative to 
laminar flow. This means that more energy 
or a greater pressure drop is required to drive 
turbulent flow compared to laminar flow. 
a	 quantitative	 way	 of	 measuring	 this	 inef-
ficiency is given by the formula for energy or 
“head” loss for flow along a pipe
h
L 






where f  is the loss coefficient, L the length 
of the artery or appropriate subsection of an 








while for turbulent flow
f
lturb 
∼            .0.316
Re1/4
 (18)





Re > 1200, which implies that turbulence 
consumes more energy relative to laminar 
flow. This result is represented schematically 







turbulent flow loses 1.5 times more energy 
relative	 to	 laminar	 flow.	 as	 Re	 approaches	
5000 turbulent flow tends to lose 3 times as 
much energy as laminar flow.
It is interesting to speculate that the 
particulate nature of blood and plasma com-
position may act to discourage the forma-
tion	of	 turbulent	flow.	each	 red	 cell,	being	
bi-concave, could change the local inter-
actions between the cells and the blood 
plasma so that the flow tends to remain 
laminar. The shape of the red cell then may 
enhance the efficiency of blood flow, in addi-
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To this point we have essentially discussed 
flow	in	series.	Much	of	the	normal	flow	and	 
some pathological flow occurs in parallel. 
For	 example,	 the	 collateral	 circulation	 in	
each segment of the body; the profunda 
system in the thigh, the geniculate system 
around the knee and the tibial systems in 
the	leg.	another	good	example	is	the	carotid	
and vertebral systems combining to form the 
cerebral circulation. In parallel circulation, 
the pressure at the separation of the two 
systems is theoretically the same for each, and 
the pressure at the re-union is also the same 
for each. The proportion of ongoing flow 
from the two systems is determined by the 
resistance of each system. These two therefore 
compete for the proportion of on-flow. This 
works well to direct or redirect the flow to the 
target tissues. The body may select priorities 
for flow, for example, the brain and heart in 
shock or the muscles during exercise. The 
branches of the great vessels and arteries to 
the tissues are resistance vessels and they have 
muscular walls for this purpose. The formula 
for resistors in parallel circuits is













where n is the number of parallel circuits.
These circuits also provide alternative 
channels should the dynamics change due to 
injury or disease. Not all parallel circuits 
are beneficial. Detrimental competing flows 
may occur with artificially created channels, 
for example, aorto-bifemoral bypass, when 
one iliac system is normal and the other 
occluded. The competing flows on the 
normal side predispose for either that limb 
of the graft or part of the iliac system on 
that	side	to	occlude.	Similarly,	with	femoro- 
popliteal bypass after long-standing super-
ficial femoral artery occlusion when the 
profunda collateral flow has been well 
developed.
In aortic dissection, the outflow from the 
false lumen is met with greater resistance than 
the outflow from the true lumen. The flows 
compete where the intima has been torn off 
the origin of a branch vessel which therefore 
comes off the false lumen and leaves a hole 
in the membrane at that point. The pressure 
Figure 8.12: Plot of the ratio of turbulent to laminar energy loss coefficients.
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is higher in the false lumen at any time in the 
cardiac cycle other than peak systole.
Figure	 8.13	 shows	 the	 trace	 from	 true	
and false lumens of a dissected aorta. Note 
the systolic pressure is same in each lumen 
at	 138	 mmhg.	 the	 diastolic	 is	 higher	 in	 
the	false	lumen	at	93	mmhg	compared	to	the	 
diastolic	 in	 the	 true	 lumen	 of	 82	 mmhg.	 
The area under the curve is the same and 
so the pulse wave in the false lumen is wider. 
The mean pressure in the false lumen is 
higher	 at	 109	 mmhg	 than	 the	 true	 lumen	
where	the	mean	is	91	mmhg.
This means that the false lumen is almost 
always the larger of the two and is more 
likely	 to	 dilate.	 Flow	 of	 contrast	 injected	
into the true lumen is not seen to flow out 
to the false lumen through the holes in the 
membrane unless the pressure of the injec-
tion and the pressure of the lumen together 
exceed the pressure of the false lumen. The 
membrane that is the remnant of the intima 
oscillates as the pressure ratio between the 
true and false lumen changes during the 
cardiac cycle. This dynamic also applies for 
a Type 1 endoleak into the residual sac of an 
aortic aneurysm treated by an endovascular 
graft.
SheaR	StReSS	aND	PReSSuRe
all	 vascular	 clinicians	 are	 familiar	 with	
the ultimate shearing force injury of high 
velocity impact when the mobile arch of the 
aorta and heart continue to move forward 
while the descending aorta, held by the 
intercostals and posterior mediastinum, is 
held to the vertebral bodies. What of subtle 
persistent long-term shear stresses and the 
relationship with the greatest risk factor 
for arterial disease – age? There are known 
common sites for occlusive atheromatous 
plaques e.g. the carotid bifurcation, aortic 
bifurcation, origins of branches of the aorta 
and coronary arteries and shear stress points 
such as the adductor canal.
atheroma	is	an	arterial	lesion.	occlusive	
and dilating diseases of the arteries progres-
sively occur with ageing, and obviously age 
is the greatest risk factor. It is not seen in 
children and only seen in veins subject to 
long term pulsatile pressure when they are 
said	to	be	“arterialised”.	For	example,	when	
a vein is used for an arterial bypass or for 
a	dialysis	fistula.	Pressure	and	pulsatility	are	
the	 forces	 involved.	 Persistent	 raised	 blood	
pressure above the norm causes progressive 
Figure 8.13: Pressure readings from the true and false lumens of a dissected abdominal aorta (courtesy 
of Dr John Anderson).
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wall damage. With age there is degeneration 
of the wall of the artery and loss of compli-
ance.	Pulse	pressure	 and	peak	 systolic	pres-
sures rise because of the loss of compliance. 
Peaks	 of	 pressure	 occur	 with	 exertion	 and	
acute	damage	may	occur	at	such	times.	age	
will eventually affect all, but some are more 
genetically predisposed to arterial lesions and 
other risk factors such as poor diet and smok-
ing accelerate any genetic predisposition.
Shear	stress	on	an	arterial	wall,	τ
w








where a is the radius of the artery and q is 
the volume flow rate of blood through the 
artery.	 From	 this	 formula	 it	 can	 be	 seen	
that shear stress increases with the increase 
of blood flow through the artery and tends 
to increase as the artery becomes smaller in 
diameter – provided that the volume flow 
rate and the viscosity are approximately 
constant.
atherosclerotic	 lesions	 form	 at	 specific	
areas where low and oscillatory endothelial 
shear	 stress	occur.	high	risk	plaques	have	a	
large lipid core, thin and inflamed fibrous 
cap and excessive expansive remodelling9. 
Wall shear stress may rupture the established 
plaque.	 Plaque	 rupture	 and	 intraplaque	
haemorrhage are recognized causes of cardiac 
events. Computational modelling of carotid 
bifurcations with atherosclerotic plaques 
that had patient-specific geometries obtained 
from	 Magnetic	 Resonance	 imaging	 (MRi)	
scans and modelled the fluid-structure 
interactions have shown that stresses in the 
fibrous cap and around the plaque shoulders 
affect plaque rupture risk, with higher stress 
and plaque rupture risk for thinner caps.10-13
FoRCeS	oN	GRaFt	SYSteMS
The performance of endoluminal grafts 
(eLG)	 was	 found	 to	 be	 different	 to	 open	
repair with a sewn replacement of the 
artery because of unsuspected influences, as 
mentioned above, that relate to sustained 
physical forces.1 The openly-sewn prosthesis 
binds the wall of the artery to the prosthesis 
with a transmural suture. The artery may 
expand above or below the prosthesis. 
however,	 at	 the	 point	 of	 attachment	 the	
artery wall is held to the fixed diameter by 
the through-wall suture for as long as the 
suture	 holds.	 eLG’s	 to	 date	 do	 not	 bind	 
the adventitia to the prosthesis – they merely 
attach.	 the	 eLG	 must	 continue	 to	 act	 to	
bridge the gap between normal artery above 
and	 below	 until,	 if	 ever,	 the	 aneurysm’s	
cavity shrinks right down. In open surgery, 
the suture is binding and the tissues around 
supportive. The diameters of the grafts used 
for the same abdominal aortic aneurysm 
(aaa)	differ	markedly	between	the	open	and	
eLG	methods.	the	common	diameters	used	
for tube replacement surgically of infrarenal 
aaa	 is	 18	 or	 20	 mm.	 the	 commonest	
diameter for an endoluminal graft is 26 or 
28	mm	and	30+	mm	is	not	uncommon.	why	
such a discrepancy when the surgeon judges 
the diameter to suitable fit? This discrepancy 
is due to the different types of attachment 
of an open graft and an endoluminal graft. 
With the former, there are sutures through 
the graft and the full thickness of the aortic 
wall. This means that the aortic diameter 
at that point is permanently fixed to the 
diameter of the graft in its pressurised state. 
The diameter of a crimped vascular graft is, 
by definition, the minimum internal distance 
between the crimps in the non-pressurised 
state. It is increased by approximately 10% 
when	pressurized.	with	the	eLG,	a	residual	
radial force is required for seal and the 
attachment may or may not be enhanced by 
latching barbs. The oversize allowance must 
accommodate elasticity and compliance while 
maintaining the seal between pulsations for 
the whole of the length of the sealing zone. 
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These latching barbs sometimes cross the 
renal arteries but have been shown to have a 
minor effect of 1 % on the renal artery flow 
rate for 3 mm diameter artery.14
With an endoluminal graft the device 
must bridge a gap for an indeterminate time 
before the body reabsorbs the contents of the 
aneurysm and encases the graft in foreign 
body fibrous tissue support. Therefore the 
long term function and durability demands 
are different and more demanding.1 Under-
standing the forces involved is basic to 
design and use of new technology and the 
weaknesses that lead to aneurysmal disease 
provides a challenge.1,15
a	mistaken	clinical	impression	is	that	the	
forces	 on	 a	 thoracic	 eLG	 should	 be	 greater	
than	those	on	an	abdominal	eLG.	the	flow	
and diameter of the thoracic aorta are greater 
and the haemodynamic forces potentially 
much	 larger.	however,	because	 the	diameter	
of the graft changes little, if at all, the down-
ward	displacement	force	in	the	thoracic	eLG	
is small as the resistance in the graft is low 
– except on the aortic arch. The resistance of 
any graft that extends into the iliac vessels is 
much greater because of the significant change 
in diameter and high resistance within the 
graft acting like a windsock or sea anchor.15 
an	aorto	uni-iliac	device	affords	greater	resist-
ance than a bifurcated graft and detachment 
at the neck and migration is a common prob-
lem due to high displacement forces. In con-
trast with the thoracic aorta there is little drag 
because there is little or no change in diame-
ter. In contrast, there is little drag on a graft in 
the thoracic aorta because there is little or no 
change in diameter along the graft. The force 
applied to the graft is on the curve and cen-
trifugal	forces	apply.	Since	every	action	has	an	
equal	 and	 opposite	 reaction	 (Newton’s	 third	
law), one must ask where is the reaction. The 
reaction is to pull the graft out from the top 
and the bottom almost equally. When endo-
luminal grafts were first used in the thorax, 
unexpected upward migration of the distal 
end emerged as the problem, especially when 
there	was	a	significant	curve	on	the	graft.	For	
the	 same	 reason,	 this	 ‘lift	 out’	 may	 also	 be	
seen from the iliacs when the graft fixation is 
weak	because	of	ectasia	and/or	short	length	of	
distal	 attachment.	type	1B	 endoleak	 can	be	
more	 dangerous	 than	type	 1a	 if	 this	 factor	
is ignored.
an	important	issue	in	vascular	interven-
tion is the durability of endoluminal grafts. 
Such	 grafts	 are	 often	used	 to	protect	 aneu-
rysms from the effects of arterial pressure. 
Unfortunately, hemodynamic forces can dis-
place a graft and thereby, potentially, inter-
rupt the seal between the graft and the neck 
of the aneurysm. It is important, therefore to 
have an understanding of the possible forces 
that may be exerted on a graft.
To illustrate the steps used in determin-
ing the forces on a graft system, via analytic 
equations, we consider the steady flow of 
blood	 through	 a	 bent	 pipe	 (Figure	 8.14).	
In this figure, the proximal inlet entrance is 









 are the diameters and cross-
sectional areas, respectively, of the graft at 
the points 1 and 2. The vector normals of 
the cross-sectional areas are, respectively, at 
angles of θ
1
 and θ 2	to	the	vertical.	Similarly	
p and v refer to the pressures and velocities 




 are the x and y 
components of the restoring force. The exter-




In our analysis, we assume steady-state, 
i.e., non-pulsatile, flow. We do this as it gives 
us a basic idea of how the system is behaving.
The first equation is the steady-state mass 
















age flow speeds, where the average is taken 
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The next analysis tool at our disposal is 
the momentum  conservation equation, 


























































































where in these formulae, we have ignored the 
weight of the graft and the weight of blood 
in the graft. These terms are easily included 
into the equations, if required. 
energy	 is	 the	 final	 conserved	 quantity	
that we can use in our analysis. The energy 

















2g  z2  hL ,
 (24)
where g is the gravitational acceleration, 





 are the vertical heights of the proxi-




amount of pressure or energy that is lost due 















 is a constant, the value of which is 
usually dependent on the shape, length and 





 are kinetic energy correction factors that 
have different values depending on the type 
of	flow.	For	example,	for	uniform	flow	α = 1, 
turbulent flow has α ≈ 1, and laminar flow 
gives α = 2.
















 in terms of quantities at the 
entrance of the graft. This then allows us to 
compute the restraining forces on the graft 
system	by	then	using	eqs	(22)	and	(23).
Figure 8.14: The characteristic velocity, pressure, area and force vectors required to compute the 
restraining forces on a bent, single-tube graft system.









 are equal and have a value of 90°. The 
inlet and outlet pressures are not equal due 
to the frictional, shear interaction between 
the blood and the graft (i.e., the head loss 
as	 given	by	eq.	 (25)).	this	 frictional	 inter-
action causes the outlet pressure, p
2
, to be 
less than the inlet pressure, p
1
. This is called 
a pressure drop. 
From	 all	 of	 this	 information,	 one	 can	




  0,  (27)
 
 
i.e., there are no vertical forces generated 











where we have set the external pressure to 
zero. In this case, the horizontal force on the 
graft is quite small, because p
1
 will only be a 
little larger than p
2
. One can conclude from 
this analysis that straight, cylindrical grafts 
only feel a relatively small drag force in the 






outlet flow speed is greater than the inlet 











 are equal and have a value of 90° and the 
inlet and outlet pressures are not equal due 
to the frictional, shear interaction between 
the blood and the graft. 
























  0 .  (31)
When you put in the appropriate num-
bers	into	eq.	(30),	it	is	found	that	the	domi-





Many	 endoluminal	 grafts	 have	 this	 ‘wind	
sock’	 shape	with	a	distal	 exit	 area,	which	 is	
smaller than the proximal, inlet area. This 
shape has a much larger drag force than for a 
cylindrical graft.
Figure 8.15: Cylindrical graft.




inlet and outlet flow speeds are also equal. 
Due to the symmetry of the situation, the 
vertical restraint force is zero, the horizontal 




















So,	 now	 both	 the	 pressure	 and	 veloc-
ity components add together to produce a 
greater total force on the graft. This result 
suggests that a curved graft may be subject 





cated	 graft,	 such	 as	 shown	 in	 Figure	 8.18,	
where the two outlet distal legs of the graft 
are at an angle α to the horizontal, the two 
distal ends are equal and gravity is ignored. 
The proximal end of the graft is labelled by 
the number 1, the symmetric distal ends by 2 
and	3.	By	satisfying	momentum	con	versation	
























The more general, non-symmetric case 
with gravity is described elsewhere. 15
Figure 8.16: An endoluminal graft in the shape of a wind-sock.
Figure 8.17: Curved graft.
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We also know to satisfy mass conversa-




























By	 applying	 Bernoulli’s	 equation	 7	 and	





 can be eliminated from equation 33.
This equation shows that the horizon-
tal restraint force is strongly dependent on 
inlet area, pressure and on the bifurcation 
angle	(especially	>	15°).	But	the	blood	inlet	
velocity or flow rate has negligible effect on 
the horizontal restraint force.16-18 Naturally, 
a steady-state assumption is questionable, 
since pulsatile flow occurs in the human 
body.	however,	it	was	shown	experimentally	
that a steady-state analytical model can be 
used, with variable pressure and flow rate 
inputs, to predict forces on a symmetric, 
bifurcated graft in pulsatile flow with reason-
able approximation within design limits.17-18 
This steady-state analytical force model is 
now used in the design of grafts.
CoMPutatioNaL	MoDeLLiNG
Computational	 fluid	 dynamics	 (CFD)	 and	
finite element modeling can assist in our 
understanding of vascular haemodynamics. 
CFD	 uses	 numerical	 methods	 to	 discretize	 
and mesh the geometry and algorithms 
to solve the equations of motion (for 
example,	 the	 Navier-Stokes	 equation)	
and other relevant equations. In the last 
several years with advances in computing 
the computational modeling capability has 
greatly improved. It is now possible to 
incorporate patient-specific geometry from 
MRi,	 Ct	 or	 magnetic	 resonance	 angio-
graphy	 (MRa)	 data.	 the	 computational	
models also now include fluid-structure 
interactions (fluid flow and wall deformation 
interaction), pulsatile flow and non- 
Newtonian	flow.	Some	computational	model-
ling of vascular haemodynamic systems 
include	 aaa	 grafts,19-22 fluid-structure 
interactions with cere bral aneurysms,23-25 
patient-specific cerebral aneurysms with 
coils,26-28 and patient-specific circle of 
Figure 8.18: Symmetric bifurcated graft.
(Rx  p1A1  ρ                                                                                cosα  . v12 cosα   pv12 A1  2A2 A122A
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Willis.29-33	For	example,	Li	and	Kleinstreuer19 
modelled blood flow and structure inter-
actions	 in	 a	aaa	with	 and	without	 a	 graft	
where they incorporated fluid-structure 
interactions, flexible walls, pulsatile flow 
and non-Newtonian blood flow. They 
confirmed that the force on the graft is 
highly dependent on the diameter, blood 
pressure and bifurcation angle. They also 
showed	 significant	 reduction	 in	 aaa	
stress, displacement and pressure after graft 
placement	as	shown	in	Figure	8.19.
endoleaks	which	are	blood	flow	between	
graft	 and	 the	 aaa	 wall	 can	 also	 cause	 
problems	in	aaa	such	as	elevated	sac	pres-
sure and high stresses which may lead to rup-
ture.	Li	and	Kleinstreuer34 modelling analysis 
indicated the sac pressure caused by type II 
endoleaks (leakage via collateral arteries) 
depends on the inlet branch pressure; thus, 
type II endoleaks may increase sac pressure 
to near the systemic pressure levels, which 
could cause more clinical concern. Other 
studies have shown that intrasac pressure 
measurements and haemodynamic analysis 
of the graft-aortic wall interactions can be 
used to detect type II endoleaks.35,36
ReCeNt	DeVeLoPMeNtS	aND	
FutuRe	DiReCtioNS	
Mathematics,	 principles	 of	 physics	 and	
com putational modelling of vascular haemo-
dynamics have been useful in verifying 
or modifying intuitive engineering of 
endovascular stent grafts; and towards 
better understanding of failure modes of the 
cardiovascular	system	and	its	prostheses.	For	
example, based on vascular haemodynamics 
analysis relating a vascular geometric ratio 
to the likelihood of aneurysm rupture, 
plaque rupture and stent graft migration. 
Figure 8.19: Effect of graft placement on blood flow and AAA wall at peak systole pressure level 
(courtesy of Professor Clement Kleinstreuer).19
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CFD	modelling	of	vascular	haemodynamics	
is currently being used in the design and 
evaluation of implanted medical devices such 
as grafts. It is still a complex process to create 
patient-specific computational models and 
difficult for clinicians to interpret the results. 
In the future, computational modelling 
of vascular haemodynamics may be used 
as a tool for patient-specific blood flow 
quantification relevant to clinical practice 
to assist intervention planning, decision-
making and optimization.
however,	 for	 computational	 model-
ling to be more easily translated to clinical 
relevance there needs to be more extensive 
comparisons of in vitro and in vivo clinical 
studies to validate the codes, with the uncer-
tainties quantified, so they can be used with 
confidence.	 Patient-specific	 geometries	 and	
measured flow distribution boundary condi-
tions should be included. There needs to be 
better models of arterial mechanical proper-
ties during each stage of a disease state (e.g. 
aneurysm formation), more accurate imag-
ing techniques that can provide better infor-
mation of the wall thicknesses, details on 
perivascular environment and much better 
coupling with vascular biology, mass trans-
port and cellular biophysics. With grafts now 
being used in high curvature areas it is more 
important to understand the forces required 
to keep the grafts in place to mitigate their 
migration.
The intersect of clinical arterial pathology, 
feedback systems in physiology and compu-
tational fluid dynamics leads us to potentially 
the most exciting time in advances for arterial 
disease ever. The vascular system is dynamic 
in its function, its response to demand, its 
injury and repair cycle and its aging. The 
arterial system is intricately designed so that 
each arterial division is specific for its func-
tion and the demands placed upon it for up 
to one hundred years. To the empirical, 
statistical, biochemical, genetic and molecular 
biology knowledge of the cardiovascular 
system must be added the central role of 
haemodynamic physics and the pathol-
ogy that results from the relentless forces of 
blood	 pressure	 and	 pulse	 wave.	 Modelling	
of arteries opens the door to much better 
understanding of why atheroma occurs at the 
known predictable sites such as the carotid 
bifurcation, the origins of branch vessels of 
the aorta and sites of stress for example the 
adductor canal.
CoNCLuSioN
Understanding the physics of the vascular 
system in health and disease will influence 
vascular management. This is a rich field for 
further	research.	Further	clues	to	atherogenesis	
may lie in the differences of the fluid dynamics 
and stresses applied to the arterial systems. 
Computational modelling will be of increasing 
importance, as the science evolves, to our 















abdominal aortic aneurysm stent-graft 
repair:	the	euRoStaR	project.	
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randomized controlled trial of early 
elective surgery or ultrasonographic 
surveillance for small abdominal aortic 
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When is intervention indicated and 
what is the index of suspicion for 





Physiological haemostasis involves complex 
interactions between endothelial cells, 
platelets and coagulation proteins, that result 
in a prompt platelet plug and then localised 
thrombus formation at the site of a break 
in vascular integrity. Numerous regulatory 
processes prevent widespread activation of 
coagulation, ensuring that blood remains 
fluid in the absence of vascular injury or other 
pathology. All components of the haemostatic 
process can be disturbed resulting in either 
a pro-thrombotic or bleeding tendency, and 
drugs that modify the haemostatic process are 
commonly used, particularly in patients with 
vascular disease. An understanding of normal 
haemostasis is therefore important for all 
clinicians that deal with this patient group. 
PRIMARY HAEMOSTASIS
Primary haemostasis is the initial response 
of the body to vascular injury, and involves 
interaction between platelets, adhesive pro-
teins located in the subendothelial matrix 
(including collagen and von Willebrand 
factor), and circulating fibrinogen.1 The 
end result of primary haemostasis is the 
formation of a stable platelet plug around 
which a fibrin network can then be built. 
This same process is responsible for the 
pathogenic thrombus formation in patients 
with arterial disease. Disorders of primary 
haemostasis tend to manifest in the main 
as mucosal bleeding, including epistaxis, 
oral bleeding and menorrhagia, and often 
immediate difficulty with haemostasis in the 
post-operative setting.
Platelets 
Platelets are small fragments of megakaryo-
cyte cytoplasm that in the resting state are 
small discoid structures. The normal range 
for circulating platelet count in adults is 
between 150 to 400 × 109/L. Although 
anucleate, platelets are metabolically active, 
and interact with the local environment 
through the binding of surface glycoprotein 
receptors to specific ligands. Platelets go 
through a predictable cycle of response 
to vessel wall injury that involves initial 
platelet adhesion to the sub-endothelium, 
subsequent intracellular signalling that 
triggers platelet shape change and activation 
with granule release, and finally aggregation 
(Figure 9.1).2
Platelet adhesion
Endothelial injury results in the exposure 
of circulating blood to the subendothelial 
9  •  Physiological Haemostasis
SIMON MCRAE
Royal Adelaide Hospital & The Queen Elizabeth Hospital, Adelaide, 
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matrix that is rich in a number of adhesive 
proteins. von Willebrand factor (vWF) is 
a large adhesive glycoprotein produced by 
endothelial cells and megakaryocytes that 
is central in initial platelet adhesion.3 The 
mature vWF molecule consists of disulphide-
linked multimers of high molecular weight 
of up to 20,000,000 daltons.4 When secreted 
into the plasma, these high molecular weight 
(HMW) vWF multimers are digested 
into smaller forms by the metalloprotease 
ADAMTS13 (a disintegrin and metallo-
protease with a thrombospondin type 1 
motif, member 13). These smaller soluble 
forms bind less readily to platelet receptors, 
reducing the chance of spontaneous platelet 
aggregation. However vWF secreted into the 
subendothelial space binds to other molecules 
such as collagen, resulting in a conformational 
change that exposes the binding site for 
platelet glycoprotein (GP) receptor Ib.4 
Subendothelial vWF is therefore ‘primed’ 
to interact with circulating platelets in the 
event of endothelial injury. Other important 
adhesive proteins include collagen type 1 
and type 4, fibronectin, thrombospondin, 
laminin and vitronectin.
Initial platelet adhesion, particularly in 
high shear conditions, involves interaction 
between vWF and the GPIb/IX/V com-
plex located on the platelet surface. This 
complex consists of four trans-membrane 
sub units GPIba, GPIbb, GPIX and GPV, 
with the N-terminal globular domain of 
GPIba responsible for the interaction with 
the A1-domain of vWF.1 Binding of vWF to 
GP Ib is often reversible, and in animal 
models platelets can be seen to initially 
slide or translocate along the subendothelial 
surface due to cyclical attachment and then 
dissociation of the GP Ib/IX/V complex to 
vWF.2 However, finally through further plate-
let receptor ligand interactions the platelet is 
stabilized on the subendothelial surface. The 





) binds collagen, an interaction that 
appears to be more important in low-shear 
conditions.5 Glycoprotein VI, a platelet surface 
receptor that belongs to the immunoglobin 
superfamily, also directly binds collagen and 
further activates the GPIa/IIa receptor via 
intracellular signaling.6 Other b
1
 integrins 









 – fibronectin), 
Figure 9.1: Mechanism of platelet aggregation
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and there is increasing evidence that early 





) receptor contributes to the initial 
adhesion process.2 Finally there is evidence 
that formation of platelet membrane teth-
ers, that consist of smooth cylinders of lipid 
membrane pulled from the platelet surface 
under the influence of hemodynamic drag 
forces, contribute to platelet adhesion in 
high shear conditions.7
Platelet activation and shape change 
Following platelet adhesion, multiple path-
ways lead to platelet activation that results 
in platelet shape change, platelet granule 
release, and conformational change in the 
GP IIb/IIIa receptor that allows binding 
to fibrinogen and vWF, leading to platelet 
aggregation. Binding of vWF to the GP Ib 
receptor and collagen to the GP VI during 
the adhesion process triggers intracellular 
signaling via a pathway that involves 
activation of Src family kinases (Src), Syk 
and PI 3-kinase (PI3K). These events lead to 
the activation of phospholipase C-b (PLC), 
which hydrolyses membrane phospholipids 
to generate inositol (1,4,5) trisphosphate 
(IP3).8 The binding of IP3 to its receptors 
(IP3R) on the dense tubular system (DTS) 
then results in mobilisation of intra-platelet 
calcium stores, which has a number of con-
sequences including;
1. Thromboxane A2 (TXA2) generation – the 
increase in intracellular calcium stimu-
lates the production of arachadonic acid 
by PLC and phospholipase A2. Aracha-
donic acid is converted into TxA2 via the 
actions of the enzymes cyclooxygenase 
1 (COX-1) and Tx synthase. TxA2 is 
released from the platelet and binds plate-
let receptors TPα and TPb. Its effects in 
platelets are mediated primarily through 
TPα. Binding of TxA2 to this G-protein 
coupled receptor results in further PLC 
activation, leading to further intracellular 
calcium increase further reinforcing plate-
let activation.9 Local diffusion of TxA2 
also contributes to the recruitment to the 
site of injury and activation of further 
platelets. Aspirin or acetyl salicylic acid 
exerts its antiplatelet effect by blocking 
TXA2 synthesis, due to the irreversible 
acetylation of Ser-529 in COX-1. Because 
platelets are anucleate, no new COX can 
be generated, explaining why aspirin has 
a persistent functional effect that lasts the 
lifespan of the platelet (approximately 
7 days). 
2. Granule release – intracellular calcium 
mobilization also results in the release 
from the platelet of both the dense and 
alpha-granules. The dense granules con-
tain high concentrations of the small 
molecules adenosine diphosphate (ADP) 
and sero tonin, which further act to 
reinforce local platelet activation by bind-
ing to specific platelet surface membrane 
receptors upon release. ADP is a central 
player in sustained platelet activation. The 





seven transmembrane receptors that are 
coupled via heterotrimeric G-proteins to 
numerous intracellular effector molecules. 
P2Y
1
 links to the G-protein Gq resulting 
in further activation of PLC and also 
protein kinase C activation. P2Y
12
 is 
linked to the G-protein Gi that has an 
inhibitory effect on adenylate cyclase. 
ADP induced activation of the P2Y
1
 
receptor induces platelet shape change 
and rapid transient aggregation,10 whereas 
activation of the P2Y
12
 receptor results 
in sustained irreversible aggregation.11 
The thienopyridine class of antiplatelet 
agents, ticlopidine, clopidogrel and 
prasugrel exert their antiplatelet effect by 
blocking the P2Y
12
 receptor. The active 
metabolites of all agents have a free thiol 
moiety that forms a disulfide bridge 
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with the extracellular cysteine residues 
Cys17 and Cys270.12 Released serotonin 
also binds to a G-protein coupled 
platelet surface receptor, the 5-HT
2A
 
receptor. Binding is also associated 
with Gq-dependent activation of PLC, 
resulting in amplification of platelet 
activation, platelet shape change, and 
weak reversible platelet aggregation.13 
3. Activation of the GP IIb/IIIa receptor – in 
its resting state the GP IIb/IIIa receptor 
is unable to bind its ligands, namely 
fibrinogen and vWF. The above platelet 
signaling events through the activation 
of the small GTPase Rap1b and its 
interaction with a Rap1-GTP interacting 
adapter molecule (RIAM), lead to the 
binding of the proteins talin and kindlin 
to b3 tail of GP IIb/IIIa receptor.14 This 
leads to activation of the receptor and 
the resulting change in conformation 
allows the surface portion of the receptor 
to bind readily to fibrinogen and vWF. 
The binding of talin to the receptor 
tail also links it to the underlying actin 
cytoskeleton of the platelet, enhancing 
adhesive strength and platelet cohesion.15
4. Platelet shape change – the normally 
discoid-shaped platelet with a smooth 
surface membrane undergoes dramatic 
shape change with stimulation, including 
extension of filopodia, and flattening or 
spreading on the subendothelial surface. 
The platelet cytoskeleton is primarily 
responsible for regulating the platelet’s 
shape. Platelet activation leads to the 
rapid reorganization and polymerization 
of actin into filaments, resulting in the 
above conformational change.16
Along with ADP, the serine protease 
thrombin appears to play an important role 
in sustaining platelet activation leading to 
irreversible platelet aggregation. Thrombin 
specific receptors, the protease-activated 
receptors (PARs), are located on the platelet 
surface. Two main PARs, PAR1 a high 
affinity receptor and PAR4, a low affinity 
receptor, are involved in thrombin mediated 
platelet activation.17 Thrombin activates 
PARs by cleaving the N-terminal of the 
receptor, unmasking a hidden receptor-
linked ligand. This ligand then interacts 
with the remainder of the receptor leading 
to G-protein coupled signaling that results 
in further platelet activation. 
Finally platelet activation also results in 
the surface expression of a number of adhe-
sion molecules, such as the glycoprotein 
P-selectin which is involved in interaction 
with both endothelial cells and also the 
recruitment of inflammatory cells to the 
area of injury, via binding of P-selectin to 
P-selectin glycoprotein ligand 1 (PSGL-
1) located on the surface of leucocytes.18 
Platelets also secrete chemokines such as 
RANTES/CCL5 and platelet factor 4 
that also increases the local recruitment of 
inflammatory cells such as monocytes. This 
contributes to and can exacerbate the local 
inflammatory response that often presents in 
atherosclerotic plaque.19 
Platelet aggregation
As the final part of the primary haemostatic 
response, platelets recruited to the site of 
vascular injury and activated by the above 
soluble agonists then undergo irreversible 
aggregation. This is mediated via the 
concurrent binding of either fibrinogen 
or vWF to the activated GP IIb/IIIa 
receptors on separate platelets, leading to 
their cross-linking and the formation of a 
platelet aggregate. In low flow vascular beds 
binding of fibrinogen to the GP IIb/IIIa 
receptor appears to be the main process 
involved in platelet aggregation, whereas the 
interaction between GP IIb/IIIa and vWF 
is more important for aggregation in high 
Physiological Haemostasis 181
shear vascular beds and pathological arterial 
thrombosis.7
INTERACTIONS BETWEEN 
PRIMARY AND SECONDARY 
HAEMOSTASIS
While the primary and secondary haemo-
static processes are often considered 
separately, they are intrinsically linked. As 
described above, the coagulation protease 
thrombin plays a central role in the 
activation of platelets. The activated platelet 
in turn provides the surface upon which 
the reaction complexes of the coagulation 
cascade form. In addition, as part of platelet 
activation the content of the negatively 
charged phospholipid phosphatidylserine on 
the outer surface of the platelet membrane 
increases from almost 0% up to 12%, 
providing a binding site for the proteins of 
the coagulation cascade.20 Release of clotting 
factors, such as factor V, from platelet alpha 
granules, and the expression of other as yet 
still poorly defined platelet receptors for 
coagulation factors on the platelet surface 
provide additional methods in which 
activation of the coagulation cascade is 
localised to the site of platelet activation and 
vascular injury.21 
SECONDARY HAEMOSTASIS
Secondary haemostasis describes the process 
whereby exposure of tissue factor to the 
bloodstream leads to a series of enzymatic 
reactions that result in a sufficient burst of 
thrombin production to convert soluble 
fibrinogen into a stable network. A repetitive 
theme in this process is the formation of a 
series of reaction complexes consisting of 
an active enzyme and a co-factor, in which 
the presence of the latter results in a order 
of magnitude increase in the efficiency 
of the enzyme to bind to and convert 
its target substrate, itself a pro-enzyme 
or zymogen, to its active form. Defects 
of secondary haemostasis, as typified by 
factor VIII deficiency or haemophilia A, result 
in muscle, joint and soft tissue bleeding, and 
delayed bleeding post surgical or traumatic 
haemostatic challenge.
The coagulation factors involved in 
secondary haemostasis belong to the class of 
proteins known as serine proteases, so called 
because they have a serine residue which, 
along with histidine and aspartic acid, forms 
a catalytic triad at the centre of the active 
site of the enzyme.21 Most of the reactions 
of secondary haemostasis take place on a 
phospholipid membrane surface, which is 
normally the surface of an activated platelet. 
Binding of the coagulation proteins to the 
phospholipid membrane surface requires 
the presence of calcium, and agents that 
chelate calcium such as EDTA or citrate 
can therefore be utilised to prevent activa-
tion of the coagulation cascade after blood 
collection. 
The coagulation factors have a modu-
lar structure, and different factors share 
similar structural features. The coagulation 
factors II, VII, with IX and X along with the 
natural inhibitors of coagulation, protein C 
and protein S, all undergo post-translational 
gamma-carboxylation of glutamate residues 
located at the amino-terminus. This modi-
fication is necessary for the efficient binding 
of these proteins to the phospholipid surface. 
The carboxylation process is dependant on 
the presence of vitamin K, which is a co-fac-
tor for this process. Vitamin K deficiency or 
Vitamin K antagonists, such as warfarin that 
prevent the conversion of vitamin K to its 
reduced form by blocking the activity of the 
enzyme vitamin K epoxide-reductase, leads 
to a reduction in the activity of the coagu-
lation factors resulting in an anticoagulant 
effect. 
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THE COAGULATION CASCADE
Early observations noted that clot formation 
in plasma would occur after the addition 
of exogenous biological material such as 
macerated brain extract, but that exposure 
of blood or plasma to surfaces such as glass 
would also precipitate clot formation without 
the addition of further material. This led 
to the concept of ‘extrinsic’ and ‘intrinsic’ 
pathways of coagulation, and over time the 
coagulation factors involved in these separate 
pathways were identified (Figure 9.2).21,22 
Tissue factor was identified as the ‘active’ 
factor in the added tissue extract, and was 
demonstrated to activate factor VII in the 
first part of the extrinsic pathway. The intrinsic 
pathway, sometimes also called the contact 
activation pathway, was found to involve 
serial activation of the coagulation factors XII, 
XI and IX, with factor VIII acting as a 
co-factor for the latter. Both extrinsic and 
intrinsic pathways were found to then 
converge on the ‘common pathway’ involving 
factor X, prothrombin (factor II), and finally 
the conversion of fibrinogen to fibrin. The 
concept of the two separate pathways was 
reinforced by the fact that the most widely 
utilised laboratory assays of coagulation 
evaluated the extrinsic (the prothrombin 
time or PT assay) and intrinsic pathway 
(the activated partial thromboplastin time or 
aPTT) separately, with both assays affected 
by common pathway defects.
Figure 9.2: The extrinsic and intrinsic pathways of coagulation
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It however became clear with time that 
the above model was unlikely to reflect phys-
iological coagulation. The observation that 
inherited factor XII deficiency was not asso-
ciated with a bleeding tendency raised ques-
tions regarding the physiological role of the 
intrinsic pathway.23 It was also demonstrated 
that activated factor VII, or factor VIIa, had 
the ability to activate factor IX as well as fac-
tor X, and therefore that cross-talk between 
the pathways was likely.24 With increasing 
knowledge of the role of the cell surface 
proteins in the coagulation process, and in 
particular the role of platelets, a cell-based 
model of haemostasis then emerged.25 This 
model divides the coagulation cascade into 
the separate steps of initiation, amplification, 
and then propagation (Figure 9.3).
Initiation
Exposure of cells expressing the trans-
membrane protein tissue factor to circulating 
blood is the physiological trigger of the 
coagulation cascade. Tissue factor (TF) is a 
transmembrane protein that is constitutively 
expressed on the surface of most non-
vascular cells, including those located in the 
subendothelium. There is also some evidence 
that tissue factor expression can be induced 
in the setting of inflammation on the 
surface of monocytes and that microparticles 
derived from monocytes may also express 
TF in pathological states.26 Upon exposure 
to circulating blood TF binds to factor VII, 
converting it to its active form factor VIIa. 
The resulting enzymatic structure is known 
as the extrinsic tenase complex, with TF 
then acting as a co-factor for VIIa and 
greatly potentiating conversion of factor X to 
factor Xa, and, to a lesser degree, factor IX 
to factor IXa. The activated factor Xa formed 
then binds to the surface of the tissue factor-
expressing cell, and converts a small amount 
of prothrombin (factor II) to thrombin, while 
the small amount of factor IXa produced 
diffuses away with the potential to bind 
locally to the surface of activated platelets.27
Amplification
The small amount of thrombin formed 
during the initiation stage, while insufficient 
Figure 9.3: Cell based model of haemostasis
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to convert adequate amounts of fibrinogen 
to fibrin, is none-the-less enough to be 
responsible for the subsequent amplification 
of the coagulation cascade. The thrombin 
produced results in 1) further local activation 
of platelets resulting in the phospholipid 
surface on which the reactions of the co-
agulation cascade can proceed; 2) activation 
of the co-factors factor V and factor VIII 
that then localize on the nearby surface 
of activated platelets; and 3) activation of 
factor XI that also binds locally to the platelet 
surface.28
Propagation
Following the activation of the co-factors and 
their localization on the platelet surface, the 
stage is set for the formation of highly effic-
ient enzymatic complexes that are responsible 
for the burst of thrombin generation that leads 
to clot formation. Factor IXa formed during 
the initiation step, binds to factor VIIIa on 
the platelet surface to form the intrinsic 
tenase complex. This then efficiently converts 
factor X to factor Xa, with the latter then 
binding to its co-factor, factor Va, to form 
the prothrombinase complex responsible 
for the effective conversion of prothrombin 
to thrombin. Factor XIa produced during 
amplification activates further factor IX, 
further reinforcing or enhancing the whole 
process from above.25 
The burst of thrombin generated dur-
ing propagation then cleaves the fibrino-
peptides a and b from soluble fibrinogen to 
form insoluble fibrin monomers. The trans-
glutaminase Factor XIII, itself activated by 
thrombin, then forms bonds between sepa-
rate fibrin monomers to form a firm network 
of cross-linked fibrin that is a requirement 
for stable thrombus formation.29
Natural inhibitors of coagulation 
Normal coagulation is kept in check by 
several regulatory processes that cause 
thrombin production to plateau and then 
diminish, preventing appropriate localized 
activation of coagulation from becoming 
an inappropriate widespread activation of 
the clotting cascade. The initiation phase 
of coagulation is regulated by tissue factor 
pathway inhibitor (TFPI), a protein produced 
by endothelial cells.30 After a sufficient local 
concentration of FXa is generated in the 
initiation step of coagulation, TFPI is able to 
form an inhibitory quaternary complex with 
FXa, FVIIa, and tissue factor, preventing 
continued activation of the cascade from 
above. 
Central to regulation of the propagation 
phase of the coagulation cascade is the pro-
tein C anticoagulant pathway that involves 
protein C and protein S, both vitamin K 
dependent plasma glycoproteins synthe-
sized in the liver.31,32 Thrombin itself initi-
ates this inhibitory pathway after binding to 
thrombomodulin, a transmembrane protein 
located on the intact endothelial cell sur-
face in all vascular beds particularly in the 
microcirculation. Binding of thrombin to 
thrombomodulin results in a change in sub-
strate specificity that favours cleavage of the 
vitamin K dependent protein C to its activated 
form activated protein C (APC).33 Binding 
of thrombin to thrombomodulin there-
fore results in its net enzymatic effect being 
switched from pro-coagulant to anti- 
coagulant. Another endothelial transmem-
brane protein, the endothelial protein C 
receptor (EPCR) binds protein C, helping to 
localize the protein at the endothelial surface 
potentiating activation by thrombomodulin 
bound thrombin. Once activated APC dif-
fuses away from EPCR, and binds to the 
extrinsic tenase and prothrombinase com-
plexes where it acts to inactivate factor VIIIa 
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and factor Va respectively. Protein S acts as 
a co-factor for protein C in these reactions, 
as well as having some direct anticoagulant 
activity.34 In plasma, PS circulates both free 
(40%) and bound to the C4b-binding pro-
tein (60%). It is the free form of PS that has 
cofactor activity.32
Finally antithrombin (AT) is a single 
chain plasma glycoprotein that belongs to 
the serine protease inhibitor superfamily 
(serpins). It plays a central role in the in-
activation of circulating activated clotting 
factors, forming a 1:1 complex that is cleared 
by the liver. It is the main physiological 
inhibitor of thrombin and also binds to 
factors Xa, IXa, XIa, and XIIa.35 Thrombin 
inhibition by AT is potentiated more than 
1000-fold by heparin, due to conformational 
change of the AT molecule upon heparin 
binding, and it is this mechanism that re-
sults in heparin’s activity as an anticoagulant 
agent.36
Inherited deficiency states of the main 
inhibitory proteins of coagulation, namely 
protein C, protein S and antithrombin, 
have all been described, and result in a pro-
thrombotic tendency. Such deficiency states 
are relatively rare accounting, when combined, 
for less than 5% of individuals with venous 
thrombosis in a Caucasian population.
Fibrinolysis
The fibrinolytic system is responsible for 
the dissolution of thrombus composed of 
cross-linked fibrin, and plays a major role in 
helping maintain a patent vascular system.37 
It is composed of a number of enzymes, 
most of which are serine proteases, that act 
in concert to convert insoluble fibrin to 
soluble fibrin degradation products (FDPs). 
The central protein of the fibrinolytic system 
is plasminogen, a single-chain glycoprotein 
consisting of 791 amino acids, which is 
converted to its active form plasmin by the 
cleavage of a single Arg561–Val562 peptide 
bond. Tissue-type plasminogen activator 
(tPA) is the physiological activator primarily 
involved in the dissolution of fibrin from 
the circulation. Activation of plasminogen 
to plasmin is potentiated in the presence of 
fibrin due to the fact that both plasminogen 
and tPA bind to lysine residues on the 
surface of fibrin, and are as a result brought 
into close proximity to each other. Both 
tPA and another plasminogen activator, 
urokinase-type plassminogen activator, play 
a role in the activation of plasminogen that 
is bound to the endothelial cell surface. 
Once activated, plasmin cleaves fibrin into 
soluble fibrin degradation products, of 
which D-dimer is one. D-dimer consists 
of two cross-linked fibrin D-domains, and 
is not normally present in the absence of 
recent plasmin activity. It is therefore used 
as a laboratory marker of active thrombosis, 
and is a sensitive test that can be used to rule 
out recent venous thromboembolism.
Like the coagulation cascade, the fibrino-
lytic system also has a number of inhibitory 
proteins that in normal circumstances pre-
vent widespread activation of fibrinolysis. 
Plasminogen activator inhibitor-1 (PAI-1) 
is a 52-kd, single-chain glycoprotein that 
belongs to the serpin family, that is the main 
inhibitor of both tPA and uPA, doing so 
by forming a 1:1 complex that is cleared by 
the liver.39 Circulating plasmin is quickly 
mopped up by α
2
-plasmin that is present 
in the circulation at a high concentration. 
The most recently described inhibitor of 
fibrino lysis is thrombin-activatable fibrinol-
ysis inhibitor (TAFI), a carboxypeptidase.40 
TAFI is activated by thrombin, a process that 
is markedly accelerated if thrombin is bound 
to thrombomodulin. The antifibrinolytic 
activity of TAFI is due the fact that it cleaves 
C-terminal lysine and arginine residues from 
fibrin. This significantly reduces the binding 
of plasminogen to fibrin, therefore decreasing 
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the activation of plasminogen by tPA on the 
surface of the fibrin clot. 
The fibrinolytic system is manipulated 
therapeutically by administration of either 
naturally occurring (streptokinase) or recom-
binant protein (r-tPA) that exert the same 
effect as endogenous tPA, leading to acti-
vation of plasmin and resulting thrombus 
lysis.
CONCLUSIONS
Primary and secondary haemostasis both 
involve carefully balanced systems that if 
disturbed can lead to issues with either bleed-
ing or pathological thrombosis. An improved 
understanding of the molecular processes 
involved has lead to the development of more 
targeted therapeutic options, such as the 
direct thrombin inhibitors and direct factor 
Xa inhibitors, with the aim of increasing the 
benefit and reducing the risks associated with 
anticoagulation. Continued advances in our 
understanding of the relationship between 
the structure and function of the proteins 
and receptors involved in haemostasis, along 
with improved technology, is likely to lead 
to further therapeutic advances in coming 
decades.
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Abnormal thrombus formation is central to 
the acute pathophysiology of both arterial 
and venous disease. Formation of thrombus 
superimposed upon the surface of ruptured 
atherosclerotic plaque, producing vessel 
occlusion and resulting tissue ischemia, is 
the common mechanism leading to acute 
symptoms and presentation in patients with 
arterial disease. Likewise deep vein throm­
bosis and pulmonary embolism, important 
community causes of morbidity and mortality, 
both result from abnormal thrombus 
formation in the venous circulation. An 
understanding of conditions that may pre­
dispose to abnormal thrombus formation, 
including a knowledge of how the presence 
of these conditions may or may not impact 
on patient management, is important for all 
clinicians involved in the management of 
vascular disease.
First used in 1937,1 and then also in the 
first description of inherited antithrombin 
deficiency, the term ‘thrombophilia’ can be 
defined as an increased tendency to develop 
thrombosis, which may be either acquired or 
inherited.3 Thrombophilic conditions vary 
both in prevalence and in the magnitude of 
the associated increase in risk of thrombosis. 
The discovery during the 1990’s of the high 
prevalence factor V Leiden and prothrombin 
gene point mutations that predispose to 
thrombosis,4,5 meant that an underlying 
thrombophilic condition could be found in 
approximately 50% of unselected patients 
with venous thrombosis.6 This fact, along 
with the belief that the presence of such a 
condition may influence prognosis and may 
therefore help guide patient management, 
has led to a significant increase in laboratory 
testing for inherited thrombophilia.7 Recent 
data has however suggested that testing 
for thrombophilia, particularly the more 
common inherited conditions, is unlikely 
to influence the management of the major­
ity of patients in whom it is performed,8 
and guidelines as a result have recommended 
against widespread testing in unselected 
patients.9 
This chapter will first describe individ­
ual inherited and acquired conditions that 
predipose to an increased risk of thrombo­
sis. The potential clinical rationale will then 
be outlined, and finally current evidence 
and recommendations regarding the clinical 
utility of laboratory testing in specific 
clinical scenarios will be discussed.
10  • Hypercoagulable States
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CLASSIFICATION OF 
THROmbOpHILIA
Thrombophilic conditions can be broadly 
classified as being either inherited or acquired 
and will be described in these two broad 
categories. 
Inherited Thrombophilia
In 2003 Crowther and colleagues proposed 
a further sub­classification of inherited 
thrombophilia into either type 1 conditions 
that involve a deficiency of one of the 
naturally occurring inhibitors of coagulation, 
and type 2 conditions that result in a gain of 
function or an increase in the level of one of 
the procoagulant proteins.10 The distinction 
is of clinical relevance as the majority of 
patients with a type 1 condition will develop 
a symptomatic episode of venous thrombosis 
during their lifetime, whereas the majority 
of individuals with a type 2 condition will 
not. Similarly the presence of a type 1 
thrombophilia clearly increases the risk of 
recurrent venous thrombosis and therefore 
influences decision making regarding the 
duration of anticoagulation, where again 
type 2 conditions in isolation do not strongly 
influence recurrence risk and their absence 
or presence should not be used in isolation 
to determine duration of treatment.12 
Type 1 Conditions 
Antithrombin Deficiency 
Antithrombin (AT) is a single chain plasma 
glycoprotein belonging to the serine protease 
inhibitor superfamily (serpins).3 It is a 
physiological inhibitor of thrombin and other 
activated coagulation factors (factors Xa, IXa, 
XIa). Heparin exerts is anticoagulant effect by 
binding to AT, resulting in a conformational 
change that increases the affinity of AT for 
thrombi more than 1000­fold. Familial 
AT deficiency, described in 1965, was the 
first identified inherited thrombophilia.2,3 
Individuals with AT deficiency typically 
have AT levels ranging between 40­80%, 
and estimates of the prevalence of the 
condition range from 0.02% to 0.15% of 
the general population.13 Approximately 
0.5­2% of unselected individuals with 
venous thromboembolism (VTe) will have 
AT deficiency.14 estimates of the increase in 
risk of VTe associated with AT deficiency 
vary from 5 to 20­fold. 
Protein C and Protein S Deficiency
protein C (pC) and protein S (pS) are both 
vitamin K dependent plasma glycoproteins 
synthesized in the liver.3 When activated 
by thrombin, a process potentiated by the 
binding of thrombin to thrombomodulin, 
pC is converted to the active serine protease, 
activated protein C (ApC).15 In combination 
with its cofactor, pS, ApC inactivates both 
factor Va and VIIIa, and plays a central role 
in controlling the procoagulant pathway. In 
plasma, pS circulates both free (40%) and 
bound to the C4b­binding protein (60%). 
It is the free form of pS that has cofactor 
activity. 
Inherited pC deficiency was first de­
scribed as a cause of venous thrombosis in 
1981,16 whereas pS deficiency was initially 
described as a cause of venous thrombosis 
in 1984.17 pC and pS deficiency both have 
type I (quantitative deficiency) and type II 
(qualitative deficiency) subgroups, and in 
addition a type III pS deficiency state with 
normal total circulating but reduced free 
levels can occur. The estimated prevalence 
of heterozygous pC deficiency in the general 
population is between 0.2 and 0.4%,18 and 
many of these individuals have no history 
of thrombosis. The community prevalence of 
pS deficiency is estimated at approximately 
0.2%.19 pC deficiency is found in 1–3%, 
and pS deficiency in 1–7% of unselected 
patients diagnosed with VTe. estimates 
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from case­control and family cohort studies 
of the increase in risk of VTe associated with 
pC deficiency range from 5.0 to 10­fold, and 
8.5 to 30­fold for pS deficiency.8
Type 2 Conditions
Factor V Leiden
In 1993, Dahlback and colleagues noted 
that plasma taken from a family with a 
strong history of venous thrombosis was 
resistant to the anticoagulant effect of ApC.20 
This phenotype became known as ApC 
Resistance. A point mutation in the factor 
V gene (G1691A) resulting in an amino 
acid change (Arg506 to Gly) at the cleavage 
site involved in the inactivation of factor Va 
by activated protein C was identified as the 
cause in more than 90% of individuals and 
became known as factor V Leiden (FVL).4,21 
The FVL mutation has a high community 
prevalence with 3 to 7% of Caucasians being 
heterozygous for the mutation, although 
a lower incidence is found in other ethnic 
groups.22 It is the most commonly identified 
cause of inherited thrombophilia, being 
present in 12 to 20% of unselected patients 
with VTe,23 and up to 50% of individuals 
from thrombophilic families presenting with 
venous thrombosis. The heterozygous state 
is a relatively low risk thrombophilia being 
associated with a 3 to 7 fold increase in risk 
of VTe,8 with one study finding greater 
than 90% of individuals remaining event 
free by the age of 65.24 Unlike individuals 
homozygous for natural anticoagulant 
deficiency states, homozygosity for FVL does 
not result in a catastrophic thrombotic state 
early in life, and it is estimated that 0.1% of 
the population are FVL homozygotes.8 The 
risk of VTe, however, in homozygotes for 
FVL is greater than that in heterozygotes, 
with estimates of the magnitude of risk 
ranging form 25 to 80­fold that of the 
healthy controls. 
The Prothrombin (G20210A) Gene 
Mutation
In 1996, poort and colleagues described 
a common mutation (G20210) of the 
prothrombin gene, which has become 
known as the prothrombin gene mutation 
(pGm).5 Located in the 3’ untranslated 
region of the gene, the mutation is associated 
with increased mean plasma prothrombin 
levels due to increased efficiency of 
3’ end processing of the gene resulting in 
accumulation of the encoded mRNA.26 The 
prevalence of the mutation in Caucasian 
populations is approximately 2%, and it is 
rare in Asian and African populations.27 In 
unselected patients with venous thrombosis 
the mutation has been found in between 
4.0 to 7.1% of individuals,8 and 18% of 
individuals with a strong family history 
of VTe. The pGm is a relatively weak risk 
factor for VTe, being associated with a 2 to 
5 fold increase in risk.8 
FVL/PGM compound heterozygotes
Given the high community prevalence 
of both the FVL and pGm mutations it 
is not uncommon for individuals to be 
heterozygous for both conditions, with 
an expected prevalence of 1 per 1000 in 
Caucasian populations.28 In a pooled analysis 
of case control studies, double heterozygotes 
were estimated to have a 20­fold increase 
in risk of VTe in comparison to healthy 
controls.28 
Other inherited conditions
Homozygosity for the C667T mutation 
in the methylenetetrahydrofolate reductase 
(mTHFR), producing a thermolabile gene 
product with reduced function, is the 
commonest inherited cause of raised plasma 
homocysteine levels.29 In prospective studies 
a 5µmol/L (micromolar) increase in total 
plasma homocysteine levels has been shown 
to be associated with an approximate 1.3­fold 
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increase in the risk of venous thrombosis,30 
and patients with peripheral vascular disease 
have been shown to have a slight elevation 
of homocysteine levels in comparison to 
controls.31 Conversely homozygosity for the 
C667T mTHFR mutation has been shown to 
have no association with venous thrombosis 
in folate replete societies,29 and to have only 
a weak association with arterial disease (OR 
1.2, 95% CI 1.0­1.4).32 performing testing for 
this mutation is therefore not recommended 
outside the research setting. 
elevated levels of the coagulation factors 
VIII, IX, XI and prothrombin (factor II) 
have all been shown to be associated with 
increased VTe risk. In the case of factor 
VIII, familial clustering of individuals with 
elevation of this factor has been demon­
strated suggesting an underlying inherited 
cause, although a specific genetic defect is 
yet to be identified.8 Other common muta­
tions within coagulation proteins that have 
been documented to increase the risk of 
venous thrombosis include the plasminogen 
Activator Inhibitor 4G/5G mutation (OR 
1.62) and the alpha­fibrinogen Thr312Ala 
point mutation (OR 1.4). However there is 
no clear evidence that the presence of these 
mutations should alter patient management 
at present. 33
Acquired Thrombophilia 
There are a number of important acquired 
conditions that predispose to venous or 
arterial thrombosis that can be defined by 
laboratory testing. external or environmental 
acquired risk factors such as recent surgery or 
hospitalization, while often playing a central 
role in the causation particularly of venous 
thrombosis, will not be discussed further.
Antiphospholipid antibodies
The term antiphospholipid antibody syn­
drome (ApLAS) was first used in the 
1980’s to describe a non­inflammatory 
autoimmune condition characterized by the 
presence of antibodies targeting a variety of 
phospholipid membrane associated proteins, 
and a history of either arterial or venous 
thrombosis or adverse pregnancy outcomes.34 
Laboratory confirmation of the presence 
of antiphospholipid antibodies requires the 
demonstration of the presence of a lupus 
anticoagulant, characterized by prolongation 
of phospholipid dependant coagulation 
assays such as the ApTT, or a positive 
immunoassay for anti­cardiolipin or anti­
beta2­glycoprotein1 antibodies. To classify a 
patient has having ApLAS, antibody testing 
should be positive on at least two occasions 
12 weeks apart.35 The risk of an initial 
thrombotic event in patients with a positive 
test for antiphospholipid antibodies varies 
from no increase in blood donors in whom 
the often transient antibodies are an incidental 
finding, to annual risk of thrombosis of 2 to 
4% in patients with SLe who are antibody 
positive.34 As will be discussed, patients 
with the ApLAS, particularly those with a 
positive test for a lupus anticoagulant, are 
at increased risk of recurrent thrombosis 
and therefore they will usually receive 
long­term anticoagulation after an initial 
event. 
Heparin Induced Thrombocytopenia 
Heparin induced thrombocytopenia (HIT) 
is immune­mediated adverse drug reaction 
to heparin. It results from the formation 
of antibodies, in the majority of patients, 
directed against a complex of heparin and 
the positively charged molecule platelet 
factor 4 (pF4).36 These antibodies then bind 
to the heparin­pF4 complex bound to the 
platelet surface, leading to platelet activation 
most likely due to signalling via the 
platelet Fc receptors. platelet and probable 
concurrent endothelial activation result in 
activation of the coagulation cascade and 
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increased thrombin generation, manifesting 
clinically as increased risk of venous and 
arterial thrombosis. Without institution of 
alternative anticoagulation, patients with 
confirmed HIT have a daily incidence of new 
thrombotic complications of up to 6%, with 
the historical risk of death or amputation 
due to venous gangrene approaching 50%. 
early recognition of HIT is therefore 
important and monitoring of platelet counts 
between day 2 and 14 of exposure should be 
performed in all patients receiving heparin. A 
fall in platelet count to less than 150 × 109/L 
or a fall in total platelet count by greater than 
50% should prompt laboratory investigation 
for HIT antibodies. patients testing positive 
for HIT antibodies should be started on a 
non­heparin alternative anticoagulant such 
as lepirudin or danaparoid.36 
Myeloproliferative Disorders
The primary bone marrow disorders poly­
cythaemia rubra vera (pRV), myelofibrosis 
and essential thrombocytosis (eT) make 
up the bcr­abl negative myeloproliferative 
disorders. In almost all patients with pRV, 
and a significant proportion with eT, a 
somatic acquired mutation known as the 
JAK2 V617F mutation will be detected.37 
patients with pRV and eT in particular 
have been shown to be at an increased risk 
of both venous and arterial thrombosis. The 
annual incidence of thrombosis in patients 
with essential thrombocytosis has been 
shown to be 12 per 1000 per year, of which 
approximately 50% will be arterial and 50% 
venous.37 This compares with a background 
incidence in the general population of 
approximately 1 per 1000. Full blood 
examination is therefore recommended in 
all patients with venous thrombosis. It has 
also been recently observed that a significant 
proportion of patients with unprovoked 
portal and mesenteric vein thrombosis will 
be found to have the JAK2 V617F mutation 
present, often without clear evidence of a 
myeloproliferative disease on the peripheral 
blood examination.38 While the therapeutic 
implications of this finding are still being 
evaluated, testing for this mutation should 
be considered in this patient group.
Potential Reasons for Performing 
Thrombophilia Testing 
Clinical utility is an important concept 
when considering laboratory investigations 
for any condition. The clinical utility of any 
investigation can be defined as the degree to 
which the clinical outcome of an individual 
patient is improved by the performance of 
that test. potential ways in which testing 
for an underlying thrombophilic condition 
may improve patient outcome are discussed 
below.
Patients With Venous Thrombosis and 
Their Relatives
a) Providing an understanding of the 
aetiology of a thrombotic event
As discussed above, a number of conditions 
have been shown to be clearly associated with 
an increased risk of a first episode of venous 
thrombosis (Table 10.1).8,9 patients with 
venous thrombosis are often keen to have an 
understanding as to why an event occurred, 
and therefore thrombophilia testing may help 
provide some explanation as to the aetiology 
of an event. It however should be emphasized 
that venous thrombosis is a multifactorial 
disease with many risk factors present at the 
time of an event, and therefore care should 
be taken in attributing an event entirely to 
an underlying thrombophilic condition. 
The cost­effectiveness of performing 
thrombophilia testing solely to understand 
the aetiology is questionable. As discussed 
below, it is also important that both the 
patient and clinician understand that testing 
for the common genetic mutations, the FVL 
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and pGm mutations, is unlikely to change 
management, and that the results of a posi­
tive test for these conditions are not over­
interpreted. Finally the potentially negative 
impact of testing including implications 
for insurance should be taken into account 
before testing is performed.
Determining risk of recurrence 
and therefore optimal duration of 
anticoagulation
patients with venous thrombosis are at risk 
of recurrent events, with approximately 
30% of affected individuals subsequently 
experiencing a recurrent event within 5 years 
of ceasing anticoagulation.38 A potential 
role for thrombophilia testing is therefore 
to identify those patients at greatest risk of 
recurrent thrombosis, in whom exposure to 
the increased risk of haemorrhage with long­
term anticoagulation may be justified. This 
is most relevant in patients with unprovoked 
venous thrombosis who have a substantially 
increased risk of recurrent thrombosis in 
comparison to patients in whom the event 
was associated with a definite provoking risk 
factor. 
The high incidence inherited throm­
bophilic conditions, the FVL and pGm 
mutations, do not significantly increase the 
risk of recurrent thrombosis. A recent meta­
analysis found that patients heterozygous 
for the FVL mutation compared to patients 
without the mutation had an approxim­
ate 1.6­fold increase in the risk of recur­
rent thrombosis.39 When this analysis was 
restricted to patients with an unprovoked 
event this decreased to a 1.2­fold increase in 
risk that was no longer statistically increased. 
The same analysis found a borderline sig­
nificant 1.4­fold increase in risk of recurrent 
venous thrombosis in patients heterozygous 
for the prothrombin gene mutation. This 
data suggests heterozygosity for the FVL or 
pGm should not be used by itself to deter­
mine duration of anticoagulation.
There is less data regarding the impact 
of antithrombin, protein C and protein S 
deficiency on the risk of recurrent venous 
thrombosis, and due to their lower incid­
ence data tends to be pooled for all three 
conditions. Data from prospective cohort 
studies of unselected patients with venous 
thrombosis has suggested an approximate 
2­fold increase in the risk of recurrence in 
patients with deficiencies of these proteins in 
comparison to patients with normal levels.8 
A retrospective study of thrombophilic 
families found that individuals with AT, pC 
and pS deficiency had a cumulative incidence 
of recurrent thrombosis of 55% by 10 years 
after ceasing anticoagulation, in comparison 
to a figure of 25% in patients with FVL, 
pGm or elevated FVIII levels.40 These data 
suggest that patients with confirmed AT, pC 
or pS deficiency may benefit from long­term 












Increase in risk of 
first episode VTE
5 to 20-fold 5 to 10-fold 5 to 30-fold 3 to 7-fold 2 to 3-fold 
Increase in risk of 
recurrent VTE
2.0-fold (pooled data) 1.2 to 1.6 fold 1.4 fold
*Refers to heterozygote state
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anticoagulation. It is important to stress that 
the levels of these proteins may be spuriously 
low, for example in the case of recent extens­
ive thrombosis, and, for protein C and S due 
to warfarin therapy. Therefore repeat testing 
in the absence of confounding factors should 
be performed to confirm the diagnosis prior 
to therapeutic decisions being made. While 
data is lacking on clinical factors that can be 
used to reliably identify patients with venous 
thrombosis that will have a deficiency of one 
of the natural inhibitors of coagulation, it 
would appear reasonable to focus testing on 
patients with unprovoked events, younger age 
(<50 yrs of age), unusual site of thrombosis, 
or a strong family history (>1 first degree rela­
tive) of venous thrombosis.
As previously mentioned, patients with 
antiphospholipid antibody syndrome have 
been demonstrated to have an increased risk 
of recurrent thrombosis, with estimates of 
risk ranging from 10 to 60% per annum.34 
In addition, patients with antiphospholipid 
antibody syndrome have been demonstrated 
to have an increased risk of death after ceas­
ing anticoagulation, contributed to by the 
fact that this patient group is at increased 
risk of not only recurrent venous thrombosis 
but also arterial complications.41 Therefore 
long­term anticoagulation is generally rec­
ommended for patients who meet the diag­
nostic criteria for this condition.
Determining the need for primary 
prophylaxis in asymptomatic family 
members
Another possible role for thrombophilia 
testing is determined if the baseline risk of 
venous thrombosis is sufficient to warrant 
primary prophylaxis with anticoagulation. 
Given the lack of evidence supporting a 
role for anti­platelet therapy in preventing 
venous thromboembolism, at present this 
would require a sufficiently high risk to 
justify exposure to the 2 to 3% annual risk of 
major haemorrhage associated with vitamin 
K antagonist therapy of which approximately 
20% will be fatal.
As shown in Table 10.2, the annual risk 
of venous thrombosis in previously asymp­
tomatic patients with venous thrombosis 
varies from approximately 0.3% with the 
pGm to up to 2% in patients with AT or 
protein S deficiency.8,9,40 This is against a 
background rate of approximately 0.1% 
per annum in the general population, with 
incidence increasing with age. It is generally 
accepted that given the risk associated with 
oral anticoagulation, that primary prophy­
laxis is therefore not justified in patients 
with any of the known inherited throm­
bophilias. It has been shown that between 
50 to 60% of episodes of venous throm­
bosis in previously asymptomatic family 
members with thrombophilia will occur in 












Overall risk (risk / 
year)
1.5–2.0% 1.0–1.5% 1.5–2.0% 0.5% 0.3–0.4% 
Oral Contraception 
(risk / yr exposure)
4 to 5% (pooled data) 0.3–0.5% 0.2%
Pregnancy (risk / 
pregnancy)
~ 4.0% (pooled data) ~2.0% ~2.0%
*Refers to heterozygote state
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the context of an additional environmental 
risk factor such as surgery. While not clearly 
demonstrated in clinical trials, it is possible 
that more aggressive thromboprophylaxis 
may be justified particularly in patients with 
type 1 thrombophilic conditions.9 Again, if 
testing is performed for this indication, care 
must be taken to avoid over­interpretation 
of the test result by both patient and other 
clinicians.
Making decisions regarding the use of the 
oral contraceptive pill
Knowledge of whether a previously asymp­
tomatic individual is a carrier of a known 
inherited thrombophilia may influence 
decision­making regarding exposure to the 
pro­thrombotic effects of oral contraception. 
estimates of the annual risk of thrombosis with 
use of a combined oestrogen/progesterone 
oral contraceptive (OCp) are shown in 
Table 10.2.8 Generally women of child bearing 
age have a low annual risk of thrombosis of 
approximately 1 to 2 per 10000 per year. 
Therefore despite the combination of oral 
contraceptive use and being heterozygous for 
the FVL mutation producing an approximate 
30­fold increase in risk, the absolute risk per 
year is still relatively low at no greater than 
0.5% per annum.
most clinicians would accept that the 
degree of risk associated with OCp use in 
patients with type 1 thrombophilic condi­
tions justifies avoidance and use of other con­
traceptive measures, including progesterone 
only pills or intrauterine devices that do not 
increase the risk of thrombosis. The decision 
regarding OCp use in women heterozygous 
for FVL and pGm is less black and white, 
and will be influenced by patient perception 
of the benefit obtained from OCp use, and 
the presence of other risk factors for venous 
thrombosis such as obesity.
Determining the need for 
thromboprophylaxis during pregnancy 
The risk of venous thrombosis during 
pregnancy in women with no prior history 
of thrombosis associated with the presence of 
common inherited thrombophilic conditions 
is shown in Table 10.2.8,9 Two­thirds of 
pregnancy related episodes of venous throm­
bosis will occur during the post­partum 
period. Again the case for prophylactic 
anti coagulation during pregnancy can be 
made most strongly for women with type 1 
conditions, particularly for antithrombin 
deficiency that in some studies is associated 
with a risk of ante­partum events of up to 10%. 
As a minimum, post­partum prophylaxis 
should be administered for 6 to 8 weeks. In 
FVL and pGm heterozygotes ante­partum 
prophylaxis is generally not recommended in 
women with no prior history of events. post­
partum prophylaxis should be considered, 
particularly in women with additional risk 
factors.
Patients with arterial thrombosis
The association between inherited throm­
bophilic conditions and arterial disease has 
not been clearly demonstrated. Case reports 
and small studies have linked antithrombin, 
protein C and protein S deficiency to arterial 
disease, however the data are inconclusive.8 
Larger studies have evaluated the link 
between the FVL and pGm mutations with 
both coronary artery disease, myocardial 
infarction and stroke. Generally the findings 
have been of either no link or a weak 
association with odds ratios of < 1.5,8,9 with 
some data suggesting a stronger association 
with myocardial infarction in younger 
patients with the additional risk factor of 
smoking. There is also no conclusive evidence 
supporting an association of thrombophilia 
with peripheral arterial disease. based on 
the lack of a clear association of inherited 
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thrombophilia with arterial disease, and no 
data supporting a change in management 
based on the knowledge that the presence of 
a thrombophilic condition improves patients 
outcome, is has been strongly recommended 
that testing for inherited thrombophilia 
should not be performed in patients with 
arterial disease.
As stated above, the association of anti­
phospholipid antibodies with an increased 
risk of arterial disease is more definitive. 
It is generally recommended that patients 
with ApLAS and arterial disease should be 
treated with warfarin rather than antiplate­
let agents, although the evidence supporting 
this approach remains minimal.34 
The clinical utility of measuring homo­
cysteine levels in patients with arterial disease 
at present remains unclear. While a number 
of trials have shown benefit of b­vitamin 
supplementation on surrogate end­points 
of arterial disease, a recent meta­analysis 
found no reduction in clinical end­points in 
patients with either cardiovascular disease or 
stroke with supplementation therapy.42 
pOTeNTIAL DeTRImeNTAL 
eFFeCTS OF THROmbOpHILIA 
TeSTING
A small number of studies have examined the 
potential psychological impact on patients of 
performing thrombophilia testing.43 While 
the general conclusion was that the impact 
was low, it was clear that many patients were 
unclear that they had been tested, and the 
knowledge of having a thrombophilia did 
cause significant distress in some individuals. 
Other potential drawbacks to testing for 
inherited thrombophilia may include diffi­
culty with obtaining or changes to the cost 
of life­insurance, and questionable cost­
effectiveness.8
CONCLUSION
It can be concluded that despite the ability 
to detect an underlying thrombophilia in up 
to 50% of patients with venous thrombosis, 
it is doubtful that performing laboratory 
testing for thrombophilias has a positive 
effect on patient outcome in the majority 
of patients. The strongest case for testing 
for inherited thrombophilia can be made for 
type 1 conditions, although these conditions 
will be detected in only approximately 5% of 
patients. The evidence that testing for FVL 
and the pGm abnormalities improves patient 
outcome is limited. Widespread testing 
in unselected patients is recommended 
against, and a stronger case can be made 
for patients with female first­degree relatives 
of child­bearing age. prior to any testing 
being performed, the clinician involved in 
test­ordering should counsel the patient 
regarding the implications of both a positive 
and negative test result, and how this will 
change patient management. If it is unclear 
how the test result will change treatment 
for the individual or relatives, then testing 
should not be performed.
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introduction
platelets are key blood components with 
a physiological role in the initiation of 
endogenous haemostasis and effective 
endothelial repair following vascular injury. 
platelets are responsible for the initiation of 
a series of complex interactions culminating 
in platelet aggregation and thrombus 
formation. as such, key platelet functions, 
such as adherence, activation, aggregation 
and interaction with coagulation factors, 
operate in the context of a complex and 
balanced interplay of receptors and mediators 
that ensure this process is controlled and 
specifically targeted to areas of vascular 
injury. however, in disease states, such as 
atherosclerosis, the abnormal initiation of 
platelet functions also contributes to the 
pathogenesis and propagation of vascular 
disease. consequently, targeted therapeutic 
inhibition of platelets has demonstrated an 
important clinical role in situations of both 
pathological and iatrogenic vascular injury, 
such as atherosclerosis and angioplasty. 
this chapter will firstly outline the relevant 
platelet receptors, their agonists and other 
important structural platelet components 
and their role in platelet function. Secondly, 
it will outline the role of these functions in 
the pathogenesis and propagation of vascular 
disease. Finally, the mechanism of therapeutic 
anti-platelet agents will be reviewed along 
with a description of currently used methods 
to assess platelet function.
platelet Function – 
adheSion and actiVation
platelets are enucleated cytoplasmic frag-
ments of bone marrow megakaryocytes 
with a limited capacity for protein synthesis. 
although lacking dna, platelets do 
contain megakarocyte mrna along with 
components necessary for protein synthesis,1 
and are capable of performing nuclear 
functions such as pre-rna splicing.2 once in 
the bloodstream, platelets have a lifespan of 
7–10 days. the primary function of platelets 
is to stop haemorrhage from sites of vascular 
injury. this is accomplished through the key 
platelet functional processes of adhesion, 
activation, cross-linking or aggregation, with 
the involvement of several important pro-
activation mediators.
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Platelet adhesion
platelet adhesion is initiated by tethering of 
circulating platelets to an area of vascular 
injury. usually, the intact endothelium 
prevents unwanted platelet activation by 
acting as a physical barrier to underlying 
thrombogenic substances (such as collagen, 
tissue factor and von Willebrand factor) and 
by releasing mediators that inhibit platelet 
activation (Figure 11.1). this involves three 
separate pathways, (1) the arachadonic acid-
prostacyclin pathway, (2) the l-arginine-
nitric oxide pathway and (3) the endothelial 
ecto-adenosine diphosphatase (ecto-adpase) 
pathway.3 endothelial cyclooxygenase 1 & 2 
(coX-1 & 2) convert arachadonic acid to 
prostacyclin metabolites (such as prostaglandin 
i2 (pGi2)) which elevate platelet intracellular 
camp levels and inhibit platelet activation 
in a process thought to be mediated by 
protein kinase a.4,5 nitric oxide, produced 
by endothelial cells, passively diffuses into 
platelets causing an increase in cytosolic 
cyclic guanine monophosphate (cGmp) 
levels and activation of cGmp dependant 
protein kinases with a consequent reduction 
in intracellular calcium.6 ecto-adpase is 
a protein constituent of the endothelial 
cell surface, which upon activation, limits 
the recruitment phase of platelet reactivity 
by reducing plasma concentrations of 
nucleotides, particularly adp.7 
endothelial cells with impairment of the 
above processes are termed dysfunctional, 
and express an ‘atherogenic’ profile of recep-
tors such as p-selectin, e-selectin, icam-1 
and Vcam-1 (as seen in Figure 11.1), as do 
endothelial cells which have been activated 
by exposure to various mediators (such as 
thrombin, tnF-α and lpS), sepsis, trauma, 
rapid temperature variations, shear stress 
and minor alterations to the local micro-
environment.8,9 these features usually also 
accompany acute vessel injury. however, in 
the absence of acute injury, an activated or 
dysfunctional endothelium may result from 
prolonged exposure to high blood pressure, 
shear stresses and dyslipidaemia, and conse-
quently result in pathological platelet activa-
tion and inflammatory cell recruitment.10
platelet adhesion begins by the exposure 
of circulating platelets to an activated or dys-
functional endothelium, or to exposed sub-
endothelial matrix proteins such as collagen, 
fibrinogen and von Willebrand factor fol-
lowing endothelial injury.11 these ligands are 
capable of binding to receptors on inactivated 
platelets at high shear rates and tethering 
them to the site of vascular injury. colla-
gen binds to glycoprotein Vi (GpVi), whilst 
von Willebrand factor binds to the platelet 
receptor Gpib-iX-V.12 in addition, collagen 
also binds von Willebrand factor, which is 
a mechanism of facilitating the adhesion of 
other inactivated platlelets. p selectin on the 
surface of activated endothelial cells, also 
binds to Gp1bα and pSGl-1 on the plate-
let surface, facilitating tethering and rolling. 
platelet adhesion triggers the process of plate-
let activation, culminating in the activ ation 
of the Gpiib/iiia receptor, enabling it to 
bind soluble fibrinogen and von Wille brand 
factor allowing firm adhesion of the platelet 
to the endothelium13 via fibrinogen bound to 
receptors on the endothelial surface (αvβ3 
and icam-1). Figure 11.1 illustrates how 
a tethered platelet becomes activated and 
firmly adherent via fibrinogen bound surface 
receptors.
Gpiib/iiia (αiibβ3, cd41/cd61) is a 
member of the superfamily of ‘integrin’ type 
receptors, which are transmembrane pro-
teins comprising of various combinations of 
non-covalently bonded subtypes of α and 
β subunits. integrins are involved in intra-
cellular and extracellular signal transduction 
(in both directions) as well as the mechanical 
coupling of cytoskeleton proteins to either 
the extracellular matrix or surface receptors 
on other cells.14 
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Platelet activation
in contrast to the relatively passive process 
of platelet adhesion, platelet activation is 
a metabolically active process involving 
several important and generally irreversible, 
biochemical and physical alterations to the 
platelet. these processes include the release 
of preformed mediators, alteration to the 
surface receptor profile and cytoskeletal 
changes resulting in a dramatic physical 
change to the platelet structure. these changes 
serve to facilitate the incorporation of the 
activated platelet into a developing platelet 
thrombus, activate neighbouring platelets 
via positive feedback mechanisms whilst also 
playing a key a role in the recruitment of 




Various non-chemical stimuli can activate 
platelets. these include hypothermia, trauma 
and alterations to acid-base balance. none-
theless, endogenous molecules mediate the 
vast majority of platelet activation in both 
Figure 11.1: Mechanisms of platelet adhesion to dysfunctional endothelium. Normal endothelial cells 
inhibit platelet activation by three primary pathways as shown. Endothelial cells activated by injury, sepsis or 
inflammation, or dysfunctional (for example, after exposure to prolonged hypertension), express an array of 
receptors that facilitate tethering of platelet to the vascular wall, removing it from the blood stream. These 
interactions, particularly with potent platelet stimulators such as collagen, promote activation of the platelet; 
enabling activated GPIIb/IIIa receptors to bind fibrinogen bound on the surface of endothelial cells by recep-
tors such as αvβ3 and ICAM-1. Platelet-adhesion is also mediated by interactions between platelet integrin 
receptors and exposed sub-endothelial matrix proteins such as collagen and von Willebrand factor. These 
mechanisms result in firm adhesion of the activated platelet to the vessel wall.
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the physiological and pathological setting, 
acting via both autocrine and paracrine 
mechanisms. the most important of these are 
collagen, thrombin, adenosine diphosphate, 
adrenaline and thromboxane a2. 
‘outside-in signaling’ refers to the pro cess 
of mediators binding to specific receptors on 
the platelet surface and initiating a second-
ary messenger response inside the platelet. 
these processes are mediated via several 
secondary messenger pathways namely: the 
phospholipase c and pi-3 kinase pathway, 
the eicosanoid and arachidonate pathway, 
protein kinase c and the camp and cGmp 
pathways.15 ‘inside out signaling’ refers to 
intracellular pathways mediating functional 
changes to surface receptors, such as the 
Gpiib/iiia receptor (as discussed below).
Thrombin and collagen
collagen and thrombin are the most potent 
platelet stimulators. collagen binds directly 




 (also known 
as Gpia/iia) and is crucial in the initial 
tethering of platelets to sites of vascular 
injury. other integrin receptors bind 
collagen bound to von Willebrand factor. 
collagen types i, iii and Vi are the most 
common type of collagen in the blood vessel 
subendothelial matrix and they bind directly 
to GpVi (see Figures 11.1 and 11.3). after 
binding, a series of intracellular signaling 
processes result in protein phosphorylation 
and consequently platelet activation.16 
thrombin is generated at sites of vascu-
lar injury from its precursor prothrombin, 
by virtue of the intrinsic, tissue factor-
driven pathway of the coagulation cascade. 
thrombin binds to G-protein linked pro-
tease activated receptors (known as pars) on 
the platelet surface. human platelets express 
two distinct par receptors, par1 and 
par4. par1 is coupled to Gα12/13, Gαq 
and Gαi proteins, which mediate cytoskele-
tal responses, increased intracellular calcium 
and reduced camp respectively, each of 
which are crucial steps in platelet activation 
(Figure 11.2). par1 appears to be a more 
potent activator of platelets than par4 
and has been proposed as a potential target 
for therapeutic inhibition (atopaxar – see 
Figure 11.3). effective inhibition of par1 
and par4 leads to near complete inhibition 
of platelet activation, even in the presence of 
high concentrations of thrombin.17
Adenosine diphosphate (ADP)
adp is generated and stored in platelets and 
red blood cells in dense granules. platelet 
activation results in the release of stored 
adp granules and activation of nearby 
platelets – a key amplifying process (Figures 
11.2 & 11.3). Several receptors, known as 
p2 receptors interact with adp resulting in 
platelet activation. present on platelets are 
the p2X2, p2Y1 and p2Y12 receptors. p2X2 
is an intrinsic ion channel, which upon 
ligand binding allows calcium influx into 
the platelet, promoting activation.18 p2Y1 is 
a G-protein coupled seven transmembrane 
domain receptor which activates protein 
phospholipase c causing release of stored 
intracellular calcium and facilitating con-
formational change of the platelet. p2Y12 is 
similarly a G-protein coupled receptor that, 
upon activation, mediates a reduction in 
intracellular camp (Figure 11.2). of these 
receptors, p2Y12 plays the more significant 
role in amplifying and sustaining the platelet 
activation process. platelet function studies 
have demonstrated that simultaneous 
activation of both p2Y1 and p2Y12 receptors 
is needed for the full platelet response to adp. 
both these features have made inhibition 





 is synthesized from 
ara chadonic acid in activated platelets via 
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the cyclooxygenase pathway. it freely diffuses 
across the platelet membrane to activate 
neighbouring platelets. thromboxane a
2
 
binds to tα or tβ receptors, which are in 
turn coupled to G-proteins Gαq, Gα12 or 
Gα13 – each of which activate phospholi-
pase c – an enzyme which degrades mem-
brane phosphoinositides creating key second 
messengers inositol triphosphate (ip3) and 
diacylglycerol (daG) which facilitate protein 
kinase c mediated intra cellular protein 
phos phorylation and raised intracellular 
calcium respectively (Figures 11.2 and 11.3). 
the G-protein linked receptors aid in 
amplification of the response to ligand 
binding as a single receptor may interact 
with multiple G-proteins.20
Figure 11.2: intracellular signaling mechanisms involved in platelet activation. The signaling pathways 
of three platelet receptors are depicted as examples: PAR-1 (protease-activated receptor-1; the main ADP 
receptor, P2Y12; PGE I2). Each of these receptors is a seven transmembrane domain G-protein coupled 
receptor. Each G-protein consists of an α and βγ subunit. The βγ subunit is involved in the formation of DAG, 
IP3 and PIP3, which play key roles in platelet activation. The Gα subunit exists in several isoforms. Gα12 
mediates platelet shape change by activating cytoskeletal proteins. Gαq plays a pivotal role by activating 
phospholipase C, and facilitating the formation DAG and IP3, which promote platelet activation by activating 
protein kinase C and raising cytosolic calcium. In addition, Gαq also promotes release of pre-formed granules 
containing pro-activating and pro-inflammatory mediators, such as ADP. Gαi and Gαs inhibit and stimulate 
cAMP production respectively with lower intracellular cAMP concentration favoring activation. Gαs is primarily 
made available in response to prostaglandin I
2
 action, primarily from release of endothelial cells, inhibiting plate-
let activation. (Adapted from Abrams CS et al ‘Platelet Biology’ – UptoDate article Jan 2010 and Bhatt DL et al 
‘Scientific and therapeutic advances in antiplatelet therapy’ (2003) Nature Reviews Drug Discovery 2: 15-18). 
cAMP = cyclic adenosine diphosphate, PGE I
2
 = prostaglandin I
2
.
Mechanisms of Vascular Disease206
Adrenaline
adrenaline is the least potent physiological 
stimulator of platelet activation. Surface α2 
adrenergic receptors are G-protein linked 
receptors which are potent inhibitors of 
camp formation, although studies suggest 
supra-physiological doses are required for 
activation of platelets by adrenaline alone.21 
nonetheless, circulating adrenaline release 
by a stress response, may serve to reduce 
Figure 11.3: Mechanisms of platelet activation and platelet inhibition. A wide array of mediators can 
trigger platelet activation. Thromboxane A2 is produced from membrane derived arachadonic acid in a process 
inhibited by aspirin. TXA
2
 can then freely diffuse across the platelet membrane and activate both its own 
and neighboring platelets. A similar mechanism of amplification is provided by the release of ADP and the 
stimulation of P2Y12 receptors. Other mediators act via specific receptors that promote platelet activation by 
raising intracellular calcium (eg. thrombin, TXA2) or reducing intracellular cAMP concentrations (ADP). These 
receptors provide useful therapeutic targets for platelet inhibition (shown in blue). Once activated, platelets 
can interact with neighboring activated platelets via fibrinogen bound to activated GPIIb/IIIa receptors, allowing 
cross linking and the formation of a platelet thrombus. (Adapted from Hankey GJ et al ‘Antiplatelet Drugs’ 
(2003) MJA 178(11): 577-8).
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overall platelet activation threshold, making 
platelets more susceptible to lower doses of 
other platelet activating mediators.
Second messenger systems
platelet-activating ligands bind to G-protein 
coupled receptors inducing intracellular 
second messenger pathways, which then 
mediate the biochemical and structural 
changes associated with platelet activation. 
G-proteins usually consist of α and βγ 
subunits. the α subunit exists in several 
isoforms, each mediating a specific intracel-
lular function.22 the α
q 
and βγ subunits 
activate phospholipase c (both) and pi3K 





 subunits promote or inhibit 
intracellular cyclic amp activity respectively 
– although the exact mechanism involved 
is as yet unclear. increased intracellular 
camp activity is associated with inhibition 
of platelet activation, a process utilized by 
the anti-platelet agent dypridimole. the 
α
12
 subunit is involved in mediation of 
shape change by promoting cytoskeletal 
reorganization (as discussed further below).23 
Figure 11.2 provides a broad outline of the 
key intracellular second messenger systems 
involved in platelet activation by several key 
receptors.
there are two central intracellular path-
ways involved in platelet activation – the 
phosphoinositide hydrolysis pathway and 
the eicosanoid synthesis pathway. the 
former is a consequence of the activation of 
phospholipase c beta (via G alpha-q subunit 
of G-protein linked receptor proteins) and 
the activation of phosphoinositol 3-kinase 
gamma (via G beta-gamma). once activated 
phospholipase c hydrolyzes pi-4,5-p(2) 
(pip2) to daG and ip(3). daG in turn 
binds to and activates protein kinase c, caus-
ing phosphorylation of key enzymes known 
as protein kinase c iso-enzymes. ip(3) binds 
to receptors within the intracellular tubular 
system, resulting the release of sequestered 
intracellular calcium.15
the eicosanoid pathway results in the 
formation of thromboxane a
2
. platelet ac-
tivation results in the release of arachido-
nate from membrane phospholipids by the 
action phospholipase a
2
, which is stimulated 
by raised intracellular calcium. arachidonate 
is then metabolized to thromboxane a
2
 by 
the action of cyclooxygenase-1 (coX-1), by 
a process inhibited by aspirin.24
Physiological consequences of 
platelet activation
platelet activation involves four primary 
features: (1) an important conformational 
change of the Gpiib/iiia integrin receptor, 
allowing it to bind fibrinogen and von 
Willebrand factor, promoting platelet aggre-
gation and the formation of a platelet 
thrombus. (2) the release of preformed 
intracellular granules of adp and throm-
boxane a
2
 promotes further platelet 
activation and a local positive feedback of the 
activation process. (3) activation results in a 
conformational change in the platelet itself, 
by rearrangement of the internal cytoskeletal 
ultra-structure. (4) it is increasingly recog-
nized that platelet activation augments 
an inflammatory response by the surface 
expression of receptors, the recruitment of 
inflammatory cells, and the release of pro-
inflammatory mediators. these functions 
have an important physiological role in the 
engagement of repair processes following 
injury. nonetheless, inappropriate activation 
of these processes are crucial elements in 
pathogenesis of atherosclerosis. 
The GP IIb/IIIa receptor and ‘inside-out’ 
signaling
the Gpiib/iiia receptor is from the β
3
 sub-
group of the integrin receptor super-family.25 
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the receptor consists of two proteins each 
with a transmembrane domain. Gpiib con - 
sists of a heavy (105kd) and light (25kd) chain 
linked via a disulfide bond. Gpiiia consist of 
a single (95kd) chain.26 once activated, the 
receptor recognizes rGd (arginine-glycine-
aspartic acid) and KQaGdV (glycine- 
glutamine-alanine-glycine-aspartic acid-valine) 
peptide seq uences present on fibrinogen 
(both sequences), von Willenbrand factor 
and fibronectin (rGd sequence) making 
each of these proteins ligands for the activated 
receptor – with fibrinogen being the most 
potent.27 as shown in Figure 11.3, one 
fibrinogen molecule can serve to crosslink 
platelets and augment platelet aggregation.25
Gpiib/iiia receptors are found exclu-
sively on platelets (with the exception of 
the platelet precursor, the megakaryocyte), 
with approximately 60-80,000 receptors per 
platelet comprising 2% of all protein present 
in the platelet. they have been utilized in the 
clinical setting as potent anti-platelet targets 
as discussed further below.
Granule exocytosis
Granule exocytosis is a key consequence 
of platelet activation, allowing platelet 
activation to be exponentially amplified 
and a local inflammatory response to 
ensue. microscopically, platelets contain 
dense, alpha and lysosomal granules. dense 
granules contain platelet agonists, which 
promote platelet activation such as adp, 
atp and serotonin. alpha granules contain 
adhesion-promoting proteins including 
fibrinogen, fibronectin, vitronectin and von 
Willebrand factor. these mediate platelet 
aggregation. lysosomal granules contain 
glycosidase and proteases, the role of 
which is unclear. Snare complex proteins 
(soluble n-ethylmaleimide-sensitive factor 
attachment protein receptors) are thought 
to be the primary mechanism regulating 
the vesicle-membrane interactions. Granule 
exocytosis is thought to be modified by the 
presence of aspirin, explaining part of its 
anti-platelet action.28
Activation-induced conformational 
change of platelets 
once activated, platelets undergo a dramatic 
physical shape change, losing their discoid 
shape and developing elongated projections 
of cytoplasm, called filopods, mediated 
by reorganization of the cytoskeletal ultra 
structure. this reorganization involves 
alterations to three primary components of 
the platelet cytoskeleton: the cytoplasmic 
actin network, the cytoskeletal rim and the 
marginal band. the membrane associated 
cytoplasmic actin network consists of both 
filamentous polymers and monomeric 
globular forms of actin, a 42kda abundant 
cytoskeletal protein. platelet activation 
results in an increase in the proportion of 
filamentous or F-actin, and reorganization of 
the actin network into longer actin filaments 
promoting conformational change. this 
process is mediated by phosphatidylinositol 
produced during platelet activation. F-actin 
filaments are anchored to the plasma 
membrane, via actin binding protein via the 
Gpib/iX complex.29 the cytoskeletal rim 
contains multiple components including 
actin, filamin, talin, vinculin, spectrin (also 
seen in red blood cells), and alpha actin along 
with multiple membrane glycoproteins. the 
interaction of filamin with actin is the key 
factor in preserving the discoid shape of the 
resting platelet. disruption of this interaction 
occurs in the presence of rising cytosolic 
calcium concentration, resulting in a loss of 
tethering of the Gpib to the cytoskeletal ring, 
promoting conformational change. Shape 
change is also facilitated by contraction of 
the tubulin polymers of the marginal band, 
however the exact biomechanical significance 
of this is still yet to be determined.30 
the net result of the above processes is the 
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physical transformation of the platelet from 
a discoid to a flat, broadened and star-shaped 
conformation known as spreading – allowing 
efficient incorporation of the platelet into an 
evolving platelet thrombus. 
plateletS and 
atheroScleroSiS
there is increasing evidence that platelets 
play a crucial role in all stages of the 
pathogenesis of vascular disease – particularly 
atherosclerosis. research over the last 
10–15 years has demonstrated that athero-
sclerosis involves an active inflammatory 
process rather than the benign accumulation 
of intra-luminal lipids.31 platelets play key 
roles in the development and progression 
of atherosclerotic plaques, by the action of 
released mediators and facilitating inter-
actions with other inflammatory cells. For 
the subset of atherosclerotic plaques that 
are unstable or prone to rupture, localized 
platelet activation and aggregation result in 
an occlusive platelet thrombus interrupting 
blood flow and causing distal ischemic injury. 
this mechanism underpins myocardial 
infarction and acute coronary syndromes, 
and explains to some degree the effectiveness 
of anti-platelet agents in the treatment and 
prevention of such conditions.32
Role of platelets in the initiation of 
atherosclerosis
platelets are the first cell to arrive at the 
developing atherosclerotic lesion. Studies 
demonstrate that platelets adhere to 
carotid endothelium of apoe deficient 
mice.33 p-selectin (cd62p) and e-selectin 
are expressed on the surface of activated 
endothelial cells (and platelets) which 
interact with Gp1βα, pSGl-1 and the 
von Willebrand receptor complex receptors 
on the platelet surface in a loose manner 
which is insufficient for stable adherence, 
but instead facilitates the rolling process34 
(Figure 11.1). in addition, soluble von 
Willebrand factor is secreted by endothel-
ium in response to inflammatory stimuli. 
mice deficient in von Willebrand factor 
demonstrate a reduced propensity towards 
atherosclerosis.35 
as platelets roll along the surface of 
activated endothelium, they become acti-
vated, and firm adhesion can occur via the 
inter action between β
3
 integrins present on 
endothelial cells and the fibrinogen bound 
Gpiib/iiia receptor on platelets (Figure 11.1). 
once activated, platelets become firmly 
adherent and are able to recruit other platelets 
to the area of endothelial injury.36 inhibition 
of platelet activation, such as suppression of 
coX-1 dependant thromboxane a2 pro-
duction or activity, has been demonstrated 




activated platelets also express p-selectin on 
their surface, which not only mediates platelet-
endothelial interactions, but also stimulates 
neighboring monocytes and macrophages 
to release pro-inflammatory mediators. 
For example, p-selectin mediated signaling 
between aggregated platelet and monocytes 
promotes up regulation of coX-2 mrna 
and the production of interleukin-1β, which 
promotes inflammation and further platelet 
activation.38 
Firmly attached platelets have also been 
shown to recruit monocytes from the blood 
stream to the site of vascular injury in a 
pro cess described as ‘tethering’. Such plate-
lets interact with circulating monocytes via 
pSGl-1 (p-selectin glycoprotein ligand-1 – 
on monocytes) and p-selectin expressed by 
platelets, multiple platelet receptors including 
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the fibrinogen bound activated Gpiib/iiia 
receptor and mac-1 (on monocytes) and 
the lymphocyte function associate antigen 
(lFa-1), which binds to icam-2 on plate-
lets. these interactions result in monocyte 
recruitment to the injured endothelium.39
these platelets release an array of 
pro-inflammatory mediators such as 
interleukin-1β, platelet factor 4, ranteS 
(regulated upon activation, normal t cell 
expressed and secreted) and cd40 ligand.25 
these mediators promote localized inflam-
mation and atherosclerotic development by 
activating the vascular endothelium to facili-




platelets have a well-established role in 
the development of a thrombus after the 
rupture of the thin fibrous cap present 
in vulnerable plaques. disruption of the 
thin fibrous cap, usually in the adjoining 
shoulder region, exposes the highly throm-
bogenic lipid core to the bloodstream, 
triggering a cascade of platelet activation and 
thrombosis.
however, the extent to which platelets 
interact with an established vulnerable plaque 
before it undergoes a clinically signific ant 
rupture is uncertain. it is circumstantially 
suggested by the success of antiplatelet thera-
pies in reducing ischemic events.40 Subclini-
cal plaque rupture is a frequent event with 
9% of autopsies on patients not dying from 
myocardial infarction demonstrating rup-
tured fibrous caps (22% in patients with 
cardiovascular risk factors). this suggests 
that rather than every plaque rupture pre-
cipitating an ischemic event, it is likely that 
the thrombotic response to plaque disrup-
tion is dynamic with thrombosis and throm-
bolysis occurring simultaneously in patients 
with acute coronary syndrome.41,42 conse-
quently, a rupture prone plaque may suffer 
periodic disruptions in its fibrous cap result-
ing in ongoing interactions with activated 
platelets.43 thus, in addition to their role in 
acute plaque rupture, at any given time, 
activated platelets may be associated with 
unstable plaques presumably in a number 
and frequency proportional to the degree 
of plaque instability. the detection of such 
activated platelets potentially may allow 
identification of unstable plaques prior to 
rupture.44
current and Future  
anti-platelet aGentS
Given the pivotal role of platelets in 
atherosclerosis, platelet inhibition provides 
major benefits in the treatment of athero-
sclerotic disease, both in the acute and pre-
ventative settings. Several targets have proven 
suitable therapeutic targets. Figure 11.3 
schematically illustrates the mechanism of 
action of these agents.
Aspirin (Salicylic acid)
aspirin, or salicylic acid, was the earliest 
known anti-platelet agent, used as early as 
500bc. aspirin irreversibly inhibits coX-1 
enzymes stored in platelets, preventing the 





, which are substrates for formation 
of thromboxane a
2
 – one of the platelet’s 
primary positive feedback system mediating 
amplification of both intra and inter-platelet 
activation (Figure 11.3). aspirin acetylates 
a key serine residue at the coX-1 catalytic 
centre, irreversibly corrupting its enzymatic 
function. platelets lack the machinery to 
resynthesize coX-1, thus aspirin leads to 
irreversible platelet inhibition for the life of 
the platelet (7-10 days), despite its relatively 
short plasma half-life of 15 minutes.45
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aspirin has a well-established clinical 
benefit in vascular disease, particularly myo-
cardial infarction and stroke, in both the 
acute and chronic setting. in acute myocardial 
infarction, aspirin demonstrated a 23% 
reduction of mortality at 5 weeks, in addi-
tion to thrombolysis – with benefits still 
measurable at 10 years.46 aspirin also reduces 
death and myocardial infarction in unstable 
angina, and is associated with reduced acute 
vessel closure following coronary angio-
plasty. With regards to secondary preven-
tion, recent metanalyses of patients with 
previously diagnosed vascular disease (coro-
nary artery disease, tia, stroke or periph-
eral vascular disease) demonstrated a 25% 
reduction in vascular death, myocardial 
infarction or stroke. in addition, patients 
with stable angina, intermittent claudication 
and atrial fibrillation (who cannot be fully 
anticoagulated) also derive similar benefit 
from aspirin.47 however, the benefits are less 
well established in the primary prevention 
population as the benefits of a reduced rate 
of myocardial infarction are tempered by an 
increased rate of hemorrhagic stroke. a net 
benefit is likely to be limited only to those 
patients with known cardiovascular risk 
factors such as diabetes.48
the optimal dose of aspirin had been 
established as 75-150mg daily, in order to 
achieve its full platelet inhibitory effect. 
higher doses (up to 325mg daily) dem-
onstrate increased gastrointestinal side 
effects with no additional anti-platelet 
effect.48
aspirin resistance is a newly recognized 
phenomenon where aspirin is unable to 
exert its full antiplatelet action and confer 
its cardiovascular protection, in certain 
patients. aspirin resistance is multifactorial. 
pharmacological reasons include: (1) com-
petitive inhibition by co-administration 
with nSaids (reversible coX-1&2 inhibi-
tors); (2) the action of possible inhibitory 
proteins, such as vitamin d binding protein 
which may act directly or indirectly; and 
(3) genetic polymorphisms in cyclooxygen-
ase making the active site less susceptible to 
the action of aspirin. non-pharmacological 
reasons include: (1) an increased reactivity 
of platelets to other activating factors such 
as collagen, adp, von Willebrand factor and 
adrenaline; (2) an increased rate of plate-
let formation, associated with myocardial 
infarction and coronary artery bypass graft 
surgery, resulting in an increased proportion 
of uninhibited platelet coX-1; (3) the pres-
ence of alternative pathways to thromboxane 
a2 generation which bypass coX-1. these 
may include coX-2 (present in the setting 
of inflammation), which requires a higher 
dose of aspirin to be effectively inhibited. 
Furthermore thromboxane a
2
 precursors may 
be acquired from monocytes and endothelial 
cells, despite inhibition of coX-1. Some 
forms of aspirin resistance are amenable to 
an increased dose of aspirin, whilst other 
forms require a reliance upon other agents 
to effectively inhibit platelets.49 
Thienopyridines
thienopyridines are pro-drugs which, when 
metabolized to their active form, cause 
irreversible inhibition of the p2Y12 receptor 
and inhibit the action of adp. the three in 
clinical use are ticlopidine, clopidogrel and 
prasugrel, of which cloidogrel is currently 
the most widely used. 
Clopidogrel 
once in the bloodstream, clopidogrel 
undergoes enzymatic alteration via a two-
step pathway to produce the short lived 
active metabolite r-130964. these steps 
involve hepatic enzymes of the cytochrome 
p450 family, particularly cYp1a2, cYp2b6, 
cYp2c9, cYp2c19 and cYp3a4/5.50,51 
binding of the active metabolite to the 
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p2Y12 receptor results in irreversible 
conformational change, which inhibits adp 
binding for the life of the platelet.52
as an antiplatelet agent, clopidogrel 
reduces platelet aggregation, platelet- 
leukocyte interactions and expression of cel-
lular adhesion molecules such as p-selectin.53 
in addition, clopidogrel’s active metabol-
ite has been shown to improve endothelial 
function possibly through blocking p2Y12 
receptor and/or by direct effects independ-
ent of its antiplatelet activity.54 clopidogrel 
also limits adp’s role in amplifying platelet 
activation through other agonists such as 
thrombin and collagen.55
the caprie trial demonstrated that 
clopidogrel had moderately improved cardio-
vascular secondary protection in patients 
with atherosclerotic disease (myocardial 
infarction, ischemic stroke, peripheral vas-
cular disease), compared to aspirin with 
similar tolerability. the combination of 
aspirin and clopidogrel, known as dual 
anti platelet therapy, significantly reduces 
the risk of subacute in-stent restenosis post 
angioplasty within the first month (bare 
metal stents) or twelve months (drug-eluting 
stents), and has an evolving clinical role in 
the long term management of refractory 
unstable angina.56
clopidogrel is dosed using a loading and 
maintenance regime. the loading dose is 
aimed at obtaining rapid antagonism of the 
p2Y12 receptor. Greater platelet inhibition is 
achieved more promptly with a 600mg load-
ing dose (maximum inhibition of 40-45% 
2–3 hours after loading dose) compared to 
a 300mg dose. however a 900mg dose does 
not lead to further improvements in platelet 
inhibition or earlier onset of action.57 the 
standard maintenance dose is 75mg daily, 
however recent studies suggest that a 150mg 
daily dose has a small additional benefit in 
reducing the risk of stroke, mi, cardiac death 
and in-stent thrombosis in the subset of 
patients undergoing pci for acute coronary 
syndromes – however the optimal duration 
of such therapy is yet to be determined.58,59
like aspirin, a proportion of the popu-
lation displays a degree of resistance to the 
therapeutic effects of clopidogrel. this is 
though to be due to polymorphisms in the 
hepatic enzyme responsible for the conver-
sion of the pro-drug to its active form. the 
most prevalent is the 681G>a polymorphism 
(also known as *2 allele) in the cYp2c19 
enzyme, which is responsible for first stage of 
clopidogrel metabolism. this allele is present 
in roughly 30% of the population with higher 
rates in the asian population (up to 50%). 
Studies have suggested the presence of this 
polymorphism is associated with a higher 
rate of in-stent thrombosis, and is associ-
ated with increased risk of ischemic stroke, 
mi and vascular death in patients with the 
mutation receiving clopidogrel for secondary 
prevention.60 Such patients may require an 
increased dose of clopidogrel, or the use of 
alternative agents. Genotyping prior to com-
mencing therapy, although available, is not 
currently routine practice, although studies 
are ongoing.58
Given its reliance upon liver metabolism, 
there exists the potential for drug inter-
actions to limit the effectiveness of clopi-
dogrel by reducing its bioavailability. in 
particular, an interaction with proton-pump 
inhibitors such as omeprazole has been pro-
posed. although retrospective and observa-
tional analyses have suggested an increased 
rate of death or hospitalization for acS,61,62 
and in vitro platelet aggregometry studies 
have suggested an impaired platelet response 
to clopidogrel in the presence of omeprazole, 
several randomized clinical trials have failed 
to identify adverse clinical endpoints attrib-
utable to clopidogrel and ppi interaction at 
this stage.63,64,65 Such studies may have been 
limited by power, and further studies are cur-
rently in progress.
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Prasugrel
prasugrel is the newest thienopyridine. it has 
several advantages over clopidogrel. Firstly, its 
onset of action is significantly quicker than 
clopidogrel (30 minutes versus 2 hours).66 
Secondly, unlike clopidogrel, prasugrel 
requires only a single hepatic enzyme step 
for conversion to its active metabolite. 
consequently, this significantly improves 
its bioavailability compared to clopidogrel.67 
the intermediate form of prasugrel is 
primarily formed through hydrolysis by 
the intestinal enzyme hce2. Subsequently, 
intestinal (cYp3a, cYp2c9, cYp2c19) 
and hepatic (cYp3a, cYp2b6, cYp2c9, 
cYp2c19) cytochromes are involved in 
conversion from intermediate form to active 
metabolite.68
the decreased reliance on hepatic 
enzymes for active metabolite formation 
and its increased bioavailability explain the 
stronger and more consistent (amongst indi-
viduals) inhibition of p2Y12 induced plate-
let activation compared to clopidogrel.69 the 
recent triton trial demonstrated a reduc-
tion in ischemic events in patients with acute 
coronary syndromes managed with pci, 
and 50% reduction in acute and sub-acute 
in-stent restenosis in patients on prasugrel 
compared to clopidogrel. however, this 
benefit came at the expense of an increased 
rate of major bleeding.70
Ticlopidine
ticlopidine was the first available 
thienopyridine. like clopidogrel, it requires 
hepatic activation in a two-stage process. 
it has several disadvantages compared to 
clopidogrel that limit its clinical usefulness. 
Firstly, its onset of action is significantly 
slower than clopidogrel. Secondly, it requires 
twice daily dosing, which noticeably reduces 
patient compliance. importantly, it also 
has several noticeable side effects including 
skin rashes, gastrointestinal upset and 
life threatening blood dyscrasias such as 
neutropaenia.71
Ticagrelor
ticagrelor is a new non-thienopyridine 
competitive p2Y12 antagonist, which 
has recently undergone phase iii clinical 
trials.72 unlike the thienopyridines, 
ticagrelor is not a pro-drug, but a direct 
p2Y12 receptor antagonist – requiring no 
hepatic or intestinal enzymatic activation. 
it has several advantages over clopidogrel: 
a more reliable pharmacokinetic profile, 
faster onset of action, and a lack of 
susceptibility to genetic based resistance as 
with thienopyridines. in addition, reversible 
inhibition allows its antiplatelet effect to 
cease rapidly after stopping therapy, unlike 
thienopyridines, which require 7–10 days 
for a return to normal platelet function. 
Furthermore, a recent randomized 
controlled clinical trial comparing ticagrelor 
with clopidogrel in patients with acute 
coronary syndromes, found a significantly 
reduced rate of death from vascular causes, 
stroke and myocardial infarction.72 unlike 
prasugrel, this benefit was not realized at the 
expense of increased major bleeding. there 
are, however, some notable issues: firstly, 
ticagrelor was associated with a higher rate 
of procedure related bleeding compared 
to clopidogrel. Secondly, ticagrelor was 
associated with idiosyncratic side effects 
of symptomatic dyspnoea and transient 
increase in ventricular pauses. lastly, 
ticagrelor requires twice daily dosing and 
would likely reduce patient adherence.71 
nonetheless, ticagrelor remains an exciting 
agent, which may address some of the 
shortcomings of the thienopyridines.
GPIIb/IIIa Antagonists
the Gpiib/iiia receptor is a useful therapeutic 
target given its prominent role in platelet 
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aggregation and thrombus development. 
diverse arrays of drugs have been developed 
to target the Gpiib/iiia receptor including 
monoclonal antibodies, cyclic peptides and 
chemical compounds. 
abciximab is a fully humanised mono-
clonal antibody specifically targeted to 
inhibit the Gpiib/iiia receptor. it consists 
of the murine generated variable domains 
linked to human igG antibody structure 
which limits the immunogenicity of abcixi-
mab.73 eptifibatide was developed from a 
template peptide extracted from the venom 
of the south-eastern pygmy rattlesnake. it 
consists of a cyclic heptapeptide with a KGd 
sequence, which confers particular specificity 
for the Gpiib/iiia receptor (as opposed to 
the rGd sequence in other endogenous 
ligands).74 tirofiban is a small molecular 
weight non-peptide compound based, again 
on a snake venom template, which inhibits 
Gpiib/iiia receptor.75 
of these agents, abciximab demonstrates 
the highest affinity for the receptor, followed 
by eptifibatide and tirofiban. taking into 
account other pharmacokinetic properties, 
abciximab has a duration of action of several 
days, compared to 2-4 hours for eptifibatide 
and tirofiban. the shorter acting agents are 
thus preferred in patients likely to undergo 
cardiac surgery following catheterisation. pro-
found thrombocytopaenia is well-described 
complication of Gpiib/iiia blocker therapy. 
it is likely mediated by a host immunological 
response towards neoepitopes exposed after 
the binding of the Gpiib/iiia blockers to the 
receptor.76
Gpiib/iiia antagonists are potent inhibi-
tors of platelet aggregation that improve 
mortality in patients presenting with acute 
coronary syndromes, particularly those under-
going percutaneous coronary intervention 
(pci).1,2 abciximab, has shown a 10-35% 
reduction in mortality. Similar results, albeit 
of a smaller magnitude, have been seen with 
the small-molecule antagonist’s tirofiban and 
eptifibatide, with a 16% to 35% reduction in 
ischemic events in patients undergoing pci. 
a greater benefit was seen in higher acuity 
patients (patients with elevated troponin 
levels and/or diabetes).77 in patients pre-
senting with an St elevation myocardial 
infarction undergoing primary angioplasty, 
Gpiib/iiia blockade reduced death, sub-
sequent infarction and need for revasculariza-
tion within 30 days by 46%.78 the addition 
of Gpiib/iiia blockage to thrombolysis 
therapy has thus far not shown to be benefi-
cial due to an increased bleeding risk.79
interestingly, instead of reducing major 
ischemic events, long-term oral Gpiib/iiia 
inhibitor therapy has uniformly increased 
the mortality rate. as a potential reason for 
this, it is postulated that exposure of Gpiib/
iiia to antagonists, which typically mimic the 
ligand fibrinogen, induce ‘outside in signal-
ing’, as would be expected for ligand binding 
to an integrin receptor.80,83 this can lead to 
paradoxical platelet activation and aggrega-
tion, implying that although Gpiib/iiia 
is a good target for platelet inhibition, the 
ligand-mimetic strategy of receptor blockade 
is not an ideal pharmacological strategy.81,82 
allosteric inhibition or selective inhibition 
of activated Gpiib/iiia receptors have been 




dipyridamole is well known antiplatelet 
agent currently in clinical use for the 
secondary prevention of stroke. dipyridamole 
increases intracellular cyclic amp by 
inhibiting enzymes responsible for adenosine 
breakdown. raised camp suppresses platelet 
activation, promotes vasodilatation, and 
stimulates prostacyclin release and coronary 
artery vasodilation.85 in combination with 
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low dose aspirin, it has been shown in one 
trial to offer additional stroke protection 
than aspirin alone.86 it has no demonstrated 
role in preventing cardiovascular disease. 
cilostazol is a type iii inhibitor of 
phosphodiesterase in platelets, promoting 
increased camp, and is currently approved 
for use in peripheral vascular disease. the 
Kamir and decreaSe trials have sug-
gested cilostazol confers a modest benefit in 
patients with coronary artery disease under-
going pci in addition to standard dual 
antiplatelet therapy with respect to cardiac 
death, stroke, mi and instent-thrombosis at 
8-12 months.87,88 however, the outcome of a 
double-blinded, randomised controlled trial 
is required before it can be recommended for 
routine use.
other new agents to mediate platelet 
inhibition are currently in development. 
one such is an oral protease receptor antago-
nist-1 (par-1) antagonist, currently known 
as atopaxar. par-1 is the primary platelet 
receptor for thrombin and is a potent activ-
ating agent. phase iii studies are underway 
to determine its clinical usefulness, with 
early phase ii data suggesting it may offer 
improved clinical outcomes with respect to 
death, stroke and mi, when added to other 
antiplatelet agents.89 Similarly, animal stud-
ies have demonstrated that inhibition of 
the platelet collagen receptor, GpVi, with 
monoclonal antibodies and Fab fragments, 
can inhibit collagen induced platelet aggre-
gation in rats. phase ii studies are currently 
in progress with a view to commence human 
trials in the near future.90 terutoban is an 
orally active inhibitor of the thromboxane 
a2 receptor, currently undergoing phase iii 
trials.91
a major limitation in the development 
of new anti-platelet agents is the recurring 
observation that with increasingly effec-
tive platelet inhibition comes an inevitable 
increased bleeding risk, either tempering or 
negating the cardiovascular benefit. novel 
classes of therapeutic drugs, currently under 
development, seek to circumvent this prob-
lem by selectively targeting activated plate-
lets, for example activation specific Gpiib/
iiia antagonists84 and pi3 kinase inhibitors.92 
these agents demonstrate potent antiplate-
let activity without prolonging bleeding time 
in animal models. clinical performance of 
these agents is still yet to be evaluated, how-
ever they remain promising.
platelet Function teStinG
platelet function testing refers to in vitro 
measurements of platelets’ response to 
activation in an attempt to quantify the 
degree of platelet aggregation. it has evolved 
significantly over the last decade from a 
laborious laboratory based process to rapid 
point of care commercially available kits. 
despite this, there still remains a surprising 
lack of standardisation of platelet function 
testing. table 11.1 summarises some of 
the currently available methods, along 
with their incumbent advantages and 
limitations.
Light transmission aggregometry
light transmittance aggregometry (lta) 
is currently the gold standard for assessing 
platelet activation as it is able to measure the 
functional ability of platelets to aggregate in 
response to known agonists such as adp. 
platelet aggregation uses the principle that 
the amount of light transmitted through 
the sample increases proportional to an 
increase in platelet aggregation. lack of 
standardization, poor reproducibility and 
spontaneous platelet activation through 
sample preparation are a few limitations of 
standard light transmittance aggregometry.93 
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Blood is centrifuged at low force to 
isolate platelet rich plasma, which 
is then stirred in a curvette at 37°C 
and placed between a light source 
and measuring photocell. Platelet 
agonists (such as ADP, collagen, 
adrenaline or ristocetin) are added. 
As individual platelets aggregate, 
turbidity of the PRP is reduced, and 
the increasing light transmission is 
detected by the photocell.
• Original ‘gold standard’ 
technique
• Limited to specialised 
laboratories as requires 
specialised expertise for 
accurate performance and 
interpretation
• Labour intensive
• Limited sensitivity in detecting 
small (<100 platelets) 
aggregates, or preformed 
aggregates. Thus, limited 
sensitivity to detect early 
aggregates in platelet 
hyperfunction.
• Limited ability to detect duration 
and efficacy of antiplatelet 




Whole blood is stirred at 37°C. 
Platinum electrodes at a fixed 
distance are added to the blood. 
Once electrically active, platelet 
aggregates amass upon the 
electrodes resulting in a measurable 
increase in electrical resistance in a 
manner proportional to the degree 
of platelet aggregation.
• Comparative accuracy with 
classical aggregometry
• Insensitive to small platelet 
aggregates




Inc, San Diego, 
California, USA) – 
previously known as 
the Ultegra Rapid 
Platelet Function 
Assay (RPFA)
A commercially available ‘point-of-
care’ assay. 
GPIIb/IIIa kit: Whole blood is added 
to disposable cartridge containing 
fibrinogen beads and an activating 
Thrombin Receptor Activating 
Peptide (TRAP). Platelets activated 
by TRAP, bind to fibrinogen in a 
degree proportional to the amount 
of available receptors. Thus the 
degree of GPIIb/IIIa blockade can 
be quantified.
Aspirin and Clopidogrel kits: These 
utilise the same principle using 
arachadonic acid and ADP as 
agonists in order to assess the 
activity of aspirin and clopidogrel 
respectively.
• Fast and easy to use with 
results available in 2–3 minutes
• Limited to assessing the 
effectiveness of antiplatelet 
therapy and no role in assessing 
platelet activity in disease states 
• Comparable sensitivity to 
classical platelet aggregometry
• Ideal cut-off points for 
diagnosing antiplatelet 
resistance are still a matter of 
conjecture. 
TAbLe 11.1: A list of commonly used platelet function tests, their advantages and 
limitations.
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Whole blood aggregometry
impendence aggregometry, a newer technique 
that measures electrical resistance due to 
aggregation of stimulated platelets on two 
platinum electrodes, has been shown to have 
improved reproducibility and sensitivity. 
the increase in resistance between electrodes 
is used to determine the amount of platelet 
aggregation after stimulation by an agonist. 
impedance aggregometry correlates well with 
lta.94
VerifyNow assay
Verify now is a cartridge based rapid point 
of care test that measures aggregation of 
platelets via Giib/iiia receptors in response 
to adp. the extent of platelet aggregation 
measured by a technique based on light 
transmittance aggregometry, is expressed 
as platelet reactivity units (pru), which is 
specific to the action of the p2Y12 platelet 
receptor. Simplicity of technique, reliability 
of results, lack of reliance on lab equipment 
Test Method Advantages and Limitations
Flow Cytometry Flow cytometry uses the principle 
of light scattering and fluorescence 
to accurately quantify platelets, 
blood cells, platelet aggregates 
and platelet leukocyte aggregates 
as well as the functional state of 
platelets. 
• Most versatile and best 
quantitative platelet function 
measurements
• Utilising gating technology, the 
expression of activation specific 
markers on platelets can be 
quantified. This provides very 
high sensitivity for detecting and 
quantifying platelet activation.
• Can identify platelet/leukocyte 
aggregates in addition to platelet 
aggregates
• Utilising fluorescence labelled 
ligands of antibodies such 
as fibrinogen-FITC or anti-P-
selectin monoclonal antibody, 
direct quantification of receptor 
blockade can be achieved (for 
example GPIIb/IIIa blockade)
• Requires considerable expertise 
and specialised laboratory





Using flow cytometry, the VASP 
Assay measures the degree of 
phosphorylation of VASP which 
correlates with the degree of activity 
of the ADP receptor. Phosphorylated 
VASP correlates with P2Y12 
receptor inhibition. The degree of 
phosphorylation in the presence of 
ADP, suggests effective antiplatelet 
activity.
• Best available test for 
identifying patients with possible 
clopidogrel resistance
• Requires considerable expertise 
and specialised laboratory
• Time consuming and expensive
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and good correlation with established tests of 
platelet function are advantages of this test. 
all point of care tests are limited by low to 
moderate sensitivity and specificity. however, 
Verifynow p2Y12 assay has been shown to 
predict clinical adverse outcomes.95
Flow cytometry
Flow cytometry enables identification 
of expression of substances on platelets 
and leukocytes, particularly formation of 
platelet-leukocyte aggregates. Fluorophores 
(substances that fluoresce when stimulated 
with energy) attached to antibodies which 
bind to substances of interest; emit light 
when excited by energy from lasers. these 
lasers transmit light at a specific frequency 
aimed at particles flowing past the laser in 
single file. the intensity of light emitted by 
the fluorophores allows quantification of the 
substance targeted by conjugated antibodies. 
however, accuracy and reproducibility of 
results vary from one protocol to the next. 
the ability to assess multiple markers relating 
to antiplatelet activity at the receptor is the 
main advantage of flow cytometry. the main 
disadvantages of this technique is the need 
for experienced operators, time consuming 
process for analysis with narrow sample 
preparation windows, lack of standardized 
lab protocols and access to lab facilities. 
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introduCtion
over the last decade aortic aneurysm has 
gained increased focus for a number of 
reasons. Firstly, the widespread use of 
imaging and screening in some countries 
has resulted in greater detection of the 
condition. Secondly since the condition 
is much more common in the elderly the 
number of patients with the problem is 
projected to increase progressively with the 
rising average age of the population. Surgical 
and endovascular treatments have not been 
shown to reduce mortality for patients with 
small abdominal aortic aneurysms (aaas) 
and thus other therapies are required to deal 
effectively with the large group of patients 
being identified with small aaas.1,2 there 
is also a need to provide better prognostic 
information for patients with aaa by risk 
stratification in terms of the likelihood of 
complications, including aaa progression 
to a stage where surgery is required and 
also other cardiovascular complications.3 
as a result of these current management 
deficiencies, there has been an explosion in 
studies directed at improved understanding 
of aaa pathogenesis. these studies have 
mainly consisted of investigations in animal 
models or assessments of human dna, 
tissue or blood samples.3 mice models have 
been particularly popular due to the ability 
to perform elegant interventions and 
assess their influence on aaa. data from 
such studies has thus had a major impact 
on pathogenesis theories and treatment 
targets. however, animal models have 
limitations and cannot be expected to be 
completely comparable to human disease. 
human aaas develop over many decades 
in patients with multiple risk factors and 
with numerous mechanisms leading to the 
final common result of an aaa. in contrast 
rodent models usually involve techniques to 
induce aortic aneurysms over a few weeks 
or result due to single genetic deficiencies. 
these models have allowed considerable 
insight not possible with human association 
studies alone but their exact importance 
will only become evident when treatment 
strategies they have suggested are examined 
by interventional trials in patients with 
small aaas.
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diFFerenCeS BetWeen 
thoraCiC and aBdominal 
aortiC aneurYSmS
numerous factors contribute to differences 
between the thoracic and abdominal aorta. 
in adults, the thickness and number of 
elastic lamellae gradually decreases along the 
aorta resulting in the wall thickness falling 
from about 1.5mm at the arch to less than 
1mm in the distal abdominal aorta.4 the 
fall in elastin is particularly notable in the 
aneurysm-prone infra-renal aorta.5 as a result, 
the abdominal aorta has a smaller cross-
sectional area and a stiffer wall. Compared 
with the thoracic aorta, the infra-renal aorta 
is exposed to reflected pressure waves from 
the iliac bifurcation, higher pulse pressures 
and increased wall shear stress due to its 
position proximal to a major bifurcation.6 
these adverse haemodynamic conditions 
make the abdominal aorta particularly prone 
to both atherosclerotic and aneurysmal 
disease.7 
the propensity for aneurysm formation 
in the infrarenal aorta may also relate to 
differences in aortic smooth muscle cell 
lineage: cells forming the arch of the aorta 
are derived from neural crest; of the thoracic 
aorta from somite-derived cells; and of the 
abdominal aorta from splanchnic mesoderm.8 
localised intrinsic aortic wall characteristics 
may influence a range of molecular pathways 
that are important in aneurysm formation 
– notably angiotensin ii and transforming 
growth factor beta (tGFβ) signaling.9 
diver gent inflammatory responses may also 
contribute to differences between thoracic 
and abdominal aortic aneurysms. the more 
florid inflammation seen in aaas may 
reflect greater vasa vasorum density and 
differential immune responsiveness.10 in 
addition, the expression of pathogen-sensing 
toll-like receptors by resident dendritic cells 
(resulting in differential t cell response) 
varies considerably, with each artery having 
a distinct profile.11
there are clear differences in the 
genetic factors associated with thoracic and 
abdominal aortic aneurysms. the importance 
of single gene mutations as causes of 
aneurysms decreases from the proximal 
to the distal aorta.9 the role of common 
susceptibility genes has yet to be clarified. 
Given that aneurysms of the abdominal 
aorta are ~5 times more common than in 
the thoracic aorta, this chapter will focus 
primarily on aaa. 
SummarY oF Current 
theorieS and StaGeS oF aaa 
eVolution
the natural history of an aaa can be divided 
into initiation, progression and rupture. 
this concept is useful since there is evidence 
that the factors promoting each stage may 
be different.12 Whilst understanding aaa 
initiation may ultimately lead to the goal 
of primary prevention, an understanding of 
aaa progression can guide the development 
of therapy for patients with small aaas in 
an attempt to reduce expansion and rupture 
rates. an attempt has been made to link 
putative mechanisms to different stages 
of aaa in table 12.1. in the subsequent 
sections the evidence implicating these 
mechanisms in aaa pathogenesis will be 
discussed.
atheroSCleroSiS and aaa
Patients with aaas frequently have 
generalized atherosclerosis, and numerous 
studies show the association of coronary 
and peripheral atherosclerosis with aaa.3 
Whether this association between aaa and 
aortic atherosclerosis is causal or simply due to 
common risk factors is unknown. the most 
compelling argument for a causative role of 
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atherosclerosis in aaa has been centered 
on arterial remodeling.13 a large body of 
in vitro, animal, and histology data suggests 
that when an arterial luminal stenosis 
develops, compensatory changes occur in the 
media in response to shear stress alterations. 
the extracellular matrix remodeling pro-
motes expansion of the artery in an attempt 
to normalize lumen diameter and shear 
stresses. excessive remodeling could explain 
the medial thinning typically seen in aaas. 
elastin breaks stimulated by medial proteoly-
sis and the diffusion of pro-inflammatory 
cytokines from inflammatory cells present 
within atheroma or associated thrombosis 
could also provide the stimulation for the 
chronic inflammation seen in aaas. on 
the basis that atherosclerosis stimulates aaa 
development, all patients with aaa would 
necessarily have significant atherosclerosis 
and thus should be considered for indicated 
medical therapy, as currently advised by 
american heart association guidelines in 
which aaa is considered an atherosclerotic 
equivalent.14 
an alternative theory suggests that the 
development of aaa and atherosclerosis 
are independent. Shared environmental 
and genetic risk factors may promote the 
development of both atherosclerosis and 
aaa in some patients, but the mechanisms 
involved are distinct. a third possibility 
is that either aortic atherosclerosis or aaa 
can develop first and both can subsequently 
stimulate the development of the other 
(Figure 12.1). Currently, evidence to support 
one of these theories over the other is largely 
limited to documenting similarities and 
differences in risk factors and findings within 
rodent models for atherosclerosis and aaa 
(table 12.2).3,15-19 
Further insight into the importance 
of atherosclerosis in aaa is of therapeutic 
relevance. recent human association studies 
have shown conflicting results on whether 
drugs that are effective for atherosclerosis, 
such as statins or angiotensin converting 
enzyme inhibitors, inhibit aaa pro-
gression.20-23 
immune meChaniSmS in aaa
relatively few studies have been carried out 
to establish the role of immune mechanisms 
in aaa by comparison to athero-thrombosis. 
examination of biopsies removed from large 
aaas demonstrate a marked inflammatory 
infiltrate, particularly within the adventitia. 
assessment of the relative numbers of 
different cell types within aaa biopsies 
have been performed using a variety of 
techniques including histology, flow cytom-
etry and genomic techniques.24,25 these 
studies suggest that in end-stage human aaa, 
the predominant inflammatory cell types are 
t and B lymphocytes.24 other inflammatory 
cells are also identified, such as macrophages, 
dendritic cells and mast cells.24 Current 
evidence implicates both innate and adaptive 
immunities in aaa pathogenesis.
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Figure 12.1: Theories regarding relationship between atherosclerosis and aaa. According to theory 1 
(thin line + arrow), environmental and genetic risk factors lead to development of aortic atherosclerosis. Resultant 
positive remodeling, intimal thrombosis, and release of proinflammatory cytokines stimulate secondary matrix 
degradation and adventitial inflammation which promotes AAA development. According to theory 2 (thick line 
+ arrow), environmental and genetic risk factors directly stimulate aortic medial degradation and adventitial 
inflammation, leading to AAA formation, which secondarily stimulates intimal atherosclerosis. More likely, both 
pathways act to some extent, with the relative proportion varying from patient to patient depending on the risk 
profile. ECM indicates extracellular matrix; LDL, low-density lipoprotein.
numbers of Cd69+dr+ active t cells with 
lower expression of adhesion molecule 
Cd62l,28 although the potential antigens 
that activate t cells remain undiscovered. 
the role of t helper (th) cells in 
human aaa is controversial. according 
to some reports a significant percentage 
of freshly isolated t cells express markers 
of a th1 immune response.29 Furthermore 
cytokines associated with th1 immune 
responses are elevated in the blood and 
aortic tissue of patients with aaa.30 in the 
CaCl
2
 aaa mouse model, absence of Cd4 
or th1 cytokine iFn-γ suppressed aaa 
formation.31 in contrast, several groups 
report different observations. these include 
high concentrations of th2 cytokines 
il4, il5, and il10, but negligible th1 
cytokines il2 and il15 in aaa biopsies.32 
in mice major histocompatibility complex 
t cells, including both Cd4+ and 
Cd8+ cells, are probably the best-studied 
inflammatory cells in human aaas. t cells 
may be demonstrated in both the adventitia 
and media of human aaa biopsies 
(Figure 12.2). the high numbers of t cells 
in human aaa may reflect both increased 
influx and also reduced clearance of these 
cells. t cells isolated from human aaas 
are more resistant to apoptosis than those 
from healthy donors or patients with aortic 
occlusion disease (aod).26 different sub-
sets of t cells may play varying roles in aaa. 
For example Cd4+Cd31– cells have been 
implicated in aaa progression by enhancing 
Cd8+ cell-mediated vascular smooth muscle 
cell (VSmC) cytolysis and macrophage-
derived matrix metalloproteinase (mmP)-2 
and -9 production.27 Compared with healthy 
aortic tissues, aaas also contain higher 
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mismatched aortic transplants develop 
an immune response dominated by il4. 
these transplanted aortas develop severe 
inflammation, elastin degradation, marked 
mmP-9 and mmP-12 expression, and aaa. 
these aaas can be prevented by anti-il4 
antibody or by concomitant il4 mutation.33 
overall it is possible from current data that 
both th1 and th2 responses are involved in 
aaa pathogenesis.
macrophages, neutrophils, and mast cells 
have also been implicated in aaa formation. 
macrophages are demonstrated within the 
adventitia and media of human aaa biopsies 
(Figure 12.2). human aaa biopsies contain 
significantly higher levels of total neutrophil 
elastases, localized in the adventitia and 
thrombus than aortic tissue from patients 
with aod or without significant disease.34 
neutrophil recruitment to aaas may be 
mediated by complement components C3a 
and C5a or neutrophil-derived il8 and 
leukotriene B4.35,36 antagonism of C3a and 
C5a blocked aaa formation in a mouse 
model.35 antibody depletion of neutrophil 
protected mice from elastase induced 
aaa development.37 diminished neutrophil 
recruitment to the elastase-injured aortic 
wall due to dipeptidyl peptidase i-deficiency 
impaired aaa formation. this protection 
was lost when wild type normally functioning 
neutrophils were restored in these mice.38 
all these data support a role for neutrophil 
in aaa formation and progression in mice 
models.
Small numbers of mast cells are found 
within the outer media and adventitia of 
human aaa (Figure 12.2) and the cell 




Smoking, hypertension, and obesity 
are common risk factors for AAA and 
aortic atherosclerosis.3
Diabetes is a negative or neutral risk 
factor for AAA but important risk factor 
for atherosclerosis.3 Male gender and 
smoking are much more dominant risk 
factors for AAA than atherosclerosis.3 
Circulating risk 
factors
AAA and atherosclerosis have many 
similar biomarkers, e.g. fibrinogen, 
CRP and HDL (negative).15
There are a number of disparate 
markers for AAA and atherosclerosis, 
e.g. LDL has no clear association with 




Family history is an important 
risk factor for both AAA and 
atherosclerosis.3 A locus on 
chromosome 9p21 is associated with 
CHD, stroke and AAA.17
Some recognised genetic 
determinants of atherosclerosis have 
no consistent association with AAA, 
e.g. Apolipoprotein E single nucleotide 
polymorphisms.18
Histology Intimal atheroma and thrombosis 
are usually present in both AAA and 
atherosclerosis.3
Marked elastin fragmentation and 
adventitial chronic inflammation is 
mainly restricted to AAA.3
Rodent models Some mice (e.g. Apolipoprotein E 
deficient) prone to atherosclerosis 
are also more sensitive to AAA 
induction.3 Interventions protective 
from AAA frequently also reduce 
atherosclerosis.3
There are examples of differential 
effects of interventions on AAA and 
atherosclerosis progression, e.g. TNF 
and MMP-12 deficiency.19
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number has been correlated with aaa 
diameter.39 neovessel area within biopsies 
of human aaas is also correlated with mast 
cell number. in rats, peri-aortic CaCl
2
 injury 
induces aaa with associated increase in 
aortic mast cell content. mast cell-deficient 
rats (Ws/Ws) or those that received mast 
cell inhibitor tranilast were protected from 
aaa formation. this effect was associated 
with reduced inflammatory cell infiltration, 
mmP-9 activity, angiogenesis and elastin 
degradation.39 Similar observations were dem-
onstrated in mast cell-deficient (KitW-sh/W-sh) 
mice.40 in an aortic elastase perfusion-induced 
aaa model, absence of mast cells protected 
mice from aaa, whilst pharmacological 
mast cell stabilization with an anti-allergy 
medicine cromolyn significantly inhibited 
aaa expansion.40 the findings suggest 
the intriguing possibility that mast cell 




examination of biopsies of large human 
aaas indicates marked medial thinning and 
deficiency of VSmCs as consistent features.3 
in human aaa lesions, the best-studied 
extracellular matrix (eCm) proteins include 
elastin and collagen. loss of functional elastin 
is an important feature of human aaa and 
may be a more generalized feature of arteries 
of patients with aneurysms.41 disruption of 
elastin has been particularly implicated in 
aaa development and progression, while 
degradation of collagen is thought to be more 
important in aaa rupture.42 the availability 
of knock-out mice models has allowed the 
dissection of some of the mechanisms by 
which the extracellular matrix might influ-
ence aaa development. these studies 
suggest that extracellular matrix elements 
play more than just a structural role. Studies 
Figure 12.2: Example of assessment of inflammatory infiltrate in a human AAA biopsy. Macrophages, 
mast cells and CD8+ T cells within the media and adventitia of human AAA biopsies. Rabbit anti-human CD8 
monoclonal (1:75, Abcam, Cambridge, MA), mouse anti-human CD68 monoclonal (1:60, Dako, Carpinteria, 
CA), and mouse anti-human tryptase (1:1500, Chemicon International, Inc., Temecula, CA) antibodies were 
used to detect CD8+ T cells, macrophages, and mast cells in paraffin sections.
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in fibrillin-1 deficient mice suggested that the 
loss of this extracellular protein led to alteration 
in the bioavailability of tGFβ. the marfan-
like phenotype stimulated by fibrillin-1 
deficiency could be inhibited by using a 
neutralizing antibody to tGFβ.43 deficiency 
of other extracellular matrix proteins such 
as fibulin-4 has also been suggested to alter 
tGFβ signaling.44 the mechanism by which 
alterations of tGFβ promotes aaa in these 
pre-clinical studies is currently controversial 
since the effects of blocking this cytokine 
varies in different models.43,45 the most 
detailed study to date suggests that at least 
in one model tGFβ protects against aortic 
aneurysm formation by inhibiting monocyte-
macrophage based tissue destruction via 
mmP-12 production.45 
inFeCtion
the development of aneurysms in which 
infection is a primary pathogen is well 
documented albeit rare. it has also been 
suggested that infection could play a more 
general role in aneurysm formation and 
progression. Chlamydia pneumonia in par-
ticular has been investigated for a role in 
aaa.46 evidence of previous C. pneumonia 
infection has been demonstrated in some 
patients with aaas although the frequency 
of this varies due to the different methods 
of detection used. Conclusive evidence of 
C. pneumonia infection in a large series 
of patients with aaa compared to controls 
is currently lacking. Serological evidence of 
C. pneumonia infection has been related to 
more rapid aaa expansion. these findings 
stimulated two small trials involving a total 
of 124 patients to examine the influence 
of short course antibiotic therapy on aaa 
progression.46 these studies both suggested 
a reduction in aaa growth over a short 
follow-up period but do not appear to have 
generated enthusiasm for larger studies 
directed at C. pneumonia eradication.46 
there are however two large on-going trials 
of doxycycline therapy in patients with 
aaa although the rationale for this therapy 
is based on mmP inhibition rather than 
antibiotic properties. 
BiomeChaniCal ForCeS
one of the suggested reasons for the 
focal nature of aaa formation has been 
the variation in haemodynamic forces 
throughout the aorta.7 hypertension is a risk 
factor for aaa in human population studies 
and in rodent models it promotes aaa 
formation.3,47 Focal increases in shear stress 
and wall strain have been demonstrated to 
inhibit aaa development in rodents due to 
reduction in macrophage induced oxidative 
stress.48 these findings have in part been 
the stimulus for a current randomized trial 
examining the effect of supervised exercise in 
patients with small aaas. results from this 
trial are expected in 2012. Biomechanical 
forces may also have a role to play in the 
development of aortic rupture.
anGioGeneSiS
new vessel formation has been demonstrated 
within the adventitia of human aaa 
biopsies and implicated in promoting influx 
of inflammatory cells.49 in the angiotensin ii 
induced mouse model, vascular endothelial 
growth factor promoted, and an angiogenesis 
inhibitor attenuated, aaa formation.50,51 
of possible relevance to human therapy, 
simvastatin has been shown to inhibit 
angiogenesis in the same aaa pre-clinical 
model.52
intra-luminal thromBuS
intra-luminal thrombus is a usual finding in 
large aaas but rare in aneurysms situated at 
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more proximal sites in the aorta. the volume 
of thrombus is closely correlated to the size 
of the aaa suggesting that the thrombus 
could simply be a result of the changes in 
flow pattern due to aortic dilatation.53 the 
thrombus is the likely source of a range 
of biomarkers which have been associated 
with aaa, such as fibrinogen degradation 
products including d-dimer.54 these 
thrombus products maybe of diagnostic 
and prognostic value for aaa.54 the 
thrombus has been demonstrated to contain 
large numbers of neutrophils, mmPs and 
cytokines.55,56 Furthermore in a rodent model 
of aaa, inhibition of platelet activation has 
been shown to slow aaa progression.55 in 
one cohort of patients with small aaas 
aspirin prescription has been associated 
with reduced aaa progression.57 trials of 
the efficacy of anti-thrombotic therapies 
in reducing aaa progression and perhaps 
reducing other complications of aaa may 
follow in the near future.
eXtraCellular matriX 
ProteolYSiS
the eCm in the healthy aortic wall is balanced 
by controlled biosynthesis and destruction. 
either impaired production or enhanced 
degradation of eCm may promote aaa 
formation. Seeding of syngeneic rat VSmC 
stabilizes experimental aaas58 and this 
effect is enhanced by adenoviral expression 
of tGF-β.59 Biosynthesis of collagen and 
elastin is regulated at both expression and 
post-translational modification. the latter is 
catalysed by poly-4-hydroxylase, procollagen 
lysyl hydroxylase (Plod) and lysyl oxidase 
(loX). disruption of the loX gene in mice 
leads to aaa formation and rupture.60 loX 
expression is reduced in aaa prone mice and 
in experimental aaa.61 a Plod mutation 
in humans predisposes to arterial rupture.62 
adenoviral expression of exogenous loX 
inhibits aaa in circumstances where 
endogenous loX activity is suppressed.63 in 
a rat CaCl
2
 model, peri-adventitia delivery 
of an aortic elastin binding polyphenol and 
stabilizer pentagalloyl glucose inhibited 
elastin degradation and attenuated aaa 
expansion, without modifying inflammation, 
calcification, and high mmP activity. the 
polyphenol protected elastin from proteases 
induced degradation.64 excessive eCm 
accumulation may also play a detrimental role 
in aaa. this theory was supported by studies 
in apolipoprotein e deficient (Apoe -/-) mice 
which express collagenase-resistant mutant 
collagen. these mice develop increased 
interstitial collagen accumulation, aortic 
wall stiffness, susceptibility to mechanical 
failure and increased aaa development after 
angiotensin ii infusion.65
eCm proteolysis in human aaa may be 
mediated by virtually all classes of proteases – 
mmPs, cysteine proteases cathepsins, and 
serine proteases that are derived from inflam-
matory or vascular cells after stimulation 
with cytokines (Figure 12.3). mmPs have 
been most studied. mmP-2, 3, 7, 12 have 
elastinolytic activity and mmP-2, 3, 7, 8, 9, 
13, 14 demonstrate collagenolytic activity.66 
Studies of human aaas biopsies suggest 
that a range of mmPs are upregulated, 
while concentrations of tissue inhibitors of 
metalloproteinase (timPs) are reduced.67,68 
it is postulated that inflammatory cells 
secrete mmPs and stimulate vascular cells 
to express mmPs in addition (Figure 12.3). 
in experimental aaa there is an inverse 
correlation between the number of inflam-
matory cells, neovessels and aortic wall 
collagen and elastin.69 mice in which mmP 
deficiency is introduced are protected from 
aaa induction.70-72 Similarly seeding of 
VSmC which express high levels of the 
mmP inhibitor timP-1 into aortas of an 
experimental model of aaa prevented aortic 
rupture.73 these findings implicate mmPs in 
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the development, progression and rupture of 
aaas.
increased expression of the cysteinyl 
cathepsins S, l, and K and decreased 
concentrations of their endogenous inhibitor 
cystatin C has previously been reported in 
human aaa biopsies.74,75 recent quantitative 
analysis suggested that cathepsins B, h, l, and 
S activities were increased by 376%, 191%, 
223%, and 20% in biopsies of human aaa 
compared to aod.76 the effect of this excess 
cathepsin activity is currently controversial. 
in the elastase perfusion model, deficiency of 
cathepsin C, also called dipeptidyl peptidase i, 
reduced neutrophil infiltration and aaa 
expansion.38 in contrast, Apoe -/- mice lacking 
cystatin C developed significantly enlarged 
aaas compared with control mice.77
the serine proteases urokinase and 
tissue-type plasminogen activator (uPa and 
tPa) have received considerable interest in 
aaa research. Plasma tissue plasminogen 
activator has been compared in subjects with 
and without aaa in 5 studies.15 only one 
of the studies reported significantly higher 
concentrations in patients with aaa. a local 
role for serine protease in aaa may be more 
plausible than a systemic one. absence of uPa 
in Apoe -/- protected mice from angiotensin ii 
induced aaa.78 intra-adventitial introduction 
of an adenovirus over-expressing plasminogen 
activator inhibitor-1 (Pai-1) completely 
prevented aaa formation in Apoe -/- mice 
infused with angiotensin ii. local delivery 
of this virus two weeks after angiotensin ii 
infusion prevented further expansion of 
small aaas, but had no significant effect on 
larger aaas.79
mast cell chymase has also recently 
been implicated in aaa formation. in 
human aaa, increased chymase expression 
within the media and adventitia has been 
reported.80 mice with deficiency of chymase 
are protected from elastase induced aaas. 
Figure 12.3: Schematic diagram summarizing the involvement of inflammatory cell infiltration and 
proteases in human AAAs. MMPs, cathepsins, plasminogen activators, chymases and tryptases are the 
best-studied proteases in AAA. Inflammatory infiltrates are the main sources of these proteases. Furthermore, 
these inflammatory cells also produce cytokines to stimulate VSMC and endothelial cells to release MMPs and 
cathepsins.
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in mice, chymase enhances the expression 
and activities of cysteinyl cathepsins, 
and promotes aortic elastin degradation, 
angiogenesis, and VSmC apoptosis.80 oral 
administration of the chymase inhibitor 
nK3201 (30mg/kg/day) significantly sup-
pressed the severity and expansion of aaas 
in the angiotensin ii induced aneurysm 
model.81 Similar observations have been 
reported in dogs where the chymase inhibitor 
nK3201 (1mg/kg/day, p.o.) inhibited 
aaa.82
Pharmacological inhibition of proteases 
has been widely investigated in animal 
models. most of these studies focus on 
inhibition of mmP activity. Both mmP 
inhibitors BB-9483 and doxycycline84-86 
are effective in preventing animal aaa 
formation. oral treatment (100mg/kg/day) 
or peri-aortic perfusion of doxycycline (0.75 
to 1mg/kg/day) inhibited elastase induced 
aaa in mice. overall doxycycline has been 
shown to inhibit aaa in experimental 
models in >10 studies supporting the 
potential of this approach in human aaa.3 
in a recent trial 60 patients awaiting open 
aaa repair were randomized to a control 
group or low, median or high doses of 
doxycycline (50, 100, 300mg/day) for two 
weeks. overall aaa biopsies from patients 
receiving doxycycline had reduced aortic 
wall neutrophil and Cd8+ t cell infiltration; 
reduced pro-inflammatory cytokine and 
mmP concentrations; and increased 
timP-1 and cystatin C concentrations.87,88 
doxycycline appeared to be well tolerated 
with no major adverse events reported. 
however, a previous double blinded trial of 
low dose doxycycline (100mg/d) given one 
month prior to open aaa surgery reported 
no effect of the medication on mmP or 
timP expression.89 two randomized trials 
are underway examining the effect of oral 
doxycyline on small aaa progression.
GenetiCS
Family history is a risk factor for all types 
of aortic aneurysms. up to 20% of thoracic 
aortic aneurysms are in individuals with a 
familial preponderance and the understanding 
of the genetics of aneurysms at this site is 
advancing rapidly. approximately 5% of 
thoracic aortic aneurysms occur in patients 
with well defined monogenetic connective 
tissue diseases, such as marfan syndrome 
(mainly due to mutation in fibrillin-1).90 
recently a range of further mutations have 
been identified in genes associated with 
thoracic aortic aneurysm, including tGFβ 
receptor type i and ii, myosin-11 and alpha 2 
actin, and aortic smooth muscle.90 it appears 
likely that genetic inheritance plays a more 
significant role in aneurysms which develop 
in the ascending aorta by comparison to the 
abdominal aorta. recent evidence for example 
suggests that the role of tGFβ receptor 
mutations in the development of aaas 
appears to be less clear cut than described 
for the ascending aortic aneurysms.91,92 it 
is possible that genes predisposing to aaa 
may have more comparability with those 
associated with atherosclerosis. a site on 
chromosome 9 originally identified in a 
whole genome association study for coron-
ary heart disease has now been repeatedly 
associated with aaa.17,93 Current evidence 
suggests that multiple genetic loci have a 
small effect in increasing the risk of aaa, 
depending on the exposure of patients to 
environmental or other complex risk factors, 
such as smoking, diet and other health 
behaviours. meta-analysis of current small 
studies suggest that contributing genes include 
angiotensin converting enzyme, angiotensin 
type 1 receptor, methyltetrahydofolate reduc-
tase and mmP-3.12,94
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aaa ruPture
recent elucidation of the biological pro-
cesses causing aneurysm development and 
expan sion has led to translational research 
investigating the use of novel pharmaco-
therapeutic agents aimed at retarding 
aneurysm growth. in contrast to the expansion 
of aaa, the biological processes initiating 
aortic aneurysm rupture have received little 
attention. aaas were traditionally considered 
to be a simple biomechanical problem, 
resulting from irreversible structural damage 
to the aortic wall that results in weakening, 
dilatation and eventual rupture when wall 
stress from the circulation exceeds the tensile 
strength of the wall. Focusing on aortic wall 
stress as the cause of rupture has led to a 
simplistic view that the natural history of 
aaas is regulated solely by biomechanical 
factors. Just as the complexity of the 
atherosclerotic plaque has become apparent, 
it is now recognised that rupture of an aaa 
is a multifaceted biological process involving 




in a search for a more specific clinical para-
meter than diameter alone, biomechanical 
investigations have tried to predict aneurysm 
rupture as a function of wall stress. Several 
investigators revealed that ruptured or 
symptomatic aaas had a significantly higher 
peak wall stress compared to asymptomatic 
aaas, independent of blood pressure or 
aaa diameter. in addition, these in vivo 
measurements of peak wall stress using finite 
element analysis (Fea) predicted rupture risk 
more accurately than the law of laplace. 
there are several limitations to the finite 
element analysis reported in these studies 
that assume the homogenicity of structure 
and thickness of the aortic wall and do 
not account for intraluminal thrombus. in 
a recent review mcGloughlin and doyle96 
suggest that aortic rupture cannot be 
predicted by wall stress alone and that wall 
strength is equally important. these authors 
suggest that biomechanical analysis has an 
increasing role to play in aortic research but 




ex vivo mechanical testing of healthy 
and aneurysmal abdominal aortic wall 
specimens revealed that the failure strength 
of a typical aaa wall was lower than that 
of non aneurysmal aorta. the mechanism 
for aneurysmal wall weakening is unknown 
but it seems likely that the increased local 
production of enzymes capable of degrading 
elastin and interstitial collagen alters the 
structural integrity and predisposes the aortic 
wall to weakening. the earliest experimental 
work on aaa rupture was by dobrin et al 
in 1984 who investigated the proteolytic 
effects of purified collagenase and elastase. 
treatment with collagenase caused the blood 
vessels to dilate, become more compliant and 
rupture. in contrast, treatment with elastase 
caused the vessels to dilate markedly and 
become stiffer (probably due to recruitment 
of previously unstretched collagen fibres) but 
was not related to rupture. these findings have 
fostered the notion that elastin degradation is 
a key step in the development of aneurysmal 
dilatation but that collagen degradation is 
ultimately required for aneurysm rupture. 
the pathological processes associated with 
the natural history of aneurysms to dilate and 
rupture are not well documented in clinical 
studies. Wilson et al found no significant 
differences in mmP levels in the aaa sac of 
large (>6.5cm) and medium (5-6.5cm) sized 
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aneurysms, or ruptured and non-ruptured 
aaa sac. When the same group analysed 
paired samples of aortic sac obtained from 
the anterior sac and the site of rupture in 
mmPs-8 and -9 were significantly higher at 
the site of rupture than in the anterior sac.97 
aortic rupture is therefore likely caused by 
localised elevations in proteolytic enzymes 
and focal wall weakening. this concept of 
localised ‘hot spots’ of mmP hyperactivity 
was supported by Vallabhaneni et al, who 
demonstrated marked heterogeneity of 




intraluminal thrombus (ilt) is found in 
about 75% of all aaas. Some authors have 
suggested that rupture is associated with 
growth of thrombus in the aneurysm, whilst 
there is evidence that larger aaa thrombus 
load is associated with a higher growth 
rate. acute hemorrhage seen in the mural 
thrombus of patients with ruptured aaas 
has led others to suggest that blood entering 
thrombus may have a role in rupture. there 
is some suggestion that aaas with thick ilt 
also had increased cytokine concentrations, 
greater inflammation, and lower tensile 
strength. it was postulated that ilt, by 
creating a hypoxic environment may lead 
to compensatory inflammatory response, 
increase in local proteolytic activity of the 
wall, local wall weakening and subsequent 
rupture.
investigations have demonstrated that 
the thrombus lining an aneurysm is an active 
and complex biological entity, containing 
many inflammatory cells, including macro-
phages and neutrophils. the ilt is a site of 
proteolytic enzyme release and activation, 
and it may be that mural thrombus acts as a 
source of proteolytic enzymes by aggregating 
platelets, trapping circulating cells and 
adsorbing plasma components. 
in the future it is hoped that research into 
the mechanism of aortic rupture will integrate 
biomechanical and basic science research 
pathways. there is considerable evidence 
from isolated systems that shear and wall 
stress can influence the behaviour of bio-
logical processes. understanding the inter-
action of these processes in the large aneurysm 
is key to unraveling the mechanisms of aortic 
rupture.
Future reSearCh
the understanding of mechanisms impor-
tant in aaa is expanding rapidly within 
pre-clinical models. this however has not 
currently been matched by large trials to 
examine the role of therapies targeting these 
pathways in patients. Such trials are urgently 
needed given the paucity of aneurysm 
specific medications currently available. it is 
hoped that over the next decade a number 
of agents efficacious in slowing aaa 
progression and reducing other aaa specific 
complications, such as the high rate of 
cardiovascular events in these patients will be 
identified.
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BaCKGRoUnD
abdominal aortic aneurysms (aaas) are 
present in 5 to 10% of men over the age 
of 65, and elective surgical intervention has 
long been the mainstay of treatment. there 
is widespread consensus that operative 
repair is the treatment of choice in larger 
aaas, where the risk of rupture increases 
with the size of the aneurysm. however, 
even elective operations carry a significant 
mortality risk, and the UK small aneurysm 
trial has shown that for smaller aneurysms 
(between 4 and 5.5cm) there is no difference 
in outcome between operation and no 
intervention. Currently such patients are 
treated with best medical therapy, but there 
has been considerable research into finding 
a pharmacological treatment to prevent 
aneurysm expansion and rupture.
sCReeninG pRoGRaMMes
a major obstacle to the prevention of 
mortality and morbidity associated with 
aneurysms has been the fact that the majority 
are asymptomatic, and therefore often remain 
undetected. abdominal aortic aneurysms 
have tended to present either as emergencies 
or as a result of their increasing size, and it has 
been shown that larger aneurysms grow more 
rapidly than their smaller counterparts and 
are at greater risk of rupture.3 these patients 
would therefore benefit most from operative 
repair rather than medical intervention. in 
order for a medical treatment to be of benefit, 
it needs to be targeted at aneurysms that are 
small and asymptomatic. the most obvious 
way of doing this would be the initiation of 
a mass screening programme, and indeed, 
the Multicentre aneurysm screening study 
(Mass)1 has shown that as many as 88% 
of screen-detected aneurysms are below the 
threshold for surgery.
the introduction of screening pro-
grammes will identify a large population of 
patients with small aortic aneurysms that 
are at present untreated. the concept of 
pharmacotherapy for aaas has evolved over 
the past decade, to encompass a medi cal 
treatment for aneurysms. pharmacotherapy 
aims to reduce the expansion and rupture 
rate of aortic aneurysms by modifying 
aortic wall biology. a pharmacotherapeutic 
approach might be used to reduce the 
expansion rate of small, screen detected, 
abdominal aneurysms, and therefore 
reduce the proportion of patients requir-
ing surgery. alternatively, effective drug 
treatment might be able to reduce rupture 
rates in patients with large aneurysms 
unsuitable for aneurysm repair. applications 
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to endovascular aneurysm repair have yet to 
be explored.2
pathophysioloGy
abdominal aortic aneurysms have long been 
known to be associated with increasing age, 
male gender, cigarette smoking, chronic 
lung disease, hypertension and genetic 
factors. Despite the fact that most of these 
risk factors are shared with patients with 
atherosclerosis, aneurysmal disease appears 
to be a separate entity. Diabetes is a strong 
risk factor for developing atherosclerosis 
but not for aaas. the genetic component 
of aneurysm aetiology is not fully defined 
at present, but may be due to inborn errors 
of the connective tissue matrix, such as 
mutation of the Col3a1 gene coding for 
the a chain of type 3 collagen. information 
from gene wide association studies is awaited 
to further inform the genetic basis of aaa.
the detailed pathophysiology of the 
developing and expanding aneurysm has 
been covered in Chapter 12. abdominal 
aortic aneurysms are characterised by several 
inter-related processes; degradation of the 
extracellular matrix, excessive proteolysis, 
apoptosis, oxidative stress, angiogenesis and 
widespread inflammation. 
an approach to developing a suitable 
pharmacotherapy may be considered from 
one of two perspectives. Firstly, the drug may 
be targeted to one of the specific processes 
that have been shown to influence aneurysm 
development. the second approach hinges 
on newer theories about the nature of arterial 
disease. increasingly it has been recognised 
that arterial disease is neither a matter of 
simple deranged lipid metabolism or of 
isolated local mechanical effects. the current 
belief is that arterial disease represents a 
low-grade systemic inflammation, which 
can therefore manifest itself at any point – 
coronary, carotid, aneurysmal or peripheral 
vascular disease. the oxford heart protection 
study has shown that generalised treatment 
of arteriopathic patients with statin therapy 
can reduce their chance of undergoing major 
adverse events including aaa rupture, 
regardless of their initial cholesterol level. 
the majority of agents proposed to 
alter aneurysm expansion have been tested 
in animal models of aneurysm disease, 
and consequently there has been the 
typical disconnect between findings in 
the experimental situation and application 
to clinical practice. it must be remembered 
that humans show a great redundancy of 
biological processes that suggests that any 
effective pharmacotherapeutic agent must 
have pleiotropic actions. the next section 
of this chapter will concentrate on agents 
that have been tested in – albeit small 
scale – clinical trials. the final section 
will examine novel therapeutic approaches 




hypertension has been associated with 
aaas, and investigations have shown that 
hypertension increases the development of 
aneurysms in the anidjar/Dobrin rat model. 
since beta-blockers have been used 
successfully in the treatment of hyper-
tension, it was not unreasonable to 
investigate the effect of beta-blockade on 
aneurysm expansion, as these agents have 
been shown to slow aneurysm progression 
in both experimental models and retro-
spective studies of patients with aaas. 
initially this was thought to be purely due 
to the drugs’ effects on blood pressure, but 
there is considerable evidence to support 
the theory that beta-blockers may exert any 
beneficial effects on aaas through enhancing 
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the cross linkage of elastin molecules, making 
them less prone to degradation.
a randomised clinical trial was instigated by 
the propanolol aneurysm trial investigators 
and reported in January 2002.3 548 patients 
with asymptomatic aneurysms between 3 and 
5cm in diameter were randomised to receive 
either placebo (n = 272) or propanolol 
(n = 276) and were followed for a mean of 
2.5 years. the primary criterion was the 
mean growth rate of the aneurysm. there 
was no significant difference in the growth 
rates of the two groups, although there was 
a trend towards more elective operations in 
the placebo group. there was no difference 
in death rates, but patients in the treatment 
arm of the study reported a poorer quality of 
life, and more of this group stopped taking 
their medication.
in this robust study it was clear that 
propanolol has little, if any, effect on the 
growth rate of aaas. subsequent studies of 
other beta-blockers have suggested that beta-




with considerable evidence to support the 
theory that aneurysm expansion and rupture 
are both mediated by the immune system, it 
is unsurprising that there has been interest 
in modifying this response as a means of 
attenuating growth.
in the rat elastase perfusion model of 
aaa, the effect of treating experimental 
aneurysms with powerful immunosupression 
was tested. at nine days post infusion, a 
significant difference in the diameters of 
the aortas was observed, with the control 
group having expanded to approximately 
three times their pre-infusion size, but the 
treatment groups only grew to around twice 
their original size. these findings indicate 
that, at least in this experimental model, 
preventing the infiltration of inflammatory 
cells could halt the main spurt of aneurysm 
growth. similar results were seen by Ricci 
et al when using a monoclonal antibody 
against the macrophage adhesion molecule 
CD-18.5
the one constant factor in these 
experiments on immune-modification has 
been that the compounds used have been 
unacceptable as clinical treatment strategies 
due to their wide range of action and many 
side effects. 
Non steroidal anti-inflammatories
indomethacin is a powerful anti-inflam-
matory drug that has been investigated both 
in the rodent elastase model and in human 
aortic aneurysmal tissue. indomethacin 
reduced both aneurysm growth and MMp-9 
activity in the rat and the levels of prostaglandin 
e2 (pGe-2), interleukin 1 beta (il-1β and 
interleukin 6 (il-6) in human tissue. 
in a retrospective analysis of the large 
group of patients in the UK small aneurysm 
trial, indomethacin was also shown to inhibit 
aneurysm growth in vivo.6 the trial was 
not designed for this purpose and was the 
result of sub-group analysis, so further trials 
would be required. there is preliminary 
evidence that non-selective CoX inhibition 
by indomethacin prevents aneurysm growth, 
but the side effects of this treatment on the 
gastrointestinal, renal and hepatic systems 
are well known. 
Matrix metalloproteinase (MMP) 
inhibition
Many observers have noted an imbalance 
between MMps and their naturally occurring 
inhibitors (tiMps) in aortic disease, and 
one of the modes of action of indomethacin 
is to reduce the activity of matrix 
metalloproteinases. Many other compounds 
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have also been investigated for their anti-
MMp properties and most have been 
effective in the experimental setting.
tetracyclines have long been known 
to prevent connective tissue breakdown 
by their inhibitory effect on MMps 
and several experimental studies have 
suggested that doxycycline reduced the 
growth of degenerative aneurysms and 
suppressed MMp-9 production in the 
rat elastase model. in a clinical trial, 
preoperative treatment with doxycycline 
caused a reduction in both the expression 
of macrophage MMp-9 mRna and the 
activity of MMp-2 in aneurysm tissue.7 
also, a small double-blinded, randomised 
and placebo controlled pilot study from 
Finland has shown that treatment with 
doxycycline for a three month period 
significantly reduced the rate of aneurysm 
growth in a cohort of patients as measured 
by serial ultrasound scans.8 at six months, 
there was also a significant reduction in 
the serum C-reactive protein levels of the 
treatment group. although the sample size 
was small and preoperative confounding 
effects are not taken into consideration, 
this trial has provided evidence to support 
further research into this area. in recent 
years a clinical trial has demonstrated 
that administration of doxycycline can 
produce a profound but selective effect 
on vascular inflammation that reduces 
aortic wall neutrophil and cytotoxic t-cell 
content.9 additionally a clinical trial of 
doxycycline after endovascular aneurysm 
repair demonstrated that patients treated 
with doxycycline exhibited greater 
decreases in maximum aortic diameter and 
significantly reduced aortic neck dilatation 
at 6 months.10 large-scale clinical trials of 
this agent appear warranted.
Anti-chlamydial therapy
the hypothesis that atherosclerosis may 
have an infective aetiology is not new, and 
it is clear that aaas and atherosclerosis 
share some of the same risk factors. these 
associations were the rationale for clinical 
trials of anti-chlamydial therapy for aaa.
one RCt examined the effect of 
roxithromycin on aneurysm growth.11 
patients with small aneurysms were given 
either roxithromycin or placebo for four 
weeks, and subsequently followed up for a 
mean of 1.5 years. once adjustments had 
been made for smoking, blood pressure and 
iga, there was a significant difference in 
aneurysm growth between treatment and 
placebo groups.
DRUGs aCtinG on the Renin/
anGiotensin aXis
in 1998 a French group reported the effects 
of angiotensin converting enzyme (aCe) 
inhibitors and angiotensin ii antagonists 
in a strain of rat prone to rupture of the 
internal elastic lamina of the aorta. to 
ensure any beneficial effects were not due to 
the antihypertensive properties of the drugs, 
they were compared to hydralazine and two 
calcium channel antagonists. Both aCe 
inhibitor and angiotensin ii antagonists 
prevented rupture of the internal elastic 
lamina, suggesting this was due to the effect 
on angiotensin ii and not on another part of 
the renin/angiotensin system. 
in recent years there has been some 
intriguing, and contrasting clinical evidence 
regarding aCe inhibition in aaa. a Canadian 
group using epidemiological methodology 
reported that patients who received aCe 
inhibitors before admission to hospital 
were significantly less likely to present with 
ruptured aneurysm (odds ratio 0.82) than 
those who did not receive aCe inhibitors.12 
Pharmacological Treatment of Aneurysms 251
similar associations were not observed for 
beta blockers, calcium channel blockers or 
angiotensin receptor blockers. Conversely, 
analysis of patients taking aCe inhibitors in 
the UK small aneurysm trial demonstrated 
that these patients had enhanced aneurysm 
growth.13 a clinical trial is underway in the 
UK to define the action of aCe inhibitors in 
aaa expansion.
hMG Co-a ReDUCtase 
inhiBitoRs
the hMG Co-a reductase inhibitors 
(statins) are a group of drugs in which there 
has been considerable interest recently. the 
statins have been used successfully for their 
lipid-lowering properties for some time now, 
but have also exhibited beneficial effects 
in cardiovascular disease unrelated to this. 
in laboratory experiments, statins have 
been proven to reduce MMp-9 expression 
by human macrophages, and their anti-
inflammatory effects are well documented. 
their pleiotropic actions are well suited to 
target aneurysm expansion and experimental 
effects are encouraging in reducing aortic 
inflammation and proteolysis.14,15
a small scale clinical trial of statin therapy 
in aaa demonstrated a reduced expansion 
rate in the treatment group16 and a recent 
systematic review and meta-analysis suggested 
that there is evidence to suggest that statins 
reduce aneurysm growth.4 however, aside 
from aneurysm expansion, there is now 
overwhelming evidence that patients with 
aneurysms and peripheral vascular disease 
derive benefit from statins with regard to 
cardiovascular death and outcome following 
surgery.17 in this regard all patients with 
aortic aneurysms should be on statin therapy 
if tolerated.
the FUtURe – Data FRoM 
ReCent eXpeRiMental 
stUDies
Recent experimental data have suggested 
some possible significant advances in 
pharmacotherapy for aaa. a recent study 
by satoh et al18 demonstrated the significant 
role that oxidative stress plays in the 
development of experimental aneurysms. 
this study revealed that angiotensin ii, 
through induction of reactive oxygen species, 
induces cyclophilin a in smooth muscle 
cells which then stimulates recruitment of 
inflammatory cells, activation of MMps and 
production of reactive oxygen species. these 
factors then initiate the biological events 
responsible for aneurysm formation. this 
study and subsequent commentaries have 
illustrated the importance of oxidative stress 
in aneurysm formation and suggest a target 
for pharmacotherapy.
perhaps the most significant new 
studies in aneurysm biology over the last 
few years have been those investigating the 
effect of inhibiting signalling pathways. 
as stated previously, aneurysms form by 
multiple pathways in the milieu of extensive 
biological redundancy. two recent reports 
using inhibition of signalling pathways 
(JnK and nFκB) have reported that 
inhibition of crucial signalling mechanisms 
can actually result in regression of established 
experimental aneurysms.19,20 these 
results clearly represent a paradigm shift in 
aneurysm pharmacotherapy and offer the 
potential goal of aneurysm regression. the 
inhibitors used would not be safe in clinical 
use but recently, drugs with the potential 
to inhibit signalling pathways have been 
investigated experimentally. Rosiglitazone – 
a drug used extensively in diabetic control 
– has the ability to inhibit JnK and MapK 
and has been effective in reducing aneurysm 
formation in the experimental setting.21 
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Clearly the goal over the next few years will 
be to discover drugs with the potential ability 
to regress established aneurysms.
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introDUction
thoracic aortic dissection (taD) is the 
most common aortic catastrophe, occurring 
in approximately 5 to 30 cases per 1 million 
persons per year.1 it carries a significant 
morbidity and mortality risk, with 21% of 
patients dying prior to hospital admission.2 
recent improvements in the understanding 
of both the molecular biology and genetics 
of vascular disease has led to greater clarity 
of the pathogenesis of acute taD and 
a number of associated diseases of the 
thoracic aorta. Since the initiation of the 
international registry of aortic Dissection 
(iraD)3 in 1996 there has been an evolution 
of terminology in relation to taD, and 
the more encompassing term acute aortic 
syndrome (aaS) is now utilised to include 
taD and a number of other pathologies 
including intramural haematoma (iMH) 
and penetrating aortic ulcer (PaU). 
in broad terms this classification reflects 
recent advances in understanding in rela-
tion to the pathology and natural history of 
taD, and the recognition that taD is part 
of a spectrum of thoracic aortic pathology. 
these individual processes will be discussed 
separately along with some of the underlying 




the formation of blood vessels occurs 
between the third and eighth week of 
embryological development. the ventral 
aortas fuse into the endocardial tube and 
circulate blood by the end of the third week. 
During this process a series of mesenchymal 
clefts lined by what will become endothelium 
fuse and form two pairs of longitudinal 
channels – one medial and one lateral. the 
medial channels form the primitive aortas 
which with elongation and folding of the 
embryo become paired into ventral and 
dorsal arrangements, joining the cephalad 
end of the primitive heart tubes (formed by 
the ventral components). Five further pairs 
of arterial arches pass around the developing 
pharynx connecting the cephalad end of the 
heart to the remaining unfused dorsal aortas. 
these branchial arch arteries in pairs form 
a number of components of the definitive 
circulation as outlined below. the paired 
aortas fuse over much of their length around 
the end of the fourth week and give a number 
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of intersegmental branches in dorsal, lateral 
and ventral patterns. During weeks 5–7 
there is a significant evolution in pattern or, 
in particular the cephalad arches regressing 
and new caudad arches forming.
the aortic arches are part of this cepha-
lad to caudal progression, with six initial 
sets of arches regressing in a step-wise fash-
ion starting around weeks four to five. the 
first, second, and fifth arches regress and are 
largely gone by the start of week five hav-
ing contributed to the formation of parts of 
the maxillary and external carotid circulation 
(1st), the stapedial arteries (2nd) and a pair 
of early regressing rudimentary vessels from 
the 5th. above the level of the 3rd arch the 
dorsal aortas remain fused and commun-
icate with the 3rd arch to form the definitive 
internal carotid artery. the common carotid 
artery is formed by the proximal parts of the 
3rd arch (hence it is also referred to as 
the carotid arch). the remaining proximal 
external carotid artery arises as new growths 
of artery from the aortic sac and are not part 
of the arches per se, but migrate up the third 
arch to their final position.
of particular relevance to the thoracic 
aorta, the 4th arches both persist, the left as 
the aortic arch and the right as the root of 
the right subclavian artery. the subclavian 
arteries initially arise as outgrowths of the 
terminal paired aortas just proximal to their 
union and subsequently the resorption of the 
right aorta between the origin of the sub-
clavian and the fused trunk causes the right 
subclavian to be isolated. 
the sixth arches fuse with the devel-
oping pulmonary arteries, the right partly 
regressing and partly forming the pulmon-
ary artery with the left becoming the ductus 
arteriosus.
there is also a concurrent change in 
cardiac anatomy at this time with the heart 
separating into its left and right sides (aortic 
and pulmonary).
there is an excellent demonstration of 
these embryological changes in Valentine 
and Wind4 and a discussion of the most 
prevalent anomalies in a paper by kau 
et al.5 conceptually this may give some 
understanding of why different segments of 
the aorta behave in different ways, and what 
the influences of the embryological deriva-
tion may be on the likelihood of differing 
pathologies in each segment. the embry-
onic origin of the vascular smooth muscle 
cells (VSMc) at differing levels of the aorta 
varies, with the predominant origin being 
neurectoderm in the thoracic aorta, versus 
mesoderm in the abdominal aorta.6 
this difference in origin influences the 
response of VSMc’s to a number of media-
tors such as transforming Growth Factor 
Beta 1 (tGFβ1), an important modulator 
of the extracellular matrix (EcM) in the 
thoracic aorta. neurectodermal VSMc 
growth is potentiated by tGFβ1, as is col-
lagen i production. this is in comparison to 
mesodermal VSMc’s where tGFβ1 inhibits 
growth and has no influence on collagen 
deposition. Given that VSMc’s are influen-
tial in aortic strength, it would be expected 
that varying concentration of VSMc’s and 
differential response to tGFβ1 and haemo-
dynamic strain in the aorta would influence 
the sites of EcM degradation and hence 
likelihood of aortic pathology such as dis-
section and/or aneurysm.7 there is some 
evidence that VSMc’s in the abdominal 
aorta under cyclical haemodynamic stress 
secrete tGFβ1, leading to an increase in 
aortic wall mass (however not in the thoracic 
aorta).6
there is also a differential pattern of elas-
tic lamellar units (the functional elastic unit 
in the aorta – combining elastin lamellae 
and VSMc’s) through the aorta, with higher 
levels of elastic lamella and VSMc’s in the 
thoracic aorta than in the abdominal. 
Similarly there is a decrease in the elastin to 
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collagen ratio in the abdominal aorta com-
pared to the thoracic aorta.6 it is interesting 
to note that acardiac foetesus do not develop 
differential structure throughout the length 
of the aorta, suggesting that there is a sig-
nificant influence of haemodynamic cyclical 
strain on the secretion of mediators such as 
tGFβ1 and hence architecture. 
Haemodynamics of Thoracic 
Compared to Abdominal Aorta
there is convincing evidence to suggest 
that dissection flaps occur at the points in 
the aorta subject to the greatest fluctuations 
in pressure over time. Due to the torsional 
manner in which the heart contracts, and 
the physical effects of cardiac motion on 
the arch of the aorta, the areas subject 
to the greatest changes in pressure are 
the ascending aorta and the proximal 
descending aorta. this was demonstrated 
elegantly in a model created by Qiao et al 
based on a thoracic aortic aneurysm.8 this 
model demonstrated differential shear and 
flow at varying points in the thoracic aorta, 
particularly the outer curves of the ascending 
and proximal descending aorta. there were 
also areas of increased transit/contact time 
on the concavity of the arch and proximal 
descending aorta (along with branch vessel 
origins in the arch) which as an aside may 
be the reason for the preponderance of 
atherosclerotic change at these points. 
the alterations in elastic recoil ability and 
collagen concentrations and function in the 
aorta that are present in a number of aortic 
pathologies, combined with the magnitude 
of the force involved in blood flow (related 
to absolute blood pressure, pulse pressure 
and dP/dt) results in the most likely sites 
of dissection being where the physical forces 
on the aorta are greatest and the diminu-
tion in aortic strength is maximal. there is 
reasonable evidence that suggests that VSMc 
apoptosis (which is influenced by tGFβ1) 
is greatest at the convexities of the ascend-
ing and descending aorta – particularly in 
patients with bicuspid aortic valves, and that 
this may alter aortic strength at these sites,7 
predisposing to dissection or aneurysm at 
these sites.
Sizes of Normal Aorta
there is an excellent outline of both the 
normal sizes of the thoracic aorta at differing 
ages, allowing a basis for sizing in different 
pathologies, in the European Society of 
cardiology task Force document.9 
claSSiFication oF aortic 
SynDroMES
the acute aortic syndromes can be classified 
in a number of ways, included chronicity, and 
anatomy and on the basis of the underlying 
pathology and complications.
Acute/Chronic
acute dissections are those present for less 




the DeBakey classification system separates 
taD into three types, with subtypes of 
type 3. initially described by De Bakey 
and colleagues in 1965,11 this classification 
is based on both the anatomy of the entry 
tear and the extent of the dissection. it 
is an anatomical classification and has 
been simplified on the basis of outcome 
measures and prognosis into the Stanford 
classification.
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Stanford Classification
the Stanford classification arose from 
the recognition that prognosis was largely 
dependant on the involvement or not of the 
ascending aorta in the dissection process and 
was published by Dailey and colleagues in 
1970.12 the De Bakey classification was thus 
simplified into two subclasses, type a and B 
depending on involvement of the ascending 
aorta. although the Stanford classification has 
allowed stratification into surgical treatment 
or conservative management groups, it 
fails to take into account the variations 
of thoracic aortic pathology that are now 
recognised to make up what is referred to 
as the acute aortic Syndrome. a review of 
recent literature proposed a more complex 
but inclusive classification which has been 
adopted by the European task Force on 
aortic Dissection.9
European Task Force
in 1999 Svensson et al13 published a 
classification of thoracic aortic pathology 
that included not only classical taD but 
also a number of newly recognised subtype 
pathologies that were felt to make up part 
of the continuum of aortic dissection. 
this system should be considered a 
subclassification to the Stanford and/or 
Debakey classifications. this classification is 
outlined in Figure 14.2.
PatHoGEnESiS oF tHoracic 
aortic DiSSEction
Hypertension is recognised as one of the 
most significant risk factors for thoracic 
aortic dissection, and the treatment regimes 
for acute dissection syndromes utilise anti-
hypertensive therapy as their mainstay. 
Table 14.1: DeBakey Classification of Class I Dissection
Type Tear extent
I Ascending Aorta Propagating up ascending aorta, across arch and 
through descending aorta
II Ascending Aorta Confined to ascending aorta/intrapericardial aorta
III Distal to the Left Subclavian 
Artery
Descending aorta +/- retrograde across arch
Subtype IIIa Confined to descending aorta above diaphragm
Subtype IIIb Extends through diaphragm into visceral or 
abdominal aorta
Table 14.2: Relationship between Stanford and DeBakey classification of class I 
dissection
Stanford Type De bakey equivalent Site of Involvement
A Type I and II Ascending aorta +/- Arch
B Type III Descending thoracic aorta distal to left subclavian 
artery
Subtype a and b Above or below diaphragm, similar to DeBakey
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FIgure 14.1: Diagramatic representation of aortic dissection class 1 divided into De Bakey and Stanford 
Classifications. Based on figure 4 from Erbel et al. 2001.
FIgure 14.2: Classes of aortic dissection. Class 1- Classical Aortic Dissection (Intimal flap between true and 
false lumen); Class 2 – Intramural haematoma (Medial disruption with formation of IMH); Class 3 – Discrete/
Subtle dissection without haematoma. Eccentric bulge at tear site; Class 4 – Penetrating Aortic Ulcer (Plaque 
rupture leading to aortic ulceration, or a classical penetrating aortic ulcer with surrounding haematoma. Usually 
sub-adventitial); Class 5 – Iatrogenic and Traumatic Dissection. Based on figure 5 from Erbel et al. 20019 and 
Svensson et al. 1999.13
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there is good evidence that suggests that 
aggressive blood pressure management 
reduces mortality, particularly the use of beta 
blockers. there is also evolving evidence that 
a number of the newer antihypertensives 
such as losartan, which exerts some effect on 
mediators such as tGFβ1, may have extra 
effects on the turnover of thoracic aortic 
EcM, and may reduce the risk of both 
dissection and aneurysmal degeneration in 
some of the connective tissue disorders. 
Smoking and hypercholesterolaemia 
have deleterious effects on the thoracic aorta 
and the catecholamine drive that is present 
in chronic tobacco use may exacerbate dis-
sections and increase the risk of aneurysm 
disease.
cocaine use is recognised as a risk factor 
for the development of the aaS, in particular 
in young african american males. ampheta-
mines similarly have a linkage with develop-
ment of taD, presumably for similar reasons 
to cocaine, with surges in catecholamines 
and concomitant acute rises in dP/dt and 
blood pressure in the aorta.15,16
Classical Thoracic Aortic Dissection 
(Class 1 Dissection)
the pathognomonic lesion in aortic 
dissection is a tear in the intima which allows 
pulsatile surging of blood into the intimo-
medial plane of the aorta. typically the entry 
site is transverse but not involving the whole 
Table 14.3: Summary of aortic dissection classification systems
Stanford Classification
Type A Dissection of the ascending and descending aorta
Type B Dissection of the descending aorta
De Bakey Classification
Type 1 Dissection of the entire aorta
Type 2 Dissection of the ascending aorta
Type 3 Dissection of the descending aorta
New Classification
Class 1 Classical aortic dissection with an intimal flap between true and false lumen
Class 2 Medial disruption with formation of intramural haematoma/haemorrhage
Class 3 Discrete/subtle dissection without haematoma, eccentric bulge at tear site
Class 4 Plaque rupture leading to aortic ulceration, penetrating aortic atherosclerotic ulcer 
with surrounding haematoma, usually subadventitial
Class 5 Iatrogenic and traumatic dissection
Class 1–5 Represent a subdivision to the Stanford or De Bakey classification
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circumference of the aorta. it usually extends 
down the left posterolateral plane of the 
aorta, in a spiral fashion.10 these dissections 
may have communication between the false 
and true lumen, with intimal flap tears being 
present in >70% of cases at autopsy.9 in a 
series of sudden deaths however, fenestrations 
were absent in 67% of cases.
Flow in the false lumen is usually ante-
grade but occurs retrograde in a small number 
of cases. Differences in the elasticity of the 
dissection flap and the aortic adventitia, and 
the increase in pressure in the false lumen 
predispose to collapse of the true lumen, with 
higher frequency of true lumen compression 
in non-fenestrated aortic dissection.
in 65% of cases of dissection, intimal 
tears occur in the ascending aorta, 20% in the 
descending and 10% in the arch, with 5% in 
the abdominal aorta.10 there is a male:female 
ratio of 5:1 with a peak incidence of 
50–60 years for proximal dissections, and 
60–70yrs for distal dissection.10
there has been no particular success in 
defining the anatomical features of particular 
aortas that make them prone to dissection 
and long-term sequelae, despite analysis of 
multiple factors including tear depth and 




intramural haematoma (iMH) otherwise 
known as class 2 aortic dissection is a less 
common precursor or variant form of taD. 
it comprises approximately 6–10% of all 
acute aortic syndromes. approximately 
10–30% of patients presenting with 
symptoms consistent with taD may have 
iMH on imaging.9 occurring in greater 
prevalence in asian populations, it makes up 
30–40% of aaS in asian series. Defined as 
a bleed into the outer layers of aortic media 
that lacks a discrete or detectable entry 
tear, it is usually seen on ct as a crescent 
shaped or concentric thickening of aortic 
wall. it may involve a longer segment of 
aorta than classical dissection. it appears as 
a ‘dissection without intimal tear’, and was 
previously described as such – however it 
is now recognised that there may be small 
atherosclerotic plaque ruptures in the wall 
of the vessel that are related to the proximal 
extent of the iMH.18 there has been some 
suggestion that there may be focal rupture of 
vasa vasorum in the aortic wall which causes 
iMH, however with the advent of newer 
multidetector ct arrays, previously invisible 
intimal defects are now being recognised. 
this has lead to the proposition that a 
ruptured vasa vasorum leads to increased 
focal transmural pressure and consequent 
‘retrograde’ rupture of a pre-existing aortic 
plaque and intimal disruption.19
two subtypes of iMH/class 2 dis-
section are recognized.9 the features of the 
two subtypes of iMH are summarized in 
table 14.4. 
 iMH seems to be associated with a lower 
risk of malperfusion syndromes than classical 
taD, although complications are common. 
Between 28–47% of cases of iMH progress 
to overt false luminal dissection. Early 
aneurysm formation or contained rupture 
develops in 20–45% of patients.14 there is 
considerable crossover between these groups 
Spontaneous regression is seen in approxi-
mately 10% of patients.9 
Predictors of progression to taD include 
recurrent/persisting pain, and presence of 
PaU. Some iMH may improve spontan-
eously with medical management only 
(particularly in asian series). younger ages, 
smaller aortic diameter (<4-4.5cm) and 
thinner haematoma (<1cm) confer better 
prognosis9,20 and may allow conservative/
non operative treatment with close obser-
vation. in one series, a 30-fold increase in 
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progression to rupture was demonstrated if 
the aortic diameter was greater than 40mm. 
Wall thickness >1cm was associated with a 
nine-fold risk of progression.21
location of iMH is also prognostic – 
ascending aorta has a high risk of progression 
to frank dissection and usually mandates 
repair. Exceptions to this seem to be Japan-
ese and korean series where there is a more 
benign course with type a iMH treated with 
BP control, bed rest and serial imaging.18 
Given recent advances in understanding 
of the contribution of genetic influences to 
MMP concentrations, elastin and collagen 
turnover and risk of syndromal aaS, it may 
be that the genotypic differences between 
asian and European groups explains the 
differences in prognosis, progression and 
prevalence in iMH. 
Penetrating Aortic Ulcer  
(Class 4 Aortic Dissection)
Pentrating aortic ulcer (PaU) was first de-
scribed in 1934 by Shennan and then sub-
sequently further characterized by Stanson 
et al in 1986. this condition can be defined 
as ulceration of an aortic atherosclerotic 
plaque penetrating through the internal 
elastic lamina into the aortic media. it is also 
classified as class 4 aortic Dissection.9
PaU comprises around 2.3–7.6% of 
acute aortic syndromes but in a series of 
15 patients, 40% (n = 6) suffered aortic rup-
ture, compared to a rate of 7.3% for type a 
dissection and <4% for type B, hence it is 
a morbid pathology when present.22 it also 
appears that for a given aortic diameter the 
presence of PaU confers a worse prognosis 
than for classical or class 1 taD.22 
PaU tends to occur in patients with 
extensive aortic atherosclerotic disease and 
in an older population than those affected 
by class 1 dissection (a mean age of 77 years 
versus 54 for type a dissection and 67 
for type B).22 it appears that the patho-
logical lesion (haemorrhage into/through an 
atherosclerotic plaque) is limited in its extent 
around the aorta by the transmural inflam-
mation of extensive surrounding atheroscle-
rosis. Penetration through, and dissection 
towards the adventitia can occur in the set-
ting of medial penetration of the localised 
plaque haemorrhage. 
Both iMH and PaU are recognised to be 
endpoints of a degenerative aortic pathology, 
Table 14.4: Subtypes of IMH
IMH Type 1 IMH Type II
Wall thickness ≤0.5cm 0.6 – 4.0cm (median >1.3cm)
Vessel diameter <3.5cm >3.5cm
Mean length in IMH <11cm >11cm
Presence of flow in IMH on 
echocardiography
Less common Common
Association with calcified 
plaque
Not usually associated Commonly associated
Intimal appearance Smooth Rough / Atherosclerotic
Echocardiographic  
appearances
Echo free zones present <30% Echo free zones present >70%
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and largely occur in the descending thoracic 
aorta. in one series,23 90% of iMH and PaU 
were confined to the descending aorta.
although such focal pathology as iMH 
and PaU seems ideally suited to treatment 
by endovascular means, it is probable that 
most patients in these groups with pathol-
ogy in the descending aorta do not require 
intervention, unless they fulfil criteria that 
would categorise them in a treatment group 
for classical taD (rupture/aneurysm etc). 
the presence of aneurysmal dilatation is a 
strong predictor of the requirement for inter-
vention in the future.




Visceral ischaemia is one of the most 
significant and catastrophic consequences 
of taD. in broad terms two main 
pathophysiological mechanisms of ischaemia 
have been described. 
the first is a classical proximal entry tear 
in the absence of a distal fenestration. this 
leads to rapid and significant increases in 
mean false luminal pressure, leading to com-
pression of the true lumen leading to distal 
ischaemia. in the context of considering 
treatment options, this pressure differential 
explains why the use of a bare stent alone 
in treating the entry tear is unlikely to suc-
ceed. it is unlikely that a bare stent would 
be able to compress the highly pressurised 
false lumen enough to divert flow without 
surpassing aortic rupture pressure.
a second pattern is where there is a distal 
fenestration present with relatively equiva-
lent luminal pressures. this situation has a 
reduced risk of distal ischaemia as flow is not 
compromised, however an extension into a 
visceral vessel can cause branch ischaemia 
in one of two ways. these are described as 
either fixed or dynamic branch ischaemia. 
Fixed occlusion is caused by false luminal 
thrombus or pressurisation leading to a 
fixed impingement of the ostia. Dynamic 
occlusion occurs in the presence of a flap 
which acts as a floating valve across the 
ostia, particularly where there is differential 
pressurisation. 
it is worthwhile remembering that 
aortic branch occlusion and malperfusion 
syndrome are not totally synonymous, given 
that partial or dynamic branch occlusion 
may not lead to significant end-organ ischae-
mia. there is some evidence that in recent 
times survival outcomes of branch occlusion 
and malperfusion syndromes have signifi-
cantly improved in comparison to previous 
data from 1965–1985.10 there is also good 
evidence to support mesenteric revascularisa-
tion prior to ascending aortic repair in par-
ticular, with improvements in mortality from 
87% to 37% over time. 
ischaemic complications are present in 
up to 30% of cases of type B dissection.10 
rupture is less common but occurs in >20% 
of cases over the patient’s lifespan. recent 
literature still suggests 16–25% mortality in 
the patient group suffering ischaemic com-
plications.17 iraD has demonstrated an 
overall mortality of 27.4% for all types of 
dissection, with mortality in distal dissections 
in the uncomplicated medical therapy cohort 
being 10.7%, rising to 31% in the complic-
ated cohort. Malperfusion syndromes occur 
in 30–42% of dissection patients.10 Spinal 
cord ischaemia is relatively rare as a complic-
ation of taD but is still present in 2–3% of 
type B dissections at presentation.10 
Fate of the False Lumen
False lumen thrombosis occurs in 2–3% 
of medically managed patients, however 
even with surgical treatment distal false 
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lumen thrombosis only occurs in 15–30% 
of treated patients. this has implications 
for recurrent dissection and aneurysmal 
degeneration, with progression to aneurysm 
formation occurring in 30–50% of patients 
within 4 years of diagnosis of the initial 
dissection.10 long-term data show that aortic 
death is the ultimate outcome in 30–40% 
of patients with medically treated dissection, 
despite reasonable rates of early mortality 
with aggressive medical therapy.17
Aneurysmal Degeneration and 
Rupture
as outlined above, aneurysmal degeneration 
and rupture is one of the potential 
consequences of aaS. in medically managed 
patients who survive their intitial dissection 
event, 25–40% will continue onwards to 
develop aneurysmal dilatation. out of this 
group 10–20% will rupture.10 Degenerative 
disease rates in iMH are as high as 45%, 
with either contained rupture or aneurysm 
formation.18 Similarly PaU rupture or 
aneurysm rates are in the region of 40% – 
with variable reports of severity/mortality 
risk. as discussed earlier, predictors of 
worse outcomes in iMH patients are initial 
aortic diameter above 4cm, and aortic wall 
thickness >1cm. these features conferred a 
30-fold and 9-fold increase in progression 
to aneurysm and rupture respectively.10 
the prognostic features for development 
of aneurysmal degeneration include aortic 
size >4cm, persistent hypertension despite 
medical therapy, and persistent patency 
of the false lumen. interestingly the recent 
data from iraD also suggests a significant 
increase in 3 year mortality in the group 
with partial thrombosis of the false lumen – 
a relative risk of 2.69, with a 3 year mortality 
rate of 31.6%.14
connEctiVE tiSSUE 
DiSorDErS anD acUtE aortic 
SynDroMES
Heritable disorders such as Marfan’s 
Syndrome (MFS), Ehlers-Danlos Syndrome 
(EDS) and loeys-Dietz Syndrome (lDS) 
are well-recognised predisposing causes for 
taD, however in large series only contribute 
14–22% of dissections.1 their presence 
predisposes patients to early dissection 
and aneurysm formation compared to the 
atherosclerotic cohort, and identification of 
these patients early in life allows targeted 
medical therapy, surveillance and early 
intervention as appropriate to prevent 
rupture and its associated mortality.
Marfan Syndrome 
initially described by antoine-Bernard 
Marfan in 1896 as a constellation of skeletal 
manifestations, Marfan Syndrome (MFS) has 
subsequently been more clearly codified into 
a recognised set of cardiovascular, skeletal 
and ocular findings. Marfan syndrome is 
responsible for approximately 5% of all 
aortic dissections and is the most common 
cause of dissection in patients under 40 years 
of age.
the classification of the syndrome was 
initially described in the Berlin nosology 
(1986) but due to advances in molecular 
biology and further understanding of the 
disease and its sub-types, there was a new 
nosology developed in 1996 – the Ghent 
nosology. this has recently been revised and 
was published in 2010.24 this allows some 
differentiation from previously overlapping 
syndromes such as the Mitral Valve Prolapse 
Syndrome (MVPS) and the MaSS (Myopia, 
Mitral Valve Prolapse, non-progressive 
aortic root Dilatation, skeletal findings and 
striae), and also further differentiation from 
some of the more recently described overlap 
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syndromes such as loeys-Deitz Syndrome. 
these other syndromes do not all carry the 
same vascular implications as MFS. Unfor-
tunately in the past the laxity of diagnostic 
criteria meant that many people had the 
diagnosis of MFS applied, when in actuality 
their vascular mortality was lower than that 
of MFS. 
the previously identified genetic basis 
of MFS is a mutation in the gene coding 
for fibrillin 1– a cysteine-rich glycoprotein 
important in the manufacture of connective 
tissues. in the aorta, fibrillin 1 is prevalent in 
the aortic adventitia, and to a lesser degree 
in the media where fibrillin 2, a similar but 
functionally different protein, is more preva-
lent.25 the anatomic abnormalities in the 
MFS aorta are those of ‘cystic medial degen-
eration’ – loss of VSMc numbers, increased 
collagen content and elastic fiber disarray.7 
the current diagnostic criteria include 
a series of major and minor criteria. Major 
criteria include aortic root dilatation/ 
dissection, Ectopia lentis, >= 4 particular 
skeletal manifestations and dural ectasia as 
defining characteristics, and the presence 
of the fibrillin 1 mutation as a component of 
diagnosis when these are not clear. in index 
patients the diagnosis must involve major 
involvement in at least two organ systems and 
minor involvement in one more. in the pres-
ence of a fibrillin 1 mutation that is known to 
cause the MFS, or when there has previously 
been a first degree relative with MFS based 
on the Ghent nosology – there need be only 
one major and one minor manifestation in 
different organ systems. the presence of the 
fibrillin1 mutation is now given more weight 
in light of the increased ease of detection. 
the 2010 Ghent nosology has been 
developed based on a more evidence-based 
approach, and in a more patient centric 
fashion with an alteration in the weighting 
of different criteria and development of more 
meaningful diagnostic thresholds. 
cardinal features such as aortic root 
dilatation and ectopia lentis are now given 
more weight, and in combination can be 
diagnostic. other systemic manifestations (in 
other organ systems) contribute to an overall 
systemic risk score that assists in diagnosis. 
MFS has variable time of onset, tissue 
distribution and severity of clinical manifesta-
tion, even in patients with identical fibrillin 
gene mutation.
of interest in MFS, levels of proteases 
such as MMP-9 are actually quite low, par-
ticularly in comparison to aaa phenotypes, 
and there is some suggestion that MFS-
related dissection and aneurysm are not as 
strongly influenced by proteases as had pre-
viously been thought.6 
Fibrillin and Marfan Syndrome
Fibrillin1 is a fundamental component of 
the vascular EcM. Fibrillin-rich microfibrils 
play a significant role in linking vascular 
SMc to adjacent elastin fibrils. they are 
thought to regulate tissue development and 
turnover of elastin, and are a template for the 
construction of elastin microfibrils.6 
the FBn-1 gene is a large gene on the 
q arm of chromosome 15 at position 21.1. 
the description of this location is 15q21.1. 
it is closely associated with the gene for 
tGFβ1. there are more than 600 described 
mutations in the FBn-1 gene that can cause 
MFS with varying degrees of penetrance. the 
majority (around 2/3) of fibrillin 1 muta-
tions are missense mutations that alter one 
amino acid out of the 2871 that make up the 
protein. approximately 20% are frameshift 
mutations, and 12% are side splice muta-
tions. around 25% of the presentations of 
MFS have a new and previously unidentified 
mutation in the fibrillin 1 gene.25
it was previously felt that the abnormality 
of the fibrillin1 gene led to structural abnor-
malities in EcM and elastin through fibril-
lin 1 weakness which were the cause of the 
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aneurysmal degeneration seen in MFS. this 
rather simplistic concept has been partly 
refuted, particularly in light of syndromes 
such as Williams-Beuren syndrome where a 
microdeletion of the elastin gene is actually 
characterised by aortic stenosis rather than 
aneurysm and dissection.6 it is now pos-
tulated that there is both a structural and a 
signalling component to the pathophysiol-
ogy. this has led to a change in the defini-
tion of Marfan’s from a purely connective 
tissue disorder to a developmental abnor-
mality with effects on the development and 
morphogenesis of multiple organ systems.
there is some evidence from mouse 
knockout models that underexpression of 
the fibrillin 1 gene results in increased MMP 
expression and elastin fragmentation, leading 
to reduced structural integrity of the aorta.26 
there is also upregulation of MMPs when 
mutated fibrillin 1 (which is more prone to 
proteolysis) undergoes degradation. there is 
similarly an increase in macrophage numbers 
in the setting of elevated concentrations of 
fibrillin 1 fragments.6 there is some evidence 
of a degree of a threshold phenomenon for 
the deterioration in vessel structure in rela-
tion to proportional amounts of normal and 
abnormal fibrillin 1 microfibrils. 
one of the proposed mechanisms by 
which fibrillin 1 mutation causes loss of 
tissue integrity is the documented impact 
of abnormal fibrillin 1 on the action of 
normal fibrillin-1 in the formation of micro-
fibrils. this is a case of a heterozygote dis-
order where there is a dominant-negative 
pattern of activity caused by the mutated 
gene product.6,27 
Fibrillin 1 gene mutations on their own 
(ie in absence of Marfan’s) that result in 
decreased fibrillin1 gene expression have 
also been linked to thoracic aortic aneurysm 
(taa) and taD. a reduction in fibrillin 1 
abundance, but with normal protein struc-
ture may lead to similar but less severe 
 phenotype to Marfan’s that is restricted to 
the vascular system.26 Similarly there appears 
to be a relationship between fibrillin 1 muta-
tion and upregulation of tGFβ1 signalling 
pathways. this may be because of structural 
and functional similarities between latent 
tGFβ1 binding protein (ltBP) and fibril-
lin 1 and the possibility that abnormalities 
in the fibrillin 1 gene cause decreased affinity 
for tGFβ1 in ltBP – hence releasing greater 
amounts of tGFβ1 to increase signalling 
of tGFβ1 and therefore increase VSMc 
apoptosis.6 
Given the large number of unique muta-
tions, genotypic/phenotypic correlations are 
difficult. there are also additions to the 
fibrillin 1 gene which can cause the related 
phenotypic abnormality that is MaSS. the 
recently described interplay between fibril-
lin 1 and tGFβ has similarly provided new 
insight into potential mechanisms for and 
explanations of the variable penetrance 
and phenotypic appearance of MFS and 
related disorders.
SMaDs are intracellular proteins that 
transduce extracellular signals from tGFβ 
ligands to the nucleus where they activate 
tGFβ gene transcription. Some recent 
evidence suggests that the majority of the 
vascular end points in MFS are related to 
the influence of fibrillin 1 mutation on 
tGFβ1 levels and the subsequent tGFβ1/
SMaD2 signalling interaction. the down-
stream effect of this on elastin manufac-
ture and disorganisation via upregulation of 
tGFβ responsive gene expression leads to 
elastolysis and EcM degradation.
The Role of Transforming Growth Factor 
Beta (TGFβ) in the Development of 
Vascular System in Health and Disease
the tGFβ signalling pathway is important 
in both embryologic development – particu-
larly in relation to body morphology and 
patterning, tissue differentiation and body 
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axis; as well as having a potent role in the 
differentiation and proliferation of a number 
of cell lines, and the stimulation of apopto-
sis – particularly in VSMcs. tGFβ muta-
tions therefore have the potential to cause a 
number of congenitally acquired disorders 
of development and function of the skeletal, 
muscular and cardiovascular systems. this 
applies to both tGFβ and tGFβ receptors 
(tGFβr) or components of the signaling 
pathway. this includes a number of ligands 
that are currently of particular interest to 
researchers in taa/aaa/taD.
the tGFβ superfamily is large, and sig-
nals via two main pathways – tGFβ/activin/
nodal receptor to downstream intracellular 
transduction proteins SMaD2 and 3, or 
alternatively bone morphogenetic proteins 
(BMPs) to SMaD1 and 5.7,28
tGFβ has three ligand subtypes -1, -2 
and -3. these are secreted as what is termed 
a large latent complex (llc) comprising 
3 polypeptide chains. these chains are the 
small dimeric tGFβ ligand, a latency asso-
ciated peptide (laP) to which tGFβ is 
non-covalently bonded and a latent tGFβ 
binding protein (ltGFBP) of which there 
are three subtypes which are covalently 
bound to the laP.28 
after secretion, the llc is sequestered in 
the EcM in association with fibrillin 1. this 
provides a pool of stable, largely inactive 
tGFβ which can be released under stimulus 
from a reservoir. the tGFβ receptors and 
EcM with a reservoir are widespread and the 
effects of tGFβ occur both locally and sys-
temically. this explains why the regulation 
of tGFβ secretion at local level by variation 
in levels of EcM components such as fibril-
lin 1 can have significant effects.
the mechanism of tGFβ ligand signal-
ling is reasonably well understood and appears 
to occur via two families of tGFβ receptor, 
type 1 and type 2 (of which there are further 
subtypes within each family). tGFβ binding 
to the type 2 receptor causes recruitment and 
subsequent phosphorylation of the type 1 
receptor, leading to the formation of an 
activated receptor complex. tGFβ affinity 
for the receptor is variable, and there are a 
number of transmembrane co-receptors such 
as betaglycan (tGFBr3), which is high affin-
ity but non-signalling, that enhance tGFβ 
binding to the type 2 receptor complex.28
the formation of the activated receptor 
complex leads to further cascading phos-
phorylation of receptor-associated SMaDs 
(r-smads or smad 2/3). the type of SMaD 
activated depends on which tGFβ1 recep-
tor subtype is activated. once the r-smad is 
activated it binds with a co-smad (SMaD4) 
to shuttle it to the nucleus to allow transcrip-
tion of the target tGFβ gene.
clearly this is a complex pathway, and 
furthermore there are a number of other 
intracellular kinases which can influence the 
phosphorylation and hence activity of 
the SMaD family, all of which can have 
outside influences.7,28,29
Ehlers-Danlos Syndrome 
Ehlers-Danlos Syndrome (EDS) is a heredi-
tary disorder of connective tissue related to 
abnormalities in the gene for collagen, with six 
different types described.30,31 it has an overall 
prevalence of approximately 1 in 25,000 
live births.31 original descriptions were by 
Edward Ehlers in 1899 and Henri alexandre 
Danlos in 1908. the most important subtype 
from the vascular perspective, and the most 
catastrophic in terms of presentation remains 
type iV or what is now known as the vascular 
type, described by andras Barbaras in 1967, 
in which he noted increased vascular fragility. 
the prevalence of the vascular type is <4% of 
all EDS cases. Presentations are heterogenous, 
and are not always entirely clear, and the 
distribution of clinical presentation reflects 
that of type iii collagen. 
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children with EDS are often misdiag-
nosed as having coagulation disorders due 
to easy bruising.30 Skeletal manifestations 
are consistent with abnormality in manufac-
ture of type iii collagen with a defect in the 
pro-α-1 type iii collagen chain, coded for 
by the col3a1 gene. abnormalities in 
these collagens lead to ligamentous laxity. 
the biochemical basis for EDS was 
described by Pope in 1975. it is a hetero-
zygous mutation of the gene for type iii 
collagen, which is located on the long arm of 
chromosome 2, and is inherited in an auto-
somal dominant fashion.31 Vascular EDS is 
best described as a monogenic orphan dis-
ease transmitted as an autosomal dominant 
trait. there is therefore a 50% chance of 
affected individuals passing on EDS to each 
child. Sporadic cases do however, account for 
up to half of all reported cases.
Diagnosis of Ehlers-Danlos Syndrome
clinical diagnostic features of vascular EDS 
include typical facial features (although 
these may be absent in some cases), skin 
abnormalities with a thin translucent 
appearance and more visible veins, rupture of 
hollow viscera and vessels and easy bruising 
or ecchymoses. the classical facies of EDS 
are described as acrogeria, an appearance of 
slim face, thin long nose, sunken cheeks and 
often bulging or protruberant eyes. there 
may be periorbital pigmentation and/or 
telangiectasis. the upper lip is often fine and 
lacks puckering.30 this is present in around 
30% of patients.31
Skin manifestations vary from the other 
types of EDS, in particular the hypermobil-
ity and classical types, in that skin hyperex-
tensibility is a less prominent feature. the 
skin does feel softer and is more translucent, 
and the subcutaneous vessels are often very 
prominent and visible – particularly on the 
trunk. Skin on the hands and feet is often 
more aged appearing than expected. With 
previous scarring, the appearance is quite 
stretched and there may be deposits of 
haemosiderin and enlargement of scars over 
mobile areas.
Easy bruising is a common finding, par-
ticularly in the younger group – in fact it is 
the most consistent clinical feature, being 
present is 66% of reported cases in one 
series.32 these bruises and subcutaneous 
haematomas are often huge – much larger 
than the inciting injury would account for. 
the presence of these bruises often prompts 
investigation of platelet function and coagu-
lation, however the underlying pathology is 
vascular fragility rather than any haemato-
logical abnormality.
Vascular complications in EDS are rela-
tively rare in infancy but prevalent in teens 
and in the third and fourth decades of life. 
More than 80% of people have had a vascu-
lar complication by the age of 40.31 Median 
survival of vascular type EDS patients is only 
48 years. Vessel complications are the leading 
cause of mortality in patients with vascular 
EDS; with aortic tears, dissection, and arterio-
venous fistulas being seen along with classi-
cal arterial rupture. these events are often 
spontaneous with no apparent cause and can 
occur in otherwise normal appearing blood 
vessels. the thoracic aorta and abdominal 
aorta are the main sites of involvement with 
more than 50% of these events occurring 
in the distal thoracic aorta.31 Middle-sized 
arteries appear to be the main vessels in 
which these events otherwise occur. Extrem-
ity vessel events contribute approximately 
25% of the complications that are seen in 
vascular EDS.31 Spontaneous arterial rupture 
into closed spaces can lead to compartment 
syndrome and limb loss. Sudden onset of 
flank or abdominal pain should mandate 
non-invasive imaging as it is a common 
presentation of intestinal, uterine or arterial 
rupture.
the most commonly seen intra-cerebral 
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catastrophe related to vascular Ehlers-Danlos 
Syndrome is carotid-cavernous fistula.30,32 
this is an exceedingly uncommon presenta-
tion in the normal population, and is seen 
almost exclusively in patients with traumatic 
injury. the occurrence of this in an atraum-
atic setting should lead to a high clinical 
suspicion of the presence of a collagen- 
vascular disorder. the mean age of occur-
rence of carotid-cavernous fistula in this 
population is 31 years compared with 58 years 
in the general population. less common 
presentations include intracranial haemor-
rhage in approximately 4% of cases.7 Most 
of these cases have a previously identified 
intracranial aneurysm. Extracranial dissec-
tion of both the vertebral and carotid arteries 
is also seen. as with carotid-cavernous fistula 
the presence of this pathology in the absence 
of trauma should suggest the presence of a 
collagen vascular disorder. other vascular 
anomalies include prominent varicose veins 
and these are widely seen in EDS patients. 
Surgical treatment of varicose veins is 
contraindicated.
Gastrointestinal and obstetric complica-
tions are also common-both of these tissue 
types being rich in type iii collagen. From 
the gastrointestinal point of view, the sig-
moid colon is the most regularly involved 
site of perforation. in contrast to the hyper-
mobility of classical types of EDS, joint 
hyper mobility is not a prominent feature 
in vascular EDS. in some studies there is 
an increased risk of congenital hip dysplasia 
and congenital clubfoot in comparison to 
the general population.30 Differential diag-
nosis of EDS includes a number of paediat-
ric coagulation disturbances and Silverman 
Syndrome, which can also have easy bruising 
and haematoma. in adults, Marfan’s disease 
should also be considered.30,33
the diagnostic criteria for EDS were 
outlined most recently in the Villefranche 
nosology34 that breaks the more classical 
description of EDS into six main types 
based on clinical presentation and the patho-
gnomonic manifestations of each type. the 
presence of two or more major criteria is 
highly indicative of the disease and labora-
tory testing is recommended.34
laboratory diagnosis involves the demon-
stration of structurally abnormal type iii 
collagen produced by fibroblasts, and 
demonstration of an abnormal col3a1 
gene. the most reliable study is assesse-
ment of procollagen iii deficiency using gel 
electro phoresis. this requires skin biopsy 
and has a risk of wound complications, thus 
site selection should be careful. Qualitative 
abnormalities in type iii collagen can be seen 
by measuring secretion of type iii collagen in 
cultured skin fibroblasts.30
Unfortunately although col3a1 gene 
analysis is intuitively more accurate and 
would seem easier, it suffers the problem 
of lack of concordance between the muta-
tion type and severity. there are numerous 
mutations possible in the gene given its large 
size, and there may be a greater prevalence of 
mutations than is currently recognised. Some 
mutations may have a degree of phenotypic 
correlation. Unfortunately the site of the 
mutation within the collagen gene has not 
been useful in predicting tissue integrity-one 
series of 135 EDS vascular type patients had 
no correlation between location of mutation 
and degree or presence of tissue fragility.35
From a biochemical perspective the most 
common point mutation that has been dem-
onstrated is the replacement of a glycine in 
the collagen triple helix chain with another 
amino acid. Unfortunately the amino acid 
substitution does not correlate with pheno-
typic expression or clinical outcome. a 
proposed hypothesis in the aetiology of the 
clinical syndrome is that the abnormal pro-
collagen components are either degraded in 
a form of ‘protein suicide’ 35 or are retained 
but their presence causes disruption of the 
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normal organisation and deposition of other 
types of collagens. this may explain the spec-
trum of differences in tissue fragility that are 
present with the same mutation. this is an 
evolving area of knowledge.31
although controversial, some experts 
recommend ongoing surveillance to deter-
mine whether there is an incidental vascular 
lesion.31 the controversy in this area arises 
from the fact that the majority of lesions 
will be treated conservatively and diagnosing 
them may increase patient anxiety unneces-
sarily. arteriography is relatively contraindi-
cated as an investigative modality in these 
patients as it is associated with a 67% com-
plication rate and mortality rate of 17%,32 
however there is evolving discussion about its 
use as a treatment modality with the utilisa-
tion of endovascular coils or stents to minimise 
the use of arterial sutures. Similarly much of 
the previous evidence in relation to interven-
tion in these patients was with larger sheaths 
and the advent of lower profile devices may 
minimise these risks.
the prognosis of Vascular EDS is dis-
mal, with 92% of late deaths in a cohort 
of 220 index patients being due to vascu-
lar catastrophes, with median survival being 
48–54 years, and patient survival to 60 years 
being as low as 55–68%.31 the average age 
of first vascular or visceral complication is 
24yrs with a 12% mortality. Pregnancy has a 
25% risk of death with each pregnancy and 
an associated 50% chance of passing on the 
mutated col3a1 gene.32
Loeys-Deitz Syndrome 
although MFS and EDS are by far the 
most commonly recognised connective tissue 
disorders (ctD) associated with aaS/taD, 
recent understanding in the molecular biol-
ogy of dissection has allowed recognition of 
a new disorder described by Bart loeys and 
Table 14.5: The diagnostic criteria for the vascular subtype of EDS.
Inheritance Pattern Autosomal dominant
Major Diagnostic Criteria Thin, translucent skin
Arterial/Intestinal/uterine fragility or rupture
Extensive bruising
Characteristic facial appearance
Minor Diagnostic Criteria Acrogeria
Hypermobility of small joints
Tendon and muscle rupture
Talipes equinovarus
Early onset varicose veins
Arteriovenous / carotid-cavernous sinus fistula
Pneumothorax/haemopneumothorax
Gingival recession
Positive family history, sudden death in (a) close relative(s)
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Harry Deitz in 2005. this autosomal domin-
ant ctD is recognised to be caused by muta-
tion in the transforming growth factor beta 
(tGFβ) receptor 1 or 2 gene. lDS preva-
lence is currently not well-described. lDS 
does appear to be intimately related to MFS, 
and this becomes clear when it is under-
stood that the genetic anomaly in lDS is a 
loss-of-function mutation in the tGFβr2 
receptor – hence this mimics some of the 
effects of alteration in the levels of available 
tGFβ seen in fibrillin 1 deficiency syn-
dromes such as MFS. 
Phenotypic features of lDS include 
hypertelorism (90%), bifid uvula, cleft 
palate, generalised arterial tortuosity, cranio-
synostosis (50%), PDa and aSD. Mental 
retardation is often present. these features 
contrast with some of the features of MFS 
such as narrow high arched palate in 
MFS versus cleft, but there are a significant 
number of shared features such as ascending 
aortic aneurysm and dissection.
lDS falls into two types, lDS type 1 
and lDS type 2. lDS1 has a number of 
similarities and overlap with MFS, including 
aortic root dilation, arachnodactyly (long 
thin fingers), dolichostenomelia (thin body 
and long extremities), pectus deformity and 
joint laxity. these patients are now discrimi-
nated from MFS patients in the new revised 
Ghent nosology by the absence of ectopia 
lentis (present in 40–56% of MFS patients) 
and other more stringent diagnostic criteria. 
lDS type 2 shares a number of similar fea-
tures to vascular EDS, including soft, velvety 
skin and the presence of aortic aneurysm or 
dissection, however EDS lacks a significant 
number of features present in lDS including 
excessive vascular tortuosity, and bifid uvula. 
the table below outlines the major differ-
ences between the syndromes.
the vascular degenerative changes asso-
ciated with lDS are significantly more 
malignant than those in MFS and occur 
at a younger age, hence early recognition 
is vital. aortic root aneurysm is reported 
in patients as young as 6 years of age. the 
underlying genetic abnormality of lDS leads 
to altered signaling in the tGF-β cytokine 
family. tGF-β plays an important role in 
EcM formation and turnover, as well as cell 
proliferation and differentiation, along with 
apoptosis. this influence on proliferation 
and differentiation is particularly apparent 
in cardiovascular embryogenesis, including 
ventricular myocardial genesis.
tGF-β signal alterations lead to dis-
arrayed elastin fibres, with loss of elastin 
content, and dilation and dissection as a 
consequence. in comparison to MFS, aortic 
and vascular aneurysms and dissections 
happen throughout the vascular tree, not 
just in the aortic root. rupture has also been 
demonstrated in vessels <4.5 cm in diameter, 
in comparison to MFS where this would 
usually be considered a ‘safe’ size to manage 
conservatively.
Histological evaluation of vessels in lDS 
has shown excessive aortic wall collagen, 
along with increased levels of phosphorylated 
nuclear smad2. this indicates increased 
tGFβ signalling despite some degree of defi-
ciency in the receptor.29 in contrast to other 
ctD’s, in particular EDS Vascular type, the 
surgical prognosis for lDS is quite good 
with reasonable surgical outcomes achiev-
able as these patients lack the inherent tissue 
fragility of vascular EDS patients.35
Familial Thoracic Aortic Aneurysm 
Disease
recent research shows that there are a 
significant number of patients who do not 
have typical named syndromes such as MFS 
but who have familial clustering of thoracic 
aortic aneurysm disease (taaD). these 
patients display features of aortic pathology 
including ascending aortic or root dilation 
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and aneurysms or dissection of the ascending 
or descending aorta. they appear to have an 
autosomal dominant pattern of inheritance 
but with variable penetrance and expression. 
that is, some carriers do not demonstrate 
the pathology, and those that develop the 
pathology within a family do so at different 
severities. there is no gender bias. this is 
largely a diagnosis of exclusion, with a focus 
being on ruling out other named congenital 
or genetic anomalies that predispose to aaS/
taaD. the age of presentation provides some 
Table 14.6: Major clinical features of Loeys-Dietz Syndrome (LDS) type 1 and 2, 
Marfan syndrome and the vascular type of Ehlers Danlos Syndrome (EDS type IV). 
Modified from Aalberts et al., 2008.
Marfan lDS 1 lDS 2 eDS 4
Vascular
Aortic aneurysm/dissection ++ +++ +++ +++
Aortic Tortuosity - +++ +++ -
ASD - + + -
Skeletal
Arachnodactylya +++ ++ ++ -
Dolichostenomeliab ++ + -
Pectus abnormalities ++ ++ ++ -
Joint laxity ++ ++ +++ + (small joints)
Pes equinovarusc - + +
Facial
Craniosynostosisd - +/++ - -
Hypertelorisme - +++ _ -
Cleft palate/bifid uvula - +++ + -
Skin
Excessive striae + - - -
Easy bruising - +++ ++
Soft, velvety, translucent - + ++/+++ +++
eyes
Ectopia lentisf ++ - - -
Other
Rupture large organs - - +/++ ++
the presence or absence of the features in italics might help to differentiate from Marfan syndrome, – infrequently, + 
around 25–50%, ++ around 50–75%, +++ >75%, along slender fingers, bthin body habitus and long extremeties,  
cclubfeet, dpremature closure of cranial sutures, eincreased distance between pupils, f lens subluxation
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hint as to the likely underlying pathology, 
with familial thoracic aortic aneurysm disease 
(FtaaD) patients presenting on average at 
older age than MFS patients, but younger 
age than sporadic taaD patients.
Familial taaD has been linked to a 
number of chromosomal abnormalities, 
some of which appear to be allelic with the 
mutations seen in well-characterised diseases 
such as MFS.
FtaaD type 1 is related to a gene defect 
on chromosome 11q23.3-4. this is an auto-
somal dominant inheritance pattern gene, 
but in comparison to a number of other 
syndromes, is a vascular-only syndrome 
with multiple segmental involvement of the 
thoracic and abdominal aorta commonly 
seen. this disease is highly penetrant in 
comparison to such diseases as MFS.
FtaaD type 2 has been linked to a 
5q13-q14 mutation which is inherited in 
autosomal dominant fashion. in comparison 
to type 1 FtaaD, there is variable pene-
trance of this disorder, particularly in women. 
in comparison to type 1 FtaaD this pro-
cess also carries with it a number of cardio-
vascular abnormalities which are similar to 
those seen in MFS. the postulation is that 
the 5q locus codes for a connective tissue 
protein of some kind.
FtaaD type 3 has a locus of mutation 
that maps to the 3p25-p24 site. this seems 
to be the site of the tGFBr2 gene, and the 
mutations that cause vascular anomalies 
appear to occur in the functionally important 
kinase domain leading to loss of function. 
this also overlaps a locus for a Marfan-like 
syndrome (the MFS2 locus). this muta-
tion is found in approximately 5% of taD 
patients. the phenotype is predominantly 
ascending aortic disease, however other site 
disease is also seen. rupture and dissection 
at smaller sizes than usual is also recognised 
in the FtaaD type 3 patients. 
Bicuspid Aortic Valve
Bicuspid aortic valve (BaV) is the most 
common congenital cardiac anomaly 
(1–2% of the population) and predisposes 
patients to increased risk of dissection, 
dilatation and aneurysm, independant of 
valvular function.26 it displays an autosomal 
dominant inheritance pattern and has been 
shown to have a strong link with taa in a 
cohort of 13 families.25
Similar medial degeneration is seen in 
BaV as that seen in fibrillin1 knockout 
mice. there is a measurable deficiency of 
fibrillin 1 and elevated levels of MMP-2 in 
bicuspid aortic valves compared to the con-
trol population.26 there is similarly evidence 
of decreased amounts of fibrillin 1 in aortic 
media in BaV patients, but normal elastin 
and collagen levels. this is in comparison 
to atherosclerotic dilation where fibrillin 1 
levels are increased. this suggests that the 
underlying pathology in BaV is similar to 
that in fibrillin 1 knockout mice – increases 
in tGFβ1 concentration and activity. 
Turners Syndrome
Monosomy X, or turners syndrome (tS) 
is a moderately common chromosomal 
disorder, (1 in 2500 live births), that carries 
with it an increased risk of aortic coarctation 
and dissection. the most commonly seen 
cardiovascular anomaly in tS is bicuspid 
aortic valve, and as discussed earlier, this 
independently increases the risk of taD. 
BaV is seen in 13–34% of tS patients 
compared with 1–2% of the general 
population. the risk of aortic dissection in 
young turners patients is significantly higher 
than the general population and dissection 
occurs at sizes below that at which dissection 
would normally be considered a risk (<5cm). 
Dissection is usually type a, although there 
is a correlation between aortic coarctation 
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(present in 4–14% of tS patients) and 
type B dissection. Given the short stature 
of tS patients, the aortic size index rather 
than the raw aortic size is preferred for 
calculating aortic dissection risk in these 
patients.
SUMMary
although previously considered a simple 
haemodynamic consequence of chronic 
hypertension, thoracic aortic dissection in 
the classical sense is now recognised as being 
part of a continuum of aortic pathologies that 
include intramural haematoma, penetrating 
aortic ulcer and a number of congenital 
connective tissue disorders. the recent 
advances in the molecular understanding 
of aspects of EcM turnover – particularly 
relating to fibrillin 1 and transforming growth 
factor – beta have allowed us to expand our 
diagnostic and treatment options into new 
areas.
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15  • Biomarkers in Vascular Disease
Ian M. nordon, robert J. HIncHlIffe
St George’s Vascular Institute, St James’ Wing, St George’s Hospital, 
blackshaw road, london, UK
IntrodUctIon
cardiovascular diseases (cVd) are the leading 
cause of morbidity and mortality in the 
developed world. these diseases encompass 
the consequences of localized atherosclerosis 
and aneurysmal arterial degeneration. 
evolution of risk factors contributes to the 
onset of subclinical disease; subclinical disease 
progresses to overt and often catastrophic 
clinical sequelae. Primary and secondary 
prevention strategies for cVd are public 
health priorities.
Whilst clinical assessment and cross-
sectional imaging remain the cornerstones 
of patient management, they have limita-
tions. there is increasing interest in the use 
of novel markers of cardiovascular disease 
as screening and risk-assessment tools to 
enhance the ability to identify the ‘vulner-
able’ patients. biomarkers are one tool to 
aid clinical assessment and identify high risk 
individuals, to ensure prompt and accurate 
disease diagnosis and to aid prognostic scor-
ing of individuals with disease.
WHat IS a bIoMarKer?
Initially described as a ‘measurable and 
quantifiable biological parameter that could 
serve as an index for health assessment’, the 
definition of a biomarker has since been 
standardized. 
‘A characteristic that is objectively meas-
ured as an indicator of normal bio-
logical pro cesses, pathogenic processes, or 
pharmacological responses to a therapeutic 
intervention’ 1
biomarkers are indicators of disease trait 
(risk factor or risk marker), disease state 
(pre clinical or clinical), or disease rate 
(progression).2 they may also serve as 
surrogate end points used as an outcome 
measure to assess efficacy of therapy. a 
biomarker may be a recording taken from an 
individual (e.g. blood pressure), it may be an 
imaging test (ct / Pet scan), or it may be 
a biosample (blood, serum, urine). although 
each of these measurements constitutes a 
biomarker, the term biomarker has become 
synonymous with a novel protein, enzyme or 
cytokine with discriminatory value in clinical 
care. 
tyPeS of bIoMarKer
biomarkers found in body fluids may 
represent the active disease process or the 
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patient’s reaction to the disease. a disease 
condition is a combination of biological 
changes directly due to disease (e.g. disease 
Progression biomarkers) and biological 
changes caused by host as it responds to 
disease (e.g. Host response biomarkers). 
disease progression biomarkers are very 
specific to disease and tend to be proteins of 
low abundance. conversely, host response 
biomarkers are less specific to the disease itself 
and are generally high abundance proteins. 
(figure 15.1) When used in the correct 
clinical context both have discriminatory 
value.
A classical clinical example
troponin is an established clinical biomarker. 
the diagnosis of myocardial infarction now 
stands on a convincing history, electro-
cardiogram changes and the detection of a 
protein biomarker for myocardial necrosis. 
the biomarker is a result of the systemic 
spillover of structural, myocardial specific 
myofilament proteins (troponins). the 
levels of protein, due to the time course and 
extent of systemic release, correlate well with 
myocardial injury. first discovered by ebashi 
in 1963, troponin’s utility as a biomarker was 
highlighted in 1989 when a standardized 
immunoassay for circulating troponin t 
was developed. It underwent clinical 
validation against the then best marker of 
myocardial ischaemia, cK-Mb, and was 
found to improve the efficiency of diagnosis 
of myocardial cell necrosis.3 In 2000 the 
american Heart association incorporated a 
positive troponin t rise into its definition 
of myocardial infarction, and it remains the 
gold standard for the diagnosis of cardiac 
ischaemia.4
Figure 15.1: Comparison of Host Response and Disease Progression Biomarkers.
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PotentIal ValUe of 
bIoMarKerS In VaScUlar 
dISeaSe
biomarkers have great potential to enhance 
all aspects of vascular care through aaa, 
carotid and peripheral vascular disease. 
aaa development is likely to represent 
a product of genetic predisposition and 
environ mental factors. aaa are character-
ized by local inflammation, matrix degrada-
tion and smooth muscle cell apoptosis.5 
once established, aaas grow at a rate of 
2.6mm/year (95% range -1.0 to 6.1mm/
year).6 Generally this growth is insidious 
and asymptomatic until rupture. during 
this growth phase the active processes of 
aaa formation are on-going, both local and 
systemic cytokines and protein levels will be 
modified in response to or as a consequence 
of this pathology. 
the principle challenge in the manage-
ment of aaas is that they generally remain 
asymptomatic until rupture. at rupture, 
survival is poor, with mortality rates up 
to 70%.7 In order to make a significant 
impact on the outcome of aaa a number of 
significant advances are required. Improved 
detection of aaas is the first step. aneurysm 
screening is currently being rolled out in the 
UK and other countries. However there 
remains doubt over the cost-effectiveness of 
these ultrasound-based programs. currently, 
maximum aortic diameter alone is generally 
the only means of assessing aaa rupture 
risk. However, the complications of aaa 
are not simply correlated to aortic diameter 
alone. Some small aaas rupture and some 
large aaas remain stable for prolonged 
periods.8,9 Patients continue to undergo 
aneurysm repair on the probability of 
rupture, with the inevitability that some 
patients will undergo unnecessary repair. an 
improved risk model is required. Identifica-
tion of blood-based biomarkers capable of 
identification and individual stratification of 
risk of progression and rupture would revo-
lutionize the provision of care for aaa. 
endovascular aaa repair (eVar) has 
sig nificantly reduced the peri-operative mor-
tality associated with elective aaa surgery.10 
the current standard of care requires regu-
lar post-deployment surveillance to ensure 
the aneurysm sac is excluded from the 
circulation and adequately depressurized. 
this surveillance is dependent on duplex 
ultrasound and computed tomographic 
imaging. a blood test, for a biomarker of 
aneurysm expansion or aneurysm sac pres-
surization that could replace serial imaging 
would reduce the cost and morbidity attrib-
uted to graft surveillance. 
Stroke is the third leading cause of death 
worldwide. approximately 15% of strokes 
and transient ischaemic attacks (tIas) are 
caused by unstable carotid artery plaque. 
Surgical treatment of a carotid artery 
stenosis by endarterectomy (cea) can sig-
nificantly reduce stroke risk, but is accompa-
nied by morbidity and mortality. equally, not 
all carotid plaques will become symptomatic 
and cause a stroke. current evidence from a 
cochrane systematic review states that cea 
for asymptomatic carotid stenosis reduces 
the risk of ipsilateral, or any stroke, by 30% 
over 3 years. fundamental to the selection of 
patients for intervention is the identification 
of plaques conferring an excess risk of neuro-
logical events. currently, selection for carotid 
intervention is determined by the grade of 
stenosis and symptomatology. It is broadly 
accepted to treat high-grade symptom atic 
carotid stenosis, but in lower grade and 
asymptomatic patients interventions are still 
a matter of debate. there is growing evidence 
that stenosis alone is a poor guide. Molecu-
lar processes such as inflammation, lipid 
accumulation, apoptosis, thrombosis, prote-
olysis and angiogenesis have been shown to 
be highly related with plaque vulnerability. 
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Serum biomarkers reflecting these processes 
may distinguish unstable from stable carotid 
stenosis and be a powerful discriminator in 
the selection of patients for carotid surgery. 
bIoMarKer dIScoVery StePS
biomarkers must be measurable, add new 
information and aid the clinicians’ manage-
ment of patients. to apply the biomarker 
to a risk prediction model it must allow 
discrimination, calibration and risk strati-
fi cation. (table 15.1) discrimination is 
the specificity and sensitivity of the marker, 
calib ration denotes the ability of the marker 
to assign predicted risks that match actual 
observed risk, and risk stratification is the 
power to assign patients into clinically 
relevant categories. 
there are two potential approaches to 
biomarker discovery. firstly there is a knowl-
edge-based approach exploring known candi-
dates based on the understanding of disease 
pathophysiology. alternatively an inductive 
approach can be undertaken, using non-
hypothesis driven exploration to discover 
novel differences in genetic, prote omic or 
metabolomic expression. the two method-
ologies are complementary. dependent on 
the understanding of molecular biology 
of disease and cell signaling pathways 
there is also cross-over between the ‘omics’ 
sciences used to trawl for novel candidates. 
(table 15.2)
aaa bIoMarKerS
candidate biomarkers have been studied 
based on present understanding of aaa 
pathogenesis. examination of aneurysmal 
aortic wall biopsies has demonstrated patho-
logical processes including medial arterial 
destruction, accumulation of inflam matory 
cells, elastin fragmentation, increased con-
centrations of proteolytic cytokines and 
in-situ thrombus. consequently investigators 
have explored enzyme, protein and cytokine 
alterations on the basis of this understanding. 
the principle limitation of this approach 
being that all these features represent the 
end-stage of aaa development and may 
not be indicative of factors initiating aaa 
development or stimulating aaa growth. 
the alternative ‘hypothesis generating’ 
approaches have been applied to aaa bio-
marker discovery. Samples of body fluids and 
vascular tissue have been compared between 
aaa patients and control subjects using 





P1 Discovery Exploratory studies to identify potential biomarkers 50
P2 Validation Capacity of biomarker to discriminate between health 
& disease
100
P3 Pre-clinical Capacity of biomarker to detect pre-clinical disease 200
P4 Prospective Prospective screening studies for sensitivity of 
biomarker
500
P5 Impact Large scale study to asses impact of biomarker on 
survival
>1000
Table 15.1: Translating biomarker discovery from the laboratory to patients
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these investigations have proposed novel 
potential circulating biomarkers of aaa. 
However, particularly in the proteomic 
studies, the studies have involved very small 
numbers of patients and similar numbers 
of control subjects. the challenge of find-
ing appropriately matched controls can also 
reduce the value of some results with inbuilt 
confounding variables likely to diminish 
the power of any preliminary discovery. 
this is particularly the case when using 
aortic wall tissue for proteomic analysis 
as the availability of normal-aged aorta is 
limited and its method and timing of har-




collagen fragmentation is typically found 
in aaa biopsies. this is associated with 
synthesis of new type I and III collagen. 
during collagen synthesis both the carboxy-
terminal and aminoterminal ends of the 
precursor molecule are released. these two 
fragments represent candidate biomarkers 
for increased extracellular matrix remodelling 
and consequent aaa formation. Small case 
control studies using radioimmunoassay 
for these peptide fragments have reported 
associations with aaa. However, contem-
porary series have failed to repeat these 
findings in a larger cohort.10 
tenascin-X was identified as a candidate 
biomarker due to its implication in ehlers-
danlos syndrome, where patients are prone 
to aortic dissection and aneurysm formation. 
elevated serum tenascin-X has been demon-
strated in aaa patients (n = 87) compared 
to controls. notably, the highest quartile of 
serum tenascin-X concentrations were asso-
ciated with a 5-fold increase in aaa risk 
(or 5.5; 95% cI, 2.0-13.8).11
Technology Objective Method Tissue









Blood, saliva, tissue, 
urine
Metabolomics Identification and 




Blood, saliva, tissue, 
urine




Data from combined 
methods









Table 15.2: Glossary of ‘omics’ methodologies used to discover novel biomarkers 
[SNP, single nucleotide polymorphism. NMR, nuclear magnetic resonance. BLAST, 
basic local alignment search tool. CT, computed tomography. MRI, magnetic 
resonance imaging. PET, positron emission tomography. SPECT, single-photon 
emission computed tomography]
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propeptide of type I 
procollagen (PICP)
Plasma PICP levels are 
significantly decreased in AAA vs. 




propeptide of type III 
procollagen (PIIINP)
Acceleration of AAA growth is 
reflected in serum PIIINP (r = 0.55)
Satta J. et al. 
199741
Tenascin-X AAA is associated with high serum 
concentrations of tenascin-X




SEP levels higher in cases prone 
to rupture relative to controls (60% 
specificity) (r = 0.40)




Cystatin-C Negative correlation with 
expansion rate (r = -0.24)
Lindholt J.S.  
et al. 200142
MMP-9 Elevated in aneurysmal aortic 
walls – correlates with expansion 
of small AAAs (r = 0.33)
Linholt J.S.  
et al. 200014
Alpha-1 antitrypsin Alpha-1 antitrypsin correlates with 
AAA growth (r = 0.55)
Vega de Ceniga 
et al. 200917
P-elastase P-elastase is positively correlated 
with the mean annual AAA 
expansion rate (r = 0.30)




Fibrinogen Fibrinogen concentrations are 
significantly higher in AAA vs. 
controls (median: 2.89 vs.  
2.53 g/L; p<0.01) and correlate 
with AAA size (r = 0.32)
Al-Barjas H.S. 
et al. 200619 
D-Dimer Annual AAA growth is positively 
and significantly associated with 
D-Dimer (r = 0.39)




HCY levels correlate with AAA 
growth rate (r = 0.28). Hyper HCY 
is related to rapid AAA growth.





Elevated serum TAT levels 
are associated with large AAA 
diameter (r = 0.57)
Yamazumi K.  
et al. 199844
Table 15.3: Substrates explored as possible biomarkers for AAA presence and 
growth 
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Serum elastin peptide (SeP) is a degrada-
tion product of elastin. the role of SeP as a 
biomarker has been explored in two separ-
ate cohorts, the Viborg aneurysm screened 
cohort and the patients from the chichester 
screened cohort who were unfit for surgery. 
Using a reproducible elISa (enzyme linked 
immunosorbent assay) a clear correlation 
between SeP and aneurysm growth rate was 
reported (r = 0.4).12 SeP was also found to 
be elevated in patients with symptomatic 
aaas and those who went on to rupture.13 
this study was underpowered to identify a 
statistically significant biomarker and has 
not yet been repeated. 
Matrix-degrading enzymes
Histological examination of aneurysm 
wall demonstrates fragmentation of the 
extracellular matrix. this has implicated 
elastases and matrix metalloproteinases 
(MMPs) in the pathophysiology of aaas. 
Specifically, MMP-9 is abundantly expressed 
in aaas and is considered to play a pivotal 
role in their formation. this candidate has 
been explored as a possible biomarker for 
aaa presence in case-control studies. the 
majority of studies confirm an elevated 
circulating MMP-9 concentration in patients 
with aaa compared to healthy controls 
or subjects with occlusive atherosclerotic 
disease.14,15 Pooled analysis of these data has 
verified this finding,16 however the variability 
in the findings, sample handling and analysis 
highlights the principle challenges in primary 
validation in biomarker discovery.
alternative elastases have been explored as 
serum biomarkers. Small studies (n < 50) have 
raised the possibility of alpha-1 antitrypsin17 
and p-elastase18 acting as serum biomarkers 
for aneurysm growth. they have not been 
repeated in larger cohorts, nor have these 
findings translated into a tool for prediction 
of rupture risk or the need for surgery. 
Proteins associated with thrombosis
the role of the intraluminal thrombus 
commonly found in aaas is yet to be fully 
related Process biomarker Proposed significance reference
Inflammation C-reactive protein 
(CRP)
CRP levels elevated in large AAAs Norman P.E.  
et al. 200422
Osteopontin (OPT) Osteopontin level correlates 
with AAA presence and growth 
(r = 0.24)
Golledge J.  
et al. 200726
IL-6 IL-6 level is independently 
associated with AAA and 
correlated with index diameter 
(r = 0.28)




Osteoprotegerin associated with 
AAA growth
Moran C.S.  
et al.25
Resistin Serum resistin concentration is 
independently associated aortic 
diameter (r = 0.19)
Golledge J.  
et al. 200726
Ig-G to C. 
Pneumoniae
Aneurysm progression correlated 
with IgG C. Pneumoniae infection 
(r = 0.45)
Lindholt et al. 
200145
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understood. examination of this thrombus 
has identified a number of proteases that 
may be implicated in aaa progression. 
Proteins associated with thrombosis have 
been explored. these proteins may represent 
either end of the signaling pathway or be a 
by-product of degradation. the principle 
markers that have been evaluated are 
fibrinogen, d-dimer, homocysteine and 
protein complexes implicit in the coagulation 
cascade. 
a positive association between plasma 
fibrinogen concentration and aaa diameter 
has been demonstrated (r = 0.323).19 the 
link between smoking and aaa is irrefuta-
ble, and raised plasma fibrinogen is induced 
by smoking. this association may only be a 
consequence of smoking and elevated fibrin-
ogen has yet to be demonstrated independ-
ent of cigarette smoking. 
d-dimer level is a routinely used valid-
ated assay in general clinical practice to 
exclude a diagnosis of dVt. Plasma concen-
trations of d-dimer reflect fibrin turnover 
in the circulation. Its role as a candidate 
biomarker for aaa has been explored. In a 
large cohort (n = 1260, 337 with aaa) aver-
age annual aaa growth was shown to be 
positively and significantly associated with 
d-dimer.20 this study went on to propose 
possible diagnostic cut-off values for aaa 
presence were d-dimer to be utilized as a 
screening tool. In their population, a level 
>400ng/ml for d-dimer had an adjusted 
odds ratio (or) of 12.1 (95% cI, 7.1-20.5) 
and >900ngml represented an or of 24.7 
((%% cI, 13.7-44.6) for aaa presence. 
d-dimer in combination with additional 
clinical risk stratification may have general 
value in aaa risk assessment. 
Hyperhomocysteinaemia has been iden-
tified as a significant cardiovascular risk fac-
tor. these findings have evolved from studies 
into coronary heart disease and stroke. a 
review of the case-control studies found all 
series to report elevated homocysteine in 
subjects with aaa.21 However this associa-
tion was weak and failed to reflect a causal 
role for homocysteine in aaa development. 
It is likely that elevated homocysteine in 
aaa patients is reflective of dietary vari-
ability or renal clearance rather than the 
presence of an aneurysm.
biomarkers to identify thrombosis are 
unlikely to translate into a universal clinical 
tool. the principle issue is that not all aaas 
contain thrombus. equally, in-situ throm-
bus is a dynamic substrate and findings from 
small studies may be a variable and not valid 
throughout the disease course. 
Markers of inflammation 
c-reactive protein (crP) is the most 
commonly investigated biomarker in cardio-
vascular disease. It is an acute phase protein 
implicit in inflammation specifically to 
activate the complement cascade in cell 
death. Its elevation is inextricably linked 
to other inflammatory cytokines including 
interleukins (Il-6) and macrophage activa-
tion. crP levels have been shown to be 
elevated in large aneurysms (40-54mm), but 
no association with aaa expansion has been 
shown.22
It has been suggested that the aaa itself 
is one source of Il-6. circulating plasma 
levels of this inflammatory cytokine are elev-
ated in aaa compared to controls (all series 
n<100). also, plasma Il-6 has been corre-
lated to aortic diameter in patients without 
aaa.23 these findings are contributory to 
the understanding of aaa pathophysiology, 
supporting the role of inflammation and 
of macrophages in aaa progression. they 
lack the specificity to translate to a clinical 
biomarker. 
other candidates explored include osteo-
pontin (oPn), osteoprotegerin (oPG) and 
resistin. these have been identified based on 
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the pathophysiology and epidemiology of 
aaa development. oPn and oPG are both 
cytokines associated with macrophage activ-
ity. Serum oPn levels show an independ-
ent but poor correlation with aaa growth 
(r = 0.24).24 a similar finding has been 
reported for oPG; in a cohort of 146 men 
with small aaas followed for 3 years, serum 
oPG showed a significant but weak correla-
tion with aaa growth rate (r = 0.2).25 the 
elevated risk of aaa associated with obesity 
has led to exploration of resistin as a puta-
tive biomarker. Serum resistin concentration 
is independently associated with aaa 
(or 1.53; 95% cI, 1.32 - 1.76) and aortic 
diameter (r = 0.19, P<0.0001).26
bIoMarKerS of aaa rUPtUre
biomarkers capable of predicting aaa 
rupture would offer the greatest clinical value. 
observing patients until rupture is rarely 
performed and unethical. as the rupture of a 
small aneurysm is a rare event, few ultrasound 
based studies have assessed the relationship 
between increasing biomarker levels and 
rupture. In the UK small aneurysm trial an 
association between cotinine and subsequent 
aaa rupture was reported.27 this is a 
marker of smoking rather than any specific 
pathophysiological process. 
elevated MMP-9 levels have been 
reported in the plasma of patients with 
ruptured aaa compared to an elective non-
ruptured population.28 In this cohort, a 
4-fold elevation in plasma MMP-9 was 
associated with non-survival at 30-days com-
pared to those patients surviving surgery. 
Whether MMP-9 is important in the patho-
genesis of rupture or simply a marker of an 
acute process is unclear. 
bIoMarKerS folloWInG 
endoVaScUlar rePaIr 
endovascular repair (eVar) has become 
the preferred strategy for the management 
of aaas in many centers. following stent 
graft deployment surveillance is required to 
ensure aneurysm exclusion and continued 
depressurization of the aneurysm sac. the 
role of biomarkers, to replace radiological 
imaging, has been explored. decreases in 
MMP-3 and MMP-9 have been reported 
after successful eVar with statistical dif-
ferences compared to patients with active 
endoleak.29 the principle problem with any 
biomarker will be its ability to discriminate 
between benign (type II) endoleaks and more 
significant (type 1 or type III) endoleaks. 
bIoMarKerS of carotId 
PlaQUe StabIlIty
one current indication for carotid end-
arterectomy is duplex derived grade of 
stenosis combined with clinical evaluation. 
there is growing awareness that in isolation 
this is a poor guide as to whether a patient 
should receive intervention. biomarkers 
capable of discrimination between those 
carotid plaques which are either currently 
unstable or may become so in the future 
would revolutionize risk stratification in 
carotid surgery. research into biomarkers for 
carotid plaque formation remains embryonic. 
the majority has come from subgroup 
analysis of large studies into coronary plaque 
risk analysis. atherosclerosis is a multi-site 
disease process throughout the vasculature, 
therefore any biomarker for carotid plaque 
instability would require optimal specificity. 
this has led to early studies looking 
specifically at the carotid plaque tissue to 
identify possible candidates that would be 
particular to carotid atherosclerosis. 
atherosclerotic plaque development 
results from interaction between modified 
lipids, extracellular matrix, macrophages 
and activated vascular smooth muscle cells 
(VSMcs). certain processes in the evolu-
tion of atherosclerotic lesions have been 
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related Process biomarker Proposed significance reference
Inflammation C-reactive protein 
(hs-CRP)
Hs-CRP associated with 
progressive atherosclerosis, 
(upper quintile OR 3.65; 95% CI 
1.65-8.08)
Schillinger M.  
et al. 200531
Seum amyloid A 
(SAA)
SAA associated with progressive 
atherosclerosis, (upper quintile OR 
2.28; 95% CI 1.24-4.20)
Schillinger M.  
et al. 200531
IL-18 IL-18 expression found to be >3x 
greater in symptomatic plaques 
than assymptomatic
Mallat Z. et al. 
200146
IL-6 Serum IL-6 elevated in 
symptomatic stenosis compared to 
asymptomatic
Koutouzis M.  
et al. 200933
Neopterin Plasma levels (nmol/L) higher in 
complex plaques vs. non-complex 
plaques (24.2 vs. 19.4 ; P=0.01)
Sugioka K.  
et al. 201047 
CD-36 Soluble CD36 elevated in patients 
with echolucent plaques vs. 
echogenic plaques 






Symptomatic carotid plaques 
are characterised by elevated 
Lp-PLA2
Mannheim D.  
et al. 200834




Thrombosis Tissue plasminogen 
activator (t-PA)
Transient increase in t-PA gene 
expression associated with plaque 
instability
Sayed S. et al 
200936
Fibrinogen Elevated fibrinogen is associated 
with carotid disease progression





Transient increase in PAI-1 gene 
expression associated with plaque 
instability
Sayed S. et al 
200936
Proteolysis MMP-9 MMP-9 level correlates with 
plaque instability. MMP-9 >  
607ng/ml best predicted presence 
of unstable plaque (OR 19.2; 95% 
CI 3.9-94.2)
Alvarez B. et al. 
200439
Table 15.4: Substrates explored as possible biomarkers for carotid artery stenosis
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associated with plaque vulnerability. these 
include inflammation, lipid accumulation, 
apoptosis, thrombosis, angiogenesis and 
proteolysis.30 these changes are connected 
to the morphological characteristics of an 
unstable plaque. the search for a biomarker 
has focused on these processes. 
Inflammation
Inflammation in the vessel wall is con-
sidered to play an essential role in the 
initiation, progression and the final steps 
of atherosclerosis, namely plaque destabil-
ization and eventual plaque rupture. crP 
may have direct pro-inflammatory effects 
and contribute to the initiation and pro-
gression of atherosclerotic lesions. In carotid 
artery stenosis hs-crP correlates with 
morphological features of rapidly progressive 
carotid atherosclerosis.31 crP has also been 
shown to predict stroke risk in a healthy 
elderly population (framingham Study).32 
Men in the highest quartile of crP had 
double the risk of ischaemic stroke (rr 2.0; 
P = 0.03), and women had almost 3 times 
increased risk (rr 2.7; P = 0.0003) com-
pared to the lowest quartile. 
Serum amyloid a (Saa) is another acute 
phase protein. It is elevated in atherosclerotic 
lesions and has previously been shown to be 
a biomarker capable of predicting poor out-
come in acute coronary syndromes. Serum 
Saa is associated with progressive carotid 
atherosclerosis, (upper quintile or 2.28; 
95% cI 1.24-4.20). the pro-inflammatory 
cytokine Il-6 has pro-atherogenic proper-
ties. Histology has demonstrated increased 
expression of Il-6 in unstable plaque 
regions. elevated serum baseline Il-6 levels 
are associated with a greater stroke risk.33
Lipid accumulation
In atherosclerotic plaques, unstable lesions 
have a greater area occupied by lipid. 
Systemic lipid lowering in patients with 
cardiovascular risk using statins has shown 
a 25% proportional reduction in first 
event rate for stroke. oxldl levels have 
been shown to be related to carotid plaque 
instability. one link between oxldl and 
plaque instability is lipoprotein-associated 
phospholipase a2 (lp-Pla2). In carotid 
artery disease, symptomatic carotid artery 
plaques express higher levels of lp-Pla2 
than asymptomatic plaques.34 no serum 
studies have been performed on this possible 
biomarker.
Apoptosis
the necrotic core at the centre of advanced 
atherosclerotic plaques contains dead 
VSMcs and debris. Smooth muscle cells and 
inflammatory cells die as a consequence of 
programmed cell death (apoptosis). VSMc 
apoptosis may weaken the fibrous cap 
creating an unstable plaque prone to rupture. 
apoptotic markers have been explored to 
identify vulnerable plaques. annexin V, a 
marker of apoptosis, has been detected in 
symptomatic carotid artery plaques. this pilot 
study utilized exogenous radiolabelling and 
only examined 4 patients. the investigation 
did indicate that molecular imaging with the 
use of technetium-99m–labeled annexin a5 
may be a new method for assessing plaque 
instability and identifying patients at risk for 
acute vascular events.35
Thrombosis
thrombotic activity on carotid plaques 
is associated with stroke and transient 
ischaemic attacks (tIa). examination of 
rna from carotid plaques removed at 
endarterectomy has shown that expression 
of thrombomodulatory genes is increased in 
unstable plaques.36 these include t-Pa and 
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plasminogen activator inhibitor-1. to date 
no study has examined the possible role of 
these factors as biomarkers. 
Plasma fibrinogen levels have been shown 
to be related to progressive atherosclerosis. 
In a cohort of 1268 assymptomatic patients 
progressive atherosclerosis was seen in 9.2%. 
the adjusted hazard ratio for atheroscle-
rosis progression was 2.45 (P = 0.002) for 
the upper quartile compared to the lower 
quartile. fibrinogen level at follow up was 
also shown to be associated with progressive 
disease (P = 0.004).37
Proteolysis
Plaque destabilization is associated with 
proteolysis. Proteolytic enzymes including 
matrix metalloproteinases appear important 
in the pathophysiology of atherosclerotic 
plaque cap rupture and consequent 
neurological events. It is likely that an 
imbalance in MMPs may lead to matrix 
degradation and plaque destabilization. 
In unstable carotid plaques there is a local 
increase in active MMP-9 concentration.38 
elevation of MMP-9 has been shown in the 
serum of patients with symptomatic carotid 
artery disease in a small cohort of 40 patients 
undergoing carotid endarterectomy.39
cHallenGeS In bIoMarKer 
dIScoVery
a cautionary tail of biomarker exploration is 
described in the field of ovarian malignancy. 
Proteomic exploration was adopted early 
and with great enthusiasm in this field of 
cancer. despite early reports citing proteins 
with 100% sensitivity, 95% specificity and a 
positive predictive value of 94% in a small 
cohort; these findings have failed to translate 
to a clinically applicable tool. the initial 
proteomic fervor was tempered and despite 
greater than 10 years exploration clinicians 
remain reliant on an older protein biomarker, 
ca-125. 
Many candidate biomarkers, based on 
current understanding of vascular patho-
physiology have been explored. none have 
translated to clinical practice. It is there-
fore the task of the discovery sciences i.e. 
proteo mics and metabolomics to further this 
endeavor. biomarkers continue to represent 
one of the most anticipated healthcare con-
cepts. yet before the potential can be fully 
realized, numerous challenges need to be 
resolved. It is unlikely that single biomarkers 
will be considered adequate for most applic-
ations. Multiple protein panels are the new 
paradigm. because of variations in sample 
complexity, the approach to biomarker dis-
covery will continue to be highly depend-
ent on the intended application, each with 
its own discovery challenges. body fluids 
are especially difficult to handle consist-
ently. Serum is vulnerable to temperature 
and fasting state whilst variations in its pro-
tein content are difficult to identify as it is 
>90% albumin. Plasma is modified by the 
clotting cascade and haemoglobin break-
down, and urinary protein excretion is prin-
cipally a product of renal filtration. High 
throughput consistent sample handling is 
essential if these biomarker panels are to be 
elucidated.
fUtUre WorK
the future of biomarker discovery lies in 
comparative proteomics combined with 
innovative bioinformatics and mathematical 
modeling. this review has demonstrated a 
large number of small independent scientific 
groups generating exciting and unique 
findings. the principle limitation consistent 
across the literature is a failure to develop 
these discoveries through validation in larger 
mixed populations. different substrates 
(blood, plasma, serum) are being explored in 
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different conditions (Snap frozen, embedded, 
fresh), using varied assays, dependent upon 
the expertise of the scientific group. large 
co-operatives tasked with biomarker dis-
covery with defined consistent protocols 
across mixed populations offer the most 
appropriate environment for biomarker 
discovery. 
conclUSIon
biomarkers will have increased utility in 
the future of vascular surgery. to date no 
biomarker for aaa or carotid stenosis has 
been translated into clinical practice. However 
with advancements in mass spectrometry 
and proteomic techniques combined with 
worldwide interest in this discovery science, 
a significant discovery cannot be far away. 
In 10 years time the decision to operate on 
a dilated aorta or carotid stenosis may be 
guided by the presence of a specific protein 
in the patient’s serum, and no longer simply 
the morphology of the lesion.
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16  •  Pathophysiology and Principles of 




Occlusive arterial lesions in humans are 
usually caused by atherosclerosis. the 
primary and secondary vasculitides are rare 
inflammatory conditions that may also 
cause such ischaemia as well as occasional 
aneurysms. these pathologies usually present 
with unusual manifestations of ischaemia, 
but may also be the cause of common 
symptoms such as stroke, hypertension, 
intermittent claudication or raynaud’s 
phenomenon. delayed recognition of these 
diseases is often associated with severe and 
irreversible complications. While the vasculi­
tides are usually managed by physicians, 
vascular surgeons should be able to recognise 
them and assist in their management when 
appropriate.
intrOductiOn
the vasculitides consist of primary and 
secondary pathologies in which non­specific 
transmural inflammation occurs within 
a blood vessel. the consequent vascular 
injury can cause vessel disruption, aneurysm 
formation or occlusion which can affect any 
blood vessel. the pathogenesis of each of these 
diseases is unclear, although they generally 
fall into one of the following groups:1
•	 Immune	 complex	 vasculitides:	 These	
are induced by circulating immune 
complexes	 or	 histamine.	 This	 results	 in	
the activation of the complement system, 
cytocines and monocytes in the vessel 
wall.
•	 Pauci-immune	 vasculitides:	 The	 anti-
neutrophil cytoplasmic antibodies 
(anca) were first described in 
conjunction with rapidly progressing 
glomerulonephritis. cytoplasmic anca 
(c­anca), perinuclear anca (p­anca) 
and	x-ANCA	(which	is	found	in	chronic	
inflammatory Git pathologies) have 
been described. in the pauci­immune 
vasculitides, activation of neutrophils 
results in vascular endothelial damage.2
•	 T-cell	 vasculitides:	 In	 these,	 vessel	 wall	
damage is caused by cd4 lymphocyte 
mediated immune reactions. 
the primary vasculitides occur rarely – 
between 20 and 100 cases per million. they 
usually present with non­specific clinical 
symptoms and signs – e.g. malaise, fever, 
weight loss – and generally evolve over a long 
duration. in addition, they may overlap with 
the manifestations of much more common 
infections, connective tissue diseases and 
malignancy. as a consequence making the 
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diagnosis is challenging and is confounded 
by	 the	 extensive	overlap	 in	 the	 clinical	 and	
pathological manifestations between the 
vasculitides. 
if unrecognised, these systemic diseases 
may be fatal. With appropriate treatment 
the majority of patients will improve but 
relapses are common. these relapses may 
be the result of recurrence, worsening of 
the inflammatory process or may be the 
consequence of complications of therapy.
classificatiOn Of 
Vasculitides
The	 heterogeneous	 nature	 and	 extensive	
overlapping clinical and pathological features 
have made classification difficult. currently, 
the most commonly used systems take 
into account the size of the vessel affected, 
the histological findings and the aetiology 
(table 16.1).1,3­5 there is also some value 
in differentiating between anca positive 
(e.g. Wegener’s granulomatosis, microscopic 
polyangiitis, churg­strauss vasculitis, drug 
induced vasculitis) and anca negative 
vasculitides.1 
Whilst, the classification systems attempt 
to highlight the differences among these 
diseases, in clinical practice these differences 
are not precise – polyarteritis nodosa for 
example	normally	considered	to	be	a	primary,	
medium vessel vasculitis, can also be caused 
by chronic hepatitis B or c infections and 
may involve small vessels.1,5
ClINICAl	PreseNTATIoN	of	
Vasculitides
in general, vasculitis should be considered to 
be present when chronic systemic symptoms 
of	inflammation,	including	pyrexia,	malaise,	
fatigue, and weight loss are associated with 
some form of organ dysfunction. arthralgia, 
myalgia, pain in the digits, rashes, anaemia 
of chronic disorders, pericarditis and a 
raised	esr	and	CrP	are	also	common.	The	
common organ specific manifestations are 
listed in table 16.2.
in general, the skin and peripheral nervous 
system signs are particularly useful because 
they tend to develop early in the course of 
Table 16.1: The major vasculitides3,22
Primary vasculitis
Predominantly large vessel vasculitis
Giant cell arteritis (also temporal  
  arteritis)
Takayasu’s arteritis
Predominantly medium vessel vasculitis
Polyarteritis nodosa
Kawasaki’s disease







No predominant vessel size
Behçet’s disease
Secondary vasculitis
Vasculitis secondary to connective tissue  
  disorders
Rheumatoid vasculitis
Systemic lupus erythematosus (SLE)
Systemic sclerosis
Scleroderma (including the CREST  
  syndrome)
Mixed connective tissue disease
Antiphospholipid antibody syndromes
Vasculitis secondary to viral disease
Hepatitis B and C virus





Thromboangitis obliterans (Buerger’s  
  disease)
Purpura fulminans (Waterhouse- 
  Friderichsen)
Thrombotic thrombocytopaenic  
  purpura 
Management of Vasculitides and Raynaud’s Syndrome 297
the disease and are easily detected. small 
vessel vasculitis is often first noted when 
palpable purpura develops while the vasculi­
tides affecting medium vessels commonly 
produce nodules, ulcers and gangrene.
the most common neurological mani­
festation of the vasculitides is mononeuritis 
multiplex.	 This	 is	 a	 distinctive	 peripheral	
neuropathy in which peripheral nerves infarct 
one at a time as a result of vasculitis in the 
vasa nervorum. sudden, asynchronous and 
asymmetrical loss of function of individual 
nerves occurs, most frequently affecting 
sensory nerves. in the absence of diabetes and 
nerve compression syndromes, mononeuritis 
multiplex	can	usually	be	assumed	to	be	due	




Haematological and serological changes will 
usually be present in individuals presenting 
with vasculitis. chronic microcytic anaemia, 
a	 raised	 esr	 and	 CrP	 are	 non-specific	
findings while red cell casts in urine, anti­
nuclear antibody (ana), complement, serum 
cryoglobulins and anca are more specific 
manifestations of the vasculitides. 
X­rays are generally not useful other than 
in Wegener’s granulomatosis where views of 
the nasal sinuses and chest, especially using 
computed tomography, may demonstrate 
diagnostic nodular lesions. 
Biopsy of involved tissues is the most 
helpful method of making a definitive 
diagnosis, especially if the biopsy is taken 
from a symptomatic site. Occasionally a 
serological test, an angiogram or another 
investigation can be pathognomonic. 
some investigations are helpful in 
excluding	 secondary	 causes	 of	 a	 vasculitis	
or those conditions that may mimic a 
vasculitis.	 examples	 include	 investigations	
to	 exclude	 drug	 reactions,	 syphilis,	 Human	
immunodeficiency Virus (HiV), infective 
endocarditis, and antiphospholipid syn­




While the vasculitides are usually treated by 
some form of immuno­suppression, the most 
important principle is to make sure that the 
treatment intensity is commensurate with 
Table 16.2: The common clinical manifestations of the vasculitides
Skin Livedo reticularis, palpable purpura, nodules, ulcers, gangrene 
Peripheral nervous system Mononeuritis multiplex, polyneuropathy
Central nervous system Stroke, seizures, encephalopathy
Eyes Blindness, scleritis
Heart Myocardial infarction, cardiomyopathy, pericarditis, arrhythmia
Lung Cough, chest pain, haemoptysis, shortness of breath
Kidney Hypertension, proteinuria, haematuria, renal failure
Gastrointestinal tract Haemorrhage, perforation
Genitals Testicular atrophy, reduced ovarian mass
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the severity of disease.6 While most forms 
of vasculitis require aggressive treatment to 
prevent morbidity and mortality, some do 
not.	for	example,	minor	vasculitis	limited	to	
the skin or where the secondary cause of the 
vasculitis can be identified and subsequently 
can be withdrawn or treated, require no such 
therapy. 
THe	vAsCulITIdes	of	sPeCIfIC	
interest tO Vascular 
surGeOns
Giant cell arteritis
Giant cell arteritis, which is also known 
as temporal arteritis, is the most common 
vasculitis found in adults. this panarteritis of 
the	extracranial	branches	of	the	carotid	artery	
occurs only in older individuals. the cause is 
unknown, but it is associated with the same 
Hlas found in rheumatoid arthritis and the 
disease process appears to be initiated by 
t cells in the adventitia responding to an 
unknown antigen. 
the classic symptoms of giant cell arteritis 
are:7




a condition that presents with acheing 
and stiffness of the shoulders, neck, and 
hip­girdle area (40%).
•	 Blindness	 (20%).	 This	 is	 the	 most	
significant complication of giant cell 
arteritis which can however be prevented 
by early treatment. the visual loss is 
caused by occlusion of the posterior 
ciliary branch of the ophthalmic artery. 
as a result, the blindness tends to be 
profound but fortunately is rarely the 
first manifestation of this complication 
and is usually preceded by episodes of 
diplopia and blurred vision.
•	 malaise	(50%).
the aorta and its major branches can also be 
involved (25%) leading to the development 
of thoracic aortic aneurysms some years after 
the first manifestation. 
Giant cell arteritis is characterised by 
a	 raised	 esr	 and	 CrP,	 and	 the	 presence	
of a normochromic, normocytic anaemia. 
ultrasound of the affected temporal arteries 
can show a characteristic ‘halo’ of peri­
vascular oedema or stenosis of the involved 
segments. angiography (usually Mra or 
cta) is required to demonstrate involve­
ment of the thoracic aorta and its branches 
if	 this	 is	 suspected,	while	PeT	can	demon-
strate occult large­vessel inflammation. the 
definitive method of making the diagnosis 
of giant cell arteritis is by histology of the 
temporal artery. as a result of the risk of 
sudden and irreversible blindness, a temporal 
artery biopsy, which has a low morbidity, 
should be performed without hesitation 
to confirm the diagnosis.8 as the artery 
may be affected by skip lesions a 3 to 5cm 
segment of artery should submitted for 
evaluation. the histology will demonstrate 
mononuclear cells infiltrating all layers of 
the artery with varying degrees of intimal 
proliferation and disruption of the internal 
elastic lamina.7 in recent years the possibility 
of	 using	 duplex	 ultrasonograpy	 to	 identify	
characteristic features of giant cell arteritis 
has been raised and further research in this 
area is warranted.
treatment with high doses of prednisone 
(40–60mg/day) and low dose aspirin should 
be started immediately when the diagnosis is 
suspected and before it has been confirmed by 
the temporal artery biopsy. if visual loss has 
been present for a few hours very high doses 
of intravenous methyl­prednisolone should 
be given as some vision may recover. usually, 
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after more than 24 hours the visual loss is 
permanent. in the long­term, in the presence 
of	 a	normal	esr	and	CrP,	 the	prednisone	
can be tapered at a rate determined by 
the	 clinical	 picture	 and	 the	 esr	 or	 CrP.8 
The	 effectiveness	 of	 methotrexate	 as	 a	
glucocorticoid­sparing drug for giant cell 
arteritis remains controversial while the role 
of biological therapies such as the tumour 
necrosis	 factor	 inhibitors,	 infliximab	 is	
unknown. 
the majority of patients with giant 
cell	 arteritis	will	 experience	 a	 relapse	 as	 the	
dose of prednisone is tapered and therefore 
prednisone will often need to be given 
for prolonged periods and with resultant 
frequent additional complications from the 
steroids therapy. 
surgical or endovascular interventions 
are occasionally indicated when the disease 
involves the aortic arch and its branches. 
Takayasu’s arteritis
this large vessel vasculitis affects mostly 
young adult women but has been found 
in infants and more rarely in the aged. 
the cause is unknown, yet the geographic 
distribution (predominantly south­east asia, 
india and africa) suggests environmental or 
genetic factors – e.g. Hla associations have 
been	found	in	Japanese	patients	–	while	the	
predominance in women of childbearing age 
points to oestrogen and progesterone playing 
a role.7 
takayasu’s arteritis is a t­cell driven, non­
specific granulomatous inflammation of all 
layers of the vessel wall which pathologically 
cannot be distinguished from giant cell 
arteritis.9 in response to the inflammation, 
cellular proliferation in the intima and 
media may lead to occlusion and stenosis 
of the artery, or weakening of the media 
and adventitia which can result in dilation and 
aneurysm formation. the most frequently 
affected vessels are the subclavian arteries, 
carotid arteries and the aorta, including the 
origin of its visceral branches. dilatation or 
aneurysm formation is usually only found 
in the aorta. the pulmonary and coronary 
arteries can be involved, albeit rarely and 
myocarditis associated with takayasu’s 
arteritis has also been described.9,10 
the disease is usually recognised by the 
manifestations of the vascular disease but 
constitutional symptoms of inflammation 
– fever, myalgia, arthralgia and weight loss 
– are commonly the earliest feature of this 
illness. the vascular manifestations include 
those associated with occlusion of arteries 
supplying the limbs, hypertension caused 
by aortic or renal artery stenosis, cerebro­
vascular manifestations due to occlusion of 
the carotid or vertebral arteries and aortic 
valve regurgitation. involvement of the 
coronary arteries, myocardium and pulmon­
ary arteries may cause angina and congestive 
cardiac failure.9­11 affected blood vessels are 
often tender and as a result, severe back pain, 
similar to that seen in patients with thoracic 
dissection, and pain in the carotid arteries is 
common.
No	 specific	 diagnostic	 test	 exists.	 An	
elevated	esr	and	CrP	are	usual	during	active	
phases of the disease.9 Microcytic anaemia 
develops in many patients. some patients 
have an elevated serum creatinine usually 
associated with longstanding hypertension, 
while glomerulonephritis occurs rarely.
Vascular imaging is essential to delineate 
the	 full	 extent	of	 the	 vascular	 involvement.	
Many favour Mra, as this can demonstrate 
changes in the vessel wall prior to luminal 
changes	being	noted.	PeT	may	detect	vascular	
inflammation but its accuracy in diagnosing 
the disease has not been determined but 
shows promise.12
the histological diagnosis is based on 
demonstrating the typical granulomatous 
vasculitis with giant cells in inflamed blood 
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vessels. this is however rarely possible, as 
biopsy of an affected artery while the disease 
is in an active phase is usually not advisable, 
and when specimens become available, 
while the disease is in a quiescent phase, 
only nonspecific transmural fibrosis can be 
found.
initial treatment requires high doses of 
prednisone in the acute phase which is then 
tapered to 10mg/day and continued for 
4 to 6 months. this regime is usually effective 
in addressing the inflammation in the 
vascular wall and abating the constitutional 
symptoms but two thirds of patients with 
Takayasu’s	 arteritis	 experience	 relapse	 of	
symptoms or progression of vascular disease. 
as a consequence life­long monitoring of 
this condition is mandatory.
methotrexate	 or	 mycophenolate	 mofetil	 
in combination with prednisone are occas­
ionally needed to reduce the inflammation 
and are also at times used without prednisone 
during phases of remission in order to 
minimise the corticosteroid side effects. 
Other drugs such as cyclophosphamide are 
used rarely because of their side effects but 
on occasion are all that some patients will 
respond	 to.	 Agents	 such	 as	 infliximab	 have	
shown promise but are usually unaffordable 
in the countries in which this disease 
predominates.9 the use of statins and low­
dose aspirin is encouraged.
the renal and cardiac dysfunction and 
hypertension that do not rapidly resolve after 
initial treatment for the acute inflammatory 
disease are managed using standard proto­
cols. diagnosing and managing these can, 
however, be challenging because of the 
diffuse vascular involvement. in patients 
who have cerebrovascular occlusive disease 
it is often also necessary to maintain a 
high blood pressure to avoid episodes of 
cerebral	 and	 brainstem	 hypoxia.	 surgical	
and endovascular interventions play an 
important role in treating occlusive and 
aneurysmal manifestations.11 the indications 
for intervention are the same as they are for 
other pathologies, i.e. usually only for life 
or limb threatening symptoms. fortunately, 
few interventions are required in the acute 
phase, as failure rates are high for procedures 
performed when acute inflammation is 
present, are high. revascularisation in our 
practice is deferred, if at all possible, until 
pharmacological therapy has completely 
suppressed the inflammation, which we 
believe	to	be	indicated	by	a	normal	CrP	and 
esr.	This	experience	is	shared	by	others.13
in the long­term once the active disease 
has been treated, most patients return to 
near normal lifestyles and survival rates. 
a significant number of patients do 
however die as a consequence of renal or 
cardiac failure,14 or from the complications 
of immuno suppressive treatment which 
is com pounded by the high prevalence of 




this condition usually occurs in young 
individuals	 after	 extended	 and	 ongoing	
exposure	to	tobacco	smoke,	but	can	affect	all	
age groups. the reason for the relationship 
between thromboangiitis obliterans and 
smoking has not been established. there 
are some indications that it has an 
immunological background, as increased 
levels of cell­mediated responses to vascular 
collagen and raised levels of anti­endothelial 
cell antibodies have been described.15 Other 
forms of smoking, such as cannabis, may 
also cause similar disease patterns.
thromboangiitis obliterans affects 
medium­sized arteries, veins and nerves. the 
lower limbs are most frequently affected but 
upper	limb	disease	is	common.	Pathologically,	
the blood vessel wall architecture is usually 
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intact, with preservation of the internal elastic 
lamina and absence of necrosis. during the 
acute phase of the disease a highly cellular, 
inflammatory thrombus is found occluding 
the lumen. in time this becomes a band of 
fibrous tissue. involvement of superficial 
veins is associated with a perivascular 
inflam matory cell infiltrate resulting in a 
thrombophlebitis.
thromboangiitis obliterans is usually 
first recognised by the presence of 
extremely	painful,	severe,	progressive	digital	
ischemia (often first thought to be splinter 
haemorrhages).15 Occasionally, the earliest 
lesion may be a superficial thrombophlebitis. 
In	advanced	cases	the	gangrene	may	extend	
well beyond the digits. Other organs are 
not	 involved.	 Prior	 to	 the	 development	 of	
gangrene,	pain	in	the	distal	extremities	may	
be due to a neuropathy. these symptoms 
are due to thickening of the tissues in the 
neurovascular bundles as a result of peri­
vascular inflammation.
the diagnosis is generally confirmed by 
identification of the typical pattern of vas­
cular	 involvement,	 exclusion	 of	 conditions	
that may mimic the disease, particularly 
atherosclerosis, and the presence of ongoing 
tobacco	 exposure.	 The	 demonstration	 of	 
typical ‘corkscrew’ collaterals in the neuro­
vascular bundles is characteristic but can 
also be found in other conditions such 
as diabetes mellitus and polyarteritis 
nodosa.15 While most diagnostic systems for 
thromboangiitis obliterans are intended to 
exclude	the	presence	of	atherosclerosis,	both	
these	 conditions	 often	 coexist,	 particularly	 
in patients over the age of 40 years.
the only effective treatment for 
thrombo angiitis obliterans is to completely 
stop smoking.15 immunosuppression and 
anticoagulation have no role. Occasional 
patients respond partially to prostaglandins. 
revascularisation, using endovascular tech­
niques or bypass grafts, is usually not feasible 
from a technical perspective, as a result of 
the inflammatory and thrombotic processes, 
and occlusion of distal runoff arteries, 
but may play a role if haemodynamically 
significant	 atherosclerotic	 lesions	 coexist	 in	
the patient. effective pain control is essential 
as patients will not be able to stop smoking 
without it.
With any ongoing smoking, which tends 
to be the norm – such patients appear to be 
particularly nicotine dependent – arterial 
disease progresses. limb loss therefore occurs 
frequently. On the other hand, complete 
abstinence is associated with remarkably 
good outcomes.
Behçet’s disease
Behçet’s disease was originally described 
as a syndrome consisting of recurrent oral 
aphthous ulcers, genital ulcers, and ocular 
inflammation. this idiopathic vasculitis 
can however, cause inflammation in almost 
any organ. the most significant morbidity 
associated with Behçet’s disease is related 
to ocular inflammation, which can cause 
blindness. Most manifestations of the 
disease are however episodic and become less 
frequent over time, but mortality may occur 
– mostly as a result of thrombosis, aneurysms 
and de novo rupture of large vessels.
Behçet’s disease is common in countries 
along the ancient silk road (eastern 
Mediterranean countries central asia to 
china) – as many as 4 per 1000 population 
have been described – and rare elsewhere. 
it mostly affects young adults and is more 
frequent in men. the distinct geographic 
distribution suggests an environmental or 
genetic aetiology. the pathologic changes 
point to an abnormal reactivity of neutro­
phils and lymphocytes causing damage 
by a vasculitic process which affects all 
types of arteries. Venous thrombosis is also 
common.16
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clinically, oral ulceration tends to be the 
earliest manifestation and must be present to 
make the diagnosis of Behçet’s disease. these 
painful ulcers, which affect the mucosa from 
the	 lips	 to	 the	 oropharynx,	 can	 be	 up	 to	 
2cm in diameter and usually have a white 
base and a red halo around the ulcer. Between 
two and five lesions are usually present at a 
time. the oral lesions tend to heal within 
two to three weeks without scarring while 
the genital ulcers tend to be larger and 
deeper, and often heal with scarring. in men 
the genital ulcers, which develop mostly 
on the scrotum and less commonly on 
the shaft of the penis, are associated with 
epididymitis. in women ulcers affect the 
vagina and vulva. Ocular inflammation is 
caused by an anterior and posterior uveitis. 
the anterior uveitis usually presents with 
a red eye, photophobia and blurred vision 
while the less common posterior uveitis, in 
combination with vasculitis affecting the 
carotid arteries and retina, can result in 
loss of vision. Other regularly encountered 
features include erythema nodosum, mig ra­
tory thrombophlebitis, arthritis, spondylitis, 
gastrointestinal aphthous ulcers, meningo­
encephalitis, stroke (thrombotic or haemor­
rhagic), sagittal sinus thrombosis, seizures, 
hearing and vestibular impairment, dementia 
and psychiatric conditions. Vascular mani­
festations, include thrombophlebitis and 
venous thrombo­embolism, occur in a 
fifth of patients while the arterial vasculitic 
manifestations are much less common – this 
arterial process particularly affects mesenteric 
and pulmonary arteries and may cause 
occlusion, aneurysm formation or primary 
rupture.17,18 
the diagnosis of Behçet’s disease rests 
predominantly on the clinical features but 
raised nonspecific markers of inflammation 
are common while the disease is active. 
serum igd levels are also often elevated. 
Histology of the aphthous ulcers reveals an 
inflammatory vascular infiltrate but a true 
vasculitis is rare.16 
the oral ulcers and other aphthous 
lesions are treated with topical steroids or 
dapsone while vision­ or life­ threatening 
complications are treated with high doses 
of intravenous corticosteroids and other 
immunosuppressive	 agents.	 Infliximab	 is	
also effective.16 Vascular interventions are 
required for symptomatic life threatening 
occlusive arterial disease, while aneurysms 
are treated according to their risk of rupture. 
all spontaneous arterial ruptures require 
emergency repair. thrombophlebitis is treated 
symptomatically and venous thrombo­
embolism is managed by anticoagulation.
Polyarteritis nodosa
this is a vasculitis confined to small and 
medium­sized arteries. Men and women are 
equally affected and the disease occurs in all 
age and ethnic groups. the association with 
chronic hepatitis B virus infection is well 
established.19
Polyarteritis	nodosa	can	involve	virtually	
all organs, but spares the lungs.20 commonly 
involved organs are:
•	 skin	 –	 includes	 livedo	 reticularis,	
nodules, papules, ulceration, and 
digital ischemia often associated with 
splinter haemorrhages which can lead to 
gangrene.
•	 Peripheral	nerves	–	usually	mononeuritis	
multiplex	 of	 the	 sural,	 peroneal,	 radial,	
and ulnar nerves.
•	 Gastrointestinal	 tract	 –	 commonly	
postprandial abdominal pain, but also 
mesenteric infarction or aneurysmal 
rupture of visceral arteries due to multiple 
microaneurysms.
•	 Kidneys	–	excluding	glomerulonephritis.	
the constitutional symptoms of inflam­
mation and pain, caused by myalgia, arthritis, 
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peripheral nerve infarction, testicular 
ischemia, or mesenteric vasculitis, are usually 
found. the other vascular presentations 
include renin­mediated hypertension, sub­
clinical arteriolar involvement of the cardiac 
circulation with occasional congestive 
cardiac failure and myocardial infarction, 
and occasional stroke. 
the diagnosis of polyarteritis nodosa is 
generally based on histology – most frequently 
of skin nodules, which specifically does not 
demonstrate granulomatous infarction – and 
the demonstration of microaneurysms in the 
visceral arteries. the ana and rheumatoid 
factor (rf) are usually negative. the anca 
tends to be positive but specific enzyme 
immunoassays for antibodies to proteinase­3 
or	myeloperoxidase	–	the	antigens	known	to	
be associated with systemic vasculitis – are 
negative.	 Polyarteritis	 nodosa	 is	 therefore	
not considered to be an anca associated 
vasculitis. 
When polyarteritis nodosa is associated 
with hepatitis B virus, polyarteritis nodosa 
tends to occur soon after the initial infection 
and these patients also have low complement 
levels.
treatment of idiopathic polyarteritis 
nodosa is similar to the other vasculitides 
already described.20 cyclophosphamide is 
required	for	approximately	half	the	patients	
whose disease is refractory to corticosteroids 
or who have significant life threatening 
involvement of major organs. Hepatitis 
B virus if present is treated with antiviral 
therapy which is the reason that the frequency 
of polyarteritis nodosa is diminishing.
the prognosis is usually favourable. Bowel 
perforation and rupture of a mesenteric 
microaneurysm however requires emergency 
surgical intervention which is the reason that 
this disease still causes mortality. recurrence 
rates after successful treatment of the initial 
clinical manifestation are unusual. 
Vasculitis secondary to connective 
tissue diseases
Systemic lupus erythematosus (SLE)
in sle, lupus vasculopathy is found in up 
to 40% of patients (mostly female). this 
usually is a typical vasculitis characterised 
by inflammation and necrosis in the vessel 




nodosa in 6%. 
lupus vasculitis is also associated with 
thrombotic thrombocytopenic purpura, 
venous thrombosis, antiphospholipid syn­
drome and urticarial vasculitis. 
lupus vasculopathy is an immunological 
disease with various autoantibodies, directly 
or indirectly affecting endothelial cells and 
cell membrane phospholipids. these cause 
chronic vessel wall damage.22 it is hypothesised 
that the endothelial deposition of circulating 
immune	 complexes	 causes	 activation	 of	
secondary inflammatory responses which 
then activate the complement cascade. this 
results in the destruction of vascular basal 
membranes.	The	expression	and	activation	of	
adhesion molecules appear to also be the key 
factors in the pathogenesis of the vasculitis 
by enabling leukocyte adhesion to the 
vessel endothelium and allowing leukocyte 
infiltration into affected tissues. in addition, 
lupus vasculitis also initiates the development 
and progression of atherosclerosis.
the antibodies involved in lupus vasculitis 
include:22,23
•	 Anti-endothelial	 cell	 antibodies	 which	
occur in over 80% of sle patients. it 
seems that their presence is typical of 
vasculitis, vascular thrombosis and lupus 
nephritis. these antibodies belong to 
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the igG, igM and iga immunoglobins 
and bind to antigens through the f(ab)2 
region. Multiple endothelial cell antigens 
react with these antibodies. 
•	 Antiphospholipid	 antibodies	which	bind	
to	exposed	endothelial	cell	phospholipids.	
these antibodies cause vascular endothelial 
damage, an increased arterial and venous 
thrombosis risk and proliferative heart 
valve lesions.
•	 ANCA.	 Their	 role	 in	 lupus	 vasculitis	
remains unclear.
•	 Anti-double-stranded	 dNA	 antibodies	
may take part in vascular damage in sle. 
they possess an anti­endothelial activity, 
which is directed against certain antigens 
on the endothelial surface.
the spectrum of the lupus vasculopathy 
ranges from the mild and most common 
form, affecting only vessels of the skin, to 
severe multiple organ dysfunction.21 the 
cutaneous lupus vasculopathy manifests as 
purpura, urticaria or bullous lesions in the 
extremities,	 and	 livedo	 reticularis	 on	 the	
trunk. Occasionally necrosis of the nail bed 
and digital ulceration is also found. lupus 
vasculitis in other organs can affect 20% of 
patients.	examples	include:
•	 focal	 segmental	 glomerulonephritis	 in	
the kidneys
•	 Necrotic	 inflammation	 in	alveolar	capil-
laries of the lungs
•	 Cognitive	dysfunction,	psychosis,	convul-
sions and strokes in the brain
•	 mononeuropathies	 in	 the	 peripheral	
nerves
•	 Gastrointestinal	 haemorrhage	 or	 per-
foration.
Antiphospholipid antibody syndrome 
(APS)
The	APs	is	defined	by	the	presence	of	at	least	
one of the many plasma antiphospholipid 
antibodies and the occurrence of at least 
one clinical feature of which venous or 
arterial thromboses, recurrent foetal loss, 
or thrombocytopenia are the most common. 
the antiphospholipid antibodies, which are 
directed against plasma proteins bound to 
anionic phospholipids, are: 24,25
•	 lupus	anticoagulants.	These	are	antibodies	
directed against plasma proteins such 
as b2 glycoprotein­1 or prothrombin 
bound to anionic phospholipids. despite 
their name, the presence of lupus 
anticoagulants is generally associated 
with thrombosis and they do not have an 
anticoagulant effect.
•	 Anticardiolipin	antibodies.




in addition to causing thrombosis, the above 
antibodies also increase vascular tone, thereby 
increasing the susceptibility to atherosclerosis, 
fetal loss and neurological damage.
the pathogenesis remains unclear. it 
appears that the antiphospholipid anti­
bodies develop in susceptible individuals 
following	 incidental	 exposure	 to	 currently	
undefined, infectious agents. Once the 
antibodies are present a second hit, such 
as an infection, prolonged immobilisation, 
pregnancy, hormone replacement therapy, 
malignancy or nephrotic syndrome is 
required for the syndrome to develop.24 
APs	 can	 either	 be	 a	 primary	 disease	 or	
can be associated with another secondary 
condition.25	for	example: 
•	 some	 healthy	 individuals	 have	 anti-
phospholipid antibodies but few ever get 
the	APs.	
•	 Autoimmune diseases – particularly sle.
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•	 Infections:
– Bacterial infections: e.g. bacterial 
septicaemia, tuberculosis, leprosy and 
post­streptococcal rheumatic fever.
– Viral infections: e.g. hepatitis a, B, 
and c, HiV, cytomegalovirus and 
epstein­Barr virus.
–	 Parasitic	 infections:	 malaria	 and	
visceral leishmaniasis 
•	 medications:	e.g.	phenothiazines,	pheny-
toin, hydralazine, α­interferon, quinine, 




ovary, breast, and bone; Hodgkin’s and 
non­Hodgkin’s lymphoma; myelofibrosis, 
polycythemia rubra vera, myeloid and 
lymphocytic leukemias.
the most common manifestations, in order 
of frequency, are deep vein thrombosis, 
thrombocytopenia, livedo reticularis, stroke, 
superficial thrombophlebitis, pulmonary 
embolism, fetal loss, transient ischemic 
attack	and	haemolytic	anaemia.	rarely,	APs	
results in ischaemic multiorgan failure. Other 
possible antiphospholipid antibodies related 
manifestations include migraine headache, 
raynaud’s phenomenon, pulmonary hyper­
tension, avascular necrosis, cutaneous ulcers 
that resemble pyoderma gangrenosum, 
adrenal insufficiency and cognitive deficits. 
The	presence	of	APs	should	be	considered	
in patients who have one or more otherwise 
unexplained	thrombotic	or	thrombo-embolic	
events, one or more adverse outcomes related 
to	 pregnancy	 or	 otherwise	 unexplained	
thrombocytopenia or bleeding.
Rheumatoid arthritis
the vasculitis associated with rheumatoid 
arthritis occurs in patients with previously 
severe disease, typically in those with long­
standing rheumatoid nodules, destructive 
joint disease, and high titres of rheumatoid 
factor. the development of a vasculitis is 
associated with new constitutional symp­
toms, skin ulceration, serositis, digital 
ischemia, and sensory and motor nerve 
dysfunction. it may also cause multiorgan 
dysfunction.
the vasculitis is caused by the deposition 
of	 immune	 complexes	 and	 antibody-
mediated destruction of endothelial cells 
resulting in vascular necrosis and luminal 
thrombosis.22 cigarette smoking and other 
factors have a significant adjunctive role. 
the diagnosis should ideally be estab­
lished by tissue biopsy. deep full­thickness 
skin biopsies from the edge of skin ulcers, that 
include some subcutaneous fat, can detect 
the presence of medium­vessel vasculitis. 
as in all the vasculitides, therapy must 
reflect the severity of organ involvement. 
When small, relatively painless infarctions 
around the nail bed develop, these do 
not necessarily require treatment. While 
this vasculitis does respond to therapy it 
generally is associated with a poor prognosis. 
fortunately, with the modern more effective 
treatment of rheumatoid arthritis, this 
condition is becoming rare.26
Scleroderma
scleroderma refers to the presence of 
thickened, hardened skin which is a common 
feature of a heterogeneous group of connec­
tive tissue disorders. When the characteristic 
skin disorder is associated with visceral organ 
involvement, the disease is termed systemic 
sclerosis. this is further subcategorised into 
diffuse cutaneous systemic sclerosis and 
limited cutaneous systemic sclerosis on the 
basis	 of	 the	 extent	 and	 distribution	 of	 the	 
skin involvement. limited systemic sclerosis 
is commonly associated with the crest 
syndrome (made up of cutaneous calci­
fication, raynaud’s phenomenon, oeso phageal 
dysmotility, sclerodactyly, and telangectasia).
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the visceral manifestations of systemic 
sclerosis are varied, including fibrotic and/or 
vascular complications of the circulatory, 
musculoskeletal, renal, pulmonary, and 
gastrointestinal systems. the characteristic 
clinical manifestation of vascular dys­
function is raynaud’s phenomenon.27 
episodes of raynaud’s phenomenon may 
be prolonged and can result in ischemic 
digital ulceration or infarction. in patients 
with limited cutaneous systemic sclerosis, 
raynaud’s phenomenon generally precedes 
other disease manifestations, often by many 
years. in contrast, in patients with diffuse 
cutaneous systemic sclerosis, the onset of 
raynaud’s phenomenon generally coincides 
with, and in some cases may even follow, 
the appearance of characteristic skin or 
musculoskeletal manifestations. Vascular 
injury and consequent chronic tissue damage 
underlies other serious complications of 
systemic sclerosis, including pulmonary 
artery hypertension, renal crisis and gastric 
antral vascular ectasia, and also contributes 
to the pathogenesis of cardiac and other 
gastrointestinal complications.28
the presence of systemic sclerosis is 
suggested by the presence of skin thickening 
and hardening that is not confined to one 
area. the diagnosis is supported by the 
presence of other non­cutaneous features 
such as:
•	 Heartburn	and/or	dysphagia	
•	 Acute	 onset	 of	 hypertension	 and	 renal	
dysfunction
•	 effort	 induced	 dyspnoea	 and	 interstitial	
pulmonary fibrosis
•	 Pulmonary	hypertension
•	 mucocutaneous	 telangiectasia	 on	 the	
face, lips, oral cavity, or hands
•	 digital	gangrene
Over 95% of patients have at least one 
autoantibody present. these include the 
presence of antinuclear antibodies and 
more specific antibodies such as anti­
topoisomerase i, anti­centromere, anti­rna 
polymerase iii and anti­beta2­glycoprotein i 
antibodies which are frequently present 
in patients with systemic sclerosis. the 
anti­topoisomerase i, anti­centromere and 
anti­rna polymerase iii antibodies are 
specific but only moderately sensitive. a skin 
biopsy is generally not needed to confirm a 
diagnosis. 
Infective vasculitides
Human immunodeficiency virus (HIV)
HiV infection can cause a range of vascular 
diseases.29 in the arterial system, HiV posi­
tive patients have been found to have both 
aneurysms and occlusive disease, mostly 
thrombotic disease. these vessel wall pathol­
ogies have unique histological characteristics 
where the inflammation is found in the vasa 
vasora. the inflammatory process consists of 
neutrophils surrounded by a cuff of plasma 
cells and lymphocytes. in addition, there 
is marked endothelial swelling with fibrin 
deposits on the luminal surface which leads 
to occlusion of the vasa vasora. in the wall 
of large arteries there are patches with acute 
inflammatory infiltrate, while in other regions 
there	 are	 areas	 of	 extensive	fibrosis	without	
inflammation. this suggests that there is a 
sequence of events starting with inflamma­
tion concentrated in the adventitia. later in 
the disease this may either cause trans­mural 
necrosis, possibly leading to aneurysm for­
mation, or the transmural inflammation 
may induce luminal thrombus.
Both HiV associated aneurysms and HiV 
associated arterial occlusion are considered to 
be acquired immunodeficiency syndrome 
(aids) defining conditions as they are 
usually associated with low cd4 counts in 
patients with other manifestations of the 
infection.
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HiV associated aneurysms have been 
found in most major arteries and are usually 
saccular in nature as a result of a localized 
region of cytoclastic activity in all layers of 
the	 arterial	 wall.	 Patients	 tend	 to	 present	
with multiple aneurysms. treatment is based 
on the usual principles of care for aneurysms 
but because of the poor general condition of 
affected patients, endovascular modalities are 
favoured.
Occlusive arterial disease most commonly 
involves the iliac arteries, but involvement 
of the coronary arteries is also found in 
young men who also smoke.30 treatment of 
these patients is hampered by the underlying 
vasculitis and is generally associated with 
a poor outcome unless the inflammatory 
process is reversed by treating the HiV 
infection. 
the association between venous 
thrombo­embolism and the HiV infection 
has also been conclusively proven.31 the 
reported incidence ranges from 0.2% to 
18%	 which	 is	 well	 in	 excess	 of	 what	 one	
would	 expect	 in	 a	 non-infected	 population	
(0.05%).	At	the	Johannesburg	Hospital	84%	
of patients who presented with deep vein 
thrombosis were found to be HiV positive. 
the severity of the HiV infection appears 
to be of significance as there is a greater 
incidence of venous thrombosis in patients 
with low cd4 counts, while the risk is even 
higher when individuals have confirmed 
aids. the reason for HiV infection’s 
relationship with venous thrombosis has not 
yet been conclusively elucidated, but appears 
to be multimodal, with all three limbs of 




in order to preserve the core temperature, the 
normal	 physiological	 response	 to	 exposure	
to a cold environment is to reduce capillary 
blood flow to the skin, mostly in the limbs 
and digits. this response is regulated by 
a	 complex	 interaction	 of	 neural	 signals,	
circulating hormones, and the release of 
local mediators mostly derived from the 
vascular endothelium. 
raynaud’s phenomenon describes an 
exaggerated	vascular	response	to	such	a	cold	
stimulus, or occasionally to emotional stress. 
the phenomenon is characterised by sharply 
demarcated colour changes of the skin of 
the digits. typically these consist initially 
of a phase of vascoconstriction and therefore 
a pale appearance (white) followed in time by 
cyanosis	 (blue)	as	a	 result	of	deoxygenation	
of haemoglobin within the affected tissues. 
finally,	 with	 reflex	 vasodilation	 as	 a	 result	
of the localised tissue ischaemia and the 
resultant	 inflow	 of	 oxygenated	 blood,	 a	
phase of hyperaemia (red) follows. Only the 
two initial phases, pallor and cyanosis, need 
to have been present for such an event to be 
recognised as a raynaud’s attack.32
Primary	 raynaud’s	 phenomenon	 des-
cribes this sequence of events in the absence 
of any associated disorders – occasionally 
called raynaud’s disease, which is inapprop­
riate as the phenomenon only describes an 
exaggerated	 physiological	 response	 in	 these	
individuals – while secondary raynaud’s 
phenomenon is associated with a known 
disease –referred to occasionally as raynaud’s 
syndrome (table 16.3).33
the defect in primary raynaud’s 
phenomenon is currently thought to be an 
increased vasoconstrictive response to α2 
adrenergic stimuli, particularly at the level 
of α2 adrenergic receptors, in the digital 
arteries and cutaneous arterioles.34	The	exact	
mechanisms have however not yet been 
established. the vascular response to the α2 
adrenergic agonists, serotonin and angiotensin 
ii is increased during cooling and can be 
reversed by tyrosine kinase inhibitors.35 
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an underlying genetic mechanism is also 
suggested by the occasional appearance of 
raynaud’s phenomenon in family clusters, 
and because women are most frequently 
afflicted by this condition, suggesting that 
some of the relevant loci are located on the 
X chromosome. the effect of oestrogen on 
α2	adrenergic	receptor	expression	may	how-
ever also be a reason for the higher prevalence 
of this condition amongst women.35
in secondary raynaud’s phenomenon, 
the many diseases, drugs, and environmental 
factors that can cause the syndrome, disrupt 
the normal mechanisms responsible for 
control of vessel reactivity, each apparently in 
a	unique	manner.	for	example,	 in	 systemic	
sclerosis (scleroderma) the primary mechanism 
is considered to be associated with intimal 
fibrosis and endothelial dysfunction. in these 
patients, endothelin­1 levels are significantly 
increased. this potent vasoconstrictor is also 
involved in the development of fibrosis and 
other structural changes in blood vessels.35 in 
addition, angiotensin ii levels are increased, 
while	 nitric	 oxide	 levels	 are	 consistently	
found to be low.
Prevalence of Raynaud’s 
Phenomenon
it is difficult to establish the prevalence of 
raynaud’s phenomenon because of the 
lack of standardisation in the diagnosis. 
However, when using at least pallor and 
cyanosis to define an episode of raynaud’s 
phenomenon, the prevalence ranges from 
3 to 20% in women and 3 to 14% in 
men.33	These	 wide	 ranges	 are	 explained	 by	
the great variation found across the world 
both in populations and in climate. for 
example	raynaud’s	phenomenon	is	common	
in central europe when compared to 
populations in the americas, africa and asia. 
it is also more common among women, in 
younger age groups (median onset 14 years), 
and in family members of individuals with 
Table 16.3: Common secondary causes of Raynaud’s phenomenon32,33,36 
Connective tissue diseases and vasculitis:
Systemic lupus erythematosus  Systemic sclerosis (scleroderma)
Rheumatoid arthritis  Giant cell arteritis 
Thromboangiitis obliterans  Primary biliary cirrhosis
Diseases of arteries in the upper limbs:
Atherosclerotic occlusive disease  Frost bite




Phaeochromocytoma  Thyroid disease
Carcinoid syndrome
Vasospastic conditions:
Vibration syndromes  Migraine and Prinzmetal angina
Haematological disorders:
Cryoglobulins and cold agglutinins  Polycythaemia
Paraproteinaemia 
Drugs and chemicals:
Ergotamines  Polyvinyl chloride
Bleomycin and Vinblastine 
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established raynaud’s phenomenon. about 
25% of individuals first develop symptoms 
after the age of 40 years and rarely after the 
age of 60 years.32 
Clinical Findings in Raynaud’s 
Phenomenon
raynaud’s phenomenon most frequently 
affects the fingers and hands. While the toes 
and feet are often also affected this tends 
not to concern patients as much. a typical 
episode usually begins in a single finger and 
then spreads to all other digits but the thumbs 
are often spared. Vasospasm of the skin of 
the ears, nose, face, knees and nipples is also 
commonly described. the ischaemic phase 
(pallor and cyanosis) usually lasts for 15 to 
20 minutes. Often when the initial phase of 
such an attack is prolonged, patients describe 
the feeling of pins and needles, numbness, 
and complain that the fingers are aching. 
these symptoms rapidly reverse in patients 
with primary raynaud’s phenomenon when 
the limb is rewarmed or the stress is alleviated. 
On the other hand in secondary raynaud’s 
phenomenon, asymmetry of symptoms, 
severe constant pain and ischaemic ulceration 
of the skin may occur, particularly when the 
mechanism of the underlying disease cannot 
be addressed.
exposure	to	cold	is	the	usual	trigger	and	
mostly occurs with rapid movement from 
a warmer to a cooler environment. as a 
consequence, air­conditioned rooms, or the 
mere washing of hands in cold water may be 
all it takes to bring on an episode. an attack 
is usually brought on by the distal limbs 
being	 exposed,	 but	 on	 occasion	 cooling	 of	
the trunk while the hands or feet areas are 
kept warm can also provoke an attack. as 
a consequence afflicted individuals should 
always ensure that all parts of their body are 
kept warm. 
Diagnosis of Raynaud’s Phenomenon
the diagnosis is mostly made when the classic 
symptoms are described. confirming the 
diagnosis by using provocative manoeuvres 
such as a cold water challenge, is unhelpful 
due to inconsistency in producing the 
syndrome. as the majority of patients 
presenting with raynaud’s phenomenon 
have no other underlying disease little benefit 
is achieved by further evaluation. 
in the small number of individuals who 
have a secondary cause or in whom symptoms 
persist, additional evaluation may be helpful, 
but	this	usually	requires	complex	diagnostic	
tools that are generally not freely available. 
the tools used to assess the vascular responses 
to environmental stimuli in the skin, include 
nail fold capillaroscopy, angiography, laser 
doppler flowmetry, and measurement of 
skin temperature. Generally, in patients with 
all forms of raynaud’s phenomenon these 
demonstrate that there is a delayed recovery 
phase	 of	 vascular	 flow	 after	 exposure	 to	
environmental stressors.32,33
every patient with primary raynaud’s 
phenomenon should be carefully evaluated 
clinically,	 to	 exclude	 a	 secondary	 cause.32 
the criteria to diagnose primary raynaud’s 
phenomenon include the presence of sym­
metrical, episodic attacks, no evidence of 
occlusive arterial disease, no gangrene, and 
if there is doubt a negative nail fold capillary 
examination	 (if	 this	 is	 available),	 a	negative	
ANA	 and	 normal	 esr/CrP.	 The	 clinical	
clues that secondary raynaud’s phenomenon 
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The	 presence	 of	 a	 raised	 esr	 or	 CrP	 and	
autoantibodies suggests an underlying 
connective tissue disease. 
ProGNosIs
Approximately	 50%	 of	 individuals	 with	
primary raynaud’s phenomenon will have 
a reduction in the frequency and severity of 
their symptoms over time, particularly if the 
onset of symptoms occurs in adolescence. 
Occasionally, raynaud’s phenomenon 
is the first manifestation of an underlying 
disease. the frequency at which individuals 
thought to initially have primary raynaud’s 
phenomenon are found to have a underlying 
cause identified is in the region of 1% per 
year, but is usually only noted 10 years or 
more after the primary presentation. the 
best predictor that this may happen is an 
abnormal nail fold capillary pattern.36 
treatMent
the initial management of patients with 
primary raynaud’s phenomenon is to 
promote lifestyle changes and to avoid the 




– dressing warmly 
–	 Keeping	all	digits	warm	even	in	very	
cold environments
– avoiding rapidly changing temper­
atures
•	 reducing	emo	tional	stress
•	 Avoid	 smoking	 and	 using	 drugs	 that	
cause vasoconstriction
if an attack occurs, the patient should be 
advised to go to a warm room and to place 
the hands under warm water, or to swing the 
upper limbs like a windmill.
in patients with secondary raynaud’s 
phenomenon the above measures are less 
helpful, as a result of more severe attacks. for 
this reason, and because of the progression 
of the ischaemia, they will usually require 
pharmacological intervention as do some 
patients with primary raynaud’s phenom­
enon in whom severe symptoms persist. 
Multiple classes of drugs are used in the 
management of raynaud’s phenomenon. 
the medications used are:37 
•	 Calcium	 channel	 blockers.	 Approxim-
ately 60% of patients have a clinically 
significant improvement of their symp­
toms (both in the reduction of the 
severity and frequency).7 not all calcium 
channel blockers are effective. nifedipine 
in relatively small doses given three to 
four times per day is the one most fre­
quently used. these drugs are introduced 
slowly in order to reduce the chance 
of	 patients	 experiencing	 headaches.	
secondary raynaud’s phenomenon is 
also less likely to benefit from this class 
of drugs.
•	 many	 direct	 and	 indirect	 vasodilators	 
have some effect but few are freely 
avail able for the management of this 
con dition. the serotonin reuptake inhib­
itors	 (such	 as	 fluoxetine),	 angiotensin	
receptor blockers (losartan) and other 
vasodilators such as buflomedil have 
demonstrated similar response rates 




analogue) are the most frequently used. 
the response rate in severely affected 
patients is in the region of 60%. infusions 
given over a few days often have benefit 
that often lasts several months.
•	 The	 phosphodiesterase	 inhibitors,	
sildenafil and tadalafil. the current data 
Management of Vasculitides and Raynaud’s Syndrome 311
supporting the use of these agents is 
sparse but promising.
•	 endothelin	 receptor	 antagonists	 e.g.	
bosentan which acts as an antagonist 
of endothelin­B receptors, has been 
demonstrated to significantly reduce the 
number of new ulcers forming in patients 
with systemic sclerosis. 
•	 Antioxidant	agents,	such	as	zinc	gluconate	
and n­acetylcysteine have demonstrated 
some improvement in small studies
•	 Atorvastatin	 does	 reduce	 the	 severity	
and frequency of raynaud’s events and 
of ulcer formation in patients with 
scleroderma. 
in addition, multiple antithrombotic agents 
have been utilised in patients with significant 
complications associated with raynaud’s 
phenomenon. these include aspirin, dipy­
ridamole, systemic anticoagulation, and 
thrombolytic therapy. the benefit of anti­
platelet therapy with aspirin (75 or 81mg/
day) is uncertain but use of this agent should 
be considered in all patients with secondary 
raynaud’s phenomenon.
the role of sympathectomy has recently 
again been considered in the management of 
severe raynaud’s phenomenon mostly as a 
result of the development of less invasive and 
more focused procedures being available.36 
these include:
•	 A	 local	 chemical	 sympathectomy	 using	
a long acting local anaesthetic agent to 
achieve a wrist or digital nerve block 
which can reverse vasoconstriction and 
relieves pain. 
•	 Intradigital	botulinum	toxin	A	has	been	
used to achieve a chemical sympathectomy. 
While this is an interesting option, the 
current	described	experience	is	limited.37
•	 Cervical	 sympathectomy	 is	 likely	 to	
result in the immediate improvement in 
blood flow, but the degree and duration 
of improvement is very variable and long 
term outcomes particularly in patients 
with secondary raynaud’s phenomenon 
are poor.
•	 localised	 microsurgical	 digital	 sym-
pathectomy has been introduced as an 
alternative	 to	 proximal	 sympathectomy.	
this option appears to have more 
durable outcomes and is often now the 
choice when sympathectomy is the last 
treatment modality available, particularly 
only after vasodilator drugs and after 
specific treatments for any reversible 
cause, such as vasculitis, have failed.
recOMMendatiOns
all patients with raynaud’s phenomenon 
should avoid cold temperatures, stress, and 
vasoconstrictors, while always being dressed 
in warm clothing, and should warm their 
hands in order to terminate an attack.
Most importantly, patients with primary 
uncomplicated raynaud’s phenomenon 
should not be over­treated. therapy 
should only be initiated in those patients 
with primary uncomplicated raynaud’s 
phenomenon in whom non­pharmacologic 
measures have failed. these medications 
should be introduced in a step wise manner 
and should only be continued if appropriate 
symptom	 relief	 is	 achieved.	 Parenteral	
medications and sympathectomy are usually 
not indicated.
Patients	 with	 secondary	 raynaud’s	
phenomenon may require more aggressive 
therapy. the major goal is to reduce the 
frequency of attacks, and to prevent digital 
ulceration. it is unlikely that any medical 
therapy on its own will completely terminate 
attacks. in general, a step wise escalation of 
therapy, initially using the oral vasodilators, 
followed by parenteral medications and lastly 
localised digital sympathectomy, should be 
used in accordance to the level of symptoms 
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and	 the	 extent	 of	 digital	 ulceration	 and	
gangrene. all such patients should also have 
the underlying disease addressed, which in 
patients with the vasculitides include the 
use of a statin and an antiplatelet agent. in 
addition appropriate and effective analgesia 
will be required. such pain control and 
surgical amputation may be the only option 
in patients with late stage ischemia or severe 
structural arterial disease.
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EPidEMioLoGY
sepsis remains a common reason for intens­
ive care unit (iCU) admission and is a leading 
cause of mortality. this disease is now 
recognized to be a time­sensitive emergency, 
because patients stand the best chance for 
survival when effective therapeutic inter­
ventions are delivered as early as possible. 
however, consistent data are lacking 
regard ing the incidence and outcome of 
sepsis in iCUs globally. data extrapolated 
from a cohort study conducted by Finfer 
et al in 2004 across twenty three closed 
multidisciplinary iCUs showed that 
the incidence of severe sepsis among adult 
patients was 0.77 patients per 1000 popu­
lation (95% Ci, 0.76–0.79). there were 
752 episodes of severe sepsis identified in 
691 patients, equating to 11.8 patients with 
severe sepsis per 100 iCU admissions (95% 
Ci, 10.9–12.6).1 the EPisEPsis study group 
conducted a nationwide, prospective, multi­
centre survey of patients with severe sepsis 
in 206 French iCUs over two consecutive 
weeks. they estimated the incidence of severe 
sepsis to be 0.95 cases per 1000 in the French 
population.2 in the United states between 
1979 and 2000 an annualized increase of 
8.7% in the incidence of sepsis was noted. 
(From about 164,000 cases (0.82 per 1000 
population) to nearly 660,000 cases (2.4 per 
1000 population)).3 
sepsis is estimated to affect 18 million 
people worldwide each year and kill 
1400 people each day. according to an 
epidemiological study, sepsis affects about 
700,000 people annually in the United 
states alone, with an overall mortality rate 
of 30%, or more than 50% in patients with 
septic shock and/or multiple system organ 
failure.3 From a financial perspective, sepsis 
represents a major burden to the health 
care system in most developed countries 
since septic patients require admission and 
aggressive treatment in the iCUs. table 17.1 
gives the overall information on the incidence 
and mortality of severe sepsis in different 
parts of the world. despite differences in 
study methodology, comparison between 
continents, countries and regions is possible, 
with some consistent themes emerging:
1) severe sepsis represents a substantial 
health­care burden in all developed 
nations;
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2) the overall incidence is increasing; 
3) the overall mortality rate is declining; 
and
4) the nature of infections is changing, 
with infections caused by gram­positive 
organisms increasing in frequency.4
historiCaL PErsPECtiVE and 
dEFinition
the word ‘sepsis’ [σηψις], is the original 
Greek word for the ‘decomposition of animal 
or vegetable organic matter in the presence 
of bacteria’.9 the word was first noted in 
homer’s poems, where ‘sepsis’ is a derivative 
of the verb form sepo [σηπω], which 
means ‘i rot’. the term is also found in the 
writings of the physician and philosopher 
hippocrates (circa 400 BC) in his Corpus 
hippocraticum. hippocrates viewed sepsis 
as the dangerous, odiferous, biological decay 
that could occur in the body.10 
in 1991, the american College of Chest 
Physicians (aCCP) and the society of 
Critical Care Medicine (sCCM) convened 
a ‘Consensus Conference’ in an attempt ‘to 
provide a conceptual and a practical frame­
work to define the systemic inflammatory 
response to infection, which is a progressive 
injurious process that falls under the 
generalized term ‘sepsis’ and includes sepsis­
associated organ dysfunction as well’.11 they 
proposed the phrase ‘systemic inflammatory 
response syndrome’ (sirs) which described 
the inflammatory process, independent of its 
cause. the systemic inflammatory response 
was seen in association with a large number 
of clinical conditions. apart from infectious 
processes, other common non­infectious 
pathologic processes include pancreatitis, 
ischemia, multiple trauma, and tissue injury. 
when sirs is the result of confirmed 
infectious process, it is termed ‘sEPsis’, and 
is frequently associated with the development 
of multiple organ dysfunction and failure. 
this is the most common cause of death 
in patients who have severe sepsis.12 the 
1991 aCCP­sCCM Consensus Conference 
also introduced the term ‘Multiple organ 
dysfunction syndrome’ (Mods). Mods 
was defined as ‘the presence of altered organ 
function in an acutely ill patient such that 
homeostasis cannot be maintained without 
intervention.’ 13
in 2001, several north american and 
European intensive care societies agreed to 
revisit the definitions for sepsis and related 
conditions. this international sepsis defin­
itions conference (Group of experts and 
opinion leaders represented by sCCM, 











Australia & New Zealand4 11.8 0.77 26.51 37.51
United States3 11.85 2.4 NR 17.9*
France2 15.36 0.95 NR 41.9
United Kingdom7 28.7 0.66 30.8 44.7
Brazil8 17.4 NR NR 47
* sepsis overall (not severe sepsis), nr: not reported
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aCCP, the European society of intensive 
Care Medicine (EsiCM), the american 
thoracic society (ats), and the surgical 
infection society (sis)) revisited the 1992 
sepsis guidelines. they expanded the list 
of signs and symptoms of sepsis to reflect 
clinical bedside experience; no evidence 
exists to support a change to the defin­
itions.14 infection was defined as a micro­
bial phenomenon characterised by an 
inflammatory response to the presence of 
microorganisms or the invasion of normally 
sterile host tissue by microorganisms.
the sirs concept is valid to the extent 
that a systemic inflammatory response is non 
specific and can be triggered by a variety of 
infectious and non­infectious conditions.
Current definitions do not allow for 
precise staging of the host response to 
infection and categorical definitions, such as 
sirs, severe sepsis, and septic shock, have 
important limitations. despite this, the 
sirs concept has been globally adopted by 
clinicians and investigators, table 17.2. 
risK FaCtors For sEPsis
Factors which are potentially responsible for 
the growing incidence of sepsis and septic 
shock include: 
1) increased awareness and sensitivity of 
the diagnosis, 




 5) Malignancy, 
 6) diabetes mellitus, 
 7) increasing number of transplant 
recipients and transplantation 
procedures, 
 8) increasing number of patients who 
have compromised immune status, 
 9) acquired immunodeficiency syndrome, 
10) increasing use of aggressive invasive 
procedures in patient management and 
diagnosis, 
11) increasing number of resistant 
microorganisms and 
12) increasing number of elderly patients.
Causative agents 
Gram­positive organisms, endotoxin­
containing Gram­negative organisms, fungi 
and other microbial pathogens can trigger 
sepsis. Gram­negative bacteria are respons­
ible for most clinical sepsis, although in 
the past decade the spectrum of invading 
microorganisms appears to be shifting to 
Gram­positive bacteria and fungi. in a recent 
australian study, infection was confirmed by 
positive culture in about 58% of episodes. 
of the organisms cultured, 48.3% were 
gram­positive and 38.5% gram­negative; 
other organisms, including yeasts, fungi, 
legionellae and mycobacteria accounted for 
the remaining 13.2%.
PathoPhYsioLoGY oF sEPsis
the pathophysiology of sepsis is a complex 
process. Pertinent factors include the bacterial 
density of contamination and the underlying 
immune status. sirs is a result of uncontrol­
led activation of innate immune effector 
mechanisms which serve to localize and 
control bacterial invasion and to initiate repair 
of injured tissue. the innate immune system, 
comprising cell ular (polymorphonuclear 
leuko cytes, macrophages, natural killer cells, 
dendritic cells) and humoral components 
(complement and coagulation systems), is 
activated in early sepsis. Components of the 
innate immune response from the first line of 
defence are involved in the recognition and 
destruction of pathogens and allow time for 
acquired immune response to be effective. 
the host–microbe interaction leads to the 
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activation of several mediators within the 
innate immune system, including 
proinflammatory and anti­inflammatory 
cytokines and the coagulation cascade. the 
consequences of a systemic proinflammatory 
reaction include endothelial damage, 
microvascular dys function, impaired 
tissue oxygenation and organ injury. 
the consequences of an excessive anti­
inflammatory response include anergy 
and immunosuppression. in addition, 
pro­ and anti­inflammatory processes 
may interfere with each other, creating a 
state of what has been termed destructive 
immunologic dissonance.16 the entire pro­
cess is often described as uncontrolled, 
maladaptive, or dysregulated. sepsis may 
therefore pathologically be described as an 
autodestructive process that permits the 
extension of a normal pathophysiologic 
response to infection that can result in 
Mods.17 
Table 17.2: Definitions of Systemic Inflammatory Response Syndrome (SIRS) and 
Different Degrees of Severity of Sepsis.15
Condition Description 
SIRS Two or more of the following conditions:
• Temperature >38.5°C or <35.0°C; 
• Heart rate of >90 beats/min; 
• Respiratory rate of >20 breaths/min or PaCO
2
 of <32mmHg; and
• White blood cell count of >12,000cells/mL, <4000cells/mL, or >10% immature 
(band) forms
Sepsis SIRS in response to documented infection (culture or Gram stain of blood, sputum, 
urine, or normally sterile body fluid positive for pathogenic microorganism; or focus 
of infection identified by visual inspection) 
Severe 
sepsis
Sepsis and at least one of the following signs of organ hypoperfusion or organ 
dysfunction: 
• Areas of mottled skin; 
• Capillary refilling of ≥3 seconds; 
• Urinary output of <0.5mL/kg for at least 1 hour or renal replacement therapy; 
lactate >2mmol/L;
• Abrupt change in mental status or abnormal EEG findings;
•  Platelet count of <100,000cells/mL or disseminated intravascular coagulation; 
• Acute lung injury/Acute Respiratory Distress Syndrome; and 
• Cardiac dysfunction (echocardiography)
Septic shock Severe sepsis and one of the following conditions: 
• Systemic mean blood pressure (BP) of <60mmHg (<80mmHg if previous 
hypertension) after 20 to 30mL/kg starch or 40 to 60mL/kg saline solution, or 
pulmonary capillary wedge pressure (PCWP) between 12 and 20mmHg. 
• Need for dopamine of >5mcg/kg/min, or nor adrenaline or epinephrine of 




Need for dopamine at >15mcg/kg/min, or nor adrenaline or adrenaline at 
>0.25mcg/kg/min to maintain mean BP at >60mmHg (80mmHg if previous 
hypertension)
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Innate immunity and toll-like 
receptors (TLRs)
sirs is a consequence of uncontrolled 
activation of innate immune responses 
triggered when ‘pattern recognition’ receptors 
sense the presence of molecular signatures that 
are present in the pathogens. Pre­eminent 
among such pattern recognition receptors 
are tLrs which serve as primary sensors of 
the innate immune system.18 Various tLrs 
have been identified in humans; tLr4 is 
expressed on the cell surface and serves as 
the primary sensor for endotoxins (also 
called lipopolysaccharides (LPs)) which 
are a constituent of the outer membrane 
of Gram­negative bacteria. the exoskeleton 
of Gram­positive bacteria is comprised of 
peptidoglycan (PGn) and lipoteichoic acid 
(Lta) which is sensed by tLr2.19
Proinflammatory response 
the primitive, but effective, local inflam­
matory processes (adherence, chemotaxis, 
phagocytosis, bacterial killing) are highly 
regulated at various levels, mainly through 
the production of macrophage cytokines. 
once a macrophage has been triggered and 
activated during the invasion of tissue by 
bacteria, it secretes cytokines (tumor necrosis 
factor (tnF), interleukins (iL)) and other 
mediators into the cell’s microenvironment. 
these cytokines and other multiple mediators 
act in concert, initiating and then amplifying 
the resultant generalised inflammatory 
processes. the overwhelming systemic 
inflam matory response that follows manifests 
itself in the shock syndrome characterised 
by endothelial damage, coagulopathy, loss 
of vascular tone, myocardial dysfunction, 
tissue hypoperfusion, and Mods. however, 
several randomised human clinical trials 
involving antagonism of pro­inflammatory 
cytokines and anti­endotoxin strategies have 
either failed to improve survival, or reported 
worsened survival. a potential reason for 
failure of these immunomodulatory strategies 
could have been that sepsis is a heterogeneous 
disorder, and the timing of the intervention(s) 
may have been inappropriate. 
Coagulation cascade 
inflammatory mediators, such as 
tnF, initiate coagulation through the 
induction of tissue factor expression, 
primarily on monocyte/macrophages, 
polymorphonuclear and endothelial cells. 
the activation of the coagulation cascade 
leads to fibrin and clot formation. there is 
also loss of native anticoagulant function, 
indicated by decreased activity and 
circulating levels of protein C. a cross–talk 
between inflammatory and coagulation 
pathways leads to self­amplifying loops of 
activation of endothelium, leading to the 
formation of microthrombi and further 
endothelial damage, thus setting the stage 
for the development of consumptive 
coagulopathy. despite improved 
understanding of the coagulation pathway, 
it remains unclear why activated Protein C 
improved ‘survival’ in a landmark clinical 
trial,21 while strategies targeted at other 
components of the coagulation cascade, 
such as tissue factor pathway inhibitor 
and antithrombin iii, had no impact on 
mortality.22 in addition to the complex 
coagulation cascade and hyperpermeable 
state of endothelium, vaso motor tone of 
the vessel is also affected. Vasoconstrictive 
(endothelin, thromboxane a2, and platelet 
activating factor (PaF)) and vasodilatory 
(nitric oxide and prostacyclin) metabolites 
are produced in certain circum stances 
with important consequences in terms 
of microcirculatory homeostasis and 
maintenance of tissue perfusion.19.
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MULtiorGan dYsFUnCtion 
sYndroME (Mods)
the precise mechanisms of cell injury and 
resulting organ dysfunction in sepsis are not 
clearly understood. Multiorgan dysfunction 
syndrome is associated with widespread 
endothelial and parenchymal cell injury, 
some of which can be explained by hypoxic 
hypoxia, direct cytotoxicity or apoptosis. 
Epithelial and endothelial 
dysfunction
Epithelial cells line the organs involved in 
Mods, including liver, lung, and intestines. 
increased permeability and loss of the 
epithelial cell barrier is hypothesized to play a 
role in Mods. increased permeability of the 
lung epithelial cells leads to acute lung injury 
(aLi) or acute respiratory distress syndrome 
(ards). the reactive oxygen species, lytic 
enzymes, and vasoactive substances (nitric 
oxide, endothelial growth factors) lead to 
microcirculatory injury, which is com­
pounded by the inability of the erythrocytes 
to navigate the septic microcirculation. 
these changes are accompanied by periph­
eral vasodilatation, hypotension, tissue 
hypoperfusion, increased permeability, and 
increased peripheral oedema leading to 
hypoxic hypoxia frequently observed in severe 
sepsis. direct cytotoxicity due to endotoxin, 
tnF­alpha, and nitric oxide may cause 
damage to mitochondrial electron transport, 
leading to disordered energy metabolism. 
this is called cytopathic or histotoxic anoxia 
which is an inability to utilize oxygen even 
when it is available. 
Immune suppression and apoptosis
Few patients die shortly after the onset of 
sepsis due to profound hypotension or 
hypoxemia whilst many will have prolonged 
iCU course and may die following noso­
comial infection. the interaction between 
proinflammatory and anti­inflammatory 
mediators plays an important role in deter­
mining the outcome of sepsis. activated 
Cd4 t cells are programmed to secrete 
cytokines with either of two distinct 
and antagonistic profiles. they secrete 
cytokines with inflammatory (type 1 helper 
t­cell [th1]) properties, including tnF, 
interferon­1 and interleukin­2, or cytokines 
with anti­inflammatory (type 2 helper t­cell 
[th2]) properties for example, interleukin­4 
and interleukin­10. the factors that 
determine whether Cd4 t cells have th1 
or th2 responses are currently unknown but 
may be influenced by the type of pathogen, 
the size of the bacterial inoculum, and the 
site of infection.17 Programmed cell death 
(apoptosis) is a normal cellular process. 
sepsis is accompanied by increased apoptosis 
of lymphoid cells, and, to a lesser extent, 
parenchymal cells. ingestion of apoptotic 
cells by macrophages may lead to a th2 
response, while ingestion of necrotic cells 
favours a th1 response, thus apoptosis 
contributes to immunosuppression. the 
proinflammatory cytokines may delay 
apoptosis in activated macrophages and 
neutrophils, but other tissues, such as the 
gut epithelium, may undergo accelerated 
apoptosis. Endogenous release of steroids 
during stress increases apop tosis. therefore, 
derangement of apop tosis appears to play a 




the widespread disruptions in severe sepsis 
can result in profound cardio­circulatory 
dysfunction. this manifests itself as shock. 
the dysfunction involves the cardiac, 
peripheral vascular (macrovascular) and 
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microcirculatory elements of the circulation, 
depending on the degrees of cardiac or 
vascular dysfunction and the volume status 
of the patient. the clinical picture ranges 
from cold, clammy and under­perfused to 
one of hyperdynamic shock. however in 
clinical practice, hyperdynamic shock is seen 
much more frequently.23
Landry and oliver20 enumerated the 
primary mechanisms for vascular smooth 
muscle relaxation in sepsis to include 
activation of atP­sensitive potassium 
channels in the plasma membrane, activation 
of inducible nitric oxide synthase, and 
vasopressin deficiency. there are numerous 
vasoregulatory mediators in septic shock, 
and distant organs, including the brain, 
adrenal glands, liver, and heart; all influence 
vascular tone.22 another potential factor that 
may contribute to persistence of vasodilation 
is impaired compensatory secretion of anti­
diuretic hormone (vasopressin). Low doses 
of vasopressin may be effective in raising 
blood pressure in patients refractory to other 
vasopressors and may have other potential 
physiologic benefits. however, the recent 
Vasst trial, a randomized, controlled trial 
comparing norepinephrine alone to nore­
pinephrine plus vasopressin at 0.03units/
min, showed no difference in outcome in the 
intent to treat population.24
the situation in septic shock is further 
complicated by widespread microcirculatory 
dysfunction, further impairing tissue oxygen 
delivery, and diminished mitochondrial 
activity resulting in impaired oxygen 
extraction. the microcirculation is a key 
target organ for injury in the sepsis syndrome. 
sepsis is associated with a decrease in the 
number of functional capillaries (capillarity), 
which causes an inability to extract oxygen 
maximally. these changes may be due to 
extrinsic compression of the capillary by tissue 
oedema, endothelial swelling, and plugging of 
the capillary lumen by leukocytes or red blood 
cells (which lose their normal deformability 
properties in sepsis). nitric oxide plays a 
pivotal and multifaceted role in the complex 
pathophysiology of sepsis in maintaining 
microcirculatory homeostasis and patency, 
especially when the microcirculation sustains 
an insult (as with sepsis).25 in the healthy 
state and under pathologic conditions, no 
maintains microcirculatory homeostasis by 
regulating microvascular tone, leukocyte 
adhesion, platelet aggregation, microthrombi 
formation, and microvascular permeability. 
direct or indirect effects of one or 
more circulating myocardial depressing 
substances results in myocardial depression, 
ventricular dilatation and/or decreased left 
ventricular ejection fraction further affecting 
circulation.26 
Endothelial injury and the inflammatory 
process due to neutrophil entrapment 
in the pulmonary vasculature leads to 
disturbed capillary blood flow and enhanced 
microvascular permeability, resulting in 
interstitial and alveolar oedema.27 ards is 
a frequent and well described manifestation 
of severe sepsis. Mechanisms by which sepsis 
and endotoxinemia might lead to acute renal 
failure are incompletely understood. sepsis 
often results in acute renal failure due to acute 
tubular necrosis and systemic hypotension, 
direct renal vasoconstriction and release of 
various cytokines are contributing factors.27 
nervous system involvement in sepsis can 
be central, causing encephalopathy, or 
peripheral resulting in neuropathy. at least 
25% of patients admitted to medical or 
surgical intensive care units for more than 
seven days have some degree of acquired 
paresis. neurological manifestations of sepsis 
includes limb muscle weakness and atrophy, 
reduced or absent deep tendon reflexes, loss 
of peripheral sensation to light touch and 
pin prick with relative preservation of cranial 
nerve function.28
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ManaGEMEnt
treatment of sepsis and septic shock rests 
upon the triad of hemodynamic resuscitation, 
antimicrobial therapy and source control. 
Establishing vascular access and initiating 
aggressive fluid resuscitation should be the 
initial priority when managing patients 
with severe sepsis or septic shock. relative 
intravascular hypovolaemia is common and 
rapid large volume infusions of intravenous 
fluids, appropriate vasopressor and inotropic 
support are indicated as initial therapy unless 
there is coexisting clinical or radiographic 
evidence of heart failure. rivers et al.29 in 
a single centre randomised controlled trial 
(rCt) demonstrated decreased mortality 
by initiating protocolized resuscitation of 
patients with sepsis induced shock in the 
first 6 hours. the goals of initial resuscitation 
involved the use of crystalloids or colloids 
to maintain central venous pressure of 
8–12mmhg and a mean arterial pressure 
(MaP) of at least 65mmhg with fluid and 
norepinephrine or dopamine as the initial 
vasopressor of choice. dobutamine may 
be indicated in patients with myocardial 
dysfunction as indicated by elevated cardiac 
filling pressures and low cardiac output. 
treatment goals, assuring vital organs are 
perfused are; to maintain a urine output 
0.5mL/kg/hr and a superior vena caval 
oxygen saturation (scvo
2
) or mixed venous 
oxygen saturation (svo
2
) less than 70% or 
65% respectively. rivers et al reported a 
mortality reduction from 47% in the control 
group to 31% in the treatment group. there 
is no evidence for the use of dopamine to 
increase urine output as a treatment goal. 
the saline versus albumin Fluid Evaluation 
(saFE study) was the largest randomised 
controlled trial ever performed in the critical 
care population. it involved almost 6997 
critically ill patients (that is, not specifically 
with sepsis), run by the australian and new 
Zealand intensive Care society Clinical 
trials Group (anZiCs CtG). Patients 
were eligible if clinicians judged that fluid 
was needed to treat intravascular volume 
depletion, and were treated with either 
4% albumin (n = 3497) or 0.9% (n = 3500) 
saline. the two groups had similar baseline 
characteristics. death from any cause 
during the 28 days after randomisation 
was the primary outcome measure. there 
were 726 deaths in the albumin group, as 
compared with 729 deaths in the saline 
group (relative risk of death, 0.99; 95% 
Ci, 0.91 to 1.09; P = 0.87). there were no 
significant differences between the groups 
in the mean (±sd) numbers of days spent 
in the iCU (6.5 ± 6.6 in the albumin group 
and 6.2 ± 6.2 in the saline group, P = 0.44), 
days spent in the hospital (15.3 ± 9.6 and 
15.6 ± 9.6, respectively; P = 0.30), days 
of mechanical ventilation (4.5 ± 6.1 and 
4.3 ± 5.7, respectively; P = 0.74), or days 
of renal­replacement therapy (0.5 ± 2.3 and 
0.4 ± 2.0, respectively; P = 0.41).30
the surviving sepsis Campaign (ssC), 
an initiative of the EsiCM, the international 
sepsis Forum and sCCM was developed 
to improve the management, diagnosis, 
and treatment of sepsis. the most recent 
version was published early in 2008.31 as per 
these ssC guidelines, the rivers study was 
considered as Grade B evidence. however, 
there were also concerns raised regarding the 
widespread implementation of this study into 
practise in other jurisdictions. one of these 
was the high mortality in the control group 
(47%). Mortality in other studies reporting 
severe sepsis has been quoted as 30–35%,7,32 
which could suggest that while Early Goal 
directed therapy may have a beneficial effect 
when baseline mortality is high, it may be less 
effective when baseline outcomes are better. 
the other concern was that introduction of 
this treatment paradigm would have huge 
implications for staffing and infrastructure 
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in the emergency department and iCU. 
the scvo
2
 may be used as warning signal 
in critically ill patients and act as a marker 
instead of svo
2
 in emergency departments 
and iCU in the early stages of hemodynamic 
optimisation. Following initial resuscitation, 
it is uncertain whether goal­ directed therapy 
should be based on scvo
2
 instead of svo
2
. 
studies have provided indirect support for 
the use of lactate in goal­directed therapy, 
but there is as yet insufficient evidence for its 
use as a resuscitation end point. single centre 
studies frequently either lack the scientific 
rigor or external validity required to support 
widespread changes in practice and their 
premature incorporation into guidelines 
may make the conduct of definitive studies 
more difficult.33 arisE (australasian 
resuscitation in sepsis Evaluation) is a 
phase iii, multi­centre, anZiCs CtG 
(australia, new Zealand intensive Care 
society­ Clinical trails Group) endorsed, 
randomised, controlled study evaluating 
early goal­directed therapy in 1600 patients 
presenting to the Emergency department 
with severe sepsis across australian, new 
Zealand and hong Kong hospitals. the 
study is being conducted over 2.5 years 
through the australian and new Zealand 
intensive Care research Centre, department 
of Epidemiology and Preventive Medicine, 
Monash University. this study will hopefully 
provide more directions towards this 
topic.
appropriate cultures should properly be 
obtained before initiating antibiotic therapy 
but this should not prevent administration of 
antimicrobial therapy. it is recommended that 
empiric antibiotic therapy be administered 
within 1 hour of the identification of severe 
sepsis. in the presence of septic shock, each 
hour delay in achieving administration of 
effective antibiotics appears to be associated 
with a measurable increase in mortality.34 
rapid diagnostic methods (polymerase 
chain reaction, micro­arrays) might aid in 
the earlier identification of pathogens.35 
specific anatomical diagnosis of infection 
and measures to control the source within 
the first 6 hours following presentation is 
recommended.31 a procalcitonin­guided 
strategy to treat suspected bacterial infections 
in non­surgical patients in intensive care 
units could also reduce antibiotic exposure 
with no apparent adverse outcomes. a 
multicentre, prospective, parallel­group, 
open­label, randomised trial demonstrated 
procalcitonin guided strategy resulted in 
sig nificantly more days without antibiotics 
when compared with control group 
(14.3 days [sd 9.1] versus 11.6 days 
[sd 8.2]; absolute difference 2.7 days, 
95% Ci .0.4 to 4.1, p<0.0001).36
Steroids
Use of corticosteroids in patients with septic 
shock has been controversial for several 
decades and continues to be controversial 
despite the publication of several trials 
including two recent large rCt’s. sepsis 
may be associated with relative adrenal 
insufficiency in a substantial subset of 
patients. 
annane et al37 in a multi­centre French 
trial, randomised 300 patients with 
septic shock to receive either placebo or 
hydrocortisone 50mg intravenously every 
six hours (plus fludrocortisone 50mcg 
enterally once a day) within eight hours of 
onset of septic shock. treatment continued 
for seven days. Based upon a high­dose 
(250mcg) aCth (adrenocorticotropic 
hormone) stimulation test, the patients were 
classified as having adequate adrenal reserve 
(maximum increase in serum cortisol of 
>9mcg/dL) (248nmol/L) or inadequate 
adrenal reserve (maximum cortisol increase of 
≤9mcg/dL (248nmol/L). this study showed 
significant shock reversal and reduction 
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of mortality rate in patients with relative 
adrenal insufficiency. Based on this study 
many clinicians still use steroids in certain 
subsets of septic patients. 
however, a recent large, European 
multicenter trial CortiCUs,38 which was 
a double blinded randomised trial assigning 
499 patients with septic shock to receive 
hydrocortisone or placebo intravenously 
every six hours for five days, followed 
by a tapering regimen, failed to show a 
survival benefit with steroid therapy for 
septic shock irrespective of the presence or 
absence of relative adrenal insufficiency. 
the therapeutic guiding role of the aCth 
stimulation test was cast into doubt by this 
trial. 
similarities between the two studies 
included a beneficial steroid effect on time 
to shock reversal, no evidence for increased 
risk of neuromuscular weakness, and no 
hyperglycaemia. differences between the two 
studies annane37 and CortiCUs trial38 
respectively include: Entry window (8 vs. 
72 hours; sBP <90mmhg (>1 hour 
vs. <1 hour); additional treatment with 
(fludrocortisone vs. no fludrocortisone); 
treatment duration (7 vs. 11 days); weaning 
(none vs. present); differences in steroid 
effects according to the response to aCth 
test (yes vs. no) and increased risk of 
superinfection (no vs. yes). 
another major difficulty regarding the 
use of steroid is the lack of definitive data 
regarding the appropriate cutoff values for 
‘relative’ adrenal insufficiency in the shock 
state. significant variability exists in the 
results of cortisol assay among research 
centres and whether they estimate free or 
total cortisol assay. Free and total cortisol 
may vary significantly based upon the 
protein concentration. which steroid is also 
a pertinent question; there is little evidence 
for steroids other than hydrocortisone.
Recombinant human activated 
protein C (rhAPC)
Coagulation plays a central role during 
inflammatory processes, particularly those 
due to infection. drotrecogin alfa (activated) 
or recombinant human activated protein C 
is a 54 kilodalton recombinant glycoprotein 
with antithrombotic, profibrinolytic, and 
anti­inflammatory properties. Protein C is 
an inactive zymogen synthesized in the liver. 
when coupled to thrombomodulin on the 
endothelial surface, protein C is converted to 
activated Protein C by thrombin. significant 
decreases in protein C levels have been well 
documented in sepsis and specifically in 
septic shock.39 the conversion of protein C 
to activated protein C may be impaired during 
sepsis as a result of the down­regulation 
of thrombomodulin by inflammatory 
cytokines. this led to interest in therapeutic 
administration of activated protein C (and 
similar agents) in early sepsis. it has now 
become the first biological therapy to report 
a mortality benefit in human rCt of 
sepsis. the recombinant human activated 
Protein C worldwide Evaluation in severe 
sepsis (ProwEss)21 was a randomized, 
double­blind, placebo­controlled, multi­
center trial. Patients with systemic inflam­
mation and organ failure due to acute 
infection were randomised to placebo or to 
receive rhaPC (24μg/kg/hr) for 96 hours. the 
primary end point was death from any cause at 
28 days. nearly 1700 patients were 
randomized but the study was stopped 
early when an interim analysis showed a 
survival benefit in the treatment arm. Based 
upon post­hoc analyses of the study data, 
drotrecogin alpha was of greater benefit 
in the most severely ill patients, including 
those with an aPaChE (acute Physiology 
and Chronic health Evaluation) ii score 
≥25 and patients with multiple organ 
dysfunction. this formed the basis for the 
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Fda decision to license rhaPC for use in 
sepsis.
a subsequent trial of rhaPC in patients 
with a low risk of death was halted after an 
interim analysis for lack of effectiveness.40 
another trial, involving the paediatric 
population who had severe sepsis, was 
stopped after approximately 400 patients 
had been enrolled, again because of futility. 
the surviving sepsis Guidelines31 suggest 
its use (if there are no contraindications) in 
adult patients with sepsis­ induced organ dys­
function associated with a clinical assessment 
of high risk of death, most of whom will 
have acute Physiology and Chronic health 
Evaluation (aPaChE) ii >25. however, 
there has been considerable criticism of 
the ProwEss trial and australian and 
new Zealand intensive Care society does 
not recommend the use of rhaPC within 
practice guidelines.41 the decision regarding 
administration of rhaPC is likely best made 
based upon clinicians assessment of high risk 
of death due to multiorgan failure versus the 
risk of bleeding complications. 
Currently another trial ‘Efficacy and safety 
of drotrecogin alfa (activated) in adult 
Patients with septic shock’ is in progress. 
the purpose of this placebo­controlled study 
is to determine if drotrecogin alfa (activated) 
treatment provides significant mortality 
reduction and organ function improvement 
in patients with septic shock compared with 
placebo treatment in patients receiving the 
current standard of care for septic shock. 
this study will also assess the effectiveness 
of drotrecogin alfa (activated) in reducing 
28­day mortality in patients with septic 
shock and concomitant severe protein C 
deficiency at baseline. 
Glucose control
hyperglycaemia is reported to be associated 
with poor clinical outcomes in critically 
ill patients. in 2001, Van den Berghe 
and colleagues42 demonstrated significant 
mortality benefit by intensive insulin infusion 
titrated to strict euglycaemia in critically 
ill surgical patients. however, a second 
study by the same author which targeted 
medical iCU patients using the same strict 
glycaemic control failed to show survival 
benefit. with the available evidence, most 
clinicians agree that glycaemic control is a 
desirable intervention in critically ill patients 
although the optimal blood glucose range is 
still controversial. a blood glucose level of 
140 to 180 mg/dL (7.7 to 10mmol/L) appears 
to be an acceptable target. a more stringent 
target (80 to 108mg/dL [4.5 to 6mmol/L]) 
was associated with higher incidence of 
hypoglycaemia and significantly higher 
90­day mortality in the recently published 
(australasian based) niCE sUGar trail. 
this study randomised 6104 patients; 3054 
were assigned to undergo intensive control 
81 to 108mg/dL (4.5 to 6.0mmol/L) and 
3050 to undergo conventional control blood 
glucose <180mg/dL (<10.0nmol/L). severe 
hypoglycaemia was reported in 6.8% of 
the intensive­control group and 0.5% of the 
conventional­control group (P<0.001).43
Renal replacement therapy
Continuous renal replacement therapy 
(Crrt) involves either dialysis based solute 
removal) or filtration (convection­based 
solute and water removal) treatments that 
operate in a continuous mode. haemofiltration 
(hF) refers to the use of a hydrostatic 
pressure gradient to induce the filtration 
(or convection) of plasma water across the 
membrane of the hemofilter. hemofiltration 
has been described as a technique which 
can lower cytokine levels. in a single­centre, 
randomized, controlled study in which con­
tinuous renal­replacement therapy was the 
sole treatment approach, survival improved 
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when the intensity of therapy was increased 
from an assigned effluent rate of 20ml/kg/hr 
to either 35 or 45ml/kg/hr.44 Bellomo and 
colleagues recently reported the results of the 
randomized Evaluation of normal versus 
augmented Level (rEnaL) replacement 
therapy study, which was conducted at 
multiple centers in australia and new 
Zealand. in the rEnaL study,45 1508 
patients with severe acute kidney injury 
who required intensive care were randomly 
assigned to receive continuous venovenous 
hemodiafiltration at a total effluent flow 
rate of either 25ml or 40ml/kg/hr. in both 
treatment groups, 44.7% of patients died in 
the first 90 days after randomization (odds 
ratio, 1.00; 95% Ci, 0.81 to 1.23). overall, 
94.4% of patients who were alive after 
90 days no longer required dialysis, with 
similar rates of recovery of kidney function 




the therapeutic use of hMG­Coa reductase 
inhibitors, also known as statins, has become 
widespread as lipid lowering agents in 
the prevention and treatment of major 
cardiovascular diseases. there is evidence 
that statins have beneficial effects on the 
perioperative risk of cardiac complications 
and sepsis. statins appear to have actions 
on vascular nitric oxide through the balance 
of inducible and endothelial nitric oxide 
synthase. statins also have anti­inflammatory 
properties, exemplified by reduced plasma 
concentrations of the inflammatory cyto­
kines tumour necrosis factor (tnF­α) and 
interleukin (iL­6). Various cohort studies 
have been published in favour of statins 
reducing mortality in sepsis. a meta­analysis 
of cohort studies (including one randomised 
trial) demonstrated a protective effect for 
statins in patients with sepsis and/or other 
infections compared to placebo for various 
infection­related outcomes; (0.61 (95% Ci, 
0.48­0.73) for 30­day mortality).46 Current 
ongoing rCts of statins in sepsis are to be 
watched with interest. 
Other adjuvant therapies in sepsis 
Cytokines and anticytokine therapies 
Granulocyte Colony stimulating Factor 
(G­CsF) is a cytokine involved in 
myelopoiesis with a predominant effect on 
the polymorphonuclear leukocyte (PMn). 
studies in humans with pneumonia have had 
encouraging results but with no mortality 
benefit. tnF plays a central role in the 
inflammatory process; but phase iii clinical 
trials of tnF antibodies and tnF fusion 
proteins led to negative results. similarly, 
studies on antagonising interleukin­1, a 
cytokine with similar properties, also led to 
negative results. 
Pooled immunoglobulin (IVIG) 
immunoglobulin has been used for 
sepsis states such as meningococcal 
and pneumococcal infections with 
some documented survival benefit. 
the mechanism of action is most likely 
immunomodulatory and binding and 
inactivation of the bacterial derived super­
antigen. its use has been suggested in 
toxic shock syndrome due to Streptococcus 
pyogenes and Staphylococcus aureus. a large 
randomised trial of 653 patients with severe 
sepsis failed to demonstrate any benefit of 
iViG. the 28­day mortality rate was 37.3% 
in the placebo group and 39.3% in the iViG 
group and thus not significantly different 
(p = 0.6695).47 Many clinical studies and 
meta­analyses have examined the utility of 
iViG, but there exists insufficient data to 
make a firm recommendations for its use in 
sepsis and septic shock. 
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Acute respiratory distress syndrome 
(ARDS)
ards is an acute (rapid onset) syndrome with 
bilateral infiltrates on chest x­ray; no evidence 
of elevated left atrial pressure (the pulmonary 
capillary wedge pressure is ≤18 mmhg if 
measured) and a ratio of arterial oxygen 





) is less than 201mmhg. Conventional 
therapy, aimed at tidal volumes (V
t 
) of 
12–15ml/kg, generated lung volumes that 
overstretched alveoli resulting in volutrauma 
(secondary lung injury). the landmark 
acute respiratory distress syndrome net­
work multicenter trial randomly assigned 
861 mechanically ventilated patients with 
ards and acute lung injury to receive 
low tidal volume ventilation (tidal volume 
of 6 mL/kg) or conventional mechanical 
ventilation (tidal volume of 12mL/kg). 
Mechanical ventilation using a lower tidal 
resulted in decreased mortality and an increase 
in the number of days without ventilator 
use.48 the overall goal was to maintain 
acceptable gas exchange and avoid alveolar 
over­distension, tolerating hypercapnia if 
indicated; thus minimizing the adverse 
effects of mechanical ventilation. 
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introduCtion
ischaemia-reperfusion injury (iri) is 
defined as the paradoxical exacerbation of 
cellular dysfunction and death, following 
restoration of blood flow to previously 
ischaemic tissues. reestablishment of blood 
flow is essential to salvage ischaemic tissues. 
However reperfusion itself paradoxically 
causes further damage, threatening function 
and viability of the organ. iri occurs in a 
wide range of organs including the heart, 
lung, kidney, gut, skeletal muscle and brain 
and may involve not only the ischaemic 
organ itself but may also induce systemic 
damage to distant organs, potentially leading 
to multi-system organ failure. reperfusion 
injury is a multi-factorial process resulting 
in extensive tissue destruction. the aim of 
this review is to summarise these molecular 
and cellular mechanisms and thus provide an 




ischaemia occurs when the blood supply is 
less than the demand required for normal 
function, resulting in deficiencies in oxygen, 
glucose and other substances required for 
metabolism. derangements in metabolic 
function begin during this ischaemic 
phase. initially, glycogen breakdown by 
mitochondrial anaerobic glycolysis produces 
two molecules of adenosine triphosphate 
(AtP) along with lactic acid, resulting in 
a decrease in tissue pH, which then acts 
by negative feedback to inhibit further 
AtP production. (Figure 18.1) AtP 
is then sequentially broken down into 
adenosine diphosphate (AdP), adenosine 
monophosphate (AmP) and inosine mono-
phosphate (imP) and then further into 
adenosine, inosine, hypoxanthine and 
xanthine. (Figure 18.2 upper panel)
At the cellular level, a lack of AtP 
production causes AtP-dependent ionic 
pumps, including the na+/K+ and Ca2+ 
pumps, to fail and the transmembrane ionic 
gradients are lost. Consequently, cytosolic 
sodium content rises, drawing with it, a 
volume of water to attempt to maintain 
the osmotic equilibrium and resulting in 
hydroponic swelling of the cells. to maintain 
the ionic balance, potassium ions escape from 
the cell into the interstitium (reviewed in1). 
Calcium is released from the mitochondria 
into the cytoplasm and into extracellular 
spaces, thereby activating mitochondrial 
calcium-dependent cytosolic proteases 
includ ing calpain, which then converts the 
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cellular enzyme xanthine dehydrogenase to 
xanthine oxidase (Figure 18.2 upper panel). 
Phospholipases are also activated during 
ischaemia, degrading membrane lipids and 
increasing the levels of circulating fatty 
acids.
Gene expression during ischaemia
As well as metabolic derangements, ischaemia 
induces expression of a large number of 
genes, which play a major role in the tissue’s 
response to ischaemic damage. An rnA 
expression microarray analysis, using mouse 
soleus muscle rendered ischaemic by femoral 
ligation, found that expression of 962 genes 
was induced and 327 genes were repressed.2 
the activated genes were largely clustered 
into cytokine genes and mediators of 
inflammation and immune cell infiltration. 
the repressed genes were largely involved in 
energy production, including mitochondrial 
respiration and fatty acid oxidation. 
Hypoxia itself also activates a number 
of genes, particularly transcription factors, 
including activating protein-1 (AP-1), 
hypoxia-inducible factor-1 (HiF-1) and 
nuclear factor-kappab (nF-kb). HiF-1 then 
activates transcription of other genes such as 
vascular endothelial growth factor (VegF), 
erythropoietin and glucose transporter-1, 
which all play an important role in the cells’ 
adaptive responses to hypoxia (reviewed in3). 
expression of both HiF-1 and cyclo- 
oxygenase-2 (CoX-2) are also induced in 
the lungs of rats subjected to haemorrhagic 
shock. CoX-2 may promote the inflam-
matory response through the rapid and 
exaggerated production of nitric oxide 
and prostaglandins, contributing to organ 
damage.4 Activation of nF-kb occurs during 
both the ischaemic and reperfusion phases 
and will therefore be discussed below.
FigURE 18.1: Dysregulation of metabolic pathways 
during ischaemia
Anaerobic glycolysis during ischaemia results in 
negative feedback which inhibits ATP production, 
thereby inducing tissue acidosis, calcium influx and 
tissue oedema. 
Pathophysiology of Reperfusion Injury 333
rePerFuSion
Reactive oxygen species
table 18.1 illustrates the major reactive 
oxygen species (roS), which play a role in 
tissue damage during iri and the sources 
of generation of these species. reactive 
oxygen species have a destructive role in 
mediating tissue damage during iri. during 
ischaemia, the degradation of AtP produces 
hypoxanthine (Figure 18.2, upper panel). 
once the ischaemic tissue is reperfused, 
an influx of molecular oxygen catalyses 
xanthine oxidase to degrade hypoxanthine 
to uric acid and thereby liberating the highly 
reactive superoxide anion (o
2
-) (Figure 18.2, 
lower panel). Superoxide is subsequently 





the hydroxyl radical (oH•) (Figure 18.2, 
lower panel). the major consequence of 
hydroxyl radical production is peroxidation 
of the lipid structures of cell membranes 
FigURE 18.2: Generation of reactive oxygen species during reperfusion
During ischaemia, ATP is degraded and xanthine dehydrogenase converted to xanthine oxidase. In the presence 
of fresh oxygenated blood, xanthine oxidase catalyses the conversion of hypoxathine to highly reactive and 
toxic superoxide anions with urea as a by-product. Superoxide then reacts with H+ to initiate the production 
of both hydrogen peroxide and the hydroxyl radical, which ultimately mediate lipid peroxidation and tissue 
damage.
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resulting in the production and systemic 
release of proinflammatory eicosanoids, 
disruption of cell permeability and ultimately 
cell death. during iri, roS also activate 
endothelial cells, elevating the activity of the 
transcription factor, nF-κb. once activated, 
the endothelial cell produces e-selectin, 
vascular cell adhesion molecule-1 (VCAm-1), 
intercellular adhesion molecule-1 (iCAm-1), 
endothelial-leukocyte adhesion molecule 
(elAm-1) plasminogen activator inhibitor-1 
(PAi-1), tissue factor and interleukin-8 
(il-8). these adhesion molecules contribute 
to important interactions between the 
neutrophil and the endothelium and will be 
discussed in more detail later.
Superoxide anions can be detected within 
ischaemic muscle and also in the venous 
effluent of reperfused limbs,5 suggesting an 
additional role for superoxide in inducing 
damage to distant organs during skeletal 
muscle reperfusion injury. Xanthine oxidase 
is located within a spectrum of cell types 
and tissues to varying degrees, indicating 
widespread distribution and differing 
susceptibility to oxidant-mediated iri. 
inhibition of xanthine oxidase activity, 
by administration of allopurinol prior 
to ischaemia, reduces the production of 
superoxide and hence reduces the severity of 
reperfusion injury in animal models using 
a range of tissues including skeletal muscle, 
brain and gut. results in humans are also 
promising. A systematic review6 provided 
evidence that allopurinol was effective in 
some studies in reducing the severity of post-
operative cardiac dysfunction and arrhythmias 
after coronary artery bypass grafting, although 
larger trials are needed. Studies in other 
clinical settings of iri remain limited. 
Eicosanoids
As discussed above, roS initiate lipid 
peroxidation of cellular membranes, releas-
ing arachidonic acid, the main substrate for 
the production of prostaglandins, throm-
boxanes and leukotrienes (Figure 18.2, 
lower panel). these derivatives of arachi-
donic acid are collectively known as the 
eicosanoids and play a major role in the 
pathophysiology of iri.
Prostaglandins, synthesised from 
arach i donic acid via the cyclo-oxygenase 
pathway, have a protective vasodilatory 
effect in iri. However, since prostaglandins 
are short-lived molecules, their rapid 
depletion subsequently leads to uninhibited 
vasoconstriction, reduced local blood flow 
and exacerbation of ischaemia. the potential 
of prostaglandins to ameliorate the degree of 
metabolic and tissue derangement following 
iri has been demonstrated in various 
tissues. in a placebo-controlled trial of 
human liver transplantation, administration 
TablE18.1: Reactive Oxygen species 
involved in IRI
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Pathophysiology of Reperfusion Injury 335
of prostacyclin was shown to improve 
postoperative graft function.7 Patients 
who received prostacyclin demonstrated 
better post-operative myocardial oxygen 
consumption after coronary artery bypass 
surgery8 and improved muscle blood flow 







minutes following skeletal muscle iri, thus 
promoting vasoconstriction and platelet 
aggregation. these events coincide with 
a rapid rise in pulmonary artery pressure 
and a subsequent increase in pulmonary 
microvascular permeability,10 which correlates 
with sequestration of polymorphonuclear 
cells in the lungs. in animal models of lower 
limb iri, thromboxane synthase inhibitors 
and synthetic thromboxane A
2 
receptor 
antagonists prevented pulmonary leuko-
sequestration, thereby increasing blood 
flow to reperfused tissues and preserving 
tissue viability and function.11 together 
these studies suggest that administration 
of thromboxane A2 antagonists may offer 
therapeutic potential to improve limb salvage 
rates after surgery for acute ischaemia.
leukotrienes are also synthesised from 
arachidonic acid through the activation 
of 5-lipoxygenase and participate in the 
inflammatory cascade of iri. leukotrienes 
lead to local and systemic injury by 
their direct proinflammatory action on 
endothelial and smooth muscle cells and 







 modify the 
endothelial cytoskeleton, leading to increased 
vascular permeability and also enhance 
smooth muscle contraction, resulting in 
vasoconstriction. the lung produces leuko-
trienes following remote iri. the direct 
effects of leukotrienes on pulmonary 
micro vessels lead to increased permeability, 
transient pulmonary hypertension and the 
activation of the endothelium to produce 
thromboxane, resulting in additional vaso-
constriction. the leukotriene b
4,
 released 
by activated neutrophils, leads to further 
pulmonary neutrophil accumulation. 
the administration of 5-lipoxygenase 
synthesis inhibitors has been successfully 
used in animal studies to attenuate iri. Such 





 and inhibit neutrophil infiltration 
normally induced by iri, reducing mucosal 
permeability.12 However, there is currently 
very little up to date information on their 
use in a clinical situation. 
Nitric oxide 
nitric oxide (no) is a signalling molecule 
synthesised from L-arginine by the nitric 
oxide synthase enzyme (noS) of which 
there are three types, constitutive (cnoS), 
inducible (inoS) and endothelial (enoS). 
An initial surge in no level in the first 
15 minutes of the ischaemic phase is due to 
transient enoS activation. this is followed 
during early reperfusion by a general 
decline in endothelial function and loss of 
functional enoS, so that no production 
falls, along with an increased production 
of reactive oxygen species. enoS-derived 
no is also necessary for the maintenance 
of vascular tone. the reduction in enoS 
levels that occurs in iri may therefore 
predispose to vasoconstriction, a common 
response seen in iri. the second surge in 
no production is largely due to cytokine-
mediated up-regulation of inoS after about 
three hours of reperfusion.
the pathophysiological role of nitric 
oxide in reperfusion injury is variable, being 
dependent on the nature of its generation 
and appears to be tissue specific. in some 
instances, no acts as an anti-oxidant and, in 
others, combines with the superoxide anion 
to form the peroxynitrite radical, a potent 
promoter of lipid peroxidation and hence 
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cellular membrane disruption (reviewed 
in13). manipulation of nitric oxide production 
during iri, using a range of techniques, has 
recently provided considerable evidence for a 
principal role for nitric oxide in the aetiology 
of iri. myocardial iri has been well studied, 
with paradoxical results, where low doses of 
no were found to be protective and high 
doses harmful. the influence of no in skeletal 
muscle iri has been less well characterized, 
with some studies suggesting that no may 
potentiate cytotoxicity and others suggesting 
a beneficial role for no in extremity iri. in 
skeletal muscle iri, no production may be 
deleterious and inhibition of noS activity 
using a non-specific noS inhibitor greatly 
reduced the severity of muscle damage.14 
the assessment of experimental data 
derived from pharmacological noS 
inhibition is difficult due to the non-
specificity of noS inhibitors; administration 
of these inhibitors at differing times during 
the injury merely adds to the complexity. 
in essence, augmentation of no delivery 
may be beneficial with respect to protection, 
particularly in the ischaemic and early 
reperfusion phase. inhibition of the inoS-
induced surge in no production at later 
times during reperfusion also mediates 
defense against iri-induced tissue damage. 
However, in the clinical setting, systemic 
distortion of no kinetics by administering 
noS inhibitors would be likely to induce 
wide-ranging physiological disturbances. 
Further investigations will be needed to define 
a role for noS inhibition in ameliorating 
the severity of iri and local administration 
of these inhibitors may be required. 
Endothelin
endothelins are potent peptide vaso-
constrictors produced by the vascular 
endo thelium. Hypoxia, growth factors, 
angiotensin ii and noradrenaline all 
stimulate their production resulting in Ca2+-
mediated vasoconstriction. endothelin-1 is 
elevated following skeletal muscle iri during 
both the ischaemic and reperfusion phases 
and mediates capillary vasoconstriction, 
neutrophil aggregation and neutrophil-
endothelial interactions. endothelin-1 inhib-
itors, including bosentan and tezosentan, 
inhibit neutrophil infiltration, increase 
functional capillary density, microvascular 
perfusion and hence tissue viability and 
function following iri.15 However these 
inhibitors are not in widespread clinical use. 
Cytokines
Hypoxia and iri both induce the expression 
of numerous cytokines, including tumour 
necrosis factor-alpha (tnF-α,) interleukin-1 
(il-1), interleukin-6 (il-6), interleukin-8 
(il-8) and platelet activating factor (PAF), in 
association with elevations in activity of the 
transcription factor, nF-kb (reviewed in16) 
these cytokines are released systemically and 
are thus important in the development of 
systemic inflammatory response syndrome 
and ultimately multi-system organ failure. 
tnF-α is a 17-kilodalton pro-
inflammatory cytokine produced by activated 
macrophages, monocytes, t-lymphocytes, 
natural killer cells and fibroblasts. it is a potent 
chemoattractant and early response cytokine, 
which subsequently induces expression of 
il-1, il-6, il-8 and PAF. elevated serum 
levels of tnF-α have been detected during 
cerebral and skeletal muscle iri and are 
known to increase neutrophil sequestration 
and permeability following pulmonary iri. 
Serum tnF-α levels increased rapidly in 
an animal model of aortic clamping, thus 
inducing up-regulation of inoS, which 
increased no production in the lungs, 
leading to more severe lung damage.17 in 
the same study, inhibition of tnF-α activity 
prior to limb ischaemia decreased pulmonary 
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no production and reduced the severity of 
iri. tnF-α can also induce the generation 
of roS and enhance the susceptibility of 
the vascular endothelium to neutrophil 
mediated injury, by inducing the expression 
of iCAm-1, which mediates binding of 
neutrophils to the activated endothelium.
numerous studies in animal models 
attest to the potential of tnF-α blockade as 
a therapeutic modality to reduce the severity 
of iri. Anti-tnF-α antibody protected 
against iri-induced pulmonary injury in 
a rat model by preventing microvascular 
damage. the introduction of humanised 
antibodies including etanercept and inflixi-
mab, has provided encouraging results in 
the treatment of other tnF-α-mediated 
inflammatory diseases, including a number 
of forms of arthritis and inflammatory bowel 
disease (reviewed in18). However, clinical 
trials to test the efficacy of tnF-α blockade 
in human iri have not yet been reported.
the cytokines il-1α and il1β are 
produced during iri by tissue macrophages, 
neutrophils and the vascular endothelium. 
il-1α is a potent chemotactic agent and 
stimulates neutrophil infiltration during 
hepatic iri. both il-1α and tnF-α also 
increase levels of expression of iCAm-1 
on the vascular endothelium. exposure of 
endothelial cells in culture to il-1α and 
tnF-α induces synthesis of e-selectin, 
which then interacts with l-selectin on the 
neutrophil surface leading to rolling on the 
endothelial surface. Permanent adhesion of 
the neutrophil to the endothelium is then 
mediated by expression of iCAm-1, il-8 
and PAF in the endothelial membranes 
(Figure 18.3). 
numerous activating stimuli synthesised 










bradykinin and AtP; all of which induce the 
synthesis of PAF by monocytes, macrophages, 
neutrophils, eosinophils, basophils, platelets 
and endothelial cells. PAF functions as both 
an inter- and intra-cellular messenger, having 
three major effects, vasoconstriction, chemo-
attraction and increased microvascular 
permeability. PAF is rapidly produced 
FigURE 18.3: Neutrophil rolling, adhesion to endothelium and extravasation
During reperfusion, activated neutrophils adhere to the activated endothelium and subsequently extravasate 
into surrounding tissue, resulting in proteolytic degradation of basement membranes. Activated neutrophils 
also generate toxic reactive oxygen species from molecular oxygen, contributing to tissue degradation during 
reperfusion.
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following skeletal muscle and renal iri with 
peak levels after 15 minutes of reperfusion. 
PAF enhances the binding of neutrophils 
to endothelial cells since a PAF-receptor 
antagonist blocked adhesion to endothelial 
cells during iri.19 Similarly pre-treatment 
with the PAF inhibitor lexipafant reduced 
the severity of intestinal barrier dysfunction 
and pulmonary and liver permeability in 
a rat model of intestinal iri.20 However 
lexipafant is unlikely to be clinically useful 
as a pharmacotherapy for iri since, alone, 
it failed to completely inhibit pulmonary 
endothelial damage after small bowel iri.21 
il-6 is a proinflammatory 19-26kda 
protein produced by monocytes, fibroblasts, 
keratinocytes and endothelial cells in 
response to il-1 and tnF-α. il-6 primes 
and stimulates the respiratory burst in 
neutrophils, stimulates endothelial cell 
expression of iCAm-1 and increases endo-
thelial permeability. il-6 is produced in 
hypoperfused skeletal muscle in patients with 
peripheral arterial disease and is released from 
the gut into the systemic circulation during 
reperfusion in aortic aneurysm surgery.22 
in the setting of renal transplantation, il-6 
was released in large amounts from the 
reperfused transplanted kidney during the 
first 30 minutes of reperfusion.23 
il-8 is a potent neutrophil chemotactic 
and activating factor. it is produced by 
monocytes, t cells, nK cells, fibroblasts, 
endothelial cells, eosinophils and neutrophils 
in response to il-1, tnF-α, endotoxin, 
histamine and hypoxia. the chemotactic 
activity of il-8 induces diapedesis of activated 
neutrophils through the endothelium. 
(Figure 18.3) elevated levels of serum il-8 
have been detected during early reperfusion 
following human lung transplantation and 
predict poor graft function.24 An anti il-8 
antibody prevented pulmonary neutrophil 
infiltration and tissue injury in a rabbit 
model of lung iri.25 
Neutrophil and endothelial 
interactions
neutrophils play a major role in tissue 
damage incurred during iri. Activated 
neutrophils are a major source of roS, 
which are generated through the activity 
of the membrane-bound nicotinamide 
adenine dinucleotide phosphate (nAdPH) 
oxidase complex. whilst oxidizing nAdPH 
to nAdP+, nAdPH oxidase also reduces 
molecular oxygen to form the superoxide 
anion. myeloperoxidase, stored in the 
azurophilic granules of neutrophils, converts 
hydrogen peroxide to toxic hypochlorous acid, 
which, in addition to its direct effects, is also 
capable of activating proteases. the activated 
neutrophils also secrete a number of proteases, 
including matrix metalloproteinases, which 
will degrade basement membrane and other 
tissue structures, contributing to the severity 
of tissue destruction.
neutrophil infiltration is observed at 
sites of tissue damage26,27 and the depletion 
of neutrophils reduces the severity of organ 
damage in a mouse model of liver iri.28 
depletion of neutrophils during cardiac 
surgery has been extensively investigated 
as a modality to reduce the severity of 
post-operative cardiac dysfunction with 
inconsistent results. Some studies have shown 
a reduction in markers of cardiac damage 
while others have been less successful in 
demonstrating a clinically relevant effect. 
Selectins are a family of transmembrane 
molecules, expressed on the surface of 
leukocytes, activated endothelial cells and in 
platelets. Selectins mediate the initial phase 
of neutrophil–endothelial cell interactions, 
often termed rolling (Figure 18.3), which 
is essential for their subsequent adhesion 
and extravasation. l-selectin is expressed 
constitutively on the surface of neutrophils 
and initiates the reversible attachment of 
neutrophils to endothelial cells and platelets. 
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Antibody-mediated blocking of l-selectin 
impairs the ability of neutrophils to roll 
on endothelial cells and reduces neutrophil 
infiltration following skeletal muscle and 
pulmonary iri.29
P-selectin is stored in the α-granules of 
platelets and the wiebel-Palade bodies of 
endothelial cells and is rapidly translocated to 
the cell surface along with PAF in response to 
thrombin, histamine, reactive oxygen species, 
complement and tnF-α. typically, peak 
levels of endothelial P-selectin are detected 
6 hours after reperfusion. endothelial 
P-selectin plays a vital role in the rolling of 
neutrophils along the activated endothelium. 
Activation of the endothelium by pro-
inflammatory mediators also results in de 
novo transcription and synthesis of e-selectin. 
expression of endothelial e-selectin is 
induced during both renal and cerebral 
iri. the focal expression of e-selectin at 
sites of endothelial activation promotes 
neutrophil adhesion and infiltration into 
adjacent tissues. in support of a vital role for 
e-selectin in mediating tissue damage during 
iri, a study showed that antibodies against 
e-selectin reduced infarct size following 
cerebral iri in mice.30 blocking the activity 
of selectins shows promise in ameliorating 
the severity of tissue damage in a number 
of animal models of iri. Although some 
promising selectin inhibitors have been 
tested in animal models of iri, this therapy 
has yet to be tested in a clinical situation 
(reviewed in31).
the integrin and immunoglobulin 
supergene families of adhesion molecules 
mediate the strong adhesion of activated 
neutrophils to the endothelium and hence 
allow their subsequent extravasation during 
iri. the integrins form a large family of 
cell surface adhesion molecules that mediate 
intercellular recognition and cellular binding 
to the extracellular matrix. the neutrophil 
β
2
-integrin adhesion glycoprotein complex 
consists of a common polypeptide chain, 
Cd18, which is non-covalently linked 
to three different α-polypeptide chains 
(Cd11a, Cd11b, Cd11c). Cd11a/Cd18 
is expressed on all leukocytes and mediates 
the attachment of stimulated neutrophils to 
the vascular endothelium through a specific 
interaction with iCAm-1 and iCAm-2. 
Chemotactic cytokines (il-1, tnF-α) and 
roS all induce neutrophil adherence to the 
endothelium by Cd11/Cd18-dependent 
mechanisms. the Cd11b/18 complex on 
activated neutrophils interacts with iCAm-1 
on the surface of the endothelial cell to 
mediate firm adhesion of neutrophils prior to 
their extravasation (reviewed in32). All of these 
molecules are required for the development 
of lung injury following skeletal muscle iri. 
using an anti-Cd18 monoclonal antibody, 
inhibition of Cd18-mediated leukocyte 
adhesion prevented vasoconstriction, inhi-
bited vessel leakage and reduced vascular 
resistance in animal models of skeletal muscle 
iri. However, despite encouraging animal 
studies, the clinical efficacy of blocking 
Cd11/Cd18-mediated interactions in iri 
remains doubtful (reviewed in33). Clinical 
trials in humans failed to demonstrate any 
effect of Cd11/Cd18 in reducing infarct 
size following primary coronary angioplasty 
in the setting of acute myocardial infarc-
tion. A more recent review34 summarised the 
results from a number of clinical trials using 
antibodies to Cd11/Cd18, including for 
myocardial infarct and stroke, all of which 
failed to show any significant benefit to the 
patient.
the immunoglobulin supergene family 
(ligands for integrins) contains a large number 
of molecules with multiple immunoglobulin-
g-like domains. Several members of this 
family are involved in leukocyte-endothelial 
cell interactions including iCAm-1, VCAm-1 
and platelet-endothelial cell adhesion 
molecule-1 (PeCAm-1). levels of expression 
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of iCAm-1 on endothelial cells are enhanced 
by exposure to circulating tnF-α that is 
generated in response to iri. VCAm-1 was 
elevated during renal iri in a mouse model 
but, unlike iCAm-1, was independent of 
tnF-α since renal iri in tnF-α knockout 
mice also upregulated VCAm-1. PeCAm-1 
is expressed constitutively on platelets, 
leukocytes and endothelial cells. iri induces 
elevated PeCAm-1 levels thereby enhancing 
activation of neutrophil-endothelial inter-
actions mediated by β-integrins and exacer-
bating neutrophil extravasation and tissue 
damage.
the therapeutic potential of blocking 
the activity of adhesion molecules has been 
tested in a number of animal models with 
encouraging results. using monoclonal 
antibodies, inhibition of iCAm-1 activity 
attenuated neutrophil adhesion in the 
liver, reduced pulmonary sequestration and 
oedema following skeletal muscle iri and 
also reduced intestinal dysfunction following 
iri.35 Antisense oligonucleotides to iCAm-1 
ameliorated renal iri and prevented delayed 
graft dysfunction in a rat model of renal 
transplantation.36 However, results obtained 
in clinical trials have not been as positive. A 
recent clinical trial of anti-iCAm-1 antibody 
therapy in ischaemic stroke (enlimomab 
Acute Stroke trial) concluded that this 
was not an effective treatment and may 
significantly worsen stroke outcome, raising 
significant doubts regarding the efficacy of 
this therapeutic modality.37
Complement activation
Complement activation and deposition also 
contribute significantly to the pathogenesis of 
iri. rubin and colleagues have 
demonstrated that reperfusion of skeletal 
muscle is associated with systemic depletion 
of the complement protein, factor b, 
indicative of activation of the alternative 
complement pathway.38 the complex 
C5b-9 is also deposited into the endothelial 
cell membrane after iri, leading to osmotic 
lysis.39 Pulmonary damage following bilat-
eral hind limb ischemia was significantly 
reduced when the soluble complement 
receptor (sCr1) was administered to rats, 
thus inhibiting complement activity.40 
in the clinical setting, a relationship has 
been demonstrated between the severity of 
multi-system organ dysfunction and degree 
of complement activation after aortic cross 
clamping.41 
inhibition of the complement cascade 
has been demonstrated to improve outcomes 
following iri in a number of different 
animal models. Complement depletion 
of circulating plasma improved the initial 
blood flow and decreased muscle necrosis 
and injury after ischaemia and prolonged 
reperfusion in dogs. Complement blockade 
also prevented leukocyte adhesion, leading 
to better capil lary perfusion and muscle 
cell viability and attenuated the increase in 
permeability index in tissues.42 unequivocal 
evidence for the importance of complement 
activation during skeletal muscle iri has 
been provided from experiments where limb 
ischaemia was induced in C5-deficient mice. 
these mice had approximately 50% less 
tissue damage than the wild-type animals.39 
An additive role of both complement and 
neutrophils in mediating skeletal muscle 
iri has also been observed, with a greater 
reduction in histological damage in 
neutropenic C5-deficient animals than in 
neutropenic or C5-deficient mice alone.39 
these data continue to demonstrate the 
multifactorial nature of tissue damage 
induced during iri since complement 
blockade failed to completely ameliorate 
tissue damage. 
Pathophysiology of Reperfusion Injury 341
tiSSue deStruCtion
Proteases and metalloproteinases
the matrix metalloproteinases (mmPs) are 
a family of zinc dependent enzymes that 
have the ability to degrade components 
of the extracellular matrix. together with 
their inhibitors, the tissue inhibitors of 
metalloproteinases (timPs), they are 
the major physiological regulators of the 
extracellular matrix. mmPs are intimately 
involved in all processes that necessitate 
degradation or synthesis of the extracellular 
matrix and important roles for these enzymes 
have been identified in wound healing, 
periodontal disease, cancer metastasis and, 
of particular relevance, vascular disease 
including the development of aneurysms, 
atherosclerotic plaques and reperfusion 
injury.
elevations of mmP-2 and mmP-9 have 
been detected following pulmonary, hepatic 
and cardiac iri. mmPs are also elevated 
following cerebral iri, corresponding 
with opening of the blood-brain barrier, 
degradation of the basal lamina, increased 
capillary permeability and cerebral oedema.43 
definitive roles for mmP-9 in the 
pathophysiology of cerebral iri have been 
demonstrated by using both selective mmP-9 
inhibitors and mmP-9 knockout mice, 
which both significantly reduce cerebral 
infarct size.44 the role for mmPs in renal iri 
is less clear. mmP-2 may have a late role in 
renal iri with an elevation detected as late 
as 8 weeks after iri.45 However the mmP 
inhibitor (batimastat) did not alter the 
severity of iri induced renal dysfunction.46
barr and co-workers47 carried out a study 
examining acute ischaemic stroke patients by 
mri and correlated systemic plasma mmP-9 
levels with a hyperintense acute reperfusion 
injury marker (HArm), measured by mri 
24 hours later. Plasma mmP-9 was a signific-
ant predictor of elevated HArm measures, 
supporting the hypothesis that elevated 
mmP-9 is associated with disruption of the 
blood brain barrier after ischaemic stroke. 
these results raise the possibility that inhibi-
tion of mmP-9 may be a useful modality to 
reduce the severity of cerebral damage.
Studies in our laboratory have demon-
strated both a local and systemic role for 
mmP-2 and mmP-9 in the degradation 
of type iV collagen in pulmonary tissues 
and in skeletal muscle following lower limb 
iri.27 Permanent ischaemia alone, without 
reperfusion, also results in elevation of 
mmP-2 and mmP-9, correlating with 
destruction of the basement membrane 
components, type iV collagen and laminin.
Apoptotic cell death during 
ischaemia-reperfusion injury
tissue destruction resulting from iri can be 
due to either necrotic or apoptotic cell death. 
Apoptosis or programmed cell death is an 
active process characterized by a series of gene-
directed events leading to a characteristic cell 
morphology, controlled dnA fragmentation 
and eventually death of the cell. the role of 
apoptosis in iri-induced tissue damage has 
been widely investigated in recent years. 
oxidative stress and the production of roS 
will induce apoptosis, the characteristics of 
which can readily be recognised following 
cerebral iri. Similarly, renal and cardiac iri 
all result in detectable levels of apoptosis 
in the damaged tissue. Apoptosis therefore 
appears to play a fundamental role in cellular 
damage occurring during iri in a number 
of tissues. However the role of apoptosis in 
skeletal muscle iri remains controversial. 
Studies conducted in our laboratory,26 in 
agreement with Knight and co-workers,48 
have failed to detect any evidence of apoptosis 
in rat skeletal myocytes following iri. this 
implicates a tissue-specific mechanism of cell 
death following iri. blocking the apoptotic 
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cascade, using specific inhibitors directed 
against pro-apoptotic caspase enzymes, 
have been partially effective in animal 
models, reducing the severity and infarct size 
following hepatic and cardiac iri.
No reflow phenomenon
no reflow is the failure of microvascular 
perfusion, following restoration of flow 
to previously ischaemic tissue. the cause 
of this phenomenon has not been fully 
elucidated (reviewed in49) but is certainly 
multifactorial. Cytokines and activated 
neutrophils act synergistically to produce 
microvascular barrier dysfunction. the 
resultant increase in permeability leads to 
the exudation of fluids and proteins, increas-
ing the interstitial pressure and decreasing the 
net intravascular pressure. in addition, Cd18-
dependent leukocyte plugging produces 
partial occlusion of post-capillary venules, 
further contributing to no-reflow. neutro-
phil depletion virtually abolishes the 
phenomenon in the myocardium, brain and 
skeletal muscle, confirming a vital role for 
neutrophils in no-reflow. 
tHerAPeutiC APProACHeS  
to iri
Ischaemic preconditioning
ischaemic preconditioning consists of brief 
and repetitive episodes of iri before the 
induction of sustained organ ischaemia and 
is effective in reducing the severity of tissue 
damage. the preconditioning effect can be 
delivered remotely instead of to the target 
organ. this treatment could be useful in 
a number of operative settings including 
transplantation, coronary bypass grafting and 
elective major vascular surgical procedures 
where the onset of ischaemia can be tightly 
controlled. in these settings, brief extremity 
iri (10 minutes) administered by tourniquet 
before surgery has been widely investigated 
and shows promise as a therapy to reduce the 
severity of iri. 
Animal models of a number of settings 
of iri have been used to investigate 
mechanisms of ischaemic preconditioning 
but the basic molecular mechanisms 
remain unclear, probably due to the 
multiple signal transduction pathways 
involved in this phenomenon. However it 
is generally recognised that brief ischaemic 
preconditioning induces a cascade of 
intracellular kinases, which subsequently 
modify mitochondrial function. A recent 
study in a rat model of lower limb iri 
illustrated clearly that two brief 10 minute 
episodes of iri before a full 60 minutes of 
ischaemia was effective in reducing pro-
inflammatory neutrophil-endothelium 
interactions. this effect was noted in both 
the lower limb itself and in remote tissues, 
illustrating the systemic nature of this 
phenomenon.50 in a mouse model of hind 
limb iri, preconditioning significantly 
reduced tissue damage in the limb itself and 
also in lung and small bowel. Preconditioned 
animals were also significantly protected 
against post-operative mortality.51
A large number of clinical trials have also 
been reported investigating the efficacy of 
ischaemic preconditioning but with varying 
degrees of success (reviewed in52). A small 
randomised clinical trial aimed to determine 
if remote lower limb ischaemic pre-
conditioning before eVAr could reduce 
the severity of renal and cardiac damage.53 
A significant reduction in urinary bio-
markers of renal injury was detected in 
the preconditioning cohort but this small 
pilot trial was unable to detect any effect 
on clinical endpoints. However, in the 
setting of open AAA repair where operative 
ischemia is profound, promising results 
were obtained. remote preconditioning 
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significantly protected against post-operative 
myocardial injury, myocardial infarc-
tion, and renal impairment.54 An excellent 
‘proof-of concept’ study of ischaemic 
preconditioning was recently reported 
in the setting of evolving St-elevation 
acute myocardial infarction. Subjects were 
randomised while in the ambulance and 
received intermittent arm ischaemia during 
transport to hospital (four cycles of 5 minute 
inflation and 5 minute deflation of a blood-
pressure cuff ). the primary endpoint was 
the myocardial salvage index 30 days after 
primary percutaneous coronary intervention, 
measured by myocardial perfusion imaging. 
the data showed convincingly that remote 
ischaemic conditioning before hospital 
admission increased myocardial salvage.55 
Further studies are needed to verify the effect 
of remote conditioning on clinical outcomes 
but this therapeutic modality currently 
appears very promising.
Ischaemic post-conditioning
ischaemic post-conditioning is defined as 
rapid sequential intermittent interruption of 
blood flow applied during the early moments 
of reperfusion. this technique is particularly 
relevant where the initial ischaemic insult 
could not have been predicted, thus a 
preconditioning approach to limiting 
tissue damage could not have been applied. 
experimental animal models have been 
used to successfully show attenuation of 
organ injury, including the heart, spinal 
cord, brain, kidney, liver, muscle, lung and 
intestines (reviewed in56). the mechanisms 
of post-conditioning are not yet entirely 
clear but appear to involve multiple 
signalling pathways and molecules, including 
protein kinases, roS, pro-inflammatory 
cytokines and no, as well as alterations in 
mitochondrial function (reviewed in57). 
Animal models of particular relevance to 
vascular surgical procedures have been tested 
widely and results show promise for post-
conditioning as an effective therapy to reduce 
the severity of iri. in a rat model of lower 
limb ischaemia induced by aortic clamping, 
rats underwent 180 minutes of ischaemia 
followed by post-conditioning consisting 
of six cycles of 10 seconds aortic occlusion 
followed by 10 seconds declamping at the 
beginning of reperfusion. Post-conditioning 
caused a significant reduction in both the 
severity of systemic inflammatory responses 
and degree of remote pulmonary and renal 
damage.58 in a similar study in the rat,59 
60 minutes infrarenal aortic cross-clamping 
followed by intermittent 4 times 15 seconds 
reperfusion-15 seconds ischaemic episodes 
before reperfusion, was effective in reducing 
production of roS, leukocyte-endothelial 
activation and cytokine production.
based on the experimental models, 
ischaemic postconditioning thus appears 
to show promise as an effective therapy in 
vascular surgery to reduce reperfusion injuries 
after aortic surgery and revascularization 
procedures (reviewed in60). Some clinical 
studies have verified these findings, although 
this has been largely limited to cardiac iri. 
However, the duration of the occlusion and 
reperfusion periods will be critical to the 
degree of protection and further studies 
are needed to calculate useful algorithms to 




Anaesthetics have been widely demon-
strated to reduce the severity of iri-induced 
damage in the setting of myocardial ischaemia 
and reperfusion during cardiac surgery 
(reviewed in61). However, there is conflicting 
evidence regarding the relative contributions 
of preconditioning, conditioning during 
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ischaemia and postconditioning to the 
significant cardioprotection provided by 
anaesthetics. the molecular mechanisms and 
signal transduction pathways involved in 
protection are an area of active investigation. 
A proteomic study demonstrated that 
volatile anaesthetics (isoflurane, sevoflurane 
or desflurane) induced long lasting changes 
in the expression of 106 proteins in the rat 
myocardium.62 evidence also suggests that 
inhibition by anaesthetics of the opening of 
the mitochondrial permeability pore may 
be a key mechanism of anaesthetic-induced 
preconditioning. Anaesthetic-induced post-
conditioning mechanisms are also multi-
factorial. Volatile anaesthetics are known to 
inhibit neutrophil adhesion in the coronary 
arteries during the reperfusion phase, 
thereby inhibiting the inflammatory action 
of activated neutrophils in post-ischaemic 
tissues (Figure 18.3). 
there is good clinical evidence for the 
cardioprotective effects of volatile anaes-
thetics during cardiac surgery. A meta-analysis 
examined randomized trials comparing 
volatile with non-volatile anaesthesia in 
coronary bypass surgery. there was no sig-
nificant difference in myocardial ischaemia, 
myocardial infarct, intensive care unit length 
of stay or in-hospital mortality. However, 
patients receiving volatile anaesthetics had 
significantly higher cardiac indices, lower 
troponin i serum concentrations and a lower 
requirement for inotropic support.63 A more 
recent large multicentre study provided 
excellent evidence that volatile anaesthesia 
significantly reduced mortality after coronary 
bypass grafting.64 evidence for anaesthetic 
protection in vascular surgical settings other 
than in cardiac iri is not currently available 
but is likely to be equally significant and 
should be actively investigated in the 
future.
Pharmacological treatments
As discussed in many of the sections above, a 
wide range of pharmacological therapies have 
been tested in both animal models and in the 
clinic. Although many of the animal models 
show considerable promise in reducing the 
severity of iri, results from clinical trials 
have uniformly been disappointing. A recent 
Cochrane review reported on treatments to 
reduce iri during liver resection under vascu-
lar control.65 they identified 15 randomised 
trials, which examined 11 pharmacological 
interventions (methylprednisolone, multi-
vitamin antioxidant infusion, vitamin e 
infusion, amrinone, prostaglandin e1, 
pentoxifylline, mannitol, trimetazidine, dex-
trose, allopurinol and a thromboxane A2 
synthetase inhibitor). Although some 
therapies improved liver enzyme levels, 
there were no significant differences between 
the groups for mortality, liver failure, or 
perioperative morbidity. A second Cochrane 
review from the same authors66 examined the 
effects of prostaglandin e1, pentoxifylline, 
dopexamine, dopamine, ulinastatin, gantaile, 
sevoflurane, and propofol during liver iri 
and reached the same conclusion that there 
were no significant differences. 
Statin therapies have been widely 
accepted into clinical practice and there is 
also considerable evidence, both experimental 
and clinical, that statins will reduce the 
severity of iri in a range of settings. Statins 
inhibit a range of cellular responses to iri-
induced inflammation, including inhibition 
of nFkb activity, which leads to decreased 
transcription of mmPs, adhesion molecules 
and cytokine genes. binding of adhesion 
molecules on activated neutrophils to 
endothelial cell surface receptors is also 
blocked. Secretion of mmPs from activated 
neutrophils is also inhibited by statins. in 
the endothelium, levels of expression of 
enoS mrnA are increased and the enoS 
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protein is activated, while expression of 
endothelin-1 is inhibited. All of these effects 
will ameliorate the severity of tissue damage 
during iri (reviewed in67).
trials of lower limb iri in the rat were 
carried out in our laboratory and illustrated 
convincingly that pre-treatment for a week 
with simvastatin before iri markedly 
protected both skeletal muscle and remote 
organs including the lungs and kidneys.14,68 
in the clinical setting, a recent review69 
discussed the efficacy of statins in patients 
undergoing a range of vascular surgical 
procedures. Symptomatic patients with 
carotid artery stenosis and taking statins 
appear to have better outcomes after carotid 
endartarectomy than those not on statins, 
although the difference between the cohorts 
is not marked. in the setting of infrainguinal 
bypass for peripheral arterial disease, the 
indications that statins may protect against 
iri during surgery are less definitive with 
some conflicting results although 1-year 
mortality was improved. evidence for any 
effect of statin treatment on the severity 
of postoperative complications after AAA 
repair is lacking, although a retrospective 
observational study showed that all-cause 
mortality was reduced in those on long term 
statin therapy.70 However, since all vascular 
patients should be receiving statin treatment 
for secondary prevention of cardiovascular 
disease, prospective randomized trials to 
obtain definitive results can no longer 
ethically be performed.
SummAry
in summary, iri is a highly complex series 
of interwoven pro-inflammatory and 
pathological events. the production, release 
and activation of cytokines, roS, proteases 
and complement if left unchecked, leads 
to both local and systemic injury with 
potentially fatal consequences. the failure 
of therapeutic interventions to translate 
into clinical practice is a reflection of this 
complexity and redundancy within the 
system. new therapeutic agents directed 
towards multiple areas within this cascade 
may be required to overcome this difficult 
clinical challenge. 
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dEFInItIon
Compartment syndrome is a clinical and 
pathological syndrome where the pressure 
within an anatomical tissue compartment 
rises above the normal physiological value for 
that compartment and detrimentally alters 
the function of the tissues either temporarily 
or permanently. acute compartment syn­
dromes affecting the abdominal cavity and 
the fascial compartments of the limbs are 
those encountered in vascular surgery.
aCUtE LIMb CoMPartMEnt 
SyndroME
the importance of acute limb compartment 
syndrome (LCS) is that, if left untreated, 
it results in rhabdomyolysis with resultant 
release of potassium, myoglobin and other 
toxins into the systemic circulation, which 
can lead to renal and/or multi­organ failure. 
the mortality of acute renal failure and 
multi­organ failure is high. these patients 
require critical care which may involve 
dialysis and other organ support. Untreated 
LCS often necessitates amputation to prevent 
further acute systemic deterioration. If the 
immediate insult is survived without the 
need for amputation a permanently disabling 
ischaemic contracture may result.1
LCS arises due to the anatomical 
arrangement of muscles surrounded by 
restrictive, inelastic osteofascial envelopes. 
Increased pressure within these fascial 
compartments can occur as a result of extrinsic 
compression such as that from plaster casts or 
bandages, or increased volume of the contents 
of the compartment. the volume within the 
compartment can be increased as a result of 
enlargement of those tissues contained within 
the compartment (e.g.muscle oedema) or 
due to the presence of a pathological space­
occupying mass (such as a haematoma or 
abscess). In the field of vascular surgery LCS 
is most commonly encountered following 
delayed revascularisation of an ischaemic 
limb, fractures with/without vascular injury 
or following radiological complications 
such as perforation during angioplasty. It 
is occasionally seen in conditions such as 
phlegmasia caerulea dolens where venous 
hypertension exists.
Incidence
the incidence of LCS after revascularisation 
depends primarily on the type of insult. 
after elective vascularisation of chronically 
ischaemic limbs the incidence is very 
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low, from 0% to 0.5%.2,3 the incidence 
increases in revascularised acutely ischaemic 
limbs to approximately 10% to 20%.4­6 
revascularisation following vascular trauma 
is the most significant risk factor for LCS, 
with a reported incidence of up to 62%,7 
particularly if this is associated with either 
a vascular injury at or below the popliteal 
artery, or a fracture (Figure 19.1).
Anatomy/Physiology
LCS develops in the limbs because of their 
particular anatomical and physiological 
characteristics. anatomically this is principally 
the arrangement of muscles within envelopes 
of dense, inelastic fibrous fascia. In addition 
to muscles, each compartment also contains 
peripheral nerves and blood vessels that 
traverse these compartments to supply distal 
parts of the limb and/or supply the structures 
within that compartment.
the anatomical arrangement of the 
capillary beds and physiological processes 
occurring within these also contributes 
to the development of LCS. Figure 19.2a 
shows the normal anatomical arrangement 
and physiological passage of fluid across 
the capillary wall. Fluid exchange across 
a capillary wall is affected by hydrostatic 
pressure and oncotic pressure. the extra­
cellular compartment has low hydrostatic and 
oncotic pressure due to the draining action 
of lymphatics. In capillaries hydrostatic and 
oncotic pressure varies along their length. at 
the arterial end of the capillary, hydrostatic 
pressure (35mmhg) is greater than tissue 
hydrostatic pressure (0mmhg). oncotic 
pressure within the capillary (28mmhg) 
is higher than tissue oncotic pressure 
(3mmhg) (therefore acting to draw fluid 
back into the capillary) but since the net 
hydrostatic pressure acting to filter fluid out 
of the capillary is greater than the net oncotic 
pressure, fluid is filtered into the extra­cellular 
space. as blood passes along the capillary to 
the venous end fluid is lost. at the venous 
end of the capillary, hydrostatic pressure is 
much lower (15mmhg) and the resultant 
net force now acts to draw fluid back into 
the capillary (net oncotic pressure is greater 
than the net hydrostatic pressure).
Aetiology/Pathophysiology
LCS causes tissue damage due to ischaemia 
within the affected compartment. this 
ischaemia is not due to interruption of the 
regional blood supply but due to the failure of 
the micro­circulation caused by the elevated 
compartment pressure (the initial insult may, 
of course, be due to regional ischaemia). the 
initial injury causes swelling of the tissues 
within the compartment that, in turn, results 
in increased intra­compartmental pressure 
(ICP).
Figure 19.1: Severe comminuted fracture of the 
tibia and fibula with distal popliteal artery injury 
demonstrated angiographically. An injury with a high 
risk of acute limb compartment syndrome.
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as ICP increases above physiological 
levels the first part of the circulation to be 
affected are the small venules, since these 
vessels have the lowest pressure. these venules 
collapse and since the arterial side of the 
capillary beds remains open, the hydrostatic 
pressure within the capillaries continues to 
filter plasma out of the blood vessels into the 
tissues. however, since the venous side of the 
capillary bed is closed, the normal return of 
extracellular fluid back into the circulation 
by combined oncotic and hydrostatic forces 
Figure 19.2: Capillary fluid exchange, a) in normal physiological circumstances, b) in the case of raised extra-
cellular tissue pressure, as in acute limb compartment syndrome.
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cannot occur and actually reverses due to 
the venous hypertension in the capillary 
(Figure 19.2b). Lymphatic drainage is also 
impaired by the high tissue pressures. the 
net result is further tissue swelling, with 
a subsequent further increase in ICP and 
thus the initiation of a vicious cycle. as 
ICP increases further the arterial side of the 
capillary bed and eventually the arterioles 
become affected causing frank ischaemia and 
permanent tissue damage shortly follows.
In the initial stages of LCS the principal 
pathological changes in muscles affected is 
oedema within and around muscle fascicles. 
as LCS progresses frank ischaemic changes 
occur in the muscle fibres.8
the most common cause of compartment 
syndrome in vascular surgery is tissue 
oedema due to the ischaemia­reperfusion 
injury caused by limb revascularisation. 
the re­establishment of a blood supply 
to ischaemic tissues has been observed to 
cause more damage than ischaemia alone. 
during ischaemia, anti­oxidant mechanisms 
are capable of dealing with any oxygen free 
radicals produced. however, the return of 
oxygenated blood to ischaemic tissues results 
in a burst in production of oxygen free 
radicals due to the action of xanthine oxidase 
(Xo) on tissue hypoxanthine, both of which 
are produced in ischaemic tissues. the return 
of oxygen upon reperfusion supplies the 
final substrate for this reaction to proceed 
and this produces a burst of superoxide 
production (Figure 19.3). Free radicals are 
produced from this superoxide and mediate 
cell damage largely via lipid peroxidation of 
cell membranes. oxygen free radicals also 
cause activation of microvascular neutrophil 
polymorphs and endothelial cells. activated 
endothelium produces arachidonic acid 
metabolites, nitric oxide (no), endothelins, 
complement and cytokines. these various 
mediators contribute to the continuation and 
extension of a local inflammatory response 
and the production of a cellular and acellular 
inflammatory infiltrate with corresponding 
tissue swelling (Figure 19.4).9
Clinical presentation
different tissues within the osteo­fascial 
compartments of the limbs are able to 
tolerate ischaemia to different degrees. the 
most sensitive to ischaemia are unmyelinated 
nerve fibres followed by myelinated nerve 
fibres, skeletal muscle, skin and then bone. 
Large arteries are relatively resistant to 
acute hypoxia and blood flow within them 
is maintained until late after the onset of 
LCS since ICP only exceeds systemic blood 
pressure at the latter stages of the disease 
process. It is these different hypoxic tolerances 
of each tissue that lead to the symptoms and 
clinical signs of LCS.
the most common symptom of LCS is 
severe pain that is unresolved by analgesics 
and the degree of which is out of proportion 
to the injury sustained. Symptoms due to 
neurological dysfunction include weakness 
and paraesthesia in the myotomes and 
dermatomes associated with the peripheral 
nerves that pass through the affected 
compartment. these symptoms will progress 
steadily over a short period of time.
Clinical signs associated with LCS are 
pain on passive movement of the muscles 
in the affected compartment, tenderness 
of the muscle bellies lying within the 
affected compartment and tenseness of 
the compartment. there may be muscle 
weakness and sensory loss (particularly two­
point discrimination due to the early loss of 
the unmyelinated nerve fibres). Commonly 
foot drop occurs in LCS affecting the lower 
leg. there may be signs of the injury that 
has caused LCS to develop such as a fracture, 
surgical dressings or bruising. Peripheral 
pulses will be maintained until long after 
LCS has become established. Signs suggestive 
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of irreversible ischaemic change include 
fixed, non­blanching skin staining or frank 
gangrene. In these cases therapy should 
be directed towards preventing systemic 
complications and death. 
Clinical assessment of suspected LCS is 
difficult. the majority of symptoms and signs 
are only reliably assessed in a fully conscious 
patient; those at highest risk of LCS often 
have an altered level of consciousness due to 
the injury or operation that has placed them 
at risk. also, many patients may have some of 
these clinical signs present due to the injury 
that has caused the LCS such as the pulseless, 
painful, paraesthetic limb of acute ischaemia. 
the most useful guide to LCS is to maintain 
a high index of clinical suspicion.
Investigation
Since clinical assessment of a limb at 
risk of LCS is difficult, a test to give an 
objective measurement of ICP is desirable. 
Many methods for measuring ICP exist. 
described techniques are wick catheters,10 
slit catheters,11 needle manometry12 and 
infra­red spectroscopy (Figure 19.5).13 
these various methods all have relative 
advantages and disadvantages. Catheter 
techniques allow continuous monitoring 
of limbs at risk and are more accurate than 
simple needle manometry10 but they are 
more complex and require prior training in 
their use. needle manometry can be simply 
performed using an 18g needle connected 
Figure 19.3: Xanthine Oxidase (XO) pathway activation by ischaemia-reperfusion and the production of 
reactive oxygen species. Ischaemia prevents oxidative phosphorylation (1) and cellular ATP cannot be 
regenerated. This leads to the accumulation of AMP and, in turn, hypoxanthine. Ischaemia also causes the 
accumulation of intracellular calcium (2). This catalyses the conversion of xanthine dehydrogenase (XD) to 
xanthine oxidase (XO) Upon reperfusion oxygen is supplied (3) and this provides the final substrate to allow 
XO to convert hypoxanthine to xanthine, producing superoxide as a by-product (4). During ischaemia iron is 
released from cytochrome, haemoglobin and other haem containing molecules (5). This iron catalyses the 
Fenton-Haber-Weiss reaction producing hydroxyl radicals from superoxide. These hydroxyl radicals damage 
to cellular and capillary membranes leading to loss of function and cell death (6).
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Figure 19.4: Pathways and effects of ischaemia-reperfusion injury. XO: xanthine oxidase, NO: nitric oxide.
Figure 19.5: Slit catheter inserted into anterior tibial compartment and connected to a pressure transducer. 
(Photograph courtesy of Mr MJ Allen.)
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to a mercury manometer, or small handheld 
electronic devices are available. near­infrared 
spectroscopy is still under evaluation. whilst 
this technique is non­invasive it requires 
relatively expensive equipment and the 
interpretation of the readings from this 
method are less intuitive than a figure for 
absolute compartment pressure expressed in 
mmhg.
normal resting ICP is 0­10mmhg.2,14 
Capillary blood pressure varies from 30– 
40mmhg at the arterial side of the capill­
ary bed to 10–15mmhg at the venous side.15 
Given the suggested pathophysiological 
processes underlying the development of 
LCS , it would be expected that symptoms 
would first occur at compartment pressures 
somewhere between these two values. Many 
authors have suggested absolute cut­off 
levels of ICP to diagnose LCS. Mubarak 
suggested a value of 30mmhg16 whilst allen 
suggested a value of 50mmhg or a value 
above 40mmhg for longer than 6 hours.17 
however, in several clinical studies clinical 
symptoms and signs of LCS have not 
correlated well with measured compartment 
pressures. tissue perfusion is dependent, 
not only on the interstitial pressure but 
also the arterial perfusion pressure. because 
of this, whitesides et al suggested that the 
difference between diastolic blood pressure 
and ICP should be used to diagnose LCS, 
with a difference of less than 30mmhg being 
diagnostic.18 It has been shown that this 
definition for diagnosing LCS results in less 
unnecessary fasciotomies that using absolute 
ICP levels of either 30mmhg or 40mmhg.19 
an alternative method is to calculate the 
difference between mean blood pressure and 
ICP, with a value of less than 40mmhg as a 
diagnostic cutoff.20
the measurement of ICP may allow 
more accurate diagnosis in those patients 
in whom clinical assessment is difficult due 
to co­existent injury or physical attributes 
but time should not be wasted on ICP 
measurement in patients who have clinically 
obvious LCS. In addition, many hospitals 
will not have the equipment or expertise 
available to accurately measure ICP. It is also 
thought that measured ICP may only reflect 
the ICP at the tip of the needle/catheter and 
not reflect the pressure change in the whole 
compartment. Since any delay in initiating 
treatment for LCS may result in a worse 
outcome once diagnosed, LCS should be 
treated expediently.
apart from the measurement of ICP 
there are no specific tests to diagnose LCS. 
In clinically advanced cases where there is 
tissue damage, the resulting inflammation 
may be manifest as a leucocytosis or, if 
there is significant tissue necrosis, serum 
creatine phosphokinase will be elevated and 
a metabolic acidosis occurs.
Treatment
the treatment of acute LCS is urgent 
fasciotomy of all affected compartments 
(Figure 19.6). In patients who present acutely 
(within 12 hours of onset of LCS) this 
should be performed immediately. delayed 
fasciotomy (longer than 12 hours after the 
onset of LCS) results in a significantly poorer 
outcome in terms of functional loss.21 In 
those patients whose presentation is delayed, 
consideration has to be given as to whether 
the limb is unsalvageable and the possibility 
that a fasciotomy in this group of patients 
may lead to significant morbidity without 
ultimately improving functional outcome. If 
fasciotomy is delayed longer than 12 hours 
but less than 36 hours infection rates increase 
but limb salvage rates are similar.22 beyond 
36 hours rates of amputation, infection, 
neurological injury and death increase such 
that early amputation rather than futile 
attempts at limb salvage should be considered 
in this group.22,23 
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Fasciotomy should be performed in such 
a manner so that all constrictive elements 
surrounding a compartment are released. In 
the limbs this is the skin and the deep fascia, 
which encloses four separate compartments, 
the anterior, peroneal (lateral), superficial 
posterior and deep posterior. these can be 
decompressed either via a single lateral 
incision24 or via two incisions, one lateral and 
one medial (Figure 19.7).25 the lateral incision 
is made over the peroneal compartment one 
finger­breadth anterior to the fibula from 
the fibular head to the ankle. the anterior 
and peroneal compartments are then opened 
along the length of the incision. the posterior 
compartments can then be opened either 
through this incision by dissecting behind the 
fibula or by removing a piece of the fibula. 
alternatively the deep posterior compartment 
can be opened by dissecting anteriorly to the 
fibula through the interosseous membrane. 
If two incisions are used the second is made 
on the medial aspect of the lower leg and the 
two posterior compartments decompressed. 
the thigh is usually decompressed medially 
and/or laterally.
Figure 19.6: a) Medial thigh and calf fasciotomies following lower limb ischaemia after traumatic vascular 
injury. b) The same wounds 5 days showing healthy granulation tissue.
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In the upper limb the forearm is the 
most commonly affected by LCS. both the 
volar and dorsal compartments can usually 
be decompressed via a single volar incision 
over the whole length of the forearm made 
in a curved fashion to avoid contractures. 
In other areas of the limbs the incisions 
should be made based on the anatomy of 
that region and positioned so as to open the 
whole length of the affected compartment. 
after the fasciotomy has been performed 
any devitalised or necrotic muscle should be 
debrided.
Several alternatives exist for the 
management of fasciotomy wounds after 
the compartment syndrome has resolved: 
skin grafting, delayed primary closure, 
secondary closure, healing by secondary 
intention and the use of skin flaps. Skin 
grafting is usually performed between 7 and 
21 days and has been suggested to reduce 
wound complications when compared to 
other methods (Figure 19.8).26
In addition to fasciotomy, methods 
directed towards reducing the degree of 
initial tissue injury causing LCS have been 
suggested. Free radical scavengers such as 
mannitol and superoxide dismutase have 
been shown to be of benefit in LCS caused by 
ischaemia­reperfusion injury in animals.27,28 
Some benefit has been shown using these 
agents in humans29 although no comparative 
studies between these treatments and 
fasciotomy have been performed. Lysine­
acetyl­salicylate, a thromboxane a2 inhibitor 
has shown some benefit in animals but has 
not been studied in humans.30 at present 
there is not enough evidence to justify the 
routine use of these compounds in clinical 
practice.  hyperbaric oxygen therapy has 
been suggested to be of use in improving the 
outcome of fasciotomy.31
Complications of LCS
Locally, LCS, if left untreated, will cause 
ischaemia and subsequent limb loss. If 
infection occurs in the devitalised tissues 
systemic sepsis can occur and may result in 
multi­organ failure. In addition to infective 
Figure 19.7: Diagrammatic cross-section through mid-calf showing four osteo-fascial compartments (left), 
arrows indicating medial and lateral incisions required for four-compartment fasciotomy. Shaded areas represent 
the tibia and fibula. AC: anterior compartment, DPC: deep posterior compartment, SPC: superficial posterior 
compartment, LC: lateral (peroneal) compartment.
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complications the metabolic consequences 
of a devitalised limb have to be considered. 
as skeletal muscle becomes ischaemic and 
necroses, myoglobin and potassium are 
released into the circulation. these have 
nephrotoxic and cardiotoxic effects if released 
in large enough quantities, and may cause 
remote organ dysfunction or failure. 
Following decompression of LCS, 
devitalised muscle released myoglobin can 
cause renal failure due to tubular blockage. 
treatment involves optimal fluid therapy 
and consideration of alkalisation of the 
urine using intravenous sodium bicarbonate, 
aiming for a urinary ph greater than 6.5 and 
a plasma ph of greater than 7.4.
In some situations, amputation above 
the level of ischaemia may be required, 
a procedure associated with a high risk 
of mortality and morbidity in an already 
severely compromised patient.
Outcome
whilst fasciotomy wounds are associated 
with a moderate degree of morbidity,26 
fasciotomy does not appear to have any 
effect on long­term calf­pump function.32 
If fasciotomy is performed without delay 
in LCS the outcome in terms of preventing 
limb loss, systemic complications and long 
term functional disability is good.33,34 Failure 
to promptly treat LCS risks the development 
of systemic complications such as multi­




the abdominal compartment syndrome 
(aCS) was first described by kron in 1984.35 
aCS is a clinical syndrome characterised 
by progressive intra­abdominal organ 
dysfunction resulting from increased intra­
abdominal pressure (IaP). In 2004, the 
world Society of abdominal Compartment 
Syndrome gathered at the International 
aCS Consensus definitions Conference in 
2004 to produce internationally accepted 
definitions.36,37 the consensus statement 
defined intra­abdominal hypertension (Iah) 
as IaP more than or equal to 12mmhg and 
aCS as a sustained IaP more than or equal 
Figure 19.8: Split skin grafting to calf fasciotomy 2 weeks post-injury (same patient as figure 19.6). The thigh 
fasciotomy has been treated by delayed closure leaving a small defect to heal by secondary intention.
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to 20mmhg that is associated with new 
organ dysfunction or failure. the severity 
of Iah was characterised into 4 grades 
(summarised in table 19.1). the concept of 
intra­abdominal perfusion pressure (IaPP) 
was also defined by the society as mean 
arterial pressure minus the IaP, as a measure 
of net pressure available for perfusion of 
intra­abdominal organs. the normal value 
of IaPP is greater than 60mmhg. 
acute elevation of intra­abdominal 
pressure causes not only dysfunction of those 
organs within the abdominal cavity (hepatic, 
gastro­intestinal and renal dysfunction) but 
has effects on more distant organ systems 
such as the cardiovascular, respiratory and 
central nervous systems. whilst it has 
most commonly been described following 
abdominal trauma,38 vascular surgical 
pro cedures are the next most common 
cause.39 aCS is important since it results 
in dysfunction of multiple organ systems 
in patients who are already significantly 
compromised and is a contributory factor in 
the development of multi­organ failure. 
In addition to acute aCS, intra­
abdominal pressure may become chronically 
elevated in patients with obesity or ascites. 
In this situation, the rise in intra­abdominal 
pressure occurs over a prolonged period 
of time and abdominal wall compliance 
increases concurrently, thus preventing the 
detrimental physiological effects of acute 
aCS.40 this condition is largely irrelevant, 
except that it may result in falsely high 
readings when assessing acute changes in 
intra­abdominal pressure in these patients.
Incidence
Papavasiliou et al41 reported that IaP was 
significantly higher after ruptured aaa 
(ruptured aaa) repair than either open 
or endovascular elective repair of non­
ruptured aaa. In the ruptured aaa group, 
55% developed IaP values of greater than 
15mmhg. djavani et al42 reported that in 
their series of 17 ruptured aaa patients 
who underwent IaP monitoring, 9 (53%) 
patients developed IaP pressures greater than 
20mmhg (Iah grade III and above) and 
7 (41%) developed clinical aCS. however 
a limitation of this study was that IaP 
monitoring was restricted to complicated 
cases. as not all patients had IaP monitor­
ing, the true incidence of aCS may be 
overestimated in their study. Mehta et al43 
reported a 20% incidence of aCS in their 
30 patients who underwent endovascular 
repair for ruptured aaa, and management 
of this syndrome is assuming increasing 
importance after endovascular surgery for 
ruptured aaa. aCS is rare following elective 
aortic surgery.44
Aetiology
In a similar fashion to LCS, raised intra­
abdominal pressure can occur as a result of 
increased intra­abdominal volume (either 
retroperitoneal or intra­peritoneal) or 
extrinsic compression, which is usually due 
to changes in the abdominal wall, either 
iatrogenic or pathological.
Expansion of retroperitoneal volume can 





IAP between 12 and 15mmHg
IAP between 16 and 20mmHg
IAP between 21 and 25mmHg
IAP greater than 25mmHg
TAbLe 19.1: Intra-abdominal hypertension grades as defined by the World Society of 
Abdominal Compartment Syndrome
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or sepsis.45,46 More commonly intra­
abdominal volume expansion is caused 
by intra­peritoneal expansion either by 
traumatic or iatrogenic bleeding, peritonitis, 
visceral oedema, or intra­abdominal packing 
for uncontrollable haemorrhage.47­51 rarely 
visceral oedema can occur following non­
abdominal trauma that is thought to be due 
to large volume fluid resuscitation.52
Extrinsic compression of the abdominal 
cavity can be caused by tight abdominal 
closure following laparotomy incisions, burns 
eschars, pneumatic anti­shock trousers and 
the repair of large hernias which results in 
an effective reduction of abdominal cavity 
volume.51,53­55 In addition high intra­thoracic 
pressure may lead to high intra­abdominal 
pressure.56
the pathophysiology of aCS after 
ruptured aaa is multifactorial.41,57­59 the 
space occupying effect of large retroperitoneal 
haematoma (primary aCS) is a significant 
factor contributing to Iah, as dictated by the 
inverse relation between pressure and volume. 
In endovascular treatment of ruptured aaa, 
any ongoing type II endoleak bleeding 
from the lumbar and inferior mesenteric 
arteries into the disrupted aneurysm sac may 
contribute to the size of the haematoma and 
exacerbate the existing Iah. this is aggravated 
in the setting of severe coagulopathy.43 
Furthermore, modifications in microvascular 
permeability associated with the shock state 
in ruptured aaa can lead to visceral and 
soft tissue oedema, worsening the Iah.41,57­59 
Secondary aCS (where pathology lies outside 
of the abdomen) is caused by massive fluid 
resuscitation­induced bowel oedema, ascites 




Elevated intra­abdominal pressure causes a 
reduction in mesenteric and hepatic arterial, 
intestinal and hepatic micro­circulatory, 
and portal venous blood flow.61,62 this 
reduction in the visceral blood flow occurs 
at pressures as low as 10mmhg and further 
impairment occurs with further increases of 
intra­abdominal pressure. as visceral blood 
flow reduces, ischaemia occurs, resulting in 
impaired cellular respiratory function and 
subsequent cellular damage. the acidosis 
which follows can be assessed by gastric 
tonometry. reduction in gastric ph has been 
shown to occur early in aCS and this can 
be reversed by abdominal decompression.63 
whilst severe tissue damage has been shown 
to only occur at high intra­abdominal 
pressures (>40mmhg),64 gastrointestinal 
bacterial translocation occurs at much lower 
pressures (25mmhg).65 Since bacterial trans­
location has been implicated as a significant 
contributory factor to the development of 
multi­organ failure, this is an important 
effect of relatively low pressure aCS.
renal impairment was one of the 
earliest noted effects of aCS.35 Progressive 
deterioration in renal function occurs as 
intra­abdominal pressure increases. oliguria 
occurs at pressures above 15mmhg whereas 
pressures of greater than 30mmhg cause 
absolute anuria.44,66,67 Compression of the 
renal veins and direct renal parenchymal 
compression causes increased vascular 
resistance with a secondary reduction in 
renal perfusion.46,66 these changes cause a 
reduction in glomerular filtration rate and 
a subsequent increase in renin, aldosterone 
and anti­diuretic hormone occurs. Further 
increases in renal vascular resistance occur as 
a result and lead to retention of sodium and 
water. Ureteral compression does not appear 
to cause renal dysfunction in aCS since the 
placement of ureteral stents has been shown 
not to improve renal function in aCS.68
Elevated intra­abdominal pressure affects 
not only those organs within the abdominal 
cavity but also has detrimental effects on 
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distant organ systems. Cardiac output 
decreases as intra­abdominal pressure 
increases as a result of decreasing preload 
and increasing afterload.57 Preload is reduced 
due to direct compression of the abdominal 
inferior vena cava and compression of 
the superior vena cava due to increased 
intra­thoracic pressure as a result of direct 
transmission of elevated intra­abdominal 
pressure across the diaphragm. Elevated intra­
thoracic pressure also directly compresses the 
heart, reducing end diastolic volume. all of 
the above results in reduced stroke volume. 
a compensatory increase in heart rate occurs 
which only partially restores cardiac output.69 
the reduced cardiac output caused by aCS 
also causes further impairment of renal 
function beyond that caused by aCS alone.
respiratory dysfunction also occurs 
as intra­abdominal pressure increases.69 
direct transmission of elevated intra­
abdominal pressure across the diaphragm 
causes elevations in intra­thoracic pressure, 
which in turn increases pulmonary vascular 
resistance. the volume of the thoracic 
cavity is also decreased due to elevation of 
the diaphragm, compressing the lungs. this 
compression results in reduced lung volume 
and compliance.70 these changes in the 
vasculature and physical properties of the 
lungs reduce respiratory function.
raised intra­abdominal pressure causes 
increased intra­cerebral pressure and reduced 
cerebral perfusion that is thought to be due 
to reduced cerebral venous drainage.71,72 
also, abdominal wall blood flow is reduced 
in aCS due to direct compression and leads 
to ischaemia and muscle swelling.73 this, in 
turn, reduces abdominal wall compliance, 
exacerbating aCS.74
Clinical presentation
Clinical evaluation of patients with aCS 
is not reliable75 and the only physical sign 
due to aCS per se may be a tense, distended 
abdomen. the majority of clinical signs of 
aCS are due to the compromise of those 
organs systems affected by aCS – respiratory, 
renal, gastrointestinal and cardiovascular 
dysfunction. the classic collection of clinical 
presentations associated with aCS includes a 
tense abdomen on physical exam with oliguria 
and increased airway pressure.35 however 
these signs and symptoms are extremely 
nonspecific in critically ill patients, in whom 
aCS occurs most frequently. Critically ill 
patients frequently undergo large­volume 
fluid resuscitation and therefore commonly 
have impaired tissue perfusion, hypotension, 
and oliguria. acute lung injury or pulmonary 
oedema are often seen in these same patients, 
either of which may result in increased airway 
pressure.76 Clinical examination therefore 
has a limited role in diagnosing aCS. In 
these patients the most important factor to 
consider is a history of an abdominal injury 
or intervention that places them at risk of 
developing aCS leading to active monitoring 
of IaP to detect aCS. 
Investigation
the investigation of choice in a patient with 
suspected aCS is the measurement of intra­
abdominal pressure. the most commonly 
applied technique is that described by kron.35 
this utilises an indwelling urinary catheter to 
obtain a direct measurement of intra­vesical 
pressure and has been shown to correlate 
well with intra­abdominal pressure.77 50ml 
of saline is introduced into the bladder via 
the aspiration port of the catheter which is 
clamped distal to this point. after allowing 
the pressure within the bladder to equilibrate 
with that in the abdominal cavity a pressure 
transducer (such as that used for measuring 
central venous pressure) is attached to an 18g 
needle inserted into the aspiration port and 
the pressure measured using the symphysis 
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pubis as a reference point (‘zero’). the intra­
abdominal pressure can then be measured. 
Modifications to this technique have been 
proposed to avoid the repeated disturbance 
of a closed system with the potential to 
introduce infection.78 this method has been 
shown to be inaccurate at low pressures 
(<15mmhg).79 alternative techniques 
include intra­gastric pressure measurement80 
and inferior vena caval pressure measurement 
via femoral vein catheterisation.81 whilst 
gastric pressure has shown good correlation 
with bladder pressure measurements at low 
intra­abdominal pressure neither of these 
methods have been validated against the high 
bladder pressure measurement in humans 
with established aCS.82
Treatment
the principles of management for aCS are 
prevention, early recognition and definit­
ive treatment of fully manifested aCS by 
surgical decompression. Prevention of aCS 
involves identification of at­risk patients by 
appreciating the risk factors, setting, and 
pathogenesis of aCS. risk factors for aCS in 
vascular cases are massive fluid resuscitation 
(>5L/24hr), sepsis or bacteraemia, mechani­
cal ventilation including use of positive end 
expiratory pressure, polytransfusion (>10U 
packed red blood cells/24hr) and acidosis.37 
Intra operative risk factors for grade III or 
IV Iah for open ruptured aaa repair were 
noted to be longer cross clamping time, 
increased operative bleeding and increased 
operative time,42 and the following risk fac­
tors identified for endovascular repair of rup­
tured aaa: use of aortic occlusion balloon, 
presence of severe coagulopathy, massive 
transfusion requirements, and the emergent 
conversion of modular bifurcated stent grafts 
to aorto­uniiliac devices.43 Presence of these 
risk factors should alert the clinician to more 
aggressive monitoring of IaP and the intro­
duction of preventive measures before full­
scale aCS develops. In general the at­risk 
patients in whom IaP should be monitored 
are detailed in table 19.2 as set out by the 
world Society of abdominal Compartment 
Syndrome.37 
there are various nonsurgical treatment 
options available for dealing with elevated 
IaP83 to prevent manifestation of aCS. Some 
of these methods (nasogastric decompression, 
effective pain management and sedation) are 
used routinely in critically ill patients. body 
positioning (avoidance of acute flexion at the 
hips and reverse trendelenburg) can relieve 
pressure on the abdomen. neuromuscular 
blockade can alleviate abdominal wall ten­
sions leading to dramatic decrease in IaP.84,85 
this can be administered quickly and safely 
to intubated ICU patients84,85 and is a use­
ful adjunct to other nonoperative measures, 
allowing measures such as removal of excess 
TAbLe 19.2: Indications for intra-abdominal pressure monitoring as defined by the world 
consensus definitions
Post operative abdominal surgery with a distended abdomen
Abdominal trauma
Mechanically ventilated patients with other organ dysfunction
Patient with a distended abdomen and signs or symptoms consistent with ACS and including  
  oliguria, hypoxia, hypotension, unexplained acidosis, mesenteric ischaemia, elevated intracranial  
  pressure
Patients with an open abdomen or abdominal packing after temporary closure
Patients who have undergone massive fluid resuscitation, secondary to fluid loss due to leaky  
  capillaries
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fluid to become effective. rectal decom­
pression with enemas or rectal tubes, and 
prokinetic agents may potentially be used in 
selective cases such as suspected toxic mega­
colon or inflammatory bowel syndrome.
other preventive measures include avoid­
ance of excess fluid resuscitation therapy. 
the end points of resuscitation need to 
be accurately determined and unnecessary 
over­vigorous fluid administration should 
be averted by meticulous and precise intens­
ive care monitoring.86 Fluid resuscitation 
should be goal­directed and titrated aggres­
sively against achieving end points such as 
decrease in lactate, adequate mixed venous 
oxygen saturation and reductions in base 
deficit. another important preventive meas­
ure against aCS is the use of prophylactic 
delayed abdominal closure and maintenance 
of an open abdomen. delayed wound 
closure in ruptured aaa repair patients 
in whom primary closure was not possible 
demonstrated a trend towards decreased 
mortality from 73% in primary closure to 
50% with delayed closure.87 an in­vitro 
abdominal simulation model demonstrated 
that the ‘bogota bag’ technique which 
involves utilising a sterile fluid administration 
bag, cut flat and sewn to close the defect 
was most effective at preventing increases 
in abdominal pressures and proposed that 
vacuum dressing is contraindicated in the 
initial phase following decompression.88 
however vacuum­pack temporary closure 
has advantages of ease of mastery, effective­
ness in patient care and comfort, consist­
ently low associated complication rate, and 
low cost in both general and vascular surgery 
and trauma patients. a series involving 258 
surgical patients undergoing open abdomen 
management with the sutureless negative 
pressure dressing reported an overall primary 
fascial closure rate of 68.4%.89 It is still 
imperative that the ICU team avoid overre­
suscitation in patients who are admitted to 
the ICU with a temporary abdominal clo­
sure. Monitoring the IaPP during this period 
may provide guidance and if it is not possible 
to maintain an IaPP >60, then additional 
surgical intervention may be necessary.
the definitive treatment of aCS is expe­
dient decompressive laparostomy. this has 
been shown to rapidly and effectively reverse 
the detrimental effects of aCS in the gastro­
intestinal, renal, cardiovascular, respiratory 
and central nervous systems.45,46,57,69,90­92 It 
has been shown that in clinically unstable 
patients with aCS, surgical decompression 
can be safely performed at the bedside in 
the ICU.93 temporary containment of the 
abdominal contents is achieved using a mesh 
(silastic, polypropylene or polygalactin), plas­
tic bag (intravenous fluid container or bowel 
bag) or vacuum systems (Figure 19.9a). alter­
natively the skin can be closed leaving the 
fascia un­apposed. Following formation of 
the laparostomy consideration has to be given 
as to the method used to close the resulting 
defect. after the patient has recovered from 
the organ dysfunction associated with aCS 
delayed primary closure can be considered. 
the rate of unsuccessful closure of the abdo­
men has been reported between 20% and 
78%.94,95 Coverage of the bowel, prevention 
and management of enterocutaneous fistulas, 
and management of large ventral hernias are 
some of the potential problems of an open 
abdomen. the incidence of failed closure 
and additional complications increases with 
delay and therefore efforts should be made to 
close the abdomen as soon as the underlying 
cause of the aCS has been dealt with. this 
window of opportunity is in general about 
7 days but varies greatly from patient to 
patient, and actual timing should be tailored 
to the individual assessment of the abdomen. 
after this time the body’s attempt to heal 
secondarily will lead to development of 
adhesions and early granulation tissue cul­
minating in a ‘frozen abdomen’ that prevents 
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Figure 9: a) Immediate containment of abdominal contents using plastic bowel bag after decompressive 
laparostomy following ruptured abdominal aortic aneurysm repair. b) The same wound after 4 weeks, the 
viscera having granulated over.
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fascial closure. In cases where primary 
closure of the fascia is not possible, the 
abdominal contents should be left to 
granulate over and then either heal by 
secondary intention or skin grafts applied 
(Figure 19.9b). the resultant ventral hernia 
will then need to be repaired at a later date.
normal intra­abdominal pressure is less 
than 10.5mmhg in men and 8.8mmhg 
in women.96 historical studies35,50 that pro­
posed threshold pressures above 25mmhg 
to start definitive decompressive treatment 
have largely been disregarded. In patients 
with ruptured aaa, Papavassiliou et al41 
demonstrated that an IaP threshold of 
15mmhg was associated with significant 
physiological dysfunction, lower than aCS 
of other aetiology. the algorithm for the 
assessment and management of patients after 
abdominal aortic aneurysm surgery as pro­
posed by Loftus et al,58 suggested immedi­
ate bladder pressure measurement of IaP in 
patients at risk after surgery and if the pres­
sure is greater than 20mmhg, abdominal 
closure should be delayed. Following surgery 
patients should be monitored, if the IaP 
rises above 30mmhg urgent decompression 
should be mandatorily performed. In those 
with IaP between 21 to 30mmhg, urgent 
decompression should be considered. In 
those with IaP between 16 and 20mmhg 
urgent decompression should be considered 
in the presence of organ dysfunction. In those 
patients with IaP less than 15mmhg physio­
logical support should be continued. Gane­
shanatham et al60 proposed a lower threshold 
of IaP more than or equal to 25mmhg for 
which to perform mandatory decompression 
in post­operative vascular patients. at IaP 
of between 16 and 25mmhg, these authors 
suggested decompressive laparotomy if there 
has been no recovery of deranged physiologi­
cal parameters despite optimisation. 
Complications of surgical 
decompression
Much of the morbidity of aCS is due to 
the decompression surgery itself. once 
healed the patient is frequently left with a 
large ventral hernia. with mesh closures, 
entero­laparostomy fistulas are not un­
common (7%) and the rate of mesh 
dehiscence from the fascia or skin was 
22%.97 Enterocutaneous fistula arose in 
5% of patients with negative pressure 
vacuum dressings.89 Infection is a potential 
complication of the temporary abdominal 
wound closures and this risk increases if more 
than one dressing application is needed.89 
the temporary open wounds are not only an 
obvious point of entry for pathogens but are 
also a potential source of excessive fluid loss. 
In hypovolaemic patients, decompression 
may result in haemodynamic instability. 
rebleeding can occur if coagulopathies are 
not reversed prior to the decompression. 
the increased pulmonary compliance from 
rapid reduction in IaP can lead to increased 
minute ventilation resulting in a respiratory 
alkalosis. the toxic metabolites entering the 
systemic circulation can precipitate a cardiac 
event as with any reperfusion injury.60
Outcome
aCS is associated with an overall high mor­
tality of between 60% and 70%, not solely 
due to the development of aCS itself but in 
addition to the insult that caused it.98,99 a 
combined analysis of 18 papers with total 
of 250 patients who underwent decom­
pressive surgery demonstrated that surgi­
cal decompression significantly reduced the 
mean IaP from 34.6mmhg to 15.5mmhg 
with associated improvements in respiratory 
function and cardiac output.100 with an 
average mortality of 49.2%, it has not been 
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definitively demonstrated whether surgi­
cal decompression for aCS confers any 
beneficial overall effect on survival although 
in many studies, aCS without intervention 
results in mortality approaching 100%. 
Given this consideration and the potential 
risks of decompressive surgery, the best treat­
ment for aCS is therefore prevention where 
possible. 
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IntrODuctIOn
pain is defined as an unpleasant sensory and 
emotional experience associated with actual 
or potential tissue damage.1
the mechanism by which a damaging 
stimulus in the body is perceived as painful 
by the brain is a complex one which is not 
yet fully understood. the complexity of the 
process results from the nervous system not 
being a ‘hard wired’ system, but exhibiting 
plasticity that enables it to modify its function 
under different conditions.
as shown by the definition, pain serves the 
purpose to prevent tissue damage and protect 
the body while it is healing. under certain 
conditions, pain can become maladaptive 
and persist as chronic pain. this pain serves 
no protective function and is described as 
pathological pain as opposed to physiological 
pain;2 it is then no longer a symptom of 
another disease, but a disease in its own 
right.3 another term for pathological pain 
has been suggested recently: dysfunctional 
pain.4
In order to adequately treat physio­
logical, but even more pathological pain, 




painful stimuli are detected by nociceptors, 
which are free nerve endings located in tissues 
and organs. they have high thresholds and, 
under normal circumstances, only respond 
to noxious stimuli. 
there are two distinct types of nociceptors
•	 High	threshold	mechanoreceptors	which	
stimulate small myelinated aδ­fibres 
and transmit a well­localised sharp or 
pricking sensation that lasts as long as the 
stimulus.
•	 Polymodal	 nociceptors	 that	 stimulate	
small unmyelinated slowly conducting c 
fibres. as well as responding to mechanical 
stimuli they are activated by thermal 
and chemical stimuli e.g. hydrogen 
ions, potassium ions, bradykinin, 
serotonin, adenosine triphosphate and 
prostaglandins. 
the ion channels for noxious stimuli 
have been partially identified; the transient 
receptor potential (trp) family of these ion 
channels and in particular the vanilloid­type 
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trp 1 (trpV1) have been studied in most 
detail.5 this receptor is sensitive to higher 
temperatures, acidity and capsaicin, an 
exogenous ligand (extract of chilli pepper) 
and receptors like this one are currently 
investigated as therapeutic targets for pain 
therapy. 
nerve growth factor (ngF) is also 
involved in the transduction process, as it 
binds to its receptor trKa and thereby triggers 
increased transduction in pain states, in 
particular inflammatory pain. a monoclonal 
antibody against ngF, tanezumab, has shown 
very promising effects in early stage trials in 
osteoarthritis and chronic low back pain.6
Conduction
Voltage­gated sodium channels mediate 
conduction along primary sensory afferents. 
as for all other impulses throughout the 
body, action potential propagation is 
depend ent on these channels. there are two 
types of sodium channels, differentiated by 
their sensitivity to tetrodotoxin. Both types 
are present in nociceptive neurons, with the 
tetrodotoxin­resistant type only present in 
nociceptors, which makes it a potential target 
for novel analgesics. Further research has 
identified two such sodium channels, labelled 
naV1.7 and naV1.8, which seem to have a 
specific role in pain modulation.7 Mutations 
of these channels are linked to congenital 
insensitivity to pain and erythromyalgia and 
attempts are made to identify blockers of 
these channels, which might be therapeutic 
in chronic or neuropathic pain. 
nociceptors also have voltage­gated 
calcium channels, which are found on the 
presynaptic membrane and are involved 
in neurotransmitter release at the dorsal 
horn. these are modulated by alpha­2­
delta compounds such as gabapentin and 
pregabalin, new first­line treatments of neuro­
pathic pain and central sensitisation.8
pain is transmitted by primary afferents, 
which have their cell bodies in the dorsal 
root ganglion (Drg). they terminate in the 
dorsal horn of the spinal cord. the dorsal 
horn cells are divided into specific regions 
or laminae called rexed’s laminae with 
lamina I being the most superficial.9 
•	 Aδ­fibres are fast conducting and transmit 
the first sharp pain on initial stimulation. 
they terminate mainly in lamina I, but 
also send some fibres to lamina V of the 
dorsal horn where they synapse with 
second order neurones. they contain the 
neurotransmitter l­glutamate.
•	 C	 fibres	 are	 unmyelinated	 slow	 con­
ducting fibres which transmit a less well 
localised persistent aching pain that 
lasts after the initial stimulus has gone. 
they terminate in lamina II of the 
dorsal horn. as well as glutamate they 
contain several other neurotransmitters 
including neuropeptides, such as sub­
stance p, and calcitonin gene­related 
peptide (cgrp), cholecystokinin, brain­
derived neurotrophic factor and glial­
derived neurotrophic factor. c fibres 
express several presynaptic receptors 
that modulate transmitter release. these 
include cholecystokinin (ccK), opioid 
and gamma­aminobutyric acid subtype 
B (gaBa B) receptors. apart from the 
ccK receptor, they inhibit the release of 
transmitter. 
•	 Aβ­fibres conduct low intensity 
mechanical stimuli which convey touch 
and not pain, however in chronic pain 
states they are involved in the transmission 
of pain. they terminate deeper in the 
dorsal horn in laminae III­VI. 
SpInal cOrD MechanISMS
primary sensory afferents terminate in the 
spinal cord where they synapse with cells 
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of the dorsal horn. nococeptive specific 
neurons are located mainly in laminae I 
and II but also lamina V and respond only 
to noxious inputs under normal conditions 
there are a number of different cells 
involved in the relay of painful stimuli 
including nociceptive specific cells and wide 
dynamic range neurons. Wide dynamic range 
neurons are located mainly in lamina V, 
but also in III and IV to a lesser extent, where 
they respond to stimuli from aβ­, aδ­ and 
c­fibres.9
the cells of the dorsal horn involved in 
nociception express a number of receptors.
•	 AMPA	(a­amino­3	hydroxy­5­methylisoxa­
zole) receptors which bind glutamate. 
•	 NMDA	(N­methyl­D	aspartate)	receptors	
which also bind glutamate, neurokinin 
receptors nK­1 which bind substance p.
•	 GABA­A	 receptors	 which	 are	 ligand­
gated calcium channels that hyperpolarize 





the ability to detect a potentially damaging 
noxious stimulus is mediated by glutamate 
acting on the aMpa receptor following 
stimulation of aδ­fibres. the other receptors 
and neurotransmitters are involved in the 
modulation of the response. 
When a high intensity noxious stimulus 
arrives at the dorsal horn via c­fibres, initially 
glutamate is released which acts via the aMpa 
receptor. as stimulus intensity increases, then 
other neurotransmitters are released such as 
Substance p. Slow post­synaptic currents are 
set up which are mediated by a number of 
receptors including the nMDa receptor. 
these are also involved in the modulation of 
the pain response.10
Ascending systems
noxious information is conveyed from the 
dorsal horn to the brain via several ascending 
tracts in the spinal cord. the majority of the 
wide dynamic range neurons and nociceptive 
specific neurons are conveyed anterolaterally 
in three pathways:11
•	 The	 spinothalamic	 tract:	 Its	 fibres	 cross	
over to the contralateral side and pass 
through the brainstem to nuclei in 
the thalamus, finally terminating in the 
somatosensory cortex where pain is 
perceived and localised. 
•	 The	 spinoreticular	 tract:	 It	 terminates	
in the reticular formation and has 
projections, which terminate in the pons, 
medulla and periaqueductal grey matter. 
It is involved in descending inhibition of 
pain.
•	 The	 spinomesencephalic	 tract:	 It	 is	 also	
involved in the modulation of descending 
control. 
Descending control
the dorsal horn receives inputs from higher 
centres that modulate the response to 
nociceptor input.12
the descending control of output from 
the dorsal horn comes mainly from areas in 
the brainstem, namely the periaqueductal 
grey matter, the raphe nuclei and the locus 
coeruleus.13 Inhibitory tracts descend 
in the dorsolateral fasciculus and synapse in 
the dorsal horn. the key neurotransmitters 
involved are noradrenaline and serotonin. 
noradrenaline acts via post synaptic α­2 
receptors, the action of serotonin is less 
specific. endogenous opioids are also 
involved in descending inhibition at a spinal 
and supraspinal level.13 these endorphins 
and enkephalins acting via the descending 
system are thought to be responsible for the 
analgesia induced by stress.
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as well as descending control from 
the brainstem, nociceptive impulses are 
also attenuated by input via aβ­fibres 
(transmitting information on touch), which 
is the basis for the use of transcutaneous 
electrical nerve Stimulation (tenS) for 
analgesia, but also for simply rubbing a 
hurting body part. this observation formed 
the basis for the initial gate­control theory 
of pain.14
paIn MODulatIOn
the above description of pain explains 
the initial sensation of pain immediately 
following injury, however it does not explain 
the more complex phenomena associated 
with pathological pain due to neuroplastic 
changes. 
these phenomena have a number of 
different causal mechanisms, which occur 
initially in the periphery, but later mainly in 
the dorsal horn as the main site modulation 
of painful stimuli.
Peripheral sensitisation
tissue injury results in the release of inflam­
matory mediators, such as bradykinin, 
histamine, K+, h+, 5­hydroxytryptamine 
(5­ht), atp and nitric oxide from damaged 
cells.15 Breakdown of arachidonic acid by 
cyclo­oxygenase produces leukotrienes and 
prostaglandins. Immune cell activation 
results in the release of further mediators 
including cytokine and growth factors. these 
mediators provide an ‘inflammatory soup’ 
which produces a painful area of primary 
hyperalgesia. these inflammatory mediators 
spread into the tissues surrounding the initial 
area of injury to produce an area of secondary 
hyperalgesia.
they act either by stimulating nociceptors 
themselves or by acting via inflammatory 
cells to stimulate release of additional pain 
inducing agents. they also modify the 
response of primary afferents to subsequent 
stimuli either by changing the sensitivity of 
the receptors or by modulating the voltage­
gated ion channels. For example, after tissue 
and nerve injury, n­type calcium channels 
become more active resulting in greater 
release of glutamate in the spinal cord.16 
the magnitude of the current generated by 
sensory­neuron specific sodium channels is 
also increased.
chronic inflammation and also nerve 
injury has an effect on the presence and 
distribution of voltage­gated sodium 
channels, which can become concentrated 
in areas of injury and produce ectopic 
discharges. Sensory­neurone­specific sodium 
channels have a significant role in chronic 
pain states. Studies have shown them to 
become concentrated in neurones proximal 
to a site of nerve injury and play a role in the 
hyperalgesia and allodynia of chronic pain 
states.9 In addition, ngF binding to trKa 
receptors increases peripheral sensitivity as 
discussed before.6
not all sensory neurons are active all 
the time and this peripheral sensitisation 
will recruit ‘dormant’ nociceptors, thus 
increasing the receptive fields of dorsal horn 
neurons and increasing the intensity and the 
area of pain.17 
Central sensitisation in the dorsal 
horn
central sensitisation is an increase in the 
excitability of the dorsal horn so that 
the dorsal horn cells have a lower threshold 
and respond to low intensity stimuli that 
are not usually painful. It also results in a 
greater response to supra threshold stimuli 
thus producing the symptoms of allodynia 
and hyperalgesia.
there are several mechanisms, which 
occur at the dorsal horn and contribute to 
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chronic pathological pain states by central 
sensitisation. these will be discussed in the 
context of neuropathic pain, as they are most 
relevant there.
neurOpathIc paIn
neuropathic pain arises following disease or 
injury to nerves from a number of aetiologies 
eg, ischaemic, traumatic, infection. char­
acteristics of neuropathic pain include 
spontaneous stimulus­independent pain and 
pain that is stimulus dependent and exhibits 
the features of allodynia and hyperalgesia. 
there are a variety of different mechanisms 
responsible for the generation of symptoms, 
which may be quite different from patient 
to patient.18
Mechanisms of neuropathic pain
the pathophysiology of neuropathic pain 
involves central and peripheral mechanisms 
and is in principle a ‘maldaptive response 
of the nervous system to damage’.4 usually 
more than one mechanism may be involved 
and producing a unifying hypothesis for all 
neuropathic pain states is inappropriate.19 
Peripheral mechanisms
electrophysiological evidence over the 
last 25 years shows that activity in sensory 
neurones after injury is necessary for the 
development of neuropathic symptoms. 
Some proposed mechanisms are:
Spontaneous ectopic discharge
normal primary afferent neurones require 
the input of a stimulus in order to reach firing 
potential. It has been shown that after a nerve 
injury spontaneous firing in the afferent 
neurone occurs. a and c fibres have been 
shown to demonstrate oscillatory activity 
resulting in ectopic firing. cross excitation 
of other neurones increases this effect. these 
phenomena may be particularly relevant to 
the development of hyperalgesia, allodynia 
and chronic pain after nerve injuries.
reorganisation of expression of ion 
channels in the peripheral nerves is responsible 
for the ectopic discharge.  Both sodium 
and calcium channels have been shown to 
be involved with their altered expression 
increasing the excitability of neurones. the 
afferent barrage provided by spontaneous 
discharge from neurones provides a constant 
input to the central nervous system that may 
induce central sensitisation.20
Altered gene expression
Damaged peripheral sensory neurones 
undergo Wallerian degeneration and lose 
contact with peripheral targets and the 
supply of neurotrophic factors. the sensory 
neurones undergo altered gene expression, 
the result of which is a change in the type 
and level of neurotransmitters released in 
the spinal cord.21 For example, some a­β 
fibres appear to release transmitters normally 
associated with nociceptors such as sub­
stance p. this seems to contribute to central 
sensitisation.22 a change in gene expression 
also results in either up or down regulation 
of ion channels, in particular different types 
of sodium channel involved in ectopic 
spontaneous activity.
Spared sensory neurons
changes have also been found in uninjured 
sensory fibres that are along side those with 
a lesion. they frequently show the opposite 
gene expression changes from their damaged 
neighbours; possibly due to increased 
bioavailability of neurotrophic factors. this 
can result in increased activity in the spared 
afferents, although the exact mechanism is 
not understood.21 
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Involvement of the sympathetic nervous 
system
Some patients exhibit neuropathic pain that 
is dependent on activity in the sympathetic 
nervous system.23 after a peripheral nerve 
injury, a coupling develops between the 
sympathetic nervous system and the sensory 
nervous system. axons involved develop 
increased α­adrenoceptors and therefore 
have an exaggerated response to circulating 
catecholamines. Morphological changes to 
the nerve follow with sympathetic axons 
sprouting into the dorsal root ganglion 
forming baskets around the cell bodies of 
sensory neurones. these changes lead to 
sympathetically maintained pain. evidence 
for a sympathetic component to a patient’s 
pain include sympathetically maintained, 
often unilateral limb pain, oedema, vaso­
motor and sudomotor asymmetries.
Collateral sprouting
Sprouting of fibres from sensory axons in the 
skin has been shown to occur in denervated 
areas, for example after crush injuries. 
however this does not occur in proportion to 
the degree of neuropathic pain experienced 
and is likely to be a small if at all significant 
factor in its pathophysiology.
Effects of bradykinin
this main plasma kinin, a vasodilator 
peptide, is involved in hyperalgesia associated 
with inflammatory pain, with a change in 
expression of its binding sites within the 
dorsal root ganglion after nerve injury.
Central mechanisms
the central mechanisms potentially involved 
in the generation of neuropathic pain are 
thought to result in neuroplastic changes in 
the cnS. a phenomenon termed central 
sensitisation occurs after peripheral nerve 
injury. central sensitisation changes the way 
the neurones respond to subsequent inputs.4 
this may result in spontaneous ongoing 
pain and abnormally evoked pain (allodynia 
and hyperalgesia).17 the mechanisms that 
are thought to be responsible occur primarily 
in the dorsal horn.
Wind-up
the term wind up describes the altered 
response of the dorsal horn neurones to 
repeated input from c­fibres.10,17 Following 
brief, repetitive c­fibre stimulation, the 
dorsal horn cells respond in a linear fashion. 
however if the stimulus continues, further 
c­fibre activation produces an amplified 
response in the dorsal horn to the same 
intensity of stimulus. 
this phenomenon is mediated by the 
nMDa receptor. activation by sustained 
c fibre input leads to opening of the 
channel, an increased intracellular calcium 
concentration and an increased response to 
glutamate. glutamate is the main excitatory 
neurotransmitter released from primary 
afferent neurones that acts at postsynaptic 
receptors. the nMDa receptor in its resting 
state is blocked by magnesium which is 
released when the cell is depolarised thus 
opening the channel in the receptor and 
allowing an influx of sodium and calcium 
and further depolarisation. When a painful 
stimulus arrives at the dorsal horn, the cells 
are initially depolarised by glutamate acting 
at the aMpa receptor thus allowing removal 
of the magnesium block. Once the stimulus 
is removed, the dorsal horn cells continue to 
fire for several seconds.
there is potential for this to be modified 
pharmacologically and a number of studies 
suggest that nMDa antagonists may 
prevent these phenomena and prevent 
hyperalgesia.10  
Wind up is relatively short lived (seconds 
to minutes), whereas central sensitisation 
persists so the exact relationship remains 
unclear.
Pathophysiology of Pain 381
Central sensitization
central sensitisation is also mediated by 
the nMDa receptor. under conditions of 
prolonged c­fibre activation, depolarisation 
of the dorsal horn cells causes the nMDa 
receptor to lose its magnesium block.10 
Substance p acting via its receptor, the 
neurokinin­1 receptor, prolongs this 
depolar isation and allows further influx 
of calcium. the increase of calcium in the 
dorsal horn activates calcium dependent 
kinases such as protein kinases a and c, 
which are then able to phosphorylate 
amino acids within the nMDa receptor 
to produce a conformational change in the 
structure. this permanently removes the 
magnesium block in the receptor and allows 
it to be activated by glutamate. the process 
of central sensitisation differs from windup 
in that the changes remain long after the 
c­fibre input has ceased. Furthermore, the 
magnesium is removed by posttranslational 
changes in the nMDa receptor and is not 
just depolarisation induced.17,22,24
Central disinhibition
central disinhibition results from loss of 
modulatory control mechanisms, which 
may lead to abnormal excitation of 
central neurones.25 the main inhibitory 
neurotransmitter is γ­aminobutyric acid 
(gaBa). It has been shown that suppression 
of this pathway results in allodynia. Within 
two weeks after a peripheral nerve injury, 
gaBa receptor levels are reduced. So it seems 
that down regulation of gaBa mediated 
pathways may be in part responsible for 
central sensitisation.
Expansion in receptive field size 
(recruitment)
 receptive fields of dorsal horn neurones 
contain subliminal areas; these represent a 
reservoir of activity.26 With ongoing activation 
after injury there is an expansion of receptive 
field size leading to increased perception of 
pain, resulting in secondary hyperalgesia. 
this expansion of receptive fields does 
not reflect peripheral nerve or nerve root 
distribution, but spinal cord architecture. 
It might therefore be confusing from a 
diagnostic point of view, as it transgresses 
the boundaries imposed by a hard­wired 
model of the cnS.27
Immediate early gene expression
Immediate changes in gene expression 
in dorsal horn cells occur in response to 
aδ­ and c­fibre stimulation. these changes 
persist for a variable length of time and 
may contribute to central neuroplasticity. 
noxious stimulation mediated by aδ­ and 
c­fibres produces an immediate change in 
the expression of certain genes within the 
dorsal horn cells.28 these changes are detected 
within minutes of stimulation and may last 
for months or even years. the gene c­fos 
encodes for a protein, fos, which forms part 
of a transcription factor which may control 
the expression of other genes which produce 
long term changes in the dorsal horn. C-fos 
activation occurs as a result of increases in 
intracellular calcium following release of 
neurotransmitters like substance p and 
glutamate involved in relay of nociceptive 
information.29 this is followed rapidly by 
the appearance of fos protein which can be 
detected in laminae I, II and V of the dorsal 
horn. the presence of fos protein can be 
used as a marker of noxious stimulation and 
thus also to determine the effect of agents to 
reduce noxious stimulation.
Anantomical re-organisation of the 
spinal cord
primary afferent neurones synapse in the 
laminae of the dorsal horn with second 
order ascending neurones. under normal 
conditions, aδ­ and c­fibres terminate in 
laminae I and II, whereas aβ­fibres terminate 
in laminae III and IV. 
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Following c­fibre injury, the large 
unmyelinated aβ­fibres sprout terminals 
into lamina II. aβ­fibres, which are activated 
by low intensity non­painful stimuli can 
thus stimulate the dorsal horn neurons 
present in lamina II, usually associated 
with noxious sensation.30 this observation 
could explain allodynia, as aβ­fibres form 
synapses with second order neurones and 
their low­threshold non­noxious inputs will 
be signalled as nociceptive in origin. 
however, doubt surrounds this theory as 
a main mechanism of allodynia as sprouting 
is not fully established until 2 weeks after the 
injury. Furthermore it has been suggested 
that this sprouting only occurs in a small 
subgroup of aβ neurones.21 
as well as sprouting fibres into lamina II, 
aβ­fibres also undergo phenotypic switching 
and produce the neurotransmitter substance 
p and calcitonin gene related peptide. these 
neurotransmitters are usually produced only 
by c­fibres, but after nerve injury their 
expression by c­fibres is down­regulated. 
aβ­fibres begin to release these at the dorsal 
horn following low intensity stimulation. 
this release of substance p can maintain the 
central sensitisation changes in the dorsal 
horn at the nMDa receptor that is usually 
only maintained by continued c­fibre input.
Contribution of glial cells to pain 
conditions
there is now increasing recognition that 
neuropathic pain is not only the result of 
changes in neuronal cells and pathways, 
but also that glial cells, thought to be not 
relevant to neuronal function, play a major 
role here.31 Schwann cells, spinal microglia 
and astrocytes, more regarded as components 
of the immune system, seem to have relevant 
contributions to the development of chronic 
pain states and make it plausible that these 
have features of a neuroimmune disorder 
and may offer new approaches to treatment. 
Symptoms of neuropathic pain
patients with neuropathic pain usually 
experience persistent and/or paroxysmal 
pain.18 the pain often has an abnormal 
quality, for example burning, electric­shock 
like, shooting, lancinating or numbing. 
neuropathic pain can occur in an area of 
neurological deficit, but might also arise 
from areas still innervated normally.32 
neuropathic pain exhibits often one or more 
of the following characteristic features:
•	 Dysaesthesia, an unpleasant abnormal 
sensation, whether spontaneous or 
evoked.
•	 Hyperalgesia, an increased response to a 
painful stimulus.
•	 Allodynia, pain elicited by a normally non 
noxious stimulus
•	 Hyperpathia, a painful syndrome char­
acterised by increased reaction to a 
stimulus, especially a repetitive stimulus, 
as well as an increased threshold.
•	 Hypoalgesia, diminished pain in response 
to a normally painful stimulus.
clinical features of neuropathic pain are 




Following nerve injury, increased c­fibre 
activity causes central sensitisation within 
the dorsal horn via activation of the nMDa 
receptor as described earlier.
central sensitisation produces three main 
effects:
1) enlargement of the sensory field of a dorsal 
horn neuron (secondary hyperalgesia)
2) increase of the response to a supra­
threshold stimulus (hyperalgesia)
3) generation of a response to a subthreshold 
stimulus (allodynia)
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these phenomena represent stimulus­
dependent pain, although the relationship 
between stimulus and response might be 
widely varying.
Stimulus independent pain
as mentioned earlier, there are two types 
of sodium channels present on sensory 
neurons. the tetrodotoxin resistant channels 
are implicated in the generation of the 
spontaneous pain of pathological pain 
states.
Following injury there is reorganisation 
of the expression and location of the various 
types of sodium channel within the neuron. 
the tetrodotoxin resistant channels relocate 
to the neuroma, where it produces areas of 
hyperexcitability and ectopic discharges. 
after nerve injury, both injured nerves 
and uninjured nerves close to the site of 
injury display spontaneous discharges. the 
alterations in expression of sodium channels 
are thought to be due to alterations in the 
supply of neurotrophins such as nerve 
growth factor and glial­derived neurotrophic 
factor.33
Sympathetically maintained pain (SMP)
In a small but significant proportion of 
chronic pain sufferers the pain has a definite 
sympathetic system element to it and is said 
to be sympathetically maintained. 
Following partial nerve injury in these 
patients, both injured and uninjured primary 
afferents express alpha­2 adrenoceptors on 
their membranes so they become sensitive to 
circulating catecholamines and noradrenaline 
release from sympathetic nerve terminals.17 
Direct coupling also occurs between the 
sympathetic and peripheral nervous systems 
with sympathetic nerves sprouting axons 
into the dorsal root ganglion to form baskets 
around the cell bodies of nociceptor neurons, 
where they form functional synapses. this 
sprouting is thought to occur under the 
influence of nerve growth factor. Other 
more central mechanisms of somatosensory­
sympathetic coupling are also investigated.23
Neuropathic pain syndromes
there are many causes of neuropathic pain 
including a number of disease states.
Peripheral neuropathies
Metabolic/Endocrine: Diabetics can develop 
different types of neuropathies, these 
include polyneuropathies, autonomic neuro­
pathy, compression neuropathy and focal 
neuropathies. there are more than 15 million 
diabetics in the uSa and more than half of 
them over 60 years have neuropathic pain. 
Many diabetics, especially those with 
poor blood glucose control develop a distal, 
symmetrical, proximally spreading and 
painful neuropathy.34 Severe pain is often 
a feature and may be described as burning, 
aching or have lightning components to it. It 
seems that the main cause is demyelination 
and to a lesser extent axonal degeneration. 
the first stage in prevention and treatment 
of early neuropathies is good glycaemic 
control. additionally, hyperglycaemia may 
have a direct effect on neuropathic pain 
by altering pain thresholds, tolerance and 
affecting opioid receptors. 
Mononeuropathies, usually involve the 
motor supply to extraocular muscles and also 
nerve supply to the limbs. the third cranial 
nerve is most frequently affected. pain is often 
a symptom. additionally, an asymmetrical 
proximal predominantly motor neuropathy 
can occur, especially in older patients with 
poor glycaemic control.
untreated hypothyroidism may result in 
neuropathic pain.
Toxic: Well­known neuropathies here include 
those caused by alcohol, chemotherapy 
(where the neuropathy maybe the dose 
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limiting factor) and, more recently anti­
aIDS drugs e.g. isoniazid.
Postinfectious: the most common problem 
here is post herpetic neuropathy (phn), 
which increases in incidence, intensity and 
persistence with age.35 the pain persists 
in the distribution of a peripheral nerve 
after herpes zoster infection (shingles). It is 
thought that chronic inflammatory changes 
result in damage to sensory nerves resulting 
in deafferentation of nociceptive fibres. the 
pain is persistent and can become intolerable 
with associated allodynia. treatment is very 
difficult, particularly in later stages.
Hereditary: Fabry’s disease, a rare lipid 
storage disorder, often presents with a painful 
neuropathy.
Malignant: neuropathies can occur as a 
non­metastatic complication of malignant 
disease, usually a sensory neuropathy that can 
sometimes be painful. neuropathic pain can 
also be caused as the result of direct tumour 
invasion involving nearby nerves. 
Idiopathic: trigeminal neuralgia (tic 
douloureux) is defined by the IaSp as a 
‘sudden, usually unilateral, severe, brief, 
stabbing, recurrent pains in the distribution 
of one or more branches of the fifth cranial 
nerve’.1 It can occasionally be secondary 
to an underlying condition e.g. tumour, 
multiple sclerosis. the diagnosis is made on 
clinical grounds as the patients describe a 
characteristic pain. It occurs most frequently 
in the maxillary division and least in the 
ophthalmic division of the trigeminal nerve. 
the pain is triggered by light touch, eating, 
talking and the cold. examination in the 
absence of other neurological symptoms 
reveals very little. there is no definitive 
diagnostic test. Magnetic resonance imaging 
(MrI) can reveal an underlying cause or nerve 
compression, but is otherwise not highly 
sensitive or specific. Magnetic resonance 
tomographic angiography (Mrta) has been 
used in delineating the pathophysiological 
process and may provide a helpful diagnostic 
image but there is insufficient evidence at 
present.
the pathophysiology is not completely 
understood. the most evidence supports 
vascular compression of the nerve, resulting 
in hyperexcitability and abnormal neuronal 
activity, causing pain. this theory is 
supported by the fact that patients often 
experience immediate pain relief from 
microvascular decompression and has been 
confirmed radiologically in a study utilising 
Mrta.36
Spontaneous remission may occur so 
surgery is reserved for those refractory to 
medical treatment. complications of surgical 
microvascular decompression include facial 
nerve damage, haematoma, cerebrospinal 
fluid leak and infection. however, despite 
its risks microvascular decompression is 
currently the best option from a variety 
of surgical procedures. the other surgical 
techniques include gasserian ganglion 
surgery, radiofrequency thermocoagulation, 
percutaneous retro gasserian glycerol 
injection or microcompression, posterior 
fossa surgery and gamma knife irradiation. 
patients should be made aware of the risks 
associated with the chosen surgical technique 
and warned that the pain relief may not be 
permanent and balance these against the 
benefit from potential long term analgesia in 
cases refractory to medical management.37
Vascular: Vascular pain is a complex issue. 
pain can be arterial, microvascular or venous 
in origin. neuropathy can in particular follow 
venous insufficiency.38 In every vascular 
disease, sympathetic changes may develop 
which contribute a neuropathic element to 
the ischaemic pain. the patient may develop 
skin hyperalgesia, dystrophic skin with a shiny 
appearance, muscle atrophy and vasomotor 
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phenomena. Sympathetic blocks may be 
beneficial.39
Posttraumatic: posttraumatic neuropathies 
are common and can develop after any nerve 
injury. even minor demyelination injuries 
without neurological sequelae can result in 
neuropathies. examples are sciatica, neuroma 
or nerve entrapment after surgery or trauma, 
phantom limb pain, complex regional 
pain syndromes (crpS) type I (without 
neurological deficit, previously called reflex 
Sympathetic Dystrophy rSD) and type II 
(with neurological deficit, previously called 
causalgia) and post­thoracotomy pain.
Central neuropathies
central pain is due to a lesion or dysfunction 
of the cnS.40 these lesions may have 
associated symptoms that affect the patient 
and their pain eg ataxia, motor weakness and 
hearing/visual loss. epilepsy and depression 
are also common with cerebral lesions. these 
aspects need to be addressed along with 
treatment of the pain.
central pain is associated with 
spinothalamocortical dysfunction and may 
develop over a length of time and varies 
widely between individuals regardless of 
aetiology. 
Vascular lesions in the brain and spinal cord: 
the aetiology here includes infarction, 
haemorrhage, and vascular malformation. 
Stroke is the most common cause of central 
pain due to its high incidence.41 around 8% 
of patients with acute stroke have been shown 
to suffer from central pain in the following 
12 months. 
Multiple sclerosis: this demyelination process 
can result in neuropathic pain by a variety 
of mechanisms. cranial nerve neuropathies, 
but also widespread central pain syndromes 
are common consequences and often difficult 
to treat.42
Trauma, tumours and infections: Brain 
injury, but by far more commonly spinal 
cord injury, can result in a variety of 
central pain syndromes.43 Syringomyelia 
and syringobulbia as a consequence of 
such injuries can cause further central pain. 
tumours of the brain and spine as well as 
infections and abscesses can cause similar 
symptoms.40
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intRoduction
the phenomenon of pain in a missing limb 
has puzzled patients, doctors and the lay 
public for centuries. in the 16th century 
the French military surgeon ambroise paré 
published a medical description of the enig­
matic affliction, while in the 17th century 
the great philosopher Rene descartes looked 
at its potential pathophysiology. the most 
famous ‘first’ description of the condition is 
attributed to the great neurologist charles 
Bell,1 but it was only in the later part of 
19th century, that the uS military surgeon 
Silas Weir Mitchell introduced the term 
‘phantom limb’: ‘There is something almost 
tragical, something ghastly, in the notion of 
these thousands of spirit limbs, haunting as 
many good soldiers, and every now and then 
tormenting them . . .’
We now know that post­amputation 
syndromes can occur with any amputated 
body part apart from limbs e.g. breast, 
tongue, teeth, genitalia and even inner organs 




Following amputation (or deafferentiation 
injury such as brachial plexus avulsion) a 
number of phenomena can develop, which 
require differentiation.
Stump Pain 
Stump pain is pain localized to the site 
of amputation. Stump pain can be acute 
(usually nociceptive) or chronic (usually 
neuropathic). Stump pain is most common 
in the immediate post­operative period.5 the 
overall incidence of chronic stump pain is in 
the range of 45%.6 the incidence of early 
stump pain is increased by the presence 
of severe pre­amputation pain7 and severe 
acute stump pain.8 the cause is unclear 
but probably multifactorial. Stump pain is 
problematic and can interfere with prosthesis 
use.
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Phantom Sensation 
phantom sensation is defined as any sensory 
perception of the missing body part with the 
exclusion of pain. almost all patients who 
have undergone amputation experience such 
phantom sensations.9 these sensations range 
from a vague awareness of the presence of the 
organ via associated paraesthesia to complete 
sensation including size, shape, position, 
temperature and movement.10 phantom 
sensations usually diminish in intensity or 
size over time, but may persist for a long 
time. ‘telescoping’ of the phantom part can 
occur with time such that the phantom limb 
gradually shrinks proximally to approach the 
stump.11 eventually the phantom limb is felt 
to be within the stump itself.
Phantom Limb Pain 
phantom limb pain (plp) is defined as any 
noxious sensory phenomenon of the missing 
limb or organ. the incidence of phantom 
limb pain is estimated to be 60–80% after 
limb amputation.5,6 the pain is independent 
of gender, level or side of amputation.5 
there is, however, a lower incidence among 
children and congenital amputees.12 
pain can be immediate or delayed 
in onset. it is typically intermittent and 
changes with time. typical characteristics of 
phantom limb pain are burning, shooting, 
crushing, throbbing, cramping, aching, 
tingling, boring; often the limb is described 
as being in a hyperextended or otherwise 
unnatural position. the pain usually occurs 
in the distal portion of the missing limb.5 
the incidence of pain may be increased if 
pre­amputation pain was present and may 
then resemble the pre­amputation pain in 
character and localisation.8,13 however, the 
exact relationship between pre­amputation 
pain and plp is not a simple one, especially 
as patients’ pain perceptions alter and may 
be exaggerated with time.5 the incidence 
of phantom pain diminishes with time 
after amputation, as does the frequency 
and intensity, being highest immediately 
following surgery.5
it is important to realise, that the terms 
for noxious syndromes, ‘stump pain’ and 
‘phantom limb pain’, are subjective descriptive 
terms that do not make assumptions on 
differences in pathophysiology. there is, in 
fact, a strong correlation between phantom 
pain and stump pain and they may be inter­




the pathophysiology of post­amputation 
pain syndromes is most likely based on 
a combination of peripheral and central 
factors, which interplay subsequent to the 
significant trauma of an amputation.
Peripheral Factors
the following changes occur after peripheral 
nerve injury such as cutting of a nerve:15
1) Sensitization of peripheral nociceptors 
with a decreased threshold to noxious 
stimulation;
2) increased response to supra­threshold 
stimulation;
3) Spontaneous activity of peripheral 
receptors due to sensitisation including 
ectopic pacemaker sites, possibly as a 
result of the increase in sodium channels, 
α­adrenergic channels, calcium channels 
and stretch­activated channels that 
follows nerve injury;
4) Sensitization of non­nociceptive receptors 
to nociceptive impulses. 
these changes contribute to hyperalgesia 
and allodynia in the stump; therefore stump 
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manipulation and revision can worsen pain 
due to repeated deafferentation injuries. the 
dorsal root ganglion may also be the site 
of ectopic neuronal activity subsequent to 
deafferentiation and thereby contributing to 
pain syndromes.
Furthermore, regrowth of severed nerves 
often produces nodules called ‘neuromas’. 
neuronal activity originating from peripheral 
neuromas either spontaneously or in 
response to mechanical, chemical or electrical 
stimulation, may cause increased sensitivity 
of the stump to different stimuli.15
other peripheral factors include increased 
muscle tension in the stump correlated 
with cramping and spasmodic pain and 
decreased blood flow to stump correlates 
with descriptions of phantom pain such as 
burning or tingling. low stump temperature 
correlates with burning pain.
overall, while physical stimulation of the 
stump may accentuate phantom limb pain, 
current evidence suggests that peripheral 
mechanisms do not cause, but at most 
modulate or perpetuate phantom limb pain. 
Spinal Factors
the combination of increased afferent input 
from sensitised nerve endings and the dorsal 
root ganglion may contribute to central 
sensitisation. the following changes occur 
in the dorsal horn of the spinal cord after 
nerve injury:15
1) increased spontaneous activity of dorsal 
horn neurones
2) increased response to afferent input 
3) after­discharges following repetitive 
stimulation 
4) expansion of peripheral receptive fields
5) Wind­up (increased neuronal activity in 
dorsal horn neurons following repetitive 
c­fibre stimulation), mainly mediated by 
n­methyl d­aspartate (nMda) receptors.
these factors play an important role 
in many chronic pain syndromes, but to 
which extent these factors are involved in 
perpetuation of phantom syndromes is 
currently unclear, although involvement 
is likely.
Supraspinal Factors
the presence of pain prior to amputation 
is thought to increase the likelihood of 
phantom pain.13 in 1971, Melzack proposed 
that the painful extremity had created a 
painful central ‘engram’. an engram is the 
schematic representation of body parts in 
the cnS caused by consistent sensory input. 
this engram was thought to persist after 
amputation causing phantom pain.
on the basis of these observations, 
the neuromatrix theory was proposed by 
Melzack in 1990.16 in this theory, the body’s 
physical self is represented by a matrix, a 
complex network of neurones connecting 
somatosensory cortex, thalamus and limbic 
system. this neuromatrix is genetically 
determined and subsequently modulated 
by sensory input, thereby creating a 
neurosignature for each body part. this 
neurosignature determines how a body 
part is consciously perceived; phantom 
sensations are the result of persistence of the 
neurosignature after the loss of the limb. the 
genetic determination of the neurosignature 
is supported by the observation that children 
who are born with a missing limb may feel 
phantom sensations of the missing part. 
in this theory, phantom limb pain is 
the result of abnormal reorganisation in the 
matrix, either due to a preexisting pain state 
or the amputation process itself.16 
By analysing neuromagnetic fields, the 
group around Flor has been able to show 
a close correlation between the degree of 
neuromatrix reorganisation and the develop­
ment of phantom limb pain;17 reorganisation 
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of somatosensory cortex occurs with 
neighbouring representation zones moving 
into the deafferented zone.18 here it is also 
of note that many of the sites of amputation 
that commonly lead to phantom sensation 
and pain are sites with a relatively large 
cortical somatosensory representation.
an alternative theory discussed in the 
literature is the dynamic reverberation theory. 
this originated from the observation that 
selective stereotactic cortectomies of the 
corona radiata or focal brain lesions in 
the parietal cortex, thalamus or cortico­
thalamic fibres on the contralateral side have 
resulted in permanent relief of phantom 
pain. this led canavero, in 1994, to the 
theory that phantom pain and sensation were 
a result of a localized dynamic reverberation 
loop between cortex and thalamus. he 
postulated that this loop could operate with 
or without sensory activation.19
cuRRent 
pathophySiological Model 
oF poSt­aMputation pain 
SyndRoMeS
a comprehensive model incorporating 
the current state of knowledge has been 
proposed by Flor et al. it includes peripheral 
and central factors as relevant contributors 
to the development and perpetuation 
of phantom limb pain.18 in principle, it 
suggests that somatosensory pain memories 
and a subsequently altered homuncular 
representation in the somatosensory cortex are 
the underlying factors of phantom limb pain, 
which can be sustained by peripheral factors. 
in more detail, it assumes that memories of 
pain established before an amputation are 
powerful causative contributors to phantom 
limb pain generation. in analogy to findings 
in other chronic pain patients, such pain 
memories increase the representation zone 
in the primary somatosensory cortex. the 
changes are then perpetuated after the 
amputation by selective c­fibre deafferenti­
ation, random input from stump neuromas, 
abnormal changes in the dorsal root ganglia 




in view of the immense difficulties in 
treating phantom limb pain once it is 
established, considerable efforts have been 
made to identify techniques to prevent the 
syndrome. Regrettably, the evidence on 
none of the methods tried has been 
conclusive, although overall results of epi­




in 1988, Bach et al. demonstrated that 
lumbar epidural blockade (leB) with 
bupivacaine plus morphine, started 72 hours 
prior to surgery, reduced the incidence of 
phantom limb pain in the first year after 
surgery.21 this promising result initiated 
a number of similar studies; Schug et al. 
investigated the use of pre­emptive lumbar 
epidural anaesthesia/analgesia preoperatively 
for 24 hours and postoperatively for 72 hours 
in a small sample of patients. at an interview 
one year after amputation, those patients 
with epidural analgesia had significantly 
less severe phantom limb pain than those 
receiving general anaesthesia.22
another study comparing pre­operative 
and intra­operative analgesia using leB 
showed no difference between groups. the 
duration of pre­operative leB, however was 
variable between patients with a median pre­
operative infusion of 18 hours.23 however, 
this study has been criticised for its quality 
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of analgesia and the inclusion of pain of any 
intensity in the results.
More recently, lambert and colleagues 
compared pre­operative epidural with peri­
neural analgesia. the leB was started 
24 hours before surgery and continued for 
three days post­operatively. no difference 
was found in stump or phantom pain or in 
phantom sensation at six and 12 months.24 
although this was a randomised trial, the 
numbers were small and it is questionable 
whether the study had sufficient power for 
phantom pain outcome measurements.
in conclusion, there have been several 
studies looking at preventive analgesia using 
leB. the results are conflicting,25 however 
a meta­analysis showed that perioperative 
epidural analgesia reduced the incidence of 
severe phantom limb pain with an nnt 
of 5.8.26 overall the results are promising and 
a protective effect has again been confirmed 
in a recent audit at our institution.
Peripheral Nerve Blockade 
infusions of local anaesthetics via peripheral 
nerve sheath catheters, usually inserted by 
the surgeon during the amputation, are a 
safe method providing excellent analgesia for 
the immediate post­operative wound pain. 
they are, however, of no proven benefit in 
the prevention of phantom pain or stump 
pain.25
NMDA Antagonists 
the use of pre­incision ketamine as pre­
emptive analgesia has been described 
previously in other settings. a small obser­
vational study suggests that the incidence of 
severe phantom limb pain may be reduced 
with the use of ketamine as a bolus followed 
by an infusion started prior to skin incision 
and continued for 72 hours post­operatively.27 
this promising study was small and used 
historical controls. a randomised controlled 
trial could not confirm these results, but was 
underpowered.28 epidural ketamine had no 
preventive effect in an Rct.29 however, a 
trial of memantine in combination with 
regional analgesia showed a preventive 
effect.30 overall, further investigations are 
justified.
evaluation oF the patient 
With poSt­aMputation pain 
SyndRoMeS
phantom sensation requires pre­ and post­
operative counselling and education but 
it should not generally pose a clinical 
problem.
Examination
examine stump to exclude common causes:
1) prosthogenic pain 
a) due to an improperly fitting 
prosthesis:
 i)  poor socket fit, cushioning or 
alignment
b) inappropriate suspension resulting in 
pistoning
c) painful adductor roll in the above­
knee amputee
d) distal residual limb weight­bearing
e) poor trim line
2) neuropathic pain
a) caused by neuroma formation
b) test for presence of wind­up by 
examining for tinel’s sign – shooting 
pains elicited by repeated tapping over 
the area
3) arthrogenic pain
a) pain originating in neighbouring joint 
or surrounding soft tissue, ligaments 
or tendons.
4) Referred pain
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excessive biomechanical stress in amputees 
may cause painful musculoskeletal conditions 
such as sacroiliac dysfunction, piriformis 
syndrome, facet syndrome or radiculopathy.31 
therefore it is important to examine posture 
and gait. 
Furthermore, it is of value to examine skin 
for areas of ulceration and infection, palpate 
for areas of tenderness, bony exostosis, 
heterotropic ossification and adherent scar 
tissue and evaluate muscle strength and 
range of movement of neighbouring joints 
to exclude contracture formation.
theRapy oF poSt­aMputation 
pain SyndRoMeS
a survey by Sherman et al. in 1980 identified 
over 50 different therapies currently in use 
for the treatment of phantom limb pain.32 
this suggests clearly that an effective 
treatment of phantom limb pain has not 
been established and that ‘the results are poor 
and usually below the expected rate of cure 
of pain with placebo treatment alone.’
Randomised controlled trials have only 
established the effectiveness of a small 
number of therapies. 
however, as early treatment is more 
effective and often multidisciplinary 
approaches are needed, patients with severe 
postamputation pain should be promptly 
referred to a multidisciplinary pain clinic 
to ensure optimal and timely pain manage­
ment.
Calcitonin
the parenteral administration of calcitonin 
is a proven treatment for phantom limb pain 
and in our experience the most effective 
in early stages,33 while there is no benefit in 
chronic phantom limb pain.34 after initial 
anecdotal reports,35 a randomised double­
blind cross­over study by Jaeger and Maier 
showed excellent effectiveness.36 200 iu of 
salmon calcitonin was given as an intravenous 
infusion over 20 minutes and provided 
complete pain relief for 76% of patients; 
71% did not experience recurrence of their 
phantom pain. calcitonin may also be given 
subcutaneously or intra­nasally.33 
the mechanism of action of calcitonin in 
inhibition or modulation of pain perception 
is unknown; however anecdotal descriptions 
of its effectiveness in a number of states 
of central sensitisation are published. Side 
effects including dysaesthesia, nausea and 
vomiting have been described, but most 
are transient and can be prevented by 
prophylactic use of anti­emetics.36 the risk 
of an anaphylactic reaction is most likely 
minimal, but needs to be considered.
Ketamine
Ketamine, an antagonist of the nMda 
receptor, is another proven treatment of 
stump and phantom limb pain. in a random­
ised trial of patients with existing pain, 
ketamine has been shown to significantly 
reduce phantom pain and stump pain. it 
was also shown to decrease wind­up like 
pain (pain evoked by repetitive mechanical 
stimuli), and to increase the pain­pressure 
threshold in patients with phantom pain 
and stump pain. it was given as a bolus of 
0.1mg/kg/5minutes followed by an infusion 
of 7mcg/kg/minute. pain recurred 30min­
utes after discontinuation of the infusion 
in most patients.15 this was confirmed in a 
more recent trial.34 
over­activity of nMda receptors may 
be a factor in the maintenance of stump pain 
and phantom pain. 
Analgesic and Co-analgesics 
Compounds
as outlined in the chapter ‘treatment of 
neuropathic pain’, these agents can play an 
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important role in pain due to nerve injury, 
but have only variable effects in phantom 
limb pain.
Opioids
generally, neuropathic pain is less responsive 
to opioids than nociceptive pain.37 however, 
a randomised double­blind study of oral 
retarded morphine sulphate (MSt) showed 
a significant reduction in phantom pain 
in opioid­sensitive patients, with pain 
reduction of over 50% occurring in 42% 
of patients. neuromagnetic source imaging 
of three patients suggested reduced cortical 
reorganization may be occurring with the 
use of MSt.38
a study comparing the effects of 
intravenous lidocaine with intravenous 
morphine showed that morphine given as 
0.05mg/kg bolus followed by 0.2mg/kg 
infusion over 40 minutes, given on three 
consecutive days, significantly reduced both 
stump and phantom pain.39 an nnt of 5.6 
and superiority over mexilitine was found for 
morphine in a more recent trial.40 tramadol 
was as effective as amitriptyline in treating 
post­amputation pain.41
Gabapentin
in a randomized, double­blind, placebo­
controlled, cross­over study, six weeks of 
gabapentin was better than placebo in 
relieving phantom limb pain. pain intensity 
difference was significantly greater for 
gabapentin than for placebo.42 these findings 
were not confirmed by a later study.43
Clonazepam
anecdotal evidence suggests that clonazepam 
may be useful in the treatment of phantom 
pain.44 there are however no studies to 
confirm this.
Lidocaine 
a randomised double blind study comparing 
the effects of intravenous lidocaine with 
intravenous morphine showed that lidocaine 
given as 1mg/kg bolus followed by 4mg/kg 
infusion, given on three consecutive days, 
significantly reduced stump pain but had no 
effect on phantom pain.39
Carbamazepine 
there is only anecdotal evidence for the 
use of carbamazepine in the treatment of 
post­amputation syndromes.45 it has been 
extensively used in the treatment of other 
neuropathic pain states. Side effects can 
be problematic. Randomised trials are 
required. 
Tricyclic Antidepressants (TCA)
in a randomised trial, chlorimipramine, a 
serotonin reuptake inhibitor, was found to 
be significantly better than nortriptyline, 
a noradrenaline reuptake inhibitor, in the 
treatment of central pain syndromes.46 amit­
riptyline and tramadol were equally effective 
in the treatment of phantom limb pain.41
Selective Serotonin Reuptake Inhibitors
venlafaxine is a serotonin and noradrenaline 
reuptake inhibitor with a side­effect profile 
significantly better than tcas.47 there are 
no Rcts on its effect on post­amputation 
pain syndromes.
Baclofen 
this gamma­aminobutyric acid (gaBa) 
agonist, when given intrathecally, has been 
shown to reduce chronic musculoskeletal 
pain.48 it may therefore be of some benefit 
if muscle spasm is the source of the pain. it 
has not been proven to be of use in phantom 
limb pain.
Capsaicin
capsaicin depletes the neurotransmitter, 
substance p from sensory nerves and may 
give relief to some patients with stump pain 
when used topically.49
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Symptomatic Treatment of Pain 
Components
the burning component of phantom 
limb pain alone can be decreased by 
pharmacological and behavioural therapies 
that increase the temperature of the stump 
such as sympathectomy, α­ or β­blockade or 
biofeedback.
cramping can be relieved by treatments 
that reduce muscle tension, for example with 
the use of baclofen or again biofeedback.
Nonpharmacological Therapies
the following therapies are thought to relieve 
phantom pain by causing increased sensory 




With the development of theories on cortical 
reorganisation as a cause for phantom limb 
pain, there are now therapies tried, which 
are based on the concept of reversing such 
reorganisation.18 Sensory discrimination 
training programs show promise here; this 
is a process during which patients have to 
discriminate the frequency or location of 
high intensity, non­painful electrical stimuli 
applied through electrodes on their stump 
in an attempt to separate merged regions on 
their cortical somatosensory map. 
a recent study using this technique 
showed that phantom limb pain was 
significantly decreased in the group who 
underwent the training process compared to 
controls. cortical reorganisation, assessed by 
neuroelectric source imaging and structural 
magnetic resonance imaging, was also 
reduced in this group.50 Mental imagery 
of limb movement51,52 and a combination of 
laterality recognition, mirror movements and 
imagined movements are other successful 
approaches based on this concept.53 
Similarly, there are now first data, that 
use of a myoelectric prosthesis may prevent 




this psychiatric treatment is thought to 
interrupt the dynamic reverberations that 
maintain central and phantom pain in the 
thalamocortical pathway19 and has been used 
in the treatment of refractory phantom pain.55 
there have been no trials in this area. 
Nerve Blockade
there is only anecdotal evidence for the use 
of peripheral nerve blockade in the treatment 
of phantom pain syndromes.56 there have 
been no trials in this area.
Spinal Cord Stimulation 
this treatment, thought to facilitate 
inhibitory descending pathways, has been 
described in the treatment of phantom pain. 
the overall success rate of this expensive and 
invasive approach in this indication is in the 
range of less than 50%.57,58
Implantable Intrathecal Delivery Systems 
infusing clonidine, local anesthetic, baclofen 
or opioids, usually in a combination, may be 
beneficial in selected patients with phantom 
limb pain, although there are no definitive 
studies.
Dorsal Root Entry Zone (DREZ) Lesions
dReZ lesioning has a limited effect for a 
limited time only in phantom limb pain;59 
this is in line with clinical experience with this 
neurodestructive approach. other types of 
surgery and neuroablation often makes pain 
worse because of repeated stimulation and/or 
deafferentation of the affected nerves.
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Psychological Therapy
pre­amputation counselling is mandatory 
as amputees go through normal grieving 
processes. it is important to identify anxiety 
and depression early, as these can magnify pain 
perception. Behavioural, cognitive, group 
therapy and pain management programs are 
all useful methods of helping patients cope 
with their pain. hypnosis, biofeedback and 
muscular relaxation training to disrupt the 
pain­anxiety­tension cycle are important 
components of chronic pain therapy. 60
FutuRe aiMS
Future aims in the management of post 
amputation syndromes focus on:
1) Further prospective randomised trials 
to evaluate the benefits of current 
pharmacological therapies.
2) clarification of the role of pre­emptive 
analgesia in the prevention of phantom 
pain.
3) evaluation of the promising methods 
that attempt to revert the cortical 
reorganization that occurs following 
amputation towards normal.
4) a multi­modal and multi­disciplinary 
approach to pain management.
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IntroDuctIon
neuropathic pain is defined by the 
International association for the Study of 
pain (IaSp) as pain following a primary 
lesion or dysfunction of the nervous system.1 
It is caused either by peripheral damage 
with lesions involving peripheral nerves, 
dorsal root ganglia and the dorsal roots 
(peripheral neuropathic pain) or by central 
damage, which may involve injury caused by 
infarction or trauma of spinal cord or brain 
(central neuropathic pain).
neuropathic pain results in persistent 
pain syndromes that have no biological 
function, but are difficult to treat and cause 
great distress to the individual. neuropathic 
pain is also referred to as neuro genic pain, 
deafferentation pain, neuralgia, neuralgic 
pain and nerve pain.
neuropathic pain may develop immedi­
ately after a nerve injury or after a variable 
interval. It may be maintained by factors 
different from the initial cause. It can persist 
for a long time and is frequently not explained 
by underlying pathology. patients are 
frequently seen by many different specialists 
and their treatment often fails to resolve the 
pain. as the pain persists other factors such 
as environmental, psychological and social 
stressors become relevant contributors to the 
overall presentation.
prIncIpleS of treatMent
treatment of neuropathic pain is not 
straightforward. the pain is often refractory 
to conventional analgesic regimens such as 
non­Steroidal anti­Inflammatory Drugs 
(nSaIDs). opioids have only limited efficacy 
in neuropathic pain as outlined later in this 
chapter; therefore so called co­analgesics, 
medications which are not typically used as 
analgesics, are often the first­line treatment 
of neuropathic pain.
Increasingly, data from randomised 
controlled trials (rcts) and meta­analyses 
are leading to improvements in management 
and a more evidence­based approach. a 
number of recent evidence­based guidelines 
have been published by various societies 
and organisations. of particular value are 
the guidelines published by the european 
federation of neurological Societies (efnS)2 
and by the Special Interest group neuro­
pathic pain of the IaSp (neupSIg).3
It is important that patients have realistic 
expectations regarding treatment efficacy 
and potential side effects in order to improve 
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compliance with medication.4 a balance 
between these should be achieved on an 
individual basis. a single drug therapy should 
be tried before combinations of drugs are 
started. non­pharmacological treatments are 
available that may be appropriate for certain 
cases. for optimal results a multidisciplinary 
approach to treatment should be adopted 





the use of opioids to treat neuropathic pain 
is controversial. In 1988 a study implied 
that patients with neuropathic pain did not 
experience pain relief from opioids.5 however, 
this study has been criticised for possible 
selection bias as most non­responders had 
previously used morphine without effective 
results and there was no individual titration 
of morphine. a number of reasons have been 
suggested for the relative opioid resistance; 
these include among others, down­regulation 
of peripheral and spinal opioid receptors6,7 
and physiological antagonism with up­ 
regulation of cholecystokinin.8 there is also 
evidence in animal experiments that long 
term use of opioids induces a state of cnS 
hyperexcitability implying that tolerance to 
opioids may have a pharmacology similar 
to hyperalgesia.9 Studies in humans have 
so far not confirmed these experimental 
data.
Since then multiple rcts in neuropathic 
pain have been conducted with morphine, 
fentanyl, oxycodone and other opioids. 
the general consensus is that pain intensity 
may be relieved by opioids titrated for that 
individual. this concept was confirmed in 
a study in which dose responses of opioids 
in nociceptive and neuropathic pain were 
compared and higher doses were indeed 
required in neuropathic pain.10 a cochrane 
review of the multiple rcts confirmed 
significant efficacy of opioids in neuropathic 
pain.11
Recommendations for clinical use of 
opioids in neuropathic pain
there is now a general consensus that a subset 
of patients with neuropathic pain benefit from 
treatment with opioids.12 however, current 
guidelines for neuropathic pain treatment do 
not recommend opioids as a first­line option 
due to the potential adverse effects and risks 
of these drugs.2,3 If a decision to use opioids 
is made, then the approach to identify these 
patients and manage their treatment should 
follow guidelines for the use of opioids in 
chronic noncancer pain (cncp).13,14
Summarising such guidelines is beyond 
the scope of this chapter; in brief they 
usually include a past/present history of drug 
addiction as a relative contraindication, the 
need for regular follow­up visits and opioids 
to be prescribed and supervised by the same 
doctor. legal issues with opioid prescriptions 
are associated with their controlled status, the 
risk of addiction and abuse and the potential 
for diversion into illegal channels by selling 
or passing on to others.15 Methadone, due 
to its additional monaminergic and nMDa 
receptor effects, might be a particularly 




tramadol is a centrally acting synthetic 
analogue of codeine; however it is not a 
conventional opioid as it has relatively 
low affinity for µ­opioid receptors and 
is classified by the fDa as an atypical 
centrally acting analgesic. tramadol together 
with its primary active metabolite has 
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three synergistic mechanisms of action to 
provide analgesia. It combines weak effects 
on opioid receptors with monoaminergic 
mechanisms. reuptake inhibition of 5­ht 
and noradrenaline contribute to the anti­
nociceptive action of tramadol.18,19 tramadol 
is a racemic mixture with opioid receptor 
activity and 5­ht reuptake inhibition mainly 
associated with the (+)­tramadol enantiomer, 
whereas (­)­tramadol is a reuptake inhibitor 
of noradrenaline.20,21 the monaminergic 
effects suggest a higher analgesic potency of 
tramadol in neuropathic than in nociceptive 
pain states; this has been recently confirmed 
by our group.22
Efficacy
tramadol has been investigated for the 
treatment of chronic pain in the past. a 
number of rcts of tramadol in patients 
with neuropathic pain have been completed. 
the first involved 131 patients with diabetic 
neuropathic pain, 37% patients withdrew, 
more from adverse effects in the tramadol 
group and more from lack of efficacy in the 
placebo group. the tramadol group had 
significantly more pain relief than placebo.23 
In a subsequent randomised placebo­
controlled crossover trial 45 patients with 
neuropathic pain were studied. Significant 
reductions in spontaneous and touch­evoked 
pain were achieved with tramadol.24
a meta­analysis of these and other rcts 
identified tramadol as an effective treatment 
for neuropathic pain; or with number needed 
to treat (nnt) for 50% pain relief of 3.8 
with therapeutic effects on paraesthesia and 
allodynia and a number needed to harm 
(nnh) of 8.3.25
Adverse effects
tramadol causes less respiratory depression26 
and constipation27 than conventional opioids. 
physical dependence to tramadol use is 
extremely rare28 and occurs in the range of 
1:100,000 users.29 Similarly, tramadol has a 
low abuse potential30 and its risk of addiction 
has been rated in the range of 1:100,000.29,31 
for these reasons, tramadol is not under 
special regulatory control in most countries. 
phase IV clinical trials have reported the 
overall incidence of side­effects from tramadol 
to be 15.3%.32 the majority of side­effects 
were found to be dose dependent.
Recommendations for clinical use of 
tramadol in neuropathic pain
experimental evidence and a meta­analysis 
have shown tramadol to be a particularly 
useful analgesic in neuropathic pain with 
a low incidence of adverse effects, mainly 
of a benign nature. In our experience (and 
that of many other pain clinics) it is the 
preferred opioid­like drug in this indication, 
in particular as a background analgesic in a 
slow­release preparation. however, it is not a 
first­line drug in neuropathic pain.2,3
Antidepressants
Tricyclic antidepressants (TCAs)
In 1960 paoli et al made the incidental 
discovery that the tricyclic antidepressant 
(tca) imipramine had an analgesic 
effect.33 Since then other tcas and other 
antidepressants have been evaluated and 
used for the treatment of neuropathic pain. 
tcas are the first class of medication to be 
proven to be effective for neuropathic pain in 
a double blind placebo controlled trial.34 the 
role of tcas in the treatment of neuropathic 
pain is now well established and has the best 
documented evidence.35 the overall nnt for 
neuropathic pain is 3.6 with better efficacy 
in diabetic neuropathy than in postherpetic 
neuralgia (phn).
amitriptyline is established as the ‘gold 
standard’ as it has the most evidence available, 
especially for the treatment of painful 
diabetic neuropathy and phn.36 however, 
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amitriptyline and other tcas have also been 
evaluated for the relief of pain in peripheral 
neuropathies and central post stroke pain. In 
comparative trials no single tca has been 
found to be superior for neuropathic pain 
except in phn where amitriptyline was 
found to be superior to maprotiline.34
Mechanism of action
Initially it was thought that the analgesic 
action of tcas was related to their 
antidepressant activity. however, it is now 
clear that there is an independent specific 
analgesic effect, as the doses used to relieve 
neuropathic pain are smaller and the 
onset of analgesic efficacy is faster than an 
antidepressant effect and analgesia does not 
appear to depend upon mood improvement 
in depressed patients.37,38 In addition, pain 
relief was found to be independent of any 
sedative effect.
tcas are inhibitors of the reuptake 
of monoaminergic transmitters and this 
mechanism mediates their analgesic effect by 
the following presumed mechanisms: 36
1) central blockade of monoamine 
re­uptake, particularly serotonin and 
nora drenaline, leads to enhancement of 
the descending inhibitory monoaminergic 
pathways in the dorsal horn of the spinal 
cord.
2) anticholinergic activity reduces firing 
of central neurones involved in pain, 
especially after deafferation.
additionally there may be a number of other 
contributing mechanisms: moderation of 
nMDa receptor activity, opioid receptor 
activity, increase in dopamine or endorphin 
levels, blockade of central or peripheral 
histamine receptors, sodium channel blockade 
and blockade of adrenergic receptors on 
regenerating sprouts.36,39
Adverse effects
the optimum analgesic dose of tcas can 
often not be reached due to unpleasant 
side effects. a systematic review of random­
ised controlled trials of tcas used to 
treat neuropathic pain found that out of 
100 patients, 30 had significant pain relief, 
30 had minor side effects and 40 had 
to discontinue their therapy due to side 
effects.40 these include:
1) anticholinergic: dry mouth, constipation, 
urinary retention and blurred vision.
2) antihistaminergic: confusion and sedation 
(the latter may be of benefit)
3) anti α­adrenergic: postural hypotension 
and sexual dysfunction.
cardiac conduction abnormalities may also 
arise due to the muscarinic anticholinergic 
actions. patients at risk should have a pre­
treatment ecg as cardiac conduction 
defects are a contraindication to treatment 
with tcas. another potential problem is 
overdose where tcas are more dangerous 
than other groups of antidepressants and 
maybe fatal due to severe cardiac arrhythmias 
and convulsions.
Desipramine, imipramine and nortrip­
tyline are more specific to noradrenergic 
blockade and are associated with less anti­
cholinergic and antihistamine side effects. 
they may be useful in patients who are not 
able to tolerate amitriptyline, before pro­
gressing to another class of drug. In phn and 
painful diabetic neuropathy, they were both 
found to be as effective as amitriptyline,34,37,41 
but associated with less side effects. physical 
withdrawal reactions have been described 
for most antidepressants, but psychological 
addiction is not an issue.36
Selective serotonin re-uptake inhibitors 
(SSRIs)
Selective serotonin re­uptake inhibitors 
such as fluoxetine and paroxetine have only 
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limited efficacy in neuropathic pain.35 they 
alter serotonergic (5­ht) far more than 
noradrenergic (ne) neurotransmission. 
how ever, due to their selectivity they do 
not interfere as much with adrenergic, 
histaminergic or muscarinic receptors and 
therefore have fewer side effects. there is 
currently insufficient evidence to make 




Venlafaxine and duloxetine are novel 
antidepressants, which belong to the class 
of SnrIs. they have similar mechanisms of 
action as tcas, but no anticholinergic effects. 
While data on venlafaxine are currently 
inconclusive, duloxetine has indications in 
the treatment of diabetic polyneuropathy 
(nnt = 6) and fibromyalgia (nnt = 8) 
and is approved for this indication in some 
countries.43 there are no direct comparisons 
to other antidepressants published, but 
SnrIs are thought to be better tolerated 
than tcas.
Recommendations for clinical use of 
antidepressants as analgesics
evidence­based decisions to use anti­
depressants in neuropathic pain states are 




•	 Duloxetine	 for	 diabetic	 neuropathy:	
nnt 5.8 ­ 6
It is difficult to generalise a dosage regimen 
for antidepressants in neuropathic pain, due 
to significant inter­individual variability.45 
McQuay et al have demonstrated a dose 
response relationship for amitriptyline with 
a greater analgesic response at 75mg/d than 
25 or 50mg/d.46
current recommendations for prescribing 
tcas are:4
1) Start with a low dose (5–10mg/d) 
especially in the elderly and increase 
this weekly to analgesic efficacy or 
unacceptable side effects.
2) once the optimal dose is achieved 
analgesic efficacy usually takes up to a 
week to achieve.
3) there have not been any trials con­
ducted for longer than 6 weeks, so there 
is no evidence base for optimum duration 
of treatment. the current practice is 
to continue the same effective dose 
for several months and then to try and 
reduce it.
4) If a therapeutic dose of a tca fails to 
provide pain relief, other antidepressants 
are also likely to fail.
5) If a tca provides pain relief at the 
expense of unacceptable side effects 
then other antidepressants (in particular 
SnrIs) with a lower side effect profile 
should be tried.
6) If due to contraindications or un­
acceptable side effects a patient is 
unable to be treated with tcas, other 
antidepressants (in particular SnrIs) 
should be tried before excluding this 
drug category.
Anticonvulsants
In the 1960s phenytoin was found to have 
an analgesic effect in the treatment of 
painful diabetic neuropathy.47 Since then 
anticonvulsants have been evaluated and 
used in neuropathic pain states, including 
old agents: carbamazepine, sodium valproate, 
phenytoin and newer agents: gabapentin, 
lamotrigine, felbamate and pregabalin. anti­
convulsants have a specific indication in 
the treatment of trigeminal neuralgia with 
carbamazepine the first line therapy. they 
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may prove effective in conditions that have 
proved intractable to other treatments.
Mechanism of action
the neuronal hyperexcitability and corres­
ponding molecular changes in neuropathic 
pain have many features in common with the 
cellular changes in certain forms of epilepsy.48 
the pain relieving effect of anticonvulsants is 
thought to be due to dampening of abnormal 
central nervous activity that follows nerve 
damage.49 this may occur by: 50,51
1) Sodium channel blockade resulting in 
a reduction of ectopic firing in both 
peripheral nerves and the dorsal root 
ganglion
2) Indirect or direct enhancement of 
inhibitory gaBaergic neurotransmission
3) Inhibition of excitatory glutaminergic 
neurotransmission
overall effects may be due to a combin­
ation of these mechanisms and longer term 
neuroplastic effects.51 the process of ectopic 
impulse generation is so sensitive to sodium 
channel blockade that these agents have an 
action at much lower concentrations than 




clonazepam is a benzodiazepine anti­
convulsant acting as a gaBa agonist. 
lorazepam, nitrazepam and diazepam have 
also been used in chronic pain. they have 
anxiolytic and anticonvulsant properties. 
however, with the exception of clonazepam, 
benzodiazepines are not generally felt to have 
specific analgesic activity and their use is not 
encouraged for this purpose due to their 
addictive nature, tolerance and cognitive 
impairment.53
however, for clonazepam several studies 
suggest a role in lancinating neuropathic 
pain. the old cross­over trial by Swerdlow 
shows clonazepam to be superior to 
carbamazepine, phenytoin and sodium 
valproate with regard to efficacy in neuro­
pathic pain and adverse effects.54
this reflects our past clinical experience, 
where clonazepam was an easy to use agent 
with excellent efficacy and minimal side 
effects, in particular sedation. however, clon­
azepam is a benzodiazepine and thereby closely 
linked to risks of tolerance, dependence and 
addiction/abuse and should no longer be used 
as a first­line agent in neuropathic pain.
Gabapentin
gabapentin is a relatively new anticonvulsant, 
available in the uSa since 1995. It is a 





 receptors or 
directly affect gaBa uptake.55 It is now clear 
that this drug has a modulating effect on 
the α2­δ subunit of voltage­gated calcium 
channels, an unexpected pharmacological 
target.56 By modulating the calcium influx 
into hyperexcitable primary afferent neurons, 
gabapentin reduces the release of excitatory 
amino acids, in particular glutamate, and 
thereby reduces the excitation of secondary 
neurons. this explains its effects in 
neuropathic pain, but also in other conditions 
presenting with hyperalgesia and allodynia 
including fibromyalgia, even postoperative57 
and burns pain58 and its anxiolytic effect 
with efficacy in generalised anxiety disorder. 
large scale rcts have demonstrated efficacy 
in phn and diabetic neuropathy at target 
doses of 3600mg/day.59­61
the cochrane review reports nnt of 
3.9 in phn and 2.9 for painful diabetic 
neuropathy.62 results indicate a similar 
efficacy of gabapentin and tcas.63
a case report cited a significant improve­
ment with gabapentin treatment in a patient 
with central post stroke pain that had failed 
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to respond to a variety of analgesics.64 
gabapentin was also effective in the treatment 
of central neuropathic pain after spinal cord 
injury.65
the most commonly reported side effects 
are somnolence, fatigue, ataxia and dizziness. 
a dose adjustment is required in renal failure, 
but not in hepatic disorders as gabapentin is 
excreted unchanged by the kidneys.
the effective analgesic dose of gabapentin 
is variable, with some patients responding at 
low doses and others requiring high doses 
(more than 3600mg/day) for the same benefit. 
this is partially due to uptake by an active 
carrier process, showing saturation kinetics. 
It has been suggested that treatment failure 
maybe due to inadequate dosage, although 
rapid dose escalation can be responsible for 
the high incidence of cnS side effects.66 
the development of pregabalin with better 
kinetics and higher efficacy has reduced the 
usage of gabapentin.
Pregabalin
pregabalin, an analogue to gabapentin, 
has been developed with an indication 
for neuropathic pain. It has a similar 
pharmacodynamic effect to gabapentin, 
i.e. modulates the α2­δ subunit of voltage­
gated calcium channels and thereby reduces 
excitatory amino acid release.56 It differs from 
gabapentin insofar as it has a higher potency, 
a better bioavailability, linear absorption 
kinetics and a longer half­life permitting 
twice instead of three times daily dosing.
pregabalin is used successfully in a 
number of neuropathic pain states of 
peripheral and central origin including 
phn, diabetic neuropathy (nnt 3.24)67 
and spinal cord injury pain.68 It has also 
been used successfully in fibromyalgia69 
and generalised anxiety disorder70 and has 
these three conditions as an indication in 
many countries. It is not only superior to 
gabapentin from a pharmacokinetic point of 
view, but also in clinical practice achieving 
better pain relief and quality of life.71
adverse effects of pregabalin include 
sedation, drowsiness, disturbance of balance 
and unexplained peripheral oedema. how­
ever, these adverse effects are often mild and 
can be partially avoided by slow and careful 
titration of the dose. Starting doses of 75mg 
in ambulatory patients (with 25mg in the 
frail), starting with an evening dose and 
higher evening than morning doses are useful 
recommendations for the titration process.
the efficacy of pregabalin and its mild 
adverse effects have made it a viable first­line 
alternative to antidepressants in the setting of 
neuropathic pain. an interesting aspect from 
a surgical perspective is its perioperative use, 
which leads to improved postoperative pain, 
reduced opioid consumption and opioid side 
effects.57 two more recent studies suggest 
further benefit from its perioperative use by 
improving recovery after laminectomy72 and 
reducing chronic neuropathic pain after knee 
joint replacement.73
Carbamazepine
carbamazepine has been the first line 
treatment for trigeminal neuralgia for 
many years.74 a recent cochrane review 
found that three placebo­controlled trials 
of carbamazepine in trigeminal neuralgia 
demonstrated a combined nnt of 2.5.75 It 
has not however been shown to be efficacious 
in phn or central pain and its use in other 
neuropathic states has been reported only in 
small uncontrolled studies. evidence shows 
carbamazepine inhibits spontaneous and 
evoked responses of spinal neurones and 
increases brain serotonin. Doses of up to 
1200mg/day can be used.
Side effects are the main limitation to 
its use and include sedation, ataxia, drug 
interactions and liver dysfunction.76 Serious 
but rare side effects are irreversible aplastic 
anaemia and Stevens­Johnson­Syndrome. 
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With carbamazepine therapy regular haema­
tological and liver function monitoring is 
required. occasional monitoring of serum 
sodium is also recommended because 
hyponatraemia can occur. the sustained 
release preparations of carbamazepine may 
limit the side effects.
Sodium valproate
this is structurally unrelated to other 
anticonvulsants and does not block sodium 
channels. the exact mechanism of action is 
unknown but may be related to increased 
gaBa synthesis and release and hence 
potentiated gaBaergic inhibition. In 
addition valproate attenuates the neuronal 
excitation caused by glutamate activation of 
nMDa receptors.77 there is evidence for its 
use in migraine prophylaxis78 and some for 
second line therapy in trigeminal neuralgia.79 
It can be used in doses up to 800mg/day.
again side effects and the risk of serious 
toxicity limit its use. these include sedation, 
gastrointestinal disturbance, altered liver 
function with potentially fatal hepatotoxicity, 
decreased platelet aggregation and other 
haematological effects and drug interactions. 
close follow up is mandatory.
Phenytoin
phenytoin can be of help in patients 
with neuropathic pain but less so than 
carbamazepine. It has fallen from favour 
mainly due to its extensive side effect profile, 
complex kinetics and drug interactions and 
a lack of supportive studies.
Side effects include sedation, gingival hyper­
trophy, hirsutism and coarsening of facial 
features. at high blood levels neurotoxicity 
occurs and cardiac conduction is affected 
and thus close blood drug level monitoring 
is required. results from rcts have shown 
an analgesic effect in diabetic neuropathy 
and fabrys disease.80,81 the cochrane review 
found that nnt for diabetic neuropathy 
with phenytoin was 2.1.75
Lamotrigine
this new anticonvulsant appears to act on 
voltage­gated cation channels (calcium and 
potassium) as well as inhibiting glutamate 
release.82 Studies (open and double blind) 
have indicated that lamotrigine can be 
effective in diabetic neuropathy, central post 
stroke pain, hIV associated polyneuropathy 
and trigeminal neuralgia.48,53,83 It may be 
useful in cases of trigeminal neuralgia that 
have proven refractory to carbamazepine 
and phenytoin, in doses of 50–400mg/day.53 
however, other evidence suggests that it may 
not be more effective than placebo in many 
other cases of neuropathic pain.82
Side effects have restricted the use of 
lamotrigine: dizziness, constipation, nausea, 
somnolence and diplopia.53 lamotrigine is 
associated with Steven­Johnson­Syndrome 
with 1:1000 patients requiring hospitalisation 
and can be rarely fatal. these side effects 
can be lessened and the incidence of rash 
significantly decreased by slow titration of 
lamotrigine, starting at a dose of 12.5 to 
25 mg per day and slowly increasing to 100 
to 200 mg per day over 1 to 2 months.
Recommendations for clinical use of 
anticonvulsants as analgesics
anticonvulsants are typically used for 
neuropathic pain that has a shooting, burning 
or lancinating character. empirically they 
are often used in combination with a tca, 
although the evidence for using both classes 
of drug in combination is not strong.
for peripheral neuropathic pain and 
spinal cord injury pain pregabalin is the 
anticonvulsant of choice.2 for trigeminal 
neuralgia only, carabamazepine is the first 
choice.2 although few trials exist for the 
treatment of central post­stroke pain, current 
opinion is that lamotrigine and gabapentin 
may be helpful.84
as with antidepressants, titration should 
start with low doses, gradually increasing to 
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a dose that either produces analgesic efficacy 
or unacceptable side effects.
Local anaesthetics and 
antiarrhythmics
In 1948 systemic procaine was identified as 
beneficial in the treatment of neuropathic 
pain. this led to the evaluation of other local 
anaesthetics for the treatment of neuropathic 
pain.
Mechanism of action
the mechanism of analgesic action is thought 
to be due to membrane stabilising effects 
by blockade of voltage­dependent sodium 
channels and hence reduced ectopic activity 
in damaged afferent nerves.50 In addition 
there maybe a central action on sodium 
channels and at the spinal level, blocking the 
actions of glutamate.85,86
Lignocaine
over the last 35 years there have been reports 
of analgesic efficacy of intravenous lignocaine 
in a wide range of neuropathic pain states, 
including diabetic neuropathy, peripheral 
nerve lesions, phn and central pain.87­92 
Sakuri and Kanazawa have reported its 
effectiveness in multiple sclerosis associated 
pain.93 there is large variation in reported 
duration of analgesic effect, varying from no 
residual effect to 20 weeks benefit in patients 
with central pain. a beneficial response to a 
lignocaine infusion may suggest a similar 
benefit from oral mexiletine, but does not 
predict this reliably.94
Mexiletine
this antiarrhythmic is an oral analogue of 
lignocaine that has been used in neuropathic 
pain with mixed results. Some effectiveness 
has been demonstrated in treating pain after 
peripheral nerve injuries and painful diabetic 
neuropathy, although these findings are not 
consistent and the effects are less than that 
provided by tcas and anticonvulsants with 
an nnt of 10.95 optimal dosing may be a 
problem with a poor therapeutic ratio and 
potential cardiotoxicity.4 Mexiletine should 
only be regarded as a last resort in the 
treatment of neuropathic pain.
Recommendations for clinical use of 
lignocaine and mexilitine in neuropathic 
pain
Side effects of both substances are cnS 
(dizziness, nausea, perioral numbness, 
convulsions & coma) and cVS effects 
(arrhythmias). contraindications therefore 
include, cardiac conduction abnormalities, 
left ventricular failure and ischaemic heart 
disease. an ecg should be obtained before 
and during treatment to monitor any cardiac 
effects. If there is a question regarding safety 
in a patient, a cardiologist’s opinion should 
be sought, prior to starting treatment.
for lignocaine the recommended starting 
dose is 1 –1.5mg/kg as a slow IV bolus; this 
is an ideal agent for the neuropathic pain 
emergency. Maintenance is by IV infusion 
of 1­3mg/min with measurement of blood 
concentrations.the recommended starting 
dose for mexiletine is 150mg three times 
a day with a slow increase to 600mg to 
1200mg per day to optimal results.
N-methyl-D-aspartate-receptor 
(NMDA) antagonists
nMDa receptors are activated by the 
excitatory neurotransmitter glutamate. 
nMDa antagonists are thought to play an 
important role in the development of central 
sensitisation following a peripheral nerve 
lesion. they may block this hyperactivity 
responsible for the maintenance of the pain. 
Drugs with nMDa receptor antagonist 
activity include ketamine, dextromethorphan, 
memantine and amantadine.
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Ketamine
Ketamine is the most commonly used 
nMDa antagonist. Its original use was as an 
anaesthetic agent, particularly ‘in the field’ 
and other difficult locations and situations. It 
has also been used for the treatment of severe 
asthma and for sedation. however, ketamine 
is known to have analgesic properties at 
subanaesthetic doses.96
analgesic efficacy of ketamine has been 
demonstrated in rcts for phn, peripheral 
nerve injuries, phantom limb pain and post 
stroke central pain.96 In peripheral97 and 
central neuropathic pain states,98 low­dose 
IV ketamine was superior to IV lignocaine. 
Ketamine may in part provide analgesia 
by reversing opioid tolerance.99 In opioid­
tolerant patients low­dose ketamine improves 
postoperative analgesia and reduces opioid 
requirements.
unpleasant side effects limit its use, 
although they occur rarely with the low doses 
commonly used to treat neuropathic pain. 
these are mostly psychomimetic: sedation, 
hallucinations, dysphoria, unpleasant sen­
sations (dissociation) and paranoid feelings. 
It is important to warn patients in advance of 
these potential effects; they can be reduced 
by co­prescribing benzodiazepines such as 
midazolam if needed. the pharmacokinetics 
of a sublingual and oral dosing form have 
been documented100 and a nasal spray of 
ketamine is under development.101
Other NMDA antagonists
Dextromethorphan, amantidine and 
meman tine have been shown to have weaker 
actions than ketamine. In a blinded trial, 
nelson et al demonstrated an analgesic 
effect with high dose dextromethorphan in 
painful diabetic neuropathy,102 but this has 
not been reproduced in other neuropathic 
pain states.103 Memantine was also shown 
to be ineffective in phantom limb pain 
treatment;104 its routine use in neuropathic 




clonidine is an α
2
­agonist with analgesic 
activity. Its analgesic action is thought to 
occur centrally and at a spinal level, mediated 
by activation of α
2
­adrenoceptors in the 
dorsal horn of the spinal cord. this results 
in direct inhibition of postsynaptic spinal 
dorsal horn neurones or by decreasing the 
release of noradrenaline from sympathetic 
nerve terminals.
Efficacy
only a small number of studies have been 
conducted to look at a potential role in the 
treatment of neuropathic pain. Significant 
improvement was reported in patients 
with phn treated with clonidine.106 
transdermal clonidine (0.1 to 0.3mg per 
day) has been used with success in patients 
with diabetic neuropathies.107,108 a double 
blind crossover study in 20 chronic pain 
patients, comparing epidural clonidine and 
an epidural combination of morphine 
and lignocaine found epidural clonidine 
to be as effective as epidural morphine in 
20 chronic pain patients.109 It is registered 
in the uSa as an adjuvant in combination 
with epidural local anaesthetics and opioids 
for resistant neuropathic pain. Side effects 
include drowsiness, dizziness and dry mouth.
Baclofen
Baclofen is a gamma­aminobutyric acid 
(gaBa) receptor agonist, capable of crossing 
the blood­brain barrier. It is an agonist at 
gaBa­B receptors and has presynaptic 
action in the spinal cord preventing the 
release of excitatory neurotransmitters.110
Baclofen causes muscle relaxation and is 
used to treat muscle spasticity. It has been 
shown to have antinociceptive action and has 
been used to treat neuropathic pain.111 It was 
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first used for this purpose to treat trigeminal 
neuralgia.112 Its efficacy has not however 
been confirmed in other neuropathic 
pain conditions.113 Baclofen has been 
administered intrathecally and may be useful 
for pain related to spinal cord injuries.114 Side 
effects include sedation, nausea, confusion, 
convulsions, hypotension, gI upset, visual 
disturbances and occasionally hepatic 
impairment (a to Z). after prolonged use, 
baclofen requires a gradual dose reduction in 
order to minimise the risk of a withdrawal 
syndrome.110
Levodopa
ertas et al found levodopa to be better 
than placebo in treating painful diabetic 
neuropathy.115 a review of placebo­controlled 
trials by Sindrup and Jensen in patients with 
diabetic neuropathy showed that nnt 
was 3.4 for levodopa, compared with 6.7 
for SSrIs.95 a placebo­controlled trial has 
demonstrated efficacy in acute herpes zoster 
pain.116
Cannabinoids
there has been increasing interest in the 
use of cannabis and cannabinoids as 
analgesics in chronic pain. cannabinoid 
receptors are located in the central and 
peripheral nervous system. animal models 
have shown that cannabinoid receptors do 
not undergo down­regulation after nerve 
lesions (unlike opioid receptors) and that 
cannabinoids may attenuate the associated 
sensory changes.8
cannabis has been used for thousands 
of years for medicinal and recreational 
purposes. there is much interest surrounding 
its legalisation and its potential role as an 
analgesic. the data situation here remains 
unclear; however, overall there is a trend to 
show some efficacy by some cannabinoids in 
some neuropathic pain states. a meta­analysis 
found efficacy in neuropathic pain states 
including multiple sclerosis.117 Similarly, a 
randomised trial of smoked cannabis in 
neuropathic pain reduced pain intensity 
and improved sleep quality.118 however, a 
trial in spinal cord injury pain failed to show 
efficacy.119 adverse effects associated with 
cannabinoids are common, the main being 
sedation, disorientation, ataxia, memory 
impairment, dry mouth and blurred vision.
larger blinded, randomised controlled 
trials are required before it can be ascertained 
whether cannabinoids are efficacious in 
neuropathic pain. the development of new 
safe and effective agonists that separates the 
psychotropic effects from the therapeutic 
ones would improve trial designs.
Topical treatments
allodynia is frequently a feature of 
neuropathic pain especially in phn, 
traumatic neuropathies and causalgia. It 
may therefore be helpful to consider the 
use of topical medications for the treatment 
of cutaneous hyperalgesia in these cases. 
there are a few options in the form of 
capsaicin, local anaesthetics (and nSaIDs 
with some reports of good pain relief from 
post herpetic neuralgia with topical aspirin 
preparations).120­122
Lignocaine 5% medicated plaster
In patients with phn, success has been 
reported using lignocaine patches or 
topically applied gel to painful areas.52,123,124 
the mechanism of action is thought to 
involve suppression of ectopic discharges 
from sensory afferents and from providing 
mechanical protection to underlying 
allodynic skin.125 In 1999 the fDa approved 
the use of 5% topical lignocaine patches for 
treatment of phn. It is recommended as a 
first­line approach for this indication and 
other localised neuropathic pain states.126 
a meta­analysis showed superiority of the 
plaster over capsaicin and pregabalin and 
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similar efficacy to gabapentin, however with 
significantly fewer systemic side effects.127
the advantages of this route of 
administration are its effectiveness, duration 
of analgesia, ease of application without dose 
titration and lack of systemic side effects. the 
safety profile is particularly advantageous 
in the elderly population whom are most 
affected by phn. the area of pain has 
however to be of limited size for practical 
application.
Capsaicin
capsaicin is the pungent component to 
chilli peppers. the chilli pepper has been 
recognised by various cultures for many years 
for its medicinal qualities.128 It is neurotoxic 
and has analgesic properties. When capsaicin 
is applied topically it initially causes a 
burning sensation and heat hyperalgesia that 
decreases with subsequent applications.
Mechanism of Action
capsaicin acts on receptors at the terminals 
of primary nociceptive afferents. In 1997 
a specific receptor on c fibres was cloned, a 
vanilloid receptor, the Vr­1 receptor. When 
capsaicin binds to this receptor, it induces 
initial activation of the nociceptors, hence 
the burning sensation. It depletes substance 
p from the sensory nerve terminals of 
peripheral nociceptors. With repeat or 
prolonged application, this is followed 
by desensitisation and inactivation of the 
receptive terminals of the nociceptors.129 
there is also evidence that it causes depletion 
of substance p in epidermal nerve fibres.130
Efficacy
In a meta­analysis of rcts, low­dose capsai­
cin cream (0.075%) repeatedly administered 
had an nnt of 6.6 for any pain relief.131 a 
commercially available patch with high­dose 
capsaicin (8%) had an nnt of 12 for 30% 
pain relief. these not very impressive results 
have to be seen in the context of a potentially 
high placebo effect, as the burning feeling 
after administration results in the patient 
effectively being unblinded. this criticism is 
confirmed by one double blind trial using a 
placebo with a similar burning sensation and 
finding no difference in analgesic efficacy 
between placebo and capsaicin.132
the use of capsaicin has been limited 
by this unpleasant burning sensation 
occurring in 60–70% patients, need for 
frequent applications and uncertain efficacy.4 
co­administration of lignocaine gel has been 
used in order to improve compliance.4
capsaicin can only be seen as an adjuvant 





this technique applies cutaneous electrodes 
to stimulate peripheral nerves to relieve 
pain. 133 this is based on the gate control 
theory of pain transmission, so that by 
stimulating aβ and aδ fibres pain trans­
mission by c­fibres is inhibited. It utilises 
a pulse generator that provides a range of 
currents, frequencies and pulse widths. the 
surface electrodes are placed on either side 
of the painful area or alternatively over the 
nerves supplying that area. the current is 
then increased until a tingling sensation is 
felt in the painful area, the timing and 
duration of pulses is a matter of titration to 
maximal response. tenS may reduce analge­
sic requirements.134 a meta­analysis shows 
improvement in neuropathic symptoms in 
patients with diabetic poly neuropathy.135
It has few side effects and complications, 
allergic dermatitis may occur at the contact 
sites and its use is contraindicated in patients 
with pacemakers. Its efficacy can be assessed 
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quickly (there is a significant placebo effect) 
and can therefore be easily trialled for 
any potential benefit to an individual.136 
unfortunately tolerance may develop 
resulting in loss of previously effective 
analgesia, changing the stimulation variables 
can sometimes attenuate this.
Spinal cord stimulation (SCS)
this technique requires an implantable device 
with electrodes positioned under direct vision 
at open laminectomy or via a needle in the 
epidural space percutaneously. the electrodes 
are placed above the level of the pain and 
connected to an inductance coil placed on 
the abdominal wall; an implantable power 
source can also be used. the mechanism 
of action is not yet clear, but it seems to be 
not effective in nociceptive pain, but only in 
neuropathic pain.137 It seems that this device 
can be as useful for a variety of neuropathic 
and chronic pain states.138 a systematic 
review describes efficacy in refractory 
neuropathic back and leg pain, failed back 
surgery syndrome and chronic regional pain 
syndrome (crpS) type 1.139
complications include infection, 
bleeding, dural puncture and hardware 
failure; decisions on use of this invasive and 
expensive approach should be made ideally 
by a multidisciplinary team experienced 
in the use of such techniques. Deep brain 
stimulation and motor cortex stimulation 
have also been used to treat neuropathic 
pain.140
Sympathetic nerve blocks
the diagnosis of sympathetically maintained 
pain can be confirmed by the response to 
a sympatholytic procedure. this may be 
helpful, if there is a significant sympathetic 
component to the patient’s pain. a patient 
should receive sustained pain relief after 
administration of a sympathetic chain or 
sympathetic plexus local anaesthetic block 
or accumulative relief from a number of 
procedures. If the patient fails to respond, a 
systematic pharmacological approach is tried. 
however, a block may be incorrectly thought 
to be successful. this can happen for one of 
two reasons: either, the local anaesthetic is 
absorbed and provides a systemic analgesic 
effect or it diffuses locally and acts on nearby 
somatic nerves.141
In case of effectiveness, progression to 
a sympatholytic procedure can be chosen. 
techniques then involve the use of neurolytic 
substances or radiofrequency ablation; 
regrettably the current scientific basis for this 
approach is poor.142
Neurosurgical destructive techniques
there has been increasing awareness that 
destructive techniques may in fact increase 
pain in the long term due to the plasticity 
of the nervous system, sometimes resulting 
in incapacitating side effects. therefore 
these techniques, which include neurectomy 
and dorsal root entry zone lesions, are now 
rarely used.143 the exception being in the 
treatment of trigeminal neuralgia, which 
has proved refractory to pharmacological 
treatments. In this situation a variety of 
surgical procedures can provide rapid 
pain relief, the most effective option being 
microvascular decompression. recurrence is 
still a risk but appears to be more frequent 
after percutaneous radiofrequency rhizotomy 
or compression with a percutaneously 
positioned balloon than the more invasive 
microvascular decompression technique.144
Cognitive-behavioural therapy
chronic neuropathic pain is best managed 
in a multidisciplinary pain clinic.145 this 
is because the patient often has cognitive, 
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affective and behavioural factors influenc­
ing their pain; however new understandings 
of the physiology of cortical reorganisation 
in chronic pain might also lead to new 
psychological approaches.146 a multi­
dis ciplinary approach will address both 
the somatic and psychological aspects of the 
patient’s condition. the main methods are 
cognitive­behavioural therapy and operant 
conditioning.
the cognitive­behavioural approach 
aims to identify and modify the patient’s 
thoughts, feelings, beliefs and behaviour. 
common problems are anxiety, depression 
and the development of fear­avoidance. 
Behavioural therapy procedures are utilised 
to bring about change. the aims are to 
enable patients to take a positive and 
active role in coping with their pain and to 
change maladaptive behaviour that may be 
aggravating the problem.
operant conditioning uses firstly con­
tinuous re­enforcement to encourage positive 
behaviour from the patient that is then 
stepped down later on. this is based on 
the belief that the consequence of certain 
behaviour determines whether it is likely to 
recur.
psychotherapy may increase levels of 
activity and decrease medication requirements 
but an actual reporting in pain reduction 
may be more modest. In addition the therapy 
may need to be extended to the carers of the 
patient in order to change their response 
to the patient’s beliefs and behaviour. the 
current data situation on this approach to 
neuropathic pain is insufficient to draw any 
conclusions on efficacy.147
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introduction
acute wounds normally heal in an orderly 
and efficient manner, and progress smoothly 
through the four distinct, but overlapping 
phases of wound healing: haemostasis, 
inflammation, proliferation and remodelling 
(Figure 23.1).1,2,3 in contrast, chronic wounds 
will similarly begin the healing process, 
but will have prolonged inflammatory, 
proliferative, or remodelling phases, resulting 
in tissue fibrosis and in non-healing ulcers.4 
the process of wound healing is complex and 
involves a variety of specialized cells, such as 
platelets, macrophages, fibroblasts, epithelial 
and endothelial cells. these cells interact 
with each other and with the extracellular 
matrix. in addition to the various cellular 
interactions, healing is also influenced by the 
action of proteins and glycoproteins, such 
as cytokines, chemokines, growth factors, 
inhibitors, and their receptors. each stage of 
wound healing has certain milestones that 
must occur in order for normal healing to 
progress. in order to identify the differences 
inherent in chronic wounds that prevent 
healing, it is important to review the process 
of healing in normal wounds 
PhaSeS oF acute wound 
healinG
Haemostasis 
haemostasis occurs immediately following 
an injury.5 to prevent exsanguination, 
vasoconstriction occurs and platelets undergo 
activation, adhesion and aggregation at the 
site of injury. Platelets become activated 
when exposed to extravascular collagen 
(such as type i collagen), which they detect 
via specific integrin receptors, cell surface 
receptors that mediate a cell’s interactions 
with the extracellular matrix. once in contact 
with collagen, platelets release the soluble 
mediators (growth factors and cyclic aMP) 
and adhesive glycoproteins, which signal 
them to become sticky and aggregate. the 
key glycoproteins released from the platelet 
alpha granules include fibrinogen, fibro-
nectin, thrombospondin, and von willebrand 
factor. as platelet aggregation proceeds, 
clotting factors are released resulting in the 
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deposition of a fibrin clot at the site of 
injury. the fibrin clot serves as a provisional 
matrix.6 the aggregated platelets become 
trapped in the fibrin web and provide the 
bulk of the clot (Figure 23.2). their mem-
branes provide a surface on which inactive 
clotting enzyme proteases are bound, become 
activated and accelerate the clotting cascade. 
Growth factors are also released from the 
platelet alpha granules, and include platelet 
derived growth factor (PdGF), transforming 
growth factor beta (tGF-β), transforming 
growth factor alpha (tGF-α), basic fibroblast 
growth factor (bFGF), insulin-like growth 
factor-1 (iGF-1), and vascular endothelial 
growth factor (VeGF). Major growth factor 
Figure 23.1: Phases of Normal Wound Healing. Cellular and molecular events during normal wound healing 
progress through four major, integrated, phases of haemostasis, inflammation, proliferation and remodelling.
Figure 23.2: Haemostasis Phase. At the time of injury, the fibrin clot forms the provisional wound matrix and 
platelets release multiple growth factors initiating the repair process.
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families are presented in table 23.1. neutro-
phils and monocytes are then recruited by 
PdGF and tGF-β from the vasculature to 
initiate the inflammatory response. a break-
down fragment generated from complement, 
c5a, and a bacterial waste product, f-Met-
leu-Phe, also provide additional chemo tactic 
signals for the recruitment of neutrophils to 
the site of injury. Meanwhile, endothelial 
cells are activated by VeGF, tGF-α and 
bFGF to initiate angiogenesis. Fibroblasts 
are then activated and recruited by PdGF 
to migrate to the wound site and begin pro-
duction of collagen and glycosaminoglycans, 
proteins in the extracellular matrix which 
facilitate cellular migration and interactions 
with the matrix supporting framework. thus, 
the healing process begins with hemostasis, 
platelet deposition at the site of injury, and 
interactions of soluble mediators and growth 
TABLe 23.1: Major growth factor families
growth factor family Cell source Actions
Transforming Growth Factor β 
   TGF-β1, TGF-β2




Fibroblast Chemotaxis and Activation
ECM Deposition 
  ⇑ Collagen Synthesis
  ⇑ TIMP Synthesis
  ⇓ MMP Synthesis
Reduces Scarring
  ⇓ Collagen
  ⇓ Fibronectin
Platelet Derived Growth Factor





Activation of Immune Cells and 
Fibroblasts
ECM Deposition
  ⇑ Collagen Synthesis
  ⇑ TIMP Synthesis
  ⇓ MMP Synthesis
Angiogenesis
Fibroblast Growth Factor






Keratinocyte Proliferation and Migration
ECM Deposition
Insulin-like Growth Factor














   EGF, HB-EGF**, TGF-α,  
   Amphiregulin, Betacellulin
Keratinocytes
Macrophages
Keratinocyte Proliferation and Migration
ECM Deposition
Connective Tissue Growth Factor




Mediates Action of TGF-βs on Collagen 
Synthesis
*KGF - keratinocyte growth factor
**HB-EGF - Heparin-binding EGF-like growth factor
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factors with the extracellular matrix to set the 
stage for subsequent healing events.1,2,7 
Inflammation
Inflammation, the next stage of wound heal-
ing occurs within the first 24 hours after 
injury and can last for up to 2 weeks in 
normal wounds and significantly longer in 
chronic non-healing wounds (Figure 23.3). 
Mast cells release granules filled with 
enzymes, histamine and other active amines, 
which are responsible for the characteristic 
signs of inflammation, the rubor (redness), 
calor (heat), tumor (swelling) and dolor (pain) 
around the wound site. neutrophils, mono-
cytes, and macrophages are the key cells dur-
ing the inflammatory phase. they cleanse the 
wound of infection and debris and release 
soluble mediators such as proinflammatory 
cytokines (including il-1, il-6, il-8, and 
tnF-α), and growth factors (such as PdGF, 
tGF-β, tGF-α, iGF-1, and FGF) that are 
involved in the recruitment and activation of 
fibroblasts and epithelial cells in preparation 
for the next phase in healing. cytokines that 
play important roles in regulating inflam-
mation in wound healing are described in 
table 23.2.
in addition to the growth factors and 
cytokines, a third important group of small 
regulatory proteins, listed in table 23.3, has 
been identified, and are collectively named 
chemokines, from a contraction of chemo-
attractive cytokine(s).8,9,10 the structural and 
functional similarities among chemokines 
were not initially appreciated, and this has led 
to an idiosyncratic nomenclature consisting 
of many acronyms that were based on their 
biological functions, (e.g., monocyte chemo-
attractant protein-1 (McP-1), macrophage 
inflammatory protein-1, MiP-1), their source 
for isolation (platelet factor-4, PF-4) or their 
biochemical properties (interferon-inducible 
protein of 10 kda (iP-10), or regulated 
upon activation normal t-cell expressed and 
secreted, ranteS). as their biochemical 
properties were established, it was recognized 
that the approximately 40 chemokines could 
be grouped into four major classes based on 
the pattern of cysteine residues located near 
the n-terminus. in fact, there has been a 
Figure 23.3: Inflammation Phase. Within a day following injury, the inflammatory phase is initiated by 
neutrophils that attach to endothelial cells in the vessel walls surrounding the wound (margination), change 
shape and move through the cell junctions (diapedesis), and migrate to the wound site (chemotaxis).
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recent trend to re-establish a more organ-
ized nomenclature system based on these 
four major classes. in general, chemokines 
have two primary functions: 1) they regu-
late the trafficking of leukocyte populations 
during normal health and development, 
and 2) they direct the recruitment and acti-
vation of neutrophils, lymphocytes, macro-
phages, eosinophils and basophils during 
inflammation. 
Neutrophils
neutrophils are the first inflammatory cells 
to respond to the soluble mediators released 
by platelets and the coagulation cascade. 
they serve as the first line of defense against 
infection by phagocytosing and killing 
bacteria, and by removing foreign materials 
and devitalized tissue. during the process 
of extravasation of inflammatory cells into 
a wound, important interactions occur 
between adhesion molecules (selectins, cell 
adhesion molecules (caMs) and cadherins) 
and receptors (integrins) that are associated 
with the plasma membranes of circulating 
leukocytes and vascular endothelial cells.11,12 
initially, leukocytes weakly adhere to the 
endothelial cell walls via their selectin 
molecules which causes them to decelerate 
and begin to roll on the surface of endothelial 
TABLe 23.2: Cytokines involved in wound healing
Cytokine Cell source Biological activity
Pro-inflammatory Cytokines
TNF-α Macrophages PMN margination and cytotoxicity,  




Fibroblast and keratinocyte chemotaxis, 
collagen synthesis













Macrophage and PMN activation; retards 






Inhibition of TNF, IL-1, IL-6 production; 




Inhibition of TNF, IL-1, IL-6 production; 
inhibits macrophage and PMN activation
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cells. while rolling, leukocytes can become 
activated by chemoattractants (cytokines, 
growth factors or bacterial products). after 
activation, leukocytes firmly adhere to 
endothelial cells as a result of the binding 
between their integrin receptors and ligands 
such as VcaM and icaM that are expressed 
on activated endothelial cells. chemotactic 
signals present outside the venule then induce 
leukocytes to squeeze between endothelial 
cells of the venule and migrate into the 
wounded tissue using their integrin receptors 
to recognize and bind to extracellular 
matrix components. the inflammatory 
cells release elastase and collagenase to help 
them migrate through the endothelial cell 
basement membrane and to migrate into 
the extracellular matrix (ecM) at the site 
of the wound. neutrophils also produce 
and release inflammatory mediators such 
as tnF-α and il-1 that further recruit and 
activate fibroblasts and epithelial cells. after 
the neutrophils migrate into the wound site, 
they generate oxygen free radicals, which 
kill phagocytized bacteria, and they release 
high levels of proteases (neutrophil elastase 
and neutrophil collagenase) which remove 
components of the extracellular matrix that 
were damaged by the injury. the persistent 
presence of bacteria in a wound may 
contribute to chronicity through continued 
recruitment of neutrophils and their release 
of proteases, cytokines and reactive oxygen 
species. usually neutrophils are depleted in 
the wound after 2 to 3 days by the process 
of apoptosis, and they are replaced by tissue 
monocytes.
Macrophages
activated macrophages play pivotal roles in 
the regulation of healing, and the healing 
process does not proceed normally without 
TABLe 23.3: Chemokine familes involved in wound healing
Chemokines Cells affected
α-CHEMOKINES (CXC) 




without glutamic acid-leucine-arginine near the N-terminal
Interferon -inducible protein of 10 kd (IP-10)
Monokine induced by interferon-γ (MIG)
Stromal-cell-derived factor 1 (SDF-1)
Activated T lymphocytes
β-CHEMOKINES (CC)
Monocyte chemoattractant proteins (MCPs):
MCP-1,-2,-3,-4,-5
Regulated upon activation normal T-cell 
  expressed and secreted (RANTES)
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macrophages. Macrophages begin as 
circulating monocytes that are attracted to 
the wound site beginning about 24 hours 
after injury (Figure 23.4). they extravasate 
by the mechanisms described for neutrophils, 
and are stimulated to differentiate into 
activated tissue macrophages in response to 
chemokines, cytokines, growth factors and 
soluble fragments of extracellular matrix 
components produced by proteolytic 
degradation of collagen and fibronectin.13 
Similar to neutrophils, tissue macrophages 
have a dual role in the healing process. 
they patrol the wound area ingesting and 
killing bacteria, and removing devitalized 
tissue through the actions of secreted 
MMPs and elastase. Macrophages differ 
from neutrophils in their ability to more 
closely regulate the proteolytic destruction 
of wound tissue by secreting inhibitors 
for the proteases. as important as their 
phagocytic role, macrophages also mediate 
the transition from the inflammatory phase 
to the proliferative phase of healing. they 
release a wide variety of growth factors and 
cytokines including PdGF, tGF-β, tGF-α, 
FGF, iGF-1, tnFα, il-1, and il-6. Some of 
these soluble mediators recruit and activate 
fibroblasts, which will then synthesize, 
deposit, and organize the new tissue matrix, 
while others promote angiogenesis. the 
absence of neutrophils and a decrease in 
the number of macrophages in the wound 
is an indication that the inflammatory phase 
is nearing an end, and that the proliferative 
phase is beginning.
Proliferative phase
the milestones during the proliferative phase 
include replacement of the provisional fibrin 
matrix with a new matrix of collagen fibers, 
proteoglycans, and fibronectin to restore the 
structure and function to the tissue. another 
important event in healing is angiogenesis, 
the in-growth of new capillaries to replace 
the previously damaged vessels and restore 
circulation. other significant events in 
this phase of healing are the formation of 
granulation tissue and epithelialization. 
Figure 23.4: Proliferation Phase. Fixed tissue monocytes activate, move into the site of injury, transform into 
activated wound macrophages that kill bacteria, release proteases that remove denatured ECM, and secrete 
growth factors that stimulate fibroblasts, epidermal cells and endothelial cells to proliferate and produce scar 
tissue.
Mechanisms of Vascular Disease430
Fibroblasts are the key cells in the proliferative 
phase of healing.
Fibroblast migration
Fibroblasts migrate into the wound in 
response to multiple soluble mediators 
released initially by platelets and later by 
macrophages (Figure 23.4). Fibroblast 
migration in the extracellular matrix depends 
on precise recognition and interaction 
with specific components of the matrix. 
Fibroblasts in normal dermis are typically 
quiescent and sparsely distributed, whereas 
in the provisional matrix of the wound site 
and in the granulation tissue, they are quite 
active and numerous. their migration and 
accumulation in the wound site requires 
them to change their morphology and to 
produce and secrete proteases to clear a path 
for their movement from the ecM into the 
wound site. 
Fibroblasts begin moving by first bind-
ing to matrix components such as fibronec-
tin, vitronectin and fibrin via their integrin 
receptors. integrin receptors attach to spe-
cific amino acid sequences (such as r-G-d 
or arginine-glycine-aspartic acid) or bind-
ing sites in these matrix components. while 
one end of the fibroblast remains bound 
to the matrix component the cell extends 
a cytoplasmic projection to find another 
binding site. when the next site is found, 
the original site is released (apparently by 
local protease activity), and the cell uses its 
cytoskeleton network of actin fibers to pull 
itself forward. 
the direction of fibroblast movement is 
determined by the concentration gradient of 
chemotactic growth factors, cytokines and 
chemokines, and by the alignment of the 
fibrils in the ecM and provisional matrix. 
Fibroblasts tend to migrate along these fibrils 
as opposed to across them. Fibroblasts secrete 
proteolytic enzymes locally to facilitate their 
forward motion through the matrix. the 
enzymes secreted by the fibroblasts include 
three types of MMPs, collagenase (MMP-1), 
gelatinases (MMP-2 and MMP-9) which 
degrade gelatin substrates, and stromelysin 
(MMP-3) which has multiple protein sub-
strates in the ecM. 
Collagen and extracellular matrix 
production
the collagen, proteoglycans and other com-
ponents that comprise granulation tissue 
are synthesized and deposited primarily by 
fibroblasts. PdGF and tGF-β are two of the 
most important growth factors that regulate 
fibroblast activity. PdGF, which predomin-
antly originates from platelets and macro-
phages, stimulates a number of fibroblast 
functions including prolifer ation, chemo-
taxis, and collagenase expression. tGF-β, 
also secreted by platelets and macrophages 
is considered to be the master control 
signal that regu lates extracellular matrix 
dep osition. through the stimulation of gene 
transcription for collagen, proteoglycans 
and fibronectin, tGF-β increases the overall 
production of matrix proteins. at the same 
time, tGF-β down-regulates the secretion of 
proteases responsible for matrix degradation 
and also stimulates synthesis of tissue inhibi-
tor of metalloproteinases (tiMP), to further 
inhibit break down of the matrix. recent data 
indicate that a new growth factor, named 
connective tissue growth factor (ctGF), 
mediates many of the effects of tGF-β on 
the synthesis of extracellular matrix.14
once the fibroblasts have migrated into 
the matrix they again change their morphol-
ogy, settle down and begin to proliferate and 
to synthesize granulation tissue compon-
ents including collagen, elastin and proteo-
glycans. Fibroblasts attach to the cables of 
the provi sional fibrin matrix and begin to 
produce collagen. at least 20 individual 
types of collagen have been identi fied to 
date. type iii collagen is initially synthesized 
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at high levels, along with other extracellu-
lar matrix proteins and proteoglycans. after 
transcription and processing of the collagen 
mrna, it is attached to polyribosomes on 
the endo plasmic reticulum where the new 
collagen chains are pro duced. during this 
process, there is an important step involv ing 
hydroxylation of proline and lysine residues. 
three protein chains associate and begin to 
form the characteristic triple helical struc ture 
of the fibrillar collagen molecule, and the 
nascent chains undergo further modification 
by the process of glycosylation. hydroxypro-
line in collagen is important because it plays 
a major role in stabilizing the triple helical 
conformation of collagen molecules. Fully 
hydroxylated collagen has a higher melting 
temperature. when levels of hydroxyproline 
are low, for example in vitamin c-deficient 
condi tions (scurvy), the collagen triple 
helix has an altered structure and denatures 
(unwinds) much more rapidly and at lower 
temperatures. to ensure optimal wound 
healing, wound care specialists should be 
sure patients are receiving good nutritional 
support with a diet with ample protein and 
vitamin c.
Finally, procollagen molecules are 
secreted into the extracellu lar space where 
they undergo further processing by proteo-
lytic cleavage of the short, non-helical seg-
ments at the n- and c-termini. the collagen 
molecules then spontaneously associate in a 
head-to-tail and side-by-side arrangement 
forming collagen fibrils, which associate 
into larger bundles that form collagen fibers. 
in the extra-cellular spaces an important 
enzyme, lysyl oxidase, acts on the collagen 
molecules to form stable, covalent, cross-
links. as the collagen matures and becomes 
older, more and more of these intramo lecular 
and intermolecular cross-links are placed in 
the mol ecules. this important cross-linking 
step gives collagen its strength and stability, 
and the older the collagen the more cross-
link formation has occurred.
dermal collagen on a per weight basis 
approaches the tensile strength of steel. in 
normal tissue, it is a strong mol ecule and 
highly organized. in contrast, collagen fibers 
formed in scar tissue are much smaller and 
have a random appearance. Scar tissue is 
always weaker and will break apart before 
the surrounding normal tissue.
Angiogensis
damaged vasculature must be replaced to 
maintain tissue viability. the process of 
angiogenesis is stimulated by local factors of 
the microenvironment including low oxygen 
tension, low ph, and high lactate levels.15 
also, certain soluble mediators are potent 
angiogenic signals for endothelial cells. Many 
of these are produced by epidermal cells, 
fibroblasts, vascular endothelial cells and 
macrophages, and include bFGF, tGF-β, 
and VeGF. it is now recognized that oxygen 
levels in tissues directly regulate angiogenesis 
by interacting with oxygen sensing proteins 
that regulate transcription of angiogenic 
and anti-angiogenic genes. For example, 
synthesis of VeGF by capillary endothelial 
cells is directly increased by hypoxia through 
the activation of the recently identified 
transcription factor, hypoxia-inducible factor 
(hiF), which binds oxygen.16 when oxygen 
levels surrounding capillary endothelial 
cells drop, levels of hiF increase inside 
the cells. hiF-1 binds to specific dna 
sequences and stimulates transcription of 
specific genes such as VeGF that promote 
angiogenesis. when oxygen levels in wound 
tissue increase, oxygen binds to hiF, leading 
to the destruction of hiF molecules in 
cells and decreased synthesis of angiogenic 
factors. regulation of angiogenesis involves 
both stimulatory factors like VeGF and 
anti-angiogenic factors like angiostatin, 
endostatin, thrombospondin, and pigment 
epithelium-derived factor (PedF). 
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binding of angiogenic factors causes 
endothelial cells of the capillaries adjacent 
to the devascularized site to begin to migrate 
into the matrix and then proliferate to form 
buds or sprouts. once again the migra-
tion of these cells into the matrix requires 
the local secretion of proteolytic enzymes, 
especially MMPs. as the tip of the sprouts 
extend from endothelial cells and encoun-
ter another sprout, they develop a cleft that 
subsequently becomes the lumen of the 
evolving vessel and complete a new vascular 
loop. this process continues until the capil-
lary system is sufficiently repaired and the 
tissue oxygenation and metabolic needs are 
met. it is these new capillary tuffs that give 
granulation tissue its characteristic bumpy 
or granular appearance. 
Granulation
Granulation tissue is a transitional replace-
ment for normal dermis, which eventually 
matures into a scar during the remodelling 
phase of healing. it is characterized from 
unwounded dermis by an extremely dense 
network of blood vessels and capillaries, 
elevated cellular density of fibroblasts and 
macrophages and randomly organized col-
lagen fibers. it also has an elevated metabolic 
rate compared to normal dermis, which 
reflects the activity required for cellular migra-
tion and division and protein synthesis. 
Epithelialization
all dermal wounds heal by three basic 
mechanisms: contraction, connective tissue 
matrix deposition and epithelialization. 
wounds that remain open heal by 
contraction; the interaction between cells and 
matrix results in movement of tissue toward 
the center of the wound. as previously 
described, matrix deposition is the process 
by which collagen, proteoglycans and 
attachment proteins are deposited to form 
a new extracellular matrix. epithelialization 
is the process where epithelial cells around 
the margin of the wound or in residual 
skin appendages such as hair follicles and 
sebaceous glands lose contact inhibition and 
by the process of epiboly begin to migrate 
into the wound area. as migration proceeds, 
cells in the basal layers begin to proliferate to 
provide additional epithelial cells.
epithelialization is a multi-step process 
that involves epithelial cell detachment and 
change in their internal structure, migra-
tion, proliferation and differentiation.17 the 
intact mature epidermis consists of 5 layers 
of differentiated epithelial cells ranging from 
the cuboidal basal keratinocytes nearest the 
dermis up to the flattened, hexagonal, tough 
keratinocytes in the uppermost layer. only the 
basal epithelial cells are capable of prolifera-
tion. these basal cells are normally attached 
to their neighboring cells by intercellular 
connectors called desmosomes and to the 
basement membrane by hemi-desmosomes. 
when growth factors such as epidermal 
growth factor (eGF), keratinocyte growth 
factor (KGF) and tGF-α are released dur-
ing the healing process, they bind to recep-
tors on these epithelial cells and stimulate 
migration and proliferation. the binding of 
the growth factors triggers the desmosomes 
and hemi-desmosomes to dissolve so the 
cells can detach in preparation for migra-
tion. integrin receptors are then expressed 
and the normally cuboidal basal epithelial 
cells flatten in shape and begin to migrate as 
a monolayer over the newly deposited granu-
lation tissue, following along collagen fibers. 
Proliferation of the basal epithelial cells near 
the wound margin supply new cells to the 
advancing monolayer apron of cells (cells 
that are actively migrating are incapable of 
proliferation). epithelial cells in the leading 
edge of the monolayer produce and secrete 
proteolytic enzymes (MMPs) which enable 
the cells to penetrate scab, surface necrosis, 
or eschar. Migration continues until the 
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epithelial cells contact other advancing cells 
to form a confluent sheet. once this con-
tact has been made, the entire epithelial 
mono layer enters a proliferative mode and 
the stratified layers of the epidermis are 
re-established and begin to mature to restore 
barrier function. tGF-β is one growth factor 
that can speed up the maturation (differen-
tiation and keratinization) of the epidermal 
layers. the intercellular desmosomes and 
the hemi-desmosome attachments to the 
newly formed basement membrane are also 
re-established. epithelialization is the clini-
cal hallmark of healing but it is not the final 
event – remodelling of the granulation tissue 
is yet to occur.
recent studies by Sen, et al. have 
demonstrated that under conditions of 
hypoxia, hiF-1alpha is stabilized which in 
turn induces the expression of specific micro 
rnas that then down-regulate epithelial cell 
proliferation (1). therefore it appears that 
there are very complex mechanisms involved 
in the role of oxygen and hypoxia during the 
process of wound healing.
Remodelling
remodelling is the final phase of the healing 
process in which the granulation tissue 
matures into scar and tissue tensile strength 
is increased (Figure 23.5). the maturation of 
granulation tissue also involves a reduction 
in the number of capillaries via aggregation 
into larger vessels and a decrease in the 
amount of glycosaminoglycans and the water 
associated with the glycosaminoglycans 
(GaGs) and proteoglycans. cell density and 
metabolic activity in the granulation tissue 
decrease during maturation. changes also 
occur in the type, amount, and organization 
of collagen, which enhance tensile strength. 
initially, type iii collagen was synthesized at 
high levels, but it becomes replaced by type 
i collagen, the dominant fibrillar collagen 
in skin. the tensile strength of a newly 
epithelialized wound is only about 25% of 
normal tissue. healed or repaired tissue is 
never as strong as normal tissues that have 
never been wounded. tissue tensile strength 
is enhanced primarily by the reorganization of 
collagen fibers that were deposited randomly 
Figure 23.5: Remodelling Phase. The initial, disorganized scar tissue is slowly replaced by a matrix that more 
closely resembles the organized ECM of normal skin.
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during granulation and increased covalent 
cross-linking of collagen molecules by the 
enzyme, lysyl oxidase, which is secreted into 
the ecM by fibroblasts. over several months 
or more, changes in collagen organization in 
the repaired tissue will slowly increase the 
tensile strength to a maximum of about 80% 
of normal tissue.
remodelling of the extracellular matrix 
proteins occurs through the actions of several 
different classes of proteolytic enzymes pro-
duced by cells in the wound bed at different 
times during the healing process. two of the 
most important families are the matrix 
metalloproteinases (MMPs) (table 23.4), and 
serine proteases. Specific MMP proteases 
that are necessary for wound healing are the 
collagenases (which degrade intact fibrillar 
collagen molecules), the gelatinases (which 
degrade damaged fibrillar collagen molecules) 




Type I, II, III, VII, and X Collagens
MMP-2 72 kDa Gelatinase
Gelatinase A
Type IV Collagenase
Type IV, V, VII, and X Collagens
MMP-3 Stromelysin-1 Type III, IV, IX, and X Collagens
Type I, III, IV, and V Gelatins




Type I, III, IV and V Gelatins
Casein, Fibronectin and Pro-collagenase
MMP-8 Neutrophil Collagenase Type I, II, and III Collagens
MMP-9 92 kDa Gelatinase
Gelatinase B
Type IV Collagenase
Type IV and V Collagens
Type I and V Gelatins
MMP-10 Stromelysin-2 Type III, IV, V, IX, and X Collagens
Type I, III, and IV Gelatins
Fibronectin, Laminin and  
Pro-collagenase
MMP-11 Stromelysin -3 Not determined
MMP-12 Macrophage Metalloelastase Soluble and insoluble elastin
MT-MMP-1 Membrane type MMP-1 Pro-MMP-2
MT-MMP-2 Membrane type MMP-2 Not determined
TIMP-1 Tissue inhibitor of Metalloproteinases-1 Collagenases
TIMP-2 Tissue inhibitor of Metalloproteinases-2 Collagenases
TIMP-3 Tissue inhibitor of Metalloproteinases-3 Collagenases
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and the stromelysins (which very effectively 
degrade proteoglycans). an important serine 
protease is neutrophil elastase which can 
degrade almost all types of protein molecules. 
under normal conditions, the destruct-
ive actions of the proteolytic enzymes are 
tightly regulated by specific enzyme inhibi-
tors, which are also produced by cells in the 
wound bed. the specific inhibitors of the 
MMPs are the tissue inhibitors of metallo-
proteinases (tiMPs) and specific inhibitors 
of serine protease are α1-protease inhibitor 
(α1-Pi) and α2 macroglobulin. 
Summary of acute wound healing
there are four phases of wound healing:
•	 Haemostasis	–	establishes	the	fibrin	pro­
visional wound matrix and platelets 
provide initial release of cytokines and 
growth factors in the wound.
•	 Inflammation	–	mediated	by	neutrophils	
and macrophages which remove bacteria 
and denatured matrix components that 
retard healing, and are the second source of 
growth factors and cytokines. Prolonged, 
elevated inflammation retards healing due 
to excessive levels of proteases and reactive 
oxygen that destroy essential factors.
•	 Proliferation	 –	 fibroblasts,	 supported	 by	
new capillaries, proliferate and synthesize 
disorganized ecM. basal epithelial 
cells proliferate and migrate over the 
granulation tissue to close the wound 
surface.
•	 Remodelling	 –	 fibroblast	 and	 capillary	
density decreases, and initial scar tissue 
is removed and replaced by ecM that 
is more similar to normal skin. ecM 
remodelling is the result of the balanced, 
regulated activity of proteases.
cellular functions during the different 
phases of wound healing are regulated by 
key cytokines, chemokines and growth 
factors. cell actions are also influenced by 
inter action with components of the ecM 
through their integrin receptors and adhesion 
molecules. MMPs produced by epidermal 
cells, fibroblasts and vascular endothelial 
cells assist in migration of the cells, while 
proteolytic enzymes produced by neutrophils 
and macrophages remove denatured ecM 
components and assist in remodelling of 
initial scar tissue.




Pathological responses to injury can result in 
non-healing wounds (ulcers), inadequately 
healing wounds (dehiscence), or in 
excessively healing wounds (hypertrophic 
scars and keloids). normal repair is the 
response that re-establishes a functional 
equilibrium between scar formation and scar 
remodelling, and is the typical response that 
most humans experience following injury. 
the pathological responses to tissue injury 
stand in sharp contrast to the normal repair 
response. in excessive healing there is too 
much deposition of connective tissue that 
results in altered structure, and thus, loss 
of function. Fibrosis, strictures, adhesions, 
keloids, hypertrophic scars and contractures 
are examples of excessive healing. contraction 
is part of the normal process of healing but 
if excessive, it becomes pathologic and is 
known as a contracture. deficient healing is 
the opposite of fibrosis. it occurs when there 
is insufficient deposition of connective tissue 
matrix and the tissue is weakened to the point 
where scars fall apart under minimal tension. 
chronic non-healing ulcers are examples of 
severely deficient healing. 




the healing process in chronic wounds 
is generally prolonged, incomplete and 
uncoordinated, resulting in a poor anatomic 
and functional outcome. chronic, non-
healing ulcers are a prime clinical example of 
the importance of the wound cytokine profile 
and the critical balance necessary for normal 
healing to proceed. Since cytokines, growth 
factors, proteases, and endocrine hormones 
play key roles in regulating acute wound 
healing, it is reasonable to hypothesize that 
alterations in the actions of these molecules 
could contribute to the failure of wounds to 
heal normally. Several methods are used to 
assess differences in molecular environments 
of healing and chronic wounds. Messenger 
ribonucleic acid (mrna) and protein levels 
can be measured in homogenates of wound 
biopsies. the proteins in wounds can be 
immunolocalized in histological sections of 
biopsies. wound fluids collected from acute 
surgical wounds and chronic skin ulcers are 
used to analyze the molecular environment 
of healing and chronic wounds. From these 
studies, several important concepts have 
emerged from the molecular analyses of 
acute and chronic wound environments.
the first major concept to emerge from 
analysis of wound fluids is that the molecu-
lar environments of chronic wounds have 
reduced mitogenic activity compared to 
the environments of acute wounds.4 Fluids 
collected from acute mastectomy wounds 
when added to cultures of normal human 
skin fibroblasts, keratinocytes or vascular 
endothelial cells, consistently stimulated 
dna synthesis of the cultured cells. in 
contrast, addition of fluids collected from 
chronic leg ulcers typically did not stimu-
late dna synthesis of the cells in culture. 
also, when acute and chronic wound fluids 
were combined the mitotic activity of acute 
wound fluids was inhibited. Similar results 
were reported by several groups of investig-
ators who also found that acute wound 
fluids promoted dna synthesis while 
chronic wound fluids did not stimulate cell 
proliferation.18,19,20
the second major concept to emerge from 
wound fluid analysis is the elevated levels 
of pro-inflammatory cytokines observed in 
chronic wounds as compared to the molecu-
lar environment of acute wounds. the ratios 
of two key inflammatory cytokines, tnFα 
and il-1β, and their natural inhibitors, P55 
and il-1 receptor antagonist, in mastectomy 
fluids were significantly higher in mastec-
tomy wound fluids than in chronic wound 
fluids. trengove and colleagues also reported 
high levels of the inflammatory cytokines 
il-1, il-6 and tnFα in fluids collected 
from venous ulcers of patients admitted to 
the hospital.21 More importantly, levels of 
the cytokines significantly decreased in fluids 
collected two weeks after the chronic ulcers 
had begun to heal. harris and colleagues also 
found cytokine levels were generally higher 
in wound fluids from non-healing ulcers 
than healing ulcers.20 these data suggest 
that chronic wounds typically have elevated 
levels of pro-inflammatory cytokines, and 
that the molecular environment changes to a 
less pro-inflammatory cytokine environment 
as chronic wounds begin to heal. 
the third concept that emerged from 
wound fluid analysis was the elevated levels 
of protease activity in chronic wounds com-
pared to acute wounds.4,22,23 For example, 
the average level of protease activity in mas-
tectomy fluids determined using the general 
MMP substrate, azocoll, was low (0.75µg 
collagenase equivalents/ml, n = 20) with a 
range of 0.1 to 1.3µg collagenase equiva-
lents/ml.24 this suggests that protease activity 
is tightly controlled during the early phase of 
wound healing. in contrast, the average level 
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of protease activity in chronic wound fluids 
(87µg collagenase equivalents/ml, n = 32) 
was approximately 116-fold higher (p<0.05) 
than in mastectomy fluids. also, the range 
of protease activity in chronic wound fluids 
is rather large (from 1 to 584µg collagenase 
equivalents/ml). More importantly, the lev-
els of protease activity decrease in chronic 
venous ulcers two weeks after the ulcers begin 
to heal.24 yager and colleagues also found 
10-fold higher levels of MMP-2 protein, 
25-fold higher levels of MMP-9 protein, and 
10-fold higher collagenase activity in fluids 
from pressure ulcers compared to surgical 
wound fluids using gelatin zymography and 
cleavage of a radioactive collagen substrate.25 
other studies using immunohistochemical 
localization observed elevated levels of MMPs 
in granulation tissue of pressure ulcers along 
with elevated levels of neutrophil elastase 
and cathepsin-G.26 tiMP-1 levels were 
found to be decreased while MMP-2 and 
MMP-9 levels were increased in fluids from 
chronic venous ulcers compared to mastec-
tomy wound fluids.27 recently, ladwig and 
colleagues reported that the ratio of active 
MMP-9/tiMP-1 was closely correlated with 
healing outcome of pressure ulcers treated by 
a variety of protocols (Figure 23.6).28 
it is interesting to note that the major 
collagenase found in non-healing chronic 
pressure ulcers was MMP-8, the neutrophil-
derived collagenase. thus, the persistent 
influx of neutrophils releasing MMP-8 and 
elastase appears to be a major underlying 
mechanism resulting in tissue and growth 
factor destruction and thus impaired heal-
ing. this suggests that chronic inflammation 
must be decreased if pressure ulcers are to 
heal. 
other classes of proteases also appear 
to be elevated in chronic wound fluids. 
Figure 23.6: Low Protease/Inhibitor Ratios Correlate with Healing. Low values of the ratio of MMP-9/TIMP-1 
in wound fluids from patients with chronic pressure ulcers correlate with healing of chronic pressure ulcers 
over 36 days of treatment, supporting the concept that high protease/inhibitor ratios prevent healing of chronic 
wounds.
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it has been reported that fluids from skin 
graft donor sites or breast surgery patients 
contained intact α1-antitrypsin, a potent 
inhibitor of serine proteases, very low levels 
of neutrophil elastase activity, and intact 
fibronectin.29 in contrast, fluids from the 
chronic venous ulcers contained degraded 
1-antitrypsin, and 10-fold to 40-fold higher 
levels of neutrophil elastase activity, and 
degraded fibronectin. chronic leg ulcers 
were also found to contain elevated MMP-2 
and MMP-9, and that fibronectin degrada-
tion in chronic wounds was dependent on 
the relative levels of elastase, α1-proteinase 
inhibitor, and α2-macroglobulin. 30,31
besides being implicated in degrading 
essential extracellular matrix components 
like fibronectin, proteases in chronic wound 
fluids also have been reported to degrade 
exogenous growth factors in vitro such as 
eGF, tGF-α, or PdGF.1,24,32,33 in contrast, 
exogenous growth factors were stable in 
acute surgical wound fluids in vitro. Sup-
porting this general concept of increased 
degradation of endogenous growth factors 
by proteases in chronic wounds, the average 
immunoreactive levels of some growth fac-
tors such as eGF, tGF-β and PdGF were 
found to be lower in chronic wound fluids 
than in acute wound fluids while PdGF-ab, 
tGF-α and iGF-1 were not lower.32,34
in general, these results suggest that many 
chronic wounds contain elevated MMP and 
neutrophil elastase activities. the physi-
ological implications of these data are that 
elevated protease activities in some chronic 
wounds may directly contribute to the fail-
ure of wounds to heal by degrading proteins 
which are necessary for wound healing such 
as extracellular matrix proteins, growth fac-
tors, their receptors and protease inhibitors. 
interestingly, Steed and colleagues35 reported 
that extensive debridement of diabetic foot 
ulcers improved healing in patients treated 
with placebo or with recombinant human 
PdGF (Figure 23.7). it is likely that frequent 
sharp debridement of diabetic ulcers helps to 
convert the detrimental molecular environ-
ment of a chronic wound into a pseudo-
acute wound molecular environment.
Figure 23.7: Frequency of Wound Debridement Correlates with Improved Healing. There was a strong 
correlation between the frequency of debridement and healing of chronic diabetic foot ulcers, supporting the 
concept that the abnormal cellular and molecular environment of chronic wounds impairs healing.




the biochemical analyses of healing and 
chronic wound fluids and biopsies have 
suggested that there are important molecular 
differences in the wound environments. 
however, these data only indicate part of 
the picture. the other essential component 
is the capacity of the wound cells to respond 
to cytokines and growth factors. interesting 
new data are emerging which suggest that 
fibroblasts in skin ulcers which have failed 
to heal for many years may not be capable 
of responding to growth factors and divide 
as fibroblasts in healing wounds. Ågren and 
colleagues36 reported that fibroblasts from 
chronic venous leg ulcers grew to lower 
density than fibroblasts from acute wounds 
from uninjured dermis. also, fibroblasts 
from venous leg ulcers that had been present 
greater than three years grew more slowly 
and responded more poorly to PdGF than 
fibroblasts from venous ulcers that had been 
present for less than three years. these results 
suggest that fibroblasts in ulcers of long 
duration may approach senescence and have 
a decreased response to exogenous growth 
factors.
FroM bench to bedSide
Role of endocrine hormones in the 
regulation of wound healing
classical endocrine hormones are molecules 
that are synthesized by specialized tissue and 
secreted into the blood stream which are 
then carried to distant target tissue where 
they interact with specific cellular receptor 
proteins and influence the expression of genes 
that ultimately regulate the physiological 
actions of the target cell. it has been known 
for decades that alterations in endocrine 
hormones can alter wound healing. diabetic 
patients frequently develop chronic wounds 
due to multiple direct and indirect effects 
of the inadequate insulin action on wound 
healing. Patients receiving anti-inflammatory 
glucocorticoids for extended periods are 
also at risk of developing impaired wound 
healing due to the direct suppression of 
collagen synthesis in fibroblasts and the 
extended suppression of inflammatory cell 
function. the association of oestrogen with 
healing was recently reported by ashcroft 
and colleagues37 when they observed that 
healing of skin biopsy sites in healthy, 
postmenopausal women was significantly 
slower than in healthy premenopausal 
women. Molecular analyses of the wound 
sites indicated that tGF-β protein and 
mrna levels were dramatically reduced in 
postmenopausal women in comparison to sites 
from premenopausal women. however, the 
rate of healing of wounds in postmenopausal 
women taking oestrogen replacement therapy 
occurred as rapidly as in premenopausal 
women. Furthermore, molecular analyses 
of wounds in postmenopausal women 
treated with oestrogen replacement therapy 
demonstrated elevated levels of tGF-β 
protein and mrna that were similar to levels 
in wounds from premenopausal women. 
aging was also associated with elevated 
levels of MMPs and decreased levels of 
tiMPs in skin wounds, which were reversed 
by oestrogen treatment.38,39 the beneficial 
effects of oestrogen on wound healing could 
be achieved with topical oestrogen and were 
also observed in healthy aged men.40 these 
data indicate the significant interactions that 
can occur between endocrine hormones and 




conditions that promote chronic wounds 
are repeated trauma, foreign bodies, pressure 
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necrosis, infection, ischemia, and tissue 
hypoxia. these wounds share a chronic 
inflammatory state characterized by an 
increased number of neutrophils, macro-
phages, and lymphocytes which produce 
inflammatory cytokines, such as tnF-α, 
il-1 and il-6. In vitro studies have shown 
that tnF-α and il-1 increase expression 
of MMPs and down-regulate expression 
of tiMP in a variety of cells including 
macrophages, fibroblasts, keratinocytes, and 
endothelial cells. all MMPs are synthesized as 
inactive proenzymes, and they are activated by 
proteolytic cleavage of the pro-MMP. Serine 
proteases, such as plasmin, as well as the 
membrane type MMPs can activate MMPs. 
another serine protease, neutrophil elastase, 
is also present in increased concentrations 
in chronic wounds, and is very important 
in directly destroying extracellular matrix 
components and in destroying the tiMPs, 
which indirectly increases the destructive 
activity of MMPs.4,22,25,33 thus, the general 
molecular profile that appears in various 
types of chronic ulcers is (1) increased 
levels of inflammatory cytokines, which 
leads to (2) increased levels of proteases 
and decreased levels of protease inhibitors, 
which (3) degrade molecules that are 
essential for healing, including growth 
factors, their receptors and ecM proteins, 
which (4) prevent wounds from healing 
normally. nwomeh and colleagues23 further 
describe this common pathway in chronic 
wounds as a self-perpetuating environment 
in which chronic inflammation produces 
elevated levels of reactive oxygen species and 
degradative enzymes that eventually exceed 
their beneficial actions of destroying bacterial 
and debriding the wound bed and produce 
destructive effects that help to establish a 
chronic wound.
based on these biochemical analyses of 
the molecular environments of acute and 
chronic human wounds, it is possible to 
propose a general model of differences 
between healing and chronic wounds. as 
shown in Figure 23.8, the molecular envi-
ronment of healing wounds promotes mito-
sis of cells, has low levels of inflammatory 
cytokines, low levels of proteases and high 
levels of growth factors and cells capable of 
rapid division. in contrast, the molecular 
environments of chronic wounds generally 
have the opposite characteristics, i.e., the 
molecular environment does not promote 
mitosis of cells, has elevated levels of inflam-
matory cytokines, has high levels of proteases 
Figure 23.8: Comparison of the Molecular and Cellular Environments of Healing and Chronic Wounds. 
Elevated levels of cytokines and proteases in chronic wounds reduce mitogenic activities and response of 
wound cells, impairing healing.
Principles of Wound Healing 441
and low levels of growth factors and cells that 
are approaching senescence.41,24,21 if these 
general concepts are correct, then it may be 
possible to develop new treatment strategies 
which would re-establish in chronic wounds 
the balance of cytokines, growth factors, 
proteases, their natural inhibitors and com-
petent cells found in healing wounds.
Chronic venous stasis ulcers
Mechanisms involved in the creation and 
perpetuation of chronic wounds are varied 
and depend on the individual wounds. in 
general, the inability of chronic venous 
stasis ulcers to heal appears to be related 
to impairment in wound epithelialization. 
the wound edges show hyperproliferative 
epidermis under microscopy, even though 
further immunohistochemical studies 
revealed optimal conditions for keratinocyte 
recruitment, proliferation, and differentiation. 
the extracellular matrix and the expression 
of integrin receptors by keratinocytes that 
allow them to translocate play an important 
regulatory role in epithelialization. after 
receiving the signal to migrate, epidermal 
cells begin by disassembling their attachments 
from basement membrane and neighboring 
cells. they then travel over a provisional 
matrix containing fibrinogen, fibronectin, 
vitronectin, and tenascin and stop when 
they encounter laminin. during this process, 
keratinocytes are producing fibronectin, and 
continue to do so until the epithelial cells 
contact, at which time they again begin 
manufacturing laminin to regenerate the 
basement membrane.
there is evidence that the interaction 
between the integrin receptors on keratino-
cytes with the ecM will transform resting 
cells to a migratory phenotype. integral 
in this transformation is the alteration in 
the pattern of integrin receptors expressed. 
after epithelialization is completed, integrin 
expression reverts back to the resting pattern. 
to further complicate this process, growth 
factors are involved in mediating keratino-
cyte activation, integrin expression, and in 
alterations in the matrix. Growth factors are 
able to differentially affect these processes. 
For example, tGF-β is able to promote 
epithelial migration while inhibiting prolif-
eration. although tGF-β induces the nec-
essary integrin expression for migration, the 
cells behind those at the leading edge have 
little proliferative ability and so epithelial 
coverage of the wound is inhibited. Some 
chronic wounds may be deficient in tGF-β 
and its receptor.42
Pressure ulcers
chronic wounds have also been demonstrated 
to have elevated matrix degrading enzymes 
and decreased levels of inhibitors for these 
enzymes. Pressure ulcers, unlike chronic 
venous stasis ulcers, appear to have difficulty 
in healing related to impairment of ecM 
production. Studies have indicated that 
neutrophil elastase present in chronic 
wounds can degrade peptide growth factors 
and is responsible for degrading fibronectin. 
Pressure ulcers have also shown an increase 
in matrix metalloproteinases and in plas-
minogen activators in tissue. chronic 
wound fluids demonstrate increased levels 
of gelatinases MMP-2 and MMP-9. levels 
of MMP-1 and MMP-8 were also found to 
be higher in pressure ulcers and in venous 
stasis ulcers than in acute healing wounds. in 
addition, several of the endogenous proteinase 
inhibitors were shown to be decreased in 
chronic wounds. Proteinase inhibitors serve 
a regulatory role in matrix degradation by 
containing the matrix-degrading enzymes. 
Factors that promote MMP production or 
activation could counteract the effectiveness 
of proteinase inhibitors, for example the 
destruction of tiMP by neutrophil elastase. 
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the tissue inhibitor level to MMP ratio may 
indicate an imbalance which contributes to 
the wound chronicity.
Future concePtS For the 
treatMent oF chronic 
woundS
although the aetiologies and the physical 
characteristics for the various types of chronic 
wounds are different, there is a common 
trend in their biochemical profiles. the 
precise pattern of growth factor expression 
in the different types of chronic wounds is 
not yet known; but it has been determined 
that there is generally a decreased level of 
growth factors and their receptors in chronic 
wound fluids. the absolute levels of growth 
factors may not be as important as the 
relative concentrations necessary to replace 
the specific deficiencies in the tissue repair 
processes. For the treatment of chronic 
wounds, robson43 proposed that growth 
factor therapy be tailored to the deficiency in 
the repair process. therefore, the effectiveness 
of the therapy is predicated on adequate 
growth factor levels and the expression of 
their receptors balanced against receptor 
degradation by proteases and the binding of 
growth factors by macromolecules such as 
macroglobulin and albumin.
Studies that evaluated topical growth 
factor treatment of chronic wounds, such as 
PdGF in diabetic foot ulcers and eGF in 
chronic venous stasis ulcers, have shown an 
improvement in healing. these findings have 
led to the hypothesis that altering the cytokine 
profile of chronic wounds through the use of 
MMP inhibitors, addition of growth factors, 
and the elimination of inflammatory tissue 
and proteases by debridement would shift 
the wound microenvironment towards that 
of an acute wound, thereby improve healing.
current treatment strategies are being 
developed to address the deficiencies (growth 
factor and protease inhibitor levels) and 
excesses (MMPs, neutrophil elastase, and 
serine protease levels) in the chronic wound 
microenvironment. although the more spe-
cific and sophisticated treatments remain in 
the lab at this time such as the new potent, 
synthetic inhibitors of MMPs and the natu-
rally occurring protease inhibitors, tiMP-1 
and 1-antitrypsin, available by recombinant 
dna technology, the use of gene therapy 
in the treatment of chronic diabetic foot 
ulcers is currently being evaluated in a clini-
cal trial. a phase iii clinical trial is under-
way to determine the efficacy of keratinocyte 
growth factor-2 (KGF-2) in the treatment of 
chronic venous stasis ulcers. the treatment 
strategy to add growth factor to a chronic 
wound has been in place for the past several 
years. regranex®, human recombinant plate-
let derived growth factor (PdGF-bb), has 
been available for the treatment of diabetic 
foot ulcers; demonstrated approximately 
20% improvement in healing compared to 
controls.44 in keeping with the strategy 
to restore a deficient wound environment, 
dermagraph® and apligrapf®, engineered 
tissue replacements, have been applied 
to chronic diabetic ulcers.45,46 although 
apligrapf® is no longer available, both tissue 
replacements have proven to be effective in 
selected types of ulcers. other approaches to 
the treatment of chronic wounds have been 
to remove the increased protease levels. this 
is in part the strategy of a vacuum-assisted 
negative pressure wound dressing47 and in 
the recent development of dressings that 
bind and remove MMPs from the wound 
fluid, such as Promogran®.48,49
there have been some advances made 
in the development of new antimicrobial 
dressings and they have been summarized by 
hamm in a recent publication (antibacterial 
dressings in advances in wound care: 
Volume 1; Mary anne libert inc. 2010, 
page 148).
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another strategy is to use synthetic pro-
tease inhibitors to decrease the activities of 
MMPs in the wound environment. doxy-
cycline, a member of the tetracycline fam-
ily of antibiotics, is a moderately effective 
inhibitor of metalloproteinases, including 
MMPs and the tnFα converting enzyme 
(tace). we have demonstrated a reduction 
in inflammatory cell infiltrate and extra-
cellular matrix in chronic pressure ulcers 
treated with 100mg doxycycline twice daily. 
low dose doxycycline 20mg, twice daily has 
been proven to be beneficial in other path-
ologic states such as periodontitis that are 
characterized by chronic, neutrophil-driven 
inflammation, and matrix destruction.50 in 
the future, treatment of chronic wounds 
may require the use of specific growth fac-
tors or inhibitors unique to the type of 
ulcer or the use of combinations of selective 
inhibitors of proteases, growth factors and 
tissue replacements to act synergistically to 
promote healing. 
as previously described, endocrine 
hormones, such as insulin, glucocorticoids, 
and oestrogen, play important roles in regu-
lating wound healing. although there is no 
current therapy that specifically addresses the 
molecular deficits created by type i or type ii 
diabetes (inadequate insulin levels or insulin 
resistance), systemic insulin injections may 
improve the local wound microenvironment. 
For patients receiving long-term corticoster-
oids, the use of vitamin a seems to facili-
tate wound healing. Studies are underway to 
determine the efficacy of topical oestrogen 
applications on skin aging.
new technologies are being developed to 
help researchers better understand the com-
plex microenvironment that exists in chronic 
wounds.51 a technique called Polymerase 
chain reaction (Pcr) can amplify the 
microbial dna that is extracted from the 
wound bed and then be used to identify and 
quantify specific organisms. the test is highly 
sensitive and there is a rapid turn around 
time. the drawback is that Pcr can only be 
used to identify known organisms and new 
unknown microbes will not be detected. 
Bacterial biofilms in chronic wounds
bacterial biofilms are well known in other 
medical specialities to cause a variety of 
chronic pathologies including periodontal 
disease, cystic fibrosis, chronic otitis media and 
osteomyelitis and prosthetic graft infection.52 
biofilms are characterized by an exopolymeric 
matrix of polysaccharides, proteins and dna 
synthesized by the multiple bacterial species 
(polymicrobial) comprising the biofilm 
community. bacteria (and fungi) contained 
within the biofilm matrix are highly tolerant 
to killing phagocytic inflammatory cells 
(neutrophils and macrophages), antibodies, 
and exogenous antibiotics, antiseptics and 
disinfectants. Several factors contribute to the 
increased tolerance of bacteria in biofilms to 
these agents, including reduced penetration 
of large proteins (antibodies) into the dense 
exopolymeric matrix, binding of oppositely 
charged molecules like antibiotics or cationic 
heavy metal ions (silver ion) by negatively 
charged components of the exopolymeric 
matrix, or neutralization of highly reactive 
chemicals like hypochlorous acid (bleach) 
by reaction with molecules comprising the 
exopolymeric matrix. also, some bacteria 
in mature biofilms become metabolically 
quiescent and these ‘persister cells’ are 
therefore highly resistant to antibiotics that 
disrupt bacterial metabolism. these factors 
contribute to make biofilms extremely 
difficult to kill and clear from chronic 
wounds. Furthermore, components of the 
biofilm matrix and products produced by 
bacteria in the biofilm stimulate chronic 
inflammation, which leads to persistently 
elevated levels of molecules like proteases 
and reactive oxygen species that kill wound 
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cells and damage proteins that are essential 
for healing. 
assessment of the ‘bioburden’ of wounds 
has traditionally relied upon relatively simple 
microbiology laboratory techniques that typ-
ically provide information on major bacterial 
and fungal species in swabs or biopsies that 
can grow under the nutritional and envir-
onmental conditions provided in the lab. 
these assessments of bacteria and fungi in 
wound samples have unquestionably gener-
ated important data that have been used for 
decades to help select therapeutic regimens 
for patients and their wounds. however, 
multiple publications have pointed out that, 
in many patients, measurements of total 
bacterial bioburden (expressed as colony 
forming units per gram of tissue biopsy or 
0-4+ levels of bacterial growth) alone do not 
correlate well with the failure of wounds to 
heal. as shown in Figure 23.9, this led to the 
concept of ‘critical colonization’ or ‘occult 
infection’ to explain the discrepancy, because 
there was an apparent link between micro-
bial bioburden in these wounds and the 
impaired healing in the wounds. however, 
it was not clear what aspect of the relatively 
low total bioburden was ‘critical’ to impair-
ing healing. More thorough evaluation of 
these ‘standard’ clinical microbiology assays 
led to the realization that these assays are 
inherently limited by the rather poor ability 
to culture or identify most of the bacterial 
and fungal species that are actually present 
in an individual chronic wound. in other 
words, standard clinical microbiology assays 
only culture planktonic bacterial and fungal 
species that are able (capable) of growing on 
agar media plates supplemented with general 
nutrients in air at 37ºc. thus, it is reason-
able to assume that a more complete picture 
of different bacterial species (aerobes, facul-
tative anaerobes, and obligate anaerobes) and 
fungal species in a particular wound should 
improve the ability to assess the microbial 
bioburden on individual wounds and to 
indicate what therapeutic strategies would 
be optimal for each wound. Fortunately, in 
the last few years sophisticated laboratory 
research techniques have been developed 
that allow a more complete assessment of 
bacterial bioburden. Specifically, these tech-
niques demonstrated that a high percentage 
(~60%) of chronic skin wounds have extens-
ive bac terial biofilms.53 using sophisticated 
polymerase chain reaction (Pcr) techniques 
dowd et al54 reported that the bacterial and 
fungal complexity of chronic wound samples 
Figure 23.9: Spectrum of Bacterial Bioburden in Wounds. Contamination and colonization of bacteria usually 
do not substantially retard healing whereas infection clearly impairs healing. The concept of critical colonization 
evolved to describe a condition where levels of planktonic bacteria were not above 106 cfu/gm, but healing was 
impaired. Since biofilm bacteria are not detected by standard clinical microbiology assays, critical colonization 
probably represents a condition when biofilm bacteria are present in wounds and stimulate chronic inflammation 
that retards healing.
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was much greater than previously thought. 
in fact, on average, approximately 60% of 
the bacterial species present in chronic pres-
sure ulcers and around 30% of those present 
in diabetic ulcers were strict anaerobic bacte-
ria, and many bacterial species were present 
that had never been reported in cultures of 
chronic wounds. these data suggest that 
many of the bacteria present in biofilms in 
a chronic wound may never be successfully 
cultured in the standard clinical micro-
biology laboratory due to obligate coopera-
tion with other bacteria that create unique 
environmental conditions in a polymicrobial 
community of bacteria in biofilms. a second 
major concept recently reported by wolcott 
and colleagues55 showed that mature biofilms 
are rapidly re-established in chronic wounds 
following surgical debridement, on the time 
frame of 24 to 72 hours. this indicates that 
sharp debridement opens a time-depend-
ent therapeutic window to prevent the re- 
establishment of mature biofilms that are 
highly tolerant to host inflammatory response 
or to exogenous antimicrobial agents.
the clinical principle that should guide 
‘biofilm-based wound care’ is to reduce plank-
tonic and biofilm bacterial burdens by the 
most appropriate and effective means (surgi-
cal debridement, curettage, irrigation, etc), 
then follow the debridement by covering the 
wound with an effective bacterial barrier dress-
ing, of which there are many types, including 
dressings with microbicidal metal ions (silver), 
quaternary amines, or occlusive films.56 
concluSion
the molecular environment of chronic 
wounds contains elevated levels of inflam-
matory cytokines and proteases, low levels 
of mitogenic activity, and cells that often 
respond poorly to growth factors compared 
to acute healing wounds. as chronic wounds 
begin to heal, this molecular pattern shifts to 
one that resembles a healing wound. as more 
information is learned about the molecular 
and cellular profiles of healing and chronic 
wounds, new therapies will be developed 
that selectively correct the abnormal aspects 
of chronic wounds and promote healing of 
these costly clinical problems. with the aging 
of the population, wound care for the elderly 
is becoming a major issue57 the wound 
healing Society has developed a series of 
guidelines for ‘acute wound care’, ‘chronic 
wound care’ and ‘Prevention Guidelines’ 
that are free as downloads on their web site 
(http://www.woundheal.org )
reFerenceS
1. bennett nt, Schultz GS. Growth 
factors and wound healing: Part ii.  
role in normal and chronic wound 
healing. Am J Surg 1993; 166: 74–81. 
2. bennett nt, Schultz GS. Growth 
factors and wound healing: 
biochemical properties of growth 
factors and their receptors. Am J Surg 
1995; 165: 728–37. 
3. lawrence wt. Physiology of the acute 
wound. Clin Plast Surg 1998;  
25: 321–340.
4. Mast ba, Schultz GS. interactions of 
cytokines, growth factors, and proteases 
in acute and chronic wounds. Wound 
Rep Regen 1996; 4: 411–20. 
5. Schultz GS. Molecular regulation of 
wound healing. in ra bryant (ed.), 
acute and chronic wounds:  nursing 
Management, 2nd ed, 413–29. 
Philadelphia: Mosby, 2000.
6. Gailit J, clark raF. wound repair in 
context of extracellular matrix. Curr 
Opin Cell Biol 1994; 6: 717–25.
7. rumalla VK, borah Gl. cytokines, 
growth factors, and plastic surgery. 
Plast Reconstr Surg. 2001;  
108: 719–33.
Mechanisms of Vascular Disease446
8. luster ad. chemokines–chemotactic 
cytokines that mediate inflammation. 
N Engl J Med 1998; 338: 436–45.
9. Gillitzer r, Goebeler M. chemokines 
in cutaneous wound healing. J Leukoc 
Biol 2001; 69: 513–21.
10. dinarello ca, Moldawer ll. 
chemokines and their receptors. 
Proinflammatory and anti-
inflammatory cytokines in 
rheumatoid arthritis, 1st ed,  
pp. 99–110. thousand oaks, ca: 
amgen inc., 2000.
11. Frenette PS, wagner dd. adhesion 
molecules, blood vessels and blood 
cells. N Eng J Med 1996; 335: 43–5. 
12. Frenette PS, wagner dd. Molecular 
medicine, adhesion molecules. N Eng J 
Med 1996; 334: 1526–9.
13. diegelmann rF, cohen iK,  
Kaplan aM. the role of macrophages 
in wound repair: a review. Plast 
Reconstr Surg 1981; 68: 107–13.
14. duncan Mr, Frazier KS,  abramson S, 
williams S, Klapper h, huang X, 
Grotendorst Gr. connective tissue 
growth factor mediates transforming 
growth factor beta-induced collagen 
synthesis: down-regulation by caMP. 
FASEB J. 1999; 13: 1774–86.
15. bhushan M, young hS, brenchley Pe,  
Griffiths ce. recent advances in 
cutaneous angiogenesis. Br J Dermatol 
2002; 147: 418–25.
16. Semenza Gl. hiF-1 and tumor 
progression: pathophysiology and 
therapeutics. Trends Mol Med. 2002;  
8: S62-S7.
17. o’toole ea. extracellular matrix 
and keratinocyte migration. Clin Exp 
Dermatol 2001; 26: 525–30.
18. bucalo b, eaglstein wh, Falanga V.  
inhibition of cell proliferation by 
chronic wound fluid. Wound Rep Reg 
1993; 1: 181–86.
19. Katz Mh, alvarez aF, Kirsner rS, 
eaglstein wh, Falanga V. human 
wound fluid from acute wounds 
stimulates fibroblast and endothelial 
cell growth. J Am Acad Dermatol 
1991; 25: 1054–58.
20. harris ir, yee Kc, walters ce, 
cunliffe wJ, Kearney Jn, wood eJ,  
ingham e. cytokine and protease levels 
in healing and non-healing chronic 
venous leg ulcers. Exp Dermatol 1995; 
4: 342–9.
21. trengove nJ, bielefeldt-ohmann h, 
Stacey Mc. Mitogenic activity and 
cytokine levels in non-healing and 
healing chronic leg ulcers. Wound Rep 
Regen 2000; 8: 13–25.
22. yager dr, nwomeh bc. the 
proteolytic environment of chronic 
wounds. Wound Rep Regen 1999;  
7: 433–41.
23. nwomeh bc, yager dr, cohen iK. 
Physiology of the chronic wound. Clin 
Plast Surg 1998; 25: 341–56.
24. trengove nJ, Stacey Mc, Macauley S,  
bennett n, Gibson J, burslem F, 
Murphy G, Schultz G. analysis 
of the acute and chronic wound 
environments: the role of proteases 
and their inhibitors. Wound Rep Regen 
1999; 7: 442–52.
25. yager dr, zhang ly, liang 
hX, diegelmann rF, cohen iK. 
wound fluids from human pressure 
ulcers contain elevated matrix 
metalloproteinase levels and activity 
compared to surgical wound fluids.  
J Invest Dermatol 1996; 107: 743–8.
26. rogers aa, burnett S, Moore Jc,  
Shakespeare PG, chen wyJ. 
involvement of proteolytic enzymes-
plasminogen activators and 
matrix metalloproteinases-in the 
pathophysiology of pressure ulcers. 
Wound Rep Regen 1995; 3: 273–83. 
Principles of Wound Healing 447
27. bullen ec, longaker Mt, updike dl, 
benton r, ladin d, hou z. tissue 
inhibitor of metalloproteinases-1 is 
decreased and activated gelatinases are 
increased in chronic wounds. J Invest 
Dermatol 1995; 104: 236–40.
28. ladwig G P, robson Mc, liu r,  
Kuhn Ma, Muir dF, Schultz GS.  
ratios of activated matrix 
metalloproteinase-9 to tissue inhibitor 
of matrix metalloproteinase-1 in 
wound fluids are inversely correlated 
with healing of pressure ulcers. Wound 
Rep Regen 2002; 10: 26–37.
29. rao cn, ladin da, liu yy,  
chilukuri K, hou zz, woodley dt. 
alpha 1-antitrypsin is degraded and 
non-functional in chronic wounds but 
intact and functional in acute wounds: 
the inhibitor protects fibronectin from 
degradation by chronic wound fluid 
enzymes. J Invest Dermatol 1995;  
105: 572–8.
30. wysocki ab, Staiano-coico l, 
Grinnell F. wound fluid from chronic 
leg ulcers contains elevated levels of 
metalloproteinases MMP-2 and  
MMP-9. J Invest Dermatol 1993;  
101: 64–8.
31. Grinnel F, zhu M. Fibronectin 
degradation in chronic wounds 
depends on the relative levels of 
elastase, a1-proteinase inhibitor, and 
a2-macroglbulin. J Invest Dermatol 
1996; 106: 335–41.
32. tarnuzzer rw, Schultz GS. 
biochemical analysis of acute and 
chronic wound environments. Wound 
Rep Regen 1996; 4: 321–5. 
33. yager dr, chen SM, ward Si, 
olutoye oo, diegelmann rF,  
cohen iK. ability of chronic 
wound fluids to degrade peptide 
growth factors is associated with 
increased levels of elastase activity 
and diminished levels of proteinase 
inhibitors. Wound Rep Regen 1997;  
5: 23–32. 
34. baker ea, leaper dJ. Proteinases, their 
inhibitors, and cytokine profiles in 
acute wound fluid. Wound Rep Regen 
2000; 8: 392–8.
35. Steed dl, donohoe d, webster Mw,  
lindsley l. effect of extensive 
debridement and treatment on the 
healing of diabetic foot ulcers. J Am 
Coll Surg 1996; 183, 61–4.
36. agren MS, eaglstein wh,  
Ferguson Mw, harding KG,  
Moore K, Saarialho-Kere uK,  
Schultz GS. causes and effects of 
the chronic inflammation in venous 
leg ulcers. Acta Derm Venereol Suppl 
(Stockh) 2000; 210: 3–17.
37. ashcroft GS, dodsworth J,  
van boxtel e, tarnuzzer rw,  
horan Ma, Schultz GS,  
Ferguson Mw. estrogen accelerates 
cutaneous wound healing associated 
with an increase in tGF-beta1 levels. 
Nat Med 1997; 3: 1209–15.
38. ashcroft GS, horan Ma, herrick Se, 
tarnuzzer rw, Schultz GS,  
Ferguson Mw. age-related differences 
in the temporal and spatial regulation 
of matrix metalloproteinases (MMPs) 
in normal skin and acute cutaneous 
wounds of healthy humans. Cell Tissue 
Res 1997; 290: 581–91.
39. ashcroft GS, herrick Se, tarnuzzer 
rw, horan Ma, Schultz GS,  
Ferguson Mw. human ageing 
impairs injury-induced in vivo 
expression of tissue inhibitor of matrix 
metalloproteinases (tiMP)-1 and -2 
proteins and mrna. J Pathol 1997; 
183: 169–76.
40. ashcroft GS, Greenwell-wild t,  
horan Ma, wahl SM, Ferguson Mw.  
topical estrogen accelerates 
Mechanisms of Vascular Disease448
cutaneous wound healing in aged 
humans associated with an altered 
inflammatory response. Am J Pathol 
1999: 155: 1137–46.
41. trengove nJ, langton Sr, Stacey Mc. 
biochemical analysis of wound fluid 
from nonhealing and healing chronic 
leg ulcers. Wound Rep Regen 1996;  
4: 234–239.
42. cowin aJ, hatzirodos n, holding ca, 
dunaiski V, harries rh, rayner t. e, 
Fitridge r, cooter rd, Schultz GS, 
belford da. effect of healing on the 
expression of transforming growth 
factor beta(s) and their receptors in 
chronic venous leg ulcers. J Invest 
Dermatol 2001; 117: 1282–9.
43. robson Mc. the role of growth 
factors in the healing of chronic 
wounds. Wound Rep Regen 1997;  
5: 12–17.
44. Smiell JM, wieman tJ, Steed dl, 
Perry b, Sampson ar, Schwab bh. 
efficacy and safety of becaplermin 
(recombinant human platelet-derived 
growth factor-bb) in patients with 
nonhealing, lower extremity diabetic 
ulcers: a combined analysis of four 
randomized studies. Wound Repair 
Regen 1999; 7: 335–46.
45. Falanga V, Margolis d, alvarez o, 
auletta M, Maggiacomo F, altman M, 
Jensen J, Sabolinski, M,  
hardin-young J. rapid healing of 
venous ulcers and lack of clinical 
rejection with an allogeneic cultured 
human skin equivalent. human Skin 
equivalent investigators Group [see 
comments]. Arch Dermatol 1998;  
134: 293–300.
46. Kirsner rS, Falanga V, eaglstein wh. 
the development of bioengineered 
skin. Trends Biotechnol 1998;  
16: 246–9.
47. argenta lc, Morykwas MJ. Vacuum-
assisted closure: a new method for 
wound control and treatment: clinical 
experience. Ann Plast Surg 1997;  
38: 563–6.
48. cullen b, Smith r, Mcculloch e, 
Silcock d, Morrison l. Mechanism of 
action of ProMoGran, a protease 
modulating matrix, for the treatment 
of diabetic foot ulcers. Wound Rep 
Regen 2002; 10: 16–25.
49. Veves a, Sheehan P, Pham ht. 
a randomized, controlled trial of 
promogran (a collagen/oxidized 
regenerated cellulose dressing) vs 
standard treatment in the management 
of diabetic foot ulcers. Arch Surg 2002; 
137: 822–7.
50. Golub l M, Mcnamara tF, ryan Me, 
Kohut b, blieden t, Payonk G,  
Sipos t, baron hJ. adjunctive 
treatment with sub-antimicrobial doses 
of doxycycline: effects on gingival fluid 
collagenase activity and attachment 
loss in adult periodontitis. J Clin 
Periodontol 2001; 28: 146–56.
51. biofilms in advances in wound care: 
Volume 1; Mary anne libert inc. 
2010, pp. 281–317.
52. Phillips Pl, wolcott rd, Fletcher J,  
Schultz GS.  biofilms Made easy.  
Wounds Int 2010; 1: 1–6.
53. James Ga, Swogger e, wolcott r,  
Pulcini ed, Secor P, Sestrich J, 
costerton Jw, Stewart PS.  biofilms in 
chronic wounds. Wound Rep Reg 2008; 
16: 37–44.
54. dowd Se, Sun y, Secor Pr,  
rhoads dd, wolcott bM, James Ga,  
wolcott rd.  Survey of bacterial 
diversity in chronic wounds using 
pyrosequencing, dGGe, and full 
ribosome shotgun sequencing.  BMC 
Microbiol 2008; 8: 1–43.
55. wolcott rd, rumbargh KP, James G,  
Schultz G, Phillips P, yang Q,  
watters c, Stewart PS, dowd Se.  
Principles of Wound Healing 449
biofilm maturity studies indicate sharp 
debridement opens a time-dependent 
therapeutic window.  J Wound Care 
2010; 19: 320–8.
56. rhoads dd, wolcott rd, Percival Sl.  
biofilms in wounds:  management 
strategies. J Wound Care 2008; 17: 
502–8.
57. age and impaired healing potential 
in advances in woundcare: Volume 1; 
Mary anne libert inc. 2010, pp. 177.

451
24  •  Pathophysiology and Principles of  
Management of Varicose Veins
Andrew w BrAdBury
College of Medical and dental Sciences, university of Birmingham, 
Birmingham, uK
IntroduCtIon
the management of superficial and deep 
venous reflux and obstruction that leads to 
the development of varicose veins (VV)1 
and the post-thrombotic syndrome (PtS)2 
forms a large part of the workload for most 
vascular and endovascular specialists and is 
likely to increase as the population ages.3 
However, the epidemiology,4,5 genetics6 and 
pathophysiology of these conditions remains 
incompletely defined7,8,9,10,11 and many 
clinicians lack a clear understanding of the 
underlying anatomy and vascular biology.12 
As a result, treatment outcomes are not 
infrequently sub-optimal.
AnAtoMy 
Venous blood from the lower limbs returns 
to the right heart against gravity through 
the superficial and deep venous systems. 
the superficial venous system comprises 
the great saphenous veins (GSV) and small 
saphenous veins (SSV) and their tributaries.13 
the GSV originates from the medial end of 
the dorsal venous arch, passes anterior to 
the medial malleolus, and continues up the 
medial aspect of the calf and then the thigh 
to enter the common femoral vein in the 
groin at the saphenofemoral junction (SFJ). 
the SSV originates from the lateral end of 
the dorsal venous arch, passes posterior to 
the lateral malleolus and then continues up 
the back of the calf between the heads of 
gastrocnemius to enter the popliteal fossa. 
It is joined variably by gastrocnemius veins 
and then usually enters the popliteal vein at 
the sapheno-popliteal junction (SPJ). the 
SPJ may be absent in which case the SSV 
continues up the postero-medial aspect of 
the thigh (Giacomini vein) and often joins 
the GSV. these two systems interconnect 
at many other (highly variable) points 
through an extensive network of tributaries. 
In the deep system, veins, which are often 
paired, accompany each named artery. the 
superficial and deep systems connect at 
numerous points at various non-junctional 
perforators in addition to the SFJ and SPJ. 
these systems and interconnections are 
interdependent, both anatomically and 
functionally in health and disease.
In health, the deep venous system 
transmits 90% of the venous return from 
the leg. the superficial system drains only 
the skin and subcutaneous tissues, with 
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most of that blood draining immediately 
into the deep system via perforators in the 
foot, calf and thigh. It also plays a role in 
thermoregulation. 
HIStoloGy
the vein wall comprises three layers but 
these are less well defined than in the arterial 
system. the intima is thin and surrounded 
by a fine elastic lamina. the media is made 
up of elastin and layers of muscular bundles 
that are arranged in different orientations. 
the relative amounts of muscle and elastin 
varies with the calibre and working pressure 
of the vein. Beyond this, the adventitia 
merges with the perivenous connective 
tissue, which contains nerve fibres and vasa 
vasorum and provides for vessel distension 
which is an important part of normal 
venous function. with increasing age, and 
particularly with the development of disease, 
abnormalities have been described in all three 
layers14 and the structure of the vein wall 
becomes progressively more disorganised.15 
typically, there is thickening of the intima 
with disorientation of the elastic fibres. the 
outer muscle layer of the media becomes 
hypertrophied with dystrophic elastic 
fibres and the adventitia is increasingly 
fibrous. 
PHySIoloGy 
Venous return against gravity is primarily 
dependent on muscle pumps located in the 
foot and the calf. Pressure on the sole of 
the foot, and muscular contraction (systole) 
in the fascial compartments of the calf 
compresses the sinusoidal intramuscular 
veins directing blood into the deep system 
and thence up the leg. Superficial veins collect 
blood from the superficial tissues, and during 
muscle relaxation (diastole) this blood enters 
the deep system through the perforating 
veins down a pressure gradient, filling the 
sinuses. reverse flow (reflux) during muscle 
relaxation is prevented by the closure of 
valves. these are delicate but strong bicuspid 
leaflets at the base of a localized dilated sinus 
in the vein. In both superficial and deep 
systems the density of valves is greatest in 
the calf and reduces gradually up the lower 
limb, with the iliac and inferior vena cava 
(IVC) frequently lacking valves altogether. 
Valves are present in venules down to about 
0.15mm diameter.
during systole, blood is prevented from 
re-entering the superficial system through 
the closure of junctional (SFJ, SPJ) and 
non-junctional perforators (nJP). this was 
originally thought to occur solely through 
the closure of valves but several studies have 
failed to demonstrate such valves in nJP. 
Instead, external pressure from the fascia 
and muscle through which the perforators 
pass is thought to be responsible for limit-
ing outward blood flow; somewhat akin to 
the ‘pinch-cock’ mechanism that prevents 
reflux at the gastro-oesophageal junction. 
Importantly, this also protects the superficial 
veins, subcutaneous tissues and skin from the 
extremely high deep venous pressures (up to 
250mmHg) generated by the calf muscle 
pump in systole.
when standing motionless, with venous 
valves in the neutral position, the pressure 
in the foot veins gradually increases as blood 
continues to enter the veins from the arterial 
side. As soon as the pressure in one venous 
segment exceeds that in the segment just 
above, the valve opens. eventually the hydro-
static pressure in the veins of the foot is that 
developed by an unbroken column from the 
foot to the right atrium – perhaps 90mmHg 
in a person of average height. with active 
movement, deep veins and sinuses are com-
pressed raising venous pressure and mov-
ing blood cranially and, initially, caudally 
(Figure 24.1A). However, valve closure 
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normally prevents retrograde flow within 
0.5-1.0 seconds. At this point, these closed 
valves divide the high-pressure, single col-
umn of venous blood described above into 
a large number of low-pressure, shorter col-
umns (Figure 24.1B). As a result, the pressure 
in the foot veins falls in health to less than 
25mmHg on walking; the normal ambula-
tory venous pressure (AVP) (Figure 24.2). 
this reduces venous pooling and lowers 
capillary hydrostatic pressure, reducing 
the tendency for accumulation of intersti-
tial fluid (oedema) in the feet.16 Patients 
with muscle pump and/or venous valve 
failure and/or venous outflow obstruc-
tion, demon strate raised AVP. It is this 
raised AVP that underlies all the symptoms 
and signs of chronic venous insufficiency 
(CVI).
VArICoSe VeInS
Varicose veins (VV) are dilated, tortuous 
subcutaneous veins that permit reverse flow. 
they are most commonly found in the lower 
limb and may be primary, or secondary to 
deep venous pathology. the GSV system is 
most frequently affected with the SSV being 
involved in about 20% of cases. the aetiology 
of VV at a microscopic level is still disputed 
but the essential defect macroscopically is 
generally agreed to be the failure of venous 
valve closure resulting in the superficial 
veins becoming dilated, elongated and 
tortuous.17,18 the main factor contributing 
to the development and progression 
of varicose veins is sustained venous 
hypertension that increases the diameter of 
the superficial veins resulting in further valve 
incompetence. 
VAlVulAr ABnorMAlItIeS
Failure of valve closure leading to valve 
incompetence and reflux may affect the deep 
and/or superficial venous systems and may 
be primary or secondary. Primary valvular 
incompetence (PVI) is believed to be due 
to loss of mural elastin and collagen, which 
Figure 24.1: Influence of calf muscle pump and valves in venous return.
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leads to dilatation and separation of the valve 
leaflets. the commonest clinical consequence 
of this process is the development of VV. As 
an investing fascia often supports the main 
GSV trunk, it is often the tributaries that 
become varicose. PVI may also affect the 
deep venous system although because other 
tissues support the deep veins, the clinical 
consequences of PVI are less obvious and 
certain. 
Secondary valvular incompetence may 
be due to a developmental weakness in the 
vein wall leading to secondary widening of 
the valve commissures, resulting in valvular 
incompetence and clinically, primary VV. 
It also follows thrombosis, most commonly 
in the deep venous system; deep venous 
thrombosis (dVt). Blood flowing within 
the lumen of the vein provides the vascu-
lar endothelium with its oxygen and nutri-
tion. dVt prevents this, therefore leading 
to endothelial destruction and inflamma-
tion within and around the affected veins. 
Although most venous segments occluded 
by dVt recanalise over the subsequent 
6–12 months the vein is often scarred and 
narrowed and, because the valves have been 
destroyed, incompetent. If recanalisation does 
not occur, blood is forced to find an alterna-
tive drainage route. For example, blood may 
be forced out of the deep venous system 
via the SFJ, SPJ and nJP leading to dilata-
tion of the superficial veins (secondary VV). 
obstruction of the iliac veins may lead to the 
development of groin and pelvic collaterals. 
Venous reflux and obstruction secondary 
to dVt leads to PtS which represents the 
most severe form of chronic venous insuffi-
ciency (CVI). the superficial venous system 
may also be affected by thrombosis, either in 
isolation or in combination with dVt, lead-
ing to superficial thrombophlebitis (SVt). 
rarely, VV and CVI may be due to 
congenital valve hypoplasia or agenesis, or 
due to arterio-venous malformations. In 
Klippel-trenaunay syndrome, for exam-
ple, there is deep venous hypoplasia and a 
laterally placed venous complex that acts as 
Figure 24.2: Resting and ambulatory venous pressure at the ankle in health.
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the main venous outflow of the limb. All 
the symptoms and signs of chronic venous 
insufficiency are due to ambulatory venous 
hypertension resulting from these various 
pathological processes acting upon the micro-
vasculature of the skin and subcutaneous 
tissues.
MuSCle PuMP FAIlure
Any cause of chronic debility or immobility 
is associated with calf muscle pump 
dysfunction; for example, old age, stroke, 
neuromuscular conditions, arthritis and 
trauma. Injuries that limit or prevent ankle 
movement have a particularly adverse effect 
upon the calf muscle pump.
VenouS reCIrCulAtIon
In patients with VV there is often a 
recirculation of venous blood within the 
leg. during calf relaxation abnormally 
large volumes of blood enter the muscle 
pump from the superficial varices (increased 
preload). during exercise the muscle pump 
expels blood from the leg only for it to 
re-enter the lower leg by refluxing down 
GSV and/or SSV VV (akin to an increase 
in afterload due to aortic regurgitation). 
this blood then re-enters the muscle pump 
through the perforating veins in the lower 
calf and so on. the effect is that the same 
blood can re-circulate up and down the leg 
several times before eventually finding its 
way up the iliac veins to the heart.
Patients with mild superficial reflux and/or 
an efficient calf pump are able to compen-
sate for this by increasing their calf muscle 
pump ‘stroke volume’ and output. this 
allows them to still reduce their AVP to 
(near) normal levels on walking. However 
severe reflux and/or a weak muscle pump 
may overwhelm the deep system and lead 
to the development of sustained venous 
hypertension and skin changes of CVI. 
this accounts for two important clinical 
observations:
•	 CVI	 &	 ulceration	 can	 develop	 without	
primary deep venous pathology
•	 In	 a	 proportion	 of	 patients	 with	 VV	 
and deep venous reflux the latter dis-
appears following eradication of super-
ficial disease.
reCurrent VArICoSe VeInS
recurrent VV after conventional surgical or 
endovenous intervention may be classified 
into three groups: new, persistent and true 
recurrent.
New varicose veins
this is the development of new VV, often in 
a second saphenous system, since the original 
operation.19 this may be due to:
1) Inadequate assessment at the time of the 
initial treatment; however, now that most 
patients undergo full duplex ultrasound 
mapping prior to intervention for their 
VV this should be less common
2) reflux developing at a site that was 
previously demonstrated to be competent; 
in other words, true disease progression
Persistent varicose veins
this is due to inadequate treatment of VV 
at the time of the original intervention. 
Again, with proper use of duplex ultrasound 
and modern techniques this should be a 
relatively uncommon scenario in current 
phlebological practice. the risk is perhaps 
greater with catheter based techniques such 
as radiofrequency ablation (rFA) and laser 
ablation (eVlA) which, while being highly 
successful in eradicating truncal reflux, 
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do not deal with the varices themselves. 
A proportion of patients undergoing rFA 
and eVlA will, therefore, need further 
treatment, either with foam sclerotherapy 
or local anaesthetic phlebectomies.
True recurrent varicose veins
this is where further VV develop in the 
same, previously treated saphenous system. 
when surgery was the main treatment 
modality most were the result of failure to 
properly perform a ‘flush’ SFJ (SPJ) ligation 
and/or to ‘strip’ the GSV or SSV.
neovascularisation (nV), defined as the 
‘development of new vessels connecting pre-
viously ligated superficial veins to the deep 
venous system’, and the role it might play in 
the development of recurrent VV after sur-
gery has received a lot of attention over the 
years. there is no doubt that in a proportion 
of patients with recurrent GSV (SSV) VV, 
duplex ultrasound clearly shows the pres-
ence of small venous channels within scar 
tissue apparently connecting the ‘stump’ of 
the GSV in the groin (SSV in the popliteal 
fossa) to recurrent VV in the thigh (calf ). 
However, it seems unlikely that such small, 
therefore high resistance, veins will be capa-
ble of transmitting significant reflux and 
thus of constituting a significant cause of 
recurrence on their own. In an era where 
the vast majority of patients can have non-
surgical treatment for their VV, the whole 
issue of nV becomes much less important. 
Going forward, most true recurrent VV 
are likely to be due to recanalisation of the 
trunk veins and/or their major tributar-
ies that have previously been occluded by 
means of foam sclerotherapy, rFA or 
eVlA.20,21 However, unlike redo surgery 
which is technically demanding and often 
associated with disappointing outcomes, 
such recanalisation can be successfully 
treated as an out-patient and so poses no 
real clinical difficulty.19
CellulAr And MoleCulAr 
BIoloGy oF VArICoSe VeInS
the molecular biology of varicose veins 
has recently been reviewed. the aetiology 
of varicose veins is undoubtedly multi-
factorial. there are some genetic disorders 
and mutations that predispose to venous 
incompetence and development of vari-
cosities (FoXC2, notCH3). However 
these diseases are rare whilst varicose veins 
are common.
In recent years there has been much 
research to define the structural and molecu-
lar events that accompany the formation 
of varicose veins, with an overall underly-
ing hypothesis that varicose vein formation 
is most likely due to a structural, cellular 
or molecular abnormality within the vein 
wall. on a gross level, varicose veins exhibit 
intimal hyperplastic areas and underly-
ing plaques with infiltration of leukocytes 
and mast cells. there is fragmentation of 
elastin fibres and the total content of elas-
tin and type III collagen is reduced. these 
extra cellular matrix abnormalities may be 
regulated by disordered MMP and tIMP 
production.
Cell types within the varicose vein may 
show disordered function with endothelial 
activation leading to vasodilatation and a 
possible loss of venous tone. Many of the 
smooth muscle cells in the varicose vessel wall 
exhibit a synthetic rather than a contractile 
phenotype, and appear to have reduced rates 
of apoptosis. these cells may have a reduced 
capacity for contraction, which may exacer-
bate the vasodilatory tendency. the stimuli 
for the disordered function demonstrated by 
these intrinsic cells remains ill defined, but 
hypoxic stress and low shear stress may play 
a role.
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there is certain to be further research 
in the next few years to further define the 
vascular biology of varicose veins. there has 
been some suggestion that this may lead to a 
medical therapy for varicose veins, although 
the practicality of this is not immediately 
apparent. nevertheless research into the 
molecular aetiology of varicose veins will 
continue to define vascular pathways.22
ConCluSIon
despite the very large numbers of patients 
affected by CVI and VV, research into 
venous disease is generally given low priority 
and so there are still significant gaps in our 
knowledge. Further work is needed if we 
are to improve our understanding of the 
aetiology of the disease and improve 
the results of treatment.
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chronic venous insufficiency (cVi) is a term 
that is used to describe changes in the leg 
that include a variety of different clinical 
problems, which are caused by several types 
of abnormalities in the veins, and which may 
occur at a number of different locations in 
the leg.1 For these reasons it has been difficult 
to make accurate comparisons of reports of 
chronic venous insufficiency from different 
institutions. as a result attempts have been 
made to formulate systems of classification 
that enable accurate comparisons to be 
made.
the most recent classification, referred 
to as the ceaP classification, was devised 
by an international panel and encompasses 
features of some of the earlier classifica­
tions.2 this classification has four categor­
ies which include – clinical (c), etiology 
(e), anatomy (a) and Pathophysiology (P). 
Within each category the different levels 
are each given a number or a letter or both. 
the clinical classification has seven levels 
from no visible or palpable signs of venous 
disease through to skin changes with active 
ulceration (table 25.1). in addition the 
Clinical categories are further character­
ized according to the presence or absence 
of symptoms. the Etiological classification 





) and secondary (e
s
) causes in venous dys­
function. the Anatomical classification can 
be represented as a simple or more detailed 
form. the simple form refers to the site at 





) or perforating (a
p
). the more 
detailed form identifies the specific veins that 
are involved and has 18 segments that can 
be identified. the Pathophysiologic classifica­
tion identifies the cause of venous dysfunc­
tion being either reflux (P
R
) or obstruction 
(P
o
), or both (P
Ro
). this classification can be 
used in part or in whole when describing the 
patients in a published report.
Leg Ulceration
leg ulceration may occur as a result of many 
different aetiological factors (table 25.2). 
For patients presenting with an ulcer on the 
leg it is imperative to determine the aetiology 
since the treatment may differ according to 
the cause. For ulcers on the leg, not including 
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the foot, the commonest aetiology is chronic 
venous disease either alone or in common 
with another cause of impaired healing such 
as arterial disease, diabetes or rheumatoid 
arthritis. the venous abnormality that 
leads to venous leg ulceration may involve 
abnormalities at different locations in the 
venous system, of different extent and 
different aetiologies. 
Assessment of Cause of Leg Ulceration
in order to determine the aetiology of a leg 
ulcer, a standardized assessment is strongly 
recommended.3 that assessment should 
consist of the following
1) history – to determine the presence of 
other known diseases that might result 
in an impairment of the healing process. 
these include disease processes listed in 
table 25.2.
2) examination –
a. General examination to assess for 
evidence of diseases in table 25.2




iii. examination of the ulcer, specif­
ically documenting 
1. location
a. Gaiter region – likely 
venous
b. More proximal on the leg 
– consider other aetiologies
c. Foot – not commonly 
venous aetiology 
2. Skin surrounding the ulcer
a. lipodermatosclerosis – 
venous disease
b. atrophie blanche – venous 
disease or vasculitis
c. atrophic skin changes – 
arterial
Class Definition
0 No visible or palpable signs of venous disease
1 Telangiectases or reticular veins
2 Varicose veins
3 Oedema
4 Skin changes ascribed to venous disease (e.g. pigmentation, eczema, 
lipodermatosclerosis)
5 Skin changes as above in conjunction with healed ulceration
6 Skin changes as above in conjunction with active ulceration
Table 25.1: Clinical classification of chronic venous disease of the lower extremity. 
The presence or absence of symptoms is denoted by the addition of ‘s’ for 











Table 25.2: Commonest causes of leg 
ulceration. 
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d. normal skin – consider 
other aetiologies
3. Ulcer edge
a. Raised – neoplastic
b. Punched out – arterial
c. Undermined – infective
d. Sloping – venous
e. Dusky – vascilitis, 
pyoderma grangenosum
4. Ulcer base 
a. necrotic tissue – arterial; 
large or small vessel disease
b. Granulating – multiple 
aetiologies including 
venous
c. Fibrotic slough – venous, 
multiple aetiologies
3) investigations
a. ankle: brachial Doppler arterial 
pressure index
b. confirmation of venous disease
i. Venous plethysmography
ii. Venous duplex scan to assess for 
sites of venous reflux
iii. Blood tests – anemia, renal failure, 
liver failure, diabetes, vasculitis
iv. Ulcer biopsy – if suspicious 
appearance or if not responding to 
adequate compression therapy
Epidemiology
a number of epidemiological studies of leg 
ulceration have been conducted in different 
Western countries and have found a similar 
prevalence of leg ulceration ranging from 
0.11% to 0.18% of the population.4­8 these 
studies have confirmed that chronic venous 
disease is the commonest cause, representing 
approximately 65% of ulcers on the leg. these 
occur most commonly in elderly people with 
a mean age in excess of 65 years. there are 
nearly twice as many women as men with 
leg ulcers, however, when these are related to 
age, the prevalence for males and females is 
similar because there are more women than 
men in the older age groups.4 
an australian epidemiological study 
found that venous ulcers are associated with 
delayed healing (with a median duration of 




the basic underlying physiological abnormal­
ity in chronic venous disease is altered return 
of blood in the veins of the leg, which results 
in ambulatory venous hypertension in the 
superficial veins.9 When venous pressures 
are measured in the surface veins in the foot 
or ankle, the pressure is normally highest 
(approximately 100mmhg) when standing 
immobile, and drops to 30 to 40mmhg when 
walking (Figure 25.1). this occurs because 
the ‘calf muscle pump’ assists the return of 
blood from the leg by compression of the 
deeper veins during muscle contraction. 
When the muscles relax, the emptied deeper 
veins have a lower pressure which allows 
more blood to flow into them from the 
surface veins, thereby reducing the pressure 
in those veins (Figure 25.2).
in patients with chronic venous insuffi­
ciency the pressure in the surface veins drops 
only a small amount, hence the term ‘ambu­
latory’ venous hypertension (Figure 25.1). 
an increase in the pressure in the surface 
veins above that present on standing is very 
uncommon, and only occurs when there is 
extensive proximal venous occlusion. the 
failure to reduce superficial venous pres­
sure on exercise occurs when there is reflux 
in either the deep veins or the surface veins. 
Reflux in the deep veins results in rapid refill­
ing of the deep veins when the calf muscles 
relax (Figure 25.3). this results in only a 
small increase in the amount of blood that 
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Figure 25.1: Superficial venous pressures in normal legs and legs with chronic venous disease.
Figure 25.2: Pressure in the deep and superficial veins in a normal leg after calf muscle contraction.
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flows from the surface veins into the deep 
veins. if the reflux is primarily in the super­
ficial veins, the superficial veins refill quickly 
and the ambulatory venous pressure remains 
elevated even though more blood may be 
flowing into the deep veins.10
Reflux in veins is caused either by destruc­
tion of the valves when a venous thrombo­
sis recanalizes, or by primary incompetence 
of the valves. the relative proportions of 
the two causes in the deep veins remain a 
point of debate. Definite evidence of previ­
ous deep vein thrombosis has been reported 
in 40 –50% of patients with venous ulcer­
ation.10,11 in chronic venous insufficiency 
the venous reflux may involve the deep veins 
or may involve only the surface and perfor­
ating veins. involvement of the deep veins 
has also been variously reported at between 
40 and 90%.11,12 the major reason for this 
variation in reporting is the use of different 
techniques for assessing the deep veins. the 
rate of deep vein involvement was reported 
at higher rates when the standard method 
of assessing veins was venography.11 Duplex 
scanning has now become the major method 
for assessing veins, and the quoted rates of 
deep vein involvement have dropped.12 this 
possibly relates to the difficulty in visualizing 




the obvious clinical finding in cVi is the 
pigmentation and fibrosis that occurs in the 
skin in the gaiter region of the leg, referred 
to as lipodermatosclerosis (Figure 25.4). 
histologically there is also an increase in 
the extent of the capillary bed in the skin, 
although there is some debate as to whether 
the capillaries are all perfused.13,14 this is 
particularly the case in areas of atrophie 
blanche (white atrophy) in which there 
are tufts of capillaries interspersed within 
Figure 25.3: Pressure in the deep and superficial veins in a leg with chronic venous disease after contraction 
of the calf muscle.
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relatively avascular skin (Figure 25.5). this 
condition is common in venous ulceration, 
but may also be present in other conditions 
such as vasculitis.15
a number of hypotheses have been pro­
posed over the years to try and explain how 
ambulatory venous hypertension affects the 
tissues and thereby leads to impaired heal­
ing. it has generally been acknowledged 
that there must be some impairment to 
the nutrition to the skin cells either due 
to reduced nutrients or reduced oxygen­
ation. to date such reduced skin nutrition 
has not been conclusively demonstrated. 
Many studies have shown reduced transcu­
taneous oxygen measurements,14 however 
because of the change to the structure of the 
skin this may not be an accurate reflection 
of tissue oxygenation.
theories that have been proposed to 
support the concept of reduced nutrition 
to the skin are arteriovenous shunting,16 the 
Figure 25.5: Atrophie blanche in a leg with chronic venous disease.
Figure 25.4: Lipodermatosclerosis and ulceration in a leg with chronic venous disease.
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presence of a diffusion barrier to oxygen 
by fibrin and other proteins that deposit 
around skin capillaries,17 and the occlusion 
of capillaries by activated white cells becom­
ing ‘trapped’ in the capillary bed.18 other 
theories have hypothesized that growth fact­
ors are trapped in the pericapillary protein 
deposits which therefore impedes the healing 
process (Figure 25.6).19 localised reperfusion 
injury has also been hypothesized in associa­
tion with intermittent periods of ambulatory 
venous hypertension and lower venous pres­
sures.20 other hypotheses have focused on 
the presence of factors that directly damage 
the tissue by activation of white cells which 
subsequently release factors such as cyto­
kines, proteases and oxygen free radicals that 
can impede healing.21,22 to date there is no 
conclusive support for any given hypothesis, 
although the presence of an excessive inflam­
matory response has been repeatedly demon­
strated in venous ulcers.
Influence of Venous Disease on the 
Wound Healing Process
the cause of impaired healing in venous 
ulceration remains uncertain. this is in 
spite of the clinical observation that non­
healing venous ulcers begin to heal once 
patients are admitted to hospital for bed 
rest. efforts are continuing to try and 
determine what is occurring at a cellular 
and molecular level to impede the healing 
process. these have demonstrated a highly 
inflammatory environment with high levels 
of inflammatory cytokines, proteases and 
large numbers of immune cells.22­24 the 
proteases that are elevated in venous ulcers 
compared to acute wounds include matrix 
metalloprotease­2 and ­9 (MMP­2 and 9) 
(Figure 25.7) and collagenases (Figure 25.8). 
it is possible that this highly inflammatory 
environment may result in destruction of 
factors that are important in the normal 
healing process. these factors may include 
growth factors, cell surface receptors, the 
matrix in the base of the wound and cellular 
adhesion molecules.
Bacteria that colonise open wounds 
may contribute to the increased inflamma­
tory wound environment. no clear link has 
been shown between the presence of bac­
teria and healing ability in venous ulcers.25,26 
Bacteria are known to form biofilms which 
consist of a matrix that is secreted by the 
Figure 25.6: Pericapillary deposit of protein – fibrinogen.
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bacteria which enables the bacteria to persist 
in an environment in which they are pro­
tected from the body’s defense mechanisms. 
the underlying causes of venous ulcer­
ation may affect both the ability to develop 
ulcers and the ability to heal ulcers; however, 
it is likely that additional factors will contrib­
ute to the impaired healing process once an 
ulcer has occurred. Further understanding of 
the factors that impede the healing process 
may lead to better treatments to improve 
ulcer healing.
Genetic Associations with Venous 
Ulceration
a number of research groups have now 
demonstrated that genetic polymorphisms 
are associated with the development of 
venous ulceration. Working independently, 
groups have demonstrated that the following 
polymorphisms to be associated with venous 
ulceration – tumour necrosis factor alpha 308 
(a regulatory polymorphism),27 fibroblast 
growth factor receptor type 2,28 oestrogen 
receptor beta29 and haemochromatosis 
Figure 25.7: Matrix metalloprotease levels in wound fluid from acute and chronic wounds.
Figure 25.8: Collagenase levels in wound fluid from chronic venous ulcers.
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factor.30 there is also a suggestion that a 
polymorphism in coagulation factor Xiii 
may be associated with delayed healing of 
venous ulceration following venous surgery.31 
all of these studies have been performed on 
relatively small samples sizes and do require 
further confirmation in larger samples sizes. 
it is likely that a number of genetic factors 
will ultimately be shown to be associated 
with the ability to heal wounds.
aSSeSSMent oF VenoUS 
FUnction
in patients with venous ulceration, the 
history and clinical signs on the leg will 
give a strong indication of the presence of 
venous disease. When surgical treatment is 
to be considered it is imperative to have a 
clear outline of the veins with reflux and 
the presence of venous obstruction. if the 
deep veins are involved, the benefits of 
operating on surface and or perforating 
veins are limited and appear to be dependent 
on the extent of the venous reflux.32,33 the 
commonest current method that is used to 
assess for sites of incompetence is Duplex 
scanning. Venography and imaging with 
contrast ct scan or MR venography are 
used infrequently and usually only when 
there is uncertainty about the information 
from the Duplex scan. other methods 
of diagnosing venous disease such as 
plethysmography and hand held Doppler 
do not give a good indication of the sites 
of venous incompetence.34,35 When perform­
ing a Duplex scan for chronic venous 
disease, the deep veins, superficial veins, 
and the communicating veins should all be 
evaluated.
tReatMent oF VenoUS 
UlceRation
the objective of the treatment of venous 
ulceration is to improve the physiological 
abnormality of ambulatory venous hyper­
tension. the two methods available are 
compression therapy applied to the leg 
or direct treatment of the veins by surgery 
or other ablative techniques such as sclero­
therapy, laser or radiofrequency ablation.36 
there are also ongoing studies to identify 
topical and systemic therapies that will have 
a direct influence on improve the healing 
process in the ulcers. the only such therapy 
that has been used in clinical practice in some 
parts of the world is topical platelet derived 
growth factor.37
Compression Therapy
compression applied to the leg improves 
the venous return in the leg, primarily by 
reducing venous reflux into the leg and also 
by reducing the leg volume.38 compression 
bandages have also been shown to significantly 
improve the time taken to heal venous 
ulcers.39 this reduces oedema in the leg that 
is considered to impede the healing process. 
the compression is applied to the leg below 
the knee from the base of the toes to just 
below the knee, and the level of compression 
that is recommended is to achieve a pressure 
of between 25 and 45mmhg at the ankle 
with a graduated reduction in pressure up 
the leg. the compression may be applied by 
either bandages or by compression stockings. 
in patients with an open ulcer, bandages 
are normally preferred because the exudate 
damages the stockings and shortens their 
lifespan.
there are many different types of bandage 
systems that have been employed for venous 
ulcers. Most benefit has been shown to 
occur with systems that are multilayered.39,40 
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the first layer consists of orthopaedic wool 
or similar padding that is placed beneath a 
plaster cast. this is to help protect the skin 
overlying bony prominences from excessive 
pressure. the next one or preferably two 
layers are the compression bandages that 
may be elastic or inelastic or a combina­
tion of the two. the top layer is one to help 
prevent slippage of the bandage. this may 
be a bandage that adheres to itself or a tubu­
lar stockingette. to date no difference has 
been shown in the efficacy of inelastic (short 
stretch) or elastic bandages (long stretch), 
as long as these are used as part of a multi­
layered system.
if a compression stocking is used this 
should be either class 2 (25–35mmhg at the 
ankle) or class 3 (35–45mmhg), and should 
aim to provide graduated compression. these 
come in a variety of sizes and should be fit­
ted to the individual’s leg. they come with 
and without zippers on one side that help 
with applying and removing the stocking. 
Patients with small or very large legs may 
need to have stockings custom made to fit 
their legs. Stockings can be difficult to both 
apply and to remove, particularly in patients 
with arthritis or in frail patients. to assist 
with application there are frames onto which 
the stockings can be placed and into which 
the patient then places their foot. Stockings 
are often useful in younger patients who 
have active jobs and for whom wearing bulky 
bandages is difficult.
Dressings
the dressing applied to the ulcer may be 
chosen from any that are available. no 
dressing, including those dressings containing 
silver and other topical antibacterial agents, 
have been shown to have a direct effect on 
improving the healing process.41 Dressings 
are chosen according the needs of the 
patient and their wound. Different dressings 
may be chosen to absorb exudate, reduce 
pain, help liquefy slough, reduce bacterial 
contamination, reduce odour from the 
wound, or to protect the surrounding skin 
from maceration. the cost of the dressing 
also needs to be considered when making 
a selection. For patients who are using 
stockings a dressing that adheres to the skin 
is preferable as this aids with applying the 
stocking over it.
the dressings and compression may be 
left on the leg and for up to one week and 
even longer in cooler climates. commonly 
however, the bandages and dressings may be 
changed anything from daily to weekly. the 
main determinants of the duration of appli­
cation are the amount of exudate, the state of 
the wound and odour from the bandages.
Surgery
Surgery to the veins in the lower leg may 
include procedures on the superficial 
varicose veins, incompetent communicating 
veins or the deep veins in the leg. Surgery to 
the superficial veins includes surgery to the 
long and/or short saphenous vein by ligation 
and stripping, together with avulsion of 
varicosities.33,42 incompetent communicating 
veins can be accurately located by Duplex 
scanning and may be approached directly by 
a small incision over the site and subfascial 
ligation. in order to avoid making incisions 
through areas of lipodermatosclerosis or 
ulceration, the perforators in the lower leg 
may be treated by subfascial endoscopic 
perforator surgery (SePS) (Figure 25.9).43 
the deep veins may be treated by direct 
repair of intact but incompetent valves. the 
repair may be directly by suture44,45 or may 
involve applying a cuff around the valve 
to reduce the diameter of the vein and to 
restore competence.46 Veins that have had 
previous venous thrombosis and which have 
recanalised with destruction of the valve can 
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have a segment of vein containing competent 
valves taken from the arm and inserted to 
replace a segment of the femoral or popliteal 
vein.47
the roles of a number of these opera­
tions in patients with venous ulcers has in 
part been clarified by recent clinical trials 
and reviews of published data.32,33 the 
benefits of surgery to the deep veins for 
patients with open or healed venous ulcers 
remain unproven and should be confined to 
studies assessing their efficacy rather than 
be used in routine clinical practice. Surgery 
to the superficial veins in combination with 
compression does not result in any improve­
ment in venous ulcer healing compared to 
compression therapy alone.32 however, sur­
gery to the superficial veins in combination 
with compression does result in a significant 
reduction in venous ulcer recurrence. indi­
viduals who are most likely to benefit from 
surgery to the superficial venous system are 
those with superficial venous incompetence 
and no deep incompetence or in patients 
with superficial incompetence and segmen­
tal deep incompetence. in both groups of 
patients there is a significant reduction in 
ulcer recurrence compared to compression 
Figure 25.9: Subfascial endoscopic perforator surgery – instruments in position and clip on a perforator.
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therapy alone. For patients with extensive 
deep vein incompetence, there was not a 
significant reduction in the rate of ulcer 
recurrence.32,33,42
the need to treat incompetent com­
municating veins at the same time as treat­
ing superficial veins remains uncertain.42 
Studies on patients with superficial venous 
incompetence and incompetent communic­
ating veins, but without deep vein abnorm­
alities, have indicated that in a majority of 
patients, the communicating veins cease to 
be incompetent after the superficial veins are 
ablated.48,49 another study has indicated that 
in the presence of deep vein reflux, ablation 
of superficial veins does not result in a return 
to competence in incompetent communic­
ating veins.50
anecdotal reports have suggested that 
operating on the superficial and perforating 
veins does improve the healing of venous 
ulcers. Randomised controlled trials have 
however, shown no improvement in venous 
ulcer healing when surgery is combined with 
compression bandaging compared to com­
pression bandaging alone.32,51 however, in 
patients who are not responding to optimal 
compression therapy and who have no or 
minimal reflux in the deep veins, the author’s 
anecdotal experience is that surgery to the 
superficial and perforating veins does result 
in an active healing process. in addition, in 
patients with very painful ulcers, this surgery 
appears to reduce their level of pain. it is still 
important to continue the compression after 
the surgery.
Surgery to correct venous obstruction has 
included vein bypass, transposition of a vein 
to bypass an obstruction,52 or balloon dila­
tation with stenting.53 the efficacy of these 
procedures remains uncertain due to the 
infrequency with which they are performed, 




once an ulcer has healed continued treatment 
should be implemented to help reduce the 
risk of ulcer recurrence. the simplest method 
is to use compression stockings.54 these have 
been shown to significantly prolong the time 
before venous ulcers recur, however, they 
do not remove the risk completely. the 
stockings that are used are class 3, however, it 
is generally considered that class 2 stockings 
will have a similar benefit.
Surgery to the leg veins in patients with 
venous ulcers is most commonly used to 
reduce the risk of ulcer recurrence. this sur­
gery is usually performed after ulcers have 
healed, to prevent the potential for wound 
contamination and infection from an open 
ulcer. as indicated above the only form 
of surgery that is used in routine practice 
is surgery to the surface and/or perforat­
ing veins. the benefits of this surgery are 
greatest in patients who have no evidence of 




techniques other than surgery have been 
used to treat varicose veins and incompet­
ent perforating veins. these include sclero­
therapy,55 ultrasound guided sclerotherapy to 
incompetent perforating veins and saphenous 
veins,56 and laser or radiofrequency ablation of 
the long saphenous vein.57 these techniques 
have not been specifically evaluated in 
the treatment of venous ulceration or the 
prevention of ulcer recurrence. it is likely 
that the benefit with these treatments 
would be commensurate with their efficacy 
in obliterating the appropriate veins 
compared to that achieved with the surgical 
techniques.
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Other Therapies
the use of other systemic or topical therapies 
is an area in which there is ongoing research. 
Many different therapies have been evaluated; 
however, to date no single therapy has been 
shown to be of sufficient benefit to be used 
in routine clinical practice. therapies that 
have or are being assessed include aspirin, 
oxpentifylline, platelet lysate or releasate, a 
number of different recombinant growth 
factors, growth factors derived from bovine 
whey, protease inhibitors, topical antibacterial 
preparations or dressings, systemic or 
topical antibacterials, and various vasoactive 
preparations.58 there is some evidence that 
oxpentifylline does improve ulcer healing.59 
other topical methods include ultrasound, 
magnetic therapy, ultraviolet light, electrical 
stimulation, and topical laser therapy.60 
to date there is no convincing evidence to 
support the efficacy of any of these therapies. 
Many therapies that have been proposed to 
aid venous ulcer healing have been selected 
on theoretical grounds rather than detailed 
knowledge of the cellular and molecular 
abnormalities that result in venous ulcers 
forming and that impede their healing. 
there is a need to better understand these 
processes so that this knowledge can be 
used to help identify improved methods for 
treating venous ulcers. 
ReFeRenceS
1. Stacey Mc. investigation and 
treatment of chronic venous ulcer 
disease. ANZ J Surg 2001; 71:  
226–229
2. eklof B, Rutherford RB, Bergen JJ, 
carpenter Ph, Gloviczki P,  
Kistner Rl, et al. Revision of the 
ceaP classification for chronic venous 
disorders: consensus statement. J Vasc 
Surg 2004; 40: 1248–52.
 3. Scottish intercollegiate Guidelines 
network (SiGn). Management of 
chronic venous ulcers. a national 
clinical guideline. SiGn: edinburgh, 
2010.
 4. Baker SR, Stacey Mc, Jopp­McKay aG, 
et al. epidemiology of chronic venous 
ulcers. Br J Surg 1991; 78: 864–7.
 5. callam MJ, harper DR, Dale JJ, 
Ruckley cV. chronic ulcer of the leg: 
clinical history. Br Med J 1987; 294: 
1389–91.
 6. nelzen o, Bergqvist D, lindhagen a,  
halbook t. chronic leg ulcers: an 
underestimated problem in primary 
health care among elderly patients.  
J Epidemiol Commun Health 1991; 45: 
184–7.
 7. cornwall JV, Dore cJ, lewis JD. leg 
ulcers: epidemiology and aetiology. Br J 
Surg 1986; 73: 693–96.
 8. Moffatt cJ, Franks PJ, Doherty Dc,  
Martin R, Blewett R, Ross F. 
Prevalence of leg ulceration in a 
london population. QJ Med 2004; 97: 
431–7.
 9. Browse nl, Burnand KG,  
lea­thomas M. Diseases of the Veins. 
london: edward arnold, 1988.
10. christopoulos D, nicolaides an, 
cook a, irvine a, Galloway JMD, 
Wilkinson a. Pathogenesis of venous 
ulceration in relation to the calf muscle 
pump function. Surgery 1989; 106: 
829–35.
11. lea­thomas M. Phlebography of the 
lower limb. edinburgh: churchill­ 
livingstone, 1982.
12. Van Rij aM, Solomon c, christie R.  
anatomic and physiologic 
characteristics of venous ulceration.  
J Vasc Surg 1994; 20: 759–64.
13. lascasas­Porto cl, Milhomens al, 
Virgini­Magalhaes ce, Fernandes FF,  
Sicuro Fl, Bouskela e. Use of 
Mechanisms of Vascular Disease472
microcirculatory parameters to evaluate 
clinical treatments of chronic venous 
disorder (cVD). Microvascular Research 
2008; 76: 66–72.
14. Junger M, Steins a, hahn M,  
hafner h­M. Microcirculatory 
dysfunction in chronic venous 
insufficiency (cVi). Microcirculation 
2000; 7: S3–12.
15. Burnand KG, Whimster i, naidoo a, 
Browse nl. Pericapillary fibrin in the 
ulcer bearing skin of the leg: the cause 
of lipodermatosclerosis and venous 
ulceration. Br Med J 1982; 1: 478–81.
16. Brewer ac. Varicose ulceration, 
arteriovenous shunts. Br Med J 1950; 
2: 269–70.
17. Browse nl, Burnand KG. the cause 
of venous ulceration. Lancet 1982; 2: 
243–5.
18. thomas P, nash G, Dormandy D.  
White cell accumulation in 
dependent leg of patients with venous 
hypertension: a possible mechanism for 
trophic changes in the skin. Br Med J 
1988; 296: 1693–5.
19. Falanga V, eaglstein W. the trap 
‘hypothesis’ of venous ulceration. 
Lancet 1993; 341: 1006–7. 
20. Greenwood Je, edwards at, 
Mccollum cn. the possible role 
of ischaemia­reperfusion in the 
pathogenesis of chronic venous 
ulceration. Wounds 1995; 7: 211–9.
21. Bucalo B, eaglstein W, Falanga V. 
inhibition of cell proliferation by 
chronic wound fluid. Wound Rep Reg 
1993; 1: 181–6.
22. trengove nJ, Bielefeldt­ohmann h, 
Stacey Mc. Mitogenic activity and 
cytokine levels in non­healing and 
healing chronic leg ulcers. Wound Rep 
Reg 2000; 8: 13–25.
23. trengove nJ, Stacey Mc, Macauley S, 
Bennett n, Gibson J, et al. analysis  
of the acute and chronic wound 
environments: the role of proteases and 
their inhibitors. Wound Rep Reg 1999; 
7: 442–52. 
24. Stacey Mc, lainez S,  
Skender­Kalnenas t, Morrison B. 
alterations in immune cells in human 
chronic leg ulcers. Phlebology 1995; 
Suppl 1: 923–5.
25. trengove nJ, Stacey Mc,  
McGechie DF, Stingemore nF,  
Mata S. Qualitative bacteriology and 
leg ulcer healing. J Wound Care 1996; 
5: 277–80.
26. Moore K, huddleston e, Stacey Mc, 
hardung KG. Venous leg ulcers – the 
search for a prognostic indicator. 
International Wound Journal 2007; 4: 
163–72.
27. Wallace hJ, Vandongen y, Stacey Mc.  
tumour necrosis factor alpha gene 
polymorphism associated with 
increased susceptibility to venous leg 
ulceration. Journal Invest Dermatol 
2006; 126: 923–6.
28. nagy n, Szolnoky G, Szabad G,  
Bata­csorgo Z, Dobozy a, Kemeny l, 
et al. Single nucleotide polymorphisms 
of the fibroflast growth factor  
receptor 2 gene in patients with 
chronic venous insufficiency with leg 
ulcer. Journal Invest Dermatol 2005; 
124: 1085–8.
29. ashworth JJ, Smyth JV, Pendleton n, 
horan M, Payton a, Worthington J, 
et al. Polymorphisms spanning the on 
exon and promoter of the estrogen 
receptor­beta gene esr2 are associated 
with venous ulceration. Clinical 
Genetics 2008; 73: 55–61.
30. Zamboni P, tognazzo S, izzo M, 
Pancaldi F, Scapoli Gl, liboni a, 
et al. hemochromatosis c282y gene 
mutation increases the risk of venous 
leg ulceration. J Vasc Surg 2005; 42: 
309–14.
Chronic Venous Insufficiency and Leg Ulceration 473
31. Gemmati D, tognazzo S, catozzi l, 
Federici F, De Palma M, Gianesini S, 
et al. influence of gene polymorphisms 
in ulcer healing process after superficial 
venous surgery. J Vasc Surg 2006; 44: 
554–62.
32. Gohel MS, Barwell JR, taylor M, 
chant t, Foy c, earnshaw JJ et al. 
long term results of compression 
therapy alone versus compression 
therapy plus surgery in chronic venous 
ulceration (eSchaR): randomized 
controlled trial. BMJ 2007; 335: 83–7.
33. howard DPJ, howard a, Kothari a, 
Wales l, Guest M, Davies ah. the 
role of superficial venous surgery in 
the management of venous ulcers; a 
systematic review. Eur J Vasc Endovasc 
Surg 2008; 36: 458–65.
34. hoare Mc, Royle JP. Doppler 
ultrasound detection of saphenofemoral 
and saphenopopliteal incompetence 
and operative venography to ensure 
precise saphenopopliteal ligation. ANZ 
J Surg 1984; 54: 49–52.
35. abramowitz hB, Queral la, 
Flinn WR, et al. the use of 
photoplethysmography in the 
assessment of venous insufficiency: 
a comparison to venous pressure 
measurement. Surgery 1979; 86:  
434–41.
36. Stirling M, Shortell cK. endovascular 
treatment of varicose veins. Semin Vasc 
Surg 2006; 19: 109–15.
37. Wieman tJ. efficacy and safety of 
recombinant human platelet­derived 
growth factor­BB (Becalpermin) in 
patients with chronic venous ulcers: a 
pilot study. Wounds 2003; 15: 8–12.
38. yang D, Vandongen yK, Stacey Mc. 
the influence of minimal­stretch and 
elasticated bandages on calf muscle 
pump in patients with chronic venous 
disease. Phlebology 1999; 14: 3–8.
39. o’Meara S, cullum na, nelson ea. 
compression for venous leg ulcers. 
cochrane Database of Systematic 
Reviews 2009, issue 1. art. no.: 
cD000265. Doi: 10.1002/14651858.
cD000265.pub2
40. Stacey M, Falanga V, Marston W,  
Moffatt c, Phillips t, et al. 
compression therapy in the treatment 
of venous leg ulcers: a recommended 
management pathway. EWMA J 2002; 
2: 9–13.
41. Palfreyman SSJ, nelson ea, lochiel R,  
Michaels Ja, Dressings for healing 
venous leg ulcers. cochrane Database 
of Systematic Reviews 2006, issue 3.  
art. no.: cD001103. Doi: 
10.1002/14651858.cD001103.pub2
42. o’Donnell tF. the present status 
of surgery of the superficial venous 
system in the management of venous 
ulcer and the evidence for the role of 
perforator interruption. J Vasc Surg 
2008; 48: 1044–52.
43. Jugenheimer M, Junginger t. 
endoscopic subfascial sectioning of 
incompetent perforating veins in 
treatment of primary varicosis. World J 
Surg 1992; 16: 971–95.
44. Kistner Rl. Surgical repair of the 
incompetent femoral vein valve. Arch 
Surg 1975; 110: 1336–41.
45. Raju S, Fredericks R. Valve 
reconstruction procedures for non­
obstructive venous insufficiency: 
Rationale, technique and results in 
107 procedures with two to eight year 
follow up. J Vasc Surg 1988; 7: 301–9.
46. Jessup G, lane Rl. Repair of 
incompetent venous valves: a new 
technique. J Vasc Surg 1988; 8: 569–75.
47. nash tP. Venous ulceration: Factors 
influencing recurrence after standard 
surgical procedures. Med J Aust 1991; 
154: 48–50.
Mechanisms of Vascular Disease474
48. Sales cM, Bilof Ml, Petrillo Ka,  
luka nl. correction of lower 
extremity deep venous incompetence 
by ablation of superficial venous reflux. 
Ann Vasc Surg 1996; 10: 186–9.
49. Walsh Jc, Bergan JJ, Beeman S, 
comer tP. Femoral venous reflux 
abolished by greater saphenous vein 
stripping. Ann Vasc Surg 1994; 8:  
566–70. 
50. Stuart WP, adam DJ, allan Pl, 
Ruckley cV, Bradbury aW. Saphenous 
surgery does not correct perforator 
incompetence in the presence of deep 
venous reflux. J Vasc Surg 1998; 28: 
834–8.
51. Guest M, Smith JJ, tripuraneni G,  
howard a, Madden P, et al. 
Randomised clinical trial of varicose 
vein surgery with compression versus 
compression alone for the treatment of 
venous ulceration. Phlebology 2003; 19: 
130–6.
52. husni ea. Reconstruction of veins: 
the need for objectivity. J Cardiovasc 
Surg 1983; 24: 525–8.
53. Blattler W, Blattler iK. Relief of 
obstructive pelvic venous symptoms 
with endoluminal stenting. J Vasc Surg 
1999; 29: 484–8.
54. Vandongen yK, Stacey Mc. Graduated 
compression elastic stockings reduce 
lipodermatosclerosis and ulcer 
recurrence. Phlebology 2000; 15: 33–7.
55. Fegan Wa. the treatment of varicose 
veins during pregnancy. Pacif Med Surg 
1964; 72: 274–9.
56. Kanter a, thibault P. Saphenofemoral 
incompetence treated by ultrasound 
guided sclerotherapy. Dermatol Surg 
1996; 22: 668–72.
57. Fassiadis n, Kianifard B,  
holdstock JM, Whiteley MS. a novel 
endoluminal technique for varicose 
vein management: the VnUS closure. 
Phlebology 2002; 16: 145–8. 
58. Robson MR, cooper DM, aslam R, 
Gould lJ, harding KG, Margolis DJ, 
et al. Guidelines for the treatment of 
venous ulcers. Wound Rep Reg 2006; 
14: 649–62.
59. Jull aB, arroll B, Parag V, Waters J.  
Pentoxifylline for treating venous 
leg ulcers. cochrane Database of 
Systematic Reviews 2007, issue 3.  
art. no.: cD001733. Doi: 
10.1002/14651858.cD001733.pub2
60. Flemming K, cullum na. laser 
therapy for venous leg ulcers. cochrane 
Database of Systematic Reviews 1999, 
issue 1. art. no.: cD001182. Doi: 
10.1002/14651828. cD001182.
475
26  •   Pathophysiology and Principles of  
Management of the Diabetic Foot
1DaviD G. armstronG, 2timothy K. Fisher,  
1Brian Lepow, 4matthew L. white, 1,4Joseph L. miLLs.
1the University of arizona, southern arizona Limb salvage alliance 
(saLsa), tucson, arizona, Usa
2rashid Centre for Diabetes and research, sheikh Khalifa hospital, 
ajman, Uae
3vascular and endovascular surgery, University of arizona, tucson,  
arizona, Usa
introDUCtion
the incidence of diabetes continues to grow 
at a staggering pace. the United states’ 
Centers for Disease Control and prevention 
estimate that 23.6 million people or 7.8% 
of the U.s. population has diabetes, with 
1.6 million new cases being diagnosed 
each year.1,2 these figures are even more 
astonishing when one considers worldwide 
estimates. Close to 4 million deaths in the 
20–79 year old age group may be attributed 
to diabetes in 2010, accounting for 6.8% 
of global all-cause mortality in this age 
group.3 the number of people with diabetes 
worldwide is expected to reach 366 million 
people by 2030, more than double the 
estimated 177 million people affected with 
the disease in 2000.2 the increased disease 
prevalence is accompanied by an increase 
in associated comorbidities. the literature 
estimates that patients with diabetes have 
nearly a 25% lifetime risk of developing 
a foot ulcer with more than 50% of these 
ulcers becoming infected and requiring 
hospitalization.4 in fact, at least 20% of 
all diabetes-related hospital admissions are 
due to diabetic foot ulcers. associated with 
foot ulcers and infection is the incidence 
of amputation. it has been conservatively 
reported that, worldwide, a major amputation 
takes place every 30 seconds with over 2500 
limbs lost per day.5 at least 60% of all non-
traumatic lower extremity amputations are 
related to complications of diabetes.1 people 
with diabetes who have had one amputation 
have a 68% risk of having another in the 
next 5 years and have a 50% mortality rate in 
the 5 years following the initial amputation.6 
it is estimated that up to 85% of diabetic 
foot-related amputations could be prevented 
through prompt intervention and with 
centers directed at educating individuals 
about proper foot care.
the economic impacts on the patient, 
national healthcare system and economy 
also impose a great burden. healthcare 
expenditures on diabetes are expected to 
account for 11.6% of the total healthcare 
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expenditure in the world in 2010.3 the 
estimated global costs to treat and prevent 
diabetes and its complications are expected 
to total at least 376 billion UsD in 2010, 
with some projections exceeding 490 billion 
UsD. Between 22 and 27% of the total 
diabetes costs are attributable to lower 
extremity disease.3,7
pathophysioLoGy oF the 
DiaBetiC Foot
Neuropathy
neuropathy, or the loss of protective 
sensation (Lops) of the lower extremity, is 
the predominant etiology for diabetic foot 
ulceration. the absence of this most basic 
nociceptive mechanism results in the patient’s 
inability to perceive local foot trauma both 
from intrinsic factors such as abnormal or 
faulty foot mechanics or deformity, as well 
as extrinsic factors such as foreign objects or 
improper footwear. these factors place the 
foot at increased risk for developing an ulcer, 
which can lead to amputation. 
neuropathy can be subdivided into 
sensory, motor, and autonomic categories. 
Sensory neuropathy typically begins dist-
ally, moving proximally, and is symmetrical. 
it is often described as a ‘stocking-glove’ 
distribution. 
Motor neuropathy results in intrinsic 
muscle wasting, causing a progressive 
deformity such as hammertoe, claw toe, 
and plantar flexion deformities of the 
metatarsals. these deformities can cause 
an increase in focal pressure at the areas of 
the interphalangeal joints of the digits and 
beneath the metatarsal heads, respectively, 
increasing the probability of ulcer 
formation. 
Autonomic neuropathy is associated with 
pathology of the sympathetic nervous system. 
in the lower extremity, this usually results 
in the absence of sweat production causing 
drying and scaling of the skin, increasing the 
likelihood of cracking and fissuring. these 
cracks or fissures, especially in the heel, may 
then serve as a portal of entry for bacteria, 
creating an increased chance of infection. 
other factors precipitating diabetic foot 
ulcers have been identified and are listed 
in table 26.1. a risk factor classification 
scheme has been developed based on Lops 
and other comorbidities (i.e. vascular disease) 
(table 26.2). this classification system 




structural deformities of the foot and 
ankle can be a potential cause of increased 
pressure and subsequent ulceration. the 
development of foot ulceration is often 
based on a biomechanical abnormality.8,9 it 
is important to evaluate both feet of a patient 
for any potential problem areas. as described 
earlier, motor neuropathy can lead to the 
loss of intrinsic foot musculature causing a 
deformity (and subsequent overpowering of 
the intrinsics by the larger extrinsic muscles). 
identification and management of any of the 
following will assist in prevention of potential 
ulceration: hammertoe, claw toe, bunion, 
tailor’s bunion (bunionette), hallux limitus/
rigidus, flat feet, high arched feet, Charcot 
deformities, or any postsurgical deformities 
such as amputations. Limited joint mobility 
should also be evaluated as it can cause an 
increase in vertical and shear force in certain 
areas, particularly to the plantar hallux, 
and lead to tissue breakdown. the achilles 
tendon should be evaluated for any type 
of functional shortening causing equinus 
deformity. it is common to find an increase 
in glycosylation of soft tissues and tendons 
causing contracture of the muscles in the 
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Table 26.1: Risk Factors For Ulceration
General or Systemic Factors local Factors
• Uncontrolled Hyperglycemia
• Duration of Diabetes
• Peripheral Vascular Disease
• Older Age
• Chronic Renal Disease
• Blindness or visual loss
• Peripheral Neuropathy
• Structural Foot Deformity
• Limited Joint Range of Motion
• Trauma
• Improperly fitted shoes
• Callus
• Prolonged Elevated Focal Pressure
• History of Previous Ulcer or Amputation
Table 26.2a: American Diabetes Association Risk Classification for The Diabetic 
Foot.
Risk 
Category Definition Treatment Recommendations
Suggested 
Follow-Up
0 No LOPS, no PAD, 
no deformity




1 LOPS + deformity –  Consider prescriptive or 
accommodative footwear
–  Consider prophylactic surgery 
if deformity cannot be safely 
accommodated in shoes. Continue 
patient education
Every 3–6 months 
(by podiatrist +/– 
specialist)
2 PAD + LOPS –  Consider prescriptive or 
accommodative footwear
–  Consider vascular consultation for 
combined follow-up
Every 2–3 months  
(by podiatrist +/– 
vascular surgeon)
3 History of ulcer or 
amputation
–  Same as category 1
–  Consider vascular consultation for 
combined follow-up if PAD present
Every 1–2 months 
–(by podiatrist)
Table 26.2b: The University of Texas (UT) Wound Classification System
UT System
Grade Description Stage
1 Pre- or post ulcerative lesion A–D
2 Superficial A–D
3 Penetrated to tendon or capsule A–D
4 Penetrates to bone A–D
stages: a = no infection or ischemia; B = infection; C = ischemia; D = infection and ischemia
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posterior compartment of the leg.10-12 this 
will cause an increase in plantar pressures in 
the forefoot making this area more prone to 
breakdown. 
Gait evaluation and muscle testing should 
also be conducted to evaluate any potential 
abnormality with ambulation and muscle 
strength. testing of the muscles in the lower 
extremity should be done both actively and 
passively, weight bearing and non-weight 
bearing. plantar foot pressures can also be 
assessed with the use of a harris ink mat or 
pressure sensitive foot mat. 
Angiopathy 
in combination with the risk factors for 
ulceration discussed above, the presence of 
vascular occlusive disease increases the risk 
of potential amputation. vascular disease 
is a common finding in individuals with 
long-standing diabetes. while vascular 
insufficiency alone is not usually the primary 
cause of ulceration, inadequate perfusion can 
inhibit ulcer healing, leading to further tissue 
necrosis and the inability to clear infection. 
table 26.3 provides a list of other potential 
risk factors for amputation. most cases of 
vascular disease in individuals with diabetes, 
interestingly, affect the infrapopliteal vessels 
with relative sparing of the pedal vessels. in 
many instances, this allows for a distal bypass 
to a pedal target artery in order to increase 
the blood flow to the foot (Figure 26.1). the 
vascular examination is addressed in further 
detail later in this chapter.
DiaGnosis
History and rapid visual screening
a thorough history and physical examination 
of each patient presenting with diabetic foot 
pathology should include a history of pedal 
wounds, history of prior amputations, and 
lower extremity vascular interventions.13,14 
physical examination should note the types 
of deformities present, neurological status, 
vascular status, and dermatological presenta-
tion. the patient should be instructed 
to remove both shoes and socks for their 
examination. a systematic approach should 
be taken in order to avoid missing any 
Table 26.3: Risk Factors for Amputation:
• Peripheral Neuropathy (LOPS)
• Vascular Insufficiency (PAD)
• Infection
• Structural Foot Deformity
• Trauma
• History of prior foot ulcer or amputation
• Charcot foot
• Poor glycaemic control
• Older age
• Male gender
• Ethnicity (higher in Hispanics and African- 
  Americans)
FiGURe 26.1: Dorsalis Pedis Bypass
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important aspects of the examination. 
all surfaces of the foot and ankle should 
be evaluated including the nails, digits, 
interdigital webspaces, the soles, and the heels, 
inspecting for cracks, blisters or bullae, hyper/
hypopigmentation, fissuring, calluses, and 
ulcers. the footwear should also be inspected 
for signs of wear patterns, foreign bodies, 
and any irregularities. any gross deformities 
as described above can be identified during 
this rapid visual screening.14
Neurological examination
as stated earlier, peripheral sensory 
neuropathy is the major risk factor for the 
development of a diabetic foot ulcer. there 
are many simple, noninvasive examinations 
that can be performed to test and monitor 
sensation. a simple history of neuropathic 
symptoms such as tingling, burning, 
numbness, the feeling of insects crawling on 
the feet (formication) can help to identify 
those patients at risk for developing foot 
ulceration.15
Monofilament testing
one of the most common methods used to 
assess neuropathy is the use of the semmes-
weinstein monofilament (10-g) wire.14,15 
the nylon monofilament is placed on ten 
different pre-determined locations on the 
foot and pressed down manually until there 
is a slight bend in the wire (Figure 26.2). 
the patient is instructed to say ‘yes’ if he or 
she thinks they feel slight pressure or 
sensation. if the patient is unable to feel the 
sensation at two or more locations then it 
is safe to assume that protective sensation 
is lost. 
Vibration testing
vibratory perception testing can be assessed 
utilizing several different modalities. the 
more traditional method of testing is by the 
use of a 128-hz tuning fork. the tuning fork 
is struck and then placed on a prominent 
bony surface of the foot, such as the great toe 
or metatarsal head. the patient is instructed 
to identify when the vibration stops.
as an alternative, a vibratory perception 
threshold monitor (vpt – Diabetica solu-
tions, san antonio, texas, Usa) (Figure 26.3) 
can be used to test for vibration perception 
threshold and is useful in identifying those 
at high risk for development of an ulcer. 
the instrument consists of a hand piece 
with a testing probe on the end, a motor, 
rheostat, and voltmeter. the probe is held 
gently on the distal aspect of each hallux, or 
distal most prominent area. the rheostat is 
slowly increased until the patient senses the 
vibration. once the patient identifies the 
sensation, the rheostat is then decreased until 
the sensation is no longer felt. the average 
value of the two numerical readings is taken 
and the level of sensation is documented 
to the location where the numbers were 
obtained. average values above 25 volts 
FiGURe 26.2: Proper use of S-W Monofilament when 
applied to the foot. Slight bend of the filament noted. 
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are considered positive for neuropathic 
changes.14
Dermatologic examination
Following assessment for any loss of sensa-
tion, evaluation of the integumen is a critical 
part of the foot screening. the skin can be 
evaluated for color, texture, turgor, quality, 
and presence of any areas of dryness or fissures. 
Calluses, if present, can be problematic as 
they indicate areas of increased pressure and 
an ulcer can form under the hyperkeratotic 
lesion, which may cause hemorrhage beneath 
the callus. Debridement of these areas is 
recommended in order to reduce a potential 
focus of pressure.16, 17
appearance of the nails should also be 
noted. if there are nails that are incurvated or 
ingrown, these could be a potential area for 
skin breakdown and possible infection. other 
nail issues to be aware of are onychomycosis 
(fungal nails), dystrophic nails, atrophy or 
hypertrophy, or paronychia (infected ingrown 
nail), as all can be potential problems. 
evaluation for any ulceration to the foot 
or lower leg should be assessed. important 
characteristics of ulcers are depth, size, 
presence of fibrotic or granulation tissue, 
location, and whether or not the area appears 
to be infected.
Anatomy of occlusive disease – 
vascular examination
For decades, clinicians incorrectly believed 
that ischemia in diabetes was due to micro-
vascular occlusion of arterioles, so-called 
small vessel disease.18 however, this assump-
tion has been disproven by subsequent 
study.19,20 Diabetic vascular disease is a macro-
vascular phenomenon, commonly affecting 
infrapopliteal arteries with calcified stenoses 
and occlusions. more than 90% of patients 
have sparing of at least one major artery at the 
ankle level. the peroneal artery is often the 
last infrapopliteal artery to occlude; it provides 
blood flow to the foot through anterior and 
posterior perforating branches to the tibial 
arteries. Bypass to an infrapopliteal artery 
usually provides adequate blood flow to the 
foot, although some patients appear to have 
more compartmentalized pedal flow. some 
patients with heel ulcers remain slow to heal 
FiGURe 26.3: Vibratory Perception Threshold Monitor (VBT)
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after dorsalis pedis artery bypass, suggesting 
inadequate pedal circulation.21 thus, if 
possible, patients with ischemic ulcers should 
preferentially receive a bypass to the arterial 
bed directly supplying the ulcer; this axiom is 
especially pertinent to patients with large heel 
ulcers.
Prediction of wound healing: 
assessment of perfusion
pedal blood flow should be assessed before 
any surgical intervention on the diabetic 
foot. absence of pedal pulses, dependent 
rubor, pallor on elevation, and loss of hair are 
clinical signs of advanced peripheral artery 
disease. if there is concern for ischemia, 
noninvasive testing is an appropriate initial 
diagnostic choice. the ankle-brachial index 
(aBi), while nearly 100% specific for paD in 
non-diabetics, can be falsely elevated (>1.3) 
in diabetic patients due to medial calcinosis 
of the affected arteries. more useful are the 
systolic toe pressure and the toe-brachial 
index, since digital arteries are seldom 
calcified in those with diabetes.22 additional 
tests to assess foot perfusion include skin 




 Currently there is no single test or 
combination of tests that can always predict 
wound healing. apelqvist and colleagues 
pros pectively studied 314 consecutive 
patients with diabetic foot ulcers.22 primary 
healing occurred in 85% of patients with a 
toe pressure greater than 45 mmhg, while 
only 36% of patients with a toe pressure 
of 45 mmhg or less healed without an 
amputation. no patients with an ankle pres-
sure less than 40 mmhg healed primarily. 
Kalani and colleagues also prospectively 
studied 50 patients with diabetic foot ulcers 
over a 12-month period.26 a toe pressure of 
at least 30 mmhg had a 15% sensitivity, 
97% specificity, and 67% positive predictive 
value for wound healing. in that same 
study, tcp
o2 
was also evaluated; a tcp
o2 
of 
at least 25 mmhg had an 85% sensitivity, 
92% specificity, and 79% positive predictive 
value for wound healing. Likewise, Carter 
and colleagues reported that tcp
o2 
measurements correlated significantly with 
the risk of major amputation, with a relative 
risk of 2.55 for a tcp
o2
 of 20 mmhg of 
less and 2.22 for a tcp
o2 
of 30 mmhg 
or less.27 in addition, an ankle pressure of 
50 mmhg or less had a 5.83 relative risk of 
major amputation. skin perfusion pressure 
(spp) has also been used to predict wound 
healing. Faris evaluated 61 diabetic subjects 
with wounds and found that only 5% healed 
with an spp less than 40 mmhg, while 88% 
of patients healed with an spp higher than 
40 mmhg.23 yamada and colleagues studied 
211 subjects, half of who were diabetic, and 
compared spp to other noninvasive methods 
to predict wound healing. they found that 
spp was superior to ankle pressure, toe 
pressure, or tcp
o2 
for predicting wound 
healing. an spp of 40 mmhg had a 72% 
sensitivity and 88% specificity for predicting 
wound healing.24 Furthermore, the accuracy 
of prediction increased when a toe pressure 
greater than 30 mmhg was combined with 
spp.
Arterial imaging
a number of techniques of arterial imaging 
are currently in use: arterial duplex scanning, 
computed tomographic angiography (Cta), 
magnetic resonance angiography (mra), 
and digital subtraction arteriography 
(Dsa). Duplex scanning is non-invasive 
and does not require administration of 
contrast. however calcification of the 
infrageniculate arteries can be problematic 
in many patients. Both Cta and mra 
have the advantage of being noninvasive; 
however, both these studies are limited 
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in diabetic patients with impaired renal 
function. Cta requires a large bolus of 
iodinated contrast, and the gadolinium-
based contrast used in mra has been 
associated with nephrogenic systemic 
fibrosis.28 in addition, mra tends to 
overestimate the degree of arterial stenosis. 
Using selective catheterization techniques, 
Dsa can produce high-quality images 
with low volumes of iso-osmolar contrast, 
thereby minimizing contrast-induced 
nephropathy. in addition, carbon dioxide 
can be selectively utilized as a ‘contrast’ 
agent; it is not nephrotoxic and quickly 
dissolves in blood before travelling to the 
lungs where it is readily expelled. Dsa 
also has the advantage that angioplasty and 
stenting, if appropriate, may be performed 
at the time of diagnostic arteriography 
(Figure 26.4).
Soft tissue imaging
imaging studies should be conducted to 
evaluate any underlying bone or soft tissue 
deformity. the diabetic foot is prone to many 
common and uncommon infectious and 
non-infectious processes due to the com-
bin ation of vascular and neurological 
impairments. imaging studies may be 
difficult to interpret and may lack specificity; 
therefore, a ‘shotgun’ approach to imaging 
studies should be avoided. appropriate 
imaging studies should be ordered to establish 
FiGURe 26.4: 56 year-old man with diabetes, renal insufficiency (serum creatinine 0.180mmol/L), absent foot 
pulses and non-healing dorsal foot ulcer for 6 weeks. Angiography showed normal arteries to the trifurcation 
and severe tibial artery occlusive disease with a long stenosis in dominant posterior tibial artery. Angioplasty 
markedly improved circulation and the wound healed with debridement, negative pressure wound therapy, and 
subsequent split-thickness skin graft placement.
a) long segment, proximal posterior tibial artery stenosis
b) 8 cm long, 4 mm percutaneous transluminal angioplasty (PTA) of proximal posterior tibial artery stenosis
c) excellent angiographic result after balloon angioplasty
a)
b) c)
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or confirm a suspected diagnosis in order to 
properly manage the patient. For example, 
it is very difficult to differentiate acute 
Charcot arthropathy from osteomyelitis on 
plain radiographs. the reliability of imaging 
studies is diminished in the presence of 
arterial occlusive disease, Charcot arthro-
pathy or after recent surgery or trauma.29 a 
thorough history and physical examination 
and clinical overview by the treating physician 
must be correlated with the imaging studies 
in order to interpret them correctly. 
plain radiographs should be the initial 
study considered for patients that present 
with any signs or symptoms of foot problems. 
these studies help to identify osteomyelitis, 
fracture, dislocation, foreign bodies, soft 
tissue gas, arterial calcification as well as any 
other biomechanical or structural deformity. 
it should be noted that it might take time for 
acute osteomyelitis to be detected on plain 
film radiographs and serial radiographs or 
magnetic resonance imaging (mri) should 
be considered if osteomyelitis is strongly 
suspected. 
Computed tomography (Ct) scans may 
be indicated if plain films fail to depict 
a suspected bone or joint deformity. Ct 
offers higher anatomic detail and resolution 
in regards to bone and joints. 3-D Ct 
reconstruction can be done to provide a 
360-degree view and increased visualization 
of any suspected abnormality. 
mri is usually preferred over a Ct 
scan for suspected osteomyelitis due to the 
increased resolution of the image. mri scans 
also allow the physician to visualize the extent 
of the infection- osteomyelitis, deep abscess 
and septic joints, but also other soft tissue 
pathology such as tendon rupture. 
Bone scans can also provide some useful 
data when evaluating the diabetic foot. 
technetium-99 methylene diphosphonate 
(tc-99 mDp) as well as indium-111 bone 
scans can be useful in determining the 
presence of osteomyelitis. however, while 
bone scans and other scintigraphic techniques 
are certainly possible tools to employ, their 
lack of specificity often makes their specific 
utility problematic, particularly if used in 
isolation. advanced imaging studies beyond 
plain radiographs should not be routine. 
rather, they should only be obtained to 
answer specific clinical questions when the 
results will alter management (e.g. concern 
over deep space infection with equivocal 
clinical picture).
CLassiFiCation systems
Diabetes mellitus foot risk 
classification
Based on a thorough history and physical 
examination, each patient should then be 
classified and assigned to a specific foot 
risk category as outlined in table 26.2a. 
these categories were designed to direct and 
expedite the referral process to the necessary 
specialist and should also serve as a guide 
for subsequent follow-up visits. increased 
categorical levels are associated with 
increasing risk for ulceration, hospitalization, 
and amputation.
University of Texas wound 
classification system
while many wound classification systems 
exist, the University of texas (Ut) ulcer 
classification system was developed to provide 
a more uniform evaluation of diabetic foot 
wounds. Like other classification systems the 
Ut wound classification system builds on 
the depth-ischemia classification however, 
the Ut system also considers infection.30 
the presence of infection and ischemia has 
been found to be more strongly predictive 
of outcome than the wound depth alone.31 
the Ut system uses a 4 by 4 matrix (classes 
Mechanisms of Vascular Disease484
a to D, wound depths 0 to 3) and evaluates 
3 factors of ulceration, which include 
depth, infection, and peripheral arterial 
disease (paD).32 the frequency and level 
of amputation increases in deeper wounds 
and in the presence of infection and paD.30 
regardless of which specific classification is 
used, the key factors of depth, infection and 
ischemia should generally be communicated 
in some form. this classification is listed in 
(table 26.2b). 
CLiniCaL proBLems anD 
prinCipLes oF manaGement
Ulceration
initial presentation of the diabetic foot usually 
entails the presence of an open ulcer, located 
on the plantar aspect of a patient’s foot. 
most patients will not suspect an ulcer on 
the bottom of their foot until they, or a loved 
one, notices blood either on the floor after 
walking or on a sock. advising the patient 
that ambulation is contraindicated with an 
open ulcer is often challenging especially if 
the patient is neuropathic, as they have lost 
the ‘gift of pain.’ 33 however, reduction of 
pressure to the foot is essential for treatment. 
By effectively off-loading the area, the risk of 
continued trauma and resultant infection is 
decreased. 
Epidemiology and risk factors
Ulceration of the diabetic foot is one of the 
single most common problems for which 
medical assistance is sought in a diabetic 
individual. Up to 25% of patients with 
diabetes will have a foot ulceration during their 
lifetime.4 remarkably, at least 50% of those 
ulcerations will become infected, and in 20% 
of those cases an amputation is required.34 
there are 81,000 major amputations 
performed on individuals with diabetes in 
the United states annually. Conservatively, 
60% of all non-traumatic amputations 
occur in the diabetic patient.35 studies have 
shown that after a major amputation the 
contralateral limb develops a serious lesion in 
50% of cases.36 the 5 year adjusted mortality 
rate after a major amputation of a limb is 
46%;6 this is alarming and is higher than the 
mortality rate for many forms of cancer. it 
has also been shown in more than 85% of 
lower extremity amputations a wound was a 
critical aspect of the causal pathway.8,34,37,38 
the cost of treating diabetic foot ulcers is 
also growing at a staggering pace, reaching 
nearly $30 billion in the United states in 
2007.39
Offloading 
numerous products are available to assist 
in redistributing pressure over a larger 
unit area (off-loading) on the foot. some 
examples include removable cast walkers, 
non-weight bearing casts with crutch/
walker assist, wedge sandals (either 
forefoot or heel wedge), healing sandals 
with a multilaminar, multidurometer foot 
bed. however, the choice of modality 
should be chosen with respect to the 
patient’s functional status. For example, if 
a patient presents with a plantar forefoot 
ulcer, a wedge shoe that does not allow 
the forefoot to bear weight would be an 
appropriate device. however, if the patient 
is not properly educated on use of the 
device and/or has issues with balance, the 
offloading modality could cause the patient 
be unstable when walking. in regards to 
diabetic shoes, whether custom-made or 
off the shelf, it is important to keep in 
mind one key fact. while diabetic shoes 
are effective in preventing ulcerations, they 
are (in general) not very effective in healing 
them. 
For many years the gold standard in off-
loading an ulceration on the foot has been 
the total contact cast (tCC).40 this fully 
weight-bearing cast consists of a multiple 
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layers of both fiberglass and plaster with 
minimal padding. when applied properly, 
the tCC allows the patient to be ambulatory. 
the tCC redirects pressure from the bottom 
of the foot, which is then redistributed over 
the bottom of the entire foot and up the cast. 
some disadvantages of using a tCC is the 
time it takes to apply, the bulkiness for the 
patient, and the fact that the patient must 
wear the cast for 1 week intervals requiring 
weekly visits to the clinic. newer tCC 
variants have reduced the time required for 
application of a traditional device whilst 
retaining many of the desirable therapeutic 
characteristics. an example of newer tCC 
variants can be seen in Figure 26.5.
recent studies have evaluated the 
use of a removable cast walker rendered 
irremovable. this technique has been termed 
the ‘instant total contact cast (itCC).’ this 
can be fabricated by simply adding a layer 
of fiberglass, cohesive bandage, or plaster 
around the leg portion (Figure 26.6). the 
itCC has proven to be an effective and 
easy offloading device that ensures patient 
adherence.41
in many instances, proper off-loading 
may be all that is necessary to achieve wound 
healing. however, if wound healing fails in 
the midst of proper off-loading, adequate 
blood flow, and satisfactory nutritional status, 
surgical intervention may be warranted.
Non-vascular surgical treatment
surgical management of the diabetic lower 
extremity can be a challenging and frus-
trating task, but can be ultimately rewarding 
both to the physician and patient upon 
healing of an ulcer and correction of the 
underlying cause of the deformity. surgery 
in the absence of critical limb ischemia is 
based on three fundamental principles: 
presence or absence of neuropathy (Lops), 
FiGURe 26.5: Anterior and lateral view of cast boot, 
which allows ambulation.
FiGURe 26.6: Example of an instant total contact 
cast (iTCC) with fiberglass wrapped around the leg 
portion, of an off-loading walking boot, to make it 
irremovable. 
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presence or absence of an open wound, 
and presence or absence of acute limb-
threatening infection.42 
a classification system has been developed 
outlining non-vascular surgical treatment of 
patients with diabetes and has been divided 
into four categories and highlighted in 
table 26.4 and is based on indications and 
perceived risk.42,43
Class I: Elective 
the goal of elective surgery is to reduce 
or eliminate any pain associated with a 
particular deformity and improve function.42 
examples of these deformities include 
bunions, hammertoes and bone spurs, all in 
patients without peripheral neuropathy and 
with a low chance for ulceration. Basically 
any type of reconstructive surgical procedure 
can fall into this category with the exception 
of an amputation. rarely are amputations 
done as an elective procedure. only in the 
case of severe deformity or instability from 
a previous injury or surgical procedure, will 
an amputation be considered. assuming 
good glycemic control, patients grouped 
to this class are not at any increased risk 
for the development of complications than 
corresponding patients without diabetes.43
Class II: Prophylactic
procedures in this class are indicated to allevi-
ate a deformity in a patient who is neuropathic 
however does not have the presence of an 
ulcer.42 the goal of prophylactic surgery is to 
reduce the plantar sheer and vertical stresses. 
many procedures for prophylactic surgery 
would be considered elective if the patient 
did not suffer from neuropathy. several 
examples of procedures in this class include 
a Charcot foot reconstruction, a metatarsal 
head resection, a Keller arthroplasty, an 
achilles tendon lengthening or a hammertoe 
repair. 
Class III: Curative 
Curative surgery often is identical to 
prophylactic surgery with the exception 
that procedures in this class are designed to 
speed the healing rate of an open wound but 
also to eliminate any potential recurrence 
of the ulceration.42 surgical procedures 
frequently utilized in this category may 
include exostectomy, digital arthroplasty, 
sesamoidectomy, single or multiple metatarsal 
head resection, joint resection or partial 
calcanectomy as well as achilles tendon 
lengthening. some surgeons may also elect 
to combine a plastic surgical flap and/or skin 
graft to help expedite healing. 
Class IV: Emergency (Urgent)
Urgent procedures are performed to limit 
the spread of acute, limb and potentially 
life-threatening infection. most often 
these procedures are done in the presence 
of significant ischemia. they require the 
removal of all infected and necrotic tissue to 
the level of viable soft tissue and bone and 
usually involve some level of amputation. 
when at all possible these procedures 
should be performed to allow for maximum 
amount of function to the extremity to be 
maintained. 
with respect to any of the above 
classifications it is best to evaluate the vascular 
status of the patient to consider the necessity 
of any prior or subsequent arterial procedure 
that may be needed.42
Post-operative management
the management of the diabetic foot 
patient in the post-operative setting is much 
the same as a patient without diabetes. 
adequate pain control, rest, elevation of 
the extremity and proper dietary intake are 
all recommended. one key difference is 
the timeframe for protected weightbearing 
or complete non-weightbearing. it is often 
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stated that diabetics require twice the healing 
time as a non-diabetic. that means that if 
a simple bunionectomy in a non-diabetic 
requires 4 weeks of protected weightbearing, 
the same procedure in a diabetic may require 
6-8 weeks of protected weightbearing. the 
same can be said for a procedure requiring 
non-weightbearing. most surgical procedures 
done for class 1–3 can be managed with 
protected weightbearing.43 most class 4 
procedures will require some period of non-
weightbearing or protection. the same can be 
said for any type of surgical implant or skin 
closure technique. For example, leaving skin 
sutures in place for an additional 1–2 weeks 
is advantageous over early removal to allow 
for the tissue to heal.
surgical and non-surgical complica-
tions in this patient population are to be 
expected. Joint dislocation, bone fracture, 
surgical incision dehiscence, new ulceration 
or re-ulceration, and infection are all 
commonplace, not infrequently leading to 
re-hospitalization. proper management by 
use of off-loading, local wound care, anti-
biotics and patient education will all be 
beneficial when dealing with any potential 
complication. it should also be kept in mind 
that not all diabetic foot complications can 
be prevented, but all can be adequately 
managed. 
Infections
the infectious Diseases society of america 
(iDsa) has produced a classification system 
for diabetic foot infections, which is based 
on clinical signs and symptoms (table 26.5). 
the iDsa divides infections into four 
categories, uninfected, mild, moderate, and 
severe.44 these guidelines and classification 
system has become a reliable clinical predictor 
of the outcome of a diabetic foot infection.45 
it is important that initial antibiotic therapy 
cover the broad range of potential aetiological 
organisms in the diabetic foot until targeted 
therapy can be instituted once appropriate 
cultures have been obtained.
Charcot arthropathy
Charcot arthropathy is defined as a pro-
gressive condition characterized by joint 
dis location, pathologic fractures, and severe 
destruction of the pedal framework 
(Figure 26.7). it is typically seen individuals 
with neuropathy and can be easily confused 
with acute infection or osteomyelitis. a 
Table 26.4: Classification of non-vascular Diabetic Foot Surgery
Class Type Definition
1 Elective Procedure performed on patient with protective sensation intact 
to eliminate pain or to improve function 
2 Prophylactic Procedure performed on patient with protective sensation absent 
but no open wound to reduce deformity and reduce occurrence/
recurrence
3 Curative Procedure performed on patient with an open wound with the goal 
of promoting healing and reducing risk for recurrence
4 Emergency Procedure performed with goal of limiting the spread of limb- or life-
threatening infection
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patient will often present with a red, hot, 
swollen extremity with no sign or history 
of ulcer or break in the skin (Figure 26.8). 
Usually all other constitutional signs of 
infection are absent and laboratory values are 
within normal limits. 
pedal manifestations of Charcot foot 
result in a debilitating deformity frequently 
leading to an amputation. while not well 
understood, several theories regarding the 
development of the disorder exist with many 
authors believing it is caused by a combination 
of the neurovascular and neurotraumatic 
theories. neuropathy and trauma seem 
to be the common event preceding the 
development of an acute Charcot foot. as a 
result of the trauma and associated autonomic 
neuropathy, blood flow to the foot increases 
causing osteopenia and weakening of the 
bony structure. Fracture is often associated 
with unrecognized injury or minor trauma 
that might otherwise appear innocuous.46,47 
an unfortunate cycle continues as the patient 
ambulates, without pain, causing further 
destruction of the foot.
the initial diagnosis of acute Charcot is 
often clinically based on the characteristics 
listed above. it can become complicated as 
FiGURe 26.7a & b: X-ray of acute Charcot arthropathy. This plain x-ray demonstrates degenerative changes 
in the tarso-metatarsal joints (Lis-franc joints) with joint space narrowing and subchondrial sclerosis, consistent 
with Charcot arthropathy. Also noted is bone destruction and pathological fracture of the proximal phalanx of 
the 4th toe, indicative of osteomyelitis of this bone. 
a) b)
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patients often present with a concomitant 
ulcer, which raises questions of possible 
osteomyelitis. someone presenting with the 
previously mentioned characteristics and lack 
of an open ulcer are more pathognomonic 
of acute Charcot arthropathy. routine 
laboratory values are often of little use in 
diagnosing Charcot. they are valuable, 
however, with respect to excluding potential 
infection. an elevated wCC with a left shift 
is often seen with acute infection and not 
with acute Charcot. elevated erythrocyte 
sedimentation rate (esr) and C-reactive 
protein (Crp) level may also be elevated 
in acute infection but they often respond 
to any inflammatory process and thus are 
nonspecific. the most important diagnostic 
aid in determination of acute Charcot is 
the high index of clinical suspicion when a 
neuropathic patient presents with a deformed 
or swollen foot. 
treatment of Charcot consists of immedi-
ate immobilization and stress reduction. 
most physicians would recommend strict 
non-weight bearing to the affected limb. 
however, this then subjects the contralateral 
extremity to increased pressure thereby 
predisposing it to repetitive stress and 
the potential for ulceration or even acute 
Charcot.48 nonetheless, non-weight bearing 
by means of a short leg plaster or fiberglass 
cast, or tCC remains the gold standard in 
the acute phase of the disease.40 
Following the initial period of off-
loading, skin temperatures and edema of 
the affected extremity will decrease. at this 
point protected weight bearing is permitted, 
usually with some sort of assistive device. 
this can be achieved through use of a 
Charcot restraint orthotic walker (Crow) 
(Figure 26.9), total contact cast, fixed ankle 
walker, bivalved casts or patellar tendon-
FiGURe 26.8: 
a)  Anterior view of acute Charcot. Notice the erythema 
and edema to the forefoot 
b)  Lateral view of acute Charcot. Marked flattening 
of the medial arch with associated edema and 
erythema.
a) b)
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prevention
Diabetic foot care requires an inter-
disciplinary team approach given the pro-
gressive nature of the disease in the foot. 
it is unlikely that one individual medical 
or surgical specialty is able to manage all 
aspects of diabetic lower extremity disease 
and appropriately manage these patients. 
recent evidence suggests a reduction in 
major amputation rates following the 
develop ment of an interdisciplinary 
approach to limb salvage.51 the components 
of a limb salvage team are predicated on 
the pathology at presentation. the core 
of the team typically starts with clinicians 
caring for the structural aspects of the foot 
(podiatrists), along with clinicians caring for 
the vascular integrity of the lower extremity 
(vascular surgeons). other specialties of 
the team, to add a more comprehensive 
care model may include endocrinology, 
infectious Diseases, orthopaedic surgery, 
physiotherapy, plastic surgery, nursing and 
orthotics/ prosthetics. 
vasculopathy and neuropathy are two 
major contributors to diabetic foot disease 
and subsequent ulceration. therefore, 
appropriate utilization of an interdisciplinary 
team approach, as stated above, will help 
to address the varying factors associated 
with lower extremity ulceration and reduce 
amputation. a diabetic rapid response 
acute foot team has been proposed in an 
effort to combine the knowledge of certain 
specialties to promote limb salvage.52 this 
is an interdisciplinary team model whose 
core involves the ability to rapidly diagnose 
and provide treatment to patients with 
lower-extremity complications of diabetes, 
utilizing seven basic skill sets (table 26.6). 
at the forefront of the team are members 
from podiatry (toe) and members from 
vascular surgery (Flow). these specialties, 
with adjunctive teams added as necessary, 
FiGURe 26.9: Charcot Restraint Orthotic Walker 
(CROW) boot. A patient is able to ambulate with this 
device once the acute phase has passed.
bearing braces, to name a few. the average 
time of rest and immobilization in a patient 
that has undergone an acute Charcot event is 
4 to 6 months before returning to permanent 
and proper footwear. 
if offloading is unsuccessful or if the 
deformity is unstable, reconstructive surgery 
may be considered. the goal of surgical 
intervention in the Charcot foot is to 
provide a stable, plantigrade foot that may 
be appropriately accommodated with proper 
shoe gear.49 most surgical interventions 
consist of an exostectomy for prominent 
plantar bony prominences or ‘rocker-bottom’ 
deformities that cause ulcerations and could 
lead to potential infection.50 other, more 
complex procedures such as arthrodesis of 
the midfoot and hindfoot, use of external 
fixation, and intramedullary nail have also 
been used in the latent stage of the Charcot 
disease process.
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combine to collectively posses the ability to 
perform the 7 essential skills, stated above, to 
be effective in promoting limb salvage. this 
model has been effective at the University 
of arizona’s southern arizona Limb salvage 
alliance (saLsa) in which the vascular 
surgery/podiatry team approach has been 
able to significantly reduce the number of 
major diabetes-associated lower-extremity 
amputations as well as provide a framework 
for prevention of diabetic ulcers. in fact, 
abundant data suggest that establishing 
such comprehensive diabetic foot care teams 
can significantly reduce the incidence of 
major amputation in both community and 
academic hospital settings.53
Table 26.6: Seven Essential Skills of a Diabetic Rapid Response Acute Foot Care 
Team (DRRAFT).
1. Ability to perform hemodynamic and anatomic vascular assessment with revascularization
2. Ability to perform a neurologic assessment
3. Ability to perform site-appropriate culture technique
4. Ability to perform wound assessment and staging/grading of infection and ischemia
5. Ability to perform site-specific bedside and intraoperative incision and debridement
6. Ability to initiate and modify culture-specific and patient-appropriate antibiotic therapy
7.  Ability to perform appropriate postoperative monitoring to reduce risks of reulceration and  
infection







Wound without inflammation or purulence Uninfected Not applicable
Presence of >2 manifestations of inflammation, 
cellulitis <2cm surrounding ulcer, no systemic 
symptoms of infection
Mild Infection Non-limb threatening
Presence of infection with  
>2 cm of surrounding cellulitis; any infection with 
presence of gangrene, abscess, deep tissue 
involvement or gas in tissue; no systemic signs/
symptoms of infection
Moderate Infection Limb threatening
Presence of infection as above with the 
presence of systemic signs or symptoms
Severe Infection Life and limb 
threatening
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ConCLUsion
treating the diabetic foot, but moreover 
the patient with diabetes, is an extremely 
challenging yet rewarding experience. as 
the incidence continues to grow worldwide 
the likelihood of people with diabetes 
constituting a significant proportion of a 
vascular and podiatric surgical practice is 
quite high. Common, seemingly trivial foot 
problems such as calluses, corns, ingrown 
nails, and dry scaly skin, may provide 
sufficient trauma to develop into limb-
threatening problems. early recognition 
and diagnosis of these factors combined 
with aggressive preventive measures and a 
multidisciplinary team approach will all be 
beneficial in the treatment of the diabetic 
foot with the ultimate goal of amputation 
reduction and prevention.
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IntRoDuctIon
the lymphatic circulation consists of a 
network of blind-ended capillaries lined 
with endothelial cells that drain into larger 
vascular trunks and eventually empty into 
the blood circulation. It is otherwise totally 
separate from the blood circulation although 
lymphatics are often anatomically related 
to arteries and veins. lymphatic vessels are 
found in nearly all tissues and have several 
important functions including transportation 
of fluids, plasma macromolecules, and cells 
back to the blood circulation. the lymphatics 
also form a major transport route for lipids 
absorbed from the intestinal tract, and are 
a critical component of the immune system 
transporting leucocytes and antigens from 
the tissues to the lymphoid organs. 
lymphoedema is an accumulation of 
tissue fluid in the interstitial space as a result 
of failure of the lymphatic circulation. this 
can be severe and disfiguring. Defects in 
the lymphatic system can be primary or 
acquired. lymphoedema most frequently 
affects the legs (80%) although can present 
as swelling of the arms, face or external 
genit alia. (Figure 27.1)
claSSIFIcatIon oF 
lyMphoeDeMa
the diagnosis of lymphoedema should 
be reserved for those patients in whom a 
secondary cause of oedematous swelling 
has been excluded. (table 27.1). chronic 
venous disease is a common cause of 
unilateral swelling and there are often other 
characteristic skin changes. Sub-clinical 
lymphoedema sometimes becomes apparent 
when other conditions such as venous 
hypertension cause an increase in fluid and 
protein forced into the interstitial space that 
overwhelms a poorly functioning lymphatic 
system. 
lymphoedema is classified as primary 
when there is an intrinsic defect in the lym-
phatic vessels or nodes that leads to failure 
to drain lymph from the tissues. It has an 
incidence of 1:6000 and is three times more 
common in women than men.1
Secondary lymphoedema is more com-
mon and occurs when the lymphatics are 
damaged by a defined external cause. the 
commonest cause worldwide with approxi-
mately 120 million cases is filarial infec-
tion (Wuchereria bancrofti, Brugia malayi 
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or Brugia timori) leading to inflammation 
and fibrosis of lymph nodes or the adjacent 
lymphatics.2 this often presents as hydrocele 
(in men), massive lymphoedema and 
elephantiasis. It is common in tropical and 
sub-tropical regions of africa, the Far east 
and South america. another common cause 
in the tropics is podoconiosis (endemic 
non-filarial elephantiasis), a geochemical 
disease that occurs in individuals exposed 
to red clay soil derived from alkalic volcanic 
rock.3 ultra fine silica particles are absorbed 
through the skin of barefoot agricultural 
workers and cause a progressive obliterative 
lymphangitis. 
In europe and north america secondary 
lymphoedema is usually related to trauma, 
surgery, and radiotherapy, often associated 
with the treatment of malignancy. 
Classification of primary 
lymphoedema
the original classification of primary 
lymphoedema according to age of onset 
into congenital (present at birth), praecox 
(appearing before 35 years of age) and 
tarda is of little use in differentiating the 
underlying disease processes. In the 1950s 
Kinmonth proposed both the clinical 
distinction of primary and secondary 
lymphoedema and a classification system 
based on lymphangiographic appearance.4 
Browse later combined these into a system 
that reflected clinical and aetiological factors 
known at the time.5
1) primary lymphoedema: lymphoedema 
caused by a primary abnormality or disease 
of the lymph conducting elements of the 
lymph vessels or lymph nodes. those in 
which the functional abnormality and its 
cause are known are divided into three 
groups:
a. large vessel abnormalities such as 
congenital aplasia of the thoracic duct 
or cysterna chyli
b. congenital lymphatic valvular incom-
petence or congenital aplasia
c. lymph node fibrosis. 
Figure 27.1 (a,b): Lower limb lymphoedema
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Table 27.1:
Secondary causes of swelling that must be 




























MRI for soft tissue swelling / vascular 
malformation
CT abdomen and pelvis
Lymphoscintigraphy
Lymphography
the remainder are characterised by a reduced 
number of lymphatics on lymphography
2) Secondary lymphoedema: oedema 
caused by disease in the nodes or vessels 
that began elsewhere (e.g., neoplasia or 
filariasis), or lymphocytic proliferative 
disorders such as hodgkin’s disease or 
following surgical extirpation of lymph 
nodes or vessels. 
More recently genetic abnormalities have 
been discovered in both congenital (present 
at birth) and delayed onset forms of lymph-
oedema and this has lead to a modified 
view of this classification. there is also a 
distinction between ‘lymphangio-obstructive’ 
and ‘lymphangio-obliterative’ to indicate 
underlying pathology.
1) Genetically determined abnormalities
a. aplasia, malformation and valvular 
incompetence of the central lymphatic 
ducts, namely the cisterna chyli and 
thoracic duct
b. aplasia, hypoplasia or dilatation 
and valvular incompetence of the 
collecting ducts in the subcutaneous 
tissues of the limb and trunk. this 
group therefore includes the familial 
conditions such as Milroy’s, Meige’s 
and lymphoedema-distichiasis syn-
dromes. this group also includes 
sporadic congenital lymphoedema 
associated with some recognised con-
genital abnormalities. (table 27.2).
2) acquired abnormalities
a. lymphangio-obliterative  




b. Intra-glandular (hilar) fibrosis; rep-
resenting the lymphangio-obliterative 
process in the lymph conducting parts 
of the lymph gland
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3) Kinmonth’s numerical hyperplasia; 
the lymphangiographical abnormality 
is of increased numbers of normally 
sized lymphatic channels associated 
with excessive numbers of small lymph 
glands. 




Milroy first described a syndrome of 
inherited, painless, non-progressive swelling 
of the legs present at birth in 1892.6 the 
family genealogy of the affected clergyman 
was followed across six generations and 22 
out of 97 descendants were thought to have 
limb swelling indicative of lymphoedema.
Milroy’s disease is an autosomal domin-
antly inherited condition. linkage studies 
have mapped the condition to a locus on 
chromosome 5q35.3. More than 30 muta-
tions in vascular endothelial growth factor 
receptor-3 (VeGFR-3), which maps to 
this region, have now been identified.7–13 
De novo mutations in the VeGFR-3 have 
also now been reported in patients with 
sporadic congenital lymphoedema.14,15
VeGFR-3 is the receptor for VeGF-c 
and VeGF-D. VeGF-c acts through 
VeGFR-2 and VeGFR-3 during forma-
tion of the vascular system, with expression 
of VeGFR-3 becoming restricted to the 
lymphatic endothelium.16,17,18 the ability to 
specifically target lymphatic endothelium 
has allowed the visualisation of channels in 
mouse and human lymphatics with markers 
such as lymphatic vessel endothelial hyaluro-
nan receptor (lyVe-1)19 (Figure 27.2).
Table 27.2:




Meige disease (Primary non-syndromic lymphoedema) 
Lymphoedema and yellow nails
Lymphoedema with ptosis 
Hennekam syndrome (Lymphoedema-lymphangiectasia-mental retardation)
Aagenaes syndrome (Hereditary intrahepatic cholestasis with lymphoedema)
Microcephaly-lymphoedema-chorioretinal dysplasia (MLCD)
Noonan syndrome
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transfection of adenoviral VeGF-c 
into the skin of mice causes massive dermal 
lymphangiogenesis,20,21,22 and transgenic 
expression of VeGF-c in mice increases 
lymphatic endothelial cell proliferation and 
causes lymphatic channel hyperplasia.23 In 
contrast, targeted deletion of VeGFR-3 in 
mice causes defective vasculogenesis and 
embryonic death.24 transgenic mice express-
ing a soluble form of VeGFR-3 that is a 
potent inhibitor of VeGF-c and –D signal-
ling survive into adulthood if a keratinocyte 
promoter is used to deliver the genetic muta-
tion selectively to the dermis.25 these animals 
have a normal blood vasculature but develop 
a lymphoedema phenotype with swollen 
limbs. these studies show that VeGFR-3 
has an essential role in lymphangiogenesis. 
Further study of patients with Milroy’s 
disease show that the lymphatics in the upper 
limb are completely normal, and in the lower 
limb they are present in the skin but there is 
no functional uptake.13
Lymphoedema-distichiasis syndrome
lymphoedema-distichiasis syndrome is an 
autosomal dominantly inherited condition 
caused by mutations in the FoXc2 (forkhead 
transcription factor) gene at 16q24 locus.26 
Distichiasis described an extra growth of 
eyelashes from the Meibomian glands, and 
30% also have ptosis. Distichiasis often causes 
corneal irritation, recurrent conjunctivitis 
and photophobia (Figure 27.3). It can 
be treated in a number a ways, including 
lubrication, plucking, electrolysis and 
surgery. the condition is associated with 
other congenital abnormalities including 
congenital heart defects (tetralogy of Fallot), 
cleft lip and palate, varicose veins and spinal 
extradural cysts.27 
In this condition distichiasis is present 
from birth and lymphoedema appears from 
puberty. It is often bilateral and is usually 
below the knee. Duplex ultrasound and 
lymphoscintigraphy reveal that patients 
have both lymph and venous reflux in lower 
Figure 27.2: Human dermal tissue stained with marker for LYVE-1 expression on lymphatic endothelium
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limbs, suggesting primary valve failure.28 
Skin bi opsies in individuals with FoXc2 
mutations demonstrate an abnormally large 
proportion of lymphatic vessels which are 
covered with smooth muscle cells, com-
pared to family members without the muta-
tion. Similar findings in FoXc2 knockout 
mice indicates that FoXc2 is both essential 
for valve morphogenesis as well as normal 
interactions between lymphatic endothe-
lial cells and pericytes.29 Venous reflux in 
lymphoedema-distichiasis syndrome could 





syndrome is caused by mutations in the 
transcription factor gene SoX18.30 this 
extremely rare syndrome is characterized 
by the association of childhood-onset 
lymphoedema in the legs, loss of hair, and 
telangiectasia, particularly in the palms. 
Inheritance is either autosomal dominant or 
autosomal recessive. Studies of the naturally 
occurring SoX18-mutant mouse strain 
suggest abnormal expression of a number 
of downstream gene targets required for 
structural integrity during microvascular 
maturation.31 SoX18 directly activates tran-
scription of the prox1 gene which controls 
lymphatic vessel development from endo-
thelial precursor cells.32
Meige disease (primary non-
syndromic lymphoedema) 
In 1898, henri Meige described the most 
common variety of primary lymphoedema.33 
Meige disease is a familial lymphoedema 
developing at or soon after puberty in which 
no other congenital abnormality is identified. 
the lymphoedema is often symmetrical, 
rarely extends above the knee, and is 
clinically indistinguishable from that found 
in lymphoedema-distichiasis syndrome. 
It occurs three times more commonly 
in females than males and has a genetic 
predisposition in about a third of cases. 
lymphography demonstrates peripheral 
Figure 27.3: Distichiasis with accessory eyelashes along the posterior border of the lid margin in the position 
of the Meibomian glands
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lymphatic hypoplasia with more proximal 
lymphatic channels remaining patent. the 
genetic abnormality in this syndrome has 
not been discovered but it has been shown 
not to involve the FoXc2 gene.34 
Other primary lymphoedema 
disorders
two other very rare forms of primary 
lymphoedema have been proposed to exist; 
lymphoedema associated with discoloured, 
slow growing and excessively curved nails 
(lymphoedema and yellow nail syndrome), 
and lymphoedema with ptosis. these may 
both represent poorly phenotyped cases rather 
than truly exist as separate entities, as yellow 
nails can be found in Milroy’s disease, Meige 
disease and lymphoedema-distichiasis, and 
ptosis occurs in lymphoedema-distichiasis.33
Many other syndromes are known to 
have lymphoedema as a clinical feature 
(table 27.2). lymphoedema may affect the 
whole body or can affect arms, legs, face, 
conjunctiva, and the genitalia in a segmen-
tal pattern. In primary lymphoedema, facial, 
conjunctival or genital lymphoedema is 
often associated with limb involvement. Sys-
temic disorders of the lymphatics include 
intestinal lymphangiectasia, chylous ascites, 
pleural effusions, pericardial effusions and 
pulmonary lymphangiectasia. the surgical 
treatment of these disorders is complex and 
may in involve ligation or excision of reflux-
ing lymphatics, or drainage procedures.
StRuctuRe anD 
DeVelopMent oF the 
lyMphatIc cIRculatIon
the lymphatic system consists of a vascular 
network of thin-walled, blind ended capil-
laries made up of a single-cell layer of 
endothelial cells joined by discontinuous 
button-like junctions that open in response 
to increased interstitial fluid pressure.35 
lymphatic capillaries have no basement 
membrane or supporting smooth muscle 
cells or pericytes, and so are highly 
permeable to protein-rich lymph fluid. they 
do, however, possess specialised anchoring 
filaments that link the endothelial cells to 
surrounding matrix and tissues; these help 
keep the capillaries open and increase their 
permeability as interstitial pressure rises.36-38 
the lymphatic capil laries converge into 
precollecting lymphatic vessels and these 
carry lymph to the main collecting trunks 
(e.g. the thoracic duct) for return to the 
venous circulation. unlike lymphatic capil-
laries, precollecting and collecting trunks 
contain smooth muscle cells and pericytes. 
collecting lymphatics also have internal 
valves to prevent retrograde flow of lymph 
fluid.
early research into the origin of the 
lymphatics relied on either injection of sub-
stances (dyes or resins) into the circulation or 
serial sectioning to visualise early lymphatic 
vessel and sac development. this resulted in 
two opposing models: the first proposed by 
anatomists and embryologists using injec-
tion techniques that the lymphatic vessels 
bud off the primitive veins and grow out by 
lymphangiogenesis;39 and the second that 
lymphatic vessels arise from the mesenchy-
mal spaces with lymphatic sacs coalescing to 
form vessels.40 
More recently molecular techniques have 
better characterised the origin of lymphatics 
in several models.41 Studies using VeGFR-3 
expression as a marker of lymphatic endothe-
lial cells (lecs) in an avian model have 
suggested a dual origin from mesodermal 
lymphangioblasts and adjacent veins42 and 
similar conclusions have been drawn in an 
amphibian model examining staged expres-
sion of the prospero-related homeobox gene, 
prox1.43 a number of other studies, both in 
mice and a zebrafish model, have concluded 
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that the majority of cells contributing to 
lec arise from primitive veins. If there is 
a haematopoietic contribution to lec this 
occurs relatively late and peripherally in 
their development, and may also contribute 
to postnatal physiological or pathological 
lymphangiogenesis.
the homeobox transcription factor, 
prox1 is required for lymphatic cell differ-
entiation. prox1 is exclusively expressed in 
a subpopulation of endothelial cells in the 
anterior cardinal vein that emerge from the 
vein and form lymph sacs.44 prox1 knock-
out mouse embryos do not develop lym-
phatic vessels44 with the budding embryonic 
venous endothelial cells defaulting to a blood 
vascular rather than lymphatic phenotype.45 
lineage tracing studies have provided further 
evidence that lecs sprout, proliferate and 
migrate from venous-derived lymph sacs and 
haematopoietic cells do not contribute to 
the mammalian lymphatic system.46 tempo-
ral inactivation of prox1 during embryonic 
and postnatal lymphangiogenesis causes loss 
of lec phenotype and reversion to a blood 
vessel endothelial phenotype.47
Recent studies suggest that the transcrip-
tion factor SoX18 controls prox1 expres-
sion. Mutations in SoX18 were identified in 
patients with hypotrichosis-lymphoedema-
telangiectasia syndrome.30 SoX18 directly 
controls prox1 expression by binding to its 
promoter; SoX18 knockout mice do not 
express prox1 in cardinal vein endothelial 
cells and develop gross oedema.32
Further proliferation and migration of 
lecs from embryonic veins is controlled by 
VeGFR-3. Initially expressed in both blood 
and lecs, expression becomes restricted 
during embryogenesis. as discussed above, 
mutations in VeGFR-3 cause Milroy’s 
disease in humans. VeGFc is the principal 
ligand of VeGFR-3; in VeGFc knockout 
mice lecS are correctly specified, as defined 
by the normal expression of lyVe-1, 
prox1 and VeGFR-3, but fail to proliferate 
and migrate.21 neuropilin-2 is a non- 
signalling transmembrane receptor that acts 
as a co-receptor for VeGFR-3; neuropilin-2 
knockout mice have lymphatic hypoplasia 
with normal development of arterial and 
venous vasculature.48 the transcription fac-
tor tbx1 activates VeGFR-3 expression in 
endothelial cells and is the major gene for 
DiGeorge syndrome in humans. tbx1 does 
not seem to be required for lec differen-
tiation but is needed for further growth and 
maintenance of lymphatic vessels; deletions 
in the gene cause widespread disruption of 
lymphangiogenesis.49
a number of other genes have been 
implic ated in further lymphatic matura-
tion and remodelling. Mutations in the 
forkhead transcription factor FoXc2 have 
been found in patients with lymphoedema-
distichiasis syndrome, as discussed above. 
lymphatic vessels are correctly differenti-
ated in FoXc2 knockout mice50 but there 
is abnormal recruitment of smooth muscle 
cells to lymphatic capillaries as well as agen-
esis of lymphatic valves.29 Recently FoXc2 
has been shown to play an important role 
in the formation of mature lymphatic col-
lectors, including the formation of valves, 
recruitment of mural cells and smooth mus-
cle, and pruning of branches.51 In addition 
the transcription factor nFatc1 interacts 
with FoXc2 binding enhancers during 
valve formation. 
Many other genes that have been implic-
ated in abnormal lymphatic maturation 
including angiopoietin-2,52 ephrinB2, 
aspp51, emilin1, Slp76 and Syk.41 For exam-
ple ang-2 knockout mice have subcutaneous 
oedema and chylous ascites; their lymphatics 
have a disorganised appearance, with poorly 
developed and disorganised circumferen-
tial smooth muscle coat. the relationship 
between these genes and human conditions 
has yet to be defined. platelets may also play 
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a role in separating blood and lymphatic ves-
sels during embryogenesis.53 understanding 
the mechanisms of lymphangiogenesis may 
lead to pro-lymphangiogenic treatments for 
lymphoedema.54
clInIcal aSpectS oF 
lyMphoeDeMa
Most patients present with unilateral leg 
swelling. at an early stage the swelling will 
easily pit if pressure is applied, but chronic 
lymphoedema is associated with fibrosis 
and the subcutaneous tissues become 
thickened and hard. at a microscopic level 
the perilymphatic space becomes chronic-
ally thickened with a granulofilamentous 
material containing degenerate elastic 
fibres and collagen. In the presence of 
poorly functioning lymphatics, interstitial 
fluid becomes stagnant and can become 
infected; sometimes an infection may be 
an initial event and the subsequent swelling 
is blamed on this, but it is more likely to 
be a consequence of pre-existing abnormal 
lymphatic drainage. Streptococcus pyogenes is 
the most common pathogen. patients may 
present with recurrent episodes of cellulitis, 
and each episode of infection predisposes 
to fibrosis and further lymphatic damage. 
acute inflammation induces hyperaemia 
and increased hydrostatic pressure as well 
as increased vascular permeability and so 
increases accumulation of protein rich 
interstitial fluid. endothelial derived nitrous 
oxide and oxygen free radicals are released; 
these are vasodilators and also inhibit the 
spontaneous tonic and phasic contractions 
of the lymphatic vessel wall smooth muscle, 
further reducing lymphatic flow.
Inguinal lymph nodes may be enlarged, 
especially if there is pelvic obstruction. cuta-
neous lymphatic vesicles or a capillary naevus 
are signs of underlying megalymphatics with 
reflux. Release of cytokines causes thickening 
of dermal keratinocytes and an acanthotic 
appearance of the dermis. Inflammatory cells 
migrate from the papillary dermal layers into 
the epidermal cell layer. Microfilament depo-
sition in the dermo-epidermal junction leads 
to a thickened epidermal basal lamina. this 
hyperplasia and hypertrophy of the dermal 
vascular endothelial and epidermal cells is 
responsible for the abnormal papillomatosis 
that develops in the skin of many patients 
with chronic lymphoedema. 
patients with megalymphatics may have 
chylous ascites, chyluria, chylometrorrhoea, 
chylothorax or other manifestations of 
lymphatic fistulae.
SuMMaRy
primary lymphoedema and other syndromes 
associated with lymphoedema cause sig-
nificant morbidity. Molecular techniques 
have greatly improved our understanding of 
lymphatic specification, lymphangiogenesis, 
and lymphatic maturation. the relevance of 
genetic abnormalities in the development 
of different types of primary lymphoedema 
is now being elucidated. Increased under-
standing of these mechanisms will increase the 
number of candidate genes for genetic testing 
in both idiopathic inherited and sporadic 
forms of lymphoedema. understanding of 
each of these processes will eventually lead 
to more effective treatments for disorders of 
the lymphatic system.
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tHe PatHoPHysioloGy oF 
GraFt HealinG
the mechanisms of graft healing are of 
central importance in understanding the 
successes and failures of current bypass 
grafts. the tissue response to implantation 
of a prosthetic graft is complex with many 
variable factors involved such as the material 
used, its construction, its porosity, and its 
length. Further important factors relate to 
the interaction between the graft and the host 
artery at the anastomotic areas. Until recently 
graft design focused on simple conduits for 
blood flow which were strong (resistant to 
pressure), biologically inert (resistant to 
biodegradation) and non-leaking. each of 
the major causes of graft failure, luminal 
thrombogenicity, compliance mismatch and 
anastomotic intimal hyperplasia, have the 
potential to be modulated if their aetiology 
could be better understood. a further stimulus 
to study of this area is the still unresolved 
puzzle of man’s inability to endothelialise a 
prosthetic graft beyond the immediate 2 cm 
or so from the anastomosis. 
The peri-anastomotic area
intimal or neointimal hyperplasia is a charac-
teristic healing reaction to vascular injury.1 
in prosthetic grafting the injury typically 
involves the direct trauma of implantation, 
and subsequent exposure of the anastomotic 
areas to haemodynamic stress (compliance 
mismatch, turbulent flow and altered 
shear stress). this results in injury which is 
transmural with endothelial removal, variable 
disruption of the internal elastic lamina and 
medial smooth muscle cells (sMC). 
the three phases of intimal hyperplasia 
will develop quite rapidly with the first being 
proliferation of medial smooth muscle cells 
as soon as 24 hours after injury and lasting 
up to 4 weeks. the second phase of sMC 
migration into the intima starts as early as 
4 days after injury and continues for about a 
month. the final phase is of intimal expan-
sion by the dual action of sMC migration 
and intimal proliferation by deposition of 
matrix proteins such as collagen, elastin 
and proteoglycan. this phase is complex and 
is mostly self-limiting but may continue 
un abated if certain factors are present, (refer 
to Chapter 7 for a more detailed discussion 
of intimal hyperplasia).
the endothelial cell plays a pivotal role via 
its mechanoreceptors which will be sensitive 
to changes in flow and shear stress. High shear 
stress, as found in laminar flow, promotes 
endothelial cell survival and quiescence, 
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and secretion of nitric oxide (no). low or 
changing shear stress direction (turbulent 
flow), promotes endothelial proliferation and 
apoptosis, shape change, and reduced secre-
tion of no. if by a process of flow change 
towards high shear stress and endothelialisa-
tion by regrowth in the injured area, a bal-
ance between stimulatory and inhibitory 
factors is achieved, the drive towards intimal 
hyperplasia will cease. if this balance is not 
achieved because of ongoing factors such 
as lack of endothelial cover, major haemo-
dynamic disturbance such as severe compli-
ance mismatch or turbulent flow with areas 
of stagnation and low shear stress, then the 
drive towards intimal hyperplasia will con-
tinue unabated leading to severe narrowing 
at the anastomosis and graft failure. in pros-
thetic grafting therefore several factors will 
persist which have the potential to promote 
intimal hyperplasia. 
Healing of prosthetic grafts
Healing of prosthetic grafts takes place by 
two main mechanisms, capillary in-growth 
through the graft wall, and growth of 
endothelial cells along the luminal surface 
of the graft from each anastomosis.2 studies 
of prosthetic graft healing in various animal 
models used short lengths of graft, typically 
10cm or less, which readily developed a full 
lining of endothelial cells. in man however, 
endothelialization is restricted to the first 
centimetre or two of the anastomotic regions 
with no evidence of healing having taken 
place beyond this area. this observation 
based on a few individual explants has led 
to the conviction that man is different from 
other species in his inability to endothelialise 
a graft.
The healing process at the anastomosis
endothelialisation along the graft from 
the host artery occurs more aggressively in 
animals compared to man. a review of all 
animal studies found that the average graft 
length was 10 cm with 89% being only 
5.5 cm. in all of these studies therefore it is 
very likely that anastomotic ingrowth was 
the sole avenue for endothelialization.4 
the speed of trans-anastomotic endothe-
lialization differs between species. Many of 
the models used young animals with rapid 
endothelialization but in low porosity grafts, 
endothelialization stopped 2 cm from the 
anastomosis. to set this species difference in 
context, trans-anastomotic endothelializa-
tion is 7–8 times more pronounced in any 
animal compared to man.4 two factors are 
foremost among the possible explanations. 
the first is the exclusive clinical use of low 
or zero porosity grafts. the second is the 
clinical reality of grafting performed in the 
sick and elderly in whom vascular cells are 
known from tissue culture studies to be less 
vigorous.
Graft porosity and permeability
the terms porosity and permeability are used 
interchangeably but have separate meanings. 
Permeability is the property of material 
to allow passage of substances through its 
interstices and classically is measured by the 
volume of water traversing a given area and 
pressure. Porosity refers to the spaces or pores 
that exist within the graft material, which 
depending on the material, may not traverse 
its entire thickness but end blindly. Zilla 
suggests that to facilitate transmural healing 
and endothelialization, graft spaces should be 
wide enough to allow ingrowth of a capillary 
tuft with accompanying fibroblasts or 
pericytes requiring minimum pore diameters 
of 60–80µm.4,9 Currently available grafts, 
even those described as having high porosity 
fail in this regard. (table 28.1)
Macrophages are the predominant 
inflam matory cells found in large num-
bers after implantation and later as part of 
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Table 28.1: The effects of graft porosity 
Low porosity ePTFE grafts: (<45µm of internodal distance)
•	 Low porosity ePTFE grafts (<30mm) no difference in healing between animal and human. 
•	 Within two weeks surface is covered with fibrin and platelet thrombus 15µm thick which over 
following months increases to between 80–300µm. 
•	 Pannus persists for years and is actively thrombogenic. 
•	 Ingrowth of connective tissue is limited to the outer graft wall.
High porosity ePTFE grafts: (>45µm internodal distance)
First layering similar to that of low porosity ePTFE grafts.
•	 In older animals very little ingrowth – luminal thrombus without any cellular component. 
•	 Early and spontaneous endothelialization is found in young animals.
•	 These changes happen as early as 1–2 weeks. 
– patches of endothelial cells and capillary orifices found approximately 100-500µm apart  
which proceed to confluence.3 
– These endothelial cells lie over a layer of arterial smooth muscle cells probably derived from 
pericytes. 
– Stable neo-intima evenly distributed along the surface, as compared to the limited peri-
anastomotic coverage in low porosity grafts. 
– This extensive endothelialization arises from cells reaching the luminal surface by 
transmural ingrowth. 
– In older primate models and also in the dog these developments take longer but only with 
sprouting capillaries reaching the outer third to one half of the graft wall.4
Low porosity Dacron grafts (woven)
•	 Immediately after implantation thin pannus of fibrin and platelets deposited on the surface. 
•	 Thrombus compacts over time and in man stabilises after one year.5
•	 Endothelialization does not happen either in animals or in humans.
– small islands of endothelial cells found after many years in explants in man.6,7
•	 Narrow graft interstices filled with fibrin. 
•	 Foreign body giant cell reaction present. 
•	 Variable spread of some capillaries and fibroblasts into interstitial spaces never breaks through 
the compacted fibrin of the inner lining.8
High porosity Dacron grafts (knitted)
•	 Initial pannus same as woven Dacron but develops to a thickness of 100–120µm increasing to 
500µm by six months. 
•	 In dogs and other animals this inner lining replaced with a confluent layer of smooth muscle 
cells resting directly on the graft surface, covered by endothelium. 
•	 These come from anastomotic ingrowth but in longer grafts endothelialization in the midgraft 
region fails to occur despite partial ingrowth of capillary fibroblasts from the adventitia. 
Prosthetic grafts made of PTFE and Dacron can show a degree of healing by endothelialization 
related to the porosity of the graft. High porosity PTFE grafts promised the best endothelialization 
but were not marketed because of concerns regarding long-term strength and the practical 
difficulties of haemorrhage and serum leakage through the graft wall at implantation.
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a chronic inflammatory process. soon after 
implantation, the interstices become filled 
with fibrin and matrix similar to any early 
wound. Macro phages form part of a normal 
inflammatory response releasing cytokines 
to stimulate migration and proliferation of 
fibroblasts and endothelial cells. in the later 
stages however, macrophages persisting in 
large number may have an adverse effect 
on healing and ingrowth. Consistently the 
outer portion of the graft has high concen-
trations of macrophages and foreign body 
giant cells while the deeper layers lose these 
cells, probably due to the dense impenetra-
ble nature of the fibrinous pannus. Dacron 
seems to be more inflammatory than poly-
tetrafluoroethylene (PtFe) where less giant 
cells develop. 
PHysiCal ProPerties oF 
ProstHetiC Materials
arterial wall pulsatility is due to a combination 
of elastic and viscous components inherent 
in the structure of the artery which can 
therefore be described as being viscoelastic. 
Most commonly this property is measured 
as compliance, defined as the ratio of change 
in diameter over change in blood pressure 
(percentage/mmHg × 10 –2). 
 arterial compliance is complex, having 
both longitudinal and circumferential com-
ponents but only this latter measurement 
is commonly quoted when the elasticity of 
different materials is compared. Compliance 
mismatch has been implicated as an impor-
tant factor in the performance of vascular 
grafts since 1976.10 this mismatch should be 
considered to have two major components, 
tubular and anastomotic.
Tubular compliance
Mismatch of tubular compliance is present 
when there is a significant difference in 
elasticity between the prosthetic graft and 
native artery. a compliant vessel acts as an 
elastic reservoir absorbing energy during 
systole which is released during diastole 
giving an extra push to pulsatile blood flow. 
a rigid conduit will consequently diminish 
this secondary pulsatile energy and reduce 
distal perfusion. at the interface between a 
compliant artery and a non-compliant graft, 
changes in impedance (defined as the resist-
ance to pulsatile flow) will diminish pulsatile 
energy by as much as 60%.11 Furthermore, 
optimal organ perfusion depends on pulsatile 
blood flow with a change from pulsatile to 
static perfusion shown to increase peripheral 
resistance by 10%.12 Finally, at the graft to 
artery interface there is wave reflection of 
pulsatile energy which can lead to increased 
velocity gradients and turbulence. as a result 
of these increased vibratory movements and 
mechanical stresses, endothelial damage and 
intimal hyperplasia occurs.
Anastomotic compliance mismatch
a sutured anastomosis generates a decrease in 
diameter and drop in compliance determined 
primarily by the lack of elasticity of the suture 
material. interrupted sutures give a more 
compliant anastomosis, while a continuous 
technique results in a ring of non-compliant 
suture material – both prolene and PtFe 
sutures are profoundly non-elastic. Within 
a few millimetres on either side of the 
suture line, there is a paradoxical increase 
of compliance which is known as the para-
anastomotic hyper-compliant zone (PHZ)13 
(Figure 28.1). intimal hyperplasia develops 
typically in these areas of hyper-compliance.
The compliance hypothesis of graft 
failure  
Compliance mismatch will lead to a region 
of excessive mechanical stress which can give 
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rise to subtle arterial wall injuries and initiate 
the first phase of intimal hyperplasia. Cyclical 
stretching is known to have a positive influ-
ence on proliferation of vascular smooth 
muscle cells and production of extracellular 
matrix. this increased cyclical stretch at the 
zones of PHZ, will cause proliferation of 
the smooth muscle cells. Finally changes in 
compliance are known to affect flow and shear 
stress. Where there is turbulent flow, there 
will be areas of low shear stress and this is 
known to promote endothelial proliferation, 
apoptosis and reduce production of nitric 
oxide. 
the clinical evidence for the compliance 
hypothesis is largely speculative but analysis 
of the clinical performance of grafts of dif-
fering compliance reveals a positive correla-
tion between compliance and patency rates 
(Figure 28.2). the most commonly used 
prosthetic grafts, namely PtFe and Dacron 
are profoundly rigid over the physiological 
pressure range. a feature of the visco-elastic 
nature of human artery is compliance which 
diminishes with increasing pressure but 
which increases exponentially as the mean 
pressure falls below 80mmHg (Figure 28.3). 
the ideal prosthetic graft should share this 
property. 
syntHetiC GraFts
the history of prosthetic grafts began in 
1952 with successful placement of Vinyon 
–n tubes into the abdominal aorta of dogs, 
and subsequent human implantation in 1954 
in 18 patients.14 an explosion of interest 
followed with synthetic grafts being made 
from various textiles but their major problem 
was loss of tensile strength. two materials 
proved to be resistant namely Dacron and 
PtFe, and because of their bio-durability 
have dominated graft development to this 
day. 
Newer developments of dacron grafts
Heparin coating has been utilised for 
improving biocompatibility of Dacron. 
Besides enhancing the function of heparin-
binding proteins, immobilised heparin also 
potentially reduces Dacron hydrophobicity. 
Figure 28.1: The peri-anastomotic hypercompliant zones (PHZ); compliance at the anastomosis is lower due 
to the suture (#) while compliance is increased compared to the vessel wall several mms from the anastomosis 
(*). This effect further aggravates compliance mismatch in bypass grafting.
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this change in surface chemistry might alter 
the proteins present at the interface, thereby 
influencing biocompatibility independent of 
the biological action of heparin. it has been 
shown that this is associated with exposure 
of the fibrinogen P2 epitope as well as the 
adhesion of monocytes.18 independent of 
the inflammatory response, the hydrophilic 
nature of the heparin coating may affect 
tissue interaction (reduction in cell adhesion, 
Figure 28.2: Correlation between typical compliance and 2 year patency of several graft materials in  
clinical use.
Figure 28.3: Compliance / Pressure curve for compliant polyurethane (CPU), Dacron (DAC), ePTFE (PTFE), 
human femoral artery (ART) and saphenous vein (VEIN). None of the prosthetic materials possess the visco-
elastic properties of artery and vein which give higher compliance at lower pressures. CPU maintains higher 
compliance at all pressures compared to Dacron or ePTFE. 
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growth and mobility). overall, compared to 
human umbilical vein (HUV) or PtFe, 
heparin-bonded Dacron shows significantly 
better primary patency up to 2 years but not 
at 5 years of follow-up.19,20
Modifications and newer 
developments of PTFE grafts
the ePtFe graft has been modified in various 
ways. thin wall ePtFe grafts have improved 
handling characteristics but still have an outer 
wrap to provide strength. stretch ePtFe 
grafts have improved longitudinal rather 
than circumferential elasticity with improved 
handling characteristics but no other benefit 
has been demonstrated in clinical studies. 
external support, either rings or spirals, is 
thought to be beneficial in extra-anatomic 
(axillo-femoral or femoro-femoral) or below 
knee grafts.
a further valuable adjunct shown in 
prospective studies to improve below knee 
PtFe graft patency is an interposition vein 
cuff or patch at the distal anastomosis.24 
this appears to improve the haemodynamic 
situation at the distal anastomosis perhaps 
acting through minimising compliance 
mismatch and improving blood flow.25
several reports indicate potential benefit 
with ePtFe aortic grafts including reduced 
bleeding and a lower risk of infection. the 
only prospective randomised comparison of 
ePtFe and Dacron aortic grafts, however, 
failed to show any difference.26 the suprem-
acy of ePtFe in lower limb bypass grafting 
has been challenged in a randomised trial 
which showed no difference between ePtFe 
and gelatin sealed Dacron.27,28
Heparin bonded PtFe is being widely 
utilised in contemporary practice. two year 
primary patency and limb salvage rates 
were similar to autologous saphenous vein 
in lower limb bypass including below-knee 
locations.29 While there are case series data 
implying that this is an effective material, 
results from randomised trials are awaited.20 
other ePtFe coating materials evaluated 
include citric-acid based biodegradable elas-
tomers. in porcine carotid artery circulation, 
they were found to be biocompatible with-
out causing increased risk of thrombosis, 
restenosis or inflammation.31 these findings 
are important as this may serve as the foun-
dation for a drug eluting vascular graft.
Polyurethane grafts
Polyurethanes are segmented polymers 
initially formulated in the early 60’s to 
provide elasticity in garment materials 
(lycra). these are a very large family of 
which the most important component is 
the urethane group present in repeating 
sequences on the main chain of the polymer. 
this forms the hard segment providing 
strength with the soft segment being the 
other main component (macromonomers 
ranging from hundreds to over a thousand 
Daltons). these hard and soft components 
have a degree of incompatibility which allows 
microphase separation delivering superior 
visco-elastic and compliant properties. 
Polyurethanes also possess excellent blood 
and tissue compatibility and are in extensive 
use in access catheters and linings of various 
prosthetic devices. Clinical experience of 
conventional polyurethane grafts has con-
firmed their superior thrombo-resistance, 
rapid ingrowth of living tissue and reduced 
anastomotic hyperplasia.32
Polyurethane vascular access grafts for 
haemodialysis have several advantages 
including easy cannulation, rapid compres-
sion haemostasis and early use after implant-
ation. Disadvantages with polyurethane 
grafts include poor patency rates when com-
pared with PtFe and most problematically 
hydrolytic degradation leading to aneurysm 
formation. it is this complication that has 
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limited their clinical use despite the advan-
tages of good compliance33-39 (table 28.1).
Newer developments of polyurethane 
vascular grafts
Conventional polyurethanes are bio-
degradable at the soft segment of the polymer 
particularly at the ester and ether groups in 
poly(ester)urethane and poly(ether)urethane. 
recent interest has focused on replacing 
these susceptible groups with other moieties 
in particular polycarbonate, which are more 
hydrolytically and oxidatively stable. one 
polycarbonate polyurethane is currently 
available for clinical use, Corvita (Corvita 
inc) and also a renal access graft composed 
of polyether polyurethane, the Vectra graft 
(Bard inc.). 
Development of a compliant small calibre 
vascular graft has been a major goal of our 
unit. the focus has been on a poly (carbon-
ate) polyurethane with a honeycomb struc-
ture (Figure 28.4) composed of an inner and 
outer skin enclosing a spongy middle wall 
thus maintaining pulsatile flow even after 
peri-graft tissue incorporation. Because this 
polymer lacks ether and ester compounds 
it resists biodegradation as proven both in 
vitro, and in long term implantation study. 
Comparison of this graft with artery, vein, 
Dacron and PtFe shows compliance similar 
to artery at mean pressures of 30–60 mm Hg, 
with very significantly superior compliance 
compared to Dacron or PtFe at all pressures 
(Figure 28.3).42,43 soldani et al have devel-
oped a new compliant small diameter graft 
with a poly (ether) urethane–polydimeth-
ylsiloxane semi-interpenetrating polymeric 
network and featuring two different porous 
wall layers; this showed superior compliance 
and patency rates in comparison with stand-
ard ePtFe, with the ability of remodeling 
in vivo being gradually replaced by natural 
tissue with no sign of calcification.44
in addition, small-diameter poly (epsilon-
caprolactone) grafts represent a promising 
alternative polyurethane with better healing 
characteristics compared with ePtFe giving 
Figure 28.4: Compliant polyurethane graft with external support; The sponge-like structure of the wall allows 
pulsatile elastic recoil even with external support and after perigraft tissue incorporation has taken place.
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faster endothelialisation and extracellular 
matrix formation, accompanied by resistance 
to structural deterioration during remodel-
ling.45,46 
reinforced polyurethane grafts using 
polyester filament yarns knitted into tubu-
lar fabrics to form a composite vascular graft 
have been demonstrated to be 5–10 times 
stronger than pure polyurethane grafts.47 a 
bioengineered microporous polycarbonate-
siloxane polyurethane graft has been devel-
oped for coronary artery bypass grafting. 
Biological agents including heparin and 
sirolimus can be impregnated into its absorb-
able collagen and hyaluronan microstruc-
ture giving a unique drug-eluting graft with 
endothelialisation without excessive intimal 
hyperplasia.48 Biodegradable polymer sys-
tems provide the opportunity for release of 
various growth factors to promote vascular 
wall regeneration. For example, fibroblast 
growth factor-2 (FGF-2) release from poly 
(ester urethane) urea scaffolds amalgamates 
the favourable mechanical properties of 
polyurethanes with the bioactivity of an 
angio genic protein.49
nitric oxide releasing polyurethanes 
reduce platelet adhesion and vascular smooth 
muscle cell growth, while stimulating 
endo thelial cell growth.50 Furthermore, the 
elastomeric copolymer, poly(1,8-octanediol 
citrate), with mechanical and degradation 
prop erties suitable for vascular tissue engi-
neering, decreases platelet adhesion.51 in 
vitro studies evaluating the biocompatibility 
of these mate rials confirm their potential for 
vascular graft coatings.52
although tissue-engineered vascular 
grafts based on biodegradable polymers have 
yielded promising results, some drawbacks 
exist. Challenges of cell sourcing are com-
pounded by long culture periods that range 
between 2 and 6 months, and the prolifera-
tive capacity of cells isolated from elderly 
patients is lim ited. 
Biological vascular grafts
Biografts, vascular grafts made from 
biological sources, have been used over 
many years. allografts (sourced from the 
same species) in current use are primarily 
umbilical and saphenous vein. Xenografts 
(derived from other species) have a long 
history with disappointing results and there 
is no xenograft currently in clinical use.
the major problems with biografts are 
biodegradation and immunogenicity which 
can be counteracted by chemical treatment 
and cryopreservation. the first clinical use 
of an allograft was in 1948 in the treatment 
of aortic coarctation.53 arterial allografts 
harvested from cadavers were first used in 
the 1960s to perform lower limb bypass but 
these were prone to significant degeneration, 
aneurysm formation and wall calcification.54
improved cryo-preservation with protect-
ant solutions to prevent intra-cellular ice crys-
tals on thawing, allowed the development of 
tissue banks to provide a ready source of allo-
grafts. Clinical use of cryopreserved allografts 
in the 1960s showed good short term func-
tion and the attractive possibility that cryop-
reservation might reduce immunogenicity.55 
Further clinical experience however revealed 
disappointing one year patency rates of less 
than 50%.56 the stable functioning of arte-
rial and venous grafts in human liver trans-
plantation suggests that immuno-suppressive 
therapy will improve the function of these 
grafts. However the associated complications 
probably make this approach unacceptable. 
Xenografts were introduced in the 1970s, 
most commonly the bovine carotid artery. 
Various chemicals including glutaraldehyde 
were used to cross link collagen to provide 
stability and reduced immunogenicity. Clini-
cal success rates of these xenografts were poor 
with biodegradation after 6 months due to 
progressive breakdown of the collagen cross 
linkages. 
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the human umbilical cord vein was 
developed as a bypass graft by Drs irving 
and Dardik.57 this was stabilised using glu-
taraldehyde supported by an external Dacron 
mesh and used specifically in lower limb 
bypass grafting but were prone to aneurysmal 
degeneration. Deficiencies in the manufactur-
ing process were corrected in the late eighties 
with apparent significant reduction of this 
problem. the graft, however, never regained 
popularity despite impressive results in a large 
series of 1,275 cases (five year secondary pat-
ency rates of 71% for femoro-popliteal and 
56% for femoro-crural bypass).58
Newer developments of biological 
vascular grafts
Bacterial cellulose is a novel vascular 
material with the potential to reduce 
surface thrombogenicity. in vitro it had the 
slowest activation of coagulation cascade 
as compared to standard synthetic graft 
materials.59 Bacterial cellulose has the added 
advantage of promoting in situ vascular 
tissue regeneration,60 so it has potential as a 
scaffold for small bore vascular grafts. 
a fibrin scaffold supported by a poly 
lactide mesh, and seeded with autologous 
arterial-derived cells prior to dynamic con-
ditioning has been used to develop condi-
tioned grafts with good mid-term patency 
and no evidence of thrombosis, aneurysm 
formation or calcification in vivo.61 they also 
show a confluent monolayer of endothelial 
cells lining the inner surface of the graft. the 
integrated biodegradable polylactide mesh 
has also been used to provide temporary 
mechanical support during the initial period 
of tissue development, while an autologous 
fibrin cell carrier system acts as the basis 
of remodeling the entire graft into a viable 
tissue structure.62 
the in-vivo evaluation of cryopreserved 
human umbilical arteries treated with poly 
(styrene sulfonate)/ poly (allylamine hydro-
chloride) has demonstrated a high graft 
patency after 3 months of implantation.63 an 
allogenic vascular graft has also been devel-
oped from a decellularised scaffold prepared 
from canine carotid arteries and modified 
through heparin immobilisation and vascular 
endothelial growth factor (VeGF) coating.64 
l’Heureux et al. have demonstrated the 
feasibility of assembling arterial bypass grafts 
exclusively from autologous cells in primate 
models.65 no synthetic or exogenous mater-
ials were used; instead, the vessels were 
created with the use of autologous fibroblasts 
and endothelial cells harvested from a small 
biopsy specimen of skin and superficial vein. 
in vivo results indi cated that the grafts were 
antithrombogenic and mechanically stable 
for 8 months, with histology and micros-
copy displaying complete tissue integration, 
regeneration of a vascular media, as well as 





Graft infection is a devastating complication 
particularly in the modern era of increasing 
methicillin-resistant Staphlococcus aureus 
(Mrsa) infection. several different strategies 
have been employed to reduce the risk of 
infection. the simplest approach is soaking 
grafts coated with albumin, collagen or gelatin 
with antibiotics, in particular rifampicin.66 
Gelatin sealed grafts prebonded with two 
antibiotics have shown resistance to infection 
by Staphylococcus aureus in a dog model.67 
in vitro studies show that antibacterial levels 
of rifampicin will remain present for 48 to 
72 hours with reduced risk of graft infection 
to bacterial challenge.68
the clinical experience of rifampicin 
bonded Dacron grafts relates to two random-
ised controlled trials the first from italy in 
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aorto-femoral grafts and the second from the 
United Kingdom in extra-anatomical bypass 
grafts. there was no long term benefit in 
terms of reduced graft infection rate found 
although early wound infection rates were 
found to be significantly reduced.69,70 How-
ever, these grafts should be used with caution 
because it has been noted that in approxi-
mately 30% of cases, microbial organisms 
isolated from infected grafts are resistant to 
rifampicin.71
a further approach to reducing infec-
tion is the binding of triclosan (irgason) to 
grafts. this is an antimicrobial with broad 
spectrum activity which in experimental 
studies appears to bind effectively to dacron 
grafts for four weeks.72 silver bonded PtFe 
grafts have been shown experimentally to 
reduce the risk of infection, and are currently 
available for clinical use73 (interguard silver 
Graft. interVascular, France). However, in 
vivo comparison in a dog model between 
rifampicin /gelatin sealed and silver/collagen 
coated Dacron grafts, revealed significantly 
greater resistance to infection for rifampicin 
bonding.74 silver-coated grafts did not dif-
fer from standard grafts and had no effect 
on reducing graft infection in a recent 
retrospect ive study.75
the other experimental strategies pro-
posed include direct pre-treatment with 
soaking prosthetic grafts in antibiotic solu-
tion (Daptomycin) which has been dissolved 
in a fibrin sealant.76 at present, all graft 
modifications intended to reduce the risk of 
infection in arterial reconstruction, although 
promising, lack evidence of effectiveness.77
Modifications to improve patency
Carbon has been used because of its lack 
of reactivity and potential reduction of 
luminal thrombogenicity with flowing 
blood. experimental studies have suggested 
improved primary and secondary patency 
rates.78 Prospective randomised comparison 
of carbon impregnated PtFe grafts with 
standard PtFe found no significant 
difference at 2 years but with a trend for 
improved patency in the carbon graft.79 
as shown earlier heparin bonded Dacron 
shows only short-term advantage in improv-
ing primary patency. a commercially available 
graft is the Fluoropassiv (terumo-Vascutek), 
a Dacron graft coated with a fluoropoly-
mer which has been shown in experimental 
studies to cause less tissue reaction and to 
have reduced thrombogenicity.80 there are 
no clinical data available to confirm any 
beneficial effect of this graft. 
Nanocomposite Grafts
recent developments in the field of nano-
te chnology have facilitated vascular tissue-
engi neering mimicking the nanostruc ture 
of native vessels. one such application is 
electro spinning of synthetic polymers into 
nanofibers.81-84 the advantages of forming 
scaffolds with high porosity as well as 
high surface area-to-volume ratio, thus 
simulating the dimensions and structure of 
native collagen and elastin fibrils holds great 
promise for future off-the-shelf-grafts.85,86
our group has developed a family of 
nanocomposite polymers-based on poly-
hedral oligomeric silsesquioxanes (Poss) 
and poly (carbonate-urea) urethane (PCU). 
Poss-PCU has been used to develop a small 
diameter bypass graft which shows match-
ing viscoelastic properties to human arter-
ies.87 Furthermore, a biofunctionalised small 
diameter graft based on this nanocompos-
ite polymer demonstrates the potential for 
relatively rapid endothelialisation from pro-
genitor cells extracted from peripheral blood 
in an in vitro model.87 an extrusion-phase-
inversion technique is used to make uniform 
walled porous conduits from Poss-PCU. 
these elastic microporous grafts demonstrate 
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favourable mechanical integrity and are 
currently undergoing in-vivo evaluation of 
durability and healing properties.88 
other groups have utilised the strength 
and flexibility of carbon nanotubes as 
fillers to enhance base polymer properties but 
although these composite polymers decrease 
thrombogenicity, toxicity of carbon nano-
tubes remains a concern.89,90
enDotHelial Cell seeDinG 
achieving endothelial cell coverage is 
impor tant in improving graft performance. 
endothelial cells have been extracted from 
three main sources – vein, subcutaneous fat 
and omentum.91 Further potentially promising 
sources are from bone marrow, circulating 
blood and mesenchymal stem cells. there is 
good experimental evidence to support the 
benefit of endothelial cell seeding of bypass 
grafts. these have better patency rates, are 
less thrombogenic, will tolerate low flow 
states and have been shown to have normal 
endothelial cell activity.92 in addition seeded 
grafts have been shown to resist bacteraemic 
infection in animal models.93-95
Single stage seeding
single stage seeding requires sourcing 
of larger numbers of endothelial cells to 
allow immediate seeding of the graft at 
implantation. With this method seeding is 
not expected to be fully confluent but rather 
is achieved over the early post-implantation 
period by endothelial cell replication. 
Herring and his colleagues in 1978 were 
the first to report the seeding of Dacron 
grafts in a dog model and showed that 
PtFe seeded more rapidly and completely 
than Dacron.9,96 this group confirmed in 
an explant from a patient that endothelium 
was present in the mid-portion of the graft 
some months after implantation.97,98 a 
further clinical study demonstrated reduced 
thrombogenicity in the endothelialised limb 
compared to the non-seeded contralateral 
limb of aorto-bi-femoral grafts.99 the major 
disadvantage of one stage seeding is a lack of 
sources of sufficient cells to allow immediate 
seeding.
Two stage seeding
two stage seeding involves harvesting a 
modest quantity of endothelial cells typically 
from a vein, and culturing sufficient 
numbers for confluent seeding. a group 
in Vienna have performed the largest and 
the most detailed study in man using two 
stage seeding with endothelial cells harvested 
from cephalic or jugular veins.100 the ePtFe 
grafts were pre-coated with fibrin glue and 
then seeded with the patient’s own cultured 
endothelial cells. this group’s experience is 
of 213 patients with patency for below knee 
reconstructions of 68% at 5 and 7 years, and 
65% at nine years.101 endothelial cell seeding 
has been successful in coronary artery bypass 
with a recent trial using two stage seeding 
of ePtFe reporting 90.5% patency rate at 
28 months.102 these early clinical results are 
very promising but two stage cell seeding 
is cumbersome, and not easily applicable 
particularly in emergency revascularisation. 
VasCUlar tissUe 
enGineerinG
there are three major approaches to creating 
blood vessels. the first is in the addition of 
vascular cells to synthetic polymers of which 
seeding of existing graft materials forms the 
most basic example. the second approach 
is in the development of bioresorbable or 
biodegradable grafts made of polymers 
which will be absorbed to varying speeds and 
degrees with eventual replacement by host 
tissue. the third approach is that of growing 
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new grafts in tissue culture made from 
endothelial cell, vascular smooth muscle cell, 
collagen and matrix. 
Non-degradable polymer and cell 
seeding 
Deutsch and colleagues in Vienna showed 
in explants of endothelial cell seeded PtFe 
grafts that a neo-media develops between the 
prosthesis and the endothelium throughout 
the entire length of the graft.103,104 the cells 
in the neo-media contained actin filaments 
and a true internal elastic membrane 
had developed to separate them from the 
endothelial layer. Probably the original 
inoculums of endothelial cells obtained 
from cephalic or jugular vein had been 
contaminated with some vascular smooth 
muscle cells or pericytes. there has been 
much debate in the past as to whether 
endothelial cells for seeding should be pure 
or whether there would be benefit from 
inclusion of vascular smooth muscle cells or 
pericytes. this finding of a neo-media with 
a well developed internal elastic membrane 
providing an inner structure very similar 
to that of a normal artery lends support to 
the argument that co-culturing of cells of 
vascular origin would be beneficial.
the reintroduction of high porosity 
prosthetic grafts (i.e. pores >90µm) merits 
further study. impermeability at the time 
of implantation using established impreg-
nation methodology avoids the risk of 
haemorrhage. once the sealant is absorbed, 
capillary tuft ingrowth with development of 
a media and intima may result. an alterna-
tive approach would be to develop highly 
porous prosthetic grafts pre-seeded with vas-
cular smooth muscle cells, collagen, and with 
a seeded inner layer of endothelial cells. the 
newer bio-resistant polyurethane polymers 




the concept of degradable or absorbable 
graft materials providing initial vessel 
integrity but in time replaced by the host’s 
own tissues has been under development for 
some time.105,106
Polyglycolic and polylactic acid are the 
two bioresorbable polymers which have 
been most fully investigated. in addition to 
polydioxanone, these are the polymers which 
have FDa approval and for this reason are 
the preferred materials.107 Polyglycolic acid 
is susceptible to in-vivo hydrolysis after 
2–4 weeks. Polylactic acid is more resistant to 
hydrolysis in-vivo and in the form of, l-poly-
lactic acid, has high mechanical strength. Co- 
polymers of these two substances are in 
wide use as absorbable sutures and are 
better known as vicryl and polyglactin 910 
(PG910). Poly dioxanone, otherwise know 
as PDs, is a much more slowly reabsorbed 
compound. the first fully bioresorbable 
vascular graft was made from sheets of vicryl 
but became aneurysmal.108
Greisler’s group in Chicago has contrib-
uted significantly in this field initially mak-
ing grafts from woven polyglycolic acid for a 
rabbit model.109,110 Four weeks after implant-
ation a confluent layer of endothelial cells 
with a medial layer of myofibroblasts sur-
rounded by dense collagen fibres was found. 
ten percent became aneurysmal early on 
probably because of reabsorption before ade-
quate ingrowth of host tissue. Grafts made 
of polydioxanone (PDs) were more slowly 
reabsorbed for up to six months. similar tis-
sue ingrowth as in the previous experiments 
with full endothelialisation over a neo-media 
was found. these were strong grafts able to 
withstand very high static bursting pressures 
(600-2000 mmHg).111
Greisler’s group then reported a compos-
ite bioresorbable graft of 74% PG910 and 
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26% PDs which at one year in a rabbit aorta 
model had 100% patency with no aneurys-
mal degeneration. Complete reabsorption 
of PG910 took place within 2 months and 
PDs within 6 months. these arteries with-
stood up to 800mmHg of pulsatile pres-
sure.112 Composite partially resorbable grafts 
were next looked at in two grafts, the first 
constituted of 69% PG910 and 31% poly-
propylene, and the second of 70% PDs and 
30% polypropylene. in a dog aorto-iliac 
interposition model, one year patency rates 
of 90% for the former graft and 86% for 
the latter graft were found.113 Despite these 
experimental successes, so far no bioresorb-




later work focused on the concept of a 
graft composed of autologous vascular cells 
with a bioresorbable scaffold providing 
sufficient strength during tissue ingrowth 
and replacement.114 the first report was of 
smooth muscle cell seeding onto polylactic 
acid scaffold in a rat model where a 
neomedia with vascular orientation of cells 
was found.115 langer and Vacanti reported 
the successful development of a tubular 
scaffold made of woven polyglactin as an 
outer layer and an inner layer of non-woven 
polyglactin onto which autologous cells were 
seeded. after seven days of culture the vessels 
were implanted into sheep pulmonary artery 
with 7 grafts remaining patent for up to 
3 months. the polymer scaffold was found 
to be replaced as expected by host cells and 
matrix, but these grafts dilated.
a more robust graft was produced using 
a composite scaffold of polyglycolic acid as 
an inner layer designed to degrade by two 
months, and polyhydroxy alkanoate as an 
outer non-porous layer, designed to degrade 
much more slowly. this graft was implanted 
into sheep abdominal aorta with full pat-
ency and no dilatation being found at up to 
150 days and complete replacement by host 
tissue. a normal endothelial layer and a 
vascular media containing collagen and elas-
tin were found.116,117
surface modulation of polyglycolic acid 
polymer with 1n naoH increases absorp-
tion of seeded smooth muscle cells.118 the 
rGD peptide, a component of fibronectin, 
is known to promote endothelial cell attach-
ment and also influence cell differentiation.119 
Much work is now focused on the incorpora-
tion of rGD peptide sequence onto polymer 
surfaces to enhance endothelial attachment. 
a further promising approach is the incorp-
oration of biologically active substances, for 
example vascular endothelial growth factor 
and basic fibroblast growth factor in order 
to stimulate and modulate the differen-




the exposure of smooth muscle cell seeded 
scaffolds to physiological and pulsatile 
pressures results in orientation into multi-
layers with collagen fibrils in the extracellular 
matrix.121 elastin and proteoglycans are 
also released into the extra-cellular matrix 
after 8 to 16 weeks of exposure to arterial 
circulation.122 Furthermore conditioning 
of seeded endothelial cells by exposure to 
pulsatile flow and shear stress has been shown 
to improve proliferation and adhesion.123
Alternative scaffolds
Biocompatible and biodegradable synthetic 
polymers made by recombinant Dna 
technology are under development. examples 
include the elastic protein-based polymers 
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such as poly (GVGP), a repeating sequence 
in the elastin molecule. Carboxy-amides are 
chemical moieties which will hydrolyse at 
varying times depending on the amino acid 
sequence. By selection of carboxy-amides 
for inclusion in the structure of the poly 
(GVGPV) polymer a planned degradation rate 
can potentially be incorporated. Differential 
degradation, resorption and replacement by 
host tissue of several layers of a graft can 
therefore be achieved while maintaining its 
structural integrity.124 these polymers have 
excellent elasticity and proven optimised cell 
attachment due to incorporation of rGD 
sequences.125 
Decellularised vessels have well pre-
served collagen fibres theoretically ideal 
for ingrowth. Good long term results from 
allogenic decellularised biological scaffolds 
have been reported with minimal immuno-
reactivity126 but this initial promise was not 
maintained in further experimental studies. 
Xenografts would be practical for human 
implantation but unfortunately even decel-
lularised scaffolds maintain a significant 
degree of immunogenicity and inflamma-
tory response sufficient to destroy elastin.127 
endothelial cell seeding with autologous 
cells has not been successful in reducing their 
immunogenicity and thrombogenecity.128 
although a very promising concept the con-
tinuing problems of antigenicity make their 
clinical application unlikely. 
a poly-l-lactide/poly-epsilon-caprolactone 
scaffold releasing heparin by a combina-
tion of electrospinning and fused deposition 
modeling technique has been used. this par-
ticular scaffold design allowed the generation 
of both a drug delivery system amenable to 
surmount thrombogenic issues and a micro-
environment able to induce endothelial dif-
ferentiation.129 silk-based fibroin grafts have 
been developed and they provide excellent 
patency when implanted in smaller vessels.130 
the fibroin graft gradually degraded with 
formation of an artery-like structure by 
endogenous endothelial cells and smooth 
muscle cells. Fibroin may hold the promise 
to generate vascular prostheses for smaller-
diameter arteries. 
Genetically-modified cells have also been 
considered for the construction of vascular 
replacements. For example, genetically- 
modified endothelial cells over-expressing 
tissue pl asminogen activator (t-Pa) and 
urokinase-type Pa, or bone marrow mesen-
chymal stem cells transduced to express 
endothelial nitric oxide synthase (enos), 
would promote cell repopulation of the graft 
and help to eliminate thrombotic events.131 
Growth-regulating substances, growth fac-
tors or antimigratory and antiproliferative 
drugs have been incorporated directly into 
prosthesis wall or delivered through drug-
eluting stents, catheters and perivascular 
collars.132,133 artificial materials releasing 
nitric oxide (no) are also being developed, 
consisting of synthetic polymers incorpor-
ated with no donors such as diazenium-
diolates and s-nitrosothiols.134
Tissue-engineered grafts
Blood vessels made purely from biological 
materials and vascular cells have the 
major potential advantage of a vaso-
active biological conduit which can both 
heal and remodel according to changing 
environment. in Japan Hiraj and Matsuda 
developed a graft from canine vascular 
cells and collagen which proved resistant 
to physiological pressures only with a 
dacron backbone.135 in 1998 the Quebec 
group reported the first successful totally 
biological graft made from cultured human 
umbilical vein cells which withstood 
physiological pressures.136 the addition 
of a period of pulsatile culture following 
an initial static culture of smooth muscle 
cells and collagen reliably produces grafts 
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which are strong and resistant to supra-
physiological burst pressures.137,138
all work in this field has been based on 
young cells. the successful translation of 
these promising developments to clinical 
application requires proof that adult or senile 
vascular cells will behave similarly. such cells 
will have to come from each individual vascu-
lar patient until such time as pluri-potential, 
non-immunogenic cells can be sourced. 
GraFt Materials For aortiC 
enDoGraFts
the endografts in current clinical use are 
mainly made from either thin woven polyester 
(Dacron) or ePtFe. sac enlargement after 
endovascular aneurysm repair (eVar), 
without evidence of endoleak, has been 
attributed largely to endotension or material 
porosity. the first-generation Gore excluder 
graft allowed serous transudate contributing 
to continued sac pressurization. aneurx 
grafts had a higher incidence of microleaks, 
or persistent transgraft blood flow, occurring 
through the thin graft material. the excluder 
and aneurx devices modified their graft 
material in 2004 with subsequent reduced 
permeability.139 stent and graft materials 
have different mechanical properties and 
any repetitive movement between them may 
damage the fabric. stronger sutures and 
tighter weaves have made current designs 
more stable, but none is yet free from fabric 
graft failure.140 
research has also been targeted to improve 
the delivery profile of endografts, which is a 
main limiting factor in utilisation of these 
grafts for thoracic aneurysms. one such 
approach is to use thin-film nitinol (niti) 
and early in vitro results have confirmed its 
feasibility.141 this device is presently being 
tested in animal models.
With the availability of new materi-
als, reducing mismatch in aortic stiffness 
and compliance may become important 
in future eVar grafts. indeed, some dif-
ferences in presently used materials have 
already been observed by van Herwaarden 
and colleagues finding differences in compli-
ance between Gore excluder and Medtronic 
talent stent-grafts at the level of aneurysm 
neck.142 in the next decade, we can expect 
continuing improvements in device design. 
Plasmid-loaded cationized gelatin (CG) 
hydrogel-coated stent grafts offer transduc-
tion of therapeutic genes into the vascular 
wall facilitating the biologic healing between 
the aorta and graft.143 novel graft materi-
als such as Poss-PCU have the potential 
to deliver compliance, antithrombogenicity, 
biocompatibility and spontaneous endothe-
lialisation to provide better configurations 
and reduce the risk of complications. 
tHe FUtUre
over the next 5 years improved prosthetic 
grafts will become available with the 
introduction of biodurable and compliant 
materials. lumen modulation by anti-
coagulant molecules, cell ligands and growth 
factors will further enhance performance thus 
adding thromboresistance to compliance. 
attachment technology will allow Dacron 
and PtFe to be similarly modified although 
these can never be sufficiently compliant to 
abolish compliance mismatch.
new compliant graft materials will be 
developed using novel spinning technologies 
to incorporate collagen and elastin polymers 
resistant to degradation. the technology for 
totally bioresorbable grafts is already in clini-
cal use for paediatric cardiovascular recon-
struction and its applicability to adult use is 
under study. similarly the development of 
totally autologous tissue engineered grafts 
is in its infancy. endothelial cell seeding is 
clinically proven but cumbersome. With 
ongoing development to match as closely as 
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possible the mechanical characteristics and 
functions of normal human arteries there 
is real potential for new graft development 
within the next decade.
reFerenCes
1. Kraiss lW, Clowes aW. response of 
the arterial wall to injury and intimal 
hyperplasia. in: sidaway an, sumpio 
Be, De Palma rG, editors. the Basic 
science of Vascular Disease. armonk, 
ny: Futura Publishing Company inc.; 
1997; 289–317.
2. shi Q, Wu MHD, Hayashida n, 
Wechezak ar, Clowes aW, sauvage lr. 
Proof of Fallout endothelialization of 
impervious Dacron Grafts in the aorta 
and inferior Vena-Cava of the Dog.  
Journal of Vascular Surgery 1994; 20(4): 
546–557.
3. Clowes aW, Zacharias rK,  
Kirkman tr. early endothelial 
Coverage of synthetic arterial Grafts – 
Porosity revisited. American Journal of 
Surgery 1987; 153(5): 501–504.
4. Davids l, Dower t, Zilla P. the lack 
of healing in conventional vascular 
grafts. in: Zilla PGH, editor. in tissue 
engineering of prosthetic vascular 
grafts. r. G. lands Co ltd. Usa; 
1999. 4–44.
5. Pepper Ms, Belin D, Montesano r, 
orci l, Vassalli JD. transforming 
Growth Factor-Beta-1 Modulates Basic 
Fibroblast Growth-Factor induced 
Proteolytic and angiogenic Properties 
of endothelial-Cells invitro. Journal of 
Cell Biology 1990; 111(2): 743–755.
6. Wu MHD, shi Q, Wechezak ar, 
Clowes aW, Gordon il, sauvage lr. 
Definitive Proof of endothelialization 
of a Dacron arterial Prosthesis in 
a Human-Being. Journal of Vascular 
Surgery 1995; 21(5): 862–867.
 7. shi Q, Wu MHD, onuki y, Ghali r,  
Hunter GC, Johansen KH et al. 
endothelium on the flow surface of 
human aortic Dacron vascular grafts. 
Journal of Vascular Surgery 1997; 25(4): 
736–742.
 8. Berger K, Wood sJ, sauvage lr,  
rao aM. Healing of arterial Prostheses 
in Man – its incompleteness. Annals of 
Surgery 1972; 175(1): 118–&.
 9. Herring M, Baughman s, Glover J, 
Kesler K, Jesseph J, Campbell J et al. 
endothelial seeding of Dacron and 
Polytetrafluoroethylene Grafts – the 
Cellular events of Healing. Surgery 
1984; 96(4): 745–755.
10. Baird rn, abbott WM. Pulsatile 
Blood-Flow in arterial Grafts. Lancet 
1976; 2(7992): 948–949.
11. strandness De, summer Ds. 
Hemodynamics for the surgeon. Grune 
and stratton inc Pub. new york; 1975.
12. Giron F, Birtwell WC, soroff Hs, 
Deterlin.ra. Hemodynamic effects 
of Pulsatile and nonpulsatile Flow. 
Archives of Surgery 1966; 93(5):  
802–&.
13. Hasson Je, Megerman J, abbott WM. 
increased Compliance near Vascular 
anastomoses. Journal of Vascular 
Surgery 1985; 2(3): 419–423.
14. Blakemore aH, Voorhees aB. the Use 
of tubes Constructed from Vinyon 
n-Cloth in Bridging arterial Defects 
– experimental and Clinical. Annals of 
Surgery 1954; 140(3): 324–334.
15. stewart GJ, essa n, Chang KHy, 
reichle Fa. scanning and transmission 
electron-Microscope study of luminal 
Coating on Dacron Prostheses in 
Canine thoracic aorta. Journal of 
Laboratory and Clinical Medicine 1975; 
85(2): 208–226.
16. sauvage lr, Berger K, Wood sJ, 
nakagawa y, MansFiel.PB. external 
Mechanisms of Vascular Disease528
Velour surface for Porous arterial 
Prostheses. Surgery 1971; 70(6):  
940–&.
17. Goldman M, Mccollum Cn,  
Hawker rJ, Drolc Z, slaney G. 
Dacron arterial Grafts – the influence 
of Porosity, Velour, and Maturity on 
thrombogenicity. Surgery 1982; 92(6): 
947–952.
18. van Bilsen PH, Krenning G, Billy D,  
Duval Jl, Huurdeman-Vincent J, 
van luyn MJ. Heparin coating of 
poly(ethylene terephthalate) decreases 
hydrophobicity, monocyte/leukocyte 
interaction and tissue interaction. 
Colloids Surf B Biointerfaces 2008; 
67(1): 46–53.
19. scharn DM, Dirven M,  
Barendregt WB, Boll aP, roelofs D, 
van d, V. Human umbilical vein versus 
heparin-bonded polyester for femoro-
popliteal bypass:  5-year results of a 
prospective randomized multicentre 
trial. Eur J Vasc Endovasc Surg 2008; 
35(1): 61–67.
20. twine CP, Mclain aD. Graft type 
for femoro-popliteal bypass surgery. 
Cochrane Database of systematic 
reviews 2010;(5): CD001487.
21. Campbell CD, Brooks DH,  
Webster MW, Bahnson Ht. 
Use of expanded Microporous 
Polytetrafluoroethylene for limb 
salvage – Preliminary-report. Surgery 
1976; 79(5): 485–491.
22. Campbell CD, Brooks DH,  
Webster MW, Bondi rP, lloyd JC,  
Hynes MF et al. addendum – 
aneurysm Formation in expanded 
Polytetrafluoroethylene Prostheses. 
Surgery 1976; 79(5): 491–493.
23. Gupta sK, Veith FJ, Kram HB, 
Wengerter Kr. Prospective, 
randomized Comparison of ringed 
and nonringed Polytetrafluoroethylene 
Femoropopliteal Bypass Grafts – a 
Preliminary-report. Journal of Vascular 
Surgery 1991; 13(1): 162–172.
24. stonebridge Pa, Prescott rJ,  
ruckley CV. randomized 
trial comparing infrainguinal 
polytetrafluoroethylene bypass grafting 
with and without vein interposition 
cuff at the distal anastomosis. Journal 
of Vascular Surgery 1997; 26(4):  
543–550.
25. tyrrell Mr, Chester JF, Vipond Mn, 
Clarke GH, taylor rs, Wolfe JHn. 
experimental evidence to support  
the use of interposition vein collars/
patches in distal PtFe anastomoses. 
european Journal of Vascular  
Surgery 4: 95–101. 1990. ref type: 
Generic
26. Polterauer P, Prager M, Holzenbein t, 
Karner J, Kretschmer G, schemper M. 
Dacron Versus Polytetrafluoroethylene 
for y-aortic Bifurcation Grafts – a 
6-year Prospective, randomized trial. 
Surgery 1992; 111(6): 626–633.
27. robinson Bi, Fletcher JP, tomlinson P, 
allen rDM, Hazelton sJ,  
richardson aJ et al. a prospective 
randomized multicentre comparison of 
expanded polytetrafluoroethylene and 
gelatin-sealed knitted Dacron grafts for 
femoropopliteal bypass. Cardiovascular 
Surgery 1999; 7(2): 214–218.
28. abbott WM, Green rM,  
Matsumoto t, Wheeler Jr, Miller n,  
Veith FJ et al. Prosthetic above-knee 
femoropopliteal bypass grafting: 
results of a multicenter randomized 
prospective trial. Journal of Vascular 
Surgery 1997; 25(1): 19–28.
29. Daenens K, schepers s, Fourneau i, 
Houthoofd s, nevelsteen a. Heparin-
bonded ePtFe grafts compared with 
vein grafts in femoropopliteal and 
femorocrural bypasses: 1- and 2-year 
Graft Materials Past and Future 529
results. J Vasc Surg 2009; 49(5):  
1210–1216.
30. Pektok e, Cikirikcioglu M, tille JC, 
Kalangos a, Walpoth BH. alcohol 
pretreatment of small-diameter 
expanded polytetrafluoroethylene 
grafts: quantitative analysis of graft 
healing characteristics in the rat 
abdominal aorta interposition model. 
Artif Organs 2009; 33(7): 532–537.
31. Kibbe Mr, Martinez J, Popowich Da, 
Kapadia Mr, ahanchi ss, aalami oo  
et al. Citric acid-based elastomers 
provide a biocompatible interface for 
vascular grafts. J Biomed Mater Res A 
2010; 93(1): 314–324.
32. Jeschke MG, Hermanutz V, Wolf se, 
Koveker GB. Polyurethane vascular 
prostheses decreases neointimal 
formation compared with expanded 
polytetrafluoroethylene. Journal of 
Vascular Surgery 1999; 29(1): 168–176.
33. Bull PG, Denck H, Guidoin r, 
Gruber H. Preliminary Clinical-
experience with Polyurethane Vascular 
Prostheses in Femoropopliteal 
reconstruction. european Journal of 
Vascular Surgery 1992; 6(2): 217–224.
34. alan rD, yuill e, nankivell l, 
Francis DM. australian multi-centre 
evaluation of a new polyurethane 
vascular access graft. J Aust N Z J Surg 
66, 738–742. 1996. ref type: Generic
35. ota K, Kawai t, teraoka s, sasaki y, 
nakagawa y. Clinical-application of 
a self-sealing Poly(ether-Urethane) 
Graft applicable to Blood access for 
Hemodialysis. Artificial Organs 1989; 
13(6): 498–503.
36. Dereume JP, van romphey a,  
Vincent G, engelmann e. 
Femoropopliteal bypass with a 
compliant composite polyurethane/
dacron graft: short term results of 
a multi-centre trial. Cardiovascular 
Surgery 1: 499–503. 1993. ref type: 
Generic
37. nakagawa y, ota K, sato y,  
Fuchinoue s, teraoka s, agishi t. 
Complications in Blood access for 
Hemodialysis. Artificial Organs 1994; 
18(4): 283–288.
38. nakagawa y, ota K, sato y, teraoka s,  
agishi t. Clinical trial of a new 
polyurethane vascular graft for 
haemodialysis compared with expanded 
polytetrafluoroethylene grafts. Artificial 
Organs 19, 1227–1232. 1995. ref 
type: Generic
39. Brothers te, stanley JC, Burkel We,  
Graham lM. small-Caliber  
Polyurethane and Polytetrafluoro-
ethylene Grafts – a Comparative-study 
in a Canine aortoiliac Model. Journal 
of Biomedical Materials Research 1990; 
24(6): 761–771.
40. salacinski HJ, tai nr, Carson rJ, 
edwards a, Hamilton G, seifalian aM. 
in vitro stability of a novel compliant 
poly(carbonate-urea) urethane to 
oxidative and hydrolytic stress. Journal 
of Biomedical Materials Research 2002; 
59(2): 207–218.
41. tai nr, salacinski HJ, seifalian aM, 
Hamilton G. an in vitro assessment 
of the resistance of compliant 
polyurethane vascular grafts to 
degradative oxidative and hydrolytic 
stress. Cardiovasc Pathol 9[4], 219. 
2000. ref type: Generic
42. tai nrM, Giudiceandrea a,  
salacinski HJ, seifalian aM,  
Hamilton G. in vivo femoropopliteal 
arterial wall compliance in subjects 
with and without lower limb vascular 
disease. Journal of Vascular Surgery 
1999; 30(5): 936–945.
43. tai nr, salacinski HJ, edwards a,  
Hamilton G, seifalian aM. 
Compliance properties of conduits 
Mechanisms of Vascular Disease530
used in vascular reconstruction. British 
Journal of Surgery 2000; 87(11):  
1516–1524.
44. soldani G, losi P, Bernabei M, 
Burchielli s, Chiappino D, Kull s  
et al. long term performance of 
small-diameter vascular grafts 
made of a poly(ether)urethane-
polydimethylsiloxane semi-
interpenetrating polymeric network. 
Biomaterials 2010; 31(9):  
2592–2605.
45. Pektok e, nottelet B, tille JC,  
Gurny r, Kalangos a, Moeller M et al. 
Degradation and healing characteristics 
of small-diameter poly(epsilon-
caprolactone) vascular grafts in the rat 
systemic arterial circulation. Circulation 
2008; 118(24): 2563–2570.
46. nottelet B, Pektok e, Mandracchia D,  
tille JC, Walpoth B, Gurny r et al. 
Factorial design optimization and 
in vivo feasibility of poly(epsilon-
caprolactone)-micro- and nanofiber-
based small diameter vascular grafts. 
J Biomed Mater Res A 2009; 89(4): 
865–875.
47. Xu W, Zhou F, ouyang C, ye W,  
yao M, Xu B. Mechanical properties of 
small-diameter polyurethane vascular 
grafts reinforced by weft-knitted 
tubular fabric. J Biomed Mater Res A 
2010; 92(1): 1–8.
48. ishii y, sakamoto s, Kronengold rt, 
Virmani r, rivera ea, Goldman sM 
et al. a novel bioengineered small-
caliber vascular graft incorporating 
heparin and sirolimus: excellent 
6-month patency. J Thorac Cardiovasc 
Surg 2008; 135(6): 1237–1245.
49. Guan J, stankus JJ, Wagner Wr. 
Biodegradable elastomeric scaffolds 
with basic fibroblast growth factor 
release. J Control Release 2007;  
120(1–2): 70–78.
50. taite lJ, yang P, Jun HW, West Jl. 
nitric oxide-releasing polyurethane-
PeG copolymer containing the yiGsr 
peptide promotes endothelialization 
with decreased platelet adhesion.  
J Biomed Mater Res B Appl Biomater 
2008; 84(1): 108–116.
51. Motlagh D, allen J, Hoshi r, yang J, 
lui K, ameer G. Hemocompatibility 
evaluation of poly(diol citrate) in 
vitro for vascular tissue engineering. 
J Biomed Mater Res A 2007; 82(4): 
907–916.
52. ravi s, Chaikof el. Biomaterials for 
vascular tissue engineering. Regen Med 
2010; 5(1): 107–120.
53. Gross re, Hurwitt es, Bill aH,  
Peirce eC. Preliminary observations 
on the Use of Human arterial 
Grafts in the treatment of Certain 
Cardiovascular Defects. New England 
Journal of Medicine 1948; 239(16): 
578–579.
54. Meade JW, linton rr, Darling rC, 
Menendez CV. arterial Homografts 
– a long-term Clinical Follow-Up. 
Archives of Surgery 1966; 93(3):  
392–&.
55. tice Da, Zerbino V. Clinical 
experience with Preserved Human 
allografts for Vascular reconstruction. 
Surgery 1972; 72(2): 260–&.
56. Wengerter K, Dardik H. Biological 
Vascular Grafts. Seminars in Vascular 
Surgery 12: 46–51. 1999. ref type: 
Generic
57. Dardik i, Dardik H. Vascular 
Heterograft – Human Umbilical-
Cord Vein as an aortic substitute in 
Baboon – Preliminary report. Journal 
of Medical Primatology 1973; 2(5): 
296–301.
58. Dardik H, Wengerter K, Qin F, 
Pangilinan a, silvestri F, Wolodiger F  
et al. Comparative decades of 
Graft Materials Past and Future 531
experience with glutaraldehyde-
tanned human umbilical cord vein 
graft for lower limb revascularization: 
an analysis of 1275 cases. Journal of 
Vascular Surgery 2002; 35(1): 64–71.
59. Fink H, Faxalv l, Molnar GF,  
Drotz K, risberg B, lindahl tl et al. 
real-time measurements of coagulation 
on bacterial cellulose and conventional 
vascular graft materials. Acta Biomater 
2010; 6(3): 1125–1130.
60. Wippermann J, schumann D,  
Klemm D, Kosmehl H,  
salehi-Gelani s, Wahlers t. Preliminary 
results of small arterial substitute 
performed with a new cylindrical 
biomaterial composed of bacterial 
cellulose. Eur J Vasc Endovasc Surg 
2009; 37(5): 592–596.
61. Koch s, Flanagan tC, sachweh Js, 
tanios F, schnoering H, Deichmann t  
et al. Fibrin-polylactide-based tissue-
engineered vascular graft in the arterial 
circulation. Biomaterials 2010; 31(17): 
4731–4739.
62. tschoeke B, Flanagan tC, Koch s, 
Harwoko Ms, Deichmann t, ella V  
et al. tissue-engineered small-caliber 
vascular graft based on a novel 
biodegradable composite fibrin-
polylactide scaffold. Tissue Eng Part A 
2009; 15(8): 1909–1918.
63. Kerdjoudj H, Berthelemy n, 
rinckenbach s, Kearney-schwartz a, 
Montagne K, schaaf P et al. small 
vessel replacement by human umbilical 
arteries with polyelectrolyte film-
treated arteries: in vivo behavior.  
J Am Coll Cardiol 2008; 52(19): 
1589–1597.
64. Zhou M, liu Z, Wei Z, liu C, Qiao t,  
ran F et al. Development and 
validation of small-diameter vascular 
tissue from a decellularized scaffold 
coated with heparin and vascular 
endothelial growth factor. Artif Organs 
2009; 33(3): 230–239.
65. l’Heureux n, Dusserre n, Konig G, 
Victor B, Keire P, Wight tn et al. 
Human tissue-engineered blood vessels 
for adult arterial revascularization. Nat 
Med 2006; 12(3): 361–365.
66. torsello G, sandmann W. Use of 
antibiotic-bonded grafts in vascular 
graft infection. European Journal of 
Vascular and Endovascular Surgery 
1997; 14: 84–87.
67. Javerliat i, Goeau-Brissonniere o, 
sivadon-tardy V, Coggia M,  
Gaillard Jl. Prevention of 
staphylococcus aureus graft infection 
by a new gelatin-sealed vascular graft 
prebonded with antibiotics. Journal of 
Vascular Surgery 2007; 46(5):  
1026–1031.
68. lachapelle K, Graham aM, symes JF.  
antibacterial activity, antibiotic 
retention, and infection-resistance 
of a rifampin-impregnated Gelatin-
sealed Dacron Graft. Journal of 
Vascular Surgery 1994; 19(4):  
675–682.
69. D’abbato M, Curti t, Freyvic a. 
Prophylaxis of Graft infection with 
rifampicin Bonded Gel-seal Graft: 
two year Follow up of a Prospective 
Clinical trial. italian investigative 
Group. Cardiovascular Surgery 4;  
200–204. 1996. ref type: Generic
70. earnshaw JJ, Whitman B, Heather BP.  
two-year results of a randomized 
controlled trial of rifampicin-bonded 
extra-anatomic Dacron grafts. British 
Journal of Surgery 2000; 87(6):  
758–759.
71. topel i, audebert F, Betz t,  
steinbauer MG. Microbial spectrum 
and Primary resistance to rifampicin 
in infectious Complications in 
Vascular surgery: limits to the Use of 
Mechanisms of Vascular Disease532
rifampicin-Bonded Prosthetic Grafts. 
Angiology 2010; 61(5): 423–426.
72. Hernandez-richter t, schardey HM, 
lohlein F, Fleischer Ct, Walli aK, 
Boos Ks et al. Binding kinetics of 
triclosan (irgasan (r)) to alloplastic 
vascular grafts: an in vitro study. 
Annals of Vascular Surgery 2000; 14(4): 
370–375.
73. illingworth Bl, tweden K,  
schroeder re, Cameron JD. in vivo 
efficacy of silver-coated (silzone (tM)) 
infection-resistant polyester fabric 
against a biofilm-producing bacteria, 
staphylococcus epidermidis. Journal 
of Heart Valve Disease 1998; 7(5): 
524–530.
74. Goeau-Brissonniere oa, Fabre D, 
leflon-Guibout V, Di Centa i, 
nicolas-Chanoine MH, Coggia M. 
Comparison of the resistance to 
infection of rifampin-bonded gelatin-
sealed and silver/collagen-coated 
polyester prostheses. Journal of Vascular 
Surgery 2002; 35(6): 1260–1263.
75. larena-avellaneda a, russmann s, 
Fein M, Debus es. Prophylactic use of 
the silver-acetate-coated graft in arterial 
occlusive disease: a retrospective, 
comparative study. J Vasc Surg 2009; 
50(4): 790–798.
76. Kuehn C, Graf K, Mashaqi B, 
Pichlmaier M, Heuer W, Hilfiker a  
et al. Prevention of early Vascular 
Graft infection Using regional 
antibiotic release. J Surg Res 2010.
77. stewart aH, eyers Ps, earnshaw JJ. 
Prevention of infection in peripheral 
arterial reconstruction: a systematic 
review and meta-analysis. J Vasc Surg 
2007; 46(1): 148–155.
78. tsuchida H, Cameron Bl, 
Marcus Cs, Wilson se. Modified 
Polytetrafluoroethylene – in-111 
labeled Platelet Deposition on 
Carbon-lined and High-Porosity 
Polytetrafluoroethylene Grafts. Journal 
of Vascular Surgery 1992; 16(4):  
643–650.
79. Bacourt F. Prospective randomized 
study of carbon-impregnated 
polytetrafluoroethylene grafts for 
below-knee popliteal and distal bypass: 
results at 2 years. Annals of Vascular 
Surgery 1997; 11(6): 596–603.
80. rhee ry, Gloviczki P, Cambria ra,  
Miller VM. experimental evaluation 
of bleeding complications, 
thrombogenicity and neointimal 
characteristics of prosthetic patch 
materials used for carotid angioplasty. 
Cardiovasc Surg 1996; 4(6): 746–752.
81. lee sJ, yoo JJ, lim GJ, atala a,  
stitzel J. in vitro evaluation of 
electrospun nanofiber scaffolds for 
vascular graft application. J Biomed 
Mater Res A 2007; 83(4): 999–1008.
82. stankus JJ, soletti l, Fujimoto K, 
Hong y, Vorp Da, Wagner Wr. 
Fabrication of cell microintegrated 
blood vessel constructs through 
electrohydrodynamic atomization. 
Biomaterials 2007; 28(17):  
2738–2746.
83. Barnes CP, sell sa, Boland eD, 
simpson DG, Bowlin Gl. nanofiber 
technology: designing the next 
generation of tissue engineering 
scaffolds. Adv Drug Deliv Rev 2007; 
59(14): 1413–1433.
84. Pham QP, sharma U, Mikos aG. 
electrospinning of polymeric 
nanofibers for tissue engineering 
applications: a review. Tissue Eng 2006; 
12(5): 1197–1211.
85. de Ma, Bolvin C, edirisinghe M,  
Hamilton G, seifalian aM. 
Development of cardiovascular 
bypass grafts: endothelialization and 
applications of nanotechnology. Expert 
Graft Materials Past and Future 533
Rev Cardiovasc Ther 2008; 6(9):  
1259–1277.
86. li D, Xia yn. electrospinning of 
nanofibers: reinventing the wheel? Adv 
Funct Mater 16[14], 1151–70. 2004.  
ref type: Generic
87. de Ma, Punshon G, ramesh B,  
sarkar s, Darbyshire a, Hamilton G  
et al. in situ endothelialization 
potential of a biofunctionalised 
nanocomposite biomaterial-based small 
diameter bypass graft. Biomed Mater 
Eng 2009; 19(4–5): 317–331.
88. sarkar s, Burriesci G, Wojcik a, 
aresti n, Hamilton G, seifalian aM. 
Manufacture of small calibre quadruple 
lamina vascular bypass grafts using 
a novel automated extrusion-phase-
inversion method and nanocomposite 
polymer. Journal of Biomechanics 2009; 
42(6): 722–730.
89. Kim Jy, Khang D, lee Je, Webster tJ.  
Decreased macrophage density 
on carbon nanotube patterns on 
polycarbonate urethane. J Biomed 
Mater Res A 2009; 88(2): 419–426.
90. Hurt rH, Monthioux M, Kane a. 
toxicology of carbon nanomaterials: 
status, trends, and perspectives on 
the special issue. Carbon 2006; 44(6): 
1028–1033.
91. tiwari a, salacinski HJ, Hamilton G,  
seifalian aM. tissue engineering 
of vascular bypass grafts: role of 
endothelial cell extraction. Eur J Vasc 
Endovasc Surg 2001; 21(3): 193–201.
92. Budd Js, allen K, Hartley J, Walsh a,  
James rF, Bell Pr. Prostacyclin 
production from seeded prosthetic 
vascular grafts. Br J Surg 1992; 79(11): 
1151–1153.
93. Birinyi lK, Douville eC, lewis sa,  
Bjornson Hs, Kempczinski rF. 
increased resistance to Bacteremic 
Graft infection after endothelial-Cell 
seeding. Journal of Vascular Surgery 
1987; 5(1): 193–197.
 94. Zilla P, Fasol r, Deutsch M,  
Fischlein t, Minar e, Hammerle a  
et al. endothelial cell seeding of 
polytetrafluoroethylene vascular grafts 
in humans: a preliminary report. J Vasc 
Surg 1987; 6(6): 535–541.
 95. Jarrell Be, Williams sK, stokes G, 
Hubbard Fa, Carabasi ra, Koolpe e 
et al. Use of freshly isolated capillary 
endothelial cells for the immediate 
establishment of a monolayer on a 
vascular graft at surgery. Surgery 1986; 
100(2): 392–399.
 96. Herring M, Gardner a, Glover J. 
single-staged technique for seeding 
Vascular Grafts with autogenous 
endothelium. Surgery 1978; 84(4): 
498–504.
 97. Herring M, Gardner a, Glover J. 
seeding human arterial prostheses with 
mechanically derived endothelium. 
the detrimental effect of smoking.  
J Vasc Surg 1984; 1(2): 279–289.
 98. Herring M, Baughman s, Glover J.  
endothelium develops on seeded 
human arterial prosthesis: a brief 
clinical note. J Vasc Surg 1985; 2(5): 
727–730.
 99. ortenwall P, Wadenvik H, risberg B. 
reduced platelet deposition on seeded 
versus unseeded segments of expanded 
polytetrafluoroethylene grafts: 
clinical observations after a 6-month 
follow-up. J Vasc Surg 1989; 10(4): 
374–380.
100. Deutsch M, Meinhart J, Fischlein t, 
Preiss P, Zilla P. Clinical autologous in 
vitro endothelialization of infrainguinal 
ePtFe grafts in 100 patients: a 9-year 
experience. Surgery 1999; 126(5): 
847–855.
101. Meinhart JG, Deutsch M, Fischlein t,  
Howanietz n, Froschl a, Zilla P. 
Mechanisms of Vascular Disease534
 Clinical autologous in vitro 
endothelialization of 153 infrainguinal 
ePtFe grafts. Ann Thorac Surg 2001; 
71(5 suppl): s327–s331.
102. laube Hr, Duwe J, rutsch W, 
Konertz W. Clinical experience with 
autologous endothelial cell-seeded 
polytetrafluoroethylene coronary artery 
bypass grafts. J Thorac Cardiovasc Surg 
2000; 120(1): 134–141.
103. Deutsch M, Meinhart J, Zilla P. 
in-vitro endothelialization elicits  
tissue re-modelling emulating native 
artery structures. in: Zilla P,  
Greisler HP, editors. tissue 
engineering of Prosthetic Vascular 
Grafts. rG landes Co. Georgetown, 
texas, Usa; 1999. 179–187.
104. Zilla P. neo-media formation in 
explanted endothelial seeded ePtFe 
grafts in lower limb bypass in man. 
Personal Communication. 2003.  
ref type: Generic
105. Bowald s, Busch C, eriksson i. 
arterial regeneration following 
polyglactin 910 suture mesh grafting. 
Surgery 1979; 86(5): 722–729.
106. Greisler HP. arterial regeneration over 
absorbable prostheses. Arch Surg 1982; 
117(11): 1425–1431.
107. Putnam aJ, Mooney DJ. tissue 
engineering using synthetic 
extracellular matrices. Nat Med 1996; 
2(7): 824–826.
108. Bowald s, Busch C, eriksson i. 
arterial regeneration following 
polyglactin 910 suture mesh grafting. 
Surgery 1979; 86(5): 722–729.
109. Greisler HP. arterial regeneration over 
absorbable prostheses. Arch Surg 1982; 
117(11): 1425–1431.
110. Greisler HP, Kim DU, Price JB, 
Voorhees aB, Jr. arterial regenerative 
activity after prosthetic implantation. 
Arch Surg 1985; 120(3): 315–323.
111. Greisler HP, ellinger J, schwarcz tH,  
Golan J, raymond rM, Kim DU.  
arterial regeneration over 
polydioxanone prostheses in the 
rabbit. Arch Surg 1987; 122(6): 
715–721.
112. Greisler HP, endean eD, Klosak JJ, 
ellinger J, Dennis JW, Buttle K et al.  
Polyglactin 910/polydioxanone 
bicomponent totally resorbable 
vascular prostheses. J Vasc Surg 1988; 
7(5): 697–705.
113. Greisler HP, tattersall CW, Klosak JJ,  
Cabusao ea, Garfield JD, Kim DU. 
Partially bioresorbable vascular grafts 
in dogs. Surgery 1991; 110(4):  
645–654.
114. Vacanti JP, langer r. tissue 
engineering: the design and 
fabrication of living replacement 
devices for surgical reconstruction and 
transplantation. Lancet 1999; 354 
suppl 1: si32–si34.
115. yue X, van der lB, schakenraad JM, 
van oene GH, Kuit JH, Feijen J  
et al. smooth muscle cell seeding in 
biodegradable grafts in rats: a new 
method to enhance the process of 
arterial wall regeneration. Surgery 
1988; 103(2): 206–212.
116. shinoka t, shum-tim D, Ma PX, 
tanel re, isogai n, langer r et al. 
Creation of viable pulmonary artery 
autografts through tissue engineering. 
J Thorac Cardiovasc Surg 1998; 
115(3): 536–545.
117. shum-tim D, stock U, Hrkach J, 
shinoka t, lien J, Moses Ma et al. 
tissue engineering of autologous aorta 
using a new biodegradable polymer. 
Ann Thorac Surg 1999; 68(6):  
2298–2304.
118. Gao J, niklason l, langer r. surface 
hydrolysis of poly(glycolic acid) 
meshes increases the seeding density of 
Graft Materials Past and Future 535
schilling t, Brandes G, Mertsching H 
et al. engineering of human vascular 
aortic tissue based on a xenogeneic 
starter matrix. Transplantation 2000; 
70(1): 7–14.
128. teebken oe, Pichlmaier aM,  
Haverich a. Cell seeded decellularised 
allogeneic matrix grafts and 
biodegradable polydioxanone-
prostheses compared with arterial 
autografts in a porcine model. Eur 
J Vasc Endovasc Surg 2001; 22(2): 
139–145.
129. Centola M, rainer a, spadaccio C,  
De Ps, Genovese Ja, trombetta M.  
Combining electrospinning and 
fused deposition modeling for the 
fabrication of a hybrid vascular graft. 
Biofabrication 2010; 2(1): 014102.
130. enomoto s, sumi M, Kajimoto K, 
nakazawa y, takahashi r,  
takabayashi C et al. long-term 
patency of small-diameter vascular 
graft made from fibroin, a silk-based 
biodegradable material. J Vasc Surg 
2010; 51(1): 155–164.
131. Zarbiv G, Preis M, Ben-yosef y, 
Flugelman My. engineering blood 
vessels by gene and cell therapy.  
Expert Opin Biol Ther 2007; 7(8): 
1183–1191.
132. lee sW, Park sW, Kim yH, yun sC,  
Park DW, lee CW et al.  
a randomized Comparison of 
sirolimus- Versus Paclitaxel-eluting 
stent implantation in Patients With 
Diabetes Mellitus 2-year Clinical 
outcomes of the Des-DiaBetes 
trial. Journal of the American College of 
Cardiology 2009; 53(9): 812–813.
133. Chlupac J, Filova e, Bacakova l. 
Blood vessel replacement: 50 years of 
development and tissue engineering 
paradigms in vascular surgery. Physiol 
Res 2009; 58 suppl 2: s119–s139.
vascular smooth muscle cells. J Biomed 
Mater Res 1998; 42(3): 417–424.
119. Massia sP, Hubbell Ja. Vascular 
endothelial cell adhesion and 
spreading promoted by the peptide 
reDV of the iiiCs region of plasma 
fibronectin is mediated by integrin 
alpha 4 beta 1. J Biol Chem 1992; 
267(20): 14019–14026.
120. niklason le, Gao J, abbott WM, 
Hirschi KK, Houser s, Marini r et al.  
Functional arteries grown in vitro. 
Science 1999; 284(5413): 489–493.
121. niklason le, abbott W, Gao J, 
Klagges B, Hirschi KK, Ulubayram K  
et al. Morphologic and mechanical 
characteristics of engineered bovine 
arteries. J Vasc Surg 2001; 33(3): 
628–638.
122. stock Ua, Wiederschain D, Kilroy sM, 
shum-tim D, Khalil Pn, Vacanti JP 
et al. Dynamics of extracellular matrix 
production and turnover in tissue 
engineered cardiovascular structures.  
J Cell Biochem 2001; 81(2): 220–228.
123. rademacher a, Paulitschke M,  
Meyer r, Hetzer r. endothelialization 
of PtFe vascular grafts under flow 
induces significant cell changes. Int J 
Artif Organs 2001; 24(4): 235–242.
124. Urry DW, Pattanaik a. elastic 
protein-based materials in tissue 
reconstruction. Ann N Y Acad Sci 
1997; 831: 32–46.
125. nicol a, Gowda DC, Urry DW. Cell 
adhesion and growth on synthetic 
elastomeric matrices containing  
arg-Gly-asp-ser-3. J Biomed Mater 
Res 1992; 26(3): 393–413.
126. Wilson GJ, yeger H, Klement P, 
lee JM, Courtman DW. acellular 
matrix allograft small caliber vascular 
prostheses. ASAIO Trans 1990; 36(3): 
M340–M343.
127. Bader a, steinhoff G, strobl K, 
Mechanisms of Vascular Disease536
134. Varu Vn, tsihlis nD, Kibbe Mr. 
Basic science review: nitric oxide – 
releasing prosthetic materials. Vasc 
Endovascular Surg 2009; 43(2):  
121–131.
135. Hirai J, Matsuda t. Venous 
reconstruction using hybrid vascular 
tissue composed of vascular cells and 
collagen: tissue regeneration process. 
Cell Transplant 1996; 5(1): 93–105.
136. l’Heureux n, Paquet s, labbe r, 
Germain l, auger Fa. a completely 
biological tissue-engineered human 
blood vessel. FASEB J 1998; 12(1): 
47–56.
137. niklason le, abbott W, Gao J, 
Klagges B, Hirschi KK, Ulubayram K  
et al. Morphologic and mechanical 
characteristics of engineered bovine 
arteries. J Vasc Surg 2001; 33(3): 
628–638.
138. Goldner s, seifalian aM,  
Baguneid Ms, Fuller BJ, Hamilton G,  
Cheetham K et al. effect of 
preconditioning living vascular graft 
matrices. Cardiovascular Pathology 
9[4], 224. 2000. ref type: Generic
139. Broker Hs, Foteh Ki, Murphy eH, 
Davis CM, Clagett GP, Modrall JG  
et al. Device-specific aneurysm sac 
morphology after endovascular 
aneurysm repair: evaluation of 
contemporary graft materials. J Vasc 
Surg 2008; 47(4): 702–706.
140. Chuter taM. Durability of 
endovascular infrarenal aneurysm 
repair: When Does late Failure 
occur and Why? Seminars in Vascular 
Surgery 2009; 22(2): 102–110.
141. rigberg D, tulloch a, Chun y, 
Mohanchandra KP, Carman G, 
lawrence P. thin-film nitinol (niti): 
a feasibility study for a novel aortic 
stent graft material. Journal of Vascular 
Surgery 2009; 50(2): 375–380.
142. van Herwaarden Ja, Muhs Be, 
Vincken Kl, van PJ, teutelink a, 
Bartels lW et al. aortic compliance 
following eVar and the influence of 
different endografts: determination 
using dynamic Mra. J Endovasc Ther 
2006; 13(3): 406–414.
143. Zhong H, Matsui o, Xu K, ogi t, 
sanada J, okamoto y et al. Gene 
transduction into aortic wall using 
plasmid-loaded cationized gelatin 
hydrogel-coated polyester stent graft.  





Department of Vascular Surgery, Westmead Hospital, Sydney, NSW, 
australia.
iNtroDuctioN
the introduction of prosthetic grafts 
has revolutionised the management of 
vascular disease but graft infection although 
uncommon, remains a dreaded complication 
with associated significant morbidity and 
mortality. Mortality occurs in approximately 
one third of all vascular graft infections,1 with 
mortality highest when an aortic prosthesis is 
involved.2,3 as many as 75% of survivors of an 
infected aortic prosthesis require amputation 
of a limb,3 with the incidence of amputation 
highest when the infection involves more 
distal prosthetic grafts.4 the incidence of 
graft infections is difficult to quantify as 
infection may manifest many years after 
implantation1 with many reports being 
isolated or as part of case series. Nevertheless, 
the reported incidence is in the order of 5%, 
varying according to the site of operation, 
being higher when a groin incision is used, 
or if the procedure is an emergency or a redo 
procedure. infection following endovascular 
stent deployment has been reported although 
its incidence is considered to be very low.
NaturaL HiStorY oF 
ProStHetic VaScuLar GraFt 
iNFectioNS 
early prosthetic vascular graft infections 
typically occurring in the first four months 
following placement are relatively uncommon 
(approximately 1%) and are usually caused 
by the more virulent micro-organisms, 
such as S. aureus, E. Coli, Pseudomonas, 
Klebsiella, Proteus and enterobacter.1 Late 
prosthetic vascular graft infections are the 
result of two possible mechanisms. Firstly, 
by haematogenous seeding from a septic 
focus elsewhere5 or by the prosthetic graft 
becoming infected with enteric contents 
following a graft-enteric erosion.6 in both 
the haematogenous and graft-enteric erosion 
situations the usual causative organisms 
are those with high virulence and clinical 
manifestations are signs and symptoms of 
sepsis. the second mode of presentation is 
insidious, caused by the less virulent coagulase 
negative staphylococci such as S. epidermidis 
with contamination likely occurring at the 
time of implantation.1 
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MecHaNiSMS oF GraFt 
coNtaMiNatioN at 
oPeratioN
Prosthetic grafts most commonly become 
infected at the time of implantation either by 
contamination from the surgical team or by 
colonised microorganisms on the patient. it 
has been demonstrated that the majority of 
patients undergoing arterial revascularisation 
are colonised with coagulase negative 
staphylococci7 and colonisation of patients 
with nosocomial bacteria is enhanced when 
the preoperative hospitalisation is lengthy.8 
the incidence of infection follow-
ing emergency aneurysmorrhapy has been 
reported to be increased to 7.5%.9 the evid-
ence of other potential mechanisms such 
as division of lymph nodes,10,11,12 infected 
transudated fluid during aortic surgery13,14,15 
and infected laminated thrombus4,14,16,17 is 
conflicting. 
PatHoGeNeSiS oF GraFt 
iNFectioNS
the exact aetiology of vascular graft infections 
is not completely understood but is likely to 
be multifactorial. according to Bandyk and 
esses18 the risk of vascular graft infection 
as demonstrated by animal models can be 
predicted by the formula:
            Dose of bacterial
risk of biomaterial = contamination X virulence
        infection          Host resistance
the dose of bacterial contamination is 
dependent on the infecting microorganism. 
experimentation in a canine aortic model has 
demonstrated that the infective threshold for 
bacteria to cause graft infection in over 50% 
of grafts was 107, 109, and 102 for S. aureus, 
S. epidermidis and P. aeruginosa respectively.19 
Virulence of microorganisms is often associ-
ated with the production of secreted toxins 
and enzymes with a resultant decline in 
structural integrity of the artery wall18 and 
the release of toxins and enzymes to control 
the perigraft environment and cause graft 
infection.19,20 Many bacterial strains, includ-
ing S. epidermidis, S. aureus and P. aeruginosa 
are known to produce extracellular polymer 
substances (slime), forming a capsule incor-
porating the bacteria. this is referred to as 
a biofilm and protects the micro-organism 
against host defences and antibiotic ther-
apy.21 Biofilms allow greater adherence of 
the microorganism to the biomaterial22, 23 
and contribute to bacterial virulence. Mul-
tiple species of microorganisms may co-exist 
in a biofilm and unless the biofilm is dis-
rupted and or the microorganism/s become 
planktonic the microorganism/s identifica-
tion is limited. Different graft materials have 
varying susceptibility to infection. Dacron 
grafts are more likely to become infected 
than grafts made of PtFe (polytetrafluor-
oethylene).24 the use of vein grafts instead 
of prosthetic material greatly reduces the risk 
of infection. 
BacterioLoGY oF VaScuLar 
GraFt iNFectioNS
Gram-positive, Gram-negative, anaerobic and 
fungal micro-organisms all have the potential 
to infect a vascular prostheses but in general the 
majority of infections are the result of a small 
number of micro-organisms. Staphylococci 
are the most prevalent organism associated 
with prosthetic graft infection.2,25,26,27 of the 
staphylococci, S. aureus is generally regarded 
as the most common causative bacteria,2,26,28,29 
particularly MrSa.27 S. epidermidis is now 
being recognised as the leading cause of 
vascular graft infection, particularly chronic 
and late onset infections.17,29,30,31,32
the Gram-negative organisms, E. Coli, 
Pseudomonas, Klebsiella, Enterobacter and 
Proteus, although relatively uncommon 
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causative organisms for graft infections are 
of particular interest and concern because of 
their high virulence and their tendency to 
destroy the vessel wall.18,33,34
Candida mycobacterium, and Aspergillus 
infections are uncommon but pose a sig-
nificant risk to patients who are immuno-
compromised.2 although uncommon they 
are all expected to increase in frequency 
because of their increasing resistance to 
standard prophylactic antibiotics.35
there is an association between the type 
of infecting organism, the type of vascu-
lar complication and the arteries that are 
involved in the anastomosis to the prosthetic 
graft. Bandyk and Bergamini2 in a collective 
survey of 1258 patients who had a vascular 
graft infection found that the majority of 
aortoenteric fistulas were the result of either 
Streptococci or E. Coli and if the anastomo-
sis involved the femoral artery, the thoracic 
aorta, the subclavian, carotid or innominate 
arteries S. epidermidis or S aureus was the 
likely causative organism. E. Coli, Entero-
cocci and Enterobacter were the more likely 
organisms to be involved in aortoiliac 
anastomoses.
iNVeStiGatioNS For 
DetectioN oF ProStHetic 
GraFt iNFectioNS
the diagnosis of vascular prosthetic 
infections can be difficult as the presentation 
may be subtle especially if it is a late 
onset infection, the prosthesis is intra-
abdominal and the micro-organism is one 
of low virulence. Presentation is thus very 
dependent on the location of infection and 
the causative microorganism/s. the diagnosis 
is aided by multiple available microbiological 
investigations and imaging but in general 
is directed more at proving the absence of 
infection rather its presence. Not only are 
investigations imperative in the diagnosis of 
vascular graft infection but they may assist 
in the planned therapy including vascular 
reconstruction when required. at times the 
only means of confirming graft infection is 
the surgical excision of the graft and further 
microbiological assessment. 
History and physical examination
the clinical clues suggesting graft infection 
especially those placed superficially include 
an inflammatory perigraft mass, overlying 
cellulitus, presence of exposed prosthetic 
graft, a sinus tract with persistent purulent 
drainage and/or bleeding and/or a palpable 
anastomotic pseudoaneurysm, graft throm-
bosis and distal septic embolisation.2-4,36,37 
the presence of intra-abdominal prosthetic 
graft infection may be non-specific, such 
as fever of unknown origin, septicaemia, 
or abdominal pain.3 upper or lower 
gastrointestinal haemorrhage either of an 
acute or chronic nature may indicate a graft-
enteric fistula17,37,38 and can only be excluded 
when another source of gastrointestinal 
haemorrhage has been identified. 
Laboratory investigations
routine laboratory studies such as white 
cell count and differential, erythrocyte 
sedimentation rate (eSr), c-reactive 
Protein (crP), and blood cultures are 
routinely obtained but the results may be 
non-specific and even normal if the organism 
is S.epidermidis.2 Wherever possible pus, 
exudates, tissue specimens, blood and wound 
cultures should be analysed microbiologically 
to aid in microorganism identification and 
to allow the commencement of appropriate 
and specific chemotherapy.39 to aid in the 
diagnosis of S.epidermidis all solid material 
should be mechanically or ultrasonically 
disrupted.40-42
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Diagnostic imaging
Various diagnostic modalities (computer-
ised tomography (ct), ultrasonography, 
Magnetic resonance imaging, Leucocyte or 
immunoglobulin labelled scanning, Positron 
emission tomography (Pet) scanning +/- 
ct, angiography and/or endoscopy) may 
assist the vascular surgeon in determining 
the presence and extent of prosthetic graft 
infection. Not infrequently, a combination 
of the diagnostic modalities to improve 
sensitivity and specificity are utilised to 
confirm the presence or absence of a vascular 
prosthetic graft infection.43 these modalities 
are also helpful in planning definitive 
surgery. the utility of ct angiography with 
the capability of vascular three dimensional 
reconstructions has largely replaced digital 
subtraction angiography as the method 
of diagnosis and therapeutic planning. 
ct guided aspiration is also of benefit in 
diagnosis. in general the features suggestive 
of graft infection include perigraft fluid and/
or gas, graft disruption, absence of graft 
incorpor ation, pseudoaneurysm formation. 
the pres ence of periprosthetic gas more 
than six weeks following graft implantation 
is an abnormal finding and should alert 
the physician to the likelihood of a graft 
infection.44
MaNaGeMeNt oF ProStHetic 
GraFt iNFectioNS
the general principles in the management 
of prosthetic graft infections are initially 
preventative, but in the event of a vascular 
graft infection, therapy needs to be individual-
ised accounting for clinical findings, graft 
material (prosthetic versus autogenous graft 
material), site of infection, microorganism/s 
involved and patient co-morbidities. it is 
imperative that not only is graft infection 
eradicated but recurrent infection be 
minimised with avoidance of significant 
morbidity and/or mortality.
Prevention
Preventive measures such as the routine use 
of skin preparations,45 the use of a depilatory 
agent,46 limiting the length of preoperative 
hospitalisation,8 operating time and intensive 
care stay all contribute to the reduction in 
wound infection and more importantly 
the chance of developing resistant multiple 
nosocomial infections.45 antimicrobial pro-
phylaxis has been shown to reduce wound 
infections in vascular surgery47 and ideally 
should be given as close to the time of incision 
and repeated in the event of haemorrhage 
and lengthy operations every four hours. 
Prophylatic antibiotics are also indicated 
with percutaneous punctures of existing 
prosthetic grafts and the implantation of 
stents. Decolonisation of nasal carriers 
of S. aureus has been shown to significantly 
reduce the number of surgical site 
S. aureus infections especially deep surgical-
site infections.48 institutional prevalence of 
resistant organism may also dictate antibiotic 
prophylaxis especially when prosthetic grafts 
are to be implanted. 
as a preventive measure host resist-
ance may be enhanced by the antimicrobial 
impregnation of grafts. a number of novel 
combinations of grafts and antibiotic with 
or without various forms of treatment have 
been trialled at both the in-vitro and in-vivo 
levels.
rifampicin, a known anti-staphylococcal 
agent, particularly methicillin resistant,49 
is a hydrophobic semisynthetic substance 
with a high affinity for gelatin.50 it inhibits 
DNa dependent rNa polymerase activity 
in bacterial cells without affecting mamma-
lian cells51 and has been passively incorp-
orated into gelatin sealed Dacron grafts 
as a mode of staphylococcal protection 
at the time of implantation. it has been 
shown to be resistant to experimental bacter-
ial contamination52-55 with in-vivo bio activity 
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to 22 days,56 and in-vitro bioactivity to 
4 days.57-59 it is these qualities plus its excel-
lent tissue and intracellular penetration59 
that make rifampicin an ideal antibiotic 
to be bonded to prosthetic grafts in order to 




using an established sheep model60 we 
replaced a segment of sheep carotid artery 
with a rifampicin soaked Gelsoft graft. 
at the time of graft removal microscopic 
assessment (perigraft abscess formation, 
presence of anastamotic disruption and graft 
thrombosis) and microbiological assessments 
(cultures of perigraft tissues, graft external 
and internal wall and total graft cultures) 
were recorded. We showed that, following 
direct inoculation of the rifampicin (1.2mg/
ml or 10mg/ml) soaked graft with 108 colony 
forming units of either methicillin resistant 
Staphylococcal aureus (MrSa) or methicillin 
resistant Staphylococcal epidermidis (MrSe), 
the rifampicin soaked graft offered significant 
prophylaxis.61-63
For the MrSe arm, in the 10mg/ml 
rifampicin group there was a significant 
reduction in graft infection when compared 
to both the control group (p < 0.05) and the 
1.2mg/ml group (p < 0.05).63 Similarly, for 
the MrSa group, in the 10mg/ml treatment 
group there was a significant reduction in the 
total number of positive cultures when com-
pared to the control group (p < 0.05) and the 
1.2mg/ml group (p < 0.05).63 
eStaBLiSHeD iNFectioN
Antibiotic therapy
once the diagnosis or suspicion of prosthetic 
vascular graft infection is made then broad 
spectrum antimicrobial therapy is initiated 
and subsequently converted to organism 
specific antibiotics.3 the length of antibiotic 
therapy following excision of the infected 
graft is unclear but Bergamini and Bandyk2 
advocate parenteral antibiotics for two weeks 
and oral for six months.
Operative management
the ‘gold standard’ treatment although 
technically challenging is the removal of 
all infected tissue and revascularisation 
extra-anatomically.64 a number of more 
conservative approaches have been advocated 
depending on the site of the infection and 
the microorganism involved. the most 
conservative of treatments is aggressive 
local wound care with graft preservation 
(prosthetic/autologous) providing that the 
graft and anastomoses are intact and the 
patient has no systemic features of sepsis.65 
calligaro et al 34 in a report of a series of 
patients who had graft preservation concluded 
that with the exception of Pseudomonas, 
vascular graft infections could be managed 
with debridement, antibiotic therapy and 
wound closure. the skeletonized prosthetic 
graft can be covered using viable regional 
rotational flaps.66 others have proposed graft 
excision and replacement with cadaveric 
arterial allografts,67 venous autografts,68 
cryopreserved saphenous vein homografts,69 
autogenous arteries and/or veins70 or 
prosthesis.71 the major drawback with in-situ 
reconstruction is recurrent graft sepsis72 with 
potential limb and/or life threatening graft 
and/or anastomotic disruption.
Schmitt, et al.22 in an in- vitro model 
comparing the bacterial adherence of four 
strains of bacteria (S. aureus, ‘mucin’ and 
‘non-mucin’ producing S. epidermidis and 
E. coli) to ePtFe, woven Dacron and velour 
knitted Dacron found that bacterial adher-
ence was greatest to velour knitted Dacron 
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and least compared to ePtFe. in addition 
Schmitt, et al.73 found that ‘mucin’ produc-
ing S. epidermidis adhered to Dacron in 
10 to 100 fold greater numbers compared 
to PtFe. Bandyk and Bergamini2 have pos-
tulated that the differential adherence of 
staphylococci relates to capsular adhesins. 
using the established sheep model60 we 
have set out to determine if the replacement 
of a staphylococcal infected vascular graft 
with a graft impregnated with rifampicin 
would be considered appropriate surgical 
management in preventing early recurrent 
infection. Gelsoft grafts without any anti-
biotic treatment were infected with over-
whelming concentrations of either MrSa 
or MrSe. the grafts were removed at three 
weeks and replaced with either control (no 
rifampicin) grafts or grafts soaked in either 
1.2mg/ml or 10mg/ml of rifampicin. the 
replacement grafts were removed 3 weeks 
following placement. 
For MrSa74 there were no statistical sig-
nificant differences between the groups for 
any of the macroscopic or microbiological 
parameters recorded. 
For S.epidermidis 74 there were no stat-
istical differences between the rifampicin 
concentrations for macroscopic findings. 
there were however, statistically significant 
reductions in the number of total infected 
specimens in the 10mg/ml group when com-
pared to both the control, (p<0.001) and the 
1.2 mg/ml groups (p<0.005).74 
the conclusions from the studies74 were 
that established S. epidermidis bacterial bio-
film graft infections model can be treated by 
the in-situ replacement of the infected pros-
thesis with a 10 mg/ml rifampicin impregnated 
Gelsoft graft. However, such management for 
MrSa established infections cannot be rec-
ommended from the results obtained in this 
particular animal model.
to date a number of groups75,76 have suc-
cessfully managed prosthetic graft infections 
with rifampicin impregnated grafts with zero 
mortality, no requirement for limb amputa-
tion and to date no recurrence of infection.
coNcLuSioN
the future management of vascular 
graft infections will be reliant on a better 
understanding of the interaction between 
the micro-organism, the prosthesis and the 
immune system. this will allow a more 
directed approach towards prevention and 
treatment. Possibilities would include more 
powerful antibiotics either administered 
parenterally or incorporated into the 
prosthesis, acting as a local delivery system 
for prolonged periods of time. the role 
of the biofilm in the pathogenesis of graft 
infection needs further understanding from 
both a molecular and an immune level.
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